<SEC-DOCUMENT>0001387131-23-003377.txt : 20230313
<SEC-HEADER>0001387131-23-003377.hdr.sgml : 20230313
<ACCEPTANCE-DATETIME>20230313172518
ACCESSION NUMBER:		0001387131-23-003377
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230313
DATE AS OF CHANGE:		20230313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tonix Pharmaceuticals Holding Corp.
		CENTRAL INDEX KEY:			0001430306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				261434750
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36019
		FILM NUMBER:		23728290

	BUSINESS ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928
		BUSINESS PHONE:		212-980-9155

	MAIL ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAMANDARE EXPLORATIONS INC.
		DATE OF NAME CHANGE:	20080320
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tnxp-10k_123122.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:tnxp="http://tonixpharma.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_023_US%2DGAAP%2D2022_stpr -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_tnxp_tonixpharma.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001430306 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_074_XDX_P%2D%2D\Clients\Tonix Pharmaceuticals Holding Corp\2023\q23%2D02916__10%2DK__iXBRL\tnxp%2D10k__123122.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_07D_SO_P%2D%2D\Clients\Tonix Pharmaceuticals Holding Corp\2023\q23%2D02916__10%2DK__iXBRL\tnxp%2D10k__123122.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_SquareFoot_0_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_Acre_0_utr%2D%2Dacre -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001430306</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0121" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0134" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RedeemablePreferredStockDividends" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues7" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues7" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:PreferredStockDeemedDividend" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:PreferredStockDeemedDividend" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:PreferredStockDeemedDividend" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues14" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues14" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues15" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues15" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues19" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues19" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues21" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues21" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues21" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="tnxp:CommonStockIssuedToAcquireResearchAndDevelopment" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="xdx2ixbrl0523" decimals="-3" scale="3" sign="-" unitRef="USD">470038</ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0525" decimals="-3" scale="3" unitRef="USD">120229</ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="xdx2ixbrl1020" decimals="4" scale="0" unitRef="Pure">0.3333</ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="xdx2ixbrl1021" decimals="4" scale="0" unitRef="Pure">0.0278</ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_srt_DirectorMember" id="xdx2ixbrl1024" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P1Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="xdx2ixbrl1146" decimals="-3" scale="3" unitRef="USD">715</ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" id="xdx2ixbrl1148" decimals="-3" scale="3" unitRef="USD">760</ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1150" decimals="-3" scale="3" unitRef="USD">328</ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1152" decimals="-3" scale="3" unitRef="USD">432</ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="xdx2ixbrl1316" decimals="4" unitRef="Pure">0.3333</ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="xdx2ixbrl1317" decimals="4" unitRef="Pure">0.0278</ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="xdx2ixbrl1321" decimals="4" unitRef="Pure">0.3333</ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="xdx2ixbrl1322" decimals="4" unitRef="Pure">0.0278</ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="tnxp-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockIssuanceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockIssuanceJanuary2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceJanuary2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockIssuanceJanuary2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceJanuary2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockIssuanceFebruary2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceFebruary2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockIssuanceFebruary2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceFebruary2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockIssuanceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockIssuanceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-152022-05-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-15</xbrli:startDate>
        <xbrli:endDate>2022-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_BuildingMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_BuildingMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LandImprovementsAndLabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:LandImprovementsAndLabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FurnitureAndAllOtherEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:FurnitureAndAllOtherEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LandImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_BuildingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_FurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:FurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_FurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:FurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-01_stpr_MD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-222021-10-01_stpr_MD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-22</xbrli:startDate>
        <xbrli:endDate>2021-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-222021-10-01_us-gaap_LandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-22</xbrli:startDate>
        <xbrli:endDate>2021-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-222021-10-01_stpr_MD_us-gaap_BuildingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-22</xbrli:startDate>
        <xbrli:endDate>2021-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-222021-10-01_stpr_MD_custom_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-22</xbrli:startDate>
        <xbrli:endDate>2021-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-28_stpr_MA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-272020-09-28_stpr_MA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-27</xbrli:startDate>
        <xbrli:endDate>2020-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-272020-09-28_stpr_MA_us-gaap_LandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-27</xbrli:startDate>
        <xbrli:endDate>2020-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-272020-09-28_stpr_MA_us-gaap_BuildingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-27</xbrli:startDate>
        <xbrli:endDate>2020-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_stpr_MA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-292022-12-31_stpr_MA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-29</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-23_stpr_MT">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MT</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-212020-12-23_stpr_MT">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MT</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-21</xbrli:startDate>
        <xbrli:endDate>2020-12-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-152022-05-16_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-15</xbrli:startDate>
        <xbrli:endDate>2022-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-26_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-26_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-122022-12-13_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-12</xbrli:startDate>
        <xbrli:endDate>2022-12-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-122022-12-13_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-12</xbrli:startDate>
        <xbrli:endDate>2022-12-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-232022-06-24_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-23</xbrli:startDate>
        <xbrli:endDate>2022-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-232022-06-24_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-23</xbrli:startDate>
        <xbrli:endDate>2022-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-23</xbrli:startDate>
        <xbrli:endDate>2022-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-042022-08-05_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-04</xbrli:startDate>
        <xbrli:endDate>2022-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-042022-08-05_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-04</xbrli:startDate>
        <xbrli:endDate>2022-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-212020-12-22_custom_AssetPurchaseAgreementMember_custom_KatanaPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:KatanaPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-21</xbrli:startDate>
        <xbrli:endDate>2020-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:TrigeminaIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-10</xbrli:startDate>
        <xbrli:endDate>2020-06-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-102020-06-11_custom_AssignmentAndAssumptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssignmentAndAssumptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-10</xbrli:startDate>
        <xbrli:endDate>2020-06-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:TRImaranPharmaIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-17</xbrli:startDate>
        <xbrli:endDate>2019-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:TRImaranPharmaIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-172019-08-19_custom_WSULicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:WSULicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-17</xbrli:startDate>
        <xbrli:endDate>2019-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-19_custom_WSULicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:WSULicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-212020-12-22_custom_LicenseAgreementMember_custom_CuriaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:CuriaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-21</xbrli:startDate>
        <xbrli:endDate>2020-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-132021-04-14_custom_LicenseAgreementMember_custom_OyaGenIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:OyaGenIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-13</xbrli:startDate>
        <xbrli:endDate>2021-04-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-072021-02-11_custom_InsermLicenseAgreementMember_custom_InsermMember_custom_OxytocinBasedTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:InsermLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:InsermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tnxp:OxytocinBasedTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-07</xbrli:startDate>
        <xbrli:endDate>2021-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:TrusteesOfColumbiaUniversityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tnxp:TFF2ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-15</xbrli:startDate>
        <xbrli:endDate>2019-09-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:TrusteesOfColumbiaUniversityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tnxp:TFF2ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-192019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:TrusteesOfColumbiaUniversityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-19</xbrli:startDate>
        <xbrli:endDate>2019-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:TrusteesOfColumbiaUniversityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-152022-08-16_custom_PurchaseAgreementWithLincolnPark2022Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnPark2022Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-15</xbrli:startDate>
        <xbrli:endDate>2022-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnPark2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnPark2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnPark2022Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-022021-12-03_custom_PurchaseAgreementWithLincolnParkMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-02</xbrli:startDate>
        <xbrli:endDate>2021-12-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-132021-05-14_custom_PurchaseAgreementWithLincolnPark2021Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnPark2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-13</xbrli:startDate>
        <xbrli:endDate>2021-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreement2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-062021-02-08_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-06</xbrli:startDate>
        <xbrli:endDate>2021-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-08_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-07</xbrli:startDate>
        <xbrli:endDate>2021-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-10</xbrli:startDate>
        <xbrli:endDate>2021-01-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-072020-04-08_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-07</xbrli:startDate>
        <xbrli:endDate>2020-04-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-13_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-03_custom_IncentiveStockOptionsPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:IncentiveStockOptionsPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-16_custom_IncentiveStockOptionsPlan2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:IncentiveStockOptionsPlan2020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-01_custom_AmendedAndRestated2020PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:AmendedAndRestated2020PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:AmendedAndRestated2020PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember_custom_TenPercentOrMoreShareholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:AmendedAndRestated2020PlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tnxp:TenPercentOrMoreShareholderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AmendedAndRestated2020PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:AmendedAndRestated2020PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_srt_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-03_custom_EmployeeStockPurchasePlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-022019-05-03_custom_EmployeeStockPurchasePlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-02</xbrli:startDate>
        <xbrli:endDate>2019-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmployeeStockPurchasePlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeeStockPurchasePlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-31_custom_EmployeeStockPurchasePlan2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_EmployeeStockPurchasePlan2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_EmployeeStockPurchasePlan2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlan2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmployeeStockPurchasePlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_Warrant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_Warrant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_Warrant3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_Warrant3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_WarrantsFromFeb2020FinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:WarrantsFromFeb2020FinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_WarrantsFromFeb2020FinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:WarrantsFromFeb2020FinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember964078343">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tnxp:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NewLeaseArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tnxp:NewLeaseArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NewLeaseArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tnxp:NewLeaseArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ResearchOrganizationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tnxp:ResearchOrganizationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ConstructionContractMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tnxp:ConstructionContractMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:DefinedContributionPlan401KPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DefinedContributionPlan401KPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:DefinedContributionPlan401KPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_country_IE">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_country_BM">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ForeignCountryMember_country_BM">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ForeignCountryMember_country_IE">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_stpr_NJ">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_stpr_MA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-02_custom_NewShareRepurchaseProgramMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_NewShareRepurchaseProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-02_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-02_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-02_custom_AssetPurchaseAgreementMember_custom_HealionBioIncMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:HealionBioIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-22</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-22</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-22</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tnxp:EmployeeStockOption1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-22</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tnxp:EmployeeStockOption1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-22</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tnxp:EmployeeStockOption1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-22</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-13_custom_SalesAgreementWithAGPMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementWithAGPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="SquareFoot">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Acre">
      <xbrli:measure>utr:acre</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<div>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>UNITED
STATES</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b>&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90A_edei--DocumentType_c20220101__20221231_ztcvQD6RMJ27"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">(Mark
One)<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b><span id="xdx_90E_edei--DocumentAnnualReport_c20220101__20221231_zL2Gd26Hg9ve"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>&#160;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the Fiscal Year Ended <span id="xdx_901_edei--DocumentPeriodEndDate_c20220101__20221231_zQgpoNBaovNb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-size: 12pt; text-align: left"><b><span id="xdx_906_edei--DocumentTransitionReport_c20220101__20221231_zPBBIwHAFJnb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commission
File Number <span id="xdx_908_edei--EntityFileNumber_c20220101__20221231_zq9GFAkoT9Yb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-36019</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span id="xdx_90C_edei--EntityRegistrantName_c20220101__20221231_zPUHckEhilRe"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">TONIX
PHARMACEUTICALS HOLDING CORP.</ix:nonNumeric></span></b></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zWLNkNeT7b96"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20220101__20221231_zEkLjOYJWeg9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">26-1434750</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other
        jurisdiction of incorporation&#160;or organization)&#160;&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer
        Identification No.)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20220101__20221231_zWJIeVuet6ea"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">26
        Main Street</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20220101__20221231_zJhCInhVYFHg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite 101</ix:nonNumeric></span></b>&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20220101__20221231_zLe3l5YTQAmg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Chatham</ix:nonNumeric></span>,
        <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20220101__20221231_zRYkPwmRdvbi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span></b>&#160;&#160;</span></p></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressPostalZipCode_c20220101__20221231_z18vKiLkdbEi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">07928</ix:nonNumeric></span>
        </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of
        principal executive office)</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="white-space: nowrap">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_906_edei--CityAreaCode_c20220101__20221231_zsiyquuiutRk" title="City area code"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">(862)</ix:nonNumeric></span>
        <span id="xdx_904_edei--LocalPhoneNumber_c20220101__20221231_zSrA7Khz6zQ8" title="Local phone number"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">799-8599</ix:nonNumeric></span></b>&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Registrant&#8217;s
        telephone number,&#160;including area code)</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
        of each class</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;
        <b>Trading Symbol</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
        of each exchange on which registered</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20220101__20221231_zSwiXPH42cY9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common
        Stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20220101__20221231_zVLHqteGwuAb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">TNXP</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_906_edei--SecurityExchangeName_c20220101__20221231_zGgi5b6hfzel"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>
        Stock Market LLC</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(g) of the Act:&#160;&#160;None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. Yes&#160;&#9744;&#160;&#160;&#160;
<span id="xdx_90E_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_zIds3Cepmaok"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes&#160;&#9744;&#160;&#160;&#160;
<span id="xdx_90D_edei--EntityVoluntaryFilers_c20220101__20221231_znkKwzTzHAj"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90A_edei--EntityCurrentReportingStatus_c20220101__20221231_zJ2COR8AMrfc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;&#160;&#160;
No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167; 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90A_edei--EntityInteractiveDataCurrent_c20220101__20221231_zR7JehC2Xf8e"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;&#160;&#160;
No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and an &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer&#160;&#9744;</span></td>
    <td style="width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Accelerated filer&#160;&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityFilerCategory_c20220101__20221231_zbrSwOva0OTk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
        filer</ix:nonNumeric></span>&#160;&#9746;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Smaller reporting company&#160;<span id="xdx_904_edei--EntitySmallBusiness_c20220101__20221231_zlHrBEMJTse1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Emerging growth company&#160;<span id="xdx_903_edei--EntityEmergingGrowthCompany_c20220101__20221231_zGGeDnIRFAw"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of
its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public
accounting firm that prepared or issued its audit report. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#9744;&#160;<span id="xdx_90B_edei--EntityShellCompany_c20220101__20221231_zd2J4JDLt6m7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
aggregate market value of the voting common equity held by non-affiliates as of June 30, 2022, based on the closing sales price of the
common stock as quoted on The NASDAQ Global Market was $<span id="xdx_905_edei--EntityPublicFloat_iI_c20220630_z26L8qRWxxIh" title="Entity public float"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,022,154</ix:nonFraction></span>.
For purposes of this computation, all officers and directors are deemed to be affiliates. Such determination should not be deemed an admission
that such directors, officers, or 5 percent beneficial owners are, in fact, affiliates of the registrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of March 13, 2023, there were <span style="color: #333333"><span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_pid_uShares_c20230313_z5J1hNQOK0N2" title="Entity common stock, shares outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-13" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,539,497</ix:nonFraction></span>
</span>shares of registrant&#8217;s common stock outstanding.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><a href="#tnxp10ka001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I</b></span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved
        Staff Comments</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety
        Disclosures</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II</b></span></a></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for
        Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
        Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative
        and Qualitative Disclosures about Market Risk</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: top"><a href="#tnxp10ka013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
        8.</span></a></td>
    <td style="white-space: nowrap; vertical-align: top"><a href="#tnxp10ka013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
        Statements and Supplementary Data</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right">
        <p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1 &#8211; F-24</span></p> </td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in
        and Disagreements with Accountants on Accounting and Financial Disclosures</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls
        and Procedures</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
        Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART III</b></span></a></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
        Executive Officers and Corporate Governance</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
        Compensation</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
        Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships
        and Related Transactions, and Director Independence</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
        Accounting Fees and Services</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</span></a></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><a href="#tnxp10ka025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></a></td>
    <td style="vertical-align: top"><a href="#tnxp10ka025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits,
        Financial Statement Schedules</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><a href="#tnxp10ka026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka002"></span>ITEM
1 - BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">This
Annual Report on Form 10-K (including the section regarding Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations) contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words
such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221;
&#8220;estimates&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are
not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this Annual Report on Form 10-K.&#160;Additionally,
statements concerning future matters are forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Although
forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our Management, such statements can only
be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties
and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking
statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically
addressed under the heading &#8220;Risks Factors&#8221; below, as well as those discussed elsewhere in this Annual Report on Form 10-K.
Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report
on Form 10-K. We file reports with the Securities and Exchange Commission (&#8220;SEC&#8221;). You can read and copy any materials we
file or will file with the SEC, which, among other places, can be found on the SEC&#8217;s website at http://www.sec.gov, as well as on
our corporate website at www.tonixpharma.com).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise
after the date of this Annual Report on Form 10-K. Readers are urged to carefully review and consider the various disclosures made throughout
the entirety of this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business,
financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Tonix
Pharmaceuticals<sup>&#174;</sup>, Tonmya<sup>&#174;</sup>, Protectic&#8482;, Angstro-Technology&#8482; and other trademarks and intellectual
property of ours appearing in this report are our property. This report contains additional trade names and trademarks of other companies.
We do not intend our use or display of other companies&#8217;&#160;trade names or trademarks to imply an endorsement or sponsorship of
us by such companies, or any relationship with any of these companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>Business
Overview </b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. We have a rich pipeline
of products in development that has been curated from internal discovery, as well as licenses, acquisitions and collaborations with academic
institutions and contract research organizations. We continue to build capabilities in synthetic biology, precision medicine, protein
engineering, medicinal chemistry, molecular biology, pharmacogenomics and clinical-scale manufacturing. Our therapeutics under development
include both small molecules and biologics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our portfolio consists of central nervous system, or CNS, rare disease,
immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic,
psychiatric and addiction conditions. Our rare disease portfolio focuses on developing novel therapies for patients with rare diseases,
including those caused by genetic disorders which are characterized by complex symptoms and for which no drug is approved. Our immunology
portfolio includes biologics to address organ transplant rejection, autoimmune diseases and cancer. Our infectious disease portfolio includes
a vaccine in development to prevent smallpox and mpox (formerly known as monkeypox), next-generation vaccines to prevent COVID-19, a platform
to make fully human monoclonal antibodies, or mAbs, to treat COVID-19 and humanized anti-SARS-CoV-2 mAbs. Our vaccine in development to
prevent smallpox and mpox also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
latest stage CNS product candidate is TNX-102 SL*, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for
bedtime administration. TNX-102 SL has active INDs for fibromyalgia, or FM, FM-type Long COVID or PASC (post-acute sequelae of
SARS-CoV-2 infection), posttraumatic stress disorder, or PTSD, agitation in Alzheimer&#8217;s disease, or AAD, and alcohol use
disorder, or AUD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-102
SL is in mid-Phase 3 development for the management of FM, a pain disorder characterized by chronic widespread pain, non-restorative
sleep, fatigue and impaired cognition. In December 2020, we reported positive results from the Phase 3 RELIEF study of TNX-102 SL
5.6 mg for the management of FM. In July 2021, we reported pre-planned interim analysis results from a second Phase 3 study, RALLY.
Based on the recommendation from the independent data monitoring committee (IDMC) that the RALLY trial was unlikely to demonstrate a
statistically significant improvement in the primary endpoint, we stopped enrollment of new participants but allowed those
participants who were already enrolled to complete the study. We reported topline data from the completed study in March of 2022. As
expected, based on interim analysis results, TNX-102 SL did not achieve statistical significance over placebo on the primary endpoint
of reduction in daily pain, and relative to the previous positive Phase 3 Study (RELIEF), RALLY had an unexpected increase in study
participant adverse event-related discontinuations in both drug and placebo groups. In April 2022, we started a new potentially
confirmatory Phase 3 study of TNX-102 SL in FM, RESILIENT. Interim analysis results are expected in the second quarter of 2023 and
topline results are expected in the fourth quarter of 2023. Following a positive outcome of the RESILIENT study, Tonix believes we
would be positioned to file a New Drug Application (NDA) for TNX-102 SL for the management of FM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-102 SL is also
being developed as a potential treatment for a type of Long COVID, the symptoms of which overlap with FM, that we term FM-type
Long COVID. We initiated enrollment in the Phase 2 study PREVAIL, in August 2022. The primary endpoint is a change in daily pain
scores from baseline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For TNX-102 SL in PTSD,
we completed the Phase 3 RECOVERY trial and reported topline results in the fourth quarter of 2020 in which TNX-102 SL did not
meet the primary efficacy endpoint. PTSD is a serious psychiatric condition that develops in response to experiencing a traumatic
event. We subsequently completed a meeting with the FDA to discuss potential new endpoints going forward for the indication of
treatment of PTSD. Future studies will employ the one month look-back CAPS-5 as the primary endpoint rather than the one week look-back
as used in prior studies.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
AAD program is Phase 2 ready with an active IND and FDA Fast Track designation. AAD, which includes emotional lability, restlessness,
irritability, and aggression, is one of the most distressing and debilitating of the behavioral complications of Alzheimer&#8217;s disease.
Tonix does not have any near-term plans to start a Phase 2 study in AAD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
AUD program is also Phase 2 ready with an active IND. AUD is a chronic relapsing brain disease characterized by compulsive alcohol use,
loss of control over alcohol intake, and a negative emotional state when not using alcohol. Tonix does not have any near-term plans to
start a Phase 2 study in AUD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-1900* (intranasal
potentiated oxytocin) is in development for the treatment of chronic migraine and obesity-associated binge eating disorder, or BED.
TNX-1900 was acquired from Trigemina, Inc. and licensed from Stanford University in 2020. The potentiated formulation includes
magnesium, which has been shown in animal studies to potentiate binding of oxytocin to the oxytocin receptor. We received IND
clearance from the FDA in the fourth quarter of 2021 to study TNX-1900 in chronic migraine and we initiated a Phase 2 study in
migraine in the first quarter of 2023. We expect interim analysis results from the first 50 percent of patients enrolled in the
fourth quarter of 2023. In March 2022, we announced an agreement with Massachusetts General Hospital, a teaching hospital of Harvard
Medical School, to conduct an investigator-initiated Phase 2 clinical trial to study TNX-1900 in BED. The Phase 2 clinical trial is
expected to start in the second quarter of 2023. We do not own an IND for BED. We also licensed technology to use TNX-1900 for the
treatment of insulin resistance from the University of Geneva and also have rights to develop it as a treatment for craniofacial
pain, but we are not imminently pursuing clinical trials in either of these indications at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-601 ER* (tianeptine hemioxalate extended-release tablets) is a CNS
product candidate in development as a treatment for major depressive disorder, or depression, and with possible additional indications
of PTSD, and neurocognitive dysfunction associated with corticosteroid use. TNX-601 ER represents a novel approach to treating depression
in the U.S., since the active ingredient tianeptine induces a neuroprotective and resilient phenotype in both neurons and microglia under
conditions of stress in animals. The dramatic and unique effects of tianeptine are illustrated in animal models by the restoration of
dendritic arborization of pyramidal neurons of CA3 region of hippocampus and the dentate gyrus region new neuron formation and integration
into hippocampal networks. In contrast, antidepressants that are marketed in the U.S. act by modulating the levels or receptor binding
of neurotransmitters in the synapse. We have completed a Phase 1 trial for formulation development outside of the U.S. We expect to initiate
a potentially pivotal Phase 2 study in the first quarter of 2023 for the treatment of major depressive disorder and we expect interim
analysis results from the first 50 percent of patients enrolled in the fourth quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Another CNS candidate in development
is TNX-1300* (double-mutant cocaine esterase) which is in Phase 2 for the treatment of life-threatening cocaine intoxication. TNX-1300
has been granted Breakthrough Therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA. TNX-1300 was licensed from
Columbia University in 2019 after a Phase 2 study showed that it rapidly and efficiently disintegrates cocaine in the blood of volunteers
who received intravenous, or i.v., cocaine. In August of 2022, we received a Federal Grant from the National Institute on Drug Abuse (NIDA)
to advance the development of TNX-1300 as a treatment for cocaine intoxication. We expect to initiate a potentially pivotal Phase 2 study
of TNX-1300 in emergency rooms in the second quarter of 2023.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Finally,
our CNS pipeline includes TNX-1600*, an inhibitor of the reuptake of neurotransmitters serotonin, norepinephrine and dopamine, or a triple
reuptake inhibitor. TNX-1600 was licensed from Wayne State University in 2019 and is expected to be developed as a treatment for PTSD,
depression and attention-deficit/hyperactivity disorder, or ADHD. TNX-1600 is in the preclinical stage of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our rare disease portfolio
consists of TNX-2900*, another magnesium-potentiated intranasal oxytocin-based therapeutic in development for the treatment of Prader-Willi
syndrome, or PWS. The technology for TNX-2900 was licensed from Inserm, the French National Institute of Health and Medical Research.
PWS, an orphan condition, is a rare genetic disorder of failure to thrive in infancy, associated with uncontrolled appetite beginning
in childhood with complications of obesity and diabetes. We have sponsored a research program at Inserm to study oxytocin on suckling
behavior in mice that have been engineered to express one of the Prader-Willi genes. TNX-2900 has been granted Orphan-Drug Designation
for the treatment of PWS and is in the pre-IND stage of development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead candidate
in the immunology pipeline is TNX-1500*, a humanized mAb, directed against CD40-ligand, or CD40L (also
known as CD154), engineered to modulate binding to Fc receptors, that is being developed as a prophylaxis against organ transplant
rejection as well as to treat autoimmune conditions. In experiments at the Massachusetts General Hospital or MGH, a teaching hospital
of Harvard Medical School, TNX-1500 is being studied as monotherapy or in combination with other immunosuppressive agents in heart
and kidney allogeneic organ transplants in non-human primates. Preliminary results from ongoing experiments in kidney and heart
transplants indicate that TNX-1500 appears to have comparable efficacy to historical experiments using the chimeric mouse/human
IgG1 version (5c8H1) of the anti-CD40L mAb 5c8. First generation anti-CD40L mAb therapies were associated with an increased risk
of blood clots or thrombosis. In the non-human primate studies with TNX-1500 for the prevention of rejection in allogeneic organ
transplants, no evidence of thrombosis has been observed so far. We expect to start a Phase 1 study of TNX-1500 in the second quarter
of 2023. TNX-1500 also is being studied in combination with other immunosuppressive agents in xenogeneic organ transplants in non-human
primates at MGH and at the University of Maryland at Baltimore or UMB. In experiments at UMB, TNX-1500 is being studied to prevent
rejection of xenogeneic hearts from genetically engineered pigs developed by the Revivicor division of United Therapeutics Corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our immunology pipeline
also includes TNX-1700*, a recombinant Trefoil Factor Family 2, or rTFF2, fusion protein that was licensed from Columbia University
in 2019. TNX-1700 consists of TFF2 fused to human serum albumin or HSA and is a biologic being developed to treat gastric and colorectal
cancers by an immune-oncology mechanism, in combination with PD1 blockers, and is in the preclinical stage of development. We recently
presented data that show a murine version of TNX-1700 consisting of a fusion protein with murine serum albumin or MSA was able
to evoke anti-tumor immunity in the MC38 mouse model of colorectal cancer as monotherapy and that TNX-1700 augmented the efficacy
of anti-PD1 therapy in both the MC38 model and the CT26.wt mouse models of colorectal cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our infectious disease
portfolio includes vaccines based on our live virus vaccine or recombinant pox vaccine, &#8220;RPV&#8221; platform. Live virus
vaccines are believed to protect against poor clinical outcomes of infectious diseases by eliciting T cell responses in addition
to antibody responses. TNX-801*, a live attenuated vaccine based on synthesized horsepox, is in the pre-IND stage of development
to protect against smallpox and mpox. Non-human primates vaccinated with TNX-801 were protected from mpox in studies reported in
the first quarter of 2020.&#160;A Phase 1 study of TNX-801 in humans is expected to start in the second half of 2023. TNX-801 also
serves as the live virus vaccine platform for other infectious diseases for which subsequent products will be designed by expressing
other viral antigens in the horsepox vector.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-1850* is a live
virus vaccine that expresses the SARS-CoV-2 spike protein from the BA.2 strain that has not yet been tested in animals. TNX-1800*
is a live virus vaccine that expresses the SARS-CoV-2 spike protein from the ancestral Wuhan strain, which has shown encouraging
results in non-human primates. Because the subsequent omicron variant out-competed the ancestral Wuhan strain, we began work on
new vaccine versions, TNX-1840* and TNX-1850*, that are designed to express spike protein from the omicron variant and from the
BA.2 variant, respectively. Of those, based on the trajectory of COVID-19, the focus is now on TNX-1850. The COVID-19 vaccines
that are approved for use, or have emergency use authorization, or EUA, in the U.S. have provided significant health benefits to
the vaccinated population; however, they have shown limitations in the durability of protection conferred and in their ability
to block forward transmission. Live virus vaccines that protect against other viral diseases by eliciting T cell responses have
shown durability of protection that lasts years to decades and some live virus vaccines have significantly inhibited forward transmission.
With respect to TNX-1800 vaccination, we reported positive efficacy data from animal challenge studies using live SARS-CoV-2 in
the first quarter of 2021. In this study, TNX-1800 vaccinated, SARS-CoV-2 challenged animals had undetectable SARS-CoV-2 in the
upper airways, which we believe relates to potential inhibition of forward transmission of this respiratory pathogen.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-2300* is a live
virus vaccine based on bovine parainfluenza virus in development to protect against COVID-19. In April 2022, Tonix extended a sponsored
research agreement with Kansas State University to develop a vaccine candidate, TNX-2300, for the prevention of COVID-19 that utilizes
a novel live virus vaccine vector platform based on bovine parainfluenza virus. The efficacy of co-expression of the CD40-ligand,
also known as CD154, to stimulate T cell immunity will also be tested. Attenuated bovine parainfluenza virus has previously been
shown to be an effective antigen delivery vector in humans. Previous work by others has shown that attenuated BPI3V is well tolerated
and immunogenic in non-human primates and human infants and children. We believe the vector is well suited for mucosal immunization
using a nasal atomizer, and can also be delivered parenterally. TNX-2300 is in the preclinical stage of development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-3600* and TNX-3800*
are mAbs directed against SARS-CoV-2 which are in development as potential therapeutic or preventative agents for COVID-19. Given
the unpredictable trajectory of the SARS-CoV-2 virus and new variants, we seek to contribute a broad set of anti-SARS-CoV-2 mAbs,
that can be scaled up quickly and potentially combined with other mAbs. We envision the future of mAb therapy for COVID-19 to be
cocktails of mAbs with specificity to variants of concern.&#160; TNX-3600 refers to a series of fully human mAbs generated by
human-human hybridomas from COVID-19 convalescent volunteers. We are collaborating with Columbia University to produce these fully
human mAbs to SARS-CoV-2 spike proteins from variants such as delta, omicron and XBB1.5 and to other viral targets. TNX-3800 refers
to three humanized murine mAbs which we licensed exclusively in December 2022 from Curia Global, Inc. for the treatment or prophylaxis
of SARS-CoV-2 infection. The initial focus is to develop COVID-19 therapeutic mAbs. We plan to seek indications similar to previously
EUA-approved therapeutic mAbs for treating individuals with mild-to-moderate COVID-19 who are at high risk for progression to severe
disease or for prophylaxis in individuals with compromised immune systems who are at high risk for severe COVID-19 disease.
None of the previously EUA-approved therapeutic or preventative mAbs are still available, because each has become obsolete since
the SARS-CoV-2 virus has mutated to evade their binding. TNX-3600 and TNX-3800 mAbs may also be used in combination therapy with
other COVID-19 therapeutic mAbs. Combination therapies with other anti-SARS-CoV-2 mAbs may reduce the emergence of resistant viral
strains. TNX-3600 and TNX-3800 are in the preclinical stage of development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-3700* is a COVID-19
mRNA vaccine candidate employing a zinc nanoparticle (ZNP) formulation. In collaboration with Kansas State University, we are developing
this ZNP technology as a potential replacement for the lipid nanoparticle (LNP) technology used in current mRNA vaccines. ZNP technology
potentially allows for improved stability which facilitates shipping and storage and addresses the limitations in current mRNA
vaccines which require ultra-cold storage and shipping. This current requirement limits the use of mRNA vaccines in less developed
countries. We plan to seek initial indications as a booster, similar to the current FDA approved mRNA vaccines for COVID-19. We
intend to conduct research with Kansas State University on ZNP SARS-CoV-2 spike based vaccines in tissue culture and animals in
the first half of 2023. TNX-3700 is in the preclinical stage of development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Relating to our COVID-19 and other infectious disease development programs,
we are developing the resources necessary to enable internal research, development and manufacturing capabilities necessary to meet the
goal of producing new vaccine candidates within 100 days of recognition within weeks of obtaining sequence information from a novel pathogen.
We seek to be a leader in the movement to re-build domestic U.S. research, development and manufacturing capabilities. Because this movement
follows a protracted period when domestic research, development and manufacturing were moved out of the U.S., or &#8220;off-shore&#8221;
by other companies to save on labor and other costs, the movement to reverse that trend has been described as &#8220;on-shoring&#8221;
or &#8220;re-domestication&#8221;. The COVID-19 pandemic taught that national borders may close during a health emergency. Therefore,
domestic capabilities are essential for the health security of the U.S., which has also been described as pandemic preparedness and biodefense.
As articulated in the American Pandemic Preparedness Plan, or AP3, released by the U.S. Office of Science and Technology Policy, this
100-day goal for vaccines is a key component of preparedness for future pandemics. We believe we have established the infrastructure necessary
to support the pandemic preparedness goals established in the AP3, specifically with respect to our RPV vaccine and potentially to other
vaccine and therapeutic platforms. This infrastructure consists of (i) our R&amp;D Center, or &#8220;RDC&#8221;, (ii) our Advanced Development
Center, or &#8220;ADC&#8221;, and (iii) our Commercial Manufacturing Center, or &#8220;CMC&#8221;. We acquired the RDC in Frederick, Maryland
consisting of one building totaling approximately 48,000 square feet. The acquisition closed in October 2021 and the facility is operational.
The RDC facility focuses on our development of vaccines and antiviral drugs against SARS-CoV-2, its variants, and other infectious diseases.
The RDC also conducts research on central nervous systema and immunology drugs. The RDC facility is mostly biosafety level 2 (BSL-2),
with some components designated BSL-3. We completed the substantial renovation of the ADC located in the New Bedford business park in
Dartmouth, Massachusetts, which became operational as of the fourth quarter 2022. This approximately 45,000 square foot BSL-2 facility
is intended to accelerate development and clinical scale manufacturing of live-virus vaccines and biologics to support clinical trials.
We also plan to build the CMC in Hamilton, Montana, where we purchased approximately 44 acres of land and have built a field office to
manage construction of the facility. The CMC will focus on developing and manufacturing commercial scale live-virus vaccines and biologics
and is also intended to be BSL-2. Site enabling work is expected to be initiated for the CMC in 2023.&#160;Together, we expect these facilities
may qualify the RPV vaccine platform for programs that are designed to carry out the goals of AP3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">*All
of our product candidates are investigational new drugs or biologics and have not been approved for any indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are led by a management team with significant industry experience in drug development. We complement our management team with a network
of scientific, clinical, and regulatory advisors that includes recognized experts in their respective fields.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We were incorporated on November 16, 2007 under the laws of the State of
Nevada as Tamandare Explorations Inc. On October 11, 2011, we changed our name to Tonix Pharmaceuticals Holding Corp. Our common stock
is listed on The NASDAQ Capital Market under the symbol &#8220;TNXP&#8221;. Our principal executive offices are located at 26 Main Street,
Suite 101, Chatham, New Jersey 07928, and our telephone number is (862) 799-8599. Our website address is&#160;www.tonixpharma.com.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
strategy is to use our integrated development engine to advance innovative programs across multiple therapeutic areas into the clinic
while maximizing asset potential, with the objective of developing and commercializing our product candidates. The principal components
of our strategy are to:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pursue
        CNS, rare disease, immunology, and infectious disease indications with high unmet medical need and significant commercial potential. </i></b>Within
        the therapeutic areas that Tonix is focusing on, we are pursuing multiple indications that are underserved with limited, effective
        treatment options. One of our latest stage product candidates, TNX-102 SL for the management of FM, a condition which affects
        between 6-12 million adults in the U.S. and fewer than half of those treated for FM receive relief from the three FDA-approved
        drugs.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We are also pursuing a treatment using TNX-102 SL for FM-type Long COVID,
a condition for which there is no currently approved therapy. Our broader development strategy is to leverage the patented formulation
and proven mechanism of action to explore the clinical potential of TNX-102 SL in multiple other, psychiatric, and addiction conditions,
including PTSD, Agitation in Alzheimer&#8217;s disease and Alcohol Use Disorder (AUD), all of which are underserved by currently approved
medications or have no approved treatment thus representing large unmet medical needs. Within CNS, Tonix is also developing TNX-1900 to
treat chronic migraine, TNX-601 ER to treat major depressive disorder and TNX-1300 to treat cocaine intoxication. Although a number of
drugs are approved for chronic migraine and major depressive disorder, there remains dissatisfaction with available options. Cocaine intoxication
is one of the leading causes of overdose deaths and for which there is no currently approved drug. With TNX-1500, we are pursuing a treatment
to prevent organ transplant rejection as well as autoimmune conditions. TNX-1500 is a third generation humanized mAb targeting the CD40L
that has the potential to deliver efficacy without compromising safety, based on modulated binding to Fc receptors. At this time, no mAb
against CD40L has been licensed anywhere in the world. Within infectious diseases, we are currently focusing on the development of TNX-801
to prevent smallpox and mpox, and TNX-1850 to protect against COVID-19. While there are FDA-approved vaccines to prevent smallpox and
mpox, we believe TNX-801 has potential to provide durable protection. While there are FDA-approved COVID-19 vaccines which use mRNA technology,
or other technologies, we believe that there are limitations to these vaccines relating to durability of protection and their relative
inability to block forward transmission.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Maximize the commercial potential
        of our lead product candidates</i></b>. We plan to commercialize each of our lead product candidates, including our latest stage candidate,
        TNX-102 SL, either on our own or through collaboration with partners. We believe our lead candidates can be marketed to U.S. physicians
        either by an internal sales force that we would build or by a contract sales organization, which we would engage. An alternative strategy
        would be to enter into partnership agreements with drug companies that already have significant marketing capabilities in the same, or
        similar, therapeutic areas. If we determine that such a strategy would be more favorable than developing our own sales capabilities, we
        would seek to enter into collaborations with pharmaceutical or biotechnology companies for commercialization.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursue a broad intellectual
        property strategy to protect our product candidates</i></b>. We are pursuing a broad patent strategy for our product candidates, and we
        endeavor to generate new patent applications as supported by our innovations and conceptions as well as to advance their prosecution.
        In the case of TNX-102 SL, we own patents and patent applications protecting its composition-of-matter, certain methods of its use, its
        formulation, and its pharmacokinetic properties. In the case of TNX-801 and TNX-1850, we own patent applications protecting their composition-of-matter
        and certain methods of use. We also own patents through in-licensing transactions for TNX-1300, TNX-1900, TNX-2900, and TNX-1700. We own
        patents outright for TNX-601 ER and have filed patent applications for TNX-1500 and TNX-3700. We plan to opportunistically apply for new
        patents to protect our product candidates. </span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pursue
        additional indications and commercial opportunities for our product candidates.</i></b> We will seek to maximize the value of our other
        product candidates by pursuing other indications and commercial opportunities for such candidates. For example, we own rights related
        to the development and commercialization of TNX-102 SL for generalized anxiety disorder, depression, and fatigue related to disordered
        sleep. For TNX-1900, we own the rights to develop this for craniofacial pain, episodic migraine, acute migraine and insulin resistance,
        in addition to chronic migraine. For TNX-601 ER, we own the rights to develop this for PTSD and neurocognitive disorder from corticosteroid
        use, in addition to major depressive disorder. Finally, our live virus platform using our RPV technology may be developed as vaccines
        for future pandemics, infectious diseases generally and oncology, in addition to smallpox and mpox.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Disease
and Market Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
product candidates address disorders that are not well served by currently available therapies or have no approved treatment which represent
large potential commercial market opportunities. Background information on the disorders and related commercial markets that may be addressed
by our product candidates in or nearing the clinical-stage is set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Central
Nervous System</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fibromyalgia
(FM)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">FM
is a chronic syndrome characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. The peak
incidence of FM occurs between 20-50 years of age, and 80-90% of diagnosed patients are female. FM may have a substantial negative impact
on social and occupational function, including disrupted relationships with family and friends, social isolation, reduced activities of
daily living and leisure activities, avoidance of physical activity, and loss of career or inability to advance in career or education.&#160;
According to the American Chronic Pain Association, an estimated six to twelve million adults in the U.S. have FM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to a report by Frost and Sullivan that we commissioned, despite the availability of approved medications, the majority of patients fail
therapy due to either insufficient efficacy, poor tolerability, or both. Prescription pain and sleep medications are frequently prescribed
off-label for symptomatic relief, despite the lack of evidence that such medications provide a meaningful or durable therapeutic benefit,
and many of these medications carry significant safety risks and risk of dependence. For example, approximately 30% of patients diagnosed
with FM take chronic opioids, despite the lack of evidence for their effectiveness and the risk of addiction and toxicity, including overdose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Long
COVID</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Long COVID, or PASC, is a condition that some survivors of COVID-19 infection
experience in varying degrees of severity. It is a chronic disabling condition that is expected to result in a significant global health
and economic burden. We are focusing development of TNX-102 SL on FM-type Long COVID. The symptoms include intense fatigue, sleep
problems, multi-site pain, and cognitive issues (&#8220;brain fog&#8221;). The proposed indication is for the management of multi-site
pain associated with PASC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Post
infection, many patients experience one or many of the symptoms of Long COVID: some patients have initial symptoms that become prolonged;
others manifest entirely new syndromes that impact more than one system or organ. According to a 2021 publication in the Journal of American
Medical Association (JAMA), over 1 in 10 healthcare workers who had recovered from COVID-19 were still coping with at least one moderate
to severe symptom eight months later. Research shows that Long COVID occurs in approximately 13% of recovered COVID-19 patients. There
is currently no approved drug for the treatment of Long COVID.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Migraine
Headaches </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Migraine
is a primary headache disorder characterized by recurrent headaches that are moderate to severe. Typically, episodes affect one side of
the head, are pulsating in nature, and last from a few hours to three days. Associated symptoms may include nausea, vomiting, and sensitivity
to light, sound, or smell. The pain is generally made worse by physical activity, although regular exercise may have prophylactic effects.
Up to one-third of people affected have aura, typically a short period of visual disturbance that signals that the headache will soon
occur. Occasionally, aura can occur with little or no headache following it. Approximately one billion individuals worldwide suffer from
migraine (~14% of the population). Migraine is the second leading cause of years lived with disability. Chronic migraine (&#8805; 15 headache/migraine
days per month) affects about 1-2% of individuals (~75-150 million individuals worldwide; 3-7 million in the U.S.). CGRP antibodies are
the only migraine specific prophylaxis drugs approved in decades, but they require parenteral administration and there are long term safety
concerns with prolonged systemic blockade of CGRP or its receptor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Major
Depressive Disorder</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Substance Abuse and Mental Health Services Administration,
an estimated 21.0 million adults in the U.S. in 2020 experienced at least one major depressive episode, representing 8.4% of all U.S.
adults. <span style="font-family: Times New Roman, Times, Serif">According
to the National Institute of Mental Health, depression affects approximately 17 million adults in the U.S., with approximately 2.5 million
adults treated with adjunctive therapy. Depression is a condition characterized by symptoms such as a depressed mood or loss of interest
or pleasure in daily activities most of the time for two weeks or more, accompanied by appetite changes, sleep disturbances, motor restlessness
or retardation, loss of energy, feelings of worthlessness or excessive guilt, poor concentration, and suicidal thoughts and behaviors.
These symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The
majority of people who suffer from depression do not respond adequately to initial antidepressant therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cocaine
Intoxication</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cocaine is an illegal
recreational drug taken for its pleasurable effects and associated euphoria. Pharmacologically, cocaine blocks the reuptake of the
neurotransmitter dopamine from central nervous system synapses, resulting in the accumulation of dopamine within the synapse and an
amplification of dopamine signaling that is related to its role in creating positive feeling. With the continued use of cocaine,
however, intense cocaine cravings occur resulting in a high potential for abuse and addiction, or dependence, as well as the risk of
cocaine intoxication. Cocaine intoxication refers to the deleterious effects on other parts of the body, especially those involving
the cardiovascular system.&#160; Common symptoms of cocaine intoxication include tachyarrhythmias and elevated blood pressure,
either of which can be life-threatening.&#160; As a result, individuals with known or suspected cocaine intoxication are sent
immediately to the emergency department, preferably by ambulance in case cardiac arrest occurs during transit.&#160; There are
approximately 505,000 emergency room visits for cocaine abuse each year in the U.S., of which 61,000 require detoxification
services.&#160;According to the National Institute on Drug Abuse, cocaine-involved deaths rose nearly 54% from 2019 to 2021,
resulting in over 24,486 deaths total.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Posttraumatic Stress Disorder, or PTSD</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">PTSD is a chronic condition that
may develop after a person is exposed to one or more traumatic events, such as warfare, sexual assault, serious injury, or threat of imminent
death. The core symptom clusters of PTSD are avoidance, emotional numbing, hyperarousal, and intrusion, where the triggering traumatic
event is commonly re-experienced by the individual through intrusive, recurrent recollections, flashbacks, and nightmares. People with
PTSD suffer significant impairment in their daily functioning, including occupational activities and social relations, and are at elevated
risk for impulsive violent behaviors toward others and themselves, including suicide. Of those who experience a significant trauma, approximately
20% of women and 8% of men develop PTSD. An estimated 12 million adults annually in the U.S. suffer from PTSD. According to the U.S. Department
of Veterans Affairs, the prevalence rate of PTSD in the military population is higher than that among civilians.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Many patients fail to adequately
respond to the medications approved for PTSD and approved medications show little evidence of a treatment effect in men, lack evidence
of efficacy in those for whom the traumatic event was combat-related, and carry suicidality warnings. Sleep disturbances are central features
of PTSD and are predictive of disease severity, depression, substance abuse, and suicidal ideation, yet are resistant to the approved
medications and present a difficult therapeutic challenge. Current PTSD treatments include off-label use of anxiolytics, sedative-hypnotics,
and antipsychotics, many of which lack reliable evidence of efficacy, and several have significant safety liabilities and dependence risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Rare
Disease</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Prader-Willi
Syndrome</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Prader-Willi
syndrome (PWS) is recognized as the most common genetic cause of life-threatening childhood obesity and affects males and females
with equal frequency and all races and ethnicities. The hallmarks of PWS are lack of suckling in infants and, in children and
adults, severe hyperphagia, an overriding physiological drive to eat, leading to severe obesity and other complications associated
with significant morbidity and mortality. PWS is an orphan disease that occurs in approximately one in 15,000 births. There is
currently no approved treatment for obesity and hyperphagia in adults and older children associated with PWS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Immunology</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Organ
Transplant Rejection</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Organ
transplant rejection occurs when the immune system of the organ recipient attacks the new organ as if it was an infection or tumor. Often
transplantation is the last resort for most end-stage organ failure patients, affecting either kidneys, liver, heart, lungs, and/or pancreas.
Genetic disparity between organ donor and recipient is often at the root of the rejection. Mismatched or not closely matched organs triggers
an immune reaction that leads to rejection. Overcoming this difficulty is paramount to a patient&#8217;s survival as organ donations are
in limited supply.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Gastric
and Colorectal cancers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Gastric or stomach cancer is a
disease in which malignant cancer cells line the inner lumen of the stomach. Development of this form of cancer is often influenced by
age, diet and other stomach diseases. This type of cancer begins to form in the mucosa, the surface of the lumen that is in direct contact
with the contents of the stomach, and spreads through the outer layers of the stomach as the tumor grows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, per the National Cancer
Institute, the 5-year relative survival for stomach cancer is 33.3%. According to 2017-2019 data, approximately 0.8 percent of men and
women will be diagnosed with stomach cancer during their lifetime. In 2019, there were an estimated 123,920 people living with stomach
cancer in the U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Colorectal cancer includes cancers
in the colon and the rectum, organs that are crucial to absorption of water by the body and the elimination of food-waste. Most colorectal
cancers start as a growth or polyp on the inner lining of the colon or rectum. Some types of polyps can change into cancer over time (usually
many years), but not all polyps become cancer. Adenomatous polyps are the ones that turn malignant with time. Similar to gastric cancer,
the malignancy begins in the mucosal layer and spreads outwards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The 5-year relative survival rate
is 65.1%, per the National Cancer Institute. According to 2017-2019 data, approximately 4.1 percent of men and women will be diagnosed
with colorectal cancer during their lifetime. In 2019, there were an estimated 1,369,005 people living with colorectal cancer in the United
States.&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Infectious
Diseases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Smallpox
and Mpox</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Smallpox is an acute contagious disease caused by the variola virus, or
VARV, which is a member of the orthopoxvirus family. Smallpox was declared eradicated in 1980 following a global immunization campaign.
Smallpox is transmitted from person to person by infective droplets during close contact with infected symptomatic people. Mpox is an
acute contagious disease caused by the monkeypox virus or MPXV, which is also a member of the orthopoxvirus family. Mpox symptoms are
similar to those of smallpox, although less severe. Mpox is emerging as an important zoonotic infection in humans in Central and West
Africa. Until 2022, only a few cases of mpox had been reported outside of Africa in patients who had been infected while in Africa. Starting
in May of 2022, mpox cases spread rapidly in the U.S. and other countries. More than 30,000 cases in the U.S. have been reported according
to the U.S. Centers for Disease Control and Prevention.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Smallpox was eradicated by a World
Health Organization program that vaccinated individuals with live replicating vaccinia vaccines wherever smallpox appeared. In the 1970s,
vaccination of civilians to protect against smallpox was discontinued in the U.S.; however, smallpox remains a material threat to national
security and a proportion of military personnel, including members of the Global Response Force continue to be vaccinated. Vaccines for
smallpox and mpox are stockpiled by the U.S. government in the strategic national stockpile and for potential widespread immunization
in the event of malicious reintroduction of VARV.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>COVID-19</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">SARS-CoV-2
is a contagious virus causing the disease COVID-19 that became a global pandemic in 2019 and has resulted in more than three million deaths.
While the infection and mortality rates have slowed in regions of the world with high vaccination rates, the struggle with the pathogen
is ongoing and evolving since SARS-CoV-2 is mutating into new variants. COVID-19 is characterized by fever, sore throat, acute shortness
of breath, cough, and oxygen desaturation in the blood. At least three major variants have swept across the world in successive waves
and overwhelmed healthcare systems during these waves. With new variants of the virus emerging, therapeutic research is addressing the
challenge of keeping up with this rapidly mutating virus. The early vaccines have been effective in limiting the severity of disease in
vaccinated individuals. Vaccines that elicit strong T cell responses are believed to have the potential to provide long-term or durable
protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Lead
Product Candidates </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that our product candidates offer innovative therapeutic approaches and may provide significant advantages relative to available
therapies. We have worldwide commercialization rights to all of our product candidates listed below. The following table summarizes our
later stage product candidates that are in or nearing the clinic:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
        Candidate</b></span></td>
    <td style="border-top: black 1pt solid; white-space: nowrap; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; width: 31%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indication</b></span></td>
    <td style="border-top: black 1pt solid; white-space: nowrap; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; width: 31%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stage
        of Development</b></span></td>
    <td style="border-top: black 1pt solid; white-space: nowrap; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNX-102 SL</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fibromyalgia</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mid-Phase 3, &gt;50% enrolled </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNX-102 SL</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FM-type Long COVID</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2 enrolling</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNX-1900</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic migraine</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2, enrolling</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNX-601 ER</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depression</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2, targeted 1Q 2023 start</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">TNX-1300</td>
    <td>&#160;</td>
    <td>Cocaine Intoxication</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Mid-Phase 2, targeted 2Q 2023 start</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNX-1500</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kidney Transplant Rejection </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1, targeted 2Q 2023 start
        </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNX-801</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smallpox and Mpox vaccine</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1, targeted 2H 2023 start
        </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNX-2900</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prader-Willi Syndrome </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">TNX-102
SL </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-102
SL, in clinical development for registration in five indications. TNX-102 SL is a proprietary sublingual tablet formulation of CBP that
efficiently delivers CBP across the oral mucosal membrane into the systemic circulation. We are developing TNX-102 SL as a bedtime treatment
for FM, PTSD, PASC or Long Covid, AAD and AUD. We own all rights to TNX-102 SL in all geographies, and we bear no obligations to third-parties
for any future development or commercialization. Excipients used in TNX-102 SL are approved for pharmaceutical use. Some of the excipients
were specially selected to promote a local oral environment that facilitates mucosal absorption of cyclobenzaprine or CBP.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
current TNX-102 SL sublingual tablets contain 2.8 mg of CBP. For the treatment of FM, TNX-102 SL 5.6 mg (two 2.8 mg tablets) at bedtime
is in Phase 3 development. We selected this dose with the goal of providing a balance of efficacy, safety, and tolerability that would
be acceptable as a first-line therapy and for long-term use, and in-patient populations characterized by burdensome symptoms and sensitivity
to medications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
active ingredient in TNX-102 SL, is CBP, a serotonin-2A and alpha-1 adrenergic receptor antagonist as well as an inhibitor of serotonin
and norepinephrine reuptake. In addition, TNX-102 SL acts upon other receptors in the central nervous system including muscarinic M1&#160;and
histaminergic H1&#160;receptors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">CBP
is the active ingredient of two products that are approved in the U.S. for the treatment of muscle spasm: Flexeril&#174;&#160;(5 mg and
10 mg oral immediate-release, or IR, tablet) and Amrix<sup>&#174;</sup>&#160;(15 mg and 30 mg oral extended-release capsule). The Flexeril
brand of CBP IR tablet has been discontinued since May 2013. There are numerous generic versions of CBP IR tablets on the market. CBP-containing
products are approved for short term use (two to three weeks) only as an adjunct to rest and physical therapy for relief of muscle spasm
associated with acute, painful musculoskeletal conditions. CBP IR tablets are recommended for three times per day dosing, which results
in relatively stable blood levels of CBP after several days of treatment. Extended-release CBP capsules taken once a day mimic, and flatten,
the pharmacokinetic profile of three times per day CBP IR tablets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
designed TNX-102 SL to be administered once-daily at bedtime and with the intention for long-term use. We believe the selected dose of
TNX-102 SL and its unique pharmacokinetic profile will enable it to achieve a desirable balance of efficacy, safety, and tolerability.
Our Phase 1 comparative trials showed that, on a dose-adjusted basis, TNX-102 SL results in faster systemic absorption and significantly
higher plasma levels of CBP in the first hour following sublingual administration relative to oral IR CBP tablets. It also showed that
the sublingual route of administration, which largely bypasses the &#8220;first pass&#8221; hepatic metabolism that swallowed medications
undergo, results in a higher plasma ratio of CBP to its main active metabolite, norcyclobenzaprine. In clinical studies, TNX-102 SL 2.8
mg and TNX-102 SL 5.6 mg were generally well-tolerated, with no drug-related serious and unexpected adverse reactions reported in these
studies. Some subjects experienced transient numbness of the tongue after TNX-102 SL administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have successfully completed
the pivotal exposure bridging study with TNX-102 SL compared to Amrix.&#160; Results from this study support the approval of TNX-102 SL
under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA, with Amrix as the reference listed drug, or RLD. In general,
the development timeline for a 505(b)(2) NDA is shorter and less expensive than an NDA developed under Section 505(b)(1), which is for
new chemical entities, or NCEs, that have never been approved in the U.S. We believe that TNX-102 SL has the potential to provide clinical
benefit to FM, Long COVID, and PTSD patients and possibly other CNS (central nervous system) indications that are underserved by currently
marketed products or have no approved treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-102
SL &#8211; FM program</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are developing TNX-102 SL as a bedtime treatment for FM under an active IND application. The potential approval of TNX-102 SL for FM is
expected to be under Section 505(b)(2) of the FDCA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Clinical
Development Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">Phase
3 RESILIENT (F307)&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The first patient was enrolled in the potentially pivotal Phase 3 RESILIENT
study in April 2022. The RESILIENT study is a double-blind, randomized, placebo-controlled adaptive design trial designed to evaluate
the efficacy and safety of TNX-102 SL in FM. The two-arm trial is expected to enroll approximately 470 participants in the U.S. and was
50% enrolled as of December 2022. The first two weeks of treatment consist of a run-in period in which participants start on TNX-102 SL
2.8 mg (1 tablet) or placebo. Thereafter, all participants increase their dose to TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) or two placebo
tablets for the remaining 12 weeks. The primary endpoint is the daily diary pain severity score change (TNX-102 SL 5.6 mg vs. placebo)
from baseline to Week 14 (using the weekly averages of the daily numerical rating scale scores), analyzed by mixed model repeated measures
with multiple imputation. An interim analysis by an IDMC will be conducted on the primary endpoint based on the first 50% of enrolled
participants for a potential sample size adjustment or early stop for futility. Interim data is expected in the second quarter of 2023.
Topline data is expected in the fourth quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">Completed
Phase 3 RALLY Study (F306)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We reported pre-planned interim analysis results from a Phase 3 study,
RALLY (F306), in July 2021. Based on the recommendation from the independent data monitoring committee that the RALLY trial was unlikely
to demonstrate a statistically significant improvement in the primary endpoint, we stopped enrollment of new participants but allowed
those participants who were already enrolled to complete the study. We reported topline data from the completed study in March of 2022.
As expected based on interim analysis results, TNX-102 SL did not achieve statistical significance over placebo on the primary endpoint
of reduction in daily pain, and relative to the previous positive Phase 3 Study (RELIEF), RALLY had an unexpected increase in study participant
adverse event-related discontinuations in both drug and placebo groups. The RALLY study was a double-blind, randomized, placebo-controlled
adaptive design trial intended to evaluate the efficacy and safety of TNX-102 SL in FM. The trial was expected to enroll approximately
670 patients across approximately 40 U.S. sites. For the first two weeks of treatment, there was a run-in period in which patients started
on TNX-102 SL 2.8 mg (1 tablet) or placebo. After the first two weeks, all patients had the dose increased to TNX-102 SL 5.6 mg (2 x 2.8
mg tablets) or two placebo tablets for 12 weeks. The primary endpoint was daily diary pain severity score change from baseline to Week
14 (using the weekly averages of the daily numerical rating scale scores), analyzed by mixed model repeated measures with multiple imputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">Completed
Phase 3 RELIEF Study (F304)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the fourth quarter of 2020, we announced the results of a randomized, double-blind, placebo-controlled, 12-week Phase 3 study of TNX-102
SL in 503 participants with FM, which we refer to as the RELIEF study. The primary objective of this study was to evaluate the potential
clinical benefit of using TNX-102 SL to treat FM at a dose of 5.6 mg, administered sublingually once daily at bedtime for 12 weeks. The
primary endpoint of the RELIEF trial was the daily diary pain severity score change from baseline to Week 14 (using the weekly averages
of the daily numerical rating scale scores), analyzed by mixed model repeated measures with multiple imputation. The RELIEF study achieved
statistical significance on the primary efficacy endpoint: change from baseline in the weekly average of daily diary pain severity numerical
rating scale (NRS) scores for TNX-102 SL 5.6 mg (LS mean [SE]: -1.9 [0.12] units) versus placebo (-1.5 [0.12] units), analyzed by mixed
model repeated measures with multiple imputation (LS mean [SE] difference: -0.4 [0.16] units, p=0.010).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
statistically significant improvement in pain is further substantiated when diary pain was analyzed by another standard statistical approach,
a 30 percent responder analysis, with 46.8% on active and 34.9% on placebo having a 30 percent or greater reduction in pain (logistic
regression; odds ratio [95% CI]: 1.67 [1.16, 2.40]; p=0.006). Consistent with the proposed mechanism that TNX-102 SL acts in fibromyalgia
through improving sleep quality, TNX-102 SL showed nominal improvement of sleep by several measures. For daily diary sleep quality ratings,
TNX-102 SL (-2.0 [0.12] units) compared to placebo (-1.5 [0.12] units) was nominally significant (LS mean difference: -0.6 [0.17] units;
p&lt;0.001). For the PROMIS Sleep Disturbance instrument, TNX-102 SL was also nominally significant over placebo on T-scores (LS mean
difference: -2.9 [0.82] units; p&lt;0.001). The effect sizes on the diary sleep ratings and PROMIS Sleep Disturbance instrument were 0.31
and 0.32, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In the RELIEF study, TNX-102 SL was similarly well tolerated as in the
Phase 2 BESTFIT and Phase 3 AFFIRM studies, which both studied TNX-102 SL at a lower dose of 2.8 mg daily. There were no new safety signals
observed in the RELIEF study at the 5.6 mg daily dose. Among participants randomized to the TNX-102 SL and placebo arms, 82.3% and 83.5%,
respectively, completed the 14-week dosing period. As expected, based on prior TNX-102 SL studies, administration site reactions are the
most commonly reported adverse events and were higher in the TNX-102 SL treatment group, including rates of oral numbness (17.3% vs. 0.8%),
oral pain/discomfort (11.7% v. 2.0%), taste impairment (6.5% vs. 0.4%), and oral tingling (5.6% v. 0.4%). Oral numbness or tingling and
taste impairment were local administration site effects nearly always temporally related to dose administration and transiently expressed
(&lt;60 minutes) in almost all occurrences. The only systemic treatment-emergent adverse events that occurred at a rate of 5.0% or greater
in either arm was somnolence/sedation at 5.6% in the TNX-102 SL arm vs. 1.2% in placebo, which was consistent with known side effects
of marketed oral cyclobenzaprine. Adverse events resulted in premature study discontinuation in 8.9% of those who received TNX-102 SL
compared with 3.9% of placebo recipients. There was a total of seven serious adverse events reported during the study, none of which were
deemed related to investigational product; five in placebo arm, and two in TNX-102 SL arm. Of the two in the TNX-102 SL arm, one was a
motor vehicle accident with multiple bone fractures, and the other was a pneumonia secondary to an infection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="text-decoration: underline">Completed
Phase 3 AFFIRM Study (F301)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the third quarter of 2016, we announced the results of a randomized, double-blind, placebo-controlled, 12-week Phase 3 study of TNX-102
SL in 519 participants with FM, which we refer to as the AFFIRM study. The primary objective of this study was to evaluate the potential
clinical benefit of using TNX-102 SL to treat FM at a dose of 2.8 mg, administered sublingually once daily at bedtime for 12 weeks. The
primary endpoint of the AFFIRM trial was the 30% pain responder analysis in which a responder is defined as a subject for whom pain intensity
was reduced by at least 30% at Week 12 as compared to baseline. AFFIRM did not achieve statistical significance at the primary endpoint
(p=0.095).&#160;Yet, statistical significance was achieved when pain was analyzed instead as a continuous variable, either by MMRM (p&lt;0.001)
or by MMRM with multiple imputation for missing data (p=0.005), a generally accepted approach to pain data.&#160;TNX-102 SL also showed
statistically significant improvements in the declared secondary analyses of the Patient Global Impression of Change, or PGIC (p=0.038)
and the Fibromyalgia Impact Questionnaire-Revised, or FIQ-R (p&lt;0.001). The study also showed statistically significant improvement
with TNX-102 SL on measures of sleep quality, including the Patient-Reported Outcomes Measurement Information System, or PROMIS, Sleep
Disturbance instrument (p&lt;0.001).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-102
SL was well tolerated in the AFFIRM trial. Among patients randomized to the active and control arms, 78% and 86%, respectively, completed
the 12-week dosing period. The most common adverse events were local in nature, with transient tongue or mouth numbness occurring in 40%
of participants on TNX-102 SL vs. 1% on placebo. These local adverse events did not appear to affect either rates of retention of study
participants or their compliance with taking TNX-102 SL. Systemic adverse events were similar between TNX-102 SL and placebo. No serious
adverse events were reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Other
NDA Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Agreed Initial Pediatric Study Plan, or Agreed iPSP, was accepted by the FDA in September 2015. An amendment to the Agreed iPSP will be
submitted for FDA agreement prior to marketing application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Based
on our discussions with the FDA and the FDA official meeting minutes, we will not have to conduct special populations, such as geriatric
and renal/hepatic impaired patients, drug-drug interaction or cardiovascular safety studies to support the TNX-102 SL NDA filing since
the pivotal systemic exposure bridging study using Amrix as the reference listed drug, or RLD, has been successfully completed. Due to
the well-established safety profile of CBP at much higher doses than we proposed for FM and the long-term safety data in PTSD, up to 15
months, on TNX-102 SL 5.6 mg, the FDA has not requested a risk management plan or medication guide for this product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Phase
1 Bioequivalence, Bridging PK, Food-Effect and Dose-Proportionality Studies </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have completed the required Phase 1 bioequivalence, multi-dose bridging pharmacokinetic, and food effect and dose-proportionality studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cyclobenzaprine
Hydrochloride Nonclinical Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In October 2016, we completed
the six-month repeated-dose toxicology study of the active ingredient, CBP, in rats and a nine-month repeated-dose toxicology study in
dogs required for the NDA filing. These chronic toxicity studies were requested by the FDA to augment the nonclinical information in the
AMRIX prescribing information, or labeling, which is necessary to support the TNX-102 SL labeling for long-term use. Due to the lack of
evidence of potential abuse in clinical studies of TNX-102 SL, the FDA agreed that nonclinical study to assess CBP abuse potential is
not required to support the TNX-102 SL NDA filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are planning to develop TNX-102 SL for the treatment of FM in Japan.
Cyclobenzaprine, the active ingredient of TNX-102 SL, has not been approved in Japan, and is considered a NCE (new chemical entity). In
February 2022, we held an End of Phase 2 Consultation with the Pharmaceuticals and Medical Devices Agency, or PMDA, an independent administrative
institution responsible for ensuring the safety, efficacy and quality of pharmaceuticals and medical devices in Japan, to discuss the
Japan development plan. Agreement was reached on the design of a Phase 1 bridging study (TNX-CY-F108/F108) in ethnic Japanese healthy
volunteers to enable clinical studies of TNX-102 SL in Japan. PMDA also provided guidance on the overall nonclinical package to support
a Japan NDA filing for TNX-102 SL for the treatment of FM.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The F108 Phase 1 study was initiated
in March 2022 and the clinical phase was completed in May 2022 and we are awaiting the final study report at the time of this filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are completing nonclinical safety, pharmacology and embryo-fetal development
toxicology studies as part of the agreed IND-enabling nonclinical data package to support clinical studies of TNX-102 SL in Japan.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX
102 SL &#8211; FM-type Long COVID Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are developing TNX-102 SL as a bedtime treatment for FM-type Long COVID. The potential approval of TNX-102 SL for Long COVID is expected
to be under Section 505(b)(2) of the FDCA.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">Phase
2 PREVAIL Study (PA201)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
initiated a Phase 2 study of TNX-102 SL as a treatment for FM-type Long COVID, which is a subset of patients affected by Long COVID whose
symptoms overlap with fibromyalgia. The trial initiated in August 2022. The study is a randomized, double-blind, placebo-controlled study
designed to evaluate the efficacy and safety of TNX-102 SL for FM-type Long COVID.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
completed a pre-IND meeting with the FDA in August 2021 to develop TNX-102 SL as a potential treatment for Long COVID. Long COVID is
a protracted syndrome experienced by many people following SARS-CoV-2 infection that can include a number of persistent disabling
symptoms, including fatigue, widespread pain, sleep disturbance, brain fog or difficulty concentrating, arthralgias, diffuse
myalgia, olfactory dysfunction, and headache. The currently enrolling Phase 2 study focuses on Long COVID patients whose primary
symptoms overlap with fibromyalgia, and, therefore, the Long COVID program leverages learnings about the pharmacodynamic activity of
TNX-102 SL from more than 1,000 participants who have been or are enrolled in our fibromyalgia trials to date. Long COVID has been
compared to fibromyalgia because of the common symptoms of sleep disturbance, persistent widespread pain, fatigue, and brain fog.
Additionally, Long COVID, like fibromyalgia, is experienced by women at a rate approximately four times that of men.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-102
SL &#8211; Posttraumatic Stress Disorder Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are developing TNX-102 SL as a bedtime treatment of PTSD under an active IND application. The potential approval of TNX-102 SL for PTSD
is expected to be under Section 505(b)(2) of the FDCA.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">Phase
3 RECOVERY Study (P302)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We initiated the RECOVERY study (P302) in March 2019. The RECOVERY Phase
3 study was a double-blind, randomized, placebo-controlled study of TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets) over 12 weeks of
treatment. The RECOVERY study was conducted at approximately 30 U.S. sites.&#160;&#160;The study planned to enroll 250 participants with
civilian and military-related PTSD.&#160; RECOVERY restricts enrollment of study participants to individuals with PTSD who experienced
an index trauma within nine years of screening. The two previous PTSD studies of TNX-102 SL (P201 and P301) restricted enrollment to participants
who experienced traumas during military service since 2001.&#160; The primary efficacy endpoint in P302 was the Week 12 mean change from
baseline in the severity of PTSD symptoms as measured by CAPS-5 between those treated with TNX-102 SL and those receiving placebo.&#160;
Based on interim analysis (IA) results of the first 50% of enrolled participants, an IDMC recommended stopping the Phase 3 RECOVERY trial
(P302) in PTSD for futility as TNX-102 SL was unlikely to demonstrate a statistically significant improvement in the primary endpoint
of overall change from baseline in the severity of PTSD symptoms between those treated with TNX-102 SL and those receiving placebo. New
enrollment for the RECOVERY study was stopped in February 2020, but we continued studying those participants currently enrolled until
completion and proceeded with a full analysis of the unblinded data to determine the next steps in this program. Topline data was reported
during the fourth quarter of 2020, which revealed that the RECOVERY study did not achieve statistical significance in the prespecified
primary efficacy endpoint of change from baseline to Week 12 in the CAPS-5 between TNX-102 SL and placebo (p=0.343; effect size (ES)=0.15).
TNX-102 SL separated from placebo in the first key secondary endpoint, CGI-S scale (p=0.024; ES=0.36) and in the PGIC, (p=0.007; ES=0.43).
TNX-102 SL also trended for improvement on the PROMIS Sleep Disturbance scale (p=0.055; ES=0.30), consistent with the proposed mechanism
of targeting the PTSD sleep disturbance. TNX-102 SL is generally well tolerated and no new safety signals were observed. Tonix met with
the FDA to discuss potential new endpoints for the indication of treatment of PTSD. The next PTSD study can use 1 month look-back CAPS-5
as endpoint v. 1 week look-back.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">Discontinued
Phase 3 HONOR Study (P301)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the third quarter of 2018, we announced the results of a randomized, double-blind, placebo-controlled Phase 3 study of TNX-102 SL, planned
for enrollment of approximately 550 participants with military-related PTSD conducted at approximately 40 U.S. sites, which we refer to
as the HONOR study. This study was an adaptive design study based on the results of the Phase 2 AtEase study. The study design was very
similar to the Phase 2 AtEase study,&#160;except there was one planned IA and the involvement of an IDMC, which reviewed the unblinded
IA results. In addition, only one active dose (5.6 mg administered as 2 x 2.8 mg tablets) was investigated, and the baseline severity entrance
criterion was a CAPS-5 total score &#8805; 33 in this Phase 3 study. The primary efficacy endpoint of the HONOR study was the 12-week
mean change from baseline in the severity of PTSD symptoms as measured by the Clinician-Administered PTSD Scale for DSM-5, or CAPS-5,
between those treated with TNX-102 SL and those receiving placebo. The CAPS-5 is a standardized structured clinical interview and serves
as the standard in research for measuring the symptom severity of PTSD.&#160; The IA was conducted when approximately 50% of the initially
planned participant enrollment was evaluable for efficacy. HONOR was discontinued after the results of the IA indicated a pre-defined
threshold p-value for continuing enrollment was not achieved, i.e. IDMC recommended stopping for futility.&#160; The modified Intent-to-Treat
(mITT) population analyzed at the time of the IA included 252 participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
most common adverse events were mostly related to local administration site reactions, such as oral hypoaesthesia (37.3%), abnormal product
taste (11.9%), and oral paraesthesia (9.7%). The most common systemic adverse event was somnolence (15.7%). Retrospective analysis of
the HONOR study revealed a treatment effect in participants who experienced trauma less than or equal to nine years prior to screening.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the participants who experienced trauma within nine years, the p-value of the CAPS-5 primary endpoint at Week 12, using mixed model repeated
measures with multiple imputation (MMRM with MI), was 0.039, with a least-squares mean difference from placebo of -5.9 units. In contrast,
there was no difference in CAPS-5 in the participants who experienced trauma more than nine years prior to screening compared to placebo.
This analysis defined an optimal treatment window for treatment with TNX-102 SL for PTSD of the first nine years after the index trauma
that resulted in PTSD and guided the design of the next Phase 3 study in PTSD, RECOVERY.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">Long-Term
Safety Exposure Study for TNX-102 SL</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
October 2019, we completed long-term safety exposure studies in participants with PTSD to evaluate the tolerability of TNX-102 SL 5.6
mg to support an NDA for the treatment of PTSD.&#160; The data provide us with exposure data of daily dosing of TNX-102 SL 5.6 mg for
at least 12 months in more than 50 individuals, and daily dosing of TNX-102 SL 5.6 mg for at least 6 months in more than 100 individuals.
The data was collected in OLE studies of the PTSD program.&#160; Based on the FDA&#8217;s guidance, the long-term safety exposure studies
in PTSD are also expected to support an NDA for the management of FM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Other
NDA Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
Agreed Initial Pediatric Study Plan, or Agreed iPSP, is required for the initial NDA submission. We submitted a revised iPSP in the first
quarter of 2017, which incorporated the FDA comments received on our iPSP submitted in the third quarter of 2016. Additional comments
from the FDA were received in second quarter of 2017 on our revised iPSP. We plan to submit an Agreed PSP once a therapeutic dose in adults
is established. An acceptable Pediatric Study Plan will be determined at the time of the NDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Based
on our discussions with the FDA and the FDA official meeting minutes, we will not have to conduct special populations (geriatric and renal/hepatic
impaired), drug-drug interaction or cardiovascular safety studies to support the TNX-102 SL NDA filing since the pivotal systemic exposure
bridging study using AMRIX as the reference listed drug, or RLD, has been successfully completed. Due to the well-established safety profile
of CBP at much higher doses than we proposed for PTSD and the long-term safety data (up to 15 months) on TNX-102 SL 2.8 mg in a prior
FM program, the FDA has not requested a risk management plan or medication guide for this product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Manufacturing</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-102 SL drug product for Phase 3 and the associated registration batches
for the NDA were manufactured at commercial cGMP facilities. We currently have 36-month stability data in the proposed packaging configurations
ready for commercialization. The FDA has reviewed the proposed CMC data package to support TNX-102 SL&#8217;s NDA approval and commercial
manufacturing plans as part of the IND process. Tonix is ready to manufacture TNX-102 SL commercial product for the forecasted FM market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i><span style="text-decoration: underline">TNX-1900 &#8211; Migraine, Craniofacial Pain and Obesity-Associated <i><span style="text-decoration: underline">Binge
Eating Disorder</span></i></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-1900
(intranasal potentiated oxytocin) is a proprietary formulation of oxytocin in development for BED, prophylaxis of chronic migraine and
for the treatment of craniofacial pain, insulin resistance and related conditions. In 2020, TNX-1900 was acquired from Trigemina, Inc.
and licensed from Stanford University. TNX-1900 is a drug-device combination product, based on an intranasal actuator device that delivers
oxytocin into the nose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Oxytocin
is a naturally occurring human hormone that acts as a neurotransmitter in the brain. Oxytocin has no recognized addiction potential. It
has been observed that low oxytocin levels in the body can lead to an increase in migraine headache frequency, and that increased oxytocin
levels can relieve migraine headaches. Certain other chronic pain conditions are also associated with decreased oxytocin levels. Migraine
attacks are caused, in part, by the activity of pain-sensing trigeminal nerve cells which, when activated, release CGRP which binds to
receptors on other nerve cells and starts a cascade of events that is believed to result in headache. Oxytocin when delivered via the
nasal route, concentrates in the trigeminal system resulting in binding of oxytocin to receptors on neurons in the trigeminal system,
inhibiting the release of CGRP and transmission of pain signals. Blocking CGRP release is a distinct mechanism compared with CGRP antagonist
and anti-CGRP antibody drugs, which block the binding of CGRP to its receptor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">With
TNX-1900, the addition of magnesium to the oxytocin formula enhances oxytocin receptor binding as well as its effects on trigeminal neurons
and craniofacial analgesic effects in animal models. Intranasal oxytocin has been well tolerated in several clinical trials in both adults
and children. Targeted nasal delivery results in low systemic exposure and lower risk of non-nervous system, off-target effects which
could potentially occur with systemic CGRP antagonists such as anti-CGRP antibodies. For example, CGRP has roles in dilating blood vessels
in response to ischemia, including in the heart. We believe nasally targeted delivery of oxytocin could translate into selective blockade
of CGRP release in the trigeminal ganglion and not throughout the body, which could be a potential safety advantage over systemic CGRP
inhibition. In addition, daily dosing is more quickly reversible, in contrast to monthly or quarterly dosing, as is the case with anti-CGRP
antibodies, giving physicians and their patients greater control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We initiated a Phase 2 study in chronic migraine in the first quarter of
2023. We also plan to develop TNX-1900 for treatment of episodic migraine, craniofacial pain and insulin resistance. Tonix has a license
with the University of Geneva to use TNX-1900 for the treatment of insulin resistance and related conditions. TNX-1900 is also being studied
as a potential treatment for BED in an investigator-initiated Phase 2 clinical trial. The Phase 2 clinical trial is expected to start
in the second quarter of 2023. In March 2022, we announced an agreement with Massachusetts General Hospital, a teaching hospital of Harvard
Medical School, to conduct this study. Tonix does not own this IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i><span style="text-decoration: underline">TNX-601
ER &#8211; Depression, PTSD, Neurocognitive Dysfunction from Corticosteroids</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
announced the development of TNX-601 ER in July 2022, a potential abuse deterrent, extended-release formulation of tianeptine
hemioxalate. TNX-601 ER is designed for once-daily daytime dosing and is being developed as a treatment for major depressive
disorder (MDD), posttraumatic stress disorder, and neurocognitive dysfunction associated with corticosteroid use. TNX-601 ER
represents a novel approach to treating depression in the U.S., since the active ingredient tianeptine induces a neuroprotective and
resilient phenotype in both neurons and microglia under conditions of stress in animals. The dramatic and unique effects of
tianeptine are illustrated in animal models by the restoration of dendritic arborization of pyramidal neurons of CA3 region of
hippocampus and the dentate gyrus region new neuron formation and integration into hippocampal networks. In contrast,
antidepressants that are marketed in the U.S. act by modulating the levels or receptor binding of neurotransmitters in the synapse.
Tianeptine sodium (amorphous) immediate release (IR) tablets have been available in Europe and many countries in Asia and Latin
America for the treatment of MDD over the more than three decades since it was first marketed in France in 1989. No
tianeptine-containing product has been approved by the FDA. The proposed mechanism of action of TNX-601 ER is distinct from
traditional monoaminergic antidepressants in the U.S. In addition to its glutamatergic properties central to its antidepressant
effect, tianeptine has weak &#181;-opioid receptor agonist properties and has been linked to illicit misuse at much higher doses
than those reported to be effective in the treatment of MDD (reported to be used daily at 8-80 times the antidepressant daily dose).
Previously, we were developing a naloxone-containing tablet, TNX-601 CR (tianeptine oxalate and naloxone controlled-release) for MDD,
that was designed to mitigate the risk of parenteral abuse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We intend to develop TNX-601 ER under Section 505(b)(1) of the Federal
Food, Drug, and Cosmetic Act (FDCA). Tonix completed a Phase 1 clinical trial for formulation development outside of the U.S in 2019.
Based on this study, the final formulation of TNX-601 ER to be used in Phase 2 testing will be 39.4 mg tianeptine hemioxalate for once
daily treatment of MDD (which is equivalent in tianeptine content to three 12.5 mg doses of tianeptine sodium). Based on the clearance
of IND 152371 by the FDA, we expect to initiate a Phase 2 study in the first quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Phase 2 study is planned to be a randomized, double-blind, placebo-controlled,
parallel group study to evaluate the efficacy and safety of TNX-601 ER monotherapy compared to placebo in MDD. Treatment duration will
be six weeks, preceded by up to five weeks in screening and followed by a two-week safety follow-up period (total up to 13 weeks of participation).
We plan to randomize approximately 300 individuals with MDD at a 1:1 ratio to two arms of 150 each for drug and placebo at approximately
30 U.S. sites. The primary efficacy endpoint will be the change from baseline to Week 6 in the Montgomery-&#197;sberg Depression Rating
Scale (MADRS) total score. An IA will be conducted once the first 50 percent of the sample has completed the study, estimated to occur
in the fourth quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i><span style="text-decoration: underline">TNX-1300
&#8211; Cocaine Intoxication</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-1300
(T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) is being developed for the treatment of cocaine intoxication. TNX-1300
is a recombinant protein enzyme produced through rDNA technology in a non-disease-producing strain of E. coli bacteria. Cocaine Esterase
(CocE) was identified in bacteria (Rhodococcus) that use cocaine as the sole source of carbon and nitrogen and that grow in soil surrounding
coca plants. The gene encoding CocE was identified and the protein was extensively characterized. CocE catalyzes the breakdown of cocaine
into metabolite ecgonine methyl ester and benzoic acid. Wild-type CocE is unstable at body temperature, so targeted mutations were introduced
in the CocE gene and resulted in the T172R/G173Q double-mutant CocE, which is active for approximately 6 hours at body temperature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Currently
there is no specific pharmacotherapy indicated for cocaine intoxication, a state characterized by acute agitation, hyperthermia, tachycardia,
arrhythmias, and hypertension, with the potential life-threatening sequalae of myocardial infarction, cerebrovascular accident, rhabdomyolysis,
respiratory failure, and seizures. Patients are currently managed only by supportive care for the adverse effects of cocaine overdose
on the cardiovascular and central nervous systems. By targeting the cause of cocaine intoxication, rather than the symptoms like other
medicines in emergency usage, we believe TNX-1300 may offer significant advantages to the current standard of care for cocaine overdose.
TNX-1300 was developed by Columbia University, University of Kentucky and University of Michigan, and in-licensed by Tonix from Columbia
University in 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
a Phase 2 randomized, double-blind, placebo-controlled clinical study, TNX-1300 at 100 mg or 200 mg i.v. doses was well tolerated and
interrupted cocaine effects after cocaine 50 mg i.v. challenge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In August 2022, we announced that we received a Cooperative Agreement grant
from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support development of TNX-1300.
The Company expects to initiate a new Phase 2 clinical study of TNX-1300 for the treatment of cocaine intoxication in the second quarter
of 2023, pending agreement on protocol design with the U.S. Food and Drug Administration (FDA). The Phase 2 trial is a single-blind, open-label,
placebo-controlled, randomized study comparing the safety of a single 200 mg dose of TNX-1300 to standard of care alone in approximately
60 emergency department patients presenting with cocaine intoxication. A positive Phase 2a study of volunteer cocaine users in a controlled
laboratory setting has been previously completed. TNX-1300 has been granted Breakthrough Therapy designation by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a biologic and new molecular entity, TNX-1300 is eligible for 12 years
of U.S. market exclusivity upon approval by the FDA, in addition to expected patent protection through 2029. Since in-licensing, Tonix
has requalified existing inventory, developed a lyophilized drug product to facilitate enhanced stability and handling conditions applicable
for an ER treatment, updated the process and analytical methods to current standards and is in the process of manufacturing Phase 2/3
drug product clinical supply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<i><span style="text-decoration: underline">TNX-2900
&#8211; Prader-Willi Syndrome</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-2900
is based on our patented intranasal potentiated oxytocin formulation, or TNX-1900, but being developed for Prader-Willi syndrome. Tonix
licensed technology using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease
from the French National Institute of Health and Medical Research (Inserm). The licensing agreement has been negotiated and signed by
Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research),
Aix-Marseille Universit&#233; and Centre Hospitalier Universitaire of Toulouse. Prader-Willi syndrome is recognized as the most common
genetic cause of life-threatening childhood obesity and affects males and females with equal frequency and all races and ethnicities.
There is currently no approved treatment for either the suckling deficit in infants or the obesity and hyperphagia in older children associated
with Prader-Willi syndrome. Since Prader-Willi syndrome is an orphan disease that occurs in approximately one in 15,000 births, Tonix
has been granted Orphan Drug Designation for TNX-2900 by the FDA. Tonix completed a pre-IND meeting with the FDA in November 2022 to discuss
the most efficient and appropriate investigational plan to establish the safety and effectiveness evidence to support the approval of
TNX-2900.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
2022, Tonix entered into a research collaboration with Inserm involving in vitro and in vivo animal studies designed to validate and characterize
the role of oxytocin in suckling and in the maturation of feeding behavior during infancy in order to support an intranasal therapeutic
approach to restore a normal nutritive suckling. The studies will include mice that have been engineered to precisely recapitulate the
genetic issue underlying Prader-Willi in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
mechanisms involved in suckling activity required for normal feeding and the role of oxytocin system in this process will be investigated.
The results of this work are expected to be useful in the clinical care of infants requiring support to achieve efficient suckling behavior.
Intranasal oxytocin has previously been shown to improve suckling in newborn animals and suppress feeding behaviors in adult animal models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;<i><span style="text-decoration: underline">TNX-1500
&#8211; Organ Transplant Rejection/Autoimmune Conditions</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-1500 is a humanized mAb directed against CD40-ligand, or CD40L (also
known as CD154), engineered to modulate binding to Fc receptors, that is being developed to prevent and treat organ transplant rejection
as well as to treat autoimmune conditions. TNX-1500 incorporates the antigen binding fragment (Fab) region of hu5c8, which has been extensively
characterized including at the atomic level in complex with CD40-ligand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In experiments at the Massachusetts General Hospital, a teaching hospital
of Harvard Medical School, TNX-1500 is being studied as monotherapy or in combination with immunosuppressive drugs in heart and kidney
organ transplants in non-human primates. Preliminary results from ongoing animal experiments in kidney and heart allogeneic transplants
indicate that TNX-1500 appears to have comparable efficacy to historical experiments using the chimeric mouse/primate version of the anti-CD40L
mAb 5c8, but to date has not shown evidence of the thromboembolic adverse events associated with the first generation mAb directed against
CD40L.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">CD40-ligand
is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. CD40-ligand is also known as CD154,
the T cell-B cell activating molecule (T-BAM), TRAP and gp39. CD154 is a member of the Tumor Necrosis Factor (TNF) Super Family. No mAb
against CD154 has been approved for commercial use anywhere in the world. Other TNF Super Family members have been successfully targeted
by antagonist mAbs. Approved mAbs against TNF&#945; include: infliximab (Remicade&#174;), adalimumab (Humira&#174;), certolizumab pegol
(Cimzia&#174;), and golimumab (Simponi&#174;) for the treatment of certain autoimmune conditions. Also, etanercept (Enbrel&#174;) is a
TNF&#945; antagonist receptor fusion protein. An approved mAb against RANKL (CD254) is denosumab (Prolia&#174; or Xgeva&#174;) for the
treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
January 2021, the World Intellectual Property Organization published a patent application filed under the Patent Cooperation Treaty covering
TNX-1500, a humanized mAb directed against CD40-ligand, which is also known as CD154. The patent application is titled &#8220;Anti-CD154
Antibodies and Uses Thereof&#8221; and published under International Publication No. WO 2021/001458 A1. The application entered national
phase in December 2021. The patent applications include claims related to proprietary anti-human CD40-ligand mAbs that were engineered
to have modified effector function, including TNX-1500, which have reduced potential for Fc binding to Fc&#947;RII. The patent applications
also claim uses of TNX-1500 for preventing and treating conditions, such as organ transplant rejection and autoimmune disorders. If claims
are granted, a patent issuing from a national stage of this application could potentially provide U.S. patent coverage for the TNX-1500
composition of matter through 2040 excluding possible patent term extensions or patent term adjustments. We also have filed a PCT patent
application, PCT/US2022/011404, in January 2022, entitled &#8220;Methods of Inducing Immune Tolerance with Modified Anti-CD154 Antibodies.&#8221;
It claims methods of inducing immune tolerance in transplant recipients using anti-CD154 antibodies having modified effector functions.
Tonix completed a pre-IND meeting with the FDA in October 2022 to discuss the most efficient and appropriate investigational plan to establish
the safety and effectiveness evidence to support the licensure of TNX-1500. We expect to start a Phase 1 study of TNX-1500 in the second
quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Remicade&#174;
and Simponi&#174; are trademarks of Janssen; Humira&#174; is a trademark of AbbVie Inc.; Cimzia&#174; is a trademark of UCB S. A.; Enbrel&#174;,
Prolia&#174; and Xgeva&#174; are trademarks of Amgen Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i><span style="text-decoration: underline">TNX-801
&#8211; Potential Smallpox and Mpox Vaccine </span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-801 is a novel
potential smallpox- and mpox-preventing vaccine based on a synthetic version of live horsepox virus, grown in cell culture. Though
it shares structural characteristics with vaccinia-based vaccines, TNX-801 has unique properties that we believe indicate potential
safety advantages over existing live replicating vaccinia virus vaccines, which have been associated with adverse side effects
such as myopericarditis in some individuals.&#160; Emergent BioSolutions&#8217; ACAM2000&#174; is the only replicating vaccinia
virus vaccine currently approved by the FDA to protect against smallpox. We believe replicating virus vaccines have potential efficacy
advantages over non-replicating vaccines, relating to the stimulation of cell mediated immunity. Bavarian Nordic&#8217;s Jynneos&#174;
is the only non-replicating virus vaccine currently approved by the FDA to protect against smallpox and mpox. We believe TNX-801
has the potential to have improved tolerability relative to replicating vaccinia vaccines and the potential to have improved efficacy
relative to non-replicating vaccinia vaccines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smallpox was eradicated
by a World Health Organization program that vaccinated individuals with live replicating vaccinia vaccines wherever smallpox appeared.
In the 1970s, vaccination of civilians to protect against smallpox was discontinued in the U.S.; however, smallpox remains a material
threat to national security and a proportion of military personnel, including members of the Global Response Force, continue to
be vaccinated. We are developing TNX-801 as a potential smallpox- and mpox-preventing vaccine for the U.S. strategic national stockpile
and for potential widespread immunization in the event of malicious reintroduction of variola, the virus that causes smallpox.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Mpox
is a growing problem in certain regions of Africa. Starting in May of 2022, cases of mpox have been reported outside of Africa in patients
who had not been infected while in Africa. More than 30,000 cases in the U.S. have been reported according to the U.S. Centers for Disease
Control and Prevention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2020 at the American Society of Microbiology Biothreats conference, we reported the results of experiments on TNX-801 that were
performed in collaboration with Southern Research, that showed TNX-801 vaccinated macaques were protected against monkeypox challenge.
The TNX-801 vaccinated macaques showed no overt clinical signs after monkeypox challenge. Furthermore, eight of eight animals vaccinated
with two different doses of TNX-801 showed no lesions after monkeypox challenge. Those studies were published as an article in the peer
reviewed journal, <i>Viruses</i> in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
hold a U.S. Patent for TNX-801 smallpox and mpox vaccine and Recombinant Pox Virus (RPV) platform technology. This patent is expected
to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments. In
addition, we expect that TNX-801 will be eligible for 12 years of non-patent-based exclusivity under the Patient Protection and Affordable
Care Act, or PPACA. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
intend to meet with the FDA to discuss the most efficient and appropriate investigational plan for TNX-801, to establish the safety and
effectiveness evidence to support the licensure TNX-801. We are currently working to develop a vaccine that meets cGMP quality to support
a clinical study. A Phase 1 study of TNX-801 is expected to be initiated in the second half of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i><span style="text-decoration: underline">TNX-1850
&#8211; Potential COVID-19 Vaccine</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
infectious disease portfolio includes a platform for vaccines for COVID-19. TNX-1800 is live virus vaccine based on our RPV platform that
expresses the SARS-CoV-2 spike protein from the ancestral Wuhan strain. Because the subsequent omicron variant has out-competed the ancestral
Wuhan strain, we are now planning new versions of this vaccine, TNX-1840 and TNX-1850, that are designed to express spike protein from
the omicron variant and from the BA.2 variant, respectively. Each of these RPV vaccines is being developed to protect against COVID-19
primarily by eliciting T cell responses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
COVID-19 vaccines that are approved for use, or have emergency use authorization, or EUA, in the U.S. have provided significant health
benefits to the vaccinated population; however, they are showing limitations in the durability of protection conferred and in their ability
to block forward transmission. Live virus vaccines that protect against other viral diseases by eliciting T cell responses have shown
durability of protection that lasts years to decades and some live virus vaccines have significantly inhibited forward transmission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We reported positive efficacy data for the TNX-1800 (spike from Wuhan strain)
from animal challenge studies using live SARS-CoV-2 in the first quarter of 2021. In this study, TNX-1800 vaccinated, SARS-CoV-2 challenged
animals had undetectable SARS-CoV-2 in the upper airways, which we believe relates to potential inhibition of forward transmission of
this respiratory pathogen. This study of non-human primates compared TNX-1800 (modified horsepox virus encoding CoV-2 spike protein) to
TNX-801 (horsepox virus, live vaccine) at two doses. A control group received a placebo. Each of these five groups (TNX-1800 high and
low dose; TNX-801 high and low dose and placebo) included four animals. At day 41 after vaccination (or placebo), each animal was exposed
to SARS-COV-2 by intra-tracheal (1 x 10<sup>6</sup> TCID50) and intra-nasal (1 x 10<sup>6</sup> TCID50) administration. Upper airway virus
was studied by oropharyngeal swabs and lower airway virus by tracheal lavage using qRT-PCR to determine the number of genome copies of
SARS-CoV-2 present in the samples. Six days after challenge, no (0/8) samples taken from animals vaccinated with TNX-1800 showed infection
(more than 1,000 genome copies of SARS CoV-2) in either upper or lower airway samples. In contrast, all (8/8) animals vaccinated with
the control vaccine TNX-801 showed infection in either the upper or lower airway samples as did all (4/4) monkeys vaccinated with vehicle
control. At day 14 after a single vaccination, all eight of the TNX-1800 vaccinated animals made anti-CoV-2 neutralizing antibodies (&#8805;1:40
titer) and, as expected, none of the eight TNX-801 vaccinated control animals, or any of the four animals in the placebo group made anti-CoV-2
neutralizing antibodies (&#8804;1:10 titer). At 6 days after CoV-2 challenge, TNX-1800 vaccinated animals showed neutralizing antibody
titers of (&#8805;1:1280 titer). The level of neutralizing anti-CoV-2 antibody production was similar between the low and high dose TNX-1800
groups (1 x 10<sup>6</sup> Plaque Forming Units [PFU] and 3 x 10<sup>6</sup> PFU, (respectively). For unvaccinated animals challenged
with SARS-CoV-2, neutralizing antibodies were measurable after vaccination (&#8805;1:40 titer) that were lower and appeared later than
neutralizing antibodies in TNX-1800 vaccinated animals. TNX-1800 and TNX-801 were well tolerated at both doses. Further, as an expected
additional outcome, all 16 animals vaccinated with either dose of TNX-1800 or the control TNX-801 manifested a &#8220;take&#8221;, or
cutaneous response, signaling that the horsepox vector elicits a strong T cell immune response. These results support the expectation
that TNX-1800 at the low dose of 1 x 10<sup>6</sup> PFU is an appropriate dose for a one-shot vaccine in humans and indicate that 100
doses per vial is the target format for commercialization, which is well suited to manufacturing and distribution at large scale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Together,
these data show that TNX-1800 induces protection against SARS-COV-2 infection in non-human primates. These data confirm that &#8220;take&#8221;
is a biomarker of protection of upper and lower airways from SARS-CoV-2 challenge, and a biomarker of immunological response to TNX-1800&#8217;s
cargo COVID-19 antigen, which is the CoV-2 spike protein. Tonix completed a pre-IND meeting with the FDA to discuss the most efficient
and appropriate investigational plan to establish the safety and effectiveness evidence to support the licensure of TNX-1800. We believe
that the animal data and manufacturing process information that we have developed for TNX-1800 will facilitate expedited development of
TNX-1840 and TNX-1850. In addition, we believe the RPV platform can be engineered to express relevant protein antigens from different
infectious diseases to make a variety of vaccines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
June 2020, we announced a partnership with FUJIFILM Diosynth Biotechnologies (FDBT) to provide contract manufacturing and development
services to support the manufacturing of our COVID-19 vaccine candidate at the time, TNX-1800, for clinical trial supply. In February
2022, this contract ended. We continue to work with other third party CMOs for the manufacturing and development of TNX-1850, in addition
to ultimately planning to utilize our in-house manufacturing capabilities which are currently in development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Tonix
announced the issuance of U.S. Patent for TNX-801 smallpox and mpox vaccine and Recombinant Pox Virus (RPV) platform technology. This
patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term
adjustments, and also expect 12 years of non-patent-based exclusivity under PPACA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
preclinical pipeline of drugs and biologic candidates also includes TNX-1600, a preclinical candidate for PTSD, ADHD and depression; TNX-1700
a preclinical candidate for cancers of the gastrointestinal system; TNX-2300, a live-virus vaccine based on bovine parainfluenza virus
for COVID-19; TNX-3600, a COVID-19 therapeutic platform; TNX-3700, a COVID-19 vaccine; TNX-3800, a COVID-19 Therapeutic/Preventative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Tonix&#8217;s
Facilities Overview </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Relating to our COVID-19
and other infectious disease development programs, we are developing the resources necessary to enable internal research, development
and manufacturing capabilities necessary to meet the goal of producing new vaccine candidates within 100 days and new diagnostics
within weeks of obtaining sequence information of a novel pathogen. We seek to be a leader in the movement to re-build domestic
U.S. research, development and manufacturing capabilities. Because this movement follows a protracted period when domestic research,
development and manufacturing were moved out of the U.S., or &#8220;off-shore&#8221; by other companies to save on labor and other
costs, the movement to reverse that trend has been described as &#8220;on-shoring&#8221; or &#8220;re-domestication&#8221;. The
COVID-19 pandemic taught that national borders may close during a health emergency. Therefore, domestic capabilities are essential
for the health security of the U.S., which has also been described as pandemic preparedness and biodefense. As articulated in the
American Pandemic Preparedness Plan, or AP3 released by the U.S. Office of Science and Technology Policy, this 100-day goal for
vaccines is a key component of preparedness for future pandemics. We are establishing the infrastructure necessary to support the
pandemic preparedness goals established in the AP3, specifically with respect to our RPV vaccine platform and potentially to other
vaccine and therapeutic platforms.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>The
Research &amp; Development Center (RDC)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We own the approximately
48,000 square foot RDC facility in Frederick, Maryland. The RDC facility is operational and focuses on our development of vaccines and
antiviral drugs against COVID-19, its variants, and other infectious diseases. The RDC also conducts research on CNS and immunology drugs.
The RDC facility is biosafety level 2 (BSL-2) with BSL-3 components. The RDC currently employs 26 staff. At full capacity, the RDC can
employ 80-100 scientists and technical support staff.<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>The
Advanced Development Center (ADC)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
ADC located in the New Bedford business park in Dartmouth, Massachusetts is operational and intended to accelerate development and clinical
scale manufacturing of live-virus vaccines and biologics to support Phase 1 and Phase 2 clinical trials. ADC includes single-use bioreactors
and purification suites with equipment for Good Manufacturing Practice (GMP) production of vaccines for and biologics clinical trials,
including the capability of producing sterile vaccines in glass bottles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;The
ADC is an approximately 45,000 square foot BSL-2 facility that currently employs 35 staff. At full capacity, the facility can employ up
to 70 researchers, scientists, manufacturing, and technical support staff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>The
Commercial Manufacturing Center (CMC)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
intend to build the CMC in Hamilton, Montana where we purchased approximately 44 acres of land. The site is on land designated by Ravalli
County as a Target Economic Development District. The CMC will focus on developing and manufacturing Phase 3 and commercial scale live-virus
vaccines and biologics and is also intended to be BSL-2. We have constructed a field office on the site to direct construction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include large pharmaceutical
and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research
institutions. We believe that key competitive factors that will affect the development and commercial success of our product candidates
are efficacy, safety, tolerability, reliability, price and reimbursement level. Many of our potential competitors, including many of the
organizations named below, have substantially greater financial, technical, and human resources than we do and significantly greater experience
in the discovery and development of product candidates, obtaining the FDA&#8217;s and other regulatory approvals of products and the commercialization
of those products. Accordingly, our competitors may be more successful than we may be in obtaining FDA approval for drugs and achieving
widespread market acceptance. Our competitors&#8217; drugs may be more effective, or more effectively marketed and sold, than any drug
we may commercialize and may render our product candidates obsolete or non-competitive before we can recover the expenses of developing
and commercializing any of our product candidates. We anticipate that we will face intense and increasing competition as new drugs enter
the market and advanced technologies become available. Further, the development of new treatment methods for the conditions we are targeting
could render our drugs non-competitive or obsolete. Summarized below is the competitive landscape for the indications in which Tonix has
product candidates in or nearing the clinical stages of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Fibromyalgia
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;Products approved for the
treatment of fibromyalgia include Lyrica&#174; (pregabalin), marketed by Pfizer; Cymbalta&#174; (duloxetine), marketed by Eli Lilly; and Savella&#174;
(milnacipran), marketed by Allergan (acquired by AbbVie).&#160;Tonix is aware of several other companies developing treatments for fibromyalgia
including Virios Therapeutics, Axsome Therapeutics, Tryp Therapeutics, Biomind Labs, Cortene, and Sorrento Therapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Chronic or
Episodic Migraine Prophylaxis</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently there are several classes of drugs that are approved for the
prophylactic treatment of chronic or episodic migraine, including generic beta blockers (propranolol, timolol), and anticonvulsants (divalproex,
topiramate). Other drug classes that are used off-label to treat migraine prophylaxis, include tricyclic antidepressants (e.g., amitriptyline).
Also, Allergan markets Botox&#174; (onabotulinumtoxinA). More recently, several products have received FDA approval including Aimovig&#174;
(erenumab), which is marketed by Amgen/Novartis; Ajovy&#174; (fremanezumab), which is marketed by Teva Pharmaceuticals; Emgality&#174;
(galcanezumab) which is marketed by Eli Lilly; and Yvepti&#174; (eptinezumab), which is marketed by Lundbeck. Also, Nurtec ODT&#174; (Rimegepant)
was more recently approved as both a preventive and an acute treatment for episodic migraine, marketed by Pfizer; and Qulipta&#174; (atogepant)
was approved for prevention of episodic migraine, marketed by AbbVie. We are aware of other companies working to develop therapeutics
for the treatment or prophylaxis of migraine including Astrocyte Pharmaceuticals, Protox, Kallyope, Crystec Pharma, Pulmatrix, and Epalex.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Major Depressive
Disorder</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Many antidepressant medications
are beyond their patent life and are generally produced by generic drug companies, including several compounds in the tricyclic class
(e.g., amitriptyline), the serotonin-selective reuptake inhibitor class (e.g, fluoxetine, paroxetine and sertraline), the serotonin-norepinephrine
reuptake inhibitor class (e.g., venlafaxine), as well as the norepinephrine-dopamine reuptake inhibitor, bupropion. Recently, Auvelity,
developed by Axsome Therapeutics, and Vraylar, developed by Allergan, received FDA approval. Tonix is aware of several companies developing
novel prescription medicines for depression including Janssen, Neumora Therapeutics (formerly BlackThorn Therapeutics), Sage Therapeutics,
Relmada Therapeutics, Clexio Biosciences Ltd., Otsuka, Seelos Therapeutics, Biomind Labs, FSD Pharma, Bright Minds Bioscienes, Vistagen,
Alto Neuroscience, Addex Therapeutics, and BetterLife Pharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Long COVID
(Post-Acute Sequelae of SARS-CoV-2 Infection or PASC)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There currently are no approved
products for the treatment of long COVID/PASC. Tonix is aware of several other companies developing therapeutics for long COVID including
Direct Biologics, American CryoStem, HopeBiosciences, Axcella Health Inc., Ampio Pharmaceuticals, Pieris Pharmaceuticals, Resolve Therapeutics,
PaxMedia, GeNeuro, Organicell, Ampio Pharmaceuticals, Lyramid, Virios Therapeutics, Berlin Cures, and Statera Biopharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">PTSD</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Products approved for
the treatment of PTSD include Paxil&#174; (paroxetine), marketed by GlaxoSmithKline and Zoloft&#174; (sertraline), marketed by
Pfizer. Tonix is aware of other companies working to develop therapeutics for the treatment of PTSD including Bionomics, Otsuka/Lundbeck,
Nobilis Therapeutics, Bright Minds Biosciences, Alto Neuroscience, Addex Therapeutics, Ophidion, Artelo Biosciences, Roche, Boehringer
Ingelheim, NRx Pharmaceuticals, Nanomerics, Seelos Therapeutics, and the Multidisciplinary Association of Psychedelic Studies (MAPS).
Acadia Pharmaceuticals is testing Nuplazid&#174; (pimavanserin) for the treatment of insomnia in veterans with PTSD.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Cocaine Intoxication</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are no approved antidotes
for the treatment of cocaine intoxication. Patients generally receive supportive care. Tonix is not aware of any drugs in development
for the treatment of cocaine intoxication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Anti-CD40-ligand
Monoclonal Antibodies&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tonix is aware of several
companies developing biologics that target the CD40L molecule and block its interaction with CD40 including UCB/Biogen, Eledon
Pharmaceuticals, Horizon Therapeutics Plc. (which is being acquired by Amgen), Lundbeck (in partnership with Aprilbio), and Sanofi.
Furthermore, Tonix is aware of several companies developing antagonistic anti-CD40 mAbs including Novartis, Boehringer
Ingelheim, Kiniska Pharmaceuticals, Boston Immune Therapies, and NapaJen Pharma, Inc.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Prader-Willi
Syndrome</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are no approved products
for the treatment of Prader-Willi syndrome. Patients generally receive care to best manage individual symptom presentation. Tonix is aware
of two companies developing a therapeutic for Prader Willi Syndrome including Acadia (which purchased Levo Therapeutics in 2022) and OT4B.
Several other companies are developing treatments for Prader-Willi syndrome including Aadvark Therapeutics, ConSynance Therapeutics, Soleno
Therapeutics, Lipidio Pharma, Helsinn, Inversago Pharma, Saniona, 9 Meters Biopharma, Neuren Pharmaceuticals, Neuracle Science, Harmony
Biosciences, and Notitia Biotechnologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Gastric and
Colorectal Cancer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Tonix is developing a small peptide/biologic
for the treatment of gastric and colorectal cancer. Tonix is aware of several other companies developing biologics for the treatment of
gastric and colorectal cancer including Bexion Pharmaceuticals Inc., Faeth Therapeutics Inc., PDS Biotechnology Corp, and F-star Alpha
Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">COVID-19
Vaccine </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vaccines granted full
FDA regulatory approval include Comirnaty&#174; (BNT162b2), marketed by Pfizer-BioNTech and Spikevax&#174; (mRNA-1273), marketed
by Moderna. Ad.26.COV2S, developed by Janssen, has FDA approval for limited use. Covovax&#174; (NVX-CoV2373), developed by Novavax,
has received EUA from the FDA. Other vaccines have received EUA in international markets.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Smallpox
and Mpox Vaccines and Antivirals</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vaccines approved for
the prevention of smallpox include ACAM2000&#174;, marketed by Emergent BioSolutions and JYNNEOS&#174;, marketed by Bavarian Nordic.
JYNNEOS&#174; is also approved for the prevention of mpox. Approved antivirals for smallpox include TPOXX&#174;, marketed by SIGA
and TEMBEXA&#174;, marketed by Chimerix. These antivirals are not FDA approved for the treatment of mpox. Tonix is aware of other
companies developing treatments for smallpox and mpox including EpiVax, HK inno.N, BioFactura, Blue Water Vaccines, NightHawk Biosciences,
Ascletis, and Hyundai Biosciences.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we have an
extensive patent portfolio and substantial know-how relating to TNX-102 SL, TNX-1300, TNX-1500, TNX-601 ER, TNX-801 and our other product
candidates. Our patent portfolio, described more fully below, includes claims directed to various compositions and methods of use related
to our product candidates. As of March 8, 2023, the patents we are either the owner of record of or own the contractual right to include
34 issued U.S. patents and 271 issued non-U.S. patents. We are actively pursuing an additional 32 U.S. patent applications, of which
7 are provisional and 25 are non-provisional, 11 international patent applications, and 247 non-U.S./non-international patent applications.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We strive to protect the proprietary
technology that we believe is important to our business, including our proprietary technology platform, our product candidates, and our
processes. We seek patent protection in the U.S. and internationally for our products, their methods of use and processes of manufacture,
and any other technology to which we have rights, where available and when appropriate. We also rely on trade secrets that may be important
to the development of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success will depend on 1)
the ability to obtain and maintain patent and other proprietary rights in commercially important technology, inventions and know-how related
to our business, 2) the validity and enforceability of our patents, 3) the continued confidentiality of our trade secrets, and 4) our
ability to operate without infringing the valid and enforceable patents and proprietary rights of third parties. We also rely on continuing
technological innovation and in-licensing opportunities to develop and maintain our proprietary position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot be certain that patents
will be granted with respect to any of our pending patent applications or with respect to any patent applications we may own or license
in the future, nor can we be certain that any of our existing patents or any patents we may own or license in the future will be useful
in protecting our technology. For this and more comprehensive risks related to our intellectual property, please see &#8220;Risk Factors&#160;&#8212;&#160;Risks
Relating to Our Intellectual Property.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The term of individual patents
depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent
term is 20 years from the date of filing the first non-provisional priority application. In the United States, a patent&#8217;s term may
be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the PTO in granting a patent or may
be shortened if a patent is terminally disclaimed over another patent.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The term of a U.S. patent that
covers a drug approved by the FDA or methods of making or using that drug may also be eligible for patent term extension, which permits
patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition
and Patent Term Restoration Act, also known as the Hatch-Waxman Act, is a federal law that encourages new drug research by restoring patent
term lost to regulatory delays by permitting a patent term extension of up to five years beyond the statutory 20-year term of the patent
for the approved product or its methods of manufacture or use if the active ingredient has not been previously approved in the U.S. The
length of the patent term extension is related to the length of time the drug is under regulatory review. A patent term extension cannot
extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an
approved drug may be extended. Similar provisions are available in Europe and some other foreign jurisdictions to extend the term of a
patent that covers an approved drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">When possible, depending upon
the length of clinical trials and other factors involved in the filing of an NDA, we expect to apply for patent term extensions for patents
covering our product candidates and their methods of use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The patent portfolios for our
proprietary technology platform and our most advanced product candidates as of March 8, 2023 are summarized below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-102
SL &#8212; Central Nervous System Conditions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
patent portfolio for TNX-102 SL includes patent applications directed to compositions of matter of CBP, formulations containing CBP, and
methods for treating CNS conditions, such as TNX-102 SL for PTSD, for acute stress disorder, for sleep disturbances in fibromyalgia, for
alcohol abuse, for disordered sleep, for sexual dysfunction, for depression in fibromyalgia, fatigue, e.g., CAP rates, post-acute sequelae
of SARS-CoV-2 infection, and for agitation in neurodegenerative conditions, e.g., AAD, utilizing these compositions and formulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Certain
eutectic compositions were discovered by development partners and are termed the &#8220;Eutectic Technology.&#8221; The patent portfolio
for TNX-102 SL relating to the Eutectic Technology includes patent applications directed to eutectic compositions containing CBP, eutectic
CBP formulations, methods for treating PTSD and other CNS conditions utilizing eutectic CBP compositions and formulations, and methods
of manufacturing eutectic CBP compositions. The Eutectic Technology patent portfolio includes U.S. patents, such as U.S. Patent No. 9,636,408,
U.S. Patent No. 9,956,188, U.S. Patent No. 10,117,936, U.S. Patent No. 10,357,465, U.S. Patent No. 10,864,175, and U.S. Patent No. 11,026,898.
If U.S. and non-U.S. patents claiming priority from those applications issue, those patents would expire in 2034 or 2035, excluding any
patent term adjustments or extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
unique pharmacokinetic profile of TNX-102 SL, or the PK Technology, was discovered by Tonix and its development partners. The patent portfolio
for TNX-102 SL relating to the PK Technology includes patent applications directed to compositions of matter of CBP, formulations containing
CBP, methods for treating PTSD, agitation in neurodegenerative conditions, and other CNS conditions utilizing these compositions and formulations.
The PK Technology patent portfolio includes U.S. Patent Application No. 13/918,692. If U.S. and non-U.S. patents claiming priority from
those applications issue, those patents would expire in 2033, excluding any patent term adjustments or extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 2, 2017, U.S. Patent No. 9,636,408 entitled &#8220;Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride&#8221;,
issued. The patent claims recite pharmaceutical compositions comprising the eutectic. The patent claims also recite methods of manufacturing
the eutectic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 13, 2017, European patent 2,501,234, entitled &#8220;Methods and Compositions for Treating Symptoms Associated with PTSD Using
Cyclobenzaprine&#8221;, issued. This patent recites the use of CBP for the treatment of PTSD, which covers the use of TNX-102 SL for the
treatment of PTSD, since the active ingredient in TNX-102 SL is CBP and provides TNX-102 SL with European market exclusivity until 2030
and may be extended based on the timing of the European marketing authorization of TNX-102 SL for PTSD.&#160; In response to an opposition
filed in June 2018 by a German law firm, the European Patent Office&#8217;s Opposition Division in October 2019 upheld the patent in unamended
form.&#160; Opponent has appealed. The Technical Board of the European Patent Office has canceled the April 27, 2023 Oral Proceedings
pending the decision of the Enlarged Board of Appeal in G 2/21 (plausibility), which seeks to clarify whether a technical effect can be
relied on when proof for the effect rests solely in post-published evidence and what role, if any, plausibility should play in this assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 15, 2017, Japanese Patent No. 6259452, entitled &#8220;Compositions and Methods for Transmucosal Absorption,&#8221; issued.&#160;
These claims relate to the pharmacokinetic profile of TNX-102 SL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 3, 2022, European Patent No. 2861223, entitled &#8220;Compositions and Methods for Transmucosal Absorption,&#8221; issued.&#160;
These claims relate to the pharmacokinetic profile of TNX-102 SL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
March 20, 2018, U.S. Patent No. 9,918,948 entitled &#8220;Methods and Compositions for Treating Symptoms Associated with PTSD Using Cyclobenzaprine,&#8221;
issued. The claims recite a method of using TNX-102 SL&#8217;s active ingredient cyclobenzaprine to treat PTSD and provides TNX-102 SL
with US market exclusivity until 2030, excluding any patent term extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
March 23, 2018, Japanese Patent No. 6310542 entitled &#8220;Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride&#8221;,
issued.&#160; The claims recite pharmaceutical compositions comprising the eutectics and methods of manufacturing these eutectic formulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 1, 2018, U.S. Patent No. 9,956,188, entitled &#8220;Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride&#8221;,
issued. The claims recite a eutectic of cyclobenzaprine hydrochloride and mannitol and methods of making those eutectics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
November 6, 2018, U.S. Patent No. 10,117,936, entitled &#8220;Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline
Hydrochloride&#8221;, issued. The claims recite pharmaceutical compositions of eutectics of cyclobenzaprine hydrochloride and mannitol
and methods of making those compositions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
April 16, 2019, Chinese Patent No. ZL 201480024011.1 entitled &#8220;Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline
Hydrochloride&#8221;, issued. The claims recite pharmaceutical compositions comprising eutectics of cyclobenzaprine hydrochloride and
mannitol and methods of making those compositions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
July 23, 2019, U.S. Patent No. 10,357,465 entitled &#8220;Eutectic Formulations of Cyclobenzaprine Hydrochloride&#8221;, issued. The claims
recite pharmaceutical compositions comprising eutectics of cyclobenzaprine hydrochloride and mannitol and methods of making those compositions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 11, 2019, European patent 2968992, entitled &#8220;Eutectic Formulations of Cyclobenzaprine Hydrochloride&#8221;, issued. This
patent recites pharmaceutical compositions comprising a eutectic of mannitol and Cyclobenzaprine HCl and methods of making the same. In
response to an opposition filed in September 2020 by Hexal AG, the European Patent Office&#8217;s Opposition Division upheld the patent
in unamended form in the January 2022 oral proceedings. The written decision is pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 25, 2019, European patent 2,683,245, entitled &#8220;Methods and Compositions for Treating Depression Using Cyclobenzaprine&#8221;,
issued. The claims recite the use of CBP for the treatment of depression in a FM patient.&#160; This patent provides TNX-102 SL with European
market exclusivity until March 2032 and may be extended based on the timing of the European marketing authorization of TNX-102 SL for
depression in a FM patient. In September 2020, Hexal AG filed an opposition against this patent. The European Patent Office&#8217;s Opposition
Division upheld the patent claims in unamended form at the February 2022 oral proceedings. The written decision is pending.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 15, 2020, U.S. Patent No. 10,864,175 entitled &#8220;Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline
Hydrochloride&#8221;, issued. The claims recite a eutectic comprising cyclobenzaprine hydrochloride and beta-mannitol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
April 8, 2021, U.S. non-provisional Patent Application No. 17/226,058 and International Patent Application No. PCT/US2021/026492, entitled
&#8220;Cyclobenzaprine Treatment for Sexual Dysfunction&#8221; were filed. The PCT application is now nationalized in Australia, Canada,
China, European Patent Office and Japan. On October 5, 2022, International Patent Application No. PCT/US2022/045791, entitled &#8220;Cyclobenzaprine
Treatment for Sexual Dysfunction&#8221; was filed. The claims of these applications are directed to methods using pharmaceutical compositions
and combinations for treating sexual dysfunction with cyclobenzaprine or pharmaceutically acceptable salts of cyclobenzaprine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
October 25, 2016 and July 28, 2020, U.S. Patent No. 9,474,728 and U.S. Patent No. 10,722,478, entitled &#8220;Methods and Compositions
for Treating Fatigue Associated with Disordered Sleep Using Very Low Dose Cyclobenzaprine&#8221;, issued, respectively. The claims are
directed to a method for monitoring the effectiveness of cyclobenzaprine treatment for disordered sleep and method for reducing CAP rates
A2 or A3 by treating a subject with a pharmaceutical composition comprising cyclobenzaprine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 11, 2018, U.S. non-provisional Patent Application No. 16/215,952 and International Patent Application No. PCT/IB2018/001509,
entitled &#8220;Cyclobenzaprine Treatment for Agitation, Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions,&#8221;
were filed. The PCT application is now nationalized in 16 countries. The claims are directed to methods for treating or preventing agitation,
cognitive decline, psychosis, and associated symptoms thereof using pharmaceutical compositions and combinations with cyclobenzaprine
or pharmaceutically acceptable salts of cyclobenzaprine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 20, 2019, International Patent Application No. PCT/IB2019/000940, entitled &#8220;Methods of Treating Acute Stress Disorder and
Posttraumatic Stress Disorder,&#8221; was filed. The PCT application is now nationalized in 18 countries. The claims are directed to methods
of treating acute stress disorder or post-traumatic stress disorder in a subject who has experienced a traumatic event using pharmaceutical
compositions with cyclobenzaprine, amitriptyline or pharmaceutically acceptable salts of cyclobenzaprine or amitriptyline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
November 19, 2021, International Patent Application No. PCT/US2021/060011, entitled &#8220;Cyclobenzaprine Treatment for Alcohol Use Disorder,&#8221;
was filed. The claims are directed to methods for treating alcohol use disorder and associated symptoms using pharmaceutical compositions
with cyclobenzaprine or pharmaceutically acceptable salts of cyclobenzaprine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 7, 2021, International Patent Application No. PCT/US2021/062244, entitled, &#8220;Cyclobenzaprine Treatment for Fibromyalgia,&#8221;
was filed. The claims are directed to methods for treating fibromyalgia and its associated symptoms of pain, sleep disturbance and/or
fatigue by transmucosally administering a eutectic with cyclobenzaprine hydrochloride and mannitol in dosage units with a basifying agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-1900
&#8212; Oxytocin-based treatments for Migraine, Pain, Insulin Resistance, Diabetes and Obesity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have acquired the migraine and pain treatment technologies of Trigemina, Inc., and have assumed its license rights to related technologies
from The Board of Trustees of the Leland Stanford Junior University. TNX-1900, an enhanced formulation of nasal oxytocin, has demonstrated
activity in several non-clinical studies in pain, including migraine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of our acquisition, we acquired International Patent Application No. PCT/US2016/012512, filed on January 7, 2016, entitled &#8220;Magnesium-Containing
Oxytocin Formulations and Methods of Use&#8221; (nationalized in 13 countries). We also acquired U.S. Patent Nos. 9,629,894 and 11,389,473,
entitled &#8220;Magnesium-Containing Oxytocin Formulations and Methods of Use&#8221;, which will expire in January 2036, excluding any
patent term extensions. We also have rights to International Patent Application No. PCT/US2019/020419, filed on April 12, 2017, entitled
&#8220;Labeled Oxytocin and Method of Manufacture and Use&#8221; (nationalized in the U.S., European Patent Office and Japan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have entered into an exclusive license to the University of Geneva&#8217;s technology for using oxytocin to treat insulin resistance and
related syndromes, including obesity. This license expands our intranasal potentiated oxytocin development program, TNX-1900, into cardiometabolic
syndromes. Under the license, we have rights to European Patent No. EP2571511B1, entitled &#8220;New Uses of Oxytocin-like Molecules and
Related Methods.&#8221; We also have rights to U.S. Patent No. 9,101,569, entitled &#8220;Methods for the Treatment of Insulin Resistance.&#8221;
The U.S. and non-U.S. patents expire in May 2031, excluding any patent term adjustments or extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-2900
&#8212; Oxytocin-based therapeutics treatments for Prader-Willi syndrome</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have licensed technology using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive
disease from the French National Institute of Health and Medical Research (INSERM). The co-exclusive license relates to TNX-2900, an intranasal
potentiated oxytocin, for the treatment of Prader-Willi syndrome and other feeding disorders. Under the license, we have rights to European
Patent No. EP2575853B1, entitled &#8220;Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset
in a Patient&#8221;; U.S. Patent No. 8,853,158, entitled &#8220;Methods for the Treatment of a Feeding Disorder with Onset During Neonate
Development Using an Agonist of the Oxytocin Receptor&#8221;; and U.S. Patent No. 9,125,862, entitled &#8220;Methods for the Treatment
of Prader-Willi-like Syndrome or Non-Organic Failure to Thrive (NOFITT) Feeding Disorder Using an Agonist of the Oxytocin Receptor.&#8221;
The U.S. and non-U.S. patents expire in May 2031, excluding any patent term extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-601
and TNX-601 ER&#8212; Depression, Posttraumatic Stress Disorder, Neurocognitive Dysfunction </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
patent portfolio for tianeptine oxalate includes U.S. Patent No. 9,314,469 and European Patent No. 2,299,822, both entitled &#8220;Method
for Treating Neurocognitive Dysfunction&#8221;, which issued on April 29, 2016 and July 26, 2017, respectively.&#160; The &#8217;822 patent
recites pharmaceutical compositions comprising various compounds (which include tianeptine) and uses thereof.&#160; This patent provides
TNX-601 with European market exclusivity until April 2029 and may be extended based on the timing of the European marketing authorization
of TNX-601 for neurocognitive side effects associated with the use of corticosteroids. The &#8216;469 patent claims methods of treating
cognitive impairment associated with corticosteroid treatment using compounds, including tianeptine, excluding patent term extensions,
the patent provides TNX-601 with US marketing exclusivity until 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
February 27, 2019, European Patent No. 3,246,031 entitled &#8220;Method for Treating Neurodegenerative Dysfunction,&#8221; issued. The
claims recite the use of TNX-601, or tianeptine oxalate and other salts, for treating neurocognitive dysfunction associated with corticosteroid
treatment. This patent provides TNX-601 with European market exclusivity until April 2029 and may be extended based on the timing of the
European market authorization of TNX-601 for neurocognitive disfunction associated with corticosteroid treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
October 22, 2019, U.S. Patent No. 10,449,203 issued.&#160; The claims recite anhydrous crystalline oxalate salts of tianeptine and provides
TNX-601 with US market exclusivity until 2037, excluding any patent term extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
March 16, 2021, U.S. Patent No. 10,946,027 issued. The claims recite pharmaceutical compositions of anhydrous crystalline oxalate salts
of tianeptine and provides TNX-601 with US market exclusivity until 2037, excluding any patent term extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
patent portfolio for TNX-601 also includes International Patent Application PCT/IB2017/001709 (now nationalized in 16 countries). It includes
claims directed to crystalline tianeptine oxalate and compositions of those crystal forms, and disclosures directed to methods of using
those crystalline forms and their compositions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
patent portfolio for TNX-601 CR includes International Patent Application No. PCT/US2022/020406, entitled &#8220;Tianeptine Oxalate and
Naloxone Treatment for Major Depressive Disorder,&#8221; was filed March 15, 2022. It includes claims directed to compositions with tianeptine
and naloxone or pharmaceutically acceptable salts of tianeptine and naloxone and methods of preventing or treating major depressive disorder
using the compositions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-1300
&#8212; Cocaine Intoxication Treatment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have licensed rights from The Trustees of Columbia University in the City of New York, The Regents of the University of Michigan, and
University of Kentucky Research Foundation to develop a potential product, TNX-1300, for the treatment of cocaine intoxication.&#160;
The licensed patents are directed to mutant cocaine esterase polypeptides and methods of using these polypeptides as anti-cocaine therapeutics.&#160;
They include U.S. Patent Nos. 8,318,156 and 9,200,265, entitled &#8220;Anti-Cocaine Compositions and Treatment&#8221; and various counterpart
patents outside of the U.S (e.g., European Patent 2046368). These patents provide TNX-1300 with US market exclusivity until February 2029,
and market exclusivity outside of the U.S. until July 10, 2027, subject to any patent term extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-1500
&#8212; anti-CD40L Therapeutics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are developing TNX-1500, a humanized mAb that targets CD40L for the prevention and treatment of organ transplant rejection.&#160; In this
regard, we filed International Application No. PCT/EP2020/068589, entitled &#8220;Anti-CD154 antibodies and uses thereof&#8221; on July
1, 2020 (nationalized in 15 countries). We also filed International Patent Application No. PCT/US2020/028002 on April 13, 2020, entitled
&#8220;Inhibitors of CD40-CD154 Binding&#8221; (nationalized in U.S., Canada, China, European Patent Office and Japan). We also filed
International Patent Application No. PCT/US2022/011404, entitled &#8220;Methods of Inducing Immune Tolerance with Modified Anti-CD154
Antibodies&#8221; on January 6, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-801
&#8212; Live Horsepox Vaccine for Prevention of Smallpox and Mpox</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
own the rights to develop a potential biodefense technology, TNX-801, a live horsepox that is being developed as a new smallpox and mpox
preventing vaccine, we have filed patent applications directed to synthetic chimeric poxviruses and methods of using these poxviruses
to protect individuals against smallpox. These applications include U.S. non-provisional Patent Application No. 15/802,189 and International
Patent Application No. PCT/US2017/059782 (nationalized in 15 countries and filed in 4 non-PCT countries). We also own the rights to develop
other vaccine candidates against smallpox.&#160; With respect to these vaccine candidates, we own International Patent Application No.
PCT/US2019/030486 and the non-convention and national phase applications related thereto (nationalized in 17 countries and filed in 2
non-PCT countries). The smallpox vaccine technologies relate to proprietary forms of live horsepox and vaccinia vaccines which may be
safer than ACAM2000, the only currently available replication competent, live vaccinia vaccine to protect against smallpox disease. We
believe that this technology, after further development, may be of interest to biodefense agencies in the U.S. and other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 31, 2022, U.S. Patent No. 11,345,896 was issued. The claims recite a synthetic chimeric orthopoxvirus (scOPV), a synthetic chimeric
horsepox virus (scHPXV), methods of generating the scOPV and scHPXV, and compositions comprising the scOPV or scHPXV.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-1850
&#8212; Live Modified Horsepox Vaccine for Prevention of COVID-19</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are developing TNX-1850, a live HPXV that is being developed as a new COVID-19 preventing vaccine. On February 26, 2021, we filed International
Patent Application No. PCT/US2021/020119, entitled &#8220;Recombinant Poxvirus Based Vaccine Against SARS-CoV-2.&#8221; On the same date,
we also filed applications in Argentina and Taiwan and we filed U.S. Application No. 17/187,678. The PCT application is not nationalized
in 18 countries. These applications are directed to synthetic poxviruses comprising a SARS-CoV-2 protein, poxvirus delivery vectors for
SARS-CoV-2 proteins and methods of using these modified poxviruses to protect individuals against COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-1700
&#8212; Recombinant Trefoil Family Factor 2 (rTFF2) to Treat Gastric and Pancreatic Cancers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have licensed rights from The Trustees of Columbia University in the City of New York to develop a potential product, TNX-1700, for the
treatment of gastric and pancreatic cancers.&#160; The licensed patents are directed to TFF2 compositions and methods of treatment.&#160;
The licensed patents U.S. Patent No. 10,124,037 and U.S. Patent No. 11,167,010.&#160;&#160; The licensed patents provide TNX-1700 with
US market exclusivity until April 2033, subject to any patent term extensions. On August 27, 2020, we filed International Patent Application
No. PCT/IB2020/000699 entitled &#8220;Modified TFF2 Polypeptides.&#8221; The PCT application is now nationalized in 12 countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-1600
&#8212; Triple Reuptake Inhibitor to Treat PTSD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have licensed rights from Wayne State University to develop a potential product, TNX-1600, for PTSD treatment.&#160; The licensed patents
directed to pyran-based derivatives and analogues.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">They
include U.S. Patent Nos. 7,915,433, 8,017,791, 8,519,159, 8,841,464, and 8,937,189, entitled &#8220;Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL
and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives&#8221; and U.S. Patent No.
9,458,124, entitled &#8220;Substituted Pyran Derivatives&#8221;.&#160; These patents provide TNX-1600 with US market exclusivity between
April 2024 and February 2034, respectively, subject to any patent term extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-701
&#8212; Radioprotection Biodefense Technology</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
own the rights to develop a potential biodefense technology, which is a potential radioprotective therapy. For protection of our intellectual
property, we have not disclosed the identity of the new development candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 7, 2021, we filed International Patent Application No. PCT/US2021/031441, entitled &#8220;Radio-and Chemo-Protective Compounds,&#8221;
and U.S. non-provisional Patent Application No. 17/315,258, entitled &#8220;Radio-Protective and Chemo-Protective Substituted Thiols.&#8221;
The PCT application is now nationalized in 10 countries. The applications claim compounds, compositions and methods of use in radioprotection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
January 31, 2023, U.S. Patent No. 11,566,032 issued. The claims recite compounds of a formula I or a pharmaceutically acceptable salt
thereof or stereoisomer thereof and a pharmaceutical composition comprising a compound of formula I.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>TNX-1200
&#8212; Smallpox Vaccine Technology</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
own the rights to develop a potential biodefense technology, TNX-1200, a live vaccinia virus that is being developed as a new smallpox
preventing vaccine, we have patent applications directed to synthetic chimeric poxviruses and methods of using these poxviruses to protect
individuals against smallpox. These applications, entitled &#8220;Synthetic Chimeric Vaccinia Virus,&#8221; include U.S. non-provisional
Patent Application No. 17/050,946 and International Patent Application No. PCT/US2019/030486 (now nationalized in 16 countries) and applications
filed in Argentina, Taiwan and Venezuela. We believe that this technology, after further development, may be of interest to biodefense
agencies in the U.S. and other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>TNX-2300 &#8212; Bovine Parainfluenza 3 Virus vaccine</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an exclusive field-of-use
option agreement with Kansas State University Research Foundation to develop TNX-2300, a bovine parainfluenza virus vaccine, as a new
COVID-19 preventing vaccine or treatment. The patent applications in this agreement include International Patent Application No. PCT/US2020/070725,
entitled &#8220;Broadly Protective Bovine Parainfluenza 3 Virus and Bovine Viral Diarrhea Virus Vaccine&#8221; (nationalized in U.S.
as Patent Application No. 17/755,359), and International Patent Application No. PCT/US2022/072433, entitled &#8220;SARS-Coronavirus 2
(SARS-CoV-2) Spike Protein Subunit Vaccines.&#8221;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>TNX-3700 &#8212; Zinc Nanoparticle mRNA vaccine</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an exclusive field-of-use
option agreement with Kansas State University Research Foundation to develop TNX-3700, a zinc nanoparticle mRNA vaccine, as a new COVID-19
preventing vaccine or treatment. The patent applications in this agreement include International Patent Application No. PCT/US2022/070739,
entitled &#8220;RNA Stabilizing Nanoparticles,&#8221; and International Patent Application No. PCT/US2022/075944, entitled &#8220;mRNA
Vaccine Formulations and Methods of Using the Same.&#8221;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>TNX-3900 &#8212; antiviral drugs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have acquired the intellectual
property rights of Healion Bio, Inc. to develop antiviral drugs. These rights include International Patent Application No. PCT/US2021/032461
(nationalized in 4 countries) and U.S. Patent Application No. 18/055,596, both entitled &#8220;Compositions and Methods for Increasing
Efficacy of a Drug,&#8221; as well as International Patent Application No. PCT/US2021/052664, entitled &#8220;Methods and Compositions
for the Treatment of Viral Diseases.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>TNX-4100 &#8212; murine anti-SARS-CoV-2 antibodies</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have exercised the option to
obtain an exclusive license from Columbia University to develop, TNX-4100, a series of murine and humanized anti-SARS-CoV-2 mAbs as new
COVID-19 preventatives or treatments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Trade
Secrets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, significant
aspects of our proprietary technology platform are based on unpatented trade secrets and know-how. Trade secrets and know-how can be difficult
to protect. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements and invention assignment
agreements with our employees, consultants, scientific advisors, contractors, and commercial partners. These agreements are designed to
protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that
are developed through a relationship with a third party. We also seek to preserve the integrity and confidentiality of our data and trade
secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While
we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have
adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.
To the extent that our contractors use intellectual property owned by others in their work for us, disputes may arise as to rights in
related or resulting inventions and know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Issued
Patents </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
current patents owned or licensed include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Anti-Cocaine
Therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,318,156</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2029</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,200,265</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 30, 2027</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2007272955</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2027</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014201653</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2027</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2657246</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2027</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">612929</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2027</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2046368 (602007045044.6 in Germany;
        502016000056543 in Italy)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe &#8211; (Germany, Spain,
        France, United Kingdom, and Italy)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2027</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2009/00197</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2027</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">305483</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2027</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">196411</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Cocaine Compositions and Treatment</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2027</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Sublingual
CBP/Amitriptyline</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6259452</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">631144</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I590820</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan R.O.C.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013274003</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I642429</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan R.O.C.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">726488</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I683660</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan R.O.C.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018241128</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2876902</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDP000076019</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">382516</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2861223</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office &#8211; Italy,
        Albania, Austria, Belgium, Bulgaria, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Latvia,
        Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland,
        United Kingdom, San Marino, Serbia, Croatia, North Macedonia and Turkey</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236268</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions for Transmucosal Delivery
        and Uses Thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015/00288</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112014031394-6</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1209361</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">398632</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A059897</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Venezuela</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MY-194495-A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2033</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; Depression&#160;</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2012225548</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Depression&#160;Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 6, 2032</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016222412</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Depression&#160;Using Cyclobenzaprine&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 6, 2032</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018204633</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Depression&#160;Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 6, 2032</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020203874</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Depression&#160;Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">March 6, 2032</span></p>
        </td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">614725</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Depression Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 6, 2032</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">714294</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Methods and
        Compositions for Treating Depression Using Cyclobenzaprine</span></p> </td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">March 6, 2032</span></p>
        </td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,829,200</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Depression Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 6, 2032</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2683245</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Methods and
        Compositions for Treating Depression Using Cyclobenzaprine</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office &#8211; Albania,
        Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Croatia,
        Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Monaco, Republic of North Macedonia, Malta, Netherlands, Norway, Poland,
        Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino, and Turkey</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 6, 2032</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; PTSD</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,918,948</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Symptoms Associated with Post-Traumatic Stress Disorder Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 18, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">2501234</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(AL/P/17/691
        in Albania; 602010045270.0 in Germany; 3094254 in Greece; 502017000142469 in Italy; MK/P/17/000807 in Republic of North Macedonia; 56634
        in Serbia; SM-T-201700578 in San Marino; 201717905 in Turkey)&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Symptoms Associated with Post-Traumatic Stress Disorder Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office &#8211; Albania,
        Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Croatia,
        Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Monaco, Republic of North Macedonia, Malta, Netherlands, Norway, Poland,
        Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino, Turkey</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 16, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK1176235</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Symptoms Associated with Post-Traumatic Stress Disorder Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 16, 2030</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
Fatigue</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,474,728</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Fatigue Associated with Disordered Sleep Using Very Low Dose Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 9, 2031</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,722,478</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Fatigue Associated with Disordered Sleep Using Very Low Dose Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 9, 2031</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP/Amitriptyline
Eutectic Formulations&#160; </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">631152</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">747040</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,636,408</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,956,188</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,117,936</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline
        Hydrochloride</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.&#160;&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,322,094</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline
        Hydrochloride</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,357,465</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,736,859</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,864,175</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,864,176</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,026,898</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride </span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6310542</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6614724</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine Hydrochloride</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6717902</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine Hydrochloride</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6088</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saudi Arabia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZL201480024011.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZL.201580050140.2</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014233277</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015317336</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I661825&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan R.O.C.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I740136</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations
        of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan R.O.C.</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDP000055516</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline
        Hydrochloride</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDP000063221</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine Hydrochloride</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDP000076872</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline
        Hydrochloride</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">2968992</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(1211591 in
        Austria, CZ2014-762323 in Czechia, 602014058260.5 in Germany, E018723 in Estonia, P20200055 in Croatia, 201361792757 P in Ireland, 2020.67
        in Monaco, P-2020/0094 in Serbia, 201431487 in Slovenia, 33269 in Slovakia, 2020000045 in San Marino, AL/P/2019/906 in Albania, MK/P/2020/67
        in Republic of North Macedonia, 3102655 in Greece, 502020000007756 in Italy)&#160;</span></p></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office -Albania,
        Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Republic of North Macedonia, Germany, Greece,
        Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, San Marino,
        Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">March 14,
        2034</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">241353</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">251218</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Methods of Producing Same</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277814</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Methods of Producing Same</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">370021</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387402</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">388137</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015/07443</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">South Africa&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017/01637</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112015022095-9</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Composition, Method
        of Fabrication, Eutectic Composition and Use of Compositions Containing Cyclobenzaprine HCl and Mannitol</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2904812</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK1218727</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 14, 2034</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MY-186047-A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">398845</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2035</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Oxytocin
therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,629,894</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 7, 2036</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,389,473</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 7, 2036</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11201705591P</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 7, 2036</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">388286</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 7, 2036</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">253347</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 7, 2036</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7030517</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 7, 2036</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZL201680013809.5</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 7, 2036</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7093559</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 12, 2037</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2575853</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Pharmaceutical Composition
        for the Treatment of a Feeding Disorder with Early-Onset in a Patient</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe &#8211; (Spain, France, and
        United Kingdom)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 25, 2031</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,853,158</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for the Treatment of a Feeding
        Disorder with Onset During Neonate Development Using an Agonist of the Oxytocin Receptor</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 25, 2031</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,125,862</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for the Treatment of Prader-Willi-like
        Syndrome or Non-Organic Failure to Thrive (NOFITT) Feeding Disorder Using an Agonist of the Oxytocin Receptor</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 25, 2031</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2571511</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Uses of Oxytocin-like Molecules
        and Related Methods</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe &#8211; (Switzerland, Spain,
        France, United Kingdom, and Ireland)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 17, 2031</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,101,569</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for the Treatment of Insulin
        Resistance</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 22, 2031</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Nociceptin/Orphanin
FQ therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,551,949</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 11, 2031</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,238,053</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2010281436</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZL 201080042858.4</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2459183 (602010028120.5 in Germany)
        </span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe &#8211; (Switzerland, Germany,
        Denmark, France, and United Kingdom) </span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1169804</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">329837</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">597763</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10201406930U</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201200584</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,769,347</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">413642</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for treatment of pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2030</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Tianeptine
Hemioxalate &#8211; Salts and Crystalline Forms</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,449,203</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 28, 2037</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,946,027</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 28, 2037</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019/04185</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 28, 2037</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017385958</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 28, 2037</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDP000082485</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 28, 2037</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">754797</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 28, 2037</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Tianeptine
&#8211; Neurocognitive Dysfunction</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,314,469</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method for Treating Neurocognitive
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 24, 2030</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2723688</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method for Treating Neurodegenerative
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 30, 2029</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2299822 (602009047361.1 in Germany
        and E911827 in Austria)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method for Treating Neurodegenerative
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office &#8211; Austria,
        Belgium, Switzerland, Germany, Spain, France, United Kingdom, Ireland, Luxembourg, Monaco, Portugal</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 30, 2029</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3246031 (602009057284.9 in Germany)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method for Treating Neurocognitive
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office &#8211; Austria,
        Belgium, Switzerland, Germany, Spain, France, United Kingdom, Ireland, Luxembourg, Monaco, Portugal</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 30, 2029</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Triple
reuptake inhibitor therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,915,433</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL
        and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">March 10,
        2028</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,017,791</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL
        and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 14, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,519,159</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL
        and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 7, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,841,464</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL
        and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 15, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,937,189</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL
        and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 12, 2027</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,458,124</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substituted Pyran Derivatives</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 6, 2034</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">TFF2
therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,124,037</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trefoil family factor proteins and
        uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2033</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,167,010</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trefoil family factor proteins and
        uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2033</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Synthetic
Chimeric Poxviruses</span></i>&#160; </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,345,896</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2, 2037</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">397516</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2, 2037</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019/02868</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2, 2037</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Radioprotection
therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration&#160;</b></span><span style="font-family: Times New Roman, Times, Serif">
        <span style="font-size: 10pt"><b>Date</b></span></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,566,032</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-Protective and Chemo-Protective
        Substituted Thiols</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 7, 2041</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pending
Patent Applications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
current pending patent applications are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CD40
and anti-CD154 Therapeutics </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/623,710</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020300002</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112021026410-8</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3145453</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202080059891.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20764933.6</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202217004870</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P00202200763</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Anti-CD154
        antibodies and uses thereof&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">289354</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-578262</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI 2021007835</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2022/000133</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">784548</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11202114433Y</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022/01378</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62022063693.5</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62022062573.0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-CD154 antibodies and uses thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2022/011404</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Inducing Immune Tolerance
        with Modified Anti-CD154 Antibodies&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3136725</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inhibitors of CD40-CD154 Binding</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20787970.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inhibitors of CD40-CD154 Binding</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-560713</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inhibitors of CD40-CD154 Binding</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/603,260</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inhibitors of CD40-CD154 Binding</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202080033531.4</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inhibitors of CD40-CD154 Binding</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP/Amitriptyline
Eutectic Formulations </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/121,547</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/082,949</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020289838</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride (Allowed)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112017005231-8</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR122020020968-2</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,961,822</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,119,755</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">201910263541.6&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202011576351.9</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15841528.1&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19214535.7</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18101200.4</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42020003105.2</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations
        of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42020019748.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42021036749.6</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3392/KOLNP/2015</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-105582</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-169539</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI 2015703142</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI 20233000078</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">730379</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">768064</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride </span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">517381123</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saudi Arabia</span></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">10201707528W</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">10201902203V</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Eutectic Formulations
        of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Eutectic Formulations
        of Cyclobenzaprine Hydrochloride</span></p></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Singapore</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Singapore</span></p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014-000391</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eutectic Formulations of Cyclobenzaprine
        Hydrochloride and Amitriptyline Hydrochloride</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Venezuela</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Sublingual
CBP/Amitriptyline</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/918,692</span></td>
    <td style="vertical-align: bottom; padding-right: 16pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P20130102101</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argentina</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Yet Assigned</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argentina</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR122019024508-8</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Brazil&#160;</span></p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,118,913</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption </span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202010024102.2</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">2013/24661&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">2013/37088&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Compositions
        and Methods for Transmucosal Absorption&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Compositions
        and Methods for Transmucosal Absorption&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Gulf Cooperation
        Council&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Gulf Cooperation
        Council&#160;</span></p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013/40660</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gulf Cooperation Council</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42020020336.2</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P-00 2021 01421</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-100154</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10201605407T</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Transmucosal
        Absorption</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; PTSD&#160; </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/951,723</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Symptoms Associated with Post-Traumatic Stress Disorder Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Assessing
Clinical Response &#8211; PTSD</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2022/015327</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An Improved Method of Assessing
        Clinical Response in the Treatment of PTSD Symptoms</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; Fatigue&#160; </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/903,965</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Fatigue Associated with Disordered Sleep Using Very Low Dose Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; Agitation in Neurodegenerative Condition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/215,952</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018383098</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment
        for Agitation, Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112020011345-0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,083,341</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201880079917.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18847270.8</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P00202004178</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">275289</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202017023747</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020-531611</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2020/006140</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI2020002800</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">765792</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">520412146</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saudi Arabia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11202004799T</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020/03243</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6202002246.2</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62021029558.5</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Agitation,
        Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; Depression&#160;</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/412,571</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating
        Depression Using Cyclobenzaprine</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19214568.8</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for Treating Depression Using Cyclobenzaprine&#160;&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Analogs
of CBP</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">16/630,832&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">CA3069699&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">201880050758.2&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">EP18831505.5&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Analogs of
        Cyclobenzaprine and Amitriptyline&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Analogs of
        Cyclobenzaprine and Amitriptyline&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Analogs of
        Cyclobenzaprine and Amitriptyline&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Analogs of
        Cyclobenzaprine and Amitriptyline&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Analogs of
        Cyclobenzaprine and Amitriptyline</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">U.S.A.&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Canada&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">China&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">European Patent
        Office&#160;</span></p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020-526592</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogs of Cyclobenzaprine and Amitriptyline</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; ASD and PTSD</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application No.</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019/38140</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gulf Cooperation Council</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108129709</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan R.O.C.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/269,106</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019323764</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI2021000802</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">772889</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112021003107-3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3109258</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201980062283.3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19802247.7</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62021045278.0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62022046260.5</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202117011223</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P00202101716</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">280921</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine or Amitriptyline
        Containing Compositions for Use in Treating Stress Disorders</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-509201</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2021/002012</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11202101443W</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021/01121</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of Treating Acute Stress
        Disorder and Posttraumatic Stress Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td></tr>
  <tr>
    <td style="width: 18%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 18%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; Fibromyalgia</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2021/062244</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Fibromyalgia</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; Alcohol Use Disorder</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2021/060011</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Alcohol
        Use Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; Sexual dysfunction</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2022/045791</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Sexual
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/226,058</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Sexual
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021253592</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Sexual
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3179754</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Sexual
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202180040673.8</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Sexual
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21721779.3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Sexual
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-562023</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Sexual
        Dysfunction</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">CBP
&#8211; Post-Acute Sequelae of SARS-CoV-2 (PASC)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/354,215</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclobenzaprine Treatment for Post-Acute
        Sequelae of (SARS)-CoV-2 Infection (PASC)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Oxytocin
therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020286221</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120170145456</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2972975</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16735422.4</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18112297.5</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-179295</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1020177021998</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Republic of Korea</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">734097</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">771693</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201705176</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use (Allowed)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/976,912</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labeled Oxytocin and Method of Manufacture
        and Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19710979.6</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labeled Oxytocin and Method of Manufacture
        and Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020-545532</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labeled Oxytocin and Method of Manufacture
        and Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/093,104</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017250505</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,020,179</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017800361853</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use (Allowed)</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023100344997</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17783080.9</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19128645.9</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-60727</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2018/012351</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">747221&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">787097</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Magnesium-Containing Oxytocin Formulations
        and Methods of Use</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Nociceptin/Orphanin
FQ therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR122021007932-3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for Treatment of Pain</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Tianeptine
Hemioxalate &#8211; Salts and Crystalline Forms&#160;</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112019013244-9</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,048,324</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201780085697.9</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17844642.3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62020006380.3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62020006381.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">267708</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs,
        Compositions Comprising Same and Uses Thereof</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201917029300</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate Salts and Polymorphs</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">2019-535330&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">2022-180549&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">MX/a/2019/007891&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">PI2019003711&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">519402021&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">11201905974W&#160;&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Tianeptine
        Oxalate Salts and Polymorphs&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Tianeptine
        Oxalate Salts and Polymorphs&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Tianeptine
        Oxalate Salts and Polymorphs&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Tianeptine
        Oxalate Salts and Polymorphs&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Tianeptine
        Oxalate Salts and Polymorphs&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Tianeptine
        Oxalate Salts and Polymorphs&#160;&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Japan&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Japan&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Mexico&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Malaysia&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Saudi Arabia&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Singapore&#160;</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Tianeptine
and Naloxone &#8211; Major Depressive Disorder</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2022/020406</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianeptine Oxalate and Naloxone
        Treatment for Major Depressive Disorder</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Synthetic
Chimeric Poxviruses</span></i>&#160; </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/827,320</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P 20170103043</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argentina</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017/34209</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gulf Cooperation Council</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017/41626</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gulf Cooperation Council</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106137976</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan R.O.C.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017353868</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112019008781-8</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR122023000373-0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,042,694</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201780078546.0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17868045.0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">201917021814&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">PID201904682&#160;&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Synthetic
        Chimeric Poxviruses&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Synthetic
        Chimeric Poxviruses&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">India&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indonesia&#160;&#160;</span></p></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">266399&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">2019-545700&#160;&#160;</span></p></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Synthetic
        Chimeric Poxviruses&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Synthetic
        Chimeric Poxviruses&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Israel&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Japan&#160;&#160;</span></p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-140113</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI2019002462</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td></tr>
  <tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">752893&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">11201903893P&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Synthetic
        Chimeric Poxviruses&#160;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Synthetic
        Chimeric Poxviruses&#160;</span></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">New Zealand&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Singapore&#160;&#160;</span></p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022/04981</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017-000418</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Venezuela</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62020003684.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62020003675.9</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Poxviruses</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Synthetic
Vaccinia Virus</span></i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019/37492</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gulf Cooperation Council&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019/41458</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gulf Cooperation Council&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20190101165</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argentina</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108115290</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan R.O.C.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/050,946</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019262149</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112020022181-3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3099330</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201980029677.9</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19796145.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202017052398</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P00202008694</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278419</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020-560920</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI 2020005696</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2020/011586</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">768999</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11202010272P</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020/06350</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62021036744.2</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62021038254.0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Chimeric Vaccinia Virus</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Stem
cells-scPV treatment&#160; </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="vertical-align: bottom; width: 1%; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019/37505</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gulf Cooperation Council</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019/41460</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gulf Cooperation Council</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20190101166</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argentina</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108115294</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan R.O.C.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/049,741</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019262150</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3098145</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising
        Synthetic Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201980029672.6</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19797026.2</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278420</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020-561064</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62021038255.7</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62021031667.0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stem Cells Comprising Synthetic
        Chimeric Vaccinia Virus and Methods of Using Them</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Poxvirus
vaccine against COVID-19</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/187,678</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110107179</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20210100512</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argentina</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/315,520</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1202200348</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">African Intellectual Property Organization</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AP/P/2022/014318</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">African Regional Intellectual Property Organization</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021226592</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112022016992-2</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3173996</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202180027983.6</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202292431</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eurasian Patent Office</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21715007.7</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202217053476</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P00202210244</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indonesia</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">295925</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-551297</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI 2022004613</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2022/010588</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">791924</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2022-7033014</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Republic of Korea</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">522440323</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saudi Arabia</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022/09895</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant Poxvirus Based Vaccine against SARS-CoV-2
        virus</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Salts
of glutathione</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/442,258</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt forms of S-(N, N-diethylcarbamolyl)
        glutathione</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020249868</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt forms of S-(N, N-diethylcarbamolyl)
        glutathione</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,134,875</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt forms of S-(N, N-diethylcarbamolyl)
        glutathione</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202080034626.8</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt forms of S-(N, N-diethylcarbamolyl)
        glutathione</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20727359.0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt forms of S-(N, N-diethylcarbamolyl)
        glutathione</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">286730</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt forms of S-(N, N-diethylcarbamolyl)
        glutathione</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-557223</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt forms of S-(N, N-diethylcarbamolyl)
        glutathione</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62022054457.6</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt forms of S-(N, N-diethylcarbamolyl)
        glutathione</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62022057646.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt forms of S-(N, N-diethylcarbamolyl)
        glutathione</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">TFF2
therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/638,761</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020338947</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3152665</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202080071768.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20781063.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202217016249</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">290910</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-513154</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2022/002337</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">786004</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022/03355</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62023066535.3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62023066928.0</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modified TFF2 polypeptides</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Radioprotection
therapeutics</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/991,292</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-Protective and Chemo-Protective
        Substituted Thiols</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/923,831</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021269125</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3182014</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td></tr>
  </table>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Yet Assigned</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective
        Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21728771.3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202217070148</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">298025</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-567802</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">793900</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">522441204</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saudi Arabia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11202254727V</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radio-and Chemo-Protective Compounds</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Clinical
data statistical analysis</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2021/056213</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randomization Honoring Methods to
        Assess the Significance of Interventions on Outcomes in Disorders</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/508,182</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randomization Honoring Methods to
        Assess the Significance of Interventions on Outcomes in Disorders</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Monoclonal
Antibodies &#8211; anti-SARS-CoV-2 Spike</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/421,137</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-SARS-CoV-2-Spike Monoclonal
        Antibodies and Antigen-Binding Fragments Thereof and Use in Treating SARS-CoV-2 Infection</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/421,138</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-SARS-CoV-2-Spike Monoclonal
        Antibodies and Antigen-Binding Fragments Thereof and Use in Treating SARS-CoV-2 Infection</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/421,141</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-SARS-CoV-2-Spike Monoclonal
        Antibodies and Antigen-Binding Fragments Thereof and Use in Treating SARS-CoV-2 Infection</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Nanoparticles
&#8211; T cell Immune Response</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/338,217</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nanoparticles for Inducing a TH1
        T Cell Immune Response</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><b><i>Nanoparticles &#8211;
mRNA vaccine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-size: 10pt"><b>Application No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Country / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">PCT/US2022/070739</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">RNA Stabilizing Nanoparticles</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">PCT</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">PCT/US2022/075944</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">mRNA Vaccine Formulations and Methods of Using the Same</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">PCT</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><b><i>Virus Vaccine &#8211;
Bovine Parainfluenza Virus Vaccine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-size: 10pt"><b>Application No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Country / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">17/755,359</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Broadly Protective Bovine Parainfluenza 3 Virus and Bovine Viral Diarrhea Virus Vaccine</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">PCT/US2022/072433</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">SARS-Coronavirus 2 (SARS-CoV-2) Spike Protein Subunit Vaccines</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">PCT</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i><span style="text-decoration: underline">Antiviral
Drugs &#8211; Cathepsin Inhibitors</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
        No.</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 62%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
        / Region</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/327,431</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic Agents and Combinations
        for Treating Viral Diseases</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/055,596</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Increasing
        Efficacy of a Drug</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021271806</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Increasing
        Efficacy of a Drug</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21803283.7</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Increasing
        Efficacy of a Drug</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Office</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-569505</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Increasing
        Efficacy of a Drug</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202217072271</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods for Increasing
        Efficacy of a Drug</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2021/052664</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods and Compositions for the
        Treatment of Viral Diseases</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Trademarks
and Service Marks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
seek trademark and service mark protection in the United States and outside of the United States where available and when appropriate.
We are the owner of the following U.S. federally registered marks: TONIX PHARMACEUTICALS (Reg. No. 4656463, issued December 16, 2014).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are the owner of the following marks for which applications for U.S. federal registration are currently pending: FYMRALIN (Serial No.
97/458017, filed June 14, 2022), MODALTIN (Serial No. 97/424052, filed May 23, 2022), RAPONTIS&#160; (Serial&#160; No. 97/424058, filed
May 23, 2022), PROTECTIC (Serial No. 97/424071, filed May 23, 2022), TONIX PHARMACEUTICALS (Serial No. 88/896150, filed April 30, 2020),
and ANGSTRO-TECHNOLOGY (Serial No. 88/690384, filed November 13, 2019) and TONMYA (Serial No. 97/185424, filed December 22, 2021).&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have approximately 94 employees dedicated to research and development. Our research and development operations are located in Chatham,
NJ, Dartmouth, MA, Frederick, Maryland, San Diego, CA, Dublin, Ireland and Montreal, Canada. We have used, and expect to continue to use,
third parties to conduct our nonclinical and clinical studies.<i>&#160;</i>We acquired the RDC in Frederick, Maryland consisting of two
buildings totaling approximately 48,000 square feet. The acquisition closed in October 2021 and is operational.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have contracted with a third-party cGMP-compliant contract manufacturer organization, or CMOs, for the manufacture of TNX-102 SL drug
substances and drug products for investigational purposes, including nonclinical and clinical testing. For TNX-102 SL, we have engaged
a cGMP facility for manufacturing of to-be-marketed product for Phase 3 clinical and commercial. Our manufacturing operations are managed
and controlled in Dublin, Ireland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
of our small molecules drug candidates are synthesized using industry standard processes, and our drug products are formulated using commercially
available pharmaceutical grade excipients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our smallpox- and mpox-preventing vaccine candidate is a biologic and employs a live form of horsepox. Both the drug substance (HPVX and the cell bank)
and the drug product (vaccine) will be manufactured by contract cGMP-compliant facilities capable of manufacturing for nonclinical/clinical
testing and licensed product.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 28, 2020,
we completed the purchase of our 45,000 square foot facility in Massachusetts, to house our new Advanced Development Center for
accelerated development and manufacturing of vaccines and biologics. As of October 1, 2022, the facility was ready for its intended
use and is operational.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 23, 2020, we completed the purchase of our approximately 44-acre site in Hamilton, Montana, for the construction of a vaccine
development and commercial scale manufacturing facility. As of December 31, 2022, the facility was not ready for its intended use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Government
Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval,
labeling, manufacture, marketing and distribution of drug products. These agencies regulate, among other things, research and development
activities and the testing, approval, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, advertising
and promotion of our product candidates. The regulatory approval process is generally lengthy and expensive, with no guarantee of a positive
result. Moreover, failure to comply with applicable requirements by the FDA or other requirements may result in civil or criminal penalties,
recall or seizure of products, injunctive relief including partial or total suspension of production, or withdrawal of a product from
the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA regulates, among other things, the research, manufacture, promotion and distribution of drugs in the U.S. under the FDCA and other
statutes and implementing regulations. The process required by the FDA before prescription drug product candidates may be marketed in
the U.S. generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of extensive nonclinical
        laboratory tests, animal studies and formulation studies, all performed in accordance with the FDA&#8217;s Good Laboratory Practice regulations;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an IND,
        which must become effective before human clinical trials may begin;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled
        human clinical trials in accordance with the FDA&#8217;s regulations, including Good Clinical Practices, to establish the safety and efficacy
        of the product candidate for each proposed indication;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an NDA
        for drug products, or a Biologics License Application, or BLA, for biologic products;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of a preapproval
        inspection by the FDA of the manufacturing facilities at which the product is produced to assess compliance with cGMP regulations; and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s review and approval
        of the NDA or BLA prior to any commercial marketing, sale or shipment of the drug.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for
our product candidates will be granted on a timely basis, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Nonclinical
tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals
and other animal studies. The results of nonclinical tests, together with manufacturing information and analytical data, are submitted
as part of an IND to the FDA. Some nonclinical testing may continue even after an IND is submitted. The IND also includes one or more
protocols for the initial clinical trial or trials and an investigator&#8217;s brochure. An IND automatically becomes effective 30 days
after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions relating to the proposed clinical
trials as outlined in the IND and places the clinical trial on a clinical hold. In such cases, the IND sponsor and the FDA must resolve
any outstanding concerns or questions before any clinical trials can begin. Clinical trial holds also may be imposed at any time before
or during studies due to safety concerns or non-compliance with regulatory requirements. An independent Institutional Review Board, or
IRB, at each of the clinical centers proposing to conduct the clinical trial must review and approve the plan for any clinical trial before
it commences at that center. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized
and are reasonable in relation to anticipated benefits. The IRB also approves the consent form signed by the trial participants and must
monitor the study until completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Clinical
Trials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Clinical
trials involve the administration of the product candidate to human subjects under the supervision of qualified medical investigators
according to approved protocols that detail the objectives of the study, dosing procedures, subject selection and exclusion criteria,
and the parameters to be used to monitor participant safety. Each protocol for a U.S. study is submitted to the FDA as part of the IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Human
clinical trials are typically conducted in three sequential phases, but the phases may overlap, or be combined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1 clinical trials typically
        involve the initial introduction of the product candidate into healthy human volunteers. In Phase 1 clinical trials, the product candidate
        is typically tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px">
        <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></p>
        <p style="margin-top: 0; margin-bottom: 0">&#160;</p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2 clinical trials are generally
        conducted in a limited patient population to gather evidence about the efficacy of the product candidate for specific, targeted indications;
        to determine dosage tolerance and optimal dosage; and to identify possible adverse effects and safety risks. Phase 2 clinical trials,
        in particular Phase 2b trials, can be undertaken to evaluate clinical efficacy and to test for safety in an expanded patient population
        at geographically dispersed clinical trial sites.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3 clinical trials are undertaken
        to evaluate clinical efficacy and to test for safety in an expanded patient population at geographically dispersed clinical trial sites.
        The size of Phase 3 clinical trials depends upon clinical and statistical considerations for the product candidate and disease. Phase
        3 clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide an adequate basis for
        product labeling.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Post-approval
clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial approval. These clinical trials are
used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety
follow-up.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Clinical
testing must satisfy the extensive regulations of the FDA. Reports detailing the results of the clinical trials must be submitted at least
annually to the FDA and safety reports must be submitted for serious and unexpected adverse events. Success in early-stage clinical trials
does not assure success in later-stage clinical trials. The FDA, an IRB or we may suspend a clinical trial at any time on various grounds,
including a finding that the research subjects or patients are being exposed to an unacceptable health risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>New
Drug Applications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Assuming
successful completion of the required clinical trials, the results of product development, nonclinical studies and clinical trials are
submitted to the FDA as part of an NDA (or BLA, in the case of a biologic product). An NDA or BLA also must contain extensive manufacturing
information, as well as proposed labeling for the finished product. An NDA or BLA applicant must develop information about the chemistry
and physical characteristics of the drug and finalize a process for manufacturing the product in accordance with cGMP. The manufacturing
process must be capable of consistently producing quality product within specifications approved by the FDA. The manufacturer must develop
methods for testing the quality, purity and potency of the final product. In addition, appropriate packaging must be selected and tested,
and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf life.
Prior to approval, the FDA will conduct an inspection of the manufacturing facilities to assess compliance with cGMP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA reviews all NDAs and BLAs submitted before it accepts them for filing. The FDA may request additional information rather than accept
an NDA for filing. In this event, the NDA or BLA must be resubmitted with the additional information and is subject to review before the
FDA accepts it for filing. After an application is filed, the FDA may refer the NDA or BLA to an advisory committee for review, evaluation
and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations
of an advisory committee, but it considers them carefully when making decisions. The FDA may deny approval of an NDA or BLA if the applicable
regulatory criteria are not satisfied. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently
than we interpret the same data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA may issue a complete response letter, which may require additional clinical or other data or impose other conditions that must be
met in order to secure final approval of the NDA or BLA. If a product receives regulatory approval, the approval may be significantly
limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value
of the product. In addition, the FDA may require us to conduct Phase 4 testing which involves clinical trials designed to further assess
a drug&#8217;s safety and effectiveness after NDA or BLA approval, and may require surveillance programs to monitor the safety of approved
products which have been commercialized. Once issued, the FDA may withdraw product approval if ongoing regulatory requirements are not
met or if safety or efficacy questions are raised after the product reaches the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;<i>Section
505(b) NDAs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are two types of NDAs: the
Section 505(b)(1) NDA, or full NDA, and the Section 505(b)(2) NDA. We intend to file Section 505(b)(2) NDAs for TNX-102 SL for FM, Long
COVID and PTSD, for TNX-1900 for chronic migraine and TNX-2900 for Prader Willi Syndrome and for certain other products, that might, if
accepted by the FDA, save time and expense in the development and testing of our product candidates. We may need to file a Section 505(b)(1)
NDA for certain other products in the future. A full NDA is submitted under Section 505(b)(1) of the FDCA, and must contain full reports
of investigations conducted by the applicant to demonstrate the safety and effectiveness of the drug. A Section 505(b)(2) NDA may be submitted
for a drug for which one or more of the investigations relied upon by the applicant was not conducted by or for the applicant and for
which the applicant has no right of reference from the person by or for whom the investigations were conducted. A Section 505(b)(2) NDA
may be submitted based in whole or in part on published literature or on the FDA&#8217;s finding of safety and efficacy of one or more
previously approved drugs, which are known as reference drugs. Thus, the filing of a Section 505(b)(2) NDA may result in approval of a
drug based on fewer clinical or nonclinical studies than would be required under a full NDA. The number and size of studies that need
to be conducted by the sponsor depends on the amount and quality of data pertaining to the reference drug that are publicly available,
and on the similarity of and differences between the applicant&#8217;s drug and the reference drug. In some cases, extensive, time-consuming,
and costly clinical and nonclinical studies may still be required for approval of a Section 505(b)(2) NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our drug approval strategy for
our new formulations of approved chemical entities is to submit Section 505(b)(2) NDAs to the FDA. As such, we plan to submit an NDA under
Section 505(b)(2) for TNX-102 SL for FM, Long COVID and PTSD; TNX-1900 for chronic migraine, and TNX-2900 for Prader Willi Syndrome. The
FDA may not agree that these product candidates are approvable as a Section 505(b)(2) NDA. If the FDA determines that a Section 505(b)(2)
NDA is not appropriate and that a full NDA is required, the time and financial resources required to obtain FDA approval could substantially
and materially increase and be less likely to be approved. If the FDA requires a full NDA or requires more extensive testing and development
for some other reason, our ability to compete with alternative products that arrive on the market more quickly than our product candidates
would be adversely impacted. If reference listed products are withdrawn from the market by the FDA for a safety reason, we may not be
able to reference such products to support our anticipated 505(b)(2) NDAs, and we may be required to follow the requirements of Section
505(b)(1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Patent
Protections</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
applicant submitting a Section 505(b)(2) NDA must certify to the FDA with respect to the patent status of the reference drug upon which
the applicant relies in support of approval of its drug. With respect to every patent listed in the FDA&#8217;s Orange Book, which is
the FDA&#8217;s list of approved drug products, as claiming the reference drug or an approved method of use of the reference drug, the
Section 505(b)(2) applicant must certify that: (1) there is no patent information listed in the orange book for the reference drug; (2)
the listed patent has expired; (3) the listed patent has not expired, but will expire on a particular date; (4) the listed patent is invalid
or will not be infringed by the manufacture, use, or sale of the product in the Section 505(b)(2) NDA; or (5) if the patent is a use patent,
that the applicant does not seek approval for a use claimed by the patent. If the applicant files a certification to the effect of clause
(1), (2) or (5), FDA approval of the Section 505(b)(2) NDA may be made effective immediately upon successful FDA review of the application,
in the absence of marketing exclusivity delays, which are discussed below. If the applicant files a certification to the effect of clause
(3), the Section 505(b)(2) NDA approval may not be made effective until the expiration of the relevant patent and the expiration of any
marketing exclusivity delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
the Section 505(b)(2) NDA applicant provides a certification to the effect of clause (4), referred to as a paragraph IV certification,
the applicant also must send notice of the certification to the patent owner and the holder of the NDA for the reference drug. The filing
of a patent infringement lawsuit within 45 days of the receipt of the notification may prevent the FDA from approving the Section 505(b)(2)
NDA for 30 months from the date of the receipt of the notification unless the court determines that a longer or shorter period is appropriate
because either party to the action failed to reasonably cooperate in expediting the action. However, the FDA may approve the Section 505(b)(2)
NDA before the 30 months have expired if a court decides that the patent is invalid or not infringed, or if a court enters a settlement
order or consent decree stating the patent is invalid or not infringed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;Notwithstanding
the approval of many products by the FDA pursuant to Section 505(b)(2), over the last few years certain brand-name pharmaceutical companies
and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA&#8217;s interpretation of Section 505(b)(2)
is successfully challenged in court, the FDA may be required to change its interpretation of Section 505(b)(2) which could delay or even
prevent the FDA from approving any Section 505(b)(2) NDA that we submit. The pharmaceutical industry is highly competitive, and it is
not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose
additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent,
the approval of the new product. Moreover, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval
while it considers and responds to the petition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Marketing
Exclusivity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Market
exclusivity provisions under the FDCA can delay the submission or the approval of Section 505(b)(2) NDAs, thereby delaying a Section 505(b)(2)
product from entering the market. The FDCA provides five-year marketing exclusivity to the first applicant to gain approval of an NDA
for an NCE, meaning that the FDA has not previously approved any other drug containing the same active moiety. This exclusivity prohibits
the submission of a Section 505(b)(2) NDA for any drug product containing the active ingredient during the five-year exclusivity period.
However, submission of a Section 505(b)(2) NDA that certifies that a listed patent is invalid, unenforceable, or will not be infringed,
as discussed above, is permitted after four years, but if a patent infringement lawsuit is brought within 45 days after such certification,
FDA approval of the Section 505(b)(2) NDA may automatically be stayed until 7&#189; years after the NCE approval date. The FDCA also provides
three years of marketing exclusivity for the approval of new and supplemental NDAs for product changes, including, among other things,
new indications, dosage forms, routes of administration or strengths of an existing drug, or for a new use, if new clinical investigations,
other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by FDA to be essential to the approval
of the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Five-year
and three-year exclusivity will not delay the submission or approval of another full NDA; however, as discussed above, an applicant submitting
a full NDA under Section 505(b)(1) would be required to conduct or obtain a right of reference to all of the nonclinical and adequate
and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
types of exclusivity in the United States include orphan drug exclusivity and pediatric exclusivity. The FDA may grant orphan drug designation
to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals
in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the
cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales
in the United States for that drug. Seven-year orphan drug exclusivity is available to a product that has orphan drug designation and
that receives the first FDA approval for the indication for which the drug has such designation. Orphan drug exclusivity prevents approval
of another application for the same drug for the same orphan indication, for a period of seven years, regardless of whether the application
is a full NDA or a Section 505(b)(2) NDA, except in limited circumstances, such as a showing of clinical superiority to the product with
orphan exclusivity. Pediatric exclusivity, if granted, provides an additional six months to an existing exclusivity or statutory delay
in approval resulting from a patent certification. This six-month exclusivity, which runs from the end of other exclusivity protection
or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written
Request&#8221; for such a study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Section
505(b)(2) NDAs are similar to full NDAs filed under Section 505(b)(1) in that they are entitled to any of these forms of exclusivity if
they meet the qualifying criteria. They also are entitled to the patent protections described above, based on patents that are listed
in the FDA&#8217;s Orange Book in the same manner as patents claiming drugs and uses approved for NDAs submitted as full NDAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Breakthrough
Therapy Designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Food and Drug Administration Safety and Innovation Act, or FDASIA, Section 902 provides for Breakthrough Therapy designation. A Breakthrough
Therapy is a drug:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intended alone or in combination
        with one or more other drugs to treat a serious or life-threatening disease or condition; and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preliminary clinical evidence indicates
        that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
        substantial treatment effects observed early in clinical development.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b><i>Fast
Track Designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
Fast Track is a designation by the FDA of an investigational drug which:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intended alone or in combination
        with one or more other drugs to treat a serious or life-threatening disease or condition; and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-clinical or clinical data demonstrate
        the potential to address an unmet medical need</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Fast
track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet
medical need. The benefits of a Fast Track designation include rolling submission of portions of the NDA for the drug candidate and eligibility
for priority review of the NDA. Additionally, more frequent meetings and written communication with the FDA regarding the development
plan and trial design for the drug candidate are encouraged throughout the entire drug development and review process, with the goal of
having earlier drug approval and access for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Material
Threat Medical Countermeasures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In 2016, the 21<sup>st </sup>Century
Cures Act, or Act, was signed into law to support ongoing biomedical innovation. One part of the Act, Section 3086, is aimed at &#8220;Encouraging
Treatments for Agents that Present a National Security Threat.&#8221; The Act created a new priority review voucher program for approved
&#8220;material threat medical countermeasure applications.&#8221; The Act defines such countermeasures as drug or biological products,
including vaccines intended to treat biological, chemical, radiological, or nuclear agents that present a national security threat or
to treat harm from a condition that may be caused by administering a drug or biological product against such an agent. The Department
of Homeland Security has identified 13 such threats, including anthrax, smallpox, Ebola/Marburg, tularemia, botulinum toxin, and pandemic
influenza, which includes the SARS coronavirus 2, known as SARS-CoV-2.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
Regulatory Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Maintaining
substantial compliance with appropriate federal, state and local statutes and regulations requires the expenditure of substantial time
and financial resources. Drug manufacturers are required to register their establishments with the FDA and certain state agencies, and
after approval, the FDA and these state agencies conduct periodic unannounced inspections to ensure continued compliance with ongoing
regulatory requirements, including cGMPs. In addition, after approval, some types of changes to the approved product, such as adding new
indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. The FDA may require
post-approval testing and surveillance programs to monitor safety and the effectiveness of approved products that have been commercialized.
Any drug products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">record-keeping requirements;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting of adverse experiences
        with the drug;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing the FDA with updated safety
        and efficacy information;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting on advertisements and
        promotional labeling;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug sampling and distribution requirements;
        and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying with electronic record
        and signature requirements.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the
market. There are numerous regulations and policies that govern various means for disseminating information to health-care professionals
as well as consumers, including to industry sponsored scientific and educational activities, information provided to the media and information
provided over the Internet. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved
label.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA has very broad enforcement authority and the failure to comply with applicable regulatory requirements can result in administrative
or judicial sanctions being imposed on us or on the manufacturers and distributors of our approved products, including warning letters,
refusals of government contracts, clinical holds, civil penalties, injunctions, restitution and disgorgement of profits, recall or seizure
of products, total or partial suspension of production or distribution, withdrawal of approvals, refusal to approve pending applications,
and criminal prosecution resulting in fines and incarceration. The FDA and other agencies actively enforce the laws and regulations prohibiting
the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant
liability. In addition, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may
result in restrictions on the product or even complete withdrawal of the product from the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">&#160;<b>Coverage
and Reimbursement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Sales
of our product candidates, if approved, will depend, in part, on the extent to which such products will be covered by third-party payors,
such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly
limiting coverage or reducing reimbursements for medical products and services. In addition, the U.S. government, state legislatures and
foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and
requirements for substitution of generic products. Third-party payors decide which therapies they will pay for and establish reimbursement
levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement
policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any drug candidates that
we develop will be made on a&#160;payor-by-payor&#160;basis. Each payor determines whether or not it will provide coverage for a therapy,
what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a payor&#8217;s
list of covered drugs, or formulary, generally determines the&#160;co-payment&#160;that a patient will need to make to obtain the therapy
and can strongly influence the adoption of such therapy by patients and physicians. Adoption of price controls and cost-containment measures,
and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and
results. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payor to not cover our product
candidates could reduce physician usage of our product candidates, once approved, and have a material adverse effect on our sales, results
of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white"><b>Other
Healthcare Laws</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Because
of our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party
payors, we will also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments
in which we will conduct our business, including our clinical research, proposed sales, marketing and educational programs. Failure to
comply with these laws, where applicable, can result in the imposition of significant civil penalties, criminal penalties, or both. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">The
U.S. laws that may affect our ability to operate, among others, include: the federal Health Insurance Portability and Accountability Act
of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of
certain electronic healthcare transactions and protects the security and privacy of protected health information; certain state laws governing
the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which
differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; the federal healthcare
programs&#8217; Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving,
offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the
purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the
Medicare and Medicaid programs; federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting,
or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; federal
criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare
matters; the Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics, and medical supplies to report
annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians
(defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment
interests held by physicians and their immediate family members; and state law equivalents of each of the above federal laws, such as
anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and
may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, to
the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
Impact of New Legislation and Amendments to Existing Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;The
FDCA is subject to routine legislative amendments with a broad range of downstream effects. In addition to new legislation, such as
the FDA Reauthorization Act of 2017 or the FDASIA in 2012, Congress introduces amendments to reauthorize drug user fees and address
emerging concerns every five years. We cannot predict the impact of these new legislative acts and their implementation of regulations
on our business. The programs established or to be established under the legislation may have adverse effects upon us, including
increased regulation of our industry. Compliance with such regulation may increase our costs and limit our ability to pursue
business opportunities. In addition, the FDA&#8217;s regulations, policies and guidance are often revised or reinterpreted by the
agency or the courts in ways that may significantly affect our business and our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">We
expect that additional federal and state, as well as foreign, healthcare reform measures will be adopted in the future, any of which could
result in reduced demand for our products or additional pricing pressure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Human
Capital Resources</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of March 13, 2023, we had 117 full-time employees, of whom 19 hold M.D. or Ph.D. degrees. We have 94 employees dedicated to research and
development. None of our employees are represented by a collective bargaining agreement. We believe that the skills, experience and industry
knowledge of our key employees significantly benefit our operations and performance. Our research and development operations are located
in Chatham, NJ, San Diego, CA, Dartmouth, MA, Frederick, Maryland, Dublin, Ireland and Montreal, Canada. We have used, and expect to continue
to use, third parties to conduct our nonclinical and clinical studies as well as part-time employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Employee
health and safety in the workplace is one of our core values. The COVID-19 pandemic has underscored for us the importance of keeping our
employees safe and healthy. In response to the pandemic, we have taken actions aligned with the World Health Organization and the Centers
for Disease Control and Prevention in an effort to protect our workforce so they can more safely and effectively perform their work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Employee
levels are managed to align with the pace of business and management believes it has sufficient human capital to operate its business
successfully.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We lease the space for our principal executive offices, which are located
at 26 Main Street, Suite 101, Chatham, New Jersey 07928, and our telephone number is (862) 799 8599. Our website address is www.tonixpharma.com.
We do not incorporate the information on our websites into this annual report, and you should not consider such information part of this
annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
were incorporated on November 16, 2007 under the laws of the State of Nevada as Tamandare Explorations Inc. On October 11, 2011, we changed
our name to Tonix Pharmaceuticals Holding Corp.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka003"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Summary
of Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a history of operating losses
        and may never generate revenues or achieve profitability.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect our operating results
        to fluctuate, which may make it difficult to predict our future performance.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates are novel
        and still in development.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not expect to generate any
        revenues from product sales in the foreseeable future, if at all.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are largely dependent on the
        success of our product candidates and cannot be certain that our product candidates will receive regulatory approval or be successfully
        commercialized.&#160;&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical studies required for our
        product candidates are expensive and time-consuming, and their outcome is uncertain.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to extensive and
        costly government regulation.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
        have never submitted an NDA before, and may be unable to do so for our product candidates we are developing.&#160;&#160;</span></p></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates may cause
        serious adverse events or undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require
        them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to meet our anticipated
        development and commercialization timelines for approval of any of our product candidates.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any breakthrough, fast track or
        orphan drug designation or grant of priority review status by the FDA may not actually lead to a faster development or regulatory review
        or approval process, nor assure FDA approval of our product candidates.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if approved, our products may
        not be accepted by the market.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may use our financial and human
        resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may
        be more profitable or for which there is a greater likelihood of success.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our independent registered public
        accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited
        financial statements. We may be unable to continue to operate without the threat of liquidation for the foreseeable future.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need additional capital.
        If additional capital is not available or is available at unattractive terms, we may be forced to delay, reduce the scope of or eliminate
        our research and development programs, reduce our commercialization efforts or curtail our operations.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outbreaks of communicable diseases
        may materially and adversely affect our business, financial condition and results of operations.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition and technological change
        may make our product candidates and technologies less attractive or obsolete.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to protect our intellectual
        property rights, our ability to pursue the development of our technologies and products would be negatively affected.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be involved in lawsuits to
        protect or enforce our patents, which could be expensive and time consuming.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we infringe the rights of third
        parties we could be prevented from selling products, forced to pay damages, and defend against litigation.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties to conduct,
        supervise and monitor our clinical studies, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to expand our operations
        and increase the size of our company, and we may experience difficulties in managing growth.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our executive officers and other
        key personnel are critical to our business, and our future success depends on our ability to retain them.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to hire additional
        qualified personnel, our ability to grow our business may be harmed.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties to manufacture
        the compounds used in our studies, and we intend to rely on them for the manufacture of any approved products for commercial sale. If
        these third parties do not manufacture our product candidates in sufficient quantities and at an acceptable cost, clinical development
        and commercialization of our product candidates could be delayed, prevented or impaired.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure by our third-party manufacturers
        to comply with the regulatory guidelines set forth by the FDA with respect to our product candidates could delay or prevent the completion
        of clinical studies, the approval of any product candidates or the commercialization of our products.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse global conditions, including economic uncertainty, may
        negatively impact our financial results.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our internal computer systems, or those of our CRO&#8217;s or
        other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development
        programs.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate and academic collaborators
        may take actions to delay, prevent, or undermine the success of our products.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data provided by collaborators and
        others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete.&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates may face
        competition sooner than expected.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to establish marketing,
        sales and distribution capabilities, or fail to enter into arrangements with third parties, we will not be able to create a market for
        our product candidates.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our relationships
        with customers, physicians, and third-party payors will be subject, directly or indirectly, to federal and state healthcare fraud and
        abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable
        to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Coverage
        and adequate reimbursement may not be available for our current or any future drug candidates, which could make it difficult for us to
        sell profitably, if approved.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare legislative reform measures may have a negative impact
        on our business and results of operations.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we obtain approval to commercialize
        any approved products outside of the United States, a variety of risks associated with international operations could materially adversely
        affect our business.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face the risk of product liability
        claims and may not be able to obtain insurance.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use hazardous chemicals in our
        business. Potential claims relating to improper handling, storage or disposal of these chemicals could affect us and be time consuming
        and costly.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we retain collaborative partners
        and our partners do not satisfy their obligations, we will be unable to develop our partnered product candidates.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unsuccessful in obtaining
        a priority review voucher for material threat medical countermeasures.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government entities may take actions that directly or indirectly
        have the effect of limiting opportunities for our vaccines for COVID-19.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If technology developed for the
        purposes of developing new medicines or vaccines can be applied to the creation or development of biological weapons, then our technology
        may be considered &#8220;dual use&#8221; technology and be subject to limitations on public disclosure or export.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face risks in connection with
        existing and future collaborations with respect to the development, manufacture, and commercialization of our product candidates.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face risks in connection with
        the testing, production and storage of our vaccine product candidates.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An active trading market for our
        common stock may not be sustained.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of our common stock has been extremely volatile
        and may continue to be volatile due to numerous circumstances beyond our control.<b>&#160;</b></span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We could be delisted from Nasdaq,
        which could seriously harm the liquidity of our stock and our ability to raise capital.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not anticipate paying dividends
        on our common stock and, accordingly, shareholders must rely on stock appreciation for any return on their investment.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that our quarterly results
        of operations will fluctuate, and this fluctuation could cause our stock price to decline.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to comply with the rules
        under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures, or if we discover material weaknesses and deficiencies
        in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If securities or industry analysts
        do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock
        price and trading volume could decline.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other companies may have difficulty
        acquiring us, even if doing so would benefit our stockholders, due to provisions under our corporate charter and bylaws, as well as Nevada
        law.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other companies may have difficulty
        acquiring us, even if doing so would benefit our stockholders, due to provisions under our corporate charter and bylaws, as well as Nevada
        law.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our bylaws designate the Eighth
        Judicial District Court of Clark County, Nevada as the sole and exclusive forum for certain types of actions and proceedings that may
        be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes
        with us or our directors, officers, employees or agents.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>RISKS
RELATED TO OUR BUSINESS&#160;&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
have a history of operating losses and expect to incur losses for the foreseeable future. We may never generate revenues or, if we are
able to generate revenues, achieve profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are focused on product development, and we have not generated any revenues to date. We have incurred losses in each year of our operations,
and we expect to continue to incur operating losses for the foreseeable future. These operating losses have adversely affected and are
likely to continue to adversely affect our working capital, total assets and shareholders&#8217; equity.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
and our prospects should be examined in light of the risks and difficulties frequently encountered by new and early-stage companies in
new and rapidly evolving markets. These risks include, among other things, the speed at which we can scale up operations, our complete
dependence upon development of our product candidates that currently have no market acceptance, our ability to establish and expand our
brand name, our ability to expand our operations to meet the commercial demand of our clients, our development of and reliance on strategic
and customer relationships and our ability to minimize fraud and other security risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The process of developing our products requires significant clinical, nonclinical
and CMC development, laboratory testing and clinical studies. In addition, commercialization of our product candidates will require that
we obtain necessary regulatory approvals and establish sales, marketing and manufacturing capabilities, either through internal hiring
or through contractual relationships with others. We expect to incur substantial losses for the foreseeable future as a result of anticipated
increases in our research and development costs, including costs associated with conducting preclinical and nonclinical testing and clinical
studies, and regulatory compliance activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to incur
substantial additional operating expenses over the next several years as our research, development, preclinical and nonclinical
testing, and clinical study activities increase<span style="text-decoration: underline">,</span> and if and when we acquire rights
to additional product candidates. The amount of future losses and when, if ever, we will achieve profitability are uncertain. We
have no products that have generated any commercial revenue, do not expect to generate revenues from the commercial sale of products
in the near future, and might never generate revenues from the sale of products. Our ability to generate revenue and achieve
profitability will depend on, among other things, successful completion of the development of our product candidates; obtaining
necessary regulatory approvals from the FDA; establishing manufacturing, sales, and marketing arrangements with third parties;
successfully commercializing our products; establishing a favorable competitive position; and raising sufficient funds to finance
our activities. Many of these factors will depend on circumstances beyond our control. We might not succeed at any of these
undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations may be
materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to
predict our future performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a development-stage biopharmaceutical
and our operations to date have been primarily limited to developing our technology and undertaking preclinical and nonclinical testing
and clinical studies of our latest stage product candidate, TNX-102 SL for FM, Long COVID and potentially other CNS conditions. We have
not yet obtained regulatory approvals for TNX-102 SL or any of our other product candidates. Consequently, any predictions made about
our future success or viability may not be as accurate as they could be if we had a longer operating history or commercialized products.
Our financial condition has varied significantly in the past and will continue to fluctuate from quarter-to-quarter or year-to-year due
to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations
include other factors described elsewhere in this annual report and also include, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to obtain additional funding
        to develop our product candidates;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in the commencement, enrollment and timing of clinical studies;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the success of our clinical studies through all phases of clinical development,
        including studies of our most advanced product candidate, TNX-102 SL for FM, Long COVID and potentially other CNS indications;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any delays in regulatory review and approval of product candidates in clinical
        development;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and maintain regulatory approval for our product candidate
        TNX-102 SL for FM and Long COVID, TNX-1900 for chronic migraine, TNX-601 ER for depression or any of our other product candidates in the
        United States and foreign jurisdictions;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential nonclinical toxicity and/or side effects of our product candidates
        that could delay or prevent commercialization, limit the indications for any approved drug, require the establishment of REMS, or cause
        an approved drug to be taken off the market;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to establish or maintain collaborations, licensing or other arrangements;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">market acceptance of our product candidates;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competition from existing products or new products that may emerge;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ability of patients or healthcare providers to obtain coverage of or sufficient
        reimbursement for our products;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to leverage our proprietary technology platform to discover and
        develop additional product candidates;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability and our licensors&#8217;
        abilities to successfully obtain, maintain, defend and enforce intellectual property rights important to our business; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential product liability claims;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, the results of any
quarterly or annual periods should not be relied upon as indications of future operating performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>RISKS RELATED TO PRODUCT DEVELOPMENT, REGULATORY
APPROVAL, MANUFACTURING AND COMMERCILAIZATION</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our product candidates are novel and still in
development.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage pharmaceutical
company focused on the development of drug product candidates, all of which are still in development. Our drug development methods may
not lead to commercially viable drugs for any of several reasons. For example, we may fail to identify appropriate targets or compounds,
our drug candidates may fail to be safe and effective in clinical studies, or we may have inadequate financial or other resources to pursue
development efforts for our drug candidates. Our drug candidates will require significant additional development, clinical studies, regulatory
clearances and additional investment by us or our collaborators before they can be commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, we and our product candidates are subject to extensive regulation
by the FDA and comparable regulatory authorities in other countries governing, among other things, research, testing, clinical studies,
manufacturing, labeling, promotion, selling, adverse event reporting and recordkeeping. We are not permitted to market any of our product
candidates in the United States until we receive approval of an NDA for a product candidate from the FDA or the equivalent approval from
a foreign regulatory authority. Obtaining FDA approval is a lengthy, expensive and uncertain process. We currently have one product candidate,
TNX-102 SL, in Phase 3 development for the treatment of FM and Phase 2 development for the treatment of Long COVID, and we have three
other products in Phase 2 development for the treatment of chronic migraine, depression and cocaine intoxication. The success of our business
currently depends on the successful development, approval and commercialization of our product candidates and TNX-102 SL. Any projected
sales or future revenue predictions are predicated upon FDA approval and market acceptance. If projected sales do not materialize for
any reason, it would have a material adverse effect on our business and our ability to continue operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>As we have no approved products on the market,
we do not expect to generate any revenues from product sales in the foreseeable future, if at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, we have no approved product
on the market and have generated no product revenues. We have funded our operations primarily from sales of our securities. We have not
received, and do not expect to receive for at least the next couple of years, if at all, any revenues from the commercialization of our
product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To obtain revenues from sales
of our product candidates, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing
and marketing drugs with commercial potential. We may never succeed in these activities, and we may not generate sufficient revenues to
continue our business operations or achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are largely dependent on the success of our
lead product candidates, and we cannot be certain that these product candidates will receive regulatory approval or be successfully commercialized.&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not yet submitted an NDA
or foreign equivalent or received marketing approval for our lead product candidates anywhere in the world. The clinical development programs
may not lead to commercial products for a number of reasons, including if we fail to obtain necessary approvals from the FDA or foreign
regulatory authorities because our clinical studies fail to demonstrate to their satisfaction that this product candidate is safe and
effective or a clinical program may be put on hold due to unexpected safety issues. We may also fail to obtain the necessary approvals
if we have inadequate financial or other resources to advance our product candidates through the clinical study process. Any failure or
delay in completing clinical studies or obtaining regulatory approvals for our lead product candidates in a timely manner would have a
material adverse impact on our business and our stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not commence or advance clinical trials
for COVID-related products if the COVID-19 disease outbreak subsides.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Disease outbreaks are unpredictable.
For example, the SARS virus disappeared just four months after it caused a global panic. In the event that COVID-19 has a similar disease
cycle, we may be forced to abandon or delay the development of our COVID-related products due to a lack of patients or government funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Successful development of our products is uncertain.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our development of current and
future product candidates is subject to the risks of failure and delay inherent in the development of new pharmaceutical products, including:
delays in product development, clinical testing, or manufacturing; unplanned expenditures in product development, clinical testing, or
manufacturing; failure to receive regulatory approvals; emergence of superior or equivalent products; inability to manufacture on its
own, or through any others, product candidates on a commercial scale; and failure to achieve market acceptance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Because of these risks, our research
and development efforts may not result in any commercially viable products. If a significant portion of these development efforts are
not successfully completed, required regulatory approvals are not obtained or any approved products are not commercially successfully,
our business, financial condition, and results of operations may be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Clinical studies required for our product candidates
are expensive and time-consuming, and their outcome is uncertain.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In order to obtain FDA approval
to market a new pharmaceutical product, we must demonstrate proof of safety and effectiveness in humans. To meet these requirements, we
must conduct &#8220;adequate and well controlled&#8221; clinical studies. Conducting clinical studies is a lengthy, time-consuming, and
expensive process. The length of time may vary substantially according to the type, complexity, novelty, and intended use of the product
candidate, and often can be several years or more per study. Delays associated with products for which we are directly conducting clinical
studies may cause us to incur additional operating expenses. The commencement and rate of completion of clinical studies may be delayed
by many factors, including, for example: inability to manufacture sufficient quantities of stable and qualified materials under cGMP,
for use in clinical studies; slower than expected rates of patient recruitment; failure to recruit a sufficient number of patients; modification
of clinical study protocols; changes in regulatory requirements for clinical studies; the lack of effectiveness during clinical studies;
the emergence of unforeseen safety issues; delays, suspension, or termination of the clinical studies due to the IRB responsible for overseeing
the study at a particular study site; and government or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination
of the studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
results from early clinical studies are not necessarily predictive of results obtained in later clinical studies. Accordingly, even if
we obtain positive results from early clinical studies, we may not be able to confirm the results in future clinical studies. In addition,
clinical studies may not demonstrate sufficient safety and effectiveness to obtain the requisite regulatory approvals for product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
clinical studies may be conducted in patients with CNS conditions, and in some cases, our product candidates are expected to be used in
combination with approved therapies that themselves have significant adverse event profiles. During the course of treatment, these patients
could suffer adverse medical events or die for reasons that may or may not be related to our product candidates. We cannot ensure that
safety issues will not arise with respect to our product candidates in clinical development.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
failure of clinical studies to demonstrate safety and effectiveness for the desired indications could harm the development of that product
candidate and other product candidates. This failure could cause us to abandon a product candidate and could delay development of other
product candidates. Any delay in, or termination of, our clinical studies would delay the filing of our NDAs with the FDA and, ultimately,
our ability to commercialize our product candidates and generate product revenues. Any change in, or termination of, our clinical studies
could materially harm our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to extensive and costly government regulation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Product
candidates employing our technology are subject to extensive and rigorous domestic government regulation including regulation by the FDA,
the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services, the United
States Department of Justice, state and local governments, and their respective foreign equivalents. The FDA regulates the research, development,
preclinical and nonclinical testing and clinical studies, manufacture, safety, effectiveness, record-keeping, reporting, labeling, storage,
approval, advertising, promotion, sale, distribution, import, and export of biopharmaceutical products. The FDA regulates small molecule
chemical entities as drugs, subject to an NDA under the FDCA. The FDA applies the same standards for biologics, requiring an IND application,
followed by a Biologic License Application, or BLA, prior to licensure. Other products, such as vaccines, are also regulated under the
Public Health Service Act. FDA has conflated the standards for approval of NDAs and BLAs so that they require the same types of information
on safety, effectiveness, and CMCs. If products employing our technologies are marketed abroad, they will also be subject to extensive
regulation by foreign governments, whether or not they have obtained FDA approval for a given product and its uses. Such foreign regulation
may be equally or more demanding than corresponding United States regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Government
regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling our products. The regulatory
review and approval process, which includes preclinical and nonclinical testing and clinical studies of each product candidate, is lengthy,
expensive, and uncertain. We or our collaborators must obtain and maintain regulatory authorization to conduct clinical studies. We or
our collaborators must obtain regulatory approval for each product we intend to market, and the manufacturing facilities used for the
products must be inspected and meet legal requirements. Securing regulatory approval requires the submission of extensive preclinical,
nonclinical and clinical data and other supporting information for each proposed therapeutic indication in order to establish the product&#8217;s
safety and efficacy, and in the case of biologics also potency and purity, for each intended use. The development and approval process
takes many years, requires substantial resources, and may never lead to the approval of a product.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
if we are able to obtain regulatory approval for a particular product, the approval may limit the indicated medical uses for the product,
may otherwise limit our ability to promote, sell, and distribute the product, may require that we conduct costly post-marketing surveillance,
and/or may require that we conduct ongoing post-marketing studies. Material changes to an approved product, such as, for example, manufacturing
changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may be withdrawn, including,
for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we, our collaborators, or our CMOs fail to comply with applicable regulatory requirements at any stage during the regulatory process,
such noncompliance could result in, among other things delays in the approval of applications or supplements to approved applications;
refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved applications;
warning letters; fines; import and/or export restrictions; product recalls or seizures; injunctions; total or partial suspension of production;
civil penalties; withdrawals of previously approved marketing applications or licenses; recommendations by the FDA or other regulatory
authorities against governmental contracts; and/or criminal prosecutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
do not have, and may never obtain, the regulatory approvals we need to market our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
completion of clinical studies, the results are evaluated and, depending on the outcome, submitted to the FDA in the form of an NDA or
BLA in order to obtain FDA approval of the product and authorization to commence commercial marketing. In responding to an NDA, the FDA
may require additional testing or information, may require that the product labeling be modified, may impose post-approval study and other
commitments or reporting requirements or other restrictions on product distribution, or may deny the application. The FDA has established
performance goals for review of NDAs or BLAs: six months for priority applications and ten months for standard applications. However,
the FDA is not required to complete its review within these time periods. The timing of final FDA review and action varies greatly but
can take years in some cases and may involve the input of an FDA advisory committee of outside experts. Product sales in the United States
may commence only when an NDA or BLA is approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
date, we have not applied for or received the regulatory approvals required for the commercial sale of any of our products in the United
States or in any foreign jurisdiction. None of our product candidates have been determined to be safe and effective, and we have not submitted
an NDA or BLA to the FDA or an equivalent application to any foreign regulatory authorities for any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">It
is possible that none of our product candidates will be approved for marketing. Failure to obtain regulatory approvals, or delays in obtaining
regulatory approvals, may adversely affect the successful commercialization of any drugs or biologics that we or our partners develop,
may impose additional costs on us or our collaborators, may diminish any competitive advantages that we or our partners may attain, and/or
may adversely affect our receipt of revenues or royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
have never submitted an NDA before, and may be unable to do so for our product candidates we are developing.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
conduct of pivotal clinical studies and the submission of a successful NDA is a complicated process. Although members of our management
team have extensive industry experience, including in the development and clinical testing of drug candidates and the commercialization
of drug, have limited experience in preparing, submitting and prosecuting regulatory filings, and have not submitted an NDA before. Consequently,
we may be unable to successfully and efficiently execute and complete this planned clinical study in a way that leads to NDA submission
and approval of our product candidates we are developing. We may require more time and incur greater costs than our competitors and may
not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our
planned clinical studies would prevent or delay commercialization of TNX-102 SL and other product candidates we are developing.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
product candidates may cause serious adverse events, or SAEs, or undesirable side effects which may delay or prevent marketing approval,
or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their
sales.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">SAEs
or undesirable side effects from any of our other product candidates could arise either during clinical development or, if approved, after
the approved product has been marketed. The results of future clinical studies may show that our product candidates cause SAEs or undesirable
side effects, which could interrupt, delay or halt clinical studies, resulting in delay of, or failure to obtain, marketing approval from
the FDA and other regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
any of our other product candidates cause SAEs or undesirable side effects or suffer from quality control issues:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may impose
        a clinical hold or risk evaluation and mitigation strategies, or REMS, which could result in substantial delays, significantly increase
        the cost of development, and/or adversely impact our ability to continue development of the product;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require
        the addition of statements, specific warnings, or contraindications to the product label, or restrict the product&#8217;s indication to
        a smaller potential treatment population;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the
        way the product is administered or conduct additional clinical studies;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we
        may be required to implement a risk minimization action plan, which could result in substantial cost increases and have a negative impact
        on our ability to commercialize the product;&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr>
  <tr style="vertical-align: top">
    <td>
        <p style="margin-top: 0; margin-bottom: 0"></p>
        <p style="margin-top: 0; margin-bottom: 0">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td>
    <td>
        <p style="margin-top: 0; margin-bottom: 0"></p>
        <p style="margin-top: 0; margin-bottom: 0">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to limit the
        participants who can receive the product;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to limitations
        on how we promote the product;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may, voluntarily or involuntarily,
        initiate field alerts for product recall, which may result in shortages;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of the product may decrease
        significantly;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require
        us to take our approved product off the market;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to litigation
        or product liability claims; and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase
commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of our
products.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we are unable to file for approval of TNX-102 SL under Section 505(b)(2) of the FDCA or if we are required to generate additional data
related to safety and efficacy in order to obtain approval under Section 505(b)(2), we may be unable to meet our anticipated development
and commercialization timelines.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our current plans for filing NDAs
for our most advanced product candidate, TNX-102 SL, include efforts to minimize the data we will be required to generate in order to
obtain marketing approval and therefore reduce the development time. We intend to file Section 505(b)(2) NDAs for TNX-102 SL for FM, Long
COVID and for other proposed indications, that might, if accepted by the FDA, save time and expense in the development and testing of
TNX-102 SL.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TNX-102 SL for FM and other
CNS indications is our most advanced development product candidate which is in mid-Phase 3 for FM. The timeline for filing and
review of our NDA for TNX-102 SL for FM is based on our plan to submit this NDA under Section 505(b)(2) of the FDCA, which would
enable us to rely in part on data in the public domain or elsewhere. We have not yet filed an NDA under Section 505(b)(2) for any of
our product candidates. Depending on the data that may be required by the FDA for approval, some of the data may be related to
products already approved by the FDA. If the data relied upon is related to products already approved by the FDA and covered by
third-party patents, we would be required to certify that we do not infringe the listed patents or that such patents are invalid or
unenforceable. As a result of the certification, the third-party would have 45 days from notification of our certification to
initiate an action against us. &#160;In the event that an action is brought in response to such a certification, the approval of our
NDA could be subject to a stay of up to 30 months or more while we defend against such a suit. Approval of our product candidates
under Section 505(b)(2) may therefore be delayed until patent exclusivity expires or until we successfully challenge the
applicability of those patents to our product candidates. Alternatively, we may elect to generate sufficient additional clinical
data so that we no longer rely on data which triggers a potential stay of the approval of our product candidates. Even if no
exclusivity periods apply to our applications under Section 505(b)(2), the FDA has broad discretion to require us to generate
additional data on the safety and efficacy of our product candidates to supplement third-party data on which we may be permitted to
rely. In either event, we could be required, before obtaining marketing approval for any of our product candidates, to conduct
substantial new research and development activities beyond those we currently plan to engage in order to obtain approval of our
product candidates. Such additional new research and development activities would be costly and time-consuming.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may not be able to realize
a shortened development timeline for TNX-102 SL for FM, Long COVID (or other proposed indications under TNX-102 SL), and the FDA may not
approve our NDA based on their review of the submitted data. If cyclobenzaprine-containing products are withdrawn from the market by the
FDA for any safety reason, we may not be able to reference such products to support a 505(b)(2) NDA for TNX-102 SL, and we may need to
fulfill the more extensive requirements of Section 505(b)(1). If we are required to generate additional data to support approval, we may
be unable to meet our anticipated development and commercialization timelines, may be unable to generate the additional data at a reasonable
cost, or at all, and may be unable to obtain marketing approval of our lead product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Any
breakthrough, fast track or orphan drug designation or grant of priority review status by the FDA may not actually lead to a faster development
or regulatory review or approval process, nor will it assure FDA approval of our product candidates. Additionally, our product candidates
may treat indications that do not qualify for priority review vouchers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
a product candidate offers major advances in treatment, the FDA may designate it eligible for priority review. The FDA has broad discretion
whether or not to grant these designations, so even if we believe a particular product candidate is eligible for these designations, we
cannot assure you that the FDA would decide to grant them. Even if we do receive fast track designation or priority review, we may not
experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation
if it believes that the designation is no longer supported by data from our clinical development program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if approved, our products will be subject to extensive post-approval regulation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Once
a product is approved, numerous post-approval requirements apply. Among other things, the holder of an approved NDA is subject to periodic
and other FDA monitoring and reporting obligations, including obligations to monitor and report adverse events and instances of the failure
of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval
for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising
and other promotional material to the FDA and report on ongoing clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Depending
on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines, injunctions, recall
or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal
to allow us to enter into supply contracts, including government contracts. In addition, even if we comply with FDA and other requirements,
new information regarding the safety or effectiveness of a product could lead the FDA to modify or withdraw product approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
if the FDA approves one or more of our product candidates, physicians and patients may not accept it or use it. Even if physicians and
patients would like to use our products, our products may not gain market acceptance among healthcare payors such as managed care formularies,
insurance companies or government programs such as Medicare or Medicaid. Acceptance and use of our products will depend upon a number
of factors including: perceptions by members of the health care community, including physicians, about the safety and effectiveness of
our drug or device product; cost-effectiveness of our product relative to competing products; availability of reimbursement for our product
from government or other healthcare payors; and effectiveness of marketing and distribution efforts by us and our licensees and distributors,
if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
degree of market acceptance of any pharmaceutical product that we develop will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effectiveness;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the safety and effectiveness of
        our products, including any significant potential side effects (including drowsiness and dry mouth), as compared to alternative products
        or treatment methods;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of market entry as compared
        to competitive products;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rate of adoption of our products
        by doctors and nurses;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product labeling or product insert
        required by the FDA for each of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reimbursement policies of government
        and third-party payors;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness of our sales, marketing
        and distribution capabilities and the effectiveness of such capabilities of our collaborative partners, if any; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable publicity concerning
        our products or any similar products.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
we expect sales of our current product candidates, if approved, to generate substantially all of our product revenues for the foreseeable
future, the failure of these products to find market acceptance would harm our business and could require us to seek additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs
or product candidates that may be more profitable or for which there is a greater likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
we have limited financial and human resources, we are currently focusing on development of our lead product candidates. As a result, we
may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial
potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.
Our spending on existing and future product candidates for specific indications may not yield any commercially viable products. If we
do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights
to that product candidate through strategic alliance, licensing or other royalty arrangements in cases in which it would have been more
advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources
to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b><i>RISKS
RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS; COMPETITION</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern
in its report on our audited financial statements. We may be unable to continue to operate without the threat of liquidation for the foreseeable
future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with our management&#8217;s
assessment, our report from our independent registered public accounting firm for the fiscal year ended December&#160;31, 2022 includes
an explanatory paragraph stating that our recurring losses from operations and net capital deficiency raise substantial doubt about our
ability to continue as a going concern. If we are unable to obtain sufficient funding, our business, prospects, financial condition and
results of operations will be materially and adversely affected and we may be unable to continue as a going concern. For example, we anticipate
that our existing cash and cash equivalents will enable us to maintain our current operations into the fourth quarter of 2023, but not
beyond. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which
those assets are carried on our consolidated financial statements, and investors will likely lose all or a part of their investment. Future
reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability
to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial
doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding
on commercially reasonable terms or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
will need additional capital. If additional capital is not available or is available at unattractive terms, we may be forced to delay,
reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to develop and bring our product candidates to market, we must commit substantial resources to costly and time-consuming research,
preclinical and nonclinical testing, clinical studies and marketing activities and the buildout of our research and development and manufacturing
facilities. We anticipate that our existing cash and cash equivalents will enable us to maintain our current operations into the fourth
quarter of 2023, but not beyond. We anticipate using our cash and cash equivalents to fund further research and development with respect
to our lead product candidate. We will, however, need to raise additional funding sooner if our business or operations change in a manner
that consumes available resources more rapidly than we anticipate. Our requirements for additional capital will depend on many factors,
including:&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">successful
        commercialization of our product candidates;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the time and costs involved in obtaining
        regulatory approval for our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs associated with protecting
        our intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development of marketing and sales
        capabilities;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments received under future collaborative
        agreements, if any; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market acceptance of our products.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent we raise additional capital through the sale of equity securities, the issuance of those securities could result in dilution
to our shareholders. In addition, if we obtain debt financing, a substantial portion of our operating cash flow may be dedicated to the
payment of principal and interest on such indebtedness, thus limiting funds available for our business activities. If adequate funds are
not available, we may be required to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization
efforts or curtail our operations. In addition, we may be required to obtain funds through arrangements with collaborative partners or
others that may require us to relinquish rights to technologies, product candidates or products that we would otherwise seek to develop
or commercialize ourselves or license rights to technologies, product candidates or products on terms that are less favorable to us than
might otherwise be available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
will require substantial additional funds to support our research and development activities, and the anticipated costs of preclinical
and nonclinical testing and clinical studies, regulatory approvals and eventual commercialization. Such additional sources of financing
may not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may be unable
to commence or complete clinical studies or obtain approval of any product candidates from the FDA and other regulatory authorities. In
addition, we could be forced to discontinue product development, forego sales and marketing efforts and forego attractive business opportunities.
Any additional sources of financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our
shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
is no assurance that we will be successful in raising the additional funds needed to fund our business plan. If we are not able to raise
sufficient capital in the near future, our continued operations will be in jeopardy and we may be forced to cease operations and sell
or otherwise transfer all or substantially all of our remaining assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Outbreaks
of communicable diseases may materially and adversely affect our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may face risks related to health epidemics or outbreaks of communicable diseases. The outbreak of such communicable diseases, such as
COVID-19, has and may result in future widespread health crisis that adversely affect general commercial activity and the economies and
financial markets of many countries. An outbreak of communicable diseases, or the perception that such an outbreak could occur, and the
measures taken by the governments of countries affected could adversely affect our business, financial condition or results of operations.
For example, an outbreak could significantly disrupt our business by limiting our ability to travel or ship materials within or outside
of an affected country and forcing temporary closure of facilities or service providers that we rely upon. An outbreak could also impact
our ability to conduct our ongoing multicenter clinical trials if trial participant attendance at requisite study visits is substantially
reduced and if a significant percentage of study participants and study staff are adversely affected by coronavirus or other infections
and the resulting disease course. Moreover, government or community shutdowns such as those caused by the COVID-19 pandemic, may impair
our ability to analyze and submit the results from our clinical and preclinical trials, leading to further delays in the development and
approval of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Competition
and technological change may make our product candidates and technologies less attractive or obsolete.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
compete with established pharmaceutical and biotechnology companies that are pursuing other forms of treatment for the same or similar
indications we are pursuing and that have greater financial and other resources. Other companies may succeed in developing products earlier
than us, obtaining FDA approval for products more rapidly, or developing products that are more effective than our product candidates.
Research and development by others may render our technology or product candidates obsolete or noncompetitive, or result in treatments
or cures superior to any therapy we develop. We face competition from companies that internally develop competing technology or acquire
competing technology from universities and other research institutions. As these companies develop their technologies, they may develop
competitive positions that may prevent, make futile, or limit our product commercialization efforts, which would result in a decrease
in the revenue we would be able to derive from the sale of any products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
can be no assurance that any of our product candidates will be accepted by the marketplace as readily as these or other competing treatments.
Furthermore, if our competitors&#8217; products are approved before ours, it could be more difficult for us to obtain approval from the
FDA. For example, at least three vaccines for the prevention of COVID-19 have been approved to date, and we expect that other vaccines
will be approved prior to the approval of our COVID-19 vaccine candidate, if it is approved at all. Even if our products are successfully
developed and approved for use by all governing regulatory bodies, there can be no assurance that physicians and patients will accept
our product(s) as a treatment of choice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
if a competitor receives FDA approval before we do for a drug that is similar to one of our product candidates, FDA approval for our product
candidate may be precluded or delayed due to periods of non-patent exclusivity and/or the listing with the FDA by the competitor of patents
covering its newly-approved drug product. Periods of non-patent exclusivity for new versions of existing drugs such as our current drug
product candidate, TNX-102 SL, can extend up to three and one-half years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
the pharmaceutical research industry is diverse, complex, and rapidly changing. By its nature, the business risks associated therewith
are numerous and significant. The effects of competition, intellectual property disputes, market acceptance, and FDA regulations preclude
us from forecasting revenues or income with certainty or even confidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>RISKS
RELATED TO OUR INTELLECTUAL PROPERTY RIGHTS AND REGULATORY EXCLUSIVITY&#160;&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we fail to protect our intellectual property rights, our ability to pursue the development of our technologies and products would be negatively
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
success will depend in part on our ability to obtain patents and maintain adequate protection of our technologies and products. If we
do not adequately protect our intellectual property, competitors may be able to use our technologies to produce and market drugs using
our technologies and patents in direct competition with us and erode our competitive advantage. Some foreign countries lack rules and
methods for defending intellectual property rights and do not protect proprietary rights to the same extent as the United States. Many
companies have had difficulty protecting their proprietary rights in these foreign countries. We may not be able to prevent misappropriation
of our proprietary rights and intellectual property rights in these and other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have received, and are currently seeking, patent protection for numerous compounds and methods of treating diseases. However, the patent
process is subject to numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our products
by obtaining and defending patents related to them. These risks and uncertainties include the following: patents that may be issued or
licensed may be challenged, invalidated, or circumvented, or otherwise may not provide us any competitive advantage; our competitors,
many of which have substantially greater resources than we and many of which have made significant investments in competing technologies,
may seek, or may already have obtained, patents that will limit, interfere with, or eliminate our ability to make, use, and sell our potential
products either in the United States or in international markets; there may be significant pressure on the United States government and
other international governmental bodies to limit the scope of patent protection both inside and outside the United States for treatments
that prove successful as a matter of public policy regarding worldwide health concerns; and countries other than the United States may
have less robust patent laws than those upheld by United States courts, allowing foreign competitors the ability to exploit these laws
to create, develop, and market competing products using our technologies and patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
any patents issued to us may not provide us with meaningful protection, or others may challenge, circumvent or narrow our patents. Third
parties may also independently develop products similar to our products, duplicate our unpatented products or design around any patents
or propriety technologies on products we develop. Additionally, extensive time is required for development, testing and regulatory review
of a potential product. While extensions of patent term due to regulatory delays may be available, it is possible that, before any of
our product candidates can be commercialized, any related patent, even with an extension, may expire or remain in force for only a short
period following commercialization, thereby reducing any advantages to us of the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the PTO and patent offices in other jurisdictions have often required that patent applications concerning pharmaceutical and/or
biotechnology-related inventions be limited or narrowed substantially to cover only the innovations specifically exemplified in the patent
application, thereby limiting the scope of protection against competitive challenges. Thus, even if we or our licensors are able to obtain
patents, the patents may be substantially narrower than anticipated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
success depends on our patents and patent applications that may be licensed exclusively to us and other patents and patent applications
to which we may obtain assignment or licenses. We may not be aware, however, of all patents, published applications or published literature
that may affect our business either by blocking our ability to commercialize our product candidates, by preventing the patentability of
our product candidates to us or our licensors, or by covering the same or similar technologies. These patents, patent applications, and
published literature may limit the scope of our future patent claims or adversely affect our ability to market our product candidates.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to patents, we rely on a combination of trade secrets, confidentiality, nondisclosure and other contractual provisions, and security
measures to protect our confidential and proprietary information. These measures may not adequately protect our trade secrets or other
proprietary information. If they do not adequately protect our rights, third parties could use our technology, and we could lose any competitive
advantage we may have. In addition, others may independently develop similar proprietary information or techniques or otherwise gain access
to our trade secrets, which could impair any competitive advantage we may have.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Patent
protection and other intellectual property protection is crucial to the success of our business and prospects, and there is a substantial
risk that such protections will prove inadequate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be involved in lawsuits to protect or enforce our patents, which could be expensive and time consuming.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
pharmaceutical industry has been characterized by extensive litigation regarding patents and other intellectual property rights, and companies
have employed intellectual property litigation to gain a competitive advantage. We may become subject to infringement claims or litigation
arising out of present and future patents and other proceedings of our competitors. The defense and prosecution of intellectual property
suits are costly and time-consuming to pursue, and their outcome is uncertain. Litigation may be necessary to determine the enforceability,
scope, and validity of the proprietary rights of others. An adverse determination in litigation to which we may become a party could subject
us to significant liabilities, require us to obtain licenses from third parties, or restrict or prevent us from selling our products in
certain markets. Although patent and intellectual property disputes might be settled through licensing or similar arrangements, the costs
associated with such arrangements may be substantial and could include our paying large fixed payments and ongoing royalties. Furthermore,
the necessary licenses may not be available on satisfactory terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Competitors
may infringe our patents, and we may file infringement claims to counter infringement or unauthorized use. Third parties may assert that
our patents are invalid and/or unenforceable in these proceedings. Such litigation can be expensive, particularly for a company of our
size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable,
or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology.
An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or
interpreted narrowly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Third
parties may also assert that our patents are invalid in patent office administrative proceedings. These proceedings include oppositions
in the European Patent Office and&#160;<i>inter partes</i>&#160;review and post-grant review proceedings in the PTO. The success rate
of these administrative challenges to patent validity in the United States is higher than it is for validity challenges in litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Interference
or derivation proceedings brought before the PTO may be necessary to determine priority of invention with respect to innovations disclosed
in our patents or patent applications. During these proceedings, it may be determined that we do not have priority of invention for one
or more aspects in our patents or patent applications and could result in the invalidation in part or whole of a patent or could put a
patent application at risk of not issuing. Even if successful, an interference or derivation proceeding may result in substantial costs
and distraction to our management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation or interference or derivation
proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, there could be
public announcements of the results of hearings, motions or other interim proceedings or developments. If investors perceive these results
to be negative, the price of our common stock could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Except
for the oppositions to European Patents 2501234, 2968992, and 2683245 (the Opposition Division in each of those oppositions maintained
our claims in unamended form; Opponent has appealed that decision in the &#8216;234 Opposition and we expect the opponents to appeal the
decisions in the &#8216;992 and &#8216;245 oppositions), there are no unresolved communications, allegations, complaints or threats of
litigation related to the possibility that our patents are invalid or unenforceable. Any litigation or claims against us, whether or not
merited, may result in substantial costs, place a significant strain on our financial resources, divert the attention of management and
harm our reputation. An adverse decision in litigation or administrative proceedings could result in inadequate protection for our product
candidates and/or reduce the value of any license agreements we have with third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we infringe the rights of third parties we could be prevented from selling products, forced to pay damages, and defend against litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
our products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantial costs
and we may have to: obtain licenses, which may not be available on commercially reasonable terms, if at all; abandon an infringing product
candidate; redesign our products or processes to avoid infringement; stop using the subject matter claimed in the patents held by others;
pay damages; and/or defend litigation or administrative proceedings which may be costly whether we win or lose, and which could result
in a substantial diversion of our financial and management resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>There
are risks to our intellectual property based on our international business initiatives.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may face risks to our technology and intellectual property as a result of our conducting strategic business discussions outside of the
United States, and particularly in jurisdictions that do not have comparable levels of protection of corporate proprietary information
and assets such as intellectual property, trademarks, trade secrets, know-how and customer information and records. While these risks
are common to many companies, conducting business in certain foreign jurisdictions, housing technology, data and intellectual property
abroad, or licensing technology to joint ventures with foreign partners may have more significant exposure. For example, we have shared
intellectual properties with entities in China pursuant to confidentiality agreements in connection with discussions on potential strategic
collaborations, which may expose us to material risks of theft of our proprietary information and other intellectual property, including
technical data, manufacturing processes, data sets or other sensitive information. For example, our technology may be reverse engineered
by the parties or other parties, which could result in our patents being infringed or our know-how or trade secrets stolen. The risk can
be by direct intrusion wherein technology and intellectual property is stolen or compromised through cyber intrusions or physical theft
through corporate espionage, including with the assistance of insiders, or via more indirect routes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>GENERAL
COMPANY-RELATED RISKS</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
preclinical and nonclinical testing or clinical studies for our product candidates are unsuccessful or delayed, we will be unable to meet
our anticipated development and commercialization timelines.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
rely and expect to continue to rely on third parties, including contract research organizations, or CROs, and outside consultants, to
conduct, supervise or monitor some or all aspects of preclinical and nonclinical testing and clinical studies involving our product candidates.
We have less control over the timing and other aspects of these preclinical and nonclinical testing activities and clinical studies than
if we performed the monitoring and supervision entirely on our own. Third parties may not perform their responsibilities for our preclinical
and nonclinical testing and clinical studies on our anticipated schedule or, for clinical studies, consistent with a clinical study protocol.
Delays in preclinical and nonclinical testing, and clinical studies could significantly increase our product development costs and delay
product commercialization. In addition, many of the factors that may cause, or lead to, a delay in the clinical studies may also ultimately
lead to denial of regulatory approval of a product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
commencement of clinical studies can be delayed for a variety of reasons, including delays in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstrating sufficient safety
        and efficacy to obtain regulatory approval to commence a clinical study;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reaching agreement on acceptable
        terms with prospective CROs and study sites;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing a stable formulation
        of a product candidate;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing sufficient quantities
        of a product candidate; and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining institutional review board,
        or IRB, approval to conduct a clinical study at a prospective site.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Once
a clinical study has begun, it may be delayed, suspended or terminated by us or the FDA or other regulatory authorities due to a number
of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ongoing discussions with the FDA
        or other regulatory authorities regarding the scope or design of our clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct clinical studies
        in accordance with regulatory requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lower than anticipated recruitment
        or retention rate of patients in clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical study
        operations or study sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding to continue
        clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative results of clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">investigational
        drug product out-of-specification; or</span></p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nonclinical or clinical safety observations,
        including adverse events and SAEs.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
clinical studies are unsuccessful, and we are not able to obtain regulatory approvals for our product candidates under development, we
will not be able to commercialize these products, and therefore may not be able to generate sufficient revenues to support our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
rely on third parties to conduct, supervise and monitor our clinical studies, and if those third parties perform in an unsatisfactory
manner, it may harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
rely on CROs and clinical study sites to ensure the proper and timely conduct of our clinical studies. While we have agreements governing
their activities, we will have limited influence over their actual performance. We will control only certain aspects of our CROs&#8217;
activities. Nevertheless, we will be responsible for ensuring that our clinical studies are conducted in accordance with the applicable
protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
and our CROs are required to comply with the FDA&#8217;s cGCP for conducting, recording and reporting the results of clinical studies
to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical study
participants are protected. The FDA enforces these cGCPs through periodic inspections of study sponsors, principal investigators and clinical
study sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical studies may be deemed
unreliable and the FDA may require us to perform additional clinical studies before approving any marketing applications. Upon inspection,
the FDA may determine that our clinical studies did not comply with cGCPs. In addition, our clinical studies, including our ongoing Phase
3 RESILIENT study, will require a sufficiently large number of fibromyalgia participants to evaluate the effectiveness and safety of TNX-102
SL in FM. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of participants, our clinical
studies may be delayed or we may be required to repeat such clinical studies, which would delay the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
CROs are not our employees, and we are not able to control whether or not they devote sufficient time and resources to our clinical studies.
These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting
clinical studies, or other drug development activities which could harm our competitive position.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or
accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements,
or for any other reasons, our clinical studies may be extended, delayed or terminated, and we may not be able to obtain regulatory approval
for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for such product
candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;We
also rely on other third parties to store and distribute drug products for our clinical studies. Any performance failure on the part of
our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products,
if approved, producing additional losses and depriving us of potential product revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
we advance our product candidates through preclinical and nonclinical testing and clinical studies, and develop new product candidates
and buildout of our research and development and manufacturing facilities, we will need to increase our product development, scientific,
regulatory and compliance and administrative headcount to manage these programs. In addition, to meet our obligations as a public company,
we will need to increase our general and administrative capabilities. Our management, personnel and systems currently in place may not
be adequate to support this future growth. Our need to effectively manage our operations, growth and various projects requires that we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully attract and recruit
        new employees with the expertise and experience we will require;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our clinical programs effectively,
        which we anticipate being conducted at numerous clinical sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop a marketing, distribution
        and sales infrastructure in addition to a post-marketing surveillance program if we seek to market our products directly; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to improve our operational,
        manufacturing, quality assurance, financial and management controls, reporting systems and procedures.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
executive officers and other key personnel are critical to our business, and our future success depends on our ability to retain them.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
success depends to a significant extent upon the continued services of Dr. Seth Lederman, our President and Chief Executive Officer and
Dr. Gregory M. Sullivan, our Chief Medical Officer. Dr. Lederman has overseen Tonix Pharmaceuticals, Inc., a wholly-owned subsidiary,
since inception and provides leadership for our growth and operations strategy as well as being an inventor on many of our patents. Dr.
Sullivan has served as our Chief Medical Officer since 2014 and directed the Phase 2 AtEase study, Phase 3 HONOR study, the Phase 3 RECOVERY
study, Phase 3 RELIEF study, the Phase 3 RALLY study and the Phase 3 RESILIENCE study. Loss of the services of Drs. Lederman or Sullivan
would have a material adverse effect on our growth, revenues, and prospective business. The loss of any of our key personnel, or the inability
to attract and retain qualified personnel, may significantly delay or prevent the achievement of our research, development or business
objectives and could materially adversely affect our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
employment agreement we enter into will not ensure the retention of the employee who is a party to the agreement. In addition, we have
only limited ability to prevent former employees from competing with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
our future success will also depend in part on the continued service of our key scientific and management personnel and our ability to
identify, hire, and retain additional personnel. We experience intense competition for qualified personnel and may be unable to attract
and retain the personnel necessary for the development of our business. Moreover, competition for personnel with the scientific and technical
skills that we seek is extremely high and is likely to remain high. Because of this competition, our compensation costs may increase significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>If we
are unable to hire additional qualified personnel, our ability to grow our business may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Over
time we will need to hire additional qualified personnel with expertise in drug development, product registration, clinical, preclinical
and nonclinical research, quality compliance, government regulation, formulation and manufacturing, financial matters and sales and marketing.
We compete for qualified individuals with numerous biopharmaceutical companies, universities and other research institutions. Competition
for such individuals is intense, and we cannot be certain that our search for such personnel will be successful. Attracting and retaining
qualified personnel will be critical to our success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
rely on third parties to manufacture the compounds used in our studies, and we intend to rely on them for the manufacture of any approved
products for commercial sale. If these third parties do not manufacture our product candidates in sufficient quantities and at an acceptable
cost, clinical development and commercialization of our product candidates could be delayed, prevented or impaired.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have no experience in the clinical or commercial-scale manufacture of drugs or in designing drug manufacturing processes. We intend to
rely on CMOs to manufacture some or all of our product candidates in clinical studies and our products that reach commercialization. Completion
of our clinical studies and commercialization of our product candidates requires the manufacture of a sufficient supply of our product
candidates. We have contracted with outside sources to manufacture our development compounds. If, for any reason, we become unable to
rely on our current sources for the manufacture of our product candidates, either for clinical studies or, at some future date, for commercial
quantities, then we would need to identify and contract with additional or replacement third-party manufacturers to manufacture compounds
for nonclinical, preclinical, clinical, and commercial purposes. Although we are in discussions with other manufacturers we have identified
as potential alternative CMOs of TNX-102 SL, we may not be successful in negotiating acceptable terms with any of them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that there are a variety of manufacturers that we may be able to retain to produce these products. However, once we retain a manufacturing
source, if our manufacturers do not perform in a satisfactory manner, we may not be able to develop or commercialize potential products
as planned. Certain specialized manufacturers are expected to provide us with modified and unmodified pharmaceutical compounds, including
finished products, for use in our preclinical and nonclinical testing and clinical studies. Some of these materials are available from
only one supplier or vendor. Any interruption in or termination of service by such sole source suppliers could result in a delay or interruption
in manufacturing until we locate an alternative source of supply. Any delay or interruption in manufacturing operations (or failure to
locate a suitable replacement for such suppliers) could materially adversely affect our business, prospects, or results of operations.
We do not have any short-term or long-term manufacturing agreements with many of these manufacturers. If we fail to contract for manufacturing
on acceptable terms or if third-party manufacturers do not perform as we expect, our development programs could be materially adversely
affected. This may result in delays in filing for and receiving FDA approval for one or more of our products. Any such delays could cause
our prospects to suffer significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Failure
by our third-party manufacturers to comply with the regulatory guidelines set forth by the FDA with respect to our product candidates
could delay or prevent the completion of clinical studies, the approval of any product candidates or the commercialization of our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Such
third-party manufacturers must be inspected by FDA for cGMP compliance before they can produce commercial product. We may be in competition
with other companies for access to these manufacturers&#8217; facilities and may be subject to delays in manufacture if the manufacturers
give other clients higher priority than they give to us. If we are unable to secure and maintain third-party manufacturing capacity, the
development and sales of our products and our financial performance may be materially affected.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;Manufacturers
are obligated to operate in accordance with FDA-mandated requirements. A failure of any of our third-party manufacturers to establish
and follow cGMP requirements and to document their adherence to such practices may lead to significant delays in the availability of material
for clinical studies, may delay or prevent filing or approval of marketing applications for our products, and may cause delays or interruptions
in the availability of our products for commercial distribution following FDA approval. This could result in higher costs to us or deprive
us of potential product revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Drug
manufacturers are subject to ongoing periodic unannounced inspections by the FDA, the Drug Enforcement Administration, or DEA, and corresponding
state and foreign agencies to ensure strict compliance with cGMP requirements and other requirements under Federal drug laws, other government
regulations and corresponding foreign standards. If we or our third-party manufacturers fail to comply with applicable regulations, sanctions
could be imposed on us, including fines, injunctions, civil penalties, failure by the government to grant marketing approval of drugs,
delays, suspension or withdrawal of approvals, seizures or recalls of product, operating restrictions and criminal prosecutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Adverse
global conditions, including economic uncertainty, may negatively impact our financial results. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Global
conditions, dislocations in the financial markets, or inflation could adversely impact our business. In addition, the global macroeconomic
environment has been and may continue to be negatively affected by, among other things, instability in global economic markets, increased
U.S. trade tariffs and trade disputes with other countries, instability in the global credit markets, supply chain weaknesses, instability
in the geopolitical environment as a result of the Russian invasion of the Ukraine, the withdrawal of the United Kingdom from the European
Union, and other political tensions, and foreign governmental debt concerns. Such challenges have caused, and may continue to cause, uncertainty
and instability in local economies and in global financial markets, which may adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could
result in a material disruption of our product development programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Despite
the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are
vulnerable to damage or disruption from computer viruses, software bugs, unauthorized access, natural disasters, terrorism, war, and telecommunication,
equipment and electrical failures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
we have not, to our knowledge, experienced any significant system failure, accident or security breach to date, if such an event were
to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of
clinical trial data from completed or ongoing clinical trials for any of our product candidates could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, our information security systems and
those of our CROs are also subject to laws and regulations requiring that we take measures to protect the privacy and security of certain
information gathered and used in our business. For example, HIPAA and its implementing regulations impose, among other requirements, certain
regulatory and contractual requirements regarding the privacy and security of personal health information. In the European Union the General
Data Protection Regulation, or GDPR, is even more restrictive with respect to all personal information, including information masked by
a coding system. In addition to HIPAA and GDPR, numerous other federal and state laws, including, without limitation, state security breach
notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure
and storage of personal information. To the extent that any disruption or security breach results in a loss of or damage to our data or
applications, or inappropriate disclosure or theft of confidential or proprietary information, we could incur liability, the further development
of our product candidates could be delayed, our competitive position could be compromised, or our business reputation could be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Corporate
and academic collaborators may take actions to delay, prevent, or undermine the success of our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
operating and financial strategy for the development, clinical testing, manufacture, and commercialization of drug candidates is heavily
dependent on our entering into collaborations with corporations, academic institutions, licensors, licensees, and other parties. Our current
strategy assumes that we will successfully establish these collaborations, or similar relationships; however, there can be no assurance
that we will be successful establishing such collaborations. Some of our existing collaborations are, and future collaborations may be,
terminable at the sole discretion of the collaborator. Replacement collaborators might not be available on attractive terms, or at all.
The activities of any collaborator will not be within our control and may not be within our power to influence. There can be no assurance
that any collaborator will perform its obligations to our satisfaction or at all, that we will derive any revenue or profits from such
collaborations, or that any collaborator will not compete with us. If any collaboration is not pursued, we may require substantially greater
capital to undertake development and marketing of our proposed products and may not be able to develop and market such products effectively,
if at all. In addition, a lack of development and marketing collaborations may lead to significant delays in introducing proposed products
into certain markets and/or reduced sales of proposed products in such markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Data
provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading,
or incomplete.</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
rely on third-party vendors, scientists, and collaborators to provide us with significant data and other information related to our projects,
clinical studies, and our business. If such third parties provide inaccurate, misleading, or incomplete data, our business, prospects,
and results of operations could be materially adversely affected.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
product candidates may face competition sooner than expected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
intend to seek data exclusivity or market exclusivity for our product candidates provided under the FDCA and similar laws in other countries.
We believe that TNX-801 could qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009,
or BPCIA, which was enacted as part of the Patient Protection and Affordable Care Act. Under the BPCIA, an application for a biosimilar
product or BLA cannot be submitted to the FDA until four years, or if approved by the FDA, until 12 years, after the original brand product
identified as the reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for the approval of biosimilar
and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and
approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity
to an existing brand product. The new law is complex and is only beginning to be interpreted and implemented by the FDA. While it is uncertain
when any such processes may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial
prospects for any of our product candidates that are biologics. There is also a risk that BPCIA could be repealed or amended to shorten
this exclusivity period, potentially creating the opportunity for biosimilar competition sooner than anticipated after the expiration
of our patent protection. Although there is no current discussion of repeal or modification of the BPCIA, the future remains uncertain.
Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference product in a way that is similar to traditional
generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that
are still developing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
product candidates that are not, or are not considered, biologics that would qualify for exclusivity under the BPCIA may be eligible for
market exclusivity as drugs under the FDCA. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to
the first applicant to gain approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug
containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity
period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA, submitted by another company
for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval.
However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The
FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations,
other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval
of the application, for example, for new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only
the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing
the original active agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
if, as we expect, our product candidates are considered to be reference products eligible for 12 years of exclusivity under the BPCIA
or five years of exclusivity under the FDCA, another company could market competing products if the FDA approves a full BLA or full NDA
for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate
the safety, purity and potency of the products. Moreover, an amendment or repeal of the BPCIA could result in a shorter exclusivity period
for our product candidates, which could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b><i>If
we fail to establish marketing, sales and distribution capabilities, or fail to enter into arrangements with third parties, we will not
be able to create a market for our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
strategy with our product candidates is to control, directly or through contracted third parties, all or most aspects of the product development
process, including marketing, sales and distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Currently,
we do not have any sales, marketing or distribution capabilities. In order to generate sales of any product candidates that receive regulatory
approval, we must either acquire or develop an internal marketing and sales force with technical expertise and with supporting distribution
capabilities or make arrangements with third parties to perform these services for us. The acquisition or development of a sales and distribution
infrastructure would require substantial resources, which may divert the attention of our management and key personnel and defer our product
development efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that we enter into marketing and sales arrangements with other companies, our revenues will depend on the efforts of others.
These efforts may not be successful. If we fail to develop sales, marketing and distribution channels, or enter into arrangements with
third parties, we will experience delays in product sales and incur increased costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Sales
of pharmaceutical products largely depend on the reimbursement of patients&#8217; medical expenses by government health care programs
and private health insurers. Without the financial support of the government or third-party payors, the market for our products will be
limited. These third-party payors are increasingly challenging the price and examining the cost effectiveness of medical products and
services. Recent proposals to change the health care system in the United States have included measures that would limit or eliminate
payments for medical products and services or subject the pricing of medical treatment products to government control. Significant uncertainty
exists as to the reimbursement status of newly approved health care products. Third-party payors may not reimburse sales of our products
or enable our collaborators to sell them at profitable prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business strategy might involve out-licensing product candidates to or collaborating with larger firms with experience in marketing and
selling pharmaceutical products. There can be no assurance that we will be able to successfully establish marketing, sales, or distribution
relationships; that such relationships, if established, will be successful; or that we will be successful in gaining market acceptance
for our products. To the extent that we enter into any marketing, sales, or distribution arrangements with third parties, our product
revenues will be lower than if we marketed and sold our products directly, and any revenues we receive will depend upon the efforts of
such third-parties. If we are unable to establish such third-party sales and marketing relationships, or choose not to do so, we will
have to establish and rely on our own in-house capabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We,
as a company, have no experience in marketing or selling pharmaceutical products and currently have no sales, marketing, or distribution
infrastructure. To market any of our products directly, we would need to develop a marketing, sales, and distribution force that both
has technical expertise and the ability to support a distribution capability. The establishment of a marketing, sales, and distribution
capability would significantly increase our costs, possibly requiring substantial additional capital. In addition, there is intense competition
for proficient sales and marketing personnel, and we may not be able to attract individuals who have the qualifications necessary to market,
sell, and distribute our products. There can be no assurance that we will be able to establish internal marketing, sales, or distribution
capabilities. If we are unable to, or choose not to establish these capabilities, or if the capabilities we establish are not sufficient
to meet our needs, we will be required to establish collaborative marketing, sales, or distribution relationships with third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="background-color: white"><b><i>Our
relationships with customers, physicians, and third-party payors will be subject, directly or indirectly, to federal and state healthcare
fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we
are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Healthcare
providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription
of any drug candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal
investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other
health care laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and
the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical
research, proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal
government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not
limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal
        Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering
        or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind,
        in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program,
        such as the Medicare and Medicaid programs;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil
        and criminal false claims laws, including, without limitation, the False Claims Act, and civil monetary penalty laws which prohibit, among
        other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare,
        Medicaid or other government payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation
        to pay money to the federal government;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal
        Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person
        from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless
        of the payor (e.g., public or private);</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended
        by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, and as amended
        again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under
        HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to HIPAA, published in January 2013, which imposes certain
        requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization
        by entities subject to the rule, such as health plans, health care clearinghouses and health care providers, and their respective business
        associates;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal transparency
        laws, including the federal Physician Payments Sunshine Act, which is part of PPACA, that require certain manufacturers of drugs, devices,
        biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program,
        with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to:
        (i)&#160;payments or other &#8220;transfers of value&#8217;&#8217; made to physicians and teaching hospitals; and (ii)&#160;ownership
        and investment interests held by physicians and their immediate family members;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state and foreign
        law equivalents of each of the above federal laws, state laws that require manufacturers to report information related to payments and
        other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws that require pharmaceutical
        companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
        by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments
        that may be made to healthcare providers; and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state and foreign
        laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant
        ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge under one or more of such laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">It
is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations
or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation
of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, damages, fines, disgorgement, imprisonment, exclusion of drugs from government funded healthcare programs, such
as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar
agreement to resolve allegations of&#160;non-compliance&#160;with these laws and the curtailment or restructuring of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">The
risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory
authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements
with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for
violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our
management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain
robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases
the possibility that a healthcare company may run afoul of one or more of the requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white"><b><i>Coverage
and adequate reimbursement may not be available for our current or any future drug candidates, which could make it difficult for us to
sell profitably, if approved.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Market
acceptance and sales of any drug candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement
for these drugs and related treatments will be available from third-party payors, including government health administration authorities,
managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish
reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage
and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any drug
candidates that we develop will be made on a&#160;payor-by-payor&#160;basis. One payor&#8217;s determination to provide coverage for a
drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party
payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor
determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what
tier of its formulary it will be placed. The position on a payor&#8217;s list of covered drugs, or formulary, generally determines the&#160;co-payment&#160;that
a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians.
Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors
to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs unless coverage is provided and reimbursement
is adequate to cover a significant portion of the cost of our drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">A
primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by
limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be
available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage
and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate
reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current
and any future drug candidates that we develop.</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Healthcare
legislative or regulatory reform measures, including government restrictions on pricing and reimbursement, may have a negative impact
on our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate
post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Among policy makers and payors
in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of
containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular
focus of these efforts and has been significantly affected by major legislative initiatives. For example, in the United States, the Patient
Protection and Affordable Care Act of 2010 (&#8220;ACA&#8221;) substantially changed the way healthcare is financed by both the government
and private insurers<span style="background-color: white"><span style="text-decoration: line-through">, </span></span>and significantly
affects the pharmaceutical industry. Many provisions of the ACA impact the biopharmaceutical industry, including that in order for a biopharmaceutical
product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies,
the manufacturer must extend discounts to entities eligible to participate in the drug pricing program under the Public Health Services
Act, or PHS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, the Inflation Reduction
Act of 2022, which took in 2023, includes policies that are designed to have a direct impact on drug prices and reduce drug spending by
the federal government. This legislation contains substantial drug pricing reforms, including the establishment of a drug price negotiation
program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum
fair price&#8221; for certain selected drugs covered by Medicare or pay an excise tax for noncompliance, the establishment of rebate payment
requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation,
and requires manufacturers to provide discounts on Part D drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Legislative, administrative, and
private payor efforts to control drug costs span a range of proposals, including drug price negotiation, Medicare Part D redesign, drug
price inflation rebates, international mechanisms, generic drug promotion and anticompetitive behavior, manufacturer reporting, and reforms
that could impact therapies utilizing the accelerated approval pathway. We cannot predict the ultimate content, timing or effect of any
changes to the ACA, the Inflation Reduction Act, or other federal and state healthcare policy reform efforts including those aimed at
drug pricing. There is no assurance that federal or state health care reform will not adversely affect our future business and financial
results, and we cannot predict how future federal or state legislative, judicial or administrative changes relating to healthcare policy
will affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">At
the federal level, the now-departed Trump administration proposed numerous prescription drug cost control measures.&#160; Similarly, the
new Biden administration has made lowering prescription drug prices one of its priorities.&#160; The Biden administration has not yet
proposed any specific plans, but we expect that these will be forthcoming in the near term. At the state level, legislatures are increasingly
passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or
patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing. Other examples of proposed changes include,
but are not limited to, expanding post-approval requirements, changing the Orphan Drug Act, and restricting sales and promotional activities
for pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
cannot be sure whether additional legislative changes will be enacted, or whether government regulations, guidance or interpretations
will be changed, or what the impact of such changes would be on the marketing approvals, sales, pricing, or reimbursement of our drug
candidates or products, if any, may be. We expect that these and other healthcare reform measures that may be adopted in the future, may
result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any
reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain
profitability, or commercialize our drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, FDA regulations and guidance may be revised or reinterpreted by the FDA in ways that may significantly affect our business and
our products. Any new regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional
costs or lengthen FDA review times for our product candidates. We cannot determine how changes in regulations, statutes, policies, or
interpretations when and if issued, enacted or adopted, may affect our business in the future. Such changes could, among other things,
require:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional clinical trials to be conducted prior to obtaining
        approval;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to manufacturing methods;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls, replacements, or discontinuance of one or more of our
        products; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional recordkeeping.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Such
changes would likely require substantial time and impose significant costs, or could reduce the potential commercial value of our product
candidates. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any other products would harm
our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international
operations could materially adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
TNX-102 SL or any of our other product candidates are approved for commercialization outside of the United States, we intend to enter
into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will
be subject to additional risks related to entering into international business relationships, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different regulatory requirements
        for drug approvals;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced protection for intellectual
        property rights, including trade secret and patent rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected changes in tariffs, trade
        barriers and regulatory requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation,
        or political instability in particular foreign economies and markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with tax, employment,
        immigration and labor laws for employees living or traveling abroad;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign taxes, including withholding
        of payroll taxes;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign currency fluctuations, which
        could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty in countries
        where labor unrest is more common than in the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting from
        any events affecting raw material supply or manufacturing capabilities abroad;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting
        from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, hurricanes, floods and fires; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty in importing and exporting
        clinical study materials and study samples.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;&#160;&#160;&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b><i>We
face the risk of product liability claims and may not be able to obtain insurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;Our
business exposes us to the risk of product liability claims that are inherent in the development of drugs. If the use of one or more of
our or our collaborators&#8217; drugs harms people, we may be subject to costly and damaging product liability claims brought against
us by clinical study participants, consumers, health care providers, pharmaceutical companies or others selling our products. Our inability
to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent
or inhibit the commercialization of pharmaceutical products we develop, alone or with collaborators. While we currently carry clinical
study insurance and product liability insurance, we cannot predict all of the possible harms or side effects that may result and, therefore,
the amount of insurance coverage we hold now or in the future may not be adequate to cover all liabilities we might incur. We intend to
expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for our drug candidates in development,
but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. If we are
unable to obtain insurance at an acceptable cost or otherwise protect against potential product liability claims, we will be exposed to
significant liabilities, which may materially and adversely affect our business and financial position. If we are sued for any injury
allegedly caused by our or our collaborators&#8217; products, our liability could exceed our total assets and our ability to pay the liability.
A product liability claim or series of claims brought against us would decrease our cash and could cause our stock price to fall.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
use hazardous chemicals in our business. Potential claims relating to improper handling, storage or disposal of these chemicals could
affect us and be time-consuming and costly.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
research and development processes and/or those of our third party contractors may involve the controlled use of hazardous materials and
chemicals. These hazardous chemicals are reagents and solvents typically found in a chemistry laboratory. Our operations also produce
hazardous waste products. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of
hazardous materials. While we attempt to comply with all environmental laws and regulations, including those relating to the outsourcing
of the disposal of all hazardous chemicals and waste products, we cannot eliminate the risk of contamination from or discharge of hazardous
materials and any resultant injury. In the event of such an accident, we could be held liable for any resulting damages and any liability
could materially adversely affect our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Compliance
with environmental laws and regulations may be expensive. Current or future environmental regulations may impair our research, development
or production efforts. We might have to pay civil damages in the event of an improper or unauthorized release of, or exposure of individuals
to, hazardous materials. We are not insured against these environmental risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we enter into collaborations with third parties, they might also work with hazardous materials in connection with our collaborations.
We may agree to indemnify our collaborators in some circumstances against damages and other liabilities arising out of development activities
or products produced in connection with these collaborations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous
or radioactive materials and waste products may require us to incur substantial compliance costs that could materially adversely affect
our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;We
carry insurance for most categories of risk that our business may encounter, however, we may not have adequate levels of coverage. We
currently maintain general liability, clinical study, property, workers&#8217; compensation, products liability and directors&#8217; and
officers&#8217; insurance, along with an umbrella policy, which collectively costs approximately $2,000,000 per annum. We cannot provide
any assurances that we will be able to maintain existing insurance at current or adequate levels of coverage. Any significant uninsured
liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b><i>If
we retain collaborative partners and our partners do not satisfy their obligations, we will be unable to develop our partnered product
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the event we enter into any collaborative agreements, we may not have day-to-day control over the activities of our collaborative partners
with respect to any of these product candidates. Any collaborative partner may not fulfill its obligations under these agreements. If
a collaborative partner fails to fulfill its obligations under an agreement with us, we may be unable to assume the development of the
products covered by that agreement or enter into alternative arrangements with a third party. In addition, we may encounter delays in
the commercialization of the product candidate that is the subject of the agreement. Accordingly, our ability to receive any revenue from
the product candidates covered by these agreements will be dependent on the efforts of our collaborative partner. We could also become
involved in disputes with a collaborative partner, which could lead to delays in or termination of our development and commercialization
programs and time-consuming and expensive litigation or arbitration. In addition, any such dispute could diminish our collaborators&#8217;
commitment to us and reduce the resources they devote to developing and commercializing our products. Conflicts or disputes with our collaborators,
and competition from them, could harm our relationships with our other collaborators, restrict our ability to enter future collaboration
agreements and delay the research, development or commercialization of our product candidates. If any collaborative partner terminates
or breaches its agreement, or otherwise fails to complete its obligations in a timely manner, our chances of successfully developing or
commercializing these product candidates would be materially and adversely affected. We may not be able to enter into collaborative agreements
with partners on terms favorable to us, or at all. Our inability to enter into collaborative arrangements with collaborative partners,
or our failure to maintain such arrangements, would limit the number of product candidates that we could develop and ultimately, decrease
our sources of any future revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be unsuccessful in obtaining a priority review voucher for material threat medical countermeasures.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2016, the 21<sup>st</sup> Century Cures Act, or the Act, was signed
into law to support ongoing biomedical innovation. One part of the Act, Section 3086, is aimed at &#8220;Encouraging Treatments for Agents
that Present a National Security Threat.&#8221; The Act created a new priority review voucher program for approved &#8220;material threat
medical countermeasures.&#8221; The Act defines such countermeasures as drug or biologic products, including vaccines, intended to treat
biological, chemical, radiological, or nuclear agents that present a national security threat or to treat harm from a condition that may
be caused by administering a drug or biological product against such an agent. The Department of Homeland Security has identified 13 such
threats, including anthrax, smallpox, Ebola/Marburg, tularemia, botulinum toxin, and pandemic influenza, which includes the SARS coronavirus
2 known as SARS-CoV-2. A priority review voucher can be applied to any other product; it shortens the FDA review timeline for a new application
from 10 to 12 months to 6 months. The recipient of a priority review voucher may transfer it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>There
may not be market interest in TNX-801.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
government is the only market for most medical countermeasures. This is because unlike other drugs and vaccines, these products are not
sold to doctors, hospitals, or pharmacies. The BioShield Special Reserve Fund, or SRF, has been the sole medical countermeasures market
for the last decade. The SRF is now appropriated annually and has not kept pace with the need for purchasing products ready for stockpiling.
During 2020, $735 million was appropriated to SRF. As such, even if TNX-801 were to receive FDA licensure, the commercial success of TNX-801
remains uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white"><b><i>Government
entities may take actions that directly or indirectly have the effect of limiting opportunities for our vaccine candidates for COVID-19.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Various
government entities, including the U.S. government, are offering incentives, grants and contracts to encourage additional investment by
commercial organizations into preventative and therapeutic agents against COVID-19, which may have the effect of increasing the number
of competitors and/or providing advantages to competitors. Accordingly, there can be no assurance that we will be able to successfully
establish a competitive market share if we ultimately receive regulatory approval for our vaccines as a vaccine for COVID-19. COVID-19
vaccines may also be subject to government pricing controls, which could adversely affect the profitability of any COVID-19 vaccine we
are able to develop and commercialize.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
technology developed for the purposes of developing new medicines or vaccines can be applied to the creation or development of biological
weapons, then our technology may be considered &#8220;dual use&#8221; technology and be subject to limitations on public disclosure or
export.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
research and development of synthetic poxviruses is dedicated not only to creating tools that better protect public health but also to
safeguarding any information with broad, dual-use potential that could be inappropriately applied. &#8220;Dual use research&#8221; is
research conducted for legitimate purposes that generates knowledge, information, technologies, and/or products that can be reasonably
anticipated to provide knowledge, information, products, or technologies that could be directly misapplied to pose a significant threat
to public health, agricultural crops, or national security. Because variola, the agent that causes smallpox, is a pox virus, the technology
we created could be considered dual use and could be subject to export control, for example under the Wassenaar Arrangement. Further,
if federal authorities determine that our research is subject to institutional oversight, we will need to implement a risk-management
plan developed in collaboration with the institutional review entity. Failure to comply with the plan may result in suspension, limitation,
or termination of federal funding or loss of future federal funding opportunities for any of our research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
face risks in connection with existing and future collaborations with respect to the development, manufacture, and commercialization of
our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
face a number of risks in connection with our current collaborations. Our collaboration agreements are subject to termination under various
circumstances. Our collaborators may change the focus of their development and commercialization efforts or may have insufficient resources
to effectively assist in the development of our products. Any future collaboration agreements may have the effect of limiting the areas
of research and development that we may pursue, either alone or in collaboration with third parties. Further, disagreements with collaborators,
including disagreements over proprietary rights, contract interpretation, or the preferred course of development, might cause delays,
might result in litigation or arbitration, or might result in termination of the research, development or commercialization of our products.
Any such disagreements would divert management attention and resources and be time-consuming and costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
face risks in connection with the testing, production and storage of our vaccine product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Developing
our TNX-1850 and TNX-801 vaccine candidates each require testing of challenges with monkeypox or SARS-CoV-2 viruses under controlled experimental
conditions. The testing of TNX-1850 and TNX-801 may carry risk of infection and harm to individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, our TNX-1850 and TNX-801 vaccine candidates are both live forms of the horsepox. We have initiated vaccine-manufacturing activities
to support further nonclinical testing of TNX-801. The production and storage of the synthesized horsepox virus stock and, once initiated,
TNX-1850 virus stock, may carry risk of infection and harm to individuals. Any such infection could expose us to product and general liability
claims, and may carry risk of infection and harm to individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>RISKS
RELATED TO OUR STOCK</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white"><b><i>Sales
of additional shares of our common stock could cause the price of our common stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Sales
of substantial amounts of our common stock in the public market, or the availability of such shares for sale, by us or others, including
the issuance of common stock upon exercise of outstanding options and warrants, could adversely affect the price of our common stock.
We and our directors and officers may sell shares into the market, which could adversely affect the market price of shares of our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>An
active trading market for our common stock may not be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Although
our common stock is listed on the NASDAQ Capital Market, the market for our shares has demonstrated varying levels of trading activity.
Furthermore, the current level of trading may not be sustained in the future. The lack of an active market for our common stock may impair
investors&#8217; ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable, may reduce
the fair market value of their shares and may impair our ability to raise capital to continue to fund operations by selling shares and
may impair our ability to acquire additional intellectual property assets by using our shares as consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
market price of our common stock has been extremely volatile and may continue to be volatile due to numerous circumstances beyond our
control.</i>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;The
market price of our common stock has fluctuated, and may continue to fluctuate, widely, due to many factors, some of which may be beyond
our control. These factors include, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;short squeezes&#8221;;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">comments by securities analysts or other third parties, including
        blogs, articles, message boards and social and other media;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">large stockholders exiting their position in our common stock
        or an increase or decrease in the short interest in our common stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated fluctuations in our financial and operating
        results;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks and uncertainties associated with the ongoing COVID-19
        pandemic;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and allocations of new product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">public perception of our product candidates and competitive
        products;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial estimates or recommendations by securities
        analysts;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the reimbursement policies of third party insurance
        companies or government agencies; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall general market fluctuations.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Stock
markets in general and our stock price in particular have experienced extreme price and volume fluctuations that have often been unrelated
or disproportionate to the operating performance of those companies and our company. Broad market fluctuations may adversely affect the
trading price of our common stock. In particular, a proportion of our common stock has been and may continue to be traded by short sellers
which may put pressure on the supply and demand for our common stock, further influencing volatility in its market price. Additionally,
these and other external factors have caused and may continue to cause the market price and demand for our common stock to fluctuate,
which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity
of our common stock.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;A
&#8220;short squeeze&#8221; due to a sudden increase in demand for shares of our common stock that largely could lead to extreme price
volatility in shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;Investors
may purchase shares of our common stock to hedge existing exposure or to speculate on the price of our common stock. Speculation on the
price of our common stock may involve long and short exposures. To the extent aggregate short exposure exceeds the number of shares of
our common stock available for purchase on the open market, investors with short exposure may have to pay a premium to repurchase shares
of our common stock for delivery to lenders of our common stock. Those repurchases may in turn, dramatically increase the price of our
common stock until additional shares of our common stock are available for trading or borrowing. This is often referred to as a &#8220;short
squeeze.&#8221; A proportion of our common stock has been and may continue to be traded by short sellers which may increase the likelihood
that our common stock will be the target of a short squeeze. A short squeeze could lead to volatile price movements in shares of our common
stock that are unrelated or disproportionate to our operating performance or prospectus and, once investors purchase the shares of our
common stock necessary to cover their short positions, the price of our common stock may rapidly decline. Investors that purchase shares
of our common stock during a short squeeze may lose a significant portion of their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
could be delisted from Nasdaq, which could seriously harm the liquidity of our stock and our ability to raise capital.&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have had in the past, and may in the future, have difficulty satisfying Nasdaq listing requirements for our common stock. If we are unable
to satisfy Nasdaq listing requirements, we will cease to be eligible to trade on Nasdaq. In such event:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may have to pursue trading on
        a less recognized or accepted market, such as the OTC Bulletin Board or the &#8220;pink sheets.&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of our common stock could
        be less liquid and marketable, thereby reducing the ability of stockholders to purchase or sell our shares as quickly and as inexpensively
        as they have done historically. If our stock is traded as a &#8220;penny stock,&#8221; transactions in our stock would be more difficult
        and cumbersome.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to access capital
        on favorable terms or at all, as companies trading on alternative markets may be viewed as less attractive investments with higher associated
        risks, such that existing or prospective institutional investors may be less interested in, or prohibited from, investing in our common
        stock. This may also cause the market price of our common stock to decline.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
do not anticipate paying dividends on our common stock and, accordingly, shareholders must rely on stock appreciation for any return on
their investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have never declared or paid cash dividends on our common stock and do not expect to do so in the foreseeable future. The declaration of
dividends is subject to the discretion of our board of directors and will depend on various factors, including our operating results,
financial condition, future prospects and any other factors deemed relevant by our board of directors. You should not rely on an investment
in our company if you require dividend income from your investment in our company. The success of your investment will likely depend entirely
upon any future appreciation of the market price of our common stock, which is uncertain and unpredictable. There is no guarantee that
our common stock will appreciate in value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
quarterly operating results are likely to fluctuate in the future. These fluctuations could cause our stock price to decline. The nature
of our business involves variable factors, such as the timing of the research, development and regulatory pathways of our product candidates,
which could cause our operating results to fluctuate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Due
to the possibility of fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results
are not a good indication of our future performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
rights of the holders of common stock may be impaired by the potential issuance of preferred stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
articles of incorporation give our board of directors the right to create new series of preferred stock. As a result, the board of directors
may, without stockholder approval, issue preferred stock with voting, dividend, conversion, liquidation or other rights which could adversely
affect the voting power and equity interest of the holders of common stock. Preferred stock, which could be issued with the right to more
than one vote per share, could be utilized as a method of discouraging, delaying or preventing a change of control. The possible impact
on takeover attempts could adversely affect the price of our common stock. Although we have no present intention to issue any shares of
preferred stock or to create a series of preferred stock, we may issue such shares in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures, or if we discover
material weaknesses and deficiencies in our internal control and accounting procedures, our stock price could decline significantly and
raising capital could be more difficult.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, or, if we discover
material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
and raising capital could be more difficult. Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness
of our internal control over financial reporting. If material weaknesses or significant deficiencies are discovered or if we otherwise
fail to achieve and maintain the adequacy of our internal control, we may not be able to ensure that we can conclude on an ongoing basis
that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Moreover,
effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial
fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors
could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding
our stock adversely, our stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about
us or our business. Our research coverage by industry and financial analysts is currently limited. Even if our analyst coverage increases,
if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts
cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in
turn could cause our stock price or trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
companies may have difficulty acquiring us, even if doing so would benefit our stockholders, due to provisions under our corporate charter
and bylaws, as well as Nevada law.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Provisions
in our articles of incorporation, our bylaws, and under Nevada law could make it more difficult for other companies to acquire us, even
if doing so would benefit our stockholders. Our articles of incorporation and bylaws contain the following provisions, among others, which
may inhibit an acquisition of our company by a third party:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance notification procedures
        for matters to be brought before stockholder meetings</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 50pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limitation on who may call stockholder
        meetings</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limitation on the removal of directors</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability of our board of directors
        to issue up to 5,000,000 shares of preferred stock without a stockholder vote</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are also subject to provisions of Nevada law that prohibit us from engaging in any business combination with any &#8220;interested stockholder,&#8221;
meaning generally that a stockholder who beneficially owns 10 percent or more of our stock cannot acquire us for a period of time after
the date this person became an interested stockholder, unless various conditions are met, such as approval of the transaction by our board
of directors and stockholders.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
bylaws designate the Eighth Judicial District Court of Clark County, Nevada as the sole and exclusive forum for certain types of actions
and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial
forum for disputes with us or our directors, officers, employees or agents.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
bylaws require that, to the fullest extent permitted by law, and unless the Company consents in writing to the selection of an alternative
forum, the Eighth Judicial District Court of Clark County, Nevada, will, to the fullest extent permitted by law, be the sole and exclusive
forum for each of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 56px; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 36.4pt; text-align: justify; text-indent: -0.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
        derivative action or proceeding brought in the name or right of the Company or on its behalf,</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 36.4pt; text-align: justify; text-indent: -0.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
        action asserting a claim for breach of any fiduciary duty owed by any director, officer, employee or agent of the Company to the Company
        or the Company&#8217;s stockholders,</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 36.4pt; text-align: justify; text-indent: -0.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
        action arising or asserting a claim arising pursuant to any provision of NRS Chapters 78 or 92A or any provision of our articles of incorporation
        or bylaws, or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-left: 36.4pt; text-align: justify; text-indent: -0.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
        action asserting a claim governed by the internal affairs doctrine, including, without limitation, any action to interpret, apply, enforce
        or determine the validity of our articles of incorporation or bylaws.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
the applicability of the exclusive forum provision is limited to the extent permitted by law, we believe that the exclusive forum provision
would not apply to suits brought to enforce any duty or liability created by the Securities Exchange Act of 1934, as amended (Exchange
Act), or any other claim for which the federal courts have exclusive jurisdiction, and that federal courts have concurrent jurisdiction
over all suits brought to enforce any duty or liability created by the Securities Act of 1933, as amended (Securities Act). We note that
there is uncertainty as to whether a court would enforce the provision and that investors cannot waive compliance with the federal securities
laws and the rules and regulations thereunder. Although we believe this provision benefits us by providing increased consistency in the
application of Nevada law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against
our directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka004"></span>&#160;ITEM
1B &#8211; UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
are no unresolved staff comments at December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka005"></span>ITEM
2 &#8211; PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
maintain our principal office at 26 Main Street, Suite 101, Chatham, New Jersey 07928. Our telephone number at that office is (862) 799-8599
and our fax number is (212) 923-5700. On August 28, 2020, we entered into a lease, whereby we agreed to lease new office space, commencing
September 2020 and expiring December 2025. In connection therewith, we maintain a letter of credit, which has a remaining balance of $140,201
as of December 31, 2022, and such amount is deposited into the restricted cash account maintained at the bank that issued the letter of
credit. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 6, 2018, we entered into a lease amendment, whereby we agreed to lease new office space in New York, New York, commencing January
15, 2019, and expiring on November 30, 2020. In August 2020, we signed a one-year extension, expiring in November 2021. In September 2021,
we signed a one-year extension, expiring in November 2022. In May 2022, we signed a one-year extension, expiring in November 2023. In
connection therewith, we maintain a letter of credit, which has a remaining balance of $100,653 as of December 31, 2022, and such amount
is deposited into the restricted cash account maintained at the bank that issued the letter of credit. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;On
October 1, 2021, we completed the purchase of a research and development facility in Maryland totaling $17.5 million, to process development
activities. As of December 31, 2022, the asset was operational and the asset was ready for its intended use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 23, 2020, we completed the purchase of our approximately 44-acre site in Hamilton, Montana for $4.5 million, for the construction
of a vaccine development and commercial scale manufacturing facility. As of December 31, 2022, the facility was not ready for its intended
use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 28, 2020, we completed the purchase of our 45,000 square foot facility in Massachusetts for $4.0 million, to house our new Advanced
Development Center for accelerated development and manufacturing of vaccines. As of December 31, 2022, the facility was operational and
ready for its intended use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Future
minimum lease payments are as follows (in thousands):&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Year&#160;Ending&#160;December&#160;31,</span></b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">441</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">159</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">775</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included interest</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">760</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that our existing facilities are suitable and adequate to meet our current business requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b><span id="tnxp10ka006"></span>ITEM
3 &#8211; LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However,
litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may
harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the
aggregate, a material adverse effect on our business, financial condition, operating results or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka007"></span>ITEM
4 &#8211; MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka008"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka009"></span>ITEM
5 &#8211; MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Market Information&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our common stock is listed on The NASDAQ Capital
Market under the symbol &#8220;TNXP&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Holders</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
March 10, 2023, the closing sale price of our common stock, as reported by The NASDAQ Stock Market, was $0.62 per share. On March 10, 2023, there were 231 holders of record of our common stock.
Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate
the total number of stockholders represented by these record holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have never paid any cash dividends on our capital stock and do not anticipate paying any cash dividends on our common stock in the foreseeable
future.&#160;We intend to retain future earnings to fund ongoing operations and future capital requirements of our business. Any future
determination to pay cash dividends will be at the discretion of the Board and will be dependent upon our financial condition, results
of operations, capital requirements and such other factors as the Board deems relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">None.<b>&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Repurchases
of Equity Securities by the Issuer and Affiliated Purchasers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
did not purchase any of our registered securities during the period covered by this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka010"></span>ITEM
6 &#8211; RESERVED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka011"></span>ITEM
7 &#8211; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>This
Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements
that reflect Management&#8217;s current views with respect to future events and financial performance. You can identify these statements
by forward-looking words such as &#8220;may&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;estimate&#8221; and &#8220;continue,&#8221; or similar words.&#160;Those statements include statements regarding the intent, belief
or current expectations of us and members of its management team as well as the assumptions on which such statements are based and should
be read together with the &#8220;Risk Factors&#8221; section of this Annual Report on Form&#160;10-K for a discussion of important factors
that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained
in the following discussion and analysis. Our actual results could differ materially from those anticipated in these forward-looking statements
as a result of various factors, including those discussed below and elsewhere in this Annual Report and in other reports we file with
the Securities and Exchange Commission, particularly those under &#8220;Risk Factors.&#8221;.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Business
Overview </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical company focused on developing
therapeutics and vaccines to treat and prevent human disease and alleviate suffering. We have a rich pipeline of products in development
that has been curated from internal discovery, as well as licenses, acquisitions and collaborations with academic institutions and contract
research organizations. We continue to build capabilities in synthetic biology, precision medicine, protein engineering, medicinal chemistry,
molecular biology, pharmacogenomics and clinical-scale manufacturing. Our therapeutics under development include both small molecules
and biologics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our portfolio consists of central nervous system, or CNS, rare disease,
immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic,
psychiatric and addiction conditions. Our rare disease portfolio focuses on developing novel therapies for patients with rare diseases,
including those caused by genetic disorders which are characterized by complex symptoms and for which no drug is approved. Our immunology
portfolio includes biologics to address organ transplant rejection, autoimmune diseases and cancer. Our infectious disease portfolio includes
a vaccine in development to prevent smallpox and mpox (formerly known as monkeypox), next-generation vaccines to prevent COVID-19, a platform
to make fully human mAbs to treat COVID-19 and humanized anti-SARS-CoV-2 mAbs. Our vaccine in development to prevent smallpox and mpox
also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our latest stage CNS product
candidate is TNX-102 SL*, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration. TNX-102
SL has active INDs for fibromyalgia, or FM, FM-type Long COVID or PASC (post-acute sequelae of SARS-CoV-2 infection), posttraumatic stress
disorder, or PTSD, agitation in Alzheimer&#8217;s disease, or AAD, and alcohol use disorder, or AUD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">TNX-102 SL is in mid-Phase 3 development for the management of FM, a pain
disorder characterized by chronic widespread pain, non-restorative sleep, fatigue and impaired cognition. In December 2020, we reported
positive results from the Phase 3 RELIEF study of TNX-102 SL 5.6 mg for the management of FM. In July 2021, we reported pre-planned interim
analysis results from a second Phase 3 study, RALLY. Based on the recommendation from the independent data monitoring committee that the
RALLY trial was unlikely to demonstrate a statistically significant improvement in the primary endpoint, we stopped enrollment of new
participants but allowed those participants who were already enrolled to complete the study. We reported topline data from the completed
study in March of 2022. As expected, based on interim analysis results, TNX-102 SL did not achieve statistical significance over placebo
on the primary endpoint of reduction in daily pain, and relative to the previous positive Phase 3 Study (RELIEF), RALLY had an unexpected
increase in study participant adverse event-related discontinuations in both drug and placebo groups. In April 2022, we started a new
potentially confirmatory Phase 3 study of TNX-102 SL in FM, RESILIENT. Interim analysis results are expected in the second quarter of
2023 and topline results are expected in the fourth quarter of 2023. Following a positive outcome of the RESILIENT study, we believe we
would be positioned to file a New Drug Application (NDA) for TNX-102 SL for the management of FM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-102 SL is also
being developed as a potential treatment for a type of Long COVID, the symptoms of which overlap with FM, that we term FM-type
Long COVID. We initiated enrollment in the Phase 2 study PREVAIL, in August 2022. The primary endpoint is a change in daily pain
scores from baseline.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For TNX-102 SL in PTSD,
we completed the Phase 3 RECOVERY trial and reported topline results in the fourth quarter of 2020 in which TNX-102 SL did not
meet the primary efficacy endpoint. PTSD is a serious psychiatric condition that develops in response to experiencing a traumatic
event. We subsequently completed a meeting with the FDA to discuss potential new endpoints for the indication of treatment of PTSD.
Future studies will employ the one month look-back CAPS-5 as the primary endpoint rather than the one week look-back used in prior
studies.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
AAD program is Phase 2 ready with an active IND and FDA Fast Track designation. AAD, which includes emotional lability, restlessness,
irritability, and aggression, is one of the most distressing and debilitating of the behavioral complications of Alzheimer&#8217;s disease.
We do not have any near-term plans to start a Phase 2 study in AAD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
AUD program is also Phase 2 ready with an active IND. AUD is a chronic relapsing brain disease characterized by compulsive alcohol use,
loss of control over alcohol intake, and a negative emotional state when not using alcohol. We do not have any near-term plans to start
a Phase 2 study in AUD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-1900* (intranasal
potentiated oxytocin) is in development for the treatment of chronic migraine and obesity-associated binge eating disorder, or BED.
TNX-1900 was acquired from Trigemina, Inc. and licensed from Stanford University in 2020. The potentiated formulation includes
magnesium, which has been shown in animal studies to potentiate binding of oxytocin to the oxytocin receptor. We received IND
clearance from the FDA in the fourth quarter of 2021 to study TNX-1900 in chronic migraine and we initiated a Phase 2 study in
migraine in the first quarter of 2023. We expect interim analysis results from the first 50 percent of patients enrolled in the
fourth quarter of 2023. In March 2022, we announced an agreement with Massachusetts General Hospital, a teaching hospital of Harvard
Medical School, to conduct an investigator-initiated Phase 2 clinical trial to study TNX-1900 in BED. The Phase 2 clinical trial is
expected to start in the second quarter of 2023. We do not own an IND for BED. We also licensed technology to use TNX-1900 for the
treatment of insulin resistance from the University of Geneva and also have rights to develop it as a treatment for craniofacial
pain, but we are not imminently pursuing clinical trials in either of these indications at this time.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TNX-601 ER* (tianeptine hemioxalate extended-release tablets) is a CNS
product candidate in development as a treatment for major depressive disorder, or depression, and with possible additional indications
of PTSD, and neurocognitive dysfunction associated with corticosteroid use. TNX-601 ER represents a novel approach to treating depression
in the U.S., since the active ingredient tianeptine induces a neuroprotective and resilient phenotype in both neurons and microglia under
conditions of stress in animals. The dramatic and unique effects of tianeptine are illustrated in animal models by the restoration of
dendritic arborization of pyramidal neurons of CA3 region of hippocampus and the dentate gyrus region new neuron formation and integration
into hippocampal networks. In contrast, antidepressants that are marketed in the U.S. act by modulating the levels or receptor binding
of neurotransmitters in the synapse. We have completed a Phase 1 trial for formulation development outside of the U.S. We expect to initiate
a potentially pivotal Phase 2 study in the first quarter of 2023 for the treatment of major depressive disorder and we expect interim
analysis results from the first 50 percent of patients enrolled in the fourth quarter of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Another CNS candidate in development
is TNX-1300* (double-mutant cocaine esterase) which is in Phase 2 for the treatment of life-threatening cocaine intoxication. TNX-1300
has been granted Breakthrough Therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA. TNX-1300 was licensed from
Columbia University in 2019 after a Phase 2 study showed that it rapidly and efficiently disintegrates cocaine in the blood of volunteers
who received intravenous, or i.v., cocaine. In August of 2022, we received a Federal Grant from the National Institute on Drug Abuse (NIDA)
to advance the development of TNX-1300 as a treatment for cocaine intoxication. We expect to initiate a potentially pivotal Phase 2 study
of TNX-1300 in emergency rooms in the second quarter of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Finally,
our CNS pipeline includes TNX-1600*, an inhibitor of the reuptake of neurotransmitters serotonin, norepinephrine and dopamine, or a triple
reuptake inhibitor. TNX-1600 was licensed from Wayne State University in 2019 and is expected to be developed as a treatment for PTSD,
depression and attention-deficit/hyperactivity disorder, or ADHD. TNX-1600 is in the preclinical stage of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our rare disease portfolio
consists of TNX-2900*, another magnesium-potentiated, intranasal oxytocin-based therapeutic in development for the treatment of Prader-Willi
syndrome, or PWS. The technology for TNX-2900 was licensed from Inserm, the French National Institute of Health and Medical Research.
PWS, an orphan condition, is a rare genetic disorder of failure to thrive in infancy, associated with uncontrolled appetite beginning
in childhood with complications of obesity and diabetes. We have sponsored a research program at Inserm to study oxytocin on suckling
behavior in mice that have been engineered to express one of the Prader-Willi genes. TNX-2900 has been granted Orphan-Drug Designation
for the treatment of PWS, and is in the pre-IND stage of development.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead candidate
in the immunology pipeline is TNX-1500*, a humanized mAb, directed against CD40-ligand, or CD40L (also
known as CD154), engineered to modulate binding to Fc receptors, that is being developed as a prophylaxis against organ transplant
rejection as well as to treat autoimmune conditions. In experiments at the Massachusetts General Hospital or MGH, a teaching hospital
of Harvard Medical School, TNX-1500 is being studied as monotherapy or in combination with other immunosuppressive agents in heart
and kidney allogeneic organ transplants in non-human primates. Preliminary results from ongoing experiments in kidney and heart
transplants indicate that TNX-1500 appears to have comparable efficacy to historical experiments using the chimeric mouse/human
IgG1 version (5c8H1) of the anti-CD40L mAb 5c8. First generation anti-CD40L mAb therapies were associated with an increased risk
of blood clots or thrombosis. In the non-human primate studies with TNX-1500 for allogeneic kidney or heart transplantation, no
evidence of thrombosis has been observed so far. We expect to start a Phase 1 study of TNX-1500 in the second quarter of 2023.
TNX-1500 also is being studied in combination with other immunosuppressive agents in xenogeneic organ transplants in non-human
primates at MGH and at the University of Maryland at Baltimore or UMB. In experiments at UMB, TNX-1500 is being studied to prevent
rejection of xenogeneic hearts from genetically engineered pigs developed by the Revivicor division of United Therapeutics Corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our immunology pipeline
also includes TNX-1700*, a recombinant Trefoil Factor Family 2, or rTFF2, fusion protein that was licensed from Columbia University
in 2019. TNX-1700 consists of TFF2 fused to human serum albumin or I and is a biologic being developed to treat gastric and colorectal
cancers by an immune-oncology mechanism, in combination with PD1 blockers, and is in the preclinical stage of development. We recently
presented data that show a murine version of TNX-1700 consisting of a fusion protein with murine serum albumin or MSA was able
to evoke anti-tumor immunity in the MC38 mouse model of colorectal cancer as monotherapy and that TNX-1700 augmented the efficacy
of anti-PD1 therapy in both the MC38 mouse model and the CT26.wt models of colorectal cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our infectious disease
portfolio includes vaccines based on our live virus vaccine or recombinant pox vaccine, &#8220;RPV&#8221; platform. Live virus
vaccines are believed to protect against poor clinical outcomes of infectious diseases by eliciting T cell responses in addition
to antibody responses. TNX-801*, a live attenuated vaccine based on synthesized horsepox is in the pre-IND stage of development
to protect against smallpox and mpox. Non-human primates vaccinated with TNX-801 were protected from monkeypox in studies reported
in the first quarter of 2020.&#160;A Phase 1 study of TNX-801 in humans is expected to start in the second half of 2023. TNX-801
also serves as the live virus vaccine platform for other infectious diseases for which subsequent products will be designed by
expressing other viral antigens in the horsepox vector.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-1850* is a live
virus vaccine that expresses the SARS-CoV-2 spike protein from the BA.2 strain that has not yet been tested in animals. TNX-1800*
is a live virus vaccine that expresses the SARS-CoV-2 spike protein from the ancestral Wuhan strain, which has shown encouraging
results in non-human primates. Because the subsequent omicron variant out-competed the ancestral Wuhan strain, we began work on
new vaccine versions, TNX-1840* and TNX-1850*, that are designed to express spike protein from the omicron variant and from the
BA.2 variant, respectively. Of those, based on the trajectory of COVID-19, the focus is now on TNX-1850. The COVID-19 vaccines
that are approved for use, or have emergency use authorization, or EUA, in the U.S. have provided significant health benefits to
the vaccinated population; however, they have shown limitations in the durability of protection conferred and in their ability
to block forward transmission. Live virus vaccines that protect against other viral diseases by eliciting T cell responses have
shown durability of protection that lasts years to decades and some live virus vaccines have significantly inhibited forward transmission.
With respect to TNX-1800 vaccination, we reported positive efficacy data from animal challenge studies using live SARS-CoV-2 in
the first quarter of 2021. In this study, TNX-1800 vaccinated, SARS-CoV-2 challenged animals had undetectable SARS-CoV-2 in the
upper airways, which we believe relates to potential inhibition of forward transmission of this respiratory pathogen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-2300* is a live
virus vaccine based on bovine parainfluenza virus in development to protect against COVID-19. In April 2022, we extended a sponsored
research agreement with Kansas State University to develop a vaccine candidate, TNX-2300, for the prevention of COVID-19 that utilizes
a novel live virus vaccine vector platform based on bovine parainfluenza virus. The efficacy of co-expression of the CD40-ligand,
also known as CD154, to stimulate T cell immunity will also be tested. Attenuated bovine parainfluenza virus has previously been
shown to be an effective antigen delivery vector in humans. Previous work by others has shown that attenuated BPI3V is tolerated
and immunogenic in non-human primates and human infants and children. We believe the vector is well suited for mucosal immunization
using a nasal atomizer, and can also be delivered parenterally. TNX-2300 is in the preclinical stage of development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-3600* and TNX-3800*
are mAbs directed against SARS-CoV-2 which are in development as potential therapeutic or preventative agents for COVID-19. Given
the unpredictable trajectory of the SARS-CoV-2 virus and new variants, we seek to contribute a broad set of anti-SARS-CoV-2 mAbs,
that can be scaled up quickly and potentially combined with other mAbs. We envision the future of mAb therapy for COVID-19 to be
cocktails of mAbs with specificity to variants of concern.&#160; TNX-3600 refers to a series of fully human mAbs generated by human-human hybridomas from COVID-19 convalescent volunteers. We are collaborating with Columbia University to produce these fully
human mAbs to SARS-CoV-2 spike proteins from variants such as delta, omicron and XBB1.5 and to other viral targets. TNX-3800 refers
to three humanized murine mAbs which we licensed exclusively in December 2022 from Curia Global, Inc. for the treatment or
prophylaxis of SARS-CoV-2 infection. The initial focus is to develop COVID-19 therapeutic mAbs. We plan to seek indications similar
to previously EUA-approved therapeutic mAbs for treating individuals with mild-to-moderate COVID-19 who are at high risk for
progression to severe disease or for prophylaxis in individuals with compromised immune systems who are at high risk for severe COVID-19 disease. None of the previously EUA-approved therapeutic or preventative mAbs are still available, because each
has become obsolete since the SARS-CoV-2 virus has mutated to evade their binding. TNX-3600 and TNX-3800 mAbs may also be used in
combination therapy with other COVID-19 therapeutic mAbs. Combination therapies with other anti-SARS-CoV-2 mAbs may reduce the
emergence of resistant viral strains. TNX-3600 and TNX-3800 are in the preclinical stage of development.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TNX-3700* is a COVID-19
mRNA vaccine candidate employing a zinc nanoparticle (ZNP) formulation. In collaboration with Kansas State University, we are developing
this ZNP technology as a potential replacement for the lipid nanoparticle (LNP) technology used in current mRNA vaccines. ZNP technology
potentially allows for improved stability which facilitates shipping and storage and addresses the limitations in current mRNA
vaccines which require ultra-cold storage and shipping. This current requirement limits the use of mRNA vaccines in less developed
countries. We plan to seek initial indications as a booster, similar to the current FDA approved mRNA vaccines for COVID-19. We
intend to conduct research with Kansas State University on ZNP SARS-CoV-2 spike based vaccines in tissue culture and animals in
the first half of 2023. TNX-3700 is in the preclinical stage of development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Relating to our COVID-19 and other infectious disease development programs,
we are developing the resources necessary to enable internal research, development and manufacturing capabilities necessary to meet the
goal of producing new vaccine candidates within 100 days of recognition within weeks of obtaining sequence information of a novel pathogen.
We seek to be a leader in the movement to re-build domestic U.S. research, development and manufacturing capabilities. Because this movement
follows a protracted period when domestic research, development and manufacturing were moved out of the U.S., or &#8220;off-shore&#8221;
by other companies to save on labor and other costs, the movement to reverse that trend has been described as &#8220;on-shoring&#8221;
or &#8220;re-domestication&#8221;. The COVID-19 pandemic taught that national borders may close during a health emergency. Therefore,
domestic capabilities are essential for the health security of the U.S., which has also been described as pandemic preparedness and biodefense.
As articulated in the American Pandemic Preparedness Plan, or AP3, released by the U.S. Office of Science and Technology Policy, this
100-day goal for vaccines is a key component of preparedness for future pandemics. We believe we have established the infrastructure necessary
to support the pandemic preparedness goals established in the AP3, specifically with respect to our RPV vaccine and potentially to other
vaccine and therapeutic platforms. This infrastructure consists of (i) our R&amp;D Center, or &#8220;RDC&#8221;, (ii) our Advanced Development
Center, or ADC, and (iii) our Commercial Manufacturing Center, or CMC. We acquired the RDC in Frederick, Maryland consisting of one building
totaling approximately 48,000 square feet. The acquisition closed in October 2021 and the facility is operational. The RDC facility focuses
on our development of vaccines and antiviral drugs against SARS-CoV-2, its variants, and other infectious diseases. The RDC also conducts
research on central nervous system and immunology drugs. The RDC facility is mostly biosafety level 2 (BSL-2), with some components designated
BSL-3. We completed the substantial renovation of the ADC located in the New Bedford business park in Dartmouth, Massachusetts, which
became operational as of the fourth quarter 2022. This approximately 45,000 square foot BSL-2 facility is intended to accelerate development
and clinical scale manufacturing of live-virus vaccines and biologics to support clinical trials. We also plan to build the CMC in Hamilton,
Montana, where we purchased approximately 44 acres of land and have built a field office to manage construction of the facility. The CMC
will focus on developing and manufacturing commercial scale live-virus vaccines and biologics and is also intended to be BSL-2. Site enabling
work is expected to be initiated for the CMC in 2023. Together, we expect these facilities may qualify the RPV vaccine platform for programs
that are designed to carry out the goals of AP3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">*All
of our product candidates are investigational new drugs or biologics and have not been approved for any indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are led by a management team with significant industry experience in drug development. We complement our management team with a network
of scientific, clinical, and regulatory advisors that includes recognized experts in their respective fields.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of our
research and development efforts and the timing and outcome of regulatory submissions. Due to these uncertainties, accurate predictions
of future operations are difficult or impossible to make.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fiscal
year Ended December 31, 2022 Compared to Fiscal year Ended December 31, 2021</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth our operating expenses for the fiscal years ended December 31, 2022 and 2021 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
        ended December 31,</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COSTS AND EXPENSES:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
        and development</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,876</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,838</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
        and administrative</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,215</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,474</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,091</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,312</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating loss</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(112,091</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(92,312</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
        income, net</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,873</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
        loss</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110,218</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(92,287</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Research
and Development Expenses</span>.</i>&#160;Research and development expenses for the fiscal year ended December 31, 2022, were $81.9 million,
an increase of $13.1 million, or 19%, from $68.8 million for the fiscal year ended December 31, 2021. This increase is predominately due
to increased employee-related expenses of $9.0 million, predominately related to new hires at the RDC and ADC, lab supplies of $3.3 million, and office-related expenses of $1.4 million related
to our new facilities offset by a decrease in regulatory expenses of $0.4 million and a decrease in market research expenses of $0.3 million.
We expect research and development expenses to increase during 2023 as we move our clinical development programs forward and continue
to invest in our development pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
table below summarizes our direct research and development expenses for our product candidates and development platform for the years
ended December 31, 2022, and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="11" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="11" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
        thousands)</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; TNX - 102 SL</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,530</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,974</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(444</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; TNX - 1800</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,819</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,049</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,230</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; TNX -&#160;&#160;&#160;601 ER</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,308</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,602</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,294</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; TNX -&#160;&#160;&#160;801</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,111</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,030</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; TNX - 1300</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,233</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,882</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,649</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; TNX - 1500</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,510</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,334</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,176</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; TNX - 1900</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,155</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,429</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,726</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; TNX - 2100</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,434</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,410</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,976</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; TNX - 3500</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,162</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,368</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,206</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct expenses &#8211; Other programs</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,912</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,861</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,051</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal staffing, overhead and
        other</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,702</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,848</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,854</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total research &amp; development</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,876</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,838</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,038</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
direct research and development expenses consist principally of external costs for clinical, nonclinical and manufacturing, such as fees
paid to contractors, consultants and CROs in connection with our development work. Included in &#8220;Internal Staffing, Overhead and
Other&#8221; is overhead, supplies, research and development employee costs (including stock option expenses), travel, regulatory and
legal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;<i><span style="text-decoration: underline">General
and Administrative Expenses</span>.</i>&#160;General and administrative expenses for the fiscal year ended December
31, 2022 were $30.2 million, an increase of $6.7 million, or 29%, from $23.5 million incurred in the fiscal year ended December 31, 2021.
The increase is primarily due to employee-related expenses of $4.3 million, of which $2.4 million relates to stock-based compensation,
an increase in legal fees of $0.1 million due to increased patent prosecution costs, an increase in software/technology expenses of $0.5
million, an increase in financial reporting expenses of $1.1 million, and an increase in travel-related of $0.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Net
Loss</span></i>. As a result of the foregoing, the net loss for the year ended December 31, 2022 was $110.2 million, compared to a net
loss of $92.3 million for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>License
Agreements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
February 13, 2023, we exercised an option to obtain an exclusive license from Columbia for the development of a portfolio of both fully
human and murine mAbs for the treatment or prophylaxis of SARS-CoV-2 infection, including our TNX-3600 and TNX-4100 product candidates,
respectively. The licensed mAbs were developed as part of a research collaboration and option agreement between us and Columbia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 12, 2022, we entered into an exclusive license agreement with Curia for the development of three humanized murine mAbs for the
treatment or prophylaxis of SARS-CoV-2 infection. We believe that the licensing of these mAbs strengthens our pipeline of next-generation
therapeutics to treat COVID-19, which is caused by SARS-CoV-2. As consideration for entering into the License Agreement, we paid a license
fee of approximately $0.4 million to Curia. The License Agreement also provides for single-digit royalties and contingent milestone payments.
As of December 31, 2022, other than the upfront fee, no payments have been accrued or paid in relation to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 18, 2022, we entered into an exclusive License Agreement with the University of Alberta focused on identifying and testing broad-spectrum
antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses. As consideration for entering into the License Agreement,
we paid a low-five digit license fee to University of Alberta. The License Agreement also provides for single-digit royalties and contingent
milestone payments. As of December 31, 2022, other than the upfront fee, no payments have been accrued or paid in relation to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
April 14, 2021, we and OyaGen, Inc. (&#8220;OyaGen&#8221;) entered into an exclusive License Agreement (the &#8220;OyaGen License Agreement&#8221;)
pursuant to which OyaGen granted us an exclusive license to certain patents and technical information related to an antiviral inhibitor
of SARS-CoV-2, sangivamycin, and to develop and commercialize products thereunder, and to acquire rights to any technology based thereon
for the prevention or treatment of Covid-19 developed by OyaGen during the term of the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As consideration for entering
into the License Agreement, we agreed to pay a low-seven digit license fee to OyaGen, and agreed to issue to OyaGen and an affiliated
entity an aggregate of 86,010 shares of our common stock, valued at $3.0 million, which are unregistered and subject to a six-month lock-up
and a voting agreement, pursuant to which OyaGen and the affiliated entity have agreed to vote the common stock on any matter put to
a vote of the shareholders of the Company in accordance with management&#8217;s recommendations. The OyaGen License also provides for
single-digit royalties and contingent milestone payments. No milestone payments were accrued or paid in relation to this agreement.&#160;In
July 2022, we notified OyaGen of our intent to terminate the License Agreement, and the agreement was terminated effective September
20, 2022.<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
February 11, 2021, we entered into a license agreement (the &#8220;Inserm License Agreement&#8221;) pursuant to which we licensed technology
using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from Inserm (the
French National Institute of Health and Medical Research), Aix-Marseille Universit&#233; and Centre Hospitalier Universitaire of Toulouse.
The Inserm License Agreement provides for the payment of annual fees and milestone payments upon the occurrence of specified sales milestones,
totaling approximately $0.4 million, as well royalties on net sales of products based on the licensed technology, and assignment/transfer
and sublicense royalties. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 16, 2019, we entered into an exclusive License Agreement (the &#8220;Columbia License Agreement&#8221;) with the Trustees of
Columbia University in the City of New York (&#8220;Columbia&#8221;), as subsequently amended, pursuant to which Columbia granted to us
an exclusive license, with the right to sublicense, certain patents and technical information (collectively, the &#8220;TFF2 Technology&#8221;)
related to a recombinant Trefoil Family Factor 2 (TFF2), and to develop and commercialize products thereunder (each, a &#8220;TFF2 Product&#8221;).
Pursuant to the terms of the Columbia License Agreement, Columbia has reserved for itself the right to practice the TFF2 Technology for
academic research and educational purposes.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
paid a five-digit license fee to Columbia as consideration for entering into the Columbia License Agreement, which was recorded to research
and development expenses in the statement of operations for the year ended December 31, 2019. We are obligated to use Commercially Reasonable
Efforts, as defined in the Columbia License Agreement, to develop and commercialize the TFF2 Product, and to achieve specified developmental
milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are obligated to pay Columbia single-digit royalties on net sales of (i) TFF2 Products sold by us or a sublicensee and (ii) any other
products that involve material or technical information related to the TFF2 Product and transferred to us pursuant to the License Agreement
(&#8220;Other Products&#8221;) sold by us or a sublicensee. Royalties on each particular TFF2 Product are payable on a country-by-country
and Product-by-Product basis until the latest of (i) the date of expiration of the last valid claim in the last to expire of the issued
patents covered by the Columbia License Agreement, and (ii) a specified period of time after the first commercial sale of a TFF2 Product
in the country in question. Royalties on each particular Other Product are payable on a country-by-country and product-by-product basis
until a specified period of time after the first commercial sale of such particular Other Product in such country. Royalties payable on
net sales of the TFF2 Product and Other Products may be reduced by 50% of the royalties payable by us to any third party for intellectual
property rights which are necessary for the practice of the rights licensed to us under the Columbia License Agreement, provided that
the royalty payable on a TFF2 Product or Other Product may not be reduced by more than 50%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are also obligated to make contingent milestone payments to Columbia totaling $4.1 million on a Product-by-Product basis upon the achievement
of certain development, approval and sales milestones related to a TFF2 Product. In addition, we shall pay Columbia 5% of consideration,
other than royalty payments and certain other categories of consideration, payable to us by a sublicensee. As of December 31, 2022, no
milestone payments have been accrued or paid in relation to this agreement.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 20, 2019, we entered into an exclusive License Agreement (the &#8220;License Agreement&#8221;) with Columbia pursuant to which Columbia,
for itself and on behalf of the University of Kentucky and the University of Michigan (collectively, the &#8220;Institutions&#8221;) granted
to us an exclusive license, with the right to sublicense, certain patents, technical information and material (collectively, the &#8220;Technology&#8221;)
related to a double-mutant cocaine esterase, and to develop and commercialize products thereunder (each, a &#8220;Product&#8221;). Pursuant
to the terms of the License Agreement, Columbia has reserved for itself and the Institutions the right to practice the Technology for
academic research and educational purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;We
paid a six-digit license fee to Columbia as consideration for entering into the License Agreement. We are obligated to use Commercially
Reasonable Efforts, as defined in the License Agreement, to develop and commercialize the Product, and to achieve specified developmental
milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are obligated to pay Columbia single-digit royalties on net sales of (i) Products sold by us or a sublicensee and (ii) any other products
that involve material or technical information related to the Product and transferred to us pursuant to the License Agreement (&#8220;Other
Products&#8221;) sold by us or a sublicensee. Royalties on each particular Product are payable on a country-by-country and Product-by-Product
basis until the latest of (i) the date of expiration of the last valid claim in the last to expire of the issued patents covered by the
License Agreement, (ii) a specified period of time after the first commercial sale of a Product in the country in question, or (iii) expiration
of any market exclusivity period granted by a regulatory agency. Royalties on each particular Other Product are payable on a country-by-country
and product-by-product basis until the later of (i) a specified period of time after the first commercial sale of such particular Other
Product in such country or (ii) expiration of any market exclusivity period granted by a regulatory agency. Royalties payable on net sales
of the Product and Other Products may be reduced by 50% of the royalties payable by us to any third party for intellectual property rights
which are necessary for the practice of the rights licensed to us under the License Agreement, provided that the royalty payable on a
Product or Other Product may not be reduced by more than 50%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are also obligated to make contingent milestone payments to Columbia totaling $3 million on a Product-by-Product basis upon the achievement
of certain development, approval and sales milestones related to a Product. In addition, we shall pay Columbia 5% of consideration, other
than royalty payments and certain other categories of consideration, payable to us by a sublicensee. As of December 31, 2022, no milestone
payments have been accrued or paid in relation to this agreement.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">Asset
Purchase Agreements</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">On
February 2, 2023, we entered into an asset purchase agreement </span><span style="font-family: Times New Roman, Times, Serif">(the &#8220;Asset
Purchase Agreement&#8221;) with Healion Bio Inc., <span style="background-color: white">pursuant to which we acquired all the pre-clinical
infectious disease assets of Healion, including its portfolio of next-generation antiviral technology assets. Healion&#8217;s drug portfolio
includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action, including
TNX-3900, formerly known as HB-121. </span>As consideration for entering into the Asset Purchase Agreement, we paid $1.2 million to Healion.
Because the Healion intellectual property was acquired prior to FDA approval, the cash consideration totaling $1.2 million, is expected
to be expensed as research and development costs since there is no alternative future use and the acquired intellectual property does
not constitute a business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 22, 2020, we entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with Katana Pharmaceuticals,
Inc. (&#8220;Katana&#8221;) pursuant to which we acquired Katana assets related to insulin resistance and related syndromes, including
obesity (the &#8220;Katana Assets&#8221;). In connection with the acquisition of the Assets, we assumed Katana&#8217;s rights and obligations
under that certain Exclusive License Agreement by and between Katana and The University of Geneva (&#8220;Geneva&#8221;) (the &#8220;Geneva
License &#8220;Agreement&#8221;) pursuant to an Assignment and Assumption Agreement with Geneva (&#8220;Geneva Assignment and Assumption
Agreement&#8221;), dated December 22, 2020. As consideration for entering into the Asset Purchase Agreement, we paid $0.7 million to Katana.
Because the Katana intellectual property was acquired prior to FDA approval, the cash consideration totaling $0.7 million, was expensed
as research and development costs since there is no alternative future use and the acquired intellectual property does not constitute
a business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the Geneva Assignment and Assumption Agreement, Geneva granted us an exclusive license, with the right to sublicense,
certain patents related to the Katana Assets. We are obligated to use commercially reasonable efforts to diligently develop, manufacture,
and sell products claimed or covered by the patent and will use commercially reasonable efforts to diligently develop markets for such
products. The Geneva License Agreement specifies developmental milestones and the period of time during which such milestones must be
completed and provides for an annual maintenance fee payable to Geneva. As of December 31, 2022, no milestone payments have been accrued
or paid in relation to this agreement.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;On
June 11, 2020, we entered into an asset purchase agreement (the &#8220;Trigemina Asset Purchase Agreement&#8221;) with Trigemina, Inc.
(&#8220;Trigemina&#8221;) and certain shareholders named therein (the &#8220;Executive Shareholders&#8221;) pursuant to which we acquired
Trigemina assets related to migraine and pain treatment technologies (the &#8220;Trigemina Assets&#8221;). In connection with the acquisition
of the Trigemina Assets, we assumed Trigemina&#8217;s rights and obligations under that certain Amended and Restated Exclusive License
Agreement, dated November 30, 2007, as amended, by and between Trigemina and The Board of Trustees of the Leland Stanford Junior University
(&#8220;Stanford&#8221;) (the &#8220;Stanford License &#8220;Agreement&#8221;) pursuant to an Assignment and Assumption Agreement with
Stanford (&#8220;Assignment and Assumption Agreement&#8221;), dated June 11, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
consideration for entering into the Trigemina Asset Purchase Agreement, we paid $824,759 to Trigemina and issued to Trigemina 62,500 shares
of our common stock and paid Stanford $250,241 pursuant to the terms of the Assignment and Assumption Agreement. The common stock is unregistered
and subject to a 12 month lock-up and a Shareholder Voting Agreement, dated June 11, 2020, pursuant to which Trigemina and the Executive
Shareholders have agreed to vote the common stock on any matter put to a vote of our shareholders in accordance with management&#8217;s
recommendations. Both the costs associated with the cash payments and share issuance, totaling $2.4 million, were recorded to research
and development in the statement of operations for the year ended December 31, 2020. Because the Trigemina intellectual property was acquired
prior to FDA approval, the cash and stock consideration was expensed as research and development costs since there is no alternative future
use and the acquired intellectual property does not constitute a business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;Pursuant
to the terms of the Assignment and Assumption Agreement, Stanford has granted us an exclusive license, with the right to sublicense, certain
patents related to the Trigemina Assets. Stanford has reserved for itself the right to practice under the patents for academic research
and educational purposes. We are obligated to use commercially reasonable efforts to diligently develop, manufacture, and sell products
claimed or covered by the patent and will use commercially reasonable efforts to diligently develop markets for such products. The Stanford
License Agreement specifies developmental milestones and the period of time during which such milestones must be completed, and provides
for an annual maintenance fee payable to Stanford. As of December 31, 2022, other than the annual maintenance fee, no milestone payments
have been accrued or paid in relation to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 19, 2019, we entered into an asset purchase agreement (the &#8220;TRImaran Asset Purchase Agreement&#8221;) with TRImaran Pharma,
Inc. (&#8220;TRImaran&#8221;) and the selling shareholders named therein (the &#8220;Selling Shareholders&#8221;) pursuant to which we
acquired TRImaran&#8217;s assets related to certain pyran-based compounds (the &#8220;TRImaran Assets&#8221;). In connection with the
acquisition of the TRImaran Assets, we entered into a First Amended and Restated Exclusive License Agreement (the &#8220;WSU License Agreement&#8221;)
with Wayne State University (&#8220;WSU&#8221;) on August 19, 2019, as subsequently amended. As consideration for entering into the TRImaran
Asset Purchase Agreement, we paid $100,000 to TRImaran and have assumed certain liabilities of TRImaran totaling $68,500. The $168,500
was recorded to research and development expenses in the statement of operations in 2019. Upon the achievement of specified development,
regulatory and sales milestones, we also agreed to pay TRImaran and the Selling Shareholders, in restricted stock or cash, at our option,
a total of approximately $3.4 million. Pursuant to the terms of the TRImaran Asset Purchase Agreement, TRImaran and the Selling Shareholders
are prohibited from disclosing confidential information related to the TRImaran Assets and are restricted from engaging, for a period
of three years, in the development or commercialization of any therapeutic containing any pyran-based drug compound for the treatment
of post-traumatic stress disorder, attention deficit hyperactivity disorder or major depressive disorder. Also for a period of three years,
if TRImaran or any Selling Shareholder engage in the research or development of any potential therapeutic compound for the treatment of
any central nervous system disorder, TRImaran or such Selling Shareholder is obliged to provide notice and opportunity to Tonix to make
an offer to acquire or license rights with respect to such product candidate. As of December 31, 2022, no milestone payments have been
accrued or paid in relation to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the WSU License Agreement, WSU granted us an exclusive license, with the right to sublicense, certain patents, technical
information and material (collectively, the &#8220;Technology&#8221;) related to the TRImaran Assets. WSU has reserved for itself the
right to practice the Technology for academic research and educational purposes. We are obligated to use commercially reasonable efforts
to obtain regulatory approval for one or more products utilizing the Technology (&#8220;WSU Products&#8221;) and to use commercially reasonable
marketing efforts throughout the term of the WSU License Agreement. The WSU License Agreement specifies developmental milestones and the
period of time during which such milestones must be completed and provides for an annual maintenance fee payable to WSU. We are obligated
to substantially manufacture WSU Products in the United States if WSU Products will be sold in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the WSU License Agreement, we paid $75,000 to WSU as reimbursement of certain patent expenses, and, upon the achievement of specified
development, regulatory and sales milestones, we also agreed to pay WSU, milestone payments totaling approximately $3.4 million. We have
also agreed to pay WSU single-digit royalties on net sales of WSU Products sold by us or a sublicensee on a tiered basis based on net
sales, and additional sublicense fees on certain consideration received from sublicensees. Royalties on each particular WSU Product are
payable on a country-by-country and Product-by-Product basis until the date of expiration of the last valid claim in the last to expire
of the issued patents covered by the WSU License Agreement. Royalties payable on net sales of WSU Products may be reduced by 50% of the
royalties payable by us to any third party for intellectual property rights which are necessary for the practice of the rights licensed
to us under the WSU License Agreement, provided that the royalty payable on a WSU Product may not be reduced by more than 50%. Each party
also has the right to terminate the agreement for customary reasons such as material breach and bankruptcy. The WSU License Agreement
contains provisions relating to termination, indemnification, confidentiality and other customary matters for an agreement of this kind.
As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2022, we had working capital of $112.6 million, comprised primarily of cash and cash equivalents of $120.2 million and
prepaid expenses and other of $10.5 million, offset by $8.1 million of accounts payable, $9.7 million of accrued expenses and other current
liabilities and $0.4 million of lease liabilities, short term. A significant portion of the accounts payable and accrued expenses are
due to work performed in relation to our Phase 3 clinical trial in FM and our vaccine program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table provides a summary of operating, investing and financing cash flows for the years ended December 31, 2022, and 2021, respectively
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net cash used in operating activities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 10%; text-align: right">(98,053</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 10%; text-align: right">(75,557</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Net cash used in investing activities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(48,147</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(35,307</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Net cash provided by financing activities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">87,844</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">212,487</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
the years ended December 31, 2022 and 2021, we used approximately $98.1 million and $75.6 million of cash in operating activities, respectively,
which represents cash outlays for research and development and general and administrative expenses in such periods. The increase in cash
outlays principally resulted from an increase in research and development and general and administrative activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Cash
used by investing activities for the years ended December 31, 2022 and 2021 was approximately $48.1 million and $35.3 million, respectively,
related to the purchase of property and equipment. A significant portion of capital expenditure relates to the build-out of the RDC and ADC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
the years ended December 31, 2022 and 2021, net proceeds from financing activities were $87.8 million and $212.5 million, respectively,
predominately from the sale of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our cash
resources at December 31, 2022 and the proceeds that we raised from equity offerings in the first quarter of 2023, net of amounts paid
to repurchase shares in the first quarter of 2023, will meet our operating and capital expenditure requirements into the fourth quarter
of 2023, but not beyond.<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
face significant challenges and uncertainties and, as a result, our available capital resources may be consumed more rapidly than currently
expected due to changes we may make in our research and development spending plans. These factors raise substantial doubt about our ability
to continue as a going concern for the one year period from the date of filing of this Form 10-K. We believe we have the ability to obtain
additional funding through public or private financing or collaborative arrangements with strategic partners to increase the funds available
to fund operations. Without additional funds, we may be forced to delay, scale back or eliminate some of our research and development
activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue our operations.
If any of these events occurs, our ability to achieve our development and commercialization goals would be adversely affected.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Future
Liquidity Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect to incur losses from operations for the near future. We expect to incur increasing research and development expenses, including
expenses related to additional clinical trials and the buildout of our research and development operations and manufacturing. We will
not have enough resources to meet our operating requirements for the one-year period from filing date of this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future capital requirements will depend on a number of factors, including the progress of our research and development of product candidates,
the timing and outcome of regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing
patent claims and other intellectual property rights, the status of competitive products, the availability of financing and our success
in developing markets for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
will need to obtain additional capital in order to fund future research and development activities. Future financing may include the issuance
of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if we are able to raise the funds required,
it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected
cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, shareholders
may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing
holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
additional financing is not available or is not available on acceptable terms, we may be required to delay, reduce the scope of or eliminate
our research and development programs, reduce our commercialization efforts or obtain funds through arrangements with collaborative partners
or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize
independently.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Share
Repurchase Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white"><span style="background-color: white">Since January 1, 2023, the Company
has repurchased </span>15,700,269 <span style="background-color: white">of its shares of common stock outstanding under a $12.5 million
share purchase program at prices ranging from $0.44 to $1.38 per share for a gross aggregate cost of approximately $12.5 million.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In January 2023, the <span style="background-color: white">Board of Directors
approved </span>a new share&#160;repurchase program&#160;pursuant to which the Company may&#160;repurchase&#160;up to an additional $12.5
million in value of its outstanding common stock from time to time on the open market and in privately negotiated transactions subject
to market conditions, share price and other factors.&#160;<span style="background-color: white">Since January 1, 2023, the Company has
repurchased </span>1,000,000 <span style="background-color: white">of its shares of common stock outstanding under the new share repurchase
program at $1.14 per share for a gross aggregate cost of $1.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Convertible Redeemable Preferred stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On October
26, 2022, we issued 1,400,000 shares of Series A Preferred Stock and 100,000 shares of Series B Preferred Stock to certain institutional
investors in a private placement. The Preferred Stock had an aggregate stated value of $15,000,000. Each share of the Preferred Stock
had a purchase price of $9.50, representing an original issue discount (&#8220;OID&#8221;) of 5% of the stated value. The shares of the
preferred stock were convertible into shares of our common stock, upon the occurrence of certain events, at a conversion price of $1.00
per share, at the option of the holder, and at our option upon the fulfillment of certain conditions and subject to certain limitations.
The Company and the holders of the preferred stock also entered into a registration rights agreement to register the resale of the shares
of common stock issuable in the event of the conversion of the preferred stock. The $14.3 million in gross proceeds of the offering were
held in an escrow account, along with an additional $1.5 million deposited by the Company to cover the aggregate OID as well as the additional
amount that would have been necessary to fund the 105% redemption price until the expiration of the redemption period for the Preferred
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
outstanding shares of the Series A Convertible Redeemable Preferred Stock and Series B Convertible Redeemable Preferred Stock were redeemed
in December 2022 at 105% of the $10.00 stated value of the Preferred Stock, or $15.8 million in the aggregate.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On June
24, 2022, we issued 2,500,000 shares of Series A Preferred Stock and 500,000 shares of Series B Preferred Stock to certain institutional
investors in a private placement. The Preferred Stock had an aggregate stated value of $30,000,000. Each share of the Preferred Stock
had a purchase price of $9.50, representing an OID of 5% of the stated value. The shares of the preferred stock were convertible into
shares of our common stock, upon the occurrence of certain events, at a conversion price of $4.00 per share, at the option of the holder,
and at our option upon the fulfillment of certain conditions and subject to certain limitations. The Company and the holders of the preferred
stock also entered into a registration rights agreement to register the resale of the shares of common stock issuable in the event of
the conversion of the preferred stock. The $28.5 million in gross proceeds of the offering were held in an escrow account, along with
an additional $3.0 million deposited by the Company to cover the aggregate OID as well as the additional amount that would have been necessary
to fund the 105% redemption price until the expiration of the redemption period for the Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All outstanding shares of the
Series A Convertible Redeemable Preferred Stock and Series B Convertible Redeemable Preferred Stock were redeemed in August 2022 at 105%
of the $10.00 stated value of the Preferred Stock, or $31.5 million in the aggregate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>2022
Lincoln Park Transaction</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 16, 2022, we entered into a purchase agreement (the &#8220;2022 Purchase Agreement&#8221;) and a registration rights agreement
(the &#8220;2022 Registration Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). Pursuant to the
terms of the 2022 Purchase Agreement, Lincoln Park has agreed to purchase from us up to $50,000,000 of our common stock (subject to certain
limitations) from time to time during the term of the 2022 Purchase Agreement. Pursuant to the terms of the 2022 Registration Rights Agreement,
we filed with the SEC a registration statement to register for resale under the Securities Act the shares that have been or may be issued
to Lincoln Park under the 2022 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the 2022 Purchase Agreement, at the time we signed the 2022 Purchase Agreement and the 2022 Registration Rights Agreement,
we issued 625,000 shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under
the 2022 Purchase Agreement. The commitment shares were valued at $1,000,000 and recorded as an addition to equity for the issuance of
the common stock and treated as a reduction to equity as a cost of capital to be raised under the 2022 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, we sold 1.0 million shares of common stock under the 2022 Purchase Agreement, for net proceeds of approximately
$0.5 million.&#160;Subsequent to December 31, 2022, the Company sold 0.6 million shares of common stock under the Purchase Agreement
with Lincoln Park for net proceeds of approximately $0.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Purchase
Agreement with Lincoln Park</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 3, 2021, we entered into a purchase agreement (the &#8220;Purchase Agreement with Lincoln Park&#8221;) and a registration rights
agreement (the &#8220;Lincoln Park Registration Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;).
Pursuant to the terms of the Purchase Agreement with Lincoln Park, Lincoln Park agreed to purchase from us up to $80,000,000 of our common
stock (subject to certain limitations) from time to time during the term of the Purchase Agreement with Lincoln Park. Pursuant to the
terms of the Lincoln Park Registration Rights Agreement, we filed with the SEC a registration statement to register for resale under the
Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase Agreement with Lincoln Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the Purchase Agreement with Lincoln Park, at the time we signed the Purchase Agreement with Lincoln Park and the Lincoln
Park Registration Rights Agreement, we issued 90,910 shares of common stock to Lincoln Park as consideration for its commitment to purchase
shares of our common stock under the Purchase Agreement with Lincoln Park. The commitment shares were valued at $1.6 million and recorded
as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost of capital to be raised under
the Purchase Agreement with Lincoln Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, we sold 2.9 million shares of common stock under the Purchase Agreement with Lincoln Park, for net proceeds
of approximately $8.7 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
applicable rules of the NASDAQ Global Market, the Company could not issue or sell more than 19.99% of the shares of its common stock outstanding
immediately prior to the execution of the Purchase Agreement (approximately 2.9 million shares) with Lincoln Park under the Purchase Agreement
without stockholder approval, unless the average price of all applicable sales of its common stock to Lincoln Park under the Purchase
Agreement equals or exceeds a threshold amount. As we have issued approximately 2.9 million shares to Lincoln Park under the Purchase
Agreement at less than the threshold amount, we will not sell any additional shares under the Purchase Agreement without shareholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2021
Lincoln Park Transaction</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 14, 2021, we entered into a purchase agreement (the &#8220;2021 Purchase Agreement&#8221;) and a registration rights agreement (the
&#8220;2021 Registration Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). Pursuant to the terms
of the 2021 Purchase Agreement, Lincoln Park agreed to purchase from us up to $80,000,000 of our common stock (subject to certain limitations)
from time to time during the term of the 2021 Purchase Agreement. Pursuant to the terms of the 2021 Registration Rights Agreement, we
filed with the SEC a registration statement to register for resale under the Securities Act the shares that have been or may be issued
to Lincoln Park under the 2021 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the 2021 Purchase Agreement, at the time we signed the 2021 Purchase Agreement and the 2021 Registration Rights Agreement,
we issued 40,000 shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under
the 2021 Purchase Agreement. The commitment shares were valued at $1.6 million and recorded as an addition to equity for the issuance
of the common stock and treated as a reduction to equity as a cost of capital to be raised under the 2021 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2021, we sold an aggregate of approximately 2.0 million shares of common stock under the 2021 Purchase Agreement,
for gross proceeds of approximately $41.3 million. During the year ended December 31, 2022, no shares of common stock were sold under
the 2021 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
applicable rules of the NASDAQ Global Market, we could not issue or sell more than 19.99% of the shares of our common stock outstanding
immediately prior to the execution of the 2021 Purchase Agreement (approximately 2.0 million shares) to Lincoln Park under the 2021 Purchase
Agreement without stockholder approval, unless the average price of all applicable sales of our common stock to Lincoln Park under the
2021 Purchase Agreement equals or exceeds a threshold amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
we have issued approximately 2.0 million shares to Lincoln Park under the 2021 Purchase Agreement, at less than the threshold amount,
we will not sell any additional shares under the 2021 Purchase Agreement without shareholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b><i>February
2021 Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">On
February 8, 2021, we entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale
of 1.8 million shares of our common stock, in a registered direct public offering (&#8220;the February 2021 Financing&#8221;), with A.G.P/Alliance
Global Partners (&#8220;AGP&#8221;), acting as placement agent. The public offering price for each share of common stock was $38.40. The
February 2021 Financing closed on February 9, 2021. AGP received a cash fee of 7% of the gross proceeds, for an aggregate amount of $4.9
million. We incurred other offering expenses of approximately $0.1 million. We received net proceeds of approximately $65.0 million, after
deducting the fees and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>January
2021 Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; background-color: white">On
January 11, 2021, we entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale
of 1.6 million shares of its common stock in a registered direct public offering (&#8220;the January 2021 Financing&#8221;), with AGP
as placement agent. The public offering price for each share of common stock was $25.60. The January 2021 Financing closed on January
13, 2021. AGP received a cash fee of 7% of the gross proceeds, for an aggregate of $2.8 million. We incurred other offering expenses of
approximately $0.3 million. The Company received net proceeds of approximately $36.9 million, after deducting the fees and other offering
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>At-the-Market
Offerings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;On
April 8, 2020, we entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with AGP pursuant to which we may issue and
sell, from time to time, shares of our common stock having an aggregate offering price of up to $320.0 million in at-the-market
offerings (&#8220;ATM&#8221;) sales. AGP will act as sales agent and will be paid a 3% commission on each sale under the Sales
Agreement. Our common stock will be sold at prevailing market prices at the time of the sale, and, as a result, prices will vary.
During the year ended December 31, 2022, we sold approximately 56.4 million shares of common stock under the Sales Agreement, for
net proceeds of approximately $85.3 million. During the year ended December 31, 2021, we sold approximately 3.5 million shares of
common stock under the Sales Agreement, for net proceeds of approximately $69.3 million. Subsequent to December 31, 2022, we sold
2.1 million shares of common stock under the Sales Agreement, for net proceeds of approximately $1.4 million.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Stock Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 3, 2019, our stockholders approved the Tonix Pharmaceuticals Holding Corp. 2019 Stock Incentive Plan (the &#8220;2019 Plan&#8221;).
The 2019 Plan provided for the issuance of up to 4,375 shares of our common stock. With the adoption of the 2020 Plan (as defined below),
no further grants may be made under the 2019 Plan. On January 16, 2020, our stockholders approved the Tonix Pharmaceuticals Holding Corp.
2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;). The 2020 Plan provided for the issuance of up to 18,750 shares of our common
stock. With the adoption of the Amended and Restated 2020 Plan (as defined below), no further grants may be made under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 1, 2020, our stockholders approved the Tonix Pharmaceuticals Holding Corp. Amended and Restated 2020 Stock Incentive Plan (&#8220;Amended
and Restated 2020 Plan&#8221;), and together with the 2020 Plan and the 2019 Plan, the &#8220;Plans&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under the terms of the Amended and Restated 2020 Plan, we may issue (1)
stock options (incentive and nonstatutory), (2) restricted stock, (3) stock appreciation rights (&#8220;SARs&#8221;), (4) RSUs, (5) other
stock-based awards, and (6) cash-based awards. The Amended and Restated 2020 Plan initially provided for the issuance of up to 312,500
shares of common stock, which amount&#160;will be increased to the extent that awards granted under the Plans are forfeited, expire or
are settled for cash (except as otherwise provided in the Amended and Restated 2020 Plan). In addition, the Amended and Restated 2020
Plan contains an &#8220;evergreen provision&#8221; providing for an annual increase in the number of shares of our common stock available
for issuance under the Amended and Restated 2020 Plan on January 1 of each year for a period of ten years, commencing on January 1, 2021
and ending on (and including) January 1, 2030, in an amount equal to the difference between (x) twenty percent (20%) of the total number
of shares of common stock outstanding on December 31<sup>st</sup> of the preceding calendar year, and (y) the total number of shares of
common stock reserved under the Amended and Restated 2020 Plan on December 31<sup>st</sup> of such preceding calendar year (including
shares subject to outstanding awards, issued pursuant to awards or available for future awards). The Board of Directors determines the
exercise price, vesting and expiration period of the grants under the Amended and Restated 2020 Plan. However, the exercise price of an
incentive stock option may not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more shareholder
and 100% of fair value for a grantee who is not a 10% shareholder. The fair value of the common stock is determined based on quoted market
price or in absence of such quoted market price, by the Board of Directors in good faith. Additionally, the expiration period of grants
under the Amended and Restated 2020 Plan may not be more than ten years. As of December 31, 2022, 627,735 shares were available for future
grants under the Amended and Restated 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We measure the fair value of stock options on the date of grant, based
on the Black Scholes option pricing model using certain assumptions discussed below, and the closing market price of the Company&#8217;s
common stock on the date of the grant. The fair value of the award is measured on the grant date. One-third of most stock options granted
pursuant to the Plans vest 12 months from the date of grant and 1/36<sup>th</sup> each month thereafter for 24 months and expire ten years
from the date of grant. In addition, the Company issues options to directors which vest over a one-year period. The Company also issues
premium options to executive officers which have an exercise price greater than the grant date fair value and has issued performance-based
options which vest when target parameters are met or probable of being met, subject in each case to a one year minimum service period
prior to vesting. Stock-based compensation expense related to awards is amortized over the applicable service period using the straight-line
method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
risk-free interest rate is based on the yield of Daily U.S. Treasury Yield Curve Rates with terms equal to the expected term of the options
as of the grant date.&#160;The expected term of options is determined using the simplified method, as provided in an SEC Staff Accounting
Bulletin,&#160;and the expected stock price volatility is based on the Company&#8217; historical stock price volatility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant date fair value of options granted during the years ended December 31, 2022 and 2021, was $5.25 and $33.78 per
share, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Stock-based
compensation expense relating to options granted of $10.9 million, of which $7.9 million and $3.0 million, related to General and Administration
and Research and Development, respectively was recognized for the year ended December 31, 2022.&#160;Stock-based compensation expense
relating to options granted of $7.9 million, of which $5.5 million and $2.4 million, related to General and Administration and Research
and Development, respectively was recognized for the year ended December 31, 2021.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2022, we have approximately $11.6 million of unrecognized compensation cost related to non-vested awards granted under
the Plans, which we expect to recognize over a weighted average period of 1.73 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Employee
Stock Purchase Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
May 3, 2019, our stockholders approved the Tonix Pharmaceuticals Holdings Corp. 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;).
As a result of adoption of the 2020 ESPP, as defined below, by the stockholders, no further grants may be made under the 2019 ESPP Plan.
On May 1, 2020, our stockholders approved the Tonix Pharmaceuticals Holdings Corp. 2020 Employee Stock Purchase Plan (the &#8220;2020
ESPP&#8221;). No further grants may be made under the 2020 ESPP Plan. On May 6, 2022, our stockholders approved the Tonix Pharmaceuticals
Holdings Corp. 2022 Employee Stock Purchase Plan (the &#8220;2022 ESPP&#8221;, and together with the 2019 ESPP and the 2020 ESPP, the
&#8220;ESPP Plans&#8221;)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
2022 ESPP allows eligible employees to purchase up to&#160;an aggregate of 93,750&#160;shares of our common stock. Under the 2022 ESPP,
on the first day of each offering period, each eligible employee for that offering period has the option to enroll for that offering period,
which allows the eligible employees to purchase shares of our common stock at the end of the offering period. Each offering period under
the 2022 ESPP is for six months, which can be modified from time-to-time. Subject to limitations, each participant will be permitted to
purchase a number of shares determined by dividing the employee&#8217;s accumulated payroll deductions for the offering period by the
applicable purchase price, which is equal to&#160;85 percent&#160;of the fair market value of our common stock at the beginning or end
of each offering period, whichever is less. A participant must designate in his or her enrollment package the percentage (if any) of compensation
to be deducted during that offering period for the purchase of stock under the 2022 ESPP, subject to the statutory limit under the Code.
As of December 31, 2022, 9 shares were available for future sales under the 2022 ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;The
2022 and 2020 ESPP are considered compensatory plans with the related compensation cost expensed over the six-month offering period. For
the year ended December 31, 2022 and 2021, $46,000 and $89,000, respectively were expensed. In January 2021, 1,703 shares that were purchased
as of December 31, 2020, under the 2020 ESPP, were issued. Accordingly, during the first quarter of 2021, approximately $28,000 of employee
payroll deductions accumulated at December 31, 2020, related to acquiring such shares, was transferred from accrued expenses to additional
paid in capital. The remaining $4,000 was returned to the employees. In January 2022, 4,033 shares that were purchased as of December
31, 2021, under the 2020 ESPP, were issued. Accordingly, during the first quarter of 2022, approximately $40,000 of employee payroll deductions
accumulated at December 31, 2021, related to acquiring such shares, was transferred from accrued expenses to additional paid in capital.
The remaining $30,000 was returned to the employees. As of December 31, 2022, approximately $43,000 of employee payroll deductions have
accumulated and have been recorded in accrued expenses.&#160;In January 2023, 93,741 shares that were purchased as of December 31, 2022,
under the 2022 ESPP, were issued. Accordingly, during the first quarter of 2023, approximately $29,000 of employee payroll deductions
accumulated at December 31, 2022, related to acquiring such shares, was transferred from accrued expenses to additional paid in capital.
The remaining $14,000 was returned to the employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have entered into contracts with various contract research organizations with outstanding commitments aggregating approximately $58.6
million at December 31, 2022 for future work to be performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have entered into a construction contract with outstanding commitments aggregating approximately $2.0 million at December 31, 2022 for
future work to be performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Operating
Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">At
December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 94%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Year&#160;Ending&#160;December&#160;31,</span></b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 85%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">441</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">159</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">775</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included interest</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">760</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
discussion and analysis of our financial condition and results of operations are based on our condensed financial statements, which have
been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements
requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. We evaluate our estimates
and judgments on an ongoing basis. We base our estimates on historical experience and on assumptions that we believe to be reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;We
believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our
consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Research
and Development. We outsource our research and development efforts and expense the related costs as incurred, including the cost of manufacturing
product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and
other intellectual property acquired was expensed as research and development costs, as it related to particular research and development
projects and had no alternative future uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under
contracts with vendors, consultants and clinical research organizations and clinical site agreements in connection with conducting clinical
trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment
flows that do not match the periods over which materials or services are provided to us under such contracts. We account for trial expenses
according to the progress of the trial as measured by participant progression and the timing of various aspects of the trial. We determine
accrual estimates that take into account discussions with applicable personnel and outside service providers as to the progress or state
of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition
if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date based on the facts
and circumstances known to us at that time. Our clinical trial accruals and prepaid assets are dependent upon the timely and accurate
reporting of contract research organizations and other third-party vendors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Stock-Based
Compensation. All stock-based payments to employees and to nonemployee directors for their services as directors consisted of grants of
restricted stock and stock options, which are measured at fair value on the grant date and recognized in the consolidated statements of
operations as compensation expense over the relevant vesting period. In addition, for awards that vest immediately and are nonforfeitable,
the measurement date is the date the award is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Redeemable
Convertible Preferred Stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured
at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within
the Company&#8217;s control, as temporary equity (&#8220;mezzanine&#8221;) until such time as the conditions are removed or lapse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
than contractual obligations incurred in the normal course of business, we do not have any off-balance sheet financing arrangements or
liabilities, guarantee contracts, retain or contingent interests in transferred assets or any obligation arising out of a material variable
interest in an unconsolidated entity.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Recently
Issued Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB issued
ASU No. 2020-06,&#160;<i>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>,
which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also
removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and
it also simplifies the diluted earnings per share calculation in certain areas. We adopted ASU 2020-06 on January 1, 2023, under the modified
retrospective method of transition. We do not anticipate the adoption of ASU 2020-06 to impact the Company&#8217;s financial position,
results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span id="tnxp10ka012"></span>ITEM
7A &#8211; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
required under Regulation S-K for &#8220;smaller reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="tnxp10ka013"></span>ITEM 8 &#8211; FINANCIAL STATEMENTS AND
SUPPLEMENTARY DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 87%"><a href="#tnxp10kb001"><span style="font-size: 10pt">Report of Independent Registered Public Accounting
        Firm</span></a></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#tnxp10kb002"><span style="font-size: 10pt">Consolidated balance sheets as of December 31, 2022 and
        2021</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#tnxp10kb003"><span style="font-size: 10pt">Consolidated statements of operations
        for the years ended December 31, 2022 and 2021</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#tnxp10kb004"><span style="font-size: 10pt">Consolidated statements of comprehensive
        loss for the years ended December 31, 2022 and 2021</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#tnxp10kb005"><span style="font-size: 10pt">Consolidated statements of stockholders&#8217;
        equity for the years ended December 31, 2022 and 2021</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-7 &#8211; F-8</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#tnxp10kb006"><span style="font-size: 10pt">Consolidated statements of cash
        flows for the years ended December 31, 2022 and 2021</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-9</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#tnxp10kb007"><span style="font-size: 10pt">Notes to consolidated financial statements</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-10 &#8211; F-24</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 70; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="tnxp10kb001"></span>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Board of Directors and Stockholders of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tonix Pharmaceuticals Holding Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Opinion on the Financial Statements </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated balance
sheets of Tonix Pharmaceuticals Holding Corp and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related
consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years then ended,
and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the consolidated financial position of the Company as of the Company as of December 31, 2022
and 2021, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with
accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has continuing
losses and negative cash flows from operating activities that raise substantial doubt about its ability to continue as a going concern.
Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis for Opinion </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The critical audit matter communicated below is a
matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit
committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on
the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion
on the critical audit matter or on the accounts or disclosures to which it relates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><b><i>Accrual and prepaid balance for clinical trial expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described in Note 2 to the consolidated financial
statements, at each balance sheet date the Company estimates its expenses resulting from its obligations under contracts with vendors,
clinical research organizations and under clinical site agreements in connection with conducting clinical trials. The Company accounts
for trial expenses according to the timing of various aspects of the trial. The Company&#8217;s accrual for clinical trial expenses of
approximately $3.3 million is included in accrued expenses and other current liabilities in the December 31, 2022 consolidated balance
sheet. The Company also recorded prepaid clinical trial expenses of approximately $8.0 million within prepaid expenses and other in the
December 31, 2022 consolidated balance sheet. The amounts recorded for clinical trial expenses represent the Company&#8217;s estimates
of the unpaid and prepaid clinical trial expenses based on facts and circumstances known to the Company at that time, and are dependent
upon the timely and accurate reporting of contract research organizations and other third-party vendors. The estimation of clinical trial
expenses was also identified as a critical accounting estimate by management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We identified the accrual for clinical trial expenses
as a critical audit matter due to the significant judgment and estimation required by management in determining progress or state of completion
of clinical trials or services completed. This in turn led to a high degree of auditor subjectivity, and significant audit effort was
required in performing our procedures and evaluating audit evidence relating to estimates made by management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Addressing the matter involved performing procedures
and evaluating audit evidence, in connection with forming our overall opinion on the consolidated financial statements. We obtained an
understanding of Management&#8217;s process and evaluated the design of controls over developing its estimate of accrued and prepaid clinical
trial expenses, including the process of estimating the expenses incurred to date based on the status of the clinical trials. Our procedures
also included, among others, reading agreements and contract amendments with vendors, consultants and clinical research organizations
and clinical site agreements in connection with conducting clinical trials, and evaluating the significant assumptions described above
and the methods used in developing the clinical trial estimates and re-calculating the amounts that were unpaid and prepaid at the balance
sheet date. We confirmed contractual commitments and amounts completed, paid and unpaid directly with the third parties involved in performing
the clinical trial services on behalf of the Company. We also made direct inquiries of financial and clinical Company personnel regarding
the contract amount including change orders, status and progress to completion of clinical trials, amounts paid to date under each contract,
and description of future commitments. We also assessed the historical accuracy of management&#8217;s estimates by comparing current expenses
to prior-period expenses to identify unusual fluctuations, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company&#8217;s auditor since
2010</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EISNERAMPER LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Iselin, New Jersey</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">March 13, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="tnxp10kb002"></span>CONSOLIDATED BALANCE
SHEETS</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2022 AND 2021</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In Thousands, Except Par Value and Share Amounts)</b></p>

<table cellspacing="0" cellpadding="0" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" id="xdx_300_111_pn3n3_zDm1e2Fgkotj" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zO5PEpqANcA5" style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_zzcGhDLEIoml" style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_znE3tEtlkxsa" style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt"><span style="font-size: 10pt">ASSETS</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_ziWHOWthuEze" style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Current assets:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzsK3_zhKek7YMvWwc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Cash and cash equivalents</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,229</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178,660</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzsK3_zooIgQdmdSkj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Prepaid expenses and other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,548</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,389</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i02TI_mtACzsK3_maAzUaB_zU0pHeyccQWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Total current assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130,777</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189,049</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzUaB_zfLA8uZLuF6l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Property and equipment, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93,814</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,558</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzUaB_zLGTTlAu9OJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Operating lease right-to-use assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">715</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">914</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherAssetsNoncurrent_i01I_maAzUaB_zcsFI403QrD1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Other non-current assets</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">384</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">379</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Assets_i01TI_mtAzUaB_zOD5ZwPsJzs8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Total assets</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">225,690</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">240,900</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z7eUg6ZSWZAi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt"><span style="font-size: 10pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesCurrentAbstract_i01B_zZVinnFJ7Fk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Current liabilities:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableCurrent_i02I_maLCzR0g_zpwezbg7LdZ6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Accounts payable</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,068</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,282</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_i02I_maLCzR0g_zmnUU5Sqlptc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Accrued expenses and other current liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,680</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,945</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzR0g_zFmInjb2voLc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Lease liability, short term</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">432</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">489</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzR0g_maLzNLn_zOmy7EpIyoIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Total current liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,180</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,716</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzNLn_zBZDRCixUfd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Lease liability, long term</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">328</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">467</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_mtLzNLn_maLASEzPKM_zNEoz7GkA3Dg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Total liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,508</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,183</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Commitments (See Note 20)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_zxtHy4LgNHRj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Stockholders&#8217; equity:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Preferred stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20221231_zM7TY1ngEJt2" title="Preferred stock, par value (in dollars per share)"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20211231_z8ODMs6zVtwl" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>
        par value; <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20221231_z5wxDV2ncTyi" title="Preferred stock, authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20211231_zyqsskwJNr85" title="Preferred stock, authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span>
        shares authorized</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Series B Convertible Preferred stock, <span id="xdx_90D_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjxQT4e7en85" title="Preferred stock, designated"><span id="xdx_902_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zK6yv5kcVJK9" title="Preferred stock, designated"><ix:nonFraction name="tnxp:PreferredStockSharesDesignated" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="tnxp:PreferredStockSharesDesignated" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span>
        shares&#160;designated as of both December 31, 2022 and 2021; issued and outstanding - <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z4igKMp3bo51" title="Preferred stock, outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKQCvsT49OC2"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zvjyX7Y9y3bl" title="Preferred stock, issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhqth8cgtFT"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">None</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--PreferredStockValue_i02I_maSEzX4v_c20221231_zQNeWLFRCifd" title="Preferred stock, $0.001 par value; 5,000,000 shares authorized Series B Convertible Preferred stock, 0 shares designated as of both December 31, 2022 and 2021; issued and outstanding - None Series A Convertible Preferred stock, 0 shares designated as of both December 31, 2022 and 2021; issued and outstanding - None" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0121">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--PreferredStockValue_i02I_c20211231_zMyWHtC6ek42" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0122">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Series A Convertible Preferred stock, <span id="xdx_90A_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znhcBxVSq1Fb" title="Preferred stock, designated"><span id="xdx_901_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zaJgnpDlTFqi" title="Preferred stock, designated"><ix:nonFraction name="tnxp:PreferredStockSharesDesignated" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="tnxp:PreferredStockSharesDesignated" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span>
        shares&#160;designated as of both December 31, 2022 and 2021; issued and outstanding - <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zm35Gs5lWH6b" title="Preferred stock, outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvLJMFPdYUK1"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFnjhWhXRvRf" title="Preferred stock, issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjDpD9IrZ4R5"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">None</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--PreferredStockValue_i02I_c20221231_zMXgmBWnwzOl" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0133">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PreferredStockValue_i02I_c20211231_zijGbDCt1lJ2" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0134">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_i02I_maSEzX4v_zrNhzBJKmw24" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Common stock, $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20221231_z6qhZZZ9LmTj" title="Common stock, par value (in dollars per share)"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20211231_zxUWP03Liyg5" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>
        par value; <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221231_zODHP9GAdSj7" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000,000</ix:nonFraction></span>
        and <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20211231_z8DXEOoERAc1" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span>&#160;shares
        authorized as of December 31, 2022 and 2021, respectively; <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20221231_zvpREobeaW97" title="Common stock, issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20221231_zWeYb8mZwNN2" title="Common stock, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,478,656</ix:nonFraction></ix:nonFraction></span></span>
        and <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20211231_zFGQ4htGwiIa" title="Common stock, issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20211231_ztHQMcEWLIBa" title="Common stock, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,638,274</ix:nonFraction></ix:nonFraction></span></span>
        shares issued and&#160;outstanding as of December 31, 2022 and 2021, respectively and <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_uShares_c20221231_z2UCEKw2uK75" title="Common stock, to be issued"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">93,741</ix:nonFraction></span>
        and <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_uShares_c20211231_z93NZpkoWZw8" title="Common stock, to be issued"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,033</ix:nonFraction></span>
        shares to be issued as of December 31, 2022 and December 31, 2021, respectively</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maSEzX4v_zbVJ4ZltnGe6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Additional paid in capital</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">677,311</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">578,613</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzX4v_zOmUr0MwWVpg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Accumulated deficit</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">470,038</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">359,820</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzX4v_zccxI0Eu7G9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Accumulated other comprehensive loss</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">167</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquity_i02TI_mtSEzX4v_maLASEzPKM_zU6R4ghioXA5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Total stockholders&#8217; equity</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">207,182</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218,717</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzPKM_zXrQS8QcvPg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Total liabilities and stockholders&#8217;
        equity</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">225,690</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">240,900</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See the accompanying notes to the consolidated
financial statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="tnxp10kb003"></span>CONSOLIDATED STATEMENTS
OF OPERATIONS</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In Thousands, Except Share and Per Share Amounts)</b>&#160;</p>

<table cellspacing="0" cellpadding="0" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" id="xdx_309_113_pn3n3_zf3by07wF7j2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49D_20220101__20221231_zSZ9zDKq98h" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49F_20210101__20211231_zL5gHWzsX4Na" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostsAndExpensesAbstract_iB_z2hyQIWRhzz5" style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">COSTS AND EXPENSES:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzUIN_z7hYVETzOPy5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Research and development</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">81,876</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68,838</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzUIN_zXXN8S9J4Op2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">General and administrative</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,215</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,474</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CostsAndExpenses_i01T_mtCzUIN_msCzUIP_zXRLPive8sse" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,091</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92,312</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_mtCzUIP_maCzxYC_zRTYwL05Ixt4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Operating loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">112,091</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92,312</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InvestmentIncomeInterest_maCzxYC_zDhxj4sp7Hhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Interest income</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,873</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_mtCzxYC_maCznmf_zMPIxXisR2Db" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Net loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">110,218</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92,287</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RedeemablePreferredStockDividends_msCznmf_zFwN8lxeNtUd" style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Preferred stock
        deemed dividend</span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RedeemablePreferredStockDividends" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,659</ix:nonFraction></span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0196">&#8212;</span></span></td>
    <td style="vertical-align: top; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtCznmf_zJkItsiNDTdg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Net loss available to common stockholders</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">116,877</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92,287</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Net loss per common share, basic and
        diluted</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pp2p0_uUSDPShares_c20220101__20221231_zUHFUymXLmm4" title="Net loss per common share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pp2p0_uUSDPShares_c20220101__20221231_zmcnjqsDV7k5" title="Net loss per common share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="2" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="2" scale="0" sign="-" unitRef="USDPShares">3.27</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pp2p0_uUSDPShares_c20210101__20211231_zPJqHP0NQTs8" title="Net loss per common share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_pp2p0_uUSDPShares_c20210101__20211231_ztAT6uGulFU3" title="Net loss per common share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="2" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="2" scale="0" sign="-" unitRef="USDPShares">8.10</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Weighted average common shares outstanding,
        basic and diluted</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0p0_c20220101__20221231_zEXCBVS381a4" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0p0_c20220101__20221231_zQj1EkPGX9O" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">35,739,057</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0p0_c20210101__20211231_z6RUqvxXgU6j" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0p0_c20210101__20211231_zouVzoitPna1" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">11,387,308</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See the accompanying notes to the consolidated
financial statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="tnxp10kb004"></span>CONSOLIDATED STATEMENTS
OF COMPREHENSIVE LOSS</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In Thousands)</b>&#160;</p>

<table cellspacing="0" cellpadding="0" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" id="xdx_30D_113_pn3n3_z31rpQc5zdKj" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_495_20220101__20221231_zbVwnLEdHwsl" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20210101__20211231_zJpbgyGYOYTd" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_maCz7Kq_zp0ura1RkfQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Net loss</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">110,218</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92,287</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_iB_zaVH8L4mx7V7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Other comprehensive loss:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_maCz7Kq_z4JXHgYZatn4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Foreign currency translation loss</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">30</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCz7Kq_zB4g7MqRXtej" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Comprehensive loss</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">110,293</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92,317</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See the accompanying notes to the consolidated
financial statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="tnxp10kb005"></span>CONSOLIDATED STATEMENTS
OF STOCKHOLDERS&#8217; EQUITY</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In Thousands, Except Share and Per Share Amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY" id="xdx_303_114_pn3n3_zGMdU8KVDNia" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z5zm2EISoHWk">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zDCjCFb06rDi">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zklQm4Ako2M7" style="text-align: center"><span style="font-size: 10pt"><b>Accumulated</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zQnJ7iLiRHph">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4B3_zNsgrhlXErEb">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Additional</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Other</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Common stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><b>Paid in</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><b>Comprehensive</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><b>Accumulated</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Capital</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Income (loss)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Deficit</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43E_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zeJCg9sBPDg8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Balance, December 31, 2021</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUNWSpJys05e" title="Balance, at beginning (in shares)" style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,638,274</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">578,613</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">359,820</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218,717</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_435_c20220101__20221231_ecustom--StockIssuedDuringPeriodValueNewIssues7_zrANOpG0a7sj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of common stock under At-the-market offering, net
        of transactional expenses of $<span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--StockIssuanceNineMember_zXqUDDqDGETf" title="Transactional expenses"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_StockIssuanceNineMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,078</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesNewIssues7_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXVfRwlHGhJ3" title="Issuance of common stock under At-the-market offering, net of transactional expenses of $3,078 (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodSharesNewIssues7" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,357,869</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues7" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues7" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85,237</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0239">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0240">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues7" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85,293</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_437_c20220101__20221231_ecustom--IssuanceOfCommonStockUnderPurchaseAgreement4_zr2m3ppxkmm5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of common stock under 2022 Purchase Agreement</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td title="Issuance of common stock under 2022 Purchase Agreement (in shares)" id="xdx_98A_ecustom--IssuanceOfCommonStockUnderPurchaseAgreementInShares4_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZg278eJYMpl" style="text-align: right"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares4" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">487</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">488</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_430_c20220101__20221231_ecustom--IssuanceOfCommonStockUnderPurchaseAgreement2_zrLigQGslGN" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of common stock under 2021 Purchase Agreement</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--IssuanceOfCommonStockUnderPurchaseAgreementInShares2_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvL7cHAphi1e" title="Issuance of common stock under 2021 Purchase Agreement (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares2" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,853,480</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,679</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0257">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0258">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,682</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20221231_ecustom--IssuanceOfCommitmentSharesUnderPurchaseAgreement_zVOA89SBg6Ek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of commitment shares under 2022 Purchase agreement</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbJ6AxH6sBJ2" title="Issuance of commitment shares under 2022 Purchase agreement (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0265">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43B_c20220101__20221231_ecustom--PreferredStockDeemedDividend_iN_di_zID19DkD4GKe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Preferred stock deemed dividend</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0271">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="tnxp:PreferredStockDeemedDividend" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,659</ix:nonFraction>)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="tnxp:PreferredStockDeemedDividend" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,659</ix:nonFraction>)</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20221231_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_zrRmThTQaO0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Employee stock purchase plan</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9OyvaIZfbR8" title="Employee stock purchase plan (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,033</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_430_c20220101__20221231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_zKRYo4oChLV7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Stock-based compensation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,914</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,914</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_431_c20220101__20221231_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_znBpVgGuuu41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Foreign currency transaction loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_43D_c20220101__20221231_eus-gaap--NetIncomeLoss_zbzG566ZvaAf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Net loss</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">110,218</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">110,218</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_430_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zLdynKwowLjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Balance, December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zElIj0H00oEh" title="Balance, at end (in shares)" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,478,656</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">677,311</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">167</ix:nonFraction></span></td>
    <td style="padding-bottom: 2pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">470,038</ix:nonFraction></span></td>
    <td style="padding-bottom: 2pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">207,182</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See the accompanying notes to the consolidated
financial statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In Thousands, Except Share and Per Share Amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zXoArv2x5m9k">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zHZlshBFgkJa">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zB21OKzbbPu" style="text-align: center"><span style="font-size: 10pt"><b>Accumulated</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zoK2q1Sgap8a">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4B3_zPJoYNMcWhWd">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Additional</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Other</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Common stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><b>Paid in</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><b>Comprehensive</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><b>Accumulated</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Capital</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Income (loss)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Deficit</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43E_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zB2YYDilDczc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Balance, December 31, 2020</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvgbVuaC43V4" title="Balance, at beginning (in shares)" style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,568,335</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">355,237</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">62</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">267,533</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87,648</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_433_c20210101__20211231_ecustom--StockIssuedDuringPeriodValueNewIssues14_iP2us-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_zvzDHhJSQNl9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of common stock in January 2021 ($<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--StockIssuanceJanuary2021Member_zOi1PAKJJyv5" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-12-31_custom_StockIssuanceJanuary2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.60</ix:nonFraction></span>
        per share), net of transactional expenses of $<span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--StockIssuanceJanuary2021Member_z8fKssV5AfUj" title="Transactional expenses"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_custom_StockIssuanceJanuary2021Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,096</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesNewIssues14_iP3custom--StockIssuedDuringPeriodValueNewIssues14_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4WpSc7qMLQ" title="Issuance of common stock in January 2021 ($25.60 per share), net of transactional expenses of $3,096 (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodSharesNewIssues14" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,562,500</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues14" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues14" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36,902</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues14" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36,904</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43E_c20210101__20211231_ecustom--StockIssuedDuringPeriodValueNewIssues1_iP3custom--StockIssuedDuringPeriodSharesNewIssues14_zDHI9HdeB2cl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of common stock in exchange for exercise of warrants
        in March 2021 ($<span id="xdx_90E_ecustom--WarrantsExercisedPrice_pid_uUSDPShares_c20210101__20211231_zIIQruevPKve" title="Warrants exercise price (in dollars per share)"><ix:nonFraction name="tnxp:WarrantsExercisedPrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></span>
        per share)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesNewIssues1_iP3custom--StockIssuedDuringPeriodValueNewIssues1_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6EB71sSz2y" title="Issuance of common stock in exchange for exercise of warrants in March 2021 ($18.24 per share) (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodSharesNewIssues1" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_432_c20210101__20211231_ecustom--StockIssuedDuringPeriodValueNewIssues15_iP3custom--StockIssuedDuringPeriodSharesNewIssues1_zVgyrc5nAnH8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of common stock in February 2021 ($<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--StockIssuanceFebruary2021Member_zU7qdqBIVJXh" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-12-31_custom_StockIssuanceFebruary2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.40</ix:nonFraction></span>
        per share), net of transactional expenses of $<span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--StockIssuanceFebruary2021Member_zTsRWjgqnCD1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_custom_StockIssuanceFebruary2021Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,002</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesNewIssues15_iP3custom--StockIssuedDuringPeriodValueNewIssues15_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrWdbYzJHMQe" title="Issuance of common stock in February 2021 ($38.40 per share), net of transactional expenses of $5,002 (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodSharesNewIssues15" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,822,917</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues15" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues15" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64,995</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues15" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64,997</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43E_c20210101__20211231_ecustom--StockIssuedDuringPeriodValueNewIssues19_iP3custom--StockIssuedDuringPeriodSharesNewIssues15_zfpwYWFLHdG" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of common stock under At-the-market offering, net
        of transactional expenses of $<span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--StockIssuanceNineMember_zH590ZZ90Gkf"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_custom_StockIssuanceNineMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,332</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesNewIssues19_iP3custom--StockIssuedDuringPeriodValueNewIssues19_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpUNEbPO1ohl" title="Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332 (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodSharesNewIssues19" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,445,297</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues19" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues19" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69,288</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues19" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69,292</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43B_c20210101__20211231_ecustom--IssuanceOfCommonStockUnderPurchaseAgreement3_iP3custom--StockIssuedDuringPeriodSharesNewIssues19_zyjtsJMHM0kk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of common stock under 2021 Purchase Agreement, net
        of transactional expenses of $<span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--StockIssuanceTwoMember_zZK4hLfPtbc8" title="Transactional expenses"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_custom_StockIssuanceTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--IssuanceOfCommonStockUnderPurchaseAgreementInShares3_iP3custom--IssuanceOfCommonStockUnderPurchaseAgreement3_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuXlBior3Qx9" title="Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75 (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares3" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,016,855</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41,194</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41,196</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_433_c20210101__20211231_ecustom--IssuanceOfCommonStockUnderPurchaseAgreement1_iP3custom--IssuanceOfCommonStockUnderPurchaseAgreementInShares3_zzfwU0Ikap62" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of commitment shares under 2021 Purchase agreement</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--IssuanceOfCommonStockUnderPurchaseAgreementInShares1_iP3custom--IssuanceOfCommonStockUnderPurchaseAgreement1_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z17JxwNbrMb9" title="Issuance of commitment shares under 2021 Purchase agreement (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares1" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43A_c20210101__20211231_ecustom--StockIssuedDuringPeriodValueNewIssues21_iP3custom--IssuanceOfCommonStockUnderPurchaseAgreementInShares1_zYtGjLsP8j9b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of common stock in the acquisition of the OyaGen license</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesNewIssues21_iP3custom--StockIssuedDuringPeriodValueNewIssues21_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx6oKwOBPE7h" title="Issuance of common stock in the acquisition of the OyaGen license (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodSharesNewIssues21" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,010</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues21" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:StockIssuedDuringPeriodValueNewIssues21" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43B_c20210101__20211231_ecustom--IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement_iP3custom--StockIssuedDuringPeriodSharesNewIssues21_zqvg4io9scE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Issuance of commitment shares under Lincoln park Purchase agreement</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares_iP3custom--IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRynkxmqMPlj" title="Issuance of commitment shares under Lincoln park Purchase agreement (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,909</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43A_c20210101__20211231_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_zx2WLrKJG8j1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Employee stock purchase plan</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkM6jlYcG8a2" title="Employee stock purchase plan (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,344</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43F_c20210101__20211231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_znkakyOpHa92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Stock-based compensation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,899</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,899</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_437_c20210101__20211231_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zBYdlvm72wva" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Foreign currency transaction loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">30</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">30</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_430_c20210101__20211231_eus-gaap--NetIncomeLoss_z3AJqHY2BVL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Net loss</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92,287</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92,287</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_431_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zo6T4eXQDebc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Balance, December 31, 2021</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">15,638,274</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">578,613</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92</ix:nonFraction></span></td>
    <td style="padding-bottom: 2pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">359,820</ix:nonFraction></span></td>
    <td style="padding-bottom: 2pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218,717</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;See the accompanying notes to the consolidated
financial statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="tnxp10kb006"></span>CONSOLIDATED STATEMENTS
OF CASH FLOWS</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In Thousands)</b>&#160;</p>

<table cellspacing="0" cellpadding="0" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" id="xdx_302_112_pn3n3_zFr4OqTwQRlf" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_498_20220101__20221231_zlDslpyefzXa" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20210101__20211231_zEEG2xDMIjKd" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zVXavuWdk0bi" style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maCzIL9_zpv3RgA5YQ7f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Net loss</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">110,218</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92,287</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zwoJg5kg6h0a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Adjustments to reconcile net loss to net cash used in operating
        activities:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzIL9_zn1kg0GXQKO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Depreciation and amortization</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,253</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--CommonStockIssuedToAcquireResearchAndDevelopment_i02_maCzIL9_zADU4BTBzLd9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Common stock issued to acquire in-process research and development</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:CommonStockIssuedToAcquireResearchAndDevelopment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_i02_maCzIL9_zkvXeI77FfL9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Stock-based compensation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,914</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,899</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_znXEgLvZYyB1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Changes in operating assets and liabilities:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msCzIL9_z0VNsJYiB6v8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Prepaid expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">164</ix:nonFraction></span></td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">518</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i02_maCzIL9_zHEeMSC1S1Ul" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Accounts payable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,045</ix:nonFraction></span></td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,526</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maCzIL9_zvV51P6WgHDa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Lease liabilities and ROU asset, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i02_maCzIL9_zYxBY27qWt3b" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Accrued expenses and other current liabilities</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,205</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,748</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCzIL9_maCzsx4_maCCERCz4Cp_zDof6WgEQxca" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Net cash used in operating activities</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">98,053</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,557</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_za1ZR607PRWi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzQCg_z0seTH9b88Ze" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Purchase of property and equipment</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,147</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,307</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzQCg_maCzsx4_maCCERCz4Cp_zLTOSx0pOp06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Net cash used in investing activities</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48,147</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35,307</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zdm9lEIMxcrk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromWarrantExercises_i01_maCzJzw_zR4t3v7y7xEf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Proceeds from exercise of warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_i01_maCzJzw_zZkPRxyxLe74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Proceeds from ESPP</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_i01_maCzJzw_zZicgTDvYrZ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">Proceeds, net of $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zZzICDkjIVBa" title="Expenses from sale of stock"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,659</ix:nonFraction></span>
        expenses, from sale of convertible redeemable preferred stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,591</ix:nonFraction></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_i01N_di_msCzJzw_zDLItuHXZal1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt">Redemption of convertible redeemable preferred stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47,250</ix:nonFraction></p></td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzJzw_zGUwtvCrfIR6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Proceeds, net of $<span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdMNcQ054Csa" title="Expenses from sale of common stock and warrants"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,078</ix:nonFraction></span>
        and $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYIkFayOdyE2"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,505</ix:nonFraction></span>
        expenses, from sale of common stock and warrants</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94,463</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212,389</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzJzw_maCzsx4_maCCERCz4Cp_z2ociX9RC6i8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Net cash provided by financing activities</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87,844</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212,487</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_maCzsx4_maCCERCz4Cp_z2qA1YLE6z45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Effect of currency rate change on cash</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">74</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">31</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCz4Cp_zT9DJt1Jc6Q6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Net (decrease) increase in cash, cash equivalents and restricted
        cash</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,430</ix:nonFraction></span></td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101,592</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zLk0YDSCWnZa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Cash, cash equivalents and restricted
        cash beginning of the period</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178,900</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77,308</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zsBgqQiJU8de" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Cash, cash equivalents and restricted
        cash end of period</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,470</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178,900</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zgWFmBjc91o1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Supplemental disclosures of cash flow information:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CapitalExpendituresIncurredButNotYetPaid_i01_zVjpfnVGF2Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Purchases of property and equipment
        included in accounts payable and accrued liabilities</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,092</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,730</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PreferredStockDividendsAndOtherAdjustments_i01_zNLWeBDJV8Kg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Preferred stock deemed dividend</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,659</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See the accompanying notes to consolidated financial
statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="tnxp10kb007"></span>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_80A_eus-gaap--NatureOfOperations_zlvvG1OMgiy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8211;
<span id="xdx_821_zacOZmUYMm59">BUSINESS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tonix Pharmaceuticals Holding
Corp., through its wholly owned subsidiary Tonix Pharmaceuticals, Inc. (&#8220;Tonix Sub&#8221;), is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing therapeutics and vaccines to treat and prevent human disease and alleviate
suffering. The therapeutics include both small molecules and biologics. All drug product and vaccine candidates are still in development
and none are approved or marketed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements include the accounts of Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiaries, Tonix Sub, Krele LLC, Tonix
Pharmaceuticals (Canada), Inc., Tonix Medicines, Inc., Jenner LLC, Tonix R&amp;D Center LLC, Tonix Pharma Holdings Limited and Tonix Pharma
Limited (collectively hereafter referred to as the &#8220;Company&#8221; or &#8220;Tonix&#8221;). All intercompany balances and transactions
have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Going
Concern</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization
of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses
from operations and negative cash flows from operating activities. At December 31, 2022, the Company had working capital of approximately
$<span id="xdx_909_ecustom--WorkingCapital_iI_pn5n6_c20221231_zMAchNvNO0be" title="Working capital"><ix:nonFraction name="tnxp:WorkingCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">112.6</ix:nonFraction></span> million. At December
31, 2022, the Company had an accumulated deficit of approximately $<span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3n3_dxL_c20221231_zFcvc05qocU6" title="Accumulated deficit::XDX::-470038"><span style="-sec-ix-hidden: xdx2ixbrl0523">470.0
million</span></span>. The Company held cash and cash equivalents of approximately $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dxL_c20221231_ziIbKtPDeCDk" title="Cash and cash equivalents::XDX::120229"><span style="-sec-ix-hidden: xdx2ixbrl0525">120.2
million</span></span> as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company believes that
its cash resources at December 31, 2022 and the proceeds that it raised from equity offerings in the first quarter of 2023, net of amounts
paid to repurchase shares in the first quarter of 2023 (See Note 22), will meet its operating and capital expenditure requirements into
the fourth quarter of 2023, but not beyond.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;These factors raise
substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company faces significant challenges and uncertainties
and, as a result, its available capital resources may be consumed more rapidly than currently expected due to changes it may make in its
research and development spending plans. The Company believes that it has the ability to obtain additional funding through public and
private financing and collaborative arrangements with strategic partners to increase the funds available to fund operations. However,
the Company may not be able to raise capital on terms acceptable to the Company. Without additional funds, it may be forced to delay,
scale back or eliminate some of its research and development activities, or other operations and potentially delay product development
in an effort to provide sufficient funds to continue operations. If any of these events occurs, the Company&#8217;s ability to achieve
its development and commercialization goals would be adversely affected. The financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</p>

</ix:nonNumeric><p id="xdx_81B_zIwsx1zMd2Di" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zm9kn7So8Ni6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
2 &#8211; <span id="xdx_824_z4KJEYWVH121">SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityPolicyTextBlock"><p id="xdx_849_eus-gaap--StockholdersEquityPolicyTextBlock_zOZ3iJLnegD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Reverse
Stock Split</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 16, 2022, the Company
filed a Certificate of Change with the Nevada Secretary of State, effective May 17, 2022. Pursuant to the Certificate of Change, the Company
effected a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20220515__20220516_zaVAYh85aOi5" title="Reverse stock split"><ix:nonNumeric contextRef="From2022-05-152022-05-16" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-32</ix:nonNumeric></span>
reverse stock split of its issued and outstanding shares of common stock. The Company accounted for the reverse stock split on a retrospective
basis pursuant to ASC 260, Earnings Per Share. All authorized, issued and outstanding common stock, common stock warrants, stock option
awards, exercise prices and per share data have been adjusted in these consolidated financial statements, on a retroactive basis, to reflect
the reverse stock split for all periods presented. Authorized preferred stock was not adjusted because of the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z85bylyw235c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Risks
and uncertainties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s primary
efforts are devoted to conducting research and development of innovative pharmaceutical and biological products to address public health
challenges. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions
to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated
revenues, and there is no assurance that if its products are approved for sale, that the Company will be able to generate cash flow to
fund operations. In addition, there can be no assurance that the Company&#8217;s research and development will be successfully completed
or that any product will be approved or commercially viable. Moreover, the extent to which COVID-19 impacts the Company&#8217;s operations
will depend on future developments, which are highly uncertain and cannot be predicted with confidence at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_847_eus-gaap--UseOfEstimates_zycH3ZaWPaDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Use
of estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in accordance with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date
of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates. Significant estimates include the assumptions used in the fair value of stock-based compensation and other equity instruments,
and the percent of completion of research and development contracts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeCsYv2kOrg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Cash
Equivalents and Restricted Cash</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers cash
equivalents to be those investments which are highly liquid, readily convertible to cash and have an original maturity of three months
or less when purchased. At December 31, 2022 and December 31, 2021, cash equivalents, which consisted of money market funds, amounted
to $<span id="xdx_90E_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20221231_z94GNFrnaeJl" title="Money market funds"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">116.3</ix:nonFraction></span> million
and $<span id="xdx_90F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20211231_zgwX3aBLcKJ4"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">120.4</ix:nonFraction></span> million, respectively.&#160;Restricted
cash, which is included in Other non-current assets on the consolidated balance sheet at December 31, 2022 and December 31, 2021 of approximately
$<span id="xdx_90E_eus-gaap--RestrictedCash_iI_pn3p0_c20221231_znWvNSUUBPEe"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">241,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn3p0_c20211231_z9QJnmrt7PY9"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">240,000</ix:nonFraction></span>,
respectively, collateralizes a letter of credit issued in connection with the lease of office space in Chatham, New Jersey and New York
City (see Note 19).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zm4EC9tOs0H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets
that sum to the total of the same amounts shown in the consolidated statement of cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><p id="xdx_23F_z2KkL273DZ88" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zHebJsAhhj9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS
HOLDING CORP.</b>&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zCdxL1lAOlF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zOZh4WPjT098" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December
        31, </b></span> <span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z8H3ZnL15rCj" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December
        31, </b></span> <span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzAEg_zJ9wBtsQLBPj" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Cash and cash equivalents</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,229</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178,660</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzAEg_z6lDGQL9tM9h" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Restricted cash</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">241</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">240</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzAEg_z21OclPlbmq2" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,470</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178,900</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zASRSTfMjLX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfbFUYyyXE0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Property
and equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#8217;s estimated
useful life, which ranges from <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MinimumMember_zvv78dahWPi9" title="Estimated useful life of property and equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_BuildingMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric></span>
to <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MaximumMember_zKg1zF1o4gDi" title="Estimated useful life of property and equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_BuildingMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">30</ix:nonNumeric></span>
years for buildings, <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LandImprovementsAndLabEquipmentMember_z3pJHCpx5zxj" title="Estimated useful life of property and equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_LandImprovementsAndLabEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">15</ix:nonNumeric></span>
years for land improvements, and laboratory equipment, <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKWRPzNxpR49" title="Estimated useful life of property and equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">three
years</ix:nonNumeric></span> for computer assets, <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndAllOtherEquipmentMember_zwoae7YmI5vb" title="Estimated useful life of property and equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_FurnitureAndAllOtherEquipmentMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">five
years</ix:nonNumeric></span> for furniture and all other equipment and term of lease for leasehold improvements. Depreciation on assets begin when the
asset is available for its intended use. Depreciation and amortization expense for the years ended December 31, 2022, and 2021 was $<span id="xdx_90B_eus-gaap--DepreciationAndAmortization_pp0p0_c20220101__20221231_zXgSwU9KAhij" title="Depreciation and amortization expense"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,253,000</ix:nonFraction></span>&#160;and
$<span id="xdx_90A_eus-gaap--DepreciationAndAmortization_pp0p0_c20210101__20211231_z4wIiMThVXRl" title="Depreciation and amortization expense"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span>,
respectively. The Company&#8217;s property and equipment is located in the United States.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"><p id="xdx_84C_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_zPuPuWvi2DZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Intangible
assets with indefinite lives</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2015, the Company purchased certain internet domain rights, which were determined to have an indefinite life. Identifiable intangibles
with indefinite lives, which are included in Other non-current assets on the consolidated balance sheet, are not amortized but are tested
for impairment annually or whenever events or changes in circumstances indicate that their carrying amount may be less than fair value.
As of December 31, 2022, and 2021, the Company believed that no impairment existed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zSRdMtHSVd58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets, lease liability, short term and lease liability, long term in the Company&#8217;s consolidated balance sheets. ROU assets represent
the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental
borrowing rate based on the information available at the transition date and subsequent lease commencement dates in determining the present
value of lease payments. This is the rate the Company would have to pay if borrowing on a collateralized basis over a similar term to
each lease. The operating lease ROU asset excludes lease incentives. The Company&#8217;s lease terms may include options to extend or
terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments made under
operating leases is recognized on a straight-line basis over the lease term.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"><p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zmlnMQJvq0Cg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Convertible
Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preferred shares subject to
mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity (&#8220;mezzanine&#8221;)
until such time as the conditions are removed or lapse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2B4gU2l2Br9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Research
and Development Costs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company outsources certain
of its research and development efforts and expenses these costs as incurred, including the cost of manufacturing products for testing,
as well as licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual
property acquired has been expensed as research and development costs, as such property is related to particular research and development
projects and had no alternative future uses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company estimates its
expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical
site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which
vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided
under such contracts. The Company accounts for trial expenses according to the timing of various aspects of the trial. The Company determines
accrual estimates taking into account discussion with applicable personnel and outside service providers as to the progress or state of
consummation of trials, or the services completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the course of a clinical
trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of
its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#8217;s
clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party
vendors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:GovernmentAssistancePolicyTextBlock"><p id="xdx_843_eus-gaap--GovernmentAssistancePolicyTextBlock_zN6kPx5OpuP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Government
Grants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may enter into
arrangements with governmental entities for the purpose of obtaining funding for research and development activities. The Company is reimbursed
for costs incurred that are associated with specified research and development activities included in the grant application approved by
the government authority. The Company classifies government grants&#160;received under these arrangements as a reduction to the related
research and development expense in the same period as the relevant expenses are incurred. In August 2022, the Company announced that
it received a Cooperative Agreement grant from the National Institute on Drug Abuse (&#8220;NIDA&#8221;), part of the National Institutes
of Health, to support the development of its TNX-1300 product candidate for the treatment of cocaine intoxication. No funding was received
during 2022.</p>

</ix:nonNumeric><p id="xdx_856_zD4GjP9ASqW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><p id="xdx_233_zfrPaUMgDv29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_z6zsITHnSEra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS
HOLDING CORP.</b>&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zW0Zj1jUnbl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwWpE0uggAn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Stock-based
compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All stock-based payments to
employees and to nonemployees for their services, including grants of restricted stock units (&#8220;RSUs&#8221;), and stock options,
are measured at fair value on the grant date and recognized in the consolidated statements of operations as compensation or other expense
over the requisite service period. The Company accounts for share-based awards in accordance with the provisions of the Accounting Standards
Codification (&#8220;ASC&#8221;) 718, Compensation &#8211; Stock Compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84A_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzyMnbsscSmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Foreign
Currency Translation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operations of the Company&#8217;s
Canadian subsidiary, Tonix Pharmaceuticals (Canada), Inc., are conducted in local currency, which represents its functional currency.
The U.S. dollar is the functional currency of the other foreign subsidiaries. Balance sheet accounts of the Canadian subsidiary were translated
from foreign currency into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated
at the average rate of exchange prevailing during the period. Translation adjustments resulting from this process were included in accumulated
other comprehensive loss on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zIX4YsfLpDx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Comprehensive
Income (Loss)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Comprehensive income (loss)
is defined as the change in equity of a business during a period from transactions and other events and circumstances from non-owners
sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Other comprehensive income (loss) represents foreign currency translation adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zhcIfHS6aHh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Income
Taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred income tax assets
and liabilities are determined based on the estimated future tax effects of net operating loss and credit carryforwards and temporary
differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted
tax rates. The Company records a valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred
income tax assets will be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes a
tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination
by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements
from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate
settlement. As of December 31, 2022, the Company has not recorded any unrecognized tax benefits. The Company&#8217;s policy is to recognize
interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zFQaNokTE3O3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Per
Share Data</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The computation of basic and
diluted loss per share for the years ended December 31, 2022 and 2021 excludes potentially dilutive securities when their inclusion would
be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All warrants issued participate
on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors, on the Company&#8217;s
common stock. For purposes of computing EPS, these warrants are considered to participate with common stock in earnings of the Company.
Therefore, the Company calculates basic and diluted EPS using the two-class method. Under the two-class method, net income for the period
is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed
earnings. No income was allocated to the warrants for the years ended December 31, 2022 and 2021, as results of operations were a loss
for the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2Jg2M9UU6Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Potentially
dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 74%"><span style="font-size: 10pt">Warrants to purchase common stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zlJ8KJutPM95" title="Potentially dilutive securities excluded from the computation of basic and diluted net loss per share" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,970</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuPWz6Kcp2Wh" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,970</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Options to purchase common stock</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6EUYcfN9HVe" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,453,031</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgD9NCZtwzCj" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">805,762</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2pt"><span style="font-size: 10pt">Totals</span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231_zHAwQlRmET47" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,473,001</ix:nonFraction></span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231_zIa3f0mUJkf5" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">825,732</ix:nonFraction></span></td>
    <td style="padding-bottom: 2pt">&#160;</td></tr>
  </table> &#160;

</ix:nonNumeric><p id="xdx_8A1_zDCKA9a5gOAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z95j2sM0cFcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Recently
Issued Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB issued
ASU No. 2020-06,&#160;<i>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>,
which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also
removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and
it also simplifies the diluted earnings per share calculation in certain areas. The Company will adopt ASU 2020-06 on January 1, 2023,
under the modified retrospective method of transition. The Company does not anticipate the adoption of ASU 2020-06 to impact the Company&#8217;s
financial position, results of operations or cash flows.</p>

</ix:nonNumeric><p id="xdx_85E_zpPf80juRY08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

</ix:nonNumeric><p id="xdx_81D_zRBp3Y4YhZtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zQaOV5iXQO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
3 &#8211; <span id="xdx_823_zP24ztM0VfCf">PROPERTY AND EQUIPMENT, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zOf7u8D41vZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property
and equipment, net consisted of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>December 31</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>December 31</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Property and equipment, net:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Land</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zHMLFED0vKZ" title="Property and equipment gross" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LandMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,011</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zd62r56k6sPe" title="Property and equipment gross" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LandMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,911</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Land improvements</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandImprovementsMember_zuUm2uRmrLD4" title="Property and equipment gross" style="text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LandImprovementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">79</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Buildings</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zlx4e3nScrYb" title="Property and equipment gross" style="text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_BuildingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,644</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Office furniture and equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_z3peqzBoilr7" title="Property and equipment gross" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_FurnitureAndEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,893</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_zIYvvdnZcc4e" title="Property and equipment gross" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_FurnitureAndEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">756</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zk1KcjNgjrci" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,440</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zoDllnstNj0f" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">347</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt">Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUvRUMMWnSLa" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWTM21u71Ard" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt">Construction in progress</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z898pzOA0HUa" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_ConstructionInProgressMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,366</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z5mGqFX9ses" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_ConstructionInProgressMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41,921</ix:nonFraction></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20221231_zlVxml4RMZP1" title="Property and equipment gross" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95,467</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20211231_zp28qnw1pEgd" title="Property and equipment gross" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,958</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Less: Accumulated depreciation and
        amortization</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20221231_zO3QDuaVS8sj" title="Less: Accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,653</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20211231_zskr3FQ6LApg" title="Less: Accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20221231_z5ehXejrwQZe" title="Property and equipment, net" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93,814</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20211231_zZ8F6JpaaKi3" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,558</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zTrF2efF0RR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 1, 2021, the Company
completed the acquisition of its approximately <span id="xdx_907_eus-gaap--AreaOfLand_iI_uSquareFoot_c20211001__srt--StatementGeographicalAxis__stpr--MD_zJhEfFlX47J3"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2021-10-01_stpr_MD" format="ixt:numdotdecimal" decimals="INF" unitRef="SquareFoot">45,000</ix:nonFraction></span>
square foot research and development facility in Frederick, Maryland totaling $<span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__srt--StatementGeographicalAxis__stpr--MD_zGTnNphCZUne" title="Facility purchase"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="From2021-09-222021-10-01_stpr_MD" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.5</ix:nonFraction></span>
million, to process development activities. Of the total purchase price, $<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zqQMALPhZ0G5"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="From2021-09-222021-10-01_us-gaap_LandMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span>
million was allocated to the value of land acquired, and $<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__srt--StatementGeographicalAxis__stpr--MD__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zL3PHz4OELl6"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="From2021-09-222021-10-01_stpr_MD_us-gaap_BuildingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.9</ix:nonFraction></span>
million was allocated to buildings, and approximately $<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__srt--StatementGeographicalAxis__stpr--MD__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember_zYMDqvGEkVS6"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="From2021-09-222021-10-01_stpr_MD_custom_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>
million was allocated to Office furniture and equipment and Laboratory equipment. During the year ended December 31, 2022, the
assets became ready for the intended use and were placed in service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 28, 2020, the
Company completed the purchase of its approximately <span id="xdx_90E_eus-gaap--AreaOfLand_iI_uSquareFoot_c20200928__srt--StatementGeographicalAxis__stpr--MA_z5FNmA5cl1ek" title="Area of facility"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2020-09-28_stpr_MA" format="ixt:numdotdecimal" decimals="INF" unitRef="SquareFoot">45,000</ix:nonFraction></span>
square foot facility in Dartmouth, Massachusetts for $<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pdn6_c20200927__20200928__srt--StatementGeographicalAxis__stpr--MA_zfeAhKq37Bxg"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="From2020-09-272020-09-28_stpr_MA" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">4</ix:nonFraction></span>.0
million, to house its new Advanced Development Center for the development and manufacturing of vaccines. Of the total purchase price,
$<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20200927__20200928__srt--StatementGeographicalAxis__stpr--MA__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zDQthcN0c6I"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="From2020-09-272020-09-28_stpr_MA_us-gaap_LandMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>
million was allocated to the value of land acquired, and $<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20200927__20200928__srt--StatementGeographicalAxis__stpr--MA__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zf78cHURNsDa"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="From2020-09-272020-09-28_stpr_MA_us-gaap_BuildingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span>
million was allocated to buildings. Additionally, the Company incurred approximately $<span id="xdx_90D_eus-gaap--PaymentsForConstructionInProcess_pn5n6_c20220101__20221231__srt--StatementGeographicalAxis__stpr--MA_zt9VFH98OS19" title="Costs incurred"><ix:nonFraction name="us-gaap:PaymentsForConstructionInProcess" contextRef="From2022-01-012022-12-31_stpr_MA" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">38.8</ix:nonFraction></span>
million of costs during the year ended December 31, 2022, bringing total costs incurred-to-date to $<span id="xdx_90D_eus-gaap--PaymentsToAcquireProductiveAssets_pn5n6_c20200929__20221231__srt--StatementGeographicalAxis__stpr--MA_zMg8c8uITYSl" title="Total costs incurred"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2020-09-292022-12-31_stpr_MA" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">61.6</ix:nonFraction></span>
million, of which the majority relates to the build-out of the facility. During the year ended December 31, 2022, the assets became
ready for the intended use and were placed in service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 23, 2020, the
Company completed the purchase of its approximately <span id="xdx_90A_eus-gaap--AreaOfLand_iI_uAcre_c20201223__srt--StatementGeographicalAxis__stpr--MT_zjpm3F5q37Dh"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2020-12-23_stpr_MT" format="ixt:numdotdecimal" decimals="INF" unitRef="Acre">44</ix:nonFraction></span>-acre
site in Hamilton, Montana for $<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20201221__20201223__srt--StatementGeographicalAxis__stpr--MT_z3ffXCrIbzU7"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="From2020-12-212020-12-23_stpr_MT" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span>
million, for the construction of a vaccine development and commercial scale manufacturing facility. As of December 31, 2022, the
asset was not ready for its intended use.</p>

</ix:nonNumeric><p id="xdx_81D_z6KQg0XLosOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:OtherBalanceSheetInformationDiclosureTextBlock"><p id="xdx_804_ecustom--OtherBalanceSheetInformationDiclosureTextBlock_zEexXqbesbWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
4 &#8211; <span id="xdx_829_ztlsn9Wh5Ni1">OTHER BALANCE SHEET INFORMATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock"><p id="xdx_894_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zZmjN0MMISXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Components
of selected captions in the consolidated balance sheets consist of:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20221231_zpaDHLoBqmvl" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zQQsSctglemb" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2022</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2021</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zpjLBKcG4czh" style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Prepaid expenses and other:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--ContractRelatedPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zgztWqrGeFUg" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Contract-related</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ContractRelatedPrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,043</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ContractRelatedPrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,726</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidInsurance_i01I_pn3n3_maPEAOAzN1F_zeeRZKyz8ONi" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Insurance</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,275</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,482</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--ProfessionalFeesAndOtherPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zTsWJ0dIya5d" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ProfessionalFeesAndOtherPrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,230</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ProfessionalFeesAndOtherPrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,181</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_mtPEAOAzN1F_zoIUDXhnGTW6" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,548</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,389</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrentAbstract_iB_zTyJXsT5VeN3" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Accrued expenses and other current liabilities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--ContractRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zhTVZS7AmCv3" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Contract-related</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ContractRelatedAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,273</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ContractRelatedAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,832</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--CompensationAndCompensationRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_ziUVNyyjNLO9" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Compensation and compensation-related</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,645</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,868</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ConstructionInProgressAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zpUJBdKzASj5" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Construction in progress</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ConstructionInProgressAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,103</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ConstructionInProgressAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,572</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProfessionalFeesAndOtherAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zaYPfZCqCLr2" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Professional fees and other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">659</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">673</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzLWJ_zGSMNqABDbh8" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,680</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,945</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zmfAn5zuV5Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

</ix:nonNumeric><p id="xdx_811_zrfa2A5nIrt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zInqEP7JQoh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
5 &#8211; <span id="xdx_828_zOtIFkQMnyNe">FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value measurements affect
the Company&#8217;s accounting for certain of its financial assets. Fair value is defined as the price that would be received to sell
an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and is measured
according to a hierarchy that includes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 15%">&#160;</td>
    <td style="width: 7%"><span style="font-size: 10pt">Level 1:</span></td>
    <td style="width: 78%; text-align: justify"><span style="font-size: 10pt">Observable inputs, such as quoted prices in active markets.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 15%">&#160;</td>
    <td style="width: 7%"><span style="font-size: 10pt">Level 2:</span></td>
    <td style="width: 78%; text-align: justify"><span style="font-size: 10pt">Inputs, other than quoted prices in active markets, that are observable
        either directly or indirectly. Level&#160;2 assets and liabilities include debt securities with quoted market prices that are traded less
        frequently than exchange-traded instruments. This category includes U.S. government agency-backed debt securities and corporate-debt securities.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 15%">&#160;</td>
    <td style="width: 7%"><span style="font-size: 10pt">Level 3:</span></td>
    <td style="width: 78%; text-align: justify"><span style="font-size: 10pt">Unobservable inputs in which there is little or no market data.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><p id="xdx_232_zqA7mav1rr9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zr26srDTU8Wf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS
HOLDING CORP.</b>&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zIgE6EEgwWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, and
December 31, 2021, the Company used Level 1 quoted prices in active markets to value cash equivalents of $<span id="xdx_907_ecustom--CashEquivalentsFairValue_iI_pn5n6_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zCAZ5TxA8Qog"><ix:nonFraction name="tnxp:CashEquivalentsFairValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">116.3</ix:nonFraction></span>
million and $<span id="xdx_90B_ecustom--CashEquivalentsFairValue_iI_pn5n6_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z391b4fVOVs9"><ix:nonFraction name="tnxp:CashEquivalentsFairValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">120.4</ix:nonFraction></span>
million, respectively. The Company did not have any Level 2 or Level 3 assets or liabilities as of both December 31, 2022 and 2021.</p>

</ix:nonNumeric><p id="xdx_815_zbPeayTPY4Hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zhdwEFEgeQc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
6 &#8211; <span id="xdx_820_zFd27WXyjVs4">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 16, 2022, the Company
filed a Certificate of Change with the Nevada Secretary of State, effective May 17, 2022. Pursuant to the Certificate of Change, the
Company effected a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpkxzitroKGl"><ix:nonNumeric contextRef="From2022-05-152022-05-16_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-32</ix:nonNumeric>
</span>reverse stock split of its issued and outstanding shares of common stock, whereby <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwxnIZSeZmD5"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-05-152022-05-16_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">599,679,596</ix:nonFraction>
</span>outstanding shares of the Company&#8217;s common stock were exchanged for <span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQHkNULtF9tl"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2022-05-152022-05-16_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,740,141</ix:nonFraction>
</span>shares of the Company&#8217;s common stock. In connection with the reverse stock split, the Company issued an additional <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSLijTjcsNG"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2022-05-152022-05-16_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,462</ix:nonFraction>
</span>shares of the Company&#8217;s common stock due to fractional shares. Furthermore, pursuant to the Certificate of Change, the number
of authorized shares of common stock was reduced from <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pdn6_c20220514_zjgzFxhLOTf6"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-05-14" format="ixt:numdotdecimal" decimals="INF" scale="6" unitRef="Shares">800</ix:nonFraction>
</span>million to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pdn6_c20220516_zryjIfEHzX95"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-05-16" format="ixt:numdotdecimal" decimals="INF" scale="6" unitRef="Shares">50</ix:nonFraction></span> million. All per
share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect
the reverse stock split.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 5, 2022, the Company
filed an amendment to its articles of incorporation, as amended, to increase the number of shares of common stock authorized from <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220803_zKrHID5DV68h"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-08-03" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span>
to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220805_z3EF34Sb6rW5"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-08-05" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 13, 2022, the
Company filed an amendment to its articles of incorporation, as amended, to increase the number of shares of common stock authorized from
<span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221211_zwNTcHPxbibi"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-11" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000,000</ix:nonFraction></span> to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221213_zUa29GK8TY0f"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-13" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000,000</ix:nonFraction></span>.</p>


</ix:nonNumeric><p id="xdx_81D_zQiK8t4ufh3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:TemporaryEquityTextBlock"><p id="xdx_80D_ecustom--TemporaryEquityTextBlock_zwifcfc9Yy3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
7 &#8211; <span id="xdx_821_zR793VlTLTGe">TEMPORARY EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 26, 2022, the Company
closed on an offering (&#8220;the October offering&#8221;) with certain institutional investors (the &#8220;Investors&#8221;), pursuant
to which the Company issued and sold, in a private placement, <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z04GH2GpG4b" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-242022-10-26_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,400,000</ix:nonFraction></span>
shares of the Company&#8217;s Series A Convertible Redeemable Preferred Stock, par value $<span id="xdx_900_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNnTTED6aR6" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share (the &#8220;Series A Preferred Stock&#8221;), and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGeWZ3Flloc8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-242022-10-26_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>
shares of the Company&#8217;s Series B Convertible Redeemable Preferred Stock, par value $<span id="xdx_902_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zu3eBO1UzpX3"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share (the &#8220;Series B Preferred Stock,&#8221; and together with the Series A Preferred Stock, the &#8220;Preferred Stock&#8221;),
at an offering price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zcEmoZMgCnT9" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.50</ix:nonFraction></span>
per share, representing a <span id="xdx_90C_ecustom--PercentageOfIssueDiscount_uPure_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zySYYQ7ayvYc"><ix:nonFraction name="tnxp:PercentageOfIssueDiscount" contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span>
original issue discount (&#8220;OID) to the stated value of $<span id="xdx_904_ecustom--StatedValuePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zRpWwqUDk3Cd"><ix:nonFraction name="tnxp:StatedValuePerShare" contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>
per share, for gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pdn6_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zdhIaxaCdMUh"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">14.3</ix:nonFraction></span>
million in the aggregate for the October offering, before the deduction of fees and offering expenses. The shares of Preferred Stock
were convertible, at a conversion price of $<span id="xdx_900_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zhKZu136wo7h"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>
per share (subject in certain circumstances to adjustments), into shares of the Company&#8217;s common stock, at the option of the holders
and, in certain circumstances, by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 13, 2022, an amendment
(the &#8220;December Amendment&#8221;) to the Company&#8217;s Articles of Incorporation, as amended, to increase the Company&#8217;s authorized
shares of common stock from <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221211_z7a8HV52cPE"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-11" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000,000</ix:nonFraction></span>
to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221213_zVBNhpl4oOt8"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-13" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000,000</ix:nonFraction></span>, was approved at
a special meeting of shareholders. The Series A Preferred Stock had the right to vote on such December Amendment on an as-converted to
common stock basis. The shares of the Series B Preferred Stock were automatically voted in a manner that &#8220;mirrored&#8221; the proportions
on which the shares of Common Stock (excluding any shares of Common Stock that were not voted) and Series A Preferred Stock were voted
to increase the Authorized Shares. The December Amendment required the approval of the majority of the votes associated with the Company&#8217;s
outstanding stock entitled to vote on the proposal. Because the Series B Preferred Stock were automatically and without further action
of the purchaser voted in a manner that &#8220;mirrored&#8221; the proportions on which the shares of Common Stock (excluding any shares
of Common Stock that were not voted) and Series A Preferred Stock were voted on the December Amendment, abstentions by common stockholders
did not have any effect on the votes cast by the holders of the Series B Preferred Stock. The Certificates of Designation for the Preferred
Stock provides that the <span id="xdx_908_eus-gaap--PreferredStockVotingRights_pid_c20221212__20221213__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zXBrgMzGr4o4" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-12-122022-12-13_us-gaap_RedeemableConvertiblePreferredStockMember" name="us-gaap:PreferredStockVotingRights">Preferred
Stock have no voting rights other than the right to vote on the December Amendment and as a class on certain other specified matters</ix:nonNumeric></span>,
and, with respect to the Series B Certificate of Designation, <span id="xdx_907_eus-gaap--PreferredStockVotingRights_pid_c20221212__20221213__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ze0InPxbVT93"><ix:nonNumeric contextRef="From2022-12-122022-12-13_us-gaap_SeriesBPreferredStockMember" name="us-gaap:PreferredStockVotingRights">the
right to cast 2,500 votes per share of Series B Preferred Stock on the December Amendment</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Preferred Stock
were entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred
Stock was convertible, at the option of the holders and, in certain circumstances, by the Company, into shares of Common Stock at a conversion
price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zKSalTY1j1x9"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>
per share. The holders of the Preferred Stock had the right to require the Company to redeem their shares of preferred stock for cash
at <span id="xdx_901_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z2wHG7OPvr87"><ix:nonFraction name="tnxp:TemporaryEquityRedemptionPricePercentage" contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction>%</span>
of the stated value of such shares through January 23, 2023. The Company had the option to redeem the Preferred Stock for cash at <span id="xdx_90A_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zDEx3N2TXe71"><ix:nonFraction name="tnxp:TemporaryEquityRedemptionPricePercentage" contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction>%</span>
of the stated value, subject to the holders&#8217; rights to convert the shares prior to such redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"></p>

<ix:exclude><p id="xdx_23A_zXsI47mpFb4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_ziy5NecqgGFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS
HOLDING CORP.</b>&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zY0zE7UPZ9d4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The $<span id="xdx_908_eus-gaap--EscrowDeposit_iI_pdn6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zJ0VcZjiZjW8"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">14.3</ix:nonFraction></span>
million in gross proceeds of the October offering was held in an escrow account, along with an additional $<span id="xdx_90B_ecustom--EscrowDepositForOriginalIssueDiscount_iI_pdn6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z0wKypglidcg"><ix:nonFraction name="tnxp:EscrowDepositForOriginalIssueDiscount" contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.5</ix:nonFraction></span>
million deposited by the Company to cover the aggregate OID as well as the additional amount that would be necessary to fund the <span id="xdx_903_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zI2WveX3oCO8"><ix:nonFraction name="tnxp:TemporaryEquityRedemptionPricePercentage" contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction>%</span>
redemption price until the expiration of the redemption period for the Preferred Stock, as applicable, subject to the earlier payment
to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in the escrow account would be disbursed to the
Company.</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" continuedAt="ConU000743-01" escape="true" name="us-gaap:TemporaryEquityTableTextBlock"><p id="xdx_89E_eus-gaap--TemporaryEquityTableTextBlock_gL3TETTB-XKNNU_zqJ8jD81ImIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. <span id="xdx_8B6_zFvQt5F2N4C3">The
Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value</span> of approximately $<span id="xdx_905_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIKIp2nesvT2" title="Temporary equity"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.7</ix:nonFraction></span>
million and $<span id="xdx_901_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbHhRLhVAnnb"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span>
million, respectively, as calculated in the following table (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWowwR0zsiRa" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        A</b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrDSnUVt6Mkc" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        B </b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--GrossProceeds_iI_pn3n3_maTECAAzHsD_zECCzRrLMIui" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Gross Proceeds</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:GrossProceeds" contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,300</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:GrossProceeds" contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">950</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Less:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_msTECAAzHsD_zdXwooGT29Fb" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in"><span style="font-size: 10pt">Preferred stock issuance costs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="tnxp:PreferredStockIssuanceCosts" contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">844</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="tnxp:PreferredStockIssuanceCosts" contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Plus:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_maTECAAzHsD_zSMJovDY5Wai" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 0.25in"><span style="font-size: 10pt">Accretion of carrying value to redemption value</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:AccretionOfCarryingValueToRedemptionValue" contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,244</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:AccretionOfCarryingValueToRedemptionValue" contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_mtTECAAzHsD_zyXeIpUafxLf" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Preferred stock subject to possible redemption</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,700</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,050</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zJKAXSk3404a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During December 2022, the
Company received redemption notices for all outstanding shares of Preferred Stock. The Preferred Stock was redeemed during December 2022
at <span id="xdx_904_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221201__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zIOZlaOpZHEc"><ix:nonFraction name="tnxp:TemporaryEquityRedemptionPricePercentage" contextRef="From2022-12-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction>%</span>
of the $<span id="xdx_907_ecustom--StatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zCUBH8qmTzK8"><ix:nonFraction name="tnxp:StatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>
stated value of the Preferred Stock, or $<span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_pn5n6_c20221201__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zVBcEWGOQizj" title="Redemption amount"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" contextRef="From2022-12-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.8</ix:nonFraction></span>
million in the aggregate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 24, 2022, the Company
closed on an offering (&#8220;the Offering&#8221;) with certain institutional investors (the &#8220;Investors&#8221;), pursuant to which
the Company issued and sold, in a private placement, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbqrFVoBuex4" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-06-232022-06-24_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span>
shares of the Company&#8217;s Series A Convertible Redeemable Preferred Stock, par value $<span id="xdx_90B_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGqWfR96jLX7" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share (the &#8220;Series A Preferred Stock&#8221;), and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zcmHaHvyzr01"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-06-232022-06-24_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span>
shares of the Company&#8217;s Series B Convertible Redeemable Preferred Stock, par value $<span id="xdx_909_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKb2fc2jPVc7"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share (the &#8220;Series B Preferred Stock,&#8221; and together with the Series A Preferred Stock, the &#8220;Preferred Stock&#8221;),
at an offering price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zKO3jsVXNM46" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.50</ix:nonFraction></span>
per share, representing a <span id="xdx_906_ecustom--PercentageOfIssueDiscount_uPure_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z2oyMKrlOVYa"><ix:nonFraction name="tnxp:PercentageOfIssueDiscount" contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span>
original issue discount (&#8220;OID) to the stated value of $<span id="xdx_908_ecustom--StatedValuePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zqjPkKS30xwd"><ix:nonFraction name="tnxp:StatedValuePerShare" contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>
per share, for gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pdn6_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zTlpLtNvrwN4"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">28.5</ix:nonFraction></span>
million in the aggregate for the Offering, before the deduction of fees and offering expenses. The shares of Preferred Stock were convertible,
at a conversion price of $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zJZBczYqnYch"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span>
per share (subject in certain circumstances to adjustments), into shares of the Company&#8217;s common stock, at the option of the holders
and, in certain circumstances, by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 5, 2022, an amendment
(the &#8220;Amendment&#8221;) to the Company&#8217;s Articles of Incorporation, as amended, to increase the Company&#8217;s authorized
shares of common stock from <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220803_zsfgb17q9jp4"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-08-03" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span>
to <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220805_zI3KSp6dOAV4" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-08-05" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000,000</ix:nonFraction></span>,
was approved at a special meeting of shareholders. The Series A Preferred Stock had the right to vote on such Amendment on an as-converted
to common stock basis. The shares of the Series B Preferred Stock were automatically voted in a manner that &#8220;mirrored&#8221; the
proportions on which the shares of Common Stock (excluding any shares of Common Stock that were not voted) and Series A Preferred Stock
were voted to increase the Authorized Shares. The Amendment required the approval of the majority of the votes associated with the Company&#8217;s
outstanding stock entitled to vote on the proposal. Because the Series B Preferred Stock were automatically and without further action
of the purchaser voted in a manner that &#8220;mirrored&#8221; the proportions on which the shares of Common Stock (excluding any shares
of Common Stock that were not voted) and Series A Preferred Stock were voted on the Amendment, abstentions by common stockholders did
not have any effect on the votes cast by the holders of the Series B Preferred Stock. The Certificates of Designation for the Preferred
Stock provides that the <span id="xdx_902_eus-gaap--PreferredStockVotingRights_pid_c20220804__20220805__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zWywwEPeKVoj" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-08-042022-08-05_us-gaap_RedeemableConvertiblePreferredStockMember" name="us-gaap:PreferredStockVotingRights">Preferred
Stock have no voting rights other than the right to vote on the Amendment and as a class on certain other specified matters</ix:nonNumeric></span>, and,
with respect to the Series B Certificate of Designation, <span id="xdx_900_eus-gaap--PreferredStockVotingRights_pid_c20220804__20220805__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zi99hxHRFDM1"><ix:nonNumeric contextRef="From2022-08-042022-08-05_us-gaap_SeriesBPreferredStockMember" name="us-gaap:PreferredStockVotingRights">the
right to cast 2,500 votes per share of Series B Preferred Stock on the Amendment</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Preferred Stock
were entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred
Stock was convertible, at the option of the holders and, in certain circumstances, by the Company, into shares of Common Stock at a conversion
price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zKHivVUHoRsh"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span>
per share. The holders of the Preferred Stock had the right to require the Company to redeem their shares of preferred stock for cash
at <span id="xdx_90B_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zHJ9oJRpS2l8"><ix:nonFraction name="tnxp:TemporaryEquityRedemptionPricePercentage" contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction>%</span>
of the stated value of such shares through September 22, 2022. The Company had the option to redeem the Preferred Stock for cash at <span id="xdx_90E_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zW8DSiTZCkGa"><ix:nonFraction name="tnxp:TemporaryEquityRedemptionPricePercentage" contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction>%</span>
of the stated value, subject to the holders&#8217; rights to convert the shares prior to such redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The $<span id="xdx_90D_eus-gaap--EscrowDeposit_iI_pdn6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zjg8euac2WMg"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">28.5</ix:nonFraction></span>
million in gross proceeds of the Offering was held in an escrow account, along with an additional $<span id="xdx_905_ecustom--EscrowDepositForOriginalIssueDiscount_iI_pdn6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z307uZsMNVTj"><ix:nonFraction name="tnxp:EscrowDepositForOriginalIssueDiscount" contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3</ix:nonFraction></span>.0
million deposited by the Company to cover the aggregate OID as well as the additional amount that would be necessary to fund the <span id="xdx_90B_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zpi0UDFLYqRl"><ix:nonFraction name="tnxp:TemporaryEquityRedemptionPricePercentage" contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction>%</span>
redemption price until the expiration of the redemption period for the Preferred Stock, as applicable, subject to the earlier payment
to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in the escrow account would be disbursed to the
Company.</p>

<div id="xdx_C07_gL3TETTB-XKNNU_zTyLjOQtmuR"><ix:continuation id="ConU000743-01">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. The Series A Preferred
Stock and Series B Preferred Stock was recorded at redemption value of approximately $<span id="xdx_902_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbkIMJNKWRmc" title="Temporary equity"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.3</ix:nonFraction></span>
million and $<span id="xdx_903_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zba28qKJdj4l" title="Temporary equity"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.2</ix:nonFraction></span>
million, respectively, as calculated in the following table (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfcNMrfrQp33" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        A</b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLYnqqg39TC6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        B </b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_ecustom--GrossProceeds_iI_pn3n3_zhzRGGwpa5R4" class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Gross Proceeds</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:GrossProceeds" contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,750</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:GrossProceeds" contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,750</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Less:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_zMP4L2SK3nB2" class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in"><span style="font-size: 10pt">Preferred stock issuance costs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="tnxp:PreferredStockIssuanceCosts" contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,046</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="tnxp:PreferredStockIssuanceCosts" contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Plus:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_zl7uAw1F24X7" class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 0.25in"><span style="font-size: 10pt">Accretion of carrying value to redemption value</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:AccretionOfCarryingValueToRedemptionValue" contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,546</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:AccretionOfCarryingValueToRedemptionValue" contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">709</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_zPI5MPtcZL8c" class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Preferred stock subject to possible redemption</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,250</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,250</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table></ix:continuation></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During August 2022, the Company
received redemption notices for all outstanding shares of Preferred Stock. The Preferred Stock was redeemed during August 2022 at <span id="xdx_907_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z7bzPZfcWpQc"><ix:nonFraction name="tnxp:TemporaryEquityRedemptionPricePercentage" contextRef="From2022-08-012022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction>%</span>
of the $<span id="xdx_90D_ecustom--StatedValuePerShare_iI_c20220831__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zw4PVYWUdo26"><ix:nonFraction name="tnxp:StatedValuePerShare" contextRef="AsOf2022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>
stated value of the Preferred Stock, or $<span id="xdx_907_eus-gaap--PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_pn5n6_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zNknnffvM9f8" title="Redemption amount"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" contextRef="From2022-08-012022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">31.5</ix:nonFraction></span>
million in the aggregate.</p>

</ix:nonNumeric><p id="xdx_81D_zGsG6rH9gmIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:AssetPurchaseAgreementWithKatanaTextBlock"><p id="xdx_800_ecustom--AssetPurchaseAgreementWithKatanaTextBlock_zIrFlKhMGfdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
8 &#8211; <span id="xdx_82B_zH2t5F1eHu13">ASSET PURCHASE AGREEMENT WITH KATANA</span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 22, 2020, the
Company entered into an asset purchase agreement (the &#8220;Katana Asset Purchase Agreement&#8221;) with Katana Pharmaceuticals, Inc.
(&#8220;Katana&#8221;) pursuant to which Tonix acquired Katana assets related to insulin resistance and related syndromes, including obesity
(the &#8220;Katana Assets&#8221;). In connection with the acquisition of the Katana Assets, Tonix assumed Katana&#8217;s rights and obligations
under that certain Exclusive License Agreement by and between Katana and The University of Geneva (&#8220;Geneva&#8221;) (the &#8220;Geneva
License &#8220;Agreement&#8221;) pursuant to an Assignment and Assumption Agreement with Geneva (&#8220;Geneva Assignment and Assumption
Agreement&#8221;), dated December 22, 2020. As consideration for entering into the Katana Asset Purchase Agreement, Tonix paid $<span id="xdx_90F_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20201221__20201222__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--KatanaPharmaceuticalsIncMember_znJOZG6yVgdf" title="Consideration paid"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-12-212020-12-22_custom_AssetPurchaseAgreementMember_custom_KatanaPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million to Katana. The costs associated with the cash payments were recorded to research and development expenses in the statement
of operations for the year ended December 31, 2020. Because the Katana intellectual property was acquired prior to U.S. Food and Drug
Administration (FDA) approval, the cash consideration totaling $<span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20201221__20201222__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--KatanaPharmaceuticalsIncMember_zlmQY2SG61Y1" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2020-12-212020-12-22_custom_AssetPurchaseAgreementMember_custom_KatanaPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million, was expensed as research and development costs since there is no alternative future use and the acquired intellectual
property does not constitute a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
Geneva Assignment and Assumption Agreement, Geneva has granted to Tonix an exclusive license, with the right to sublicense, certain patents
related to the Katana Assets. Tonix is obligated to use commercially reasonable efforts to diligently develop, manufacture, and sell products
claimed or covered by the patent and will use commercially reasonable efforts to diligently develop markets for such products. The Geneva
License Agreement specifies developmental milestones and the period of time during which such milestones must be completed and provides
for an annual maintenance fee payable to Geneva. As of December 31, 2022, no milestone payments have been accrued or paid in relation
to this agreement.</p>

</ix:nonNumeric><p id="xdx_81C_zGAqLJW0DLz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock"><p id="xdx_80C_ecustom--AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock_zDppIBS9jo4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
9 &#8211; <span id="xdx_820_zpjak9qwOSZg">ASSET PURCHASE AGREEMENT WITH TRIGEMINA</span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 11, 2020, the Company
entered into an asset purchase agreement (the &#8220;Trigemina Asset Purchase Agreement&#8221;) with Trigemina, Inc. (&#8220;Trigemina&#8221;)
and certain shareholders named therein (the &#8220;Executive Shareholders&#8221;) pursuant to which Tonix acquired Trigemina assets related
to migraine and pain treatment technologies (the &#8220;Trigemina Assets&#8221;). In connection with the acquisition of the Trigemina
Assets, Tonix assumed Trigemina&#8217;s rights and obligations under that certain Amended and Restated Exclusive License Agreement, dated
November 30, 2007, as amended, by and between Trigemina and The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;)
(the &#8220;Stanford License &#8220;Agreement&#8221;) pursuant to an Assignment and Assumption Agreement with Stanford (&#8220;Assignment
and Assumption Agreement&#8221;), dated June 11, 2020. As consideration for entering into the Asset Purchase Agreement, Tonix paid $<span id="xdx_900_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_zYOqrO5cZNci" title="Payment for purchase of assets"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">824,759</ix:nonFraction></span>
to Trigemina and issued to Trigemina <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_z4kJXPnGfLul" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">62,500</ix:nonFraction></span>
shares of the Company&#8217;s common stock, valued at $<span id="xdx_907_ecustom--CommonStockValuePerShares_pip0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_zfJzmjmG9Rrb" title="Common stock value (per share)"><ix:nonFraction name="tnxp:CommonStockValuePerShares" contextRef="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">21.76</ix:nonFraction></span>
per share, based on the closing stock price on June 11, 2020, and paid Stanford $<span id="xdx_905_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssignmentAndAssumptionAgreementMember_zaC2ibO4oHj7" title="Payment for purchase of assets"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-06-102020-06-11_custom_AssignmentAndAssumptionAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,241</ix:nonFraction></span>
pursuant to the terms of the Assignment and Assumption Agreement. The common stock is unregistered and subject to a 12-month lock-up and
a Shareholder Voting Agreement, dated June 11, 2020, pursuant to which Trigemina and the Executive Shareholders have agreed to vote the
common stock on any matter put to a vote of the shareholders of the Company in accordance with management&#8217;s recommendations. Both
the costs associated with the cash payments and share issuance, totaling $<span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_zFOhi0ISYZsa" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span>
million, were recorded to research and development expenses in the statement of operations for the year ended December 31, 2020.
Because the Trigemina intellectual property was acquired prior to FDA approval, the cash and stock consideration, was expensed as research
and development costs since there is no alternative future use and the acquired intellectual property does not constitute a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
Assignment and Assumption Agreement, Stanford has granted to Tonix an exclusive license, with the right to sublicense, certain patents
related to the Trigemina Assets. Stanford has reserved for itself the right to practice under the patents for academic research and educational
purposes. Tonix is obligated to use commercially reasonable efforts to diligently develop, manufacture, and sell products claimed or covered
by the patent and will use commercially reasonable efforts to diligently develop markets for such products. The Trigemina License Agreement
specifies developmental milestones and the period of time during which such milestones must be completed and provides for an annual maintenance
fee payable to Stanford. As of December 31, 2022, other than the annual maintenance fee, no milestone payments have been accrued or paid
in relation to this agreement.</p>

</ix:nonNumeric><p id="xdx_817_zTUyTI913fFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AssetAcquisitionTextBlock"><p id="xdx_803_eus-gaap--AssetAcquisitionTextBlock_ztjIp2a21GYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
10 &#8211; <span id="xdx_82A_zzfBSoQFeikl">ASSET PURCHASE AGREEMENT WITH TRIMARAN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 19, 2019, the Company
entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with TRImaran Pharma, Inc. (&#8220;TRImaran&#8221;)
and the selling shareholders named therein (the &#8220;Selling Shareholders&#8221;) pursuant to which Tonix acquired TRImaran&#8217;s
assets related to certain pyran-based compounds (the &#8220;Assets&#8221;). In connection with the acquisition of the Assets, Tonix entered
into a First Amended and Restated Exclusive License Agreement (the &#8220;WSU License Agreement&#8221;) with Wayne State University (&#8220;WSU&#8221;)
on August 19, 2019, as subsequently amended. As consideration for entering into the Asset Purchase Agreement, Tonix paid $<span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_z2oMKhoZZKUc" title="Payment for purchase of assets"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>
to TRImaran and has assumed certain liabilities of TRImaran totaling $<span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_zsiM8nTtqfV1" title="Liabilities assumed"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,500</ix:nonFraction></span>.
The $<span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_zNGJWpnbILR2" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">168,500</ix:nonFraction></span>
was previously recorded to research and development expenses in the statement of operations. Upon the achievement of specified development,
regulatory and sales milestones, Tonix also agreed to pay TRImaran and the Selling Shareholders, in restricted stock or cash, at Our option,
a total of approximately $<span id="xdx_909_ecustom--AchievementPaymentsPayable_iI_pn5n6_c20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_zmDTMzUmQ1z5" title="Contingent milestone payment obligation"><ix:nonFraction name="tnxp:AchievementPaymentsPayable" contextRef="AsOf2019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span>
million. Pursuant to the terms of the Asset Purchase Agreement, TRImaran and the Selling Shareholders are prohibited from disclosing
confidential information related to the Assets and are restricted from engaging, for a period of three years, in the development or commercialization
of any therapeutic containing any pyran-based drug compound for the treatment of post-traumatic stress disorder, attention deficit hyperactivity
disorder or major depressive disorder. Also for a period of three years, if TRImaran or any Selling Shareholder engage in the research
or development of any potential therapeutic compound for the treatment of any central nervous system disorder, TRImaran or such Selling
Shareholder is obliged to provide notice and opportunity to Tonix to make an offer to acquire or license rights with respect to such product
candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
WSU License Agreement, WSU has granted to Tonix an exclusive license, with the right to sublicense, certain patents, technical information
and material (collectively, the &#8220;Technology&#8221;) related to the Assets. WSU has reserved for itself the right to practice the
Technology for academic research and educational purposes. Tonix is obligated to use commercially reasonable efforts to obtain regulatory
approval for one or more products utilizing the Technology (&#8220;WSU Products&#8221;) and to use commercially reasonable marketing efforts
throughout the term of the WSU License Agreement. The WSU License Agreement specifies developmental milestones and the period of time
during which such milestones must be completed and provides for an annual maintenance fee payable to WSU. Tonix is obligated to substantially
manufacture WSU Products in the United States if WSU Products will be sold in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><p id="xdx_237_zvoXP7uqBzof" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS
HOLDING CORP.</b>&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zYJ6EpUlIIk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the WSU License
Agreement, Tonix paid $<span id="xdx_905_ecustom--ReimbursementOfPatentExpenses_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zMbUHTlrnkc" title="Reimbursement of patent expenses"><ix:nonFraction name="tnxp:ReimbursementOfPatentExpenses" contextRef="From2019-08-172019-08-19_custom_WSULicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></span>
to WSU as reimbursement of certain patent expenses, and, upon the achievement of specified development, regulatory and sales milestones,
the Company also agreed to pay WSU, milestone payments totaling approximately $<span id="xdx_905_ecustom--ContingentMilestonePaymentObligation_iI_pn5n6_c20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zzuL0bQa1O5e"><ix:nonFraction name="tnxp:ContingentMilestonePaymentObligation" contextRef="AsOf2019-08-19_custom_WSULicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span>
million. Tonix has also agreed to pay WSU single-digit royalties on net sales of WSU Products sold by Tonix or a sublicensee on
a tiered basis based on net sales, and additional sublicense fees on certain consideration received from sublicensees. Royalties on each
particular WSU Product are payable on a country-by-country and Product-by-Product basis until the date of expiration of the last valid
claim in the last to expire of the issued patents covered by the WSU License Agreement. Royalties payable on net sales of WSU Products
may be reduced by <span id="xdx_903_ecustom--PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_pip0_dp_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zQUD7VdYEra1"><ix:nonFraction name="tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" contextRef="From2019-08-172019-08-19_custom_WSULicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the royalties payable by Tonix to any third party for intellectual property rights which are necessary for the practice of the rights
licensed to Tonix under the WSU License Agreement, provided that the royalty payable on a WSU Product may not be reduced by more than
<span id="xdx_90D_ecustom--MaximumPercentageReductionOfRoyaltiesPayable_pip0_dp_uPure_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zJ92oUJDlrRc" title="Maximum percentage reduction of royalties payable"><ix:nonFraction name="tnxp:MaximumPercentageReductionOfRoyaltiesPayable" contextRef="From2019-08-172019-08-19_custom_WSULicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%.
Each party also has the right to terminate the agreement for customary reasons such as material breach and bankruptcy. The WSU License
Agreement contains provisions relating to termination, indemnification, confidentiality and other customary matters for an agreement of
this kind. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.</p>

</ix:nonNumeric><p id="xdx_81A_zlesGkzHBuT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:LicenseAgreementCuriaTextBlock"><p id="xdx_807_ecustom--LicenseAgreementCuriaTextBlock_zmVMdNiVDNxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
11 &#8211; <span id="xdx_824_zk8ewTuFmCM1">LICENSE AGREEMENT WITH CURIA</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 12, 2022,
the Company entered into an exclusive license agreement with Curia for the development of three humanized murine mAbs for the
treatment or prophylaxis of SARS-CoV-2 infection. We believe that the licensing of these mAbs strengthens our pipeline of
next-generation therapeutics to treat COVID-19, which is caused by SARS-CoV-2. As consideration for entering into the License
Agreement, we paid a license fee of approximately $<span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20201221__20201222__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--CuriaMember_znz5GLmHjf63" title="Payment for purchase of assets"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-12-212020-12-22_custom_LicenseAgreementMember_custom_CuriaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million to Curia. The License Agreement also provides for single-digit royalties and contingent milestone payments. As of
December 31, 2022, other than the upfront fee, no payments have been accrued or paid in relation to this agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:LicenseAgreementUniversityOfAlbertaTextBlock"><p id="xdx_80A_ecustom--LicenseAgreementUniversityOfAlbertaTextBlock_zPO8BKylQcNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
12 &#8211; <span id="xdx_827_znrREsD4ZjT4">LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 18, 2022, the
Company entered into an exclusive License Agreement with the University of Alberta focused on identifying and testing broad-spectrum
antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses. As consideration for entering into the License
Agreement, Tonix paid a low-five digit license fee to University of Alberta. The License Agreement also provides for single-digit
royalties and contingent milestone payments. As of December 31, 2022, other than the upfront fee, no milestone payments have been
accrued or paid in relation to this agreement.</p>

</ix:nonNumeric><p id="xdx_81C_zQysNvUSSrH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:LicenseAgreementOyagenTextBlock"><p id="xdx_805_ecustom--LicenseAgreementOyagenTextBlock_zk6ikIDYblvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
13 &#8211; <span id="xdx_824_z9Ivl92pT0I9">LICENSE AGREEMENT WITH OYAGEN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 14, 2021, the Company
and OyaGen, Inc. (&#8220;OyaGen&#8221;) entered into an exclusive License Agreement (the &#8220;OyaGen License Agreement&#8221;) pursuant
to which OyaGen granted to Tonix an exclusive license to certain patents and technical information related to an antiviral inhibitor of
SARS-CoV-2, sangivamycin, and to develop and commercialize products thereunder, and to acquire rights to any technology based thereon
for the prevention or treatment of COVID-19 developed by OyaGen during the term of the License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As consideration for entering
into the License Agreement, Tonix paid a low-seven digit license fee to OyaGen, and issued to OyaGen and an affiliated entity an aggregate
of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210413__20210414__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--OyaGenIncMember_z0FEluzy5aza" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-04-132021-04-14_custom_LicenseAgreementMember_custom_OyaGenIncMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">86,010</ix:nonFraction>
</span>shares of the Company&#8217;s common stock. The shares were valued at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210413__20210414__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--OyaGenIncMember_zFH5CW9x6IDe" title="Value of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-04-132021-04-14_custom_LicenseAgreementMember_custom_OyaGenIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3</ix:nonFraction></span>.0
million, which was recorded as research and development expense. The OyaGen License also provided for single-digit royalties and contingent
milestone payments.&#160;In July 2022, the Company notified OyaGen of its intent to terminate the OyaGen License Agreement, and the agreement
was terminated effective September 20, 2022.</p>

</ix:nonNumeric><p id="xdx_81E_z7XFFta8HGxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:LicenseAgreementWithInsermTextBlock"><p id="xdx_80F_ecustom--LicenseAgreementWithInsermTextBlock_z9vTIhWRIYki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
14 &#8211; <span id="xdx_825_zuH0EoTXRfQ8">LICENSE AGREEMENT WITH INSERM</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 11, 2021,
the Company entered into a license agreement (the &#8220;Inserm License Agreement&#8221;) pursuant to which it licensed technology
using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from Inserm
(the French National Institute of Health and Medical Research), Aix-Marseille Universit&#233; and Centre Hospitalier Universitaire
of Toulouse. The Inserm License Agreement provides for the payment of annual fees and milestone payments upon the occurrence of
specified sales milestones totaling approximately $<span id="xdx_905_ecustom--SalesMilestones_pn5n6_c20210207__20210211__us-gaap--TypeOfArrangementAxis__custom--InsermLicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--InsermMember__us-gaap--BusinessAcquisitionAxis__custom--OxytocinBasedTherapeuticsMember_ze9LYZdlwqa"><ix:nonFraction name="tnxp:SalesMilestones" contextRef="From2021-02-072021-02-11_custom_InsermLicenseAgreementMember_custom_InsermMember_custom_OxytocinBasedTherapeuticsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million, as well royalties on net sales of products based on the licensed technology, and assignment/transfer and sublicense
royalties. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.</p>

</ix:nonNumeric><p id="xdx_813_zBN64FFqcs87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_z18pYIUDsTjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
15 &#8211; <span id="xdx_82C_zUPdDVsYYye">LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 16, 2019, the
Company entered into an exclusive License Agreement (the &#8220;Columbia License Agreement&#8221;) with the Trustees of Columbia University
in the City of New York (&#8220;Columbia&#8221;), as subsequently amended, pursuant to which Columbia granted to Tonix an exclusive license,
with the right to sublicense, certain patents and technical information (collectively, the &#8220;TFF2 Technology&#8221;) related to a
recombinant Trefoil Family Factor 2 (TFF2), and to develop and commercialize products thereunder (each, a &#8220;TFF2 Product&#8221;).
Pursuant to the terms of the Columbia License Agreement, Columbia reserved for itself the right to practice the TFF2 Technology for academic
research and educational purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company paid a five-digit
license fee to Columbia as consideration for entering into the Columbia License Agreement, which was recorded to research and development
expenses in the statement of operations for the year ended December 31, 2019. The Company is obligated to use Commercially Reasonable
Efforts, as defined in the Columbia License Agreement, to develop and commercialize the TFF2 Product, and to achieve specified developmental
milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><p id="xdx_230_zDxbyK3yjg15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zBmQIH5P8MYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>TONIX PHARMACEUTICALS
HOLDING CORP.</b>&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zh8srE78TjMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is obligated to
pay Columbia single-digit royalties on net sales of (i) TFF2 Products sold by Tonix or a sublicensee and (ii) any other products that
involve material or technical information related to the TFF2 Product and transferred to Tonix pursuant to the Columbia License Agreement
(&#8220;Other Products&#8221;) sold by Tonix or a sublicensee. Royalties on each particular TFF2 Product are payable on a country-by-country
and Product-by-Product basis until the latest of (i) the date of expiration of the last valid claim in the last to expire of the issued
patents covered by the Columbia License Agreement, and (ii) a specified period of time after the first commercial sale of a TFF2 Product
in the country in question. Royalties on each particular Other Product are payable on a country-by-country and product-by-product basis
until a specified period of time after the first commercial sale of such particular Other Product in such country. Royalties payable on
net sales of the TFF2 Product and Other Products may be reduced by <span id="xdx_907_ecustom--PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_pii_dp_uPure_c20190915__20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_zEa5slyh3Gbb" title="Percentage of third party royalties payable for reduction in royalties payable"><ix:nonFraction name="tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" contextRef="From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the royalties payable by Tonix to any third party for intellectual property rights which are necessary for the practice of the rights
licensed to Tonix under the Columbia License Agreement, provided that the royalty payable on a Product or Other Product may not be reduced
by more than <span id="xdx_904_ecustom--MaximumPercentageReductionOfRoyaltiesPayable_pid_dp_c20190915__20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_z6EHqMRDJbT4"><ix:nonFraction name="tnxp:MaximumPercentageReductionOfRoyaltiesPayable" contextRef="From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also
obligated to make contingent milestone payments to Columbia totaling $<span id="xdx_907_ecustom--ContingentMilestonePaymentObligation_iI_pn5n6_c20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_zSmiqv9VEsBj"><ix:nonFraction name="tnxp:ContingentMilestonePaymentObligation" contextRef="AsOf2019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.1</ix:nonFraction></span>
million on a Product-by-Product basis upon the achievement of certain development, approval and sales milestones related to a
TFF2 Product. In addition, the Company shall pay Columbia <span id="xdx_906_ecustom--PercentagePadOfConsideration_pii_dp_uPure_c20190915__20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_zeYxuX7xrI93"><ix:nonFraction name="tnxp:PercentagePadOfConsideration" contextRef="From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
of consideration, other than royalty payments and certain other categories of consideration, payable to the Company by a
sublicensee. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 20, 2019, the Company
entered into an exclusive License Agreement (the &#8220;License Agreement&#8221;) with Columbia pursuant to which Columbia, for itself
and on behalf of the University of Kentucky and the University of Michigan (collectively, the &#8220;Institutions&#8221;) granted to the
Company an exclusive license, with the right to sublicense, certain patents, technical information and material (collectively, the &#8220;Technology&#8221;)
related to a double-mutant cocaine esterase, and to develop and commercialize products thereunder (each, a &#8220;Product&#8221;). Pursuant
to the terms of the License Agreement, Columbia has reserved for itself and the Institutions the right to practice the Technology for
academic research and educational purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company paid a six-digit
license fee to Columbia as consideration for entering into the License Agreement. The Company is obligated to use Commercially Reasonable
Efforts, as defined in the License Agreement, to develop and commercialize the Product, and to achieve specified developmental milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agreed to pay
Columbia single-digit royalties on net sales of (i) Products sold by the Company or a sublicensee and (ii) any other products that involve
material or technical information related to the Product and transferred to the Company pursuant to the License Agreement (&#8220;Other
Products&#8221;) sold by the Company or a sublicensee. Royalties on each particular Product are payable on a country-by-country and Product-by-Product
basis until the latest of (i) the date of expiration of the last valid claim in the last to expire of the issued patents covered by the
License Agreement, (ii) a specified period of time after the first commercial sale of a Product in the country in question, or (iii) expiration
of any market exclusivity period granted by a regulatory agency. Royalties on each particular Other Product are payable on a country-by-country
and product-by-product basis until the later of (i) a specified period of time after the first commercial sale of such particular Other
Product in such country or (ii) expiration of any market exclusivity period granted by a regulatory agency. Royalties payable on net sales
of the Product and Other Products may be reduced by <span id="xdx_90E_ecustom--PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_pii_dp_uPure_c20190519__20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z3Ah1vyNKzfa" title="Percentage of third party royalties payable for reduction in royalties payable"><ix:nonFraction name="tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" contextRef="From2019-05-192019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the royalties payable by the Company to any third party for intellectual property rights which are necessary for the practice of the
rights licensed to the Company under the License Agreement, provided that the royalty payable on a Product or Other Product may not be
reduced by more than <span id="xdx_909_ecustom--MaximumPercentageReductionOfRoyaltiesPayable_pii_dp_uPure_c20190519__20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zLBjcBcHGDdf"><ix:nonFraction name="tnxp:MaximumPercentageReductionOfRoyaltiesPayable" contextRef="From2019-05-192019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also
obligated to make contingent milestone payments to Columbia totaling $<span id="xdx_900_ecustom--ContingentMilestonePaymentObligation_iI_pn6n6_c20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zETW1gpFSL7l"><ix:nonFraction name="tnxp:ContingentMilestonePaymentObligation" contextRef="AsOf2019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction> </span>million
on a Product-by-Product basis upon the achievement of certain development, approval and sales milestones related to a Product. In
addition, the Company shall pay Columbia <span id="xdx_90D_ecustom--PercentagePadOfConsideration_pii_dp_c20190519__20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zmkLfTqx8ti4"><ix:nonFraction name="tnxp:PercentagePadOfConsideration" contextRef="From2019-05-192019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
of consideration, other than royalty payments and certain other categories of consideration, payable to the Company by a
sublicensee. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.</p>

</ix:nonNumeric><p id="xdx_813_zTuBCjvu6jJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:SaleOfCommonStockTextBlock"><p id="xdx_801_ecustom--SaleOfCommonStockTextBlock_zkqgYm651y81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
16 &#8211; <span id="xdx_829_znZ5hxBTWOm2">SALE OF COMMON STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">2022
Lincoln Park Transaction</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2022, the Company
entered into a purchase agreement (the &#8220;2022 Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;2022 Registration
Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). Pursuant to the terms of the 2022 Purchase
Agreement, Lincoln Park has agreed to purchase from the Company up to $<span id="xdx_906_ecustom--CommitmentToPurchaseSharesUnderAgreement_c20220815__20220816__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z50KXIyDKuF7"><ix:nonFraction name="tnxp:CommitmentToPurchaseSharesUnderAgreement" contextRef="From2022-08-152022-08-16_custom_PurchaseAgreementWithLincolnPark2022Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>
of the Company&#8217;s common stock (subject to certain limitations) from time to time during the term of the 2022 Purchase Agreement.
Pursuant to the terms of the 2022 Registration Rights Agreement, the Company filed with the SEC a registration statement to register for
resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the 2022 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
2022 Purchase Agreement, at the time the Company signed the 2022 Purchase Agreement and the 2022 Registration Rights Agreement, the Company
issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20220815__20220816__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z4LIr3qQQrQ3"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-08-152022-08-16_custom_PurchaseAgreementWithLincolnPark2022Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625,000</ix:nonFraction></span>
shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of the Company&#8217;s common stock under
the 2022 Purchase Agreement. The commitment shares were valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220815__20220816__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zRzFBi8lXsde"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-08-152022-08-16_custom_PurchaseAgreementWithLincolnPark2022Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></span>
and recorded as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost of capital to
be raised under the 2022 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, the Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pin6_uShares_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member_z8bNL6UaqGfg"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnPark2022Member" format="ixt:numdotdecimal" decimals="INF" scale="6" unitRef="Shares">1</ix:nonFraction></span>.0
million shares of common stock under the 2022 Purchase Agreement, for net proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member_zIUrLx7pxS47"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnPark2022Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to December
31, 2022, the Company sold <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWWQp9yQGgZe"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">0.6</ix:nonFraction></span>
million shares of common stock under the 2022 Purchase Agreement with Lincoln Park for net proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zk9p11hapJT7"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><p id="xdx_230_zNOjiiMdB3Ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;<b>TONIX
PHARMACEUTICALS HOLDING CORP.</b>&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zymeGwpbBYA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zAzHGMJ6LtDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Purchase
Agreement with Lincoln Park</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 3, 2021, the Company
entered into a purchase agreement (the &#8220;Purchase Agreement with Lincoln Park&#8221;) and a registration rights agreement (the &#8220;Lincoln
Park Registration Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). Pursuant to the terms of
the Purchase Agreement with Lincoln Park, Lincoln Park agreed to purchase from the Company up to $<span id="xdx_904_ecustom--CommitmentToPurchaseSharesUnderAgreement_pp0p0_c20211202__20211203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zf4X4ncK4tSk" title="Commitment to purchase shares under agreement"><ix:nonFraction name="tnxp:CommitmentToPurchaseSharesUnderAgreement" contextRef="From2021-12-022021-12-03_custom_PurchaseAgreementWithLincolnParkMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000,000</ix:nonFraction></span>
of the Company&#8217;s common stock (subject to certain limitations) from time to time during the term of the Purchase Agreement with
Lincoln Park. Pursuant to the terms of the Lincoln Park Registration Rights Agreement, the Company filed with the SEC a registration statement
to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase Agreement
with Lincoln Park.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
Purchase Agreement with Lincoln Park, at the time the Company signed the Purchase Agreement with Lincoln Park and the Lincoln Park Registration
Rights Agreement, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20211202__20211203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuyjH4acUWUh" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-12-022021-12-03_custom_PurchaseAgreementWithLincolnParkMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,910</ix:nonFraction></span>
shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under the Purchase Agreement
with Lincoln Park. The commitment shares were valued at $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20211202__20211203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zrMlS9NSOZ25" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-12-022021-12-03_custom_PurchaseAgreementWithLincolnParkMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span>
million and recorded as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost
of capital to be raised under the Purchase Agreement with Lincoln Park.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, the Company sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_zpe0SyFDZCo2" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">2.9</ix:nonFraction></span>
million shares of common stock under the Purchase Agreement with Lincoln Park, for net proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_z39QCFnChULi" title="Proceeds from equity offerings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.7</ix:nonFraction></span>
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules of
the NASDAQ Global Market, the Company could not issue or sell more than <span id="xdx_90B_ecustom--PercentageOfIssuanceByIssuerOfCommonStock_pid_dp_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_zXHHpWeJzW2c" title="Percentage of issuance by issuer of common stock"><ix:nonFraction name="tnxp:PercentageOfIssuanceByIssuerOfCommonStock" contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span>%
of the shares of its common stock outstanding immediately prior to the execution of the Purchase Agreement with Lincoln Park (approximately
<span id="xdx_907_ecustom--MaximumNumberOfSharesIssuedWIthoutShareholderApproval_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_zQLTeK74SRu"><ix:nonFraction name="tnxp:MaximumNumberOfSharesIssuedWIthoutShareholderApproval" contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">2.9</ix:nonFraction>
million</span> shares) to Lincoln Park under the Purchase Agreement with Lincoln Park without stockholder approval, unless the average
price of all applicable sales of its common stock to Lincoln Park under the Purchase Agreement with Lincoln Park equals or exceeds a threshold
amount. As the Company has issued approximately <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_ztTVAweLUA45" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">2.9</ix:nonFraction></span>
million shares to Lincoln Park, by December 31, 2022, under the Purchase Agreement with Lincoln Park at less than the threshold
amount, the Company will not sell any additional shares under the Purchase Agreement with Lincoln Park without shareholder approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">2021
Lincoln Park Transaction</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 14, 2021, the Company
entered into a purchase agreement (the &#8220;2021 Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;2021 Registration
Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). Pursuant to the terms of the 2021 Purchase
Agreement, Lincoln Park agreed to purchase from the Company up to $<span id="xdx_904_ecustom--CommitmentToPurchaseSharesUnderAgreement_pp0p0_c20210513__20210514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2021Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zj5xIMcex5x6" title="Commitment to purchase shares under agreement"><ix:nonFraction name="tnxp:CommitmentToPurchaseSharesUnderAgreement" contextRef="From2021-05-132021-05-14_custom_PurchaseAgreementWithLincolnPark2021Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000,000</ix:nonFraction></span>
of the Company&#8217;s common stock (subject to certain limitations) from time to time during the term of the 2021 Purchase Agreement.
Pursuant to the terms of the 2021 Registration Rights Agreement, the Company filed with the SEC a registration statement to register for
resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the 2021 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
2021 Purchase Agreement, at the time the Company signed the 2021 Purchase Agreement and the 2021 Registration Rights Agreement, the Company
issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210513__20210514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2021Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z4BxbODE4YOc" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-05-132021-05-14_custom_PurchaseAgreementWithLincolnPark2021Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span>
shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under the 2021 Purchase
Agreement. The commitment shares were valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210513__20210514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2021Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zdPJYy0Cz8k4" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-05-132021-05-14_custom_PurchaseAgreementWithLincolnPark2021Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span>
million and recorded as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost
of capital to be raised under the 2021 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">During
the year ended December 31, 2021, the Company sold an aggregate of approximately <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zi9nt3a3jY88"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">2</ix:nonFraction></span>.0
million shares of common stock under the 2021 Purchase Agreement, for gross proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zpceiXFLrtJb"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">41.3</ix:nonFraction></span>
million. During the year ended December 31, 2022, no shares of common stock were sold under the 2021 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules of
the NASDAQ Global Market, the Company could not issue or sell more than <span id="xdx_90B_ecustom--PercentageOfIssuanceByIssuerOfCommonStock_pid_dp_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zemlrmf9tmQl"><ix:nonFraction name="tnxp:PercentageOfIssuanceByIssuerOfCommonStock" contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span>%
of the shares of its common stock outstanding immediately prior to the execution of the 2021 Purchase Agreement (approximately <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zkIKkhByQBRj"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">2</ix:nonFraction></span>.0
million shares) to Lincoln Park under the 2021 Purchase Agreement without stockholder approval, unless the average price of all applicable
sales of its common stock to Lincoln Park under the 20121 Purchase Agreement equals or exceeds a threshold amount. As the Company has
issued approximately <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zyovP8OIVAh8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">2</ix:nonFraction></span>.0
million shares to Lincoln Park under the 2021 Purchase Agreement, at less than the threshold amount, the Company will not sell any additional
shares under the 2021 Purchase Agreement without shareholder approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">February
2021 Financing</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 8, 2021, the Company
entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210206__20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zTbIrfm3ncvf" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-02-062021-02-08_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.8</ix:nonFraction></span>
million shares of its common stock, in a registered direct public offering (the &#8220;February 2021 Financing&#8221;), with A.G.P/Alliance
Global Partners (&#8220;AGP&#8221;), acting as placement agent. The public offering price for each share of common stock was $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pii_uUSDPShares_c20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zhAvZ68ejCpi" title="Sale of stock, price (in dollars per share)"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-02-08_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.40</ix:nonFraction></span>.
The February 2021 Financing closed on February 9, 2021. AGP received a cash fee of <span id="xdx_904_ecustom--CashFeePercentage_pii_dp_uPure_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zhnRVLhBCvsc" title="Cash fee"><ix:nonFraction name="tnxp:CashFeePercentage" contextRef="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>%
of the gross proceeds, for an aggregate amount of $<span id="xdx_901_ecustom--UnderwritingDiscount_pn5n6_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zWDUMiZTt4Tj" title="Underwriting discount"><ix:nonFraction name="tnxp:UnderwritingDiscount" contextRef="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction></span>
million. The Company incurred other offering expenses of approximately $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zHiesFvN8xk1" title="Expenses from sale of stock"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million. The Company received net proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0n6_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zx5bIdqVzCw6" title="Proceeds from equity offerings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">65</ix:nonFraction></span>.0
million, after deducting the fees and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">January
2021 Financing</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 11, 2021, the Company
entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zS8vPSSFQpv1" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.6</ix:nonFraction></span>
million shares of its common stock in a registered direct public offering (the &#8220;January 2021 Financing&#8221;), with AGP as placement
agent. The public offering price for each share of common stock was $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pii_uUSDPShares_c20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zjRo6y7SNWOe" title="Sale of stock, price (in dollars per share)"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.60</ix:nonFraction></span>.
The January 2021 Financing closed on January 13, 2021. AGP received a cash fee of <span id="xdx_90F_ecustom--CashFeePercentage_pii_dp_uPure_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zaXicIi3WK54" title="Cash fee"><ix:nonFraction name="tnxp:CashFeePercentage" contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>%
of the gross proceeds, for an aggregate of $<span id="xdx_903_ecustom--UnderwritingDiscount_pn5n6_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zlBSWUVvau65" title="Underwriting discount"><ix:nonFraction name="tnxp:UnderwritingDiscount" contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span>
million. The Company incurred other offering expenses of approximately $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z5Rja3KLIdZ" title="Expenses from sale of stock"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million. The Company received net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zE2vi2vmdGP5" title="Proceeds from equity offerings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">36.9</ix:nonFraction></span>
million, after deducting the fees and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<ix:exclude><p id="xdx_239_zEgMK5SMpT17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS
HOLDING CORP.</b>&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zGn1S9MNeqdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zA8af9zf4Ufl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">At-the-Market Offerings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;On April 8, 2020, the
Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with AGP pursuant to which the Company may issue and sell,
from time to time, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<span id="xdx_902_ecustom--OfferingPricePerAgreement_pp0n6_c20200407__20200408__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember_zbR37rECCVK9" title="Offering price per agreement"><ix:nonFraction name="tnxp:OfferingPricePerAgreement" contextRef="From2020-04-072020-04-08_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">320</ix:nonFraction></span>.0
million in at-the-market offerings (&#8220;ATM&#8221;) sales. AGP will act as sales agent and will be paid a <span id="xdx_908_ecustom--SalesAgentCommissionPercentage_pid_dp_c20200407__20200408__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember_zhNEkmYMNiEd" title="Commission to agent"><ix:nonFraction name="tnxp:SalesAgentCommissionPercentage" contextRef="From2020-04-072020-04-08_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>%
commission on each sale under the Sales Agreement. The Company&#8217;s common stock will be sold at prevailing market prices at the time
of the sale, and, as a result, prices will vary. During the year ended December 31, 2022, the Company sold approximately <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zofP0hjxw8yg" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">56.4</ix:nonFraction></span>
million shares of common stock under the Sales Agreement, for net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zQRFYB55csR2" title="Proceeds from equity offerings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-01-012022-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">85.3</ix:nonFraction></span>
million. During the year ended December 31, 2021, the Company sold approximately <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zEhdmqnIEhFi" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">3.5</ix:nonFraction></span>
million shares of common stock under the Sales Agreement, for net proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z9OLykwE979j" title="Proceeds from equity offerings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-01-012021-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">69.3</ix:nonFraction></span>
million. Subsequent to December 31, 2022, the Company has sold <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP35eL8qUe99" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-13_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">2.1</ix:nonFraction></span>
million shares of common stock under the Sales Agreement, for net proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuctuwBxR2N3" title="Proceeds from equity offerings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-012023-03-13_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span>
million.&#160;</p>

</ix:nonNumeric><p id="xdx_81E_zx8kgJy9fozc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z714NrcDyBge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
17 &#8211; <span id="xdx_823_ziwiO9BYfRr6">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Stock
Incentive Plans</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 3, 2019, the Company&#8217;s
stockholders approved the Tonix Pharmaceuticals Holding Corp. 2019 Stock Incentive Plan (the &#8220;2019 Plan&#8221;). The 2019 Plan provided
for the issuance of up to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20190503__us-gaap--PlanNameAxis__custom--IncentiveStockOptionsPlan2019Member_zaL8suJWocxf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2019-05-03_custom_IncentiveStockOptionsPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,375</ix:nonFraction></span>
shares of common stock. With the adoption of the 2020 Plan (as defined below), no further grants may be made under the 2019 Plan. On January
16, 2020, the Company&#8217;s stockholders approved the Tonix Pharmaceuticals Holding Corp. 2020 Stock Incentive Plan (the &#8220;2020
Plan&#8221;). The 2020 Plan provided for the issuance of up to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200116__us-gaap--PlanNameAxis__custom--IncentiveStockOptionsPlan2020Member_zam1TCfr9Ipc" title="Number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-01-16_custom_IncentiveStockOptionsPlan2020Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,750</ix:nonFraction></span>
shares of common stock. With the adoption of the Amended and Restated 2020 Plan (as defined below), no further grants may be made under
the 2020 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2020, the Company&#8217;s
stockholders approved the Tonix Pharmaceuticals Holding Corp. Amended and Restated 2020 Stock Incentive Plan (&#8220;Amended and Restated
2020 Plan&#8221;), and together with the 2020 Plan and the 2019 Plan, the &#8220;Plans&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the Amended
and Restated 2020 Plan, the Company may issue (1) stock options (incentive and nonstatutory), (2) restricted stock, (3) stock appreciation
rights (&#8220;SARs&#8221;), (4) RSUs, (5) other stock-based awards, and (6) cash-based awards. The Amended and Restated 2020 Plan initially
provided for the issuance of up to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_uShares_c20200501__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_zrXzoHb7MVYc" title="Percentage of additional shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-05-01_custom_AmendedAndRestated2020PlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">312,500</ix:nonFraction>
</span>shares of common stock, which amount&#160;will be increased to the extent that awards granted under the Plans are forfeited, expire
or are settled for cash (except as otherwise provided in the Amended and Restated 2020 Plan). In addition, the Amended and Restated 2020
Plan contains an &#8220;evergreen provision&#8221; providing for an annual increase in the number of shares of our common stock available
for issuance under the Amended and Restated 2020 Plan on January 1 of each year for a period of ten years, commencing on January 1, 2021
and ending on (and including) January 1, 2030, in an amount equal to the difference between (x) twenty percent (<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_z5JN5TZDMruc" title="Percentage of additional shares authorized"><ix:nonFraction name="tnxp:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" contextRef="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>%)
of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, and (y) the total number of
shares of common stock reserved under the Amended and Restated 2020 Plan on December 31<sup>st</sup> of such preceding calendar year
(including shares subject to outstanding awards, issued pursuant to awards or available for future awards). The Board of Directors determines
the exercise price, vesting and expiration period of the grants under the Amended and Restated 2020 Plan. However, the exercise price
of an incentive stock option may not be less than <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TenPercentOrMoreShareholderMember_zKhcrQyZ8KO4"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember_custom_TenPercentOrMoreShareholderMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">110</ix:nonFraction></span>%
of fair value of the common stock at the date of the grant for a 10% or more shareholder and <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_zH1a80XjbmUk"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%
of fair value for a grantee who is not a 10% shareholder. The fair value of the common stock is determined based on quoted market price
or in absence of such quoted market price, by the Board of Directors in good faith. Additionally, the expiration period of grants under
the Amended and Restated 2020 Plan may not be more than <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dt_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_zogx3eLsmzri" title="Expiration period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span>. As of December 31, 2022, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_z0dC6IryuFB"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_AmendedAndRestated2020PlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">627,744</ix:nonFraction>
</span>options were available for future grants under the Amended and Restated 2020 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhcqcmcrSy7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;A
summary of the stock option&#160;activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted- Average</b></span>
        <span style="font-size: 10pt"><b>Exercise&#160;Price</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span>
        <span style="font-size: 10pt"><b>Remaining&#160;</b></span> <span style="font-size: 10pt"><b>Contractual&#160;Term</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Aggregate</b></span> <span style="font-size: 10pt"><b>Intrinsic</b></span>
        <span style="font-size: 10pt"><b>Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Outstanding at December 31, 2020</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_z8QEF9Ldn2Ae" title="Outstanding at beginning" style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">319,179</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zXwgtIPhAWm4" title="Outstanding at beginning" style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.93</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zCCVNJiiNH67" title="Weighted average remaining contractual term" style="width: 15%; text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="From2020-01-012020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.26</ix:nonNumeric></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zV7Y3IVFQpma" title="Beginning, Aggregate Intrinsic Value" style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">131,558</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Grants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zfiIfBvbsM0j" title="Grants" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">486,639</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zOG86dylxtf8" title="Grants" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.85</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Forfeitures or expirations</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_zKjEzdjLrTjf" title="Forfeitures or expirations" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56</ix:nonFraction>)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zYFeC7ZW3OO8" title="Forfeitures or expirations" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">149,713.14</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Outstanding at December 31, 2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_z9MNdSsWT9Cj" title="Outstanding at end" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">805,762</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231_zx8pJKNcryj5" title="Outstanding at end" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">78.02</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zqr2cpE1k0G6" title="Weighted average remaining contractual term" style="text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.83</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Grants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zVwtcF2kU1L3" title="Grants" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,695,608</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zHGKSimzqy61" title="Grants" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.06</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Forfeitures or expirations</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_zJlazzscnvEb" title="Forfeitures or expirations" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,339</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zeyG8JWfNyvf" title="Forfeitures or expirations" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">255.40</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Outstanding at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_z7anQ9MzTHXe" title="Outstanding at end" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,453,031</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231_z3zk9WvoIDZj" title="Outstanding at end" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.93</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zZDC6CBOJOH2" title="Weighted average remaining contractual term" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.70</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Exercisable at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zctTAL3gFE74" title="Exercisable at end" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">590,582</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231_zmQTYImGOZde" title="Exercisable at end" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">70.82</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zvIpaX7vLUkj" title="Exercisable at end" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.64</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zkfAKwaYTs56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value
in the preceding table represents the total pretax intrinsic value, based on options with an exercise price less than the Company&#8217;s
closing stock price at the respective dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The weighted average grant
date fair value of options granted during the years ended December 31, 2022 and 2021, was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231_zmAM6aMsywm9" title="Weighted average grant date fair value of options (in dollars per share)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span>
and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231_zsA6nSKoDZpe" title="Weighted average grant date fair value of options (in dollars per share)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">33.78</ix:nonFraction></span>
per share, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><p id="xdx_23F_zEoDGqYWUx6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS
HOLDING CORP.</b>&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zKmHFHV1Yylj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_z8lcqbpsCCX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company measures the
fair value of stock options on the date of grant, based on the Black Scholes option pricing model using certain assumptions
discussed below, and the closing market price of the Company&#8217;s common stock on the date of the grant. The fair value of the
award is measured on the grant date. <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4p0_dxL_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z1VA1CI012M9" title="Vesting percentage::XDX::0.3333"><span style="-sec-ix-hidden: xdx2ixbrl1020">One-third </span></span>of
most stock options granted pursuant to the Plans vest 12 months from the date of grant and <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4p0_dxL_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zUk6ZZi0p1V7" title="::XDX::0.0278"><span style="-sec-ix-hidden: xdx2ixbrl1021">1/36</span><sup>th </sup></span>each
month thereafter for 24 months and expire <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNkgTBl1Gks5"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span> from the date of grant. In addition, the Company issues options to directors which vest over a <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zzdHhXaHRwG1" title="Vesting period::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1024">one-year</span></span> period. The Company also issues premium options to executive officers which have an exercise price greater than the grant
date fair value and has issued performance-based options which vest when target parameters are met or probable of being met, subject
in each case to a <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dt_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_z3rvzDOnmCZg" title="Service period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_srt_ExecutiveOfficerMember" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">one
year</ix:nonNumeric></span> minimum service period prior to vesting. Stock-based compensation expense related to awards is amortized over the
applicable service period using the straight-line method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zohZPBPNS2ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows:&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20220101__20221231_zEHr2YtfTD2g" title="Risk-free interest rate - Minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.67</ix:nonFraction></span>%
        to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20220101__20221231_zj83l5FCbyFi" title="Risk-free interest rate - Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.05</ix:nonFraction></span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20210101__20211231_z7zgsb62MYJj" title="Risk-free interest rate - Minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.79</ix:nonFraction></span>%
        to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20210101__20211231_zSZG5dwWmFo" title="Risk-free interest rate - Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.63</ix:nonFraction></span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Expected term of option</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zsSuL8lrJP0d" title="Expected term of option"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span>
        to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zXqxUtnnjALi" title="Expected term of option"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span>
        years</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zzSShwBZa0ci" title="Expected term of option"><ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span>
        to <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zPPZOPlezia2" title="Expected term of option"><ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span>
        years</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Expected stock price volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20220101__20221231_zWx2tt7XZ9ke" title="Expected stock price volatility - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">120.32</ix:nonFraction></span>%
        - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20220101__20221231_zw8PbQelsC11" title="Expected stock price volatility - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">133.22</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20210101__20211231_zTRrTh3rQWWa" title="Expected stock price volatility - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">124.37</ix:nonFraction></span>%
        to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20210101__20211231_ztMZAIvH0p67" title="Expected stock price volatility - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">137.73</ix:nonFraction></span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 64%"><span style="font-size: 10pt">Expected dividend yield</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20220101__20221231_zptWT381s0ac" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20210101__20211231_zelPGnsdwk4c" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_ziP5tLr2ywr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risk-free interest rate
is based on the yield of Daily U.S. Treasury Yield Curve Rates with terms equal to the expected term of the options as of the grant date.&#160;The
expected term of options is determined using the simplified method, as provided in an SEC Staff Accounting Bulletin,&#160;and the expected
stock price volatility is based on the Company&#8217; historical stock price volatility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation expense
relating to options granted of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQoO2M336M3e" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.9</ix:nonFraction></span>
million, of which $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEMYASB0chNh" title="General and administrative"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.9</ix:nonFraction></span>
million and $<span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_pp0n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0fuFMSWg6Be" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3</ix:nonFraction></span>.0
million, related to General and Administration and Research and Development, respectively was recognized for the year ended December 31,
2022.&#160;Stock-based compensation expense relating to options granted of $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSRCOiVD7Omh" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.9</ix:nonFraction></span>
million, of which $<span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zql36sCXS7L6" title="General and administrative"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction></span>
million and $<span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcqkGMlVgnv7" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span>
million, related to General and Administration and Research and Development, respectively was recognized for the year ended December
31, 2021.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, the
Company had approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV3X3Kgj2xLe" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.6</ix:nonFraction></span>
million of unrecognized compensation cost related to non-vested awards granted under the Plans, which the Company expects to recognize
over a weighted average period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoo7X38FIeY7" title="Unrecognized compensation cost, recognition period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.73</ix:nonNumeric></span>
years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Employee
Stock Purchase Plans</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 3, 2019, the Company&#8217;s
stockholders approved the Tonix Pharmaceuticals Holdings Corp. 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;). As a result
of adoption of the 2020 ESPP, as defined below, by the stockholders, no further grants may be made under the 2019 ESPP Plan. On May 1,
2020, the Company&#8217;s stockholders approved the Tonix Pharmaceuticals Holdings Corp. 2020 Employee Stock Purchase Plan (the &#8220;2020
ESPP&#8221;). No further grants may be made under the 2020 ESPP Plan. On May 6, 2022, the Company&#8217;s stockholders approved the Tonix
Pharmaceuticals Holdings Corp. 2022 Employee Stock Purchase Plan (the &#8220;2022 ESPP&#8221;, and together with the 2019 ESPP and the
2020 ESPP, the &#8220;ESPP Plans&#8221;)).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2022 ESPP allows eligible
employees to purchase up to&#160;an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_uShares_c20190503__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member_zuHNaliqJsC7" title="Number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2019-05-03_custom_EmployeeStockPurchasePlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">93,750</ix:nonFraction></span>&#160;shares
of the Company&#8217;s common stock. Under the 2022 ESPP, on the first day of each offering period, each eligible employee for that offering
period has the option to enroll for that offering period, which allows the eligible employees to purchase shares of the Company&#8217;s
common stock at the end of the offering period. Each offering period under the 2022 ESPP is for six months, which can be modified from
time-to-time. Subject to limitations, each participant will be permitted to purchase a number of shares determined by dividing the employee&#8217;s
accumulated payroll deductions for the offering period by the applicable purchase price, which is equal to&#160;<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20190502__20190503__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member_zbU14m199Yc7" title="Percent of fair value of common stock at grant date"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2019-05-022019-05-03_custom_EmployeeStockPurchasePlan2022Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85</ix:nonFraction></span>
percent&#160;of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. A participant
must designate in his or her enrollment package the percentage (if any) of compensation to be deducted during that offering period for
the purchase of stock under the 2022 ESPP, subject to the statutory limit under the Code. As of December 31, 2022, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member_zbGVUGmtuH09" title="Number of shares available for future grants"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_EmployeeStockPurchasePlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9</ix:nonFraction></span>
shares were available for future sales under the 2022 ESPP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;The 2022 and 2020 ESPP
are considered compensatory plans with the related compensation cost expensed over the six-month offering period. For the year ended December
31, 2022 and 2021, $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlansMember_zVMq5N5BQDj4" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_custom_EmployeeStockPurchasePlansMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,000</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlansMember_zdYaFxp6sHc" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlansMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,000</ix:nonFraction></span>,
respectively were expensed. In January 2021, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20210101__20210131__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zO9nldlnmN38" title="Employee stock purchase plan (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2021-01-012021-01-31_custom_EmployeeStockPurchasePlan2020Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,703</ix:nonFraction></span>
shares that were purchased as of December 31, 2020, under the 2020 ESPP, were issued. Accordingly, during the first quarter of 2021, approximately
$<span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c20210101__20210331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zP09K8f98sZe" title="Transfer to additional paid in capital"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-03-31_custom_EmployeeStockPurchasePlan2020Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000</ix:nonFraction></span>
of employee payroll deductions accumulated at December 31, 2020, related to acquiring such shares, was transferred from accrued expenses
to additional paid in capital. The remaining $<span id="xdx_90F_ecustom--AmountReturnToEmployee1_c20210101__20210331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_ztRDzRWV6EO3" title="ESPP withholdings returned to employees"><ix:nonFraction name="tnxp:AmountReturnToEmployee1" contextRef="From2021-01-012021-03-31_custom_EmployeeStockPurchasePlan2020Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span>
was returned to the employees. In January 2022, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20220101__20220131__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zC3r7Sdrw2N2" title="Employee stock purchase plan (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2022-01-012022-01-31_custom_EmployeeStockPurchasePlan2020Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,033</ix:nonFraction></span>
shares that were purchased as of December 31, 2021, under the 2020 ESPP, were issued. Accordingly, during the first quarter of 2022, approximately
$<span id="xdx_90B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c20220101__20220331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zmzm71UeSVqd" title="Transfer to additional paid in capital"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlan2020Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span>
of employee payroll deductions accumulated at December 31, 2021, related to acquiring such shares, was transferred from accrued expenses
to additional paid in capital. The remaining $<span id="xdx_901_ecustom--AmountReturnToEmployee1_c20220101__20220331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zcfoyQVTHzKb" title="ESPP withholdings returned to employees"><ix:nonFraction name="tnxp:AmountReturnToEmployee1" contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlan2020Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span>
was returned to the employees. As of December 31, 2022, approximately $<span id="xdx_90E_ecustom--AccumulatedEmployeePayrollDeductions_iI_pp0p0_c20221231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlansMember_zoiDGqcXI7Lb"><ix:nonFraction name="tnxp:AccumulatedEmployeePayrollDeductions" contextRef="AsOf2022-12-31_custom_EmployeeStockPurchasePlansMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,000</ix:nonFraction></span>
of employee payroll deductions have accumulated and have been recorded in accrued expenses.&#160;In January 2023, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20230101__20230131__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1acdjwTc82i" title="Employee stock purchase plan (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2023-01-012023-01-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">93,741</ix:nonFraction></span>
shares that were purchased as of December 31, 2022, under the 2022 ESPP, were issued. Accordingly, during the first quarter of 2023, approximately
$<span id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c20230101__20230331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvgE3ZgVcE2k" title="Transfer to additional paid in capital"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></span>
of employee payroll deductions accumulated at December 31, 2023, related to acquiring such shares, was transferred from accrued expenses
to additional paid in capital. The remaining $<span id="xdx_90D_ecustom--AmountReturnToEmployee1_c20230101__20230331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zujTIrYagfg3" title="ESPP withholdings returned to employees"><ix:nonFraction name="tnxp:AmountReturnToEmployee1" contextRef="From2023-01-012023-03-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></span>
was returned to the employees.</p>

</ix:nonNumeric><p id="xdx_810_zYe3ePLgaBF3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:StockWarrantsTextBlock"><p id="xdx_80C_ecustom--StockWarrantsTextBlock_zjKWOHygrJTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
18 &#8211; <span id="xdx_82D_zMDxE7PHHdh1">WARRANTS TO PURCHASE COMMON STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zj70aoJ5PEa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zPJrhweMGqxe">The
following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Expiration</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Price</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Outstanding</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zCRzvyBA0lhg" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">16.00</ix:nonFraction></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z3WDRbN4k58d" title="Number Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">779</ix:nonFraction></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 52%; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zwvsV3Q0zeg8" title="Expiration date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_Warrant1Member" format="ixt:datemonthyearen" name="tnxp:ClassOfWarrantsOrRightExpirationDate">November
        2024</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zP7p8O46Jl69" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_Warrant2Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">18.24</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zKYtXM5JYcAk" title="Number Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_Warrant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,860</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z59AAoLC2HR9" title="Expiration date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_Warrant2Member" format="ixt:datemonthyearen" name="tnxp:ClassOfWarrantsOrRightExpirationDate">February
        2025</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zUzJwgpiox7d" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_Warrant3Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1,120.00</ix:nonFraction></span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zJScLaqvFVii" title="Number Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_Warrant3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,331</ix:nonFraction></span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zgKKtWuc4mU2" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_Warrant3Member" format="ixt:datemonthyearen" name="tnxp:ClassOfWarrantsOrRightExpirationDate">December
        2023</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231_z3Ravt8OtHy6" title="Number Outstanding" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,970</ix:nonFraction></span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

</ix:nonNumeric><p id="xdx_8A1_zKAb5nBoRudc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><p id="xdx_23D_zjMBFY6HpHhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_z7fmogguEBqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS
HOLDING CORP.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zdotuY9EXS3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No warrants were exercised
during the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2021, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromFeb2020FinancingMember_zI7auKdDr2Ra" title="Number of exercised warrants"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_custom_WarrantsFromFeb2020FinancingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107</ix:nonFraction></span>
warrants from the February 2020 Financing, with an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromFeb2020FinancingMember_zACUVUYqijqe" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_WarrantsFromFeb2020FinancingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></span>,
were exercised for proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromFeb2020FinancingMember_zUN48XedUuba" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-12-31_custom_WarrantsFromFeb2020FinancingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2021, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTpnxnGDpZM7" title="Number of warrants expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember964078343" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,441</ix:nonFraction></span>
and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--Warrant1Member_zBRLV7oD9KP9" title="Number of warrants expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-12-31_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">474</ix:nonFraction></span>
warrants with a per share exercise price of $<span id="xdx_906_ecustom--ExercisePriceOfWarrantsExpired_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvNiuFlMtzk6" title="Exercise price of warrants expired (in dollars per share)"><ix:nonFraction name="tnxp:ExercisePriceOfWarrantsExpired" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember964078343" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">630.00</ix:nonFraction></span>
and $<span id="xdx_902_ecustom--ExercisePriceOfWarrantsExpired_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--Warrant1Member_zq5LKyxh6HY9" title="Exercise price of warrants expired (in dollars per share)"><ix:nonFraction name="tnxp:ExercisePriceOfWarrantsExpired" contextRef="From2021-01-012021-12-31_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">687.50</ix:nonFraction></span>,
respectively, expired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zOLPMTwxzxyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
19 &#8211; <span id="xdx_82D_znOKrZPwTda7">LEASES</span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has various operating
lease agreements, which are primarily for office space. These agreements frequently include one or more renewal options and require the
Company to pay for utilities, taxes, insurance and maintenance expense. No lease agreement imposes a restriction on the Company&#8217;s
ability to engage in financing transactions or enter into further lease agreements. At December 31, 2022, the Company has right-of-use
assets of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_dxL_c20221231_zmW3UlGEQsZ4" title="Right-of-use assets, net::XDX::715"><span style="-sec-ix-hidden: xdx2ixbrl1146">0.7
million</span></span> and a total lease liability for operating leases of $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_pn3n3_dxL_c20221231_zQAOQYVs8pS7" title="Total lease liability::XDX::760"><span style="-sec-ix-hidden: xdx2ixbrl1148">0.7
million</span></span> of which $<span id="xdx_90E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_dxL_c20221231_zqDQBdfx97E7" title="Lease liability, net of current portion::XDX::328"><span style="-sec-ix-hidden: xdx2ixbrl1150">0.3
million</span></span> is included in long-term lease liabilities and $<span id="xdx_905_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_dxL_c20221231_zSuqWCRq4M8k" title="Lease liability, current::XDX::432"><span style="-sec-ix-hidden: xdx2ixbrl1152">0.4
million</span></span> is included in current lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zEJCFisgJnFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zIwIJWsuho85">At
December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 88%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b><span style="text-decoration: underline">Year&#160;Ending&#160;December&#160;31,</span></b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zCCQaPJv0y3" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1eV_zLp5OcVo0Bvg" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 85%"><span style="font-size: 10pt">2023</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">441</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1eV_zDZtryDitfu1" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">164</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1eV_zYuUd8SsbYG3" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">159</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1eV_zxMdw3u8PkT5" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2026</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1eV_zPrq8T8ost92" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">2027</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1eV_zqeTNpUY4Efd" style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">775</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z6yd4QrARzZ" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Included interest</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zbSFKU1qEcEh" style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">760</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zOZ4gWu8uiJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, the Company entered into new operating leases and lease amendments, resulting in the Company recognizing an additional operating
lease liability of approximately $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zUsqH7eY7eD3" title="Total lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31_custom_NewLeaseArrangementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">386,000</ix:nonFraction></span>
based on the present value of the minimum rental payments. The Company also recognized a corresponding increase to ROU assets of approximately
$<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zUoVpP096WXc" title="Right-of-use assets, net"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31_custom_NewLeaseArrangementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">386,000</ix:nonFraction></span>,
which represents a non-cash investing and financing activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2021, the Company entered into lease amendments, resulting in the Company recognizing an operating lease liability of approximately
$<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20211231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zsShrMUBfFH7" title="Total lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31_custom_NewLeaseArrangementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">467,000</ix:nonFraction></span>
based on the present value of the future minimum rental payments. The Company also recognized corresponding ROU assets of approximately
$<span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zS67rRsgacx7" title="Right-of-use assets, net"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31_custom_NewLeaseArrangementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">467,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating lease expense was
$<span id="xdx_90C_eus-gaap--OperatingLeaseExpense_pp0n6_c20220101__20221231_zFxoeT3Zq08d" title="Operating lease expense"><span id="xdx_90A_eus-gaap--OperatingLeaseExpense_pp0n6_c20210101__20211231_zpUd512ddby8" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.6</ix:nonFraction></ix:nonFraction></span></span>
million for both years ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="tnxp:SummaryOfOtherInformationRelatedToLeasesTableTextBlock"><p id="xdx_890_ecustom--SummaryOfOtherInformationRelatedToLeasesTableTextBlock_zZQ884hZvyXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span id="xdx_8B7_z6iTv0Mk00qk">Other
information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Cash paid for amounts included in the
        measurement of lease liabilities:</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31,  2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31,  2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Operating cash flow from operating leases (in
        thousands)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220101__20221231_zPTNP0tOFsq6" title="Operating cash flow from operating leases"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">598</ix:nonFraction></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--OperatingLeasePayments_c20210101__20211231_zxA2Wr6ED0pj" title="Operating cash flow from operating leases"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">632</ix:nonFraction></span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Weighted Average Remaining Lease Term</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Operating leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_z3HNyxEj2II" title="Weighted average remaining lease term operating leases"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.20</ix:nonNumeric></span>
        years</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_znQeP7VQh7pi" title="Weighted average remaining lease term operating leases"><ix:nonNumeric contextRef="AsOf2021-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.71</ix:nonNumeric></span>
        years</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Weighted Average Discount Rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Operating leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20221231_zWKb6FI3X5N2" title="Weighted average discount rate operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.19</ix:nonFraction></span></span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20211231_zpE9w2mRcp3" title="Weighted average discount rate operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.34</ix:nonFraction></span></span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zn30dbCnzhv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><p id="xdx_81E_z5ZkFlQdxuDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsDisclosureTextBlock_zEYp0uEbb6u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
20 &#8211; <span id="xdx_82B_zf5jgiyywzp5">COMMITMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Contractual
agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered into
contracts with various contract research organizations with outstanding commitments aggregating approximately $<span id="xdx_905_eus-gaap--OtherCommitment_iI_pn5n6_c20221231__us-gaap--OtherCommitmentsAxis__custom--ResearchOrganizationsMember_z7pGx69zPL2j" title="Outstanding commitments"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2022-12-31_custom_ResearchOrganizationsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">58.6</ix:nonFraction></span>
million at December 31, 2022 for future work to be performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a
construction contract with outstanding commitments aggregating approximately $<span id="xdx_902_eus-gaap--OtherCommitment_iI_pn5n6_c20221231__us-gaap--OtherCommitmentsAxis__custom--ConstructionContractMember_ztsNR34Q3Sw8"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2022-12-31_custom_ConstructionContractMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2</ix:nonFraction></span>.0
million at December 31, 2022 for future work to be performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Defined
contribution plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a qualified
defined contribution plan (the &#8220;401(k) Plan&#8221;) pursuant to Section 401(k) of the Code, whereby all eligible employees may&#160;participate.
Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) Plan, subject to defined limitations. The
Company is required to make contributions to the 401(k) Plan equal to <span id="xdx_907_eus-gaap--DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_pp2p2_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_z0nrLLNDcYh3" title="Employer matching contribution"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" contextRef="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember" format="ixt:numdotdecimal" decimals="2" scale="-2" unitRef="Pure">100</ix:nonFraction></span>
percent of each participant&#8217;s pretax contributions of up to <span id="xdx_905_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pp2p2_dc_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_zm6o3kA1C7nf" title="Maximum annual contributions per employee"><ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember" format="ixt-sec:numwordsen" decimals="2" scale="-2" unitRef="Pure">six</ix:nonFraction></span>
percent of his or her eligible compensation, and the Company is also required to make a contribution equal to <span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pp2p2_dc_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_zTjULTFvkAH1" title="Maximum annual contributions per employer"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember" format="ixt-sec:numwordsen" decimals="2" scale="-2" unitRef="Pure">three</ix:nonFraction></span>
percent of each participant&#8217;s salary, on an annual basis, subject to limitations under the Code. The Company charged operations
$<span id="xdx_90D_eus-gaap--DefinedContributionPlanAdministrativeExpenses_pn5n6_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_zEkwjy1H6Hb1" title="Administrative expenses"><ix:nonFraction name="us-gaap:DefinedContributionPlanAdministrativeExpenses" contextRef="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span>
million and $<span id="xdx_900_eus-gaap--DefinedContributionPlanAdministrativeExpenses_pn5n6_c20210101__20211231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_z3isMgXWhtil" title="Administrative expenses"><ix:nonFraction name="us-gaap:DefinedContributionPlanAdministrativeExpenses" contextRef="From2021-01-012021-12-31_custom_DefinedContributionPlan401KPlanMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million for the year ended December 31, 2022, and 2021, respectively, for contributions under the 401(k) Plan.</p>

</ix:nonNumeric><p id="xdx_816_zympSW8V5KV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zK67rGSS6ckc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
21 &#8211; <span id="xdx_822_zsxHdSaWNw33">INCOME TAXES</span> &#8211; </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zjEhisVJR1K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span id="xdx_8BA_zkrsWCnn7Dhg">Components
of the net loss consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20220101__20221231_ztWF3FRkKBc5" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20211231_zwJljXzTgmm9" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_maNILz5B4_zjwSRzlxvSb8" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><span style="font-size: 10pt">Foreign</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">88,478</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">73,689</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maNILz5B4_zD5HtakXfWIb" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Domestic</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,740</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,598</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_mtNILz5B4_zWli3YAq4N52" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">110,218</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92,287</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zM55ZPdKQFB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, the foreign losses
are primarily comprised of $<span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn5n6_di_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--IE_zMk3XEm5QkTc" title="Foreign losses"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_country_IE" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">86.7</ix:nonFraction></span>
million related to the Irish operations and $<span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn5n6_di_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--BM_zw0XCZZd7wSa"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_country_BM" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">1.5</ix:nonFraction></span>
million related to the Bermudan operations of Tonix International Holding. In 2021, the foreign losses were primarily comprised
of $<span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn5n6_di_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--BM_zmMsXvvDnXfk"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2021-01-012021-12-31_us-gaap_ForeignCountryMember_country_BM" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">71.9</ix:nonFraction></span>
million related to the Bermudan operations of Tonix International Holding.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zKciEbcJCate" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zfk7VEREzlRg">A
reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate
the Company&#8217;s income tax provision is as follows:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_499_20220101__20221231_zahNZGVzxMBh" style="text-align: center">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49C_20210101__20211231_zCeZkwzAOsSl" style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Year Ended December&#160;31,</b></span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maITP_zISccJzeiwI7" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 46%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Statutory federal income tax</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">)%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span></td>
    <td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_msITP_zkI4qy92Ybmg" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.6</ix:nonFraction></span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_msITP_zPoyg7cYdzSa" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Foreign loss not subject to income tax</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange_pid_dp_uPure_msITP_zeJ7uWoD4SBb" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Attribute reduction from control change</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="tnxp:EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.0</ix:nonFraction></span></td>
    <td style="white-space: nowrap">%<span style="font-size: 10pt"></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="tnxp:EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.2</ix:nonFraction></span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_msITP_zz24AVYh3qHg" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.4</ix:nonFraction></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">%</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.2</ix:nonFraction></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtITP_zBwqkK0JoRN3" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Income Tax Provision</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><span style="font-size: 10pt">%</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><span style="font-size: 10pt">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z65NfV8SQWCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyovoei5FTde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zdnJIiIjnKH8">Deferred
tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands):</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_494_20221231_zhQ3rRxBmsW" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49F_20211231_ztCNS99boig2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsNetAbstract_iB_pn3n3_zR96kMS6Cvmf" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Deferred tax assets/(liabilities):</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGz7el_zqoraYjYLR0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%"><span style="font-size: 10pt">Net operating loss carryforward</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,642</ix:nonFraction></span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,297</ix:nonFraction></span></td>
    <td style="width: 3%">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3n3_maDTAGz7el_zAo1RF4kaHck" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Stock-based compensation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,353</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,832</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGz7el_zxFVpCJ1aaFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,997</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,285</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGz7el_maDTALNzDL0_zZVByPplpQI9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Total deferred assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,992</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,414</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzDL0_zwdP8L1COg83" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Valuation allowance</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,992</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,414</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzDL0_zoryXsKDhVnj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Net deferred tax assets</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1270">&#8212;</span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8212;</span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zSI8MIp4vITj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has incurred research
and development (&#8220;R&amp;D&#8221;) expenses, a portion of which qualifies for tax credits. The Company conducted an R&amp;D credit
study to quantify the amount of credits and has claimed an R&amp;D credit on its 2014-2017 tax returns. A portion of these R&amp;D credit
carryforwards are subject to annual limitations in their use in accordance with Internal Revenue Service Code (&#8220;IRC&#8221;) section
383. The R&amp;D credit carryforwards at December 31, 2022 have been reduced to $<span id="xdx_90C_eus-gaap--TaxCreditCarryforwardAmount_iI_pdn6_c20221231__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zBiyqVopiSZ7" title="Credit carryforwards"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2022-12-31_us-gaap_ResearchMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0</ix:nonFraction></span>.0
million to reflect IRC section 383 ownership changes through December 31, 2022 and the resulting inability to utilize a portion of the
R&amp;D credit prior to its expiration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, 2022, the
Company has $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--IE_zBr2As3oyQvi" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember_country_IE" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">165.5</ix:nonFraction>
</span>million of Ireland net operating loss (&#8220;NOL&#8221;) carryforwards that do not expire. As of December 31, 2022, the Company's
Federal NOL carryforwards of $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfHfIEDMvfCg"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction>
</span>million, which do
not expire, but their utilization is limited to <span id="xdx_908_ecustom--OperatingLossCarryforwardsLimitationsOnUsePercent_dp_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZv5YtHAjuI7" title="Utilization NOL (percent)"><ix:nonFraction name="tnxp:OperatingLossCarryforwardsLimitationsOnUsePercent" contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction>%</span> of taxable income. Additionally, the Company has New Jersey NOL carryforwards
of $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__srt--StatementGeographicalAxis__stpr--NJ_zyetk2emhH13"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_stpr_NJ" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction>
</span>million and Massachusetts NOL carryforwards of $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__srt--StatementGeographicalAxis__stpr--MA_zP3srFVf1vm9"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_stpr_MA" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction>
</span>million, which both <span id="xdx_906_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z9tvvqbEUZci" title="Operating loss carryforwards expiration"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse">expire
in 20 years</ix:nonNumeric></span>. The NOL carryforwards at December 31, 2022 have been reduced to reflect IRC section 382 ownership changes through December
31, 2022 and the resultant inability due to annual limitations, to utilize a portion of the NOL prior to its expiration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management assesses the available
positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets.
A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December
31, 2022. Such objective evidence limits the ability to consider other subjective evidence such as our projections for future growth.
As such, the Company has determined that it is not more likely than not that the deferred tax assets will be realized and accordingly,
has provided a full valuation allowance against its gross deferred tax assets. The increase in the valuation allowance for the years ended
December 31, 2022 and 2021 were $<span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20220101__20221231_zQjexi6KaKtf" title="Increase in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.5</ix:nonFraction></span>
million, and $<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20210101__20211231_zmzO8o1zst3i"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.3</ix:nonFraction></span>
million respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognizes interest
accrued related to unrecognized tax benefits and penalties as income tax expense. However, as of December 31, 2022 there are no unrecognized
tax benefits recorded. The Company is subject to taxation in the United States and various states and foreign jurisdictions. As of December
31, 2022, the Company&#8217;s tax returns remain open and subject to examination by the tax authorities for the tax years 2019 and after.</p>

</ix:nonNumeric><p id="xdx_81D_zBrhOEKkpUyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zebVu2qqZbLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
22 &#8211; <span id="xdx_829_zXhDsNlEwME9">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Since
January 1, 2023, the Company has repurchased </span><span id="xdx_90B_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pip0_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember_zAxJF3HrGrV2"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,700,269</ix:nonFraction></span><span>
of its shares of common stock outstanding under its $<span id="xdx_90D_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn5n6_c20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember_zrwdihlIrRoc"><ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="AsOf2023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.5</ix:nonFraction> </span>million
s</span>hare repurchase program at prices ranging from $<span id="xdx_90E_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember__srt--RangeAxis__srt--MinimumMember_zrTqGdx6zKVi" title="Price of shares repurchased (in dollars per share)"><ix:nonFraction name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.44</ix:nonFraction> </span>to
$<span id="xdx_900_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember__srt--RangeAxis__srt--MaximumMember_z7wuixmg6nj9"><ix:nonFraction name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.38</ix:nonFraction></span><span style="background-color: white">
per share for a gross aggregate cost of approximately $<span id="xdx_908_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn5n6_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember_zw9qmPv0oxf4" title="Value of shares repurchased"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.5</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
January 2023, the <span style="background-color: white">Board of Directors approved </span>a new share&#160;repurchase
program&#160;pursuant to which the Company may&#160;repurchase&#160;up to $<span id="xdx_903_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn5n6_c20230102__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeoFBUU0My89" title="Repurchase program amount"><ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="AsOf2023-01-02_custom_NewShareRepurchaseProgramMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.5</ix:nonFraction></span>
million in value of its outstanding common stock from time to time on the open market and in privately negotiated transactions
subject to market conditions, share price and other factors.&#160;<span style="background-color: white">Since January 1, 2023, the
Company has repurchased </span><span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pip0_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember_zECEdf3vV2xf" title="Number of shares repurchased (in shares)"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_NewShareRepurchaseProgramMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,000,000</ix:nonFraction></span> <span style="background-color: white">of
its shares of common stock outstanding under the new share repurchase program at $<span id="xdx_90A_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_pid_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember_zam0u8T1YMQl"><ix:nonFraction name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_NewShareRepurchaseProgramMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></span>
per share for a gross aggregate cost of $<span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn5n6_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember_zHus7B20ow9c"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_NewShareRepurchaseProgramMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
timing and amount of any shares</span>&#160;repurchased&#160;<span style="background-color: white">will be determined based on the Company&#8217;s
evaluation of market conditions and other factors and the</span>&#160;New Share Repurchase Program&#160;<span style="background-color: white">may
be discontinued or suspended at any time.&#160;</span>Repurchases&#160;<span style="background-color: white">will be made in accordance
with the rules and regulations promulgated by the Securities and Exchange Commission and certain other legal requirements to which the
Company may be subject.&#160;</span>Repurchases&#160;<span style="background-color: white">may be made, in part, under a Rule 10b5-1 plan,
which allows stock&#160;</span>repurchases&#160;<span style="background-color: white">when the Company might otherwise be precluded from
doing so. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Subsequent
to December 31, 2022, <span style="background-color: white">the Company regained compliance with the minimum bid price requirement for
continued listing on The Nasdaq Capital Market because the Company&#8217;s shares had a closing bid price at or above $<span id="xdx_907_ecustom--MinimumBidRequirementPerShare_iI_c20230102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGYiIz2QN2oi" title="Minimum bid price requirements NASDAQ"><ix:nonFraction name="tnxp:MinimumBidRequirementPerShare" contextRef="AsOf2023-01-02_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>
per share for a minimum of <span id="xdx_90E_ecustom--ConsecutiveBusinessDaysForMinimumBidPrice_dtD_c20230101__20230102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6i1jkwSBmo8" title="Consecutive business days for minimum bid price"><ix:nonNumeric contextRef="From2023-01-012023-01-02_us-gaap_SubsequentEventMember" format="ixt-sec:durday" name="tnxp:ConsecutiveBusinessDaysForMinimumBidPrice">10</ix:nonNumeric></span>
consecutive business days, as set forth in Nasdaq Listing Rule 5550(a)(2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
February 2, 2023, the Company entered into an asset purchase agreement </span>(the &#8220;Asset Purchase Agreement&#8221;) with Healion
Bio Inc., <span style="background-color: white">pursuant to which the Company acquired all the pre-clinical infectious disease assets
of Healion, including its portfolio of next-generation antiviral technology assets. Healion&#8217;s drug portfolio includes a class of
broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action, including TNX-3900, formerly
known as HB-121. </span>As consideration for entering into the Asset Purchase Agreement, the Company paid $<span id="xdx_909_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20230201__20230202__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--HealionBioIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z66gS0EEifMi" title="Consideration paid"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-02-012023-02-02_custom_AssetPurchaseAgreementMember_custom_HealionBioIncMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>
million to Healion. Because the Healion intellectual property was acquired prior to FDA approval, the cash consideration totaling
$<span id="xdx_903_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20230201__20230202__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--HealionBioIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv1HhJC88a9a" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-02-012023-02-02_custom_AssetPurchaseAgreementMember_custom_HealionBioIncMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>
million, is expected to be expensed as research and development costs since there is no alternative future use and the acquired
intellectual property does not constitute a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 13, 2023, the
Company announced that it exercised an option to obtain an exclusive license from Columbia for the development of a portfolio of both
fully human and murine mAbs for the treatment or prophylaxis of SARS-CoV-2 infection, including the Company&#8217;s TNX-3600 and TNX-4100
product candidates, respectively. The licensed mAbs were developed as part of a research collaboration and option agreement between the
Company and Columbia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2023, the
Company granted options to purchase an aggregate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4xieYygDOzj" title="Number of options granted (in shares)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">4,394,303</ix:nonFraction>
</span>shares of the Company&#8217;s common stock to employees with an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zo56V5eVzWG8" title="Exercise price of options granted (in dollars per share)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span>,
with a term of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZnnpm2YCgR2" title="Options term"><ix:nonNumeric contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span>, vesting <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zsMewqp61N04" title="Vesting percentage::XDX::0.3333"><span style="-sec-ix-hidden: xdx2ixbrl1316">1/3
</span></span>on the first anniversary and <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z5PUZMxXm7df" title="::XDX::0.0278"><span style="-sec-ix-hidden: xdx2ixbrl1317">1/36</span></span><sup>th
</sup>each month thereafter for 24 months. Additionally, the Company granted options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHMOmNAyB7Xb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,327,500</ix:nonFraction>
</span>shares of the Company&#8217;s common stock to certain employees with an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhjkoXv2l6o5"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.91</ix:nonFraction></span>,
with a term of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znxmrHMTDbF4"><ix:nonNumeric contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span>, vesting <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zNskKi4uIm9c" title="::XDX::0.3333"><span style="-sec-ix-hidden: xdx2ixbrl1321">1/3
</span></span>on the first anniversary and <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z5OtPNl1UTgb" title="::XDX::0.0278"><span style="-sec-ix-hidden: xdx2ixbrl1322">1/36</span></span><sup>th
</sup>each month thereafter for 24 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to December 31,
2022, the Company sold <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementWithAGPMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znFI14KGqBka" title="Number of shares issued (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-13_custom_SalesAgreementWithAGPMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">2.1</ix:nonFraction></span>
million shares of common stock under the Sales Agreement with AGP for net proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementWithAGPMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoNSnEIa5xG2" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-012023-03-13_custom_SalesAgreementWithAGPMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span>
million.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to December 31,
2022, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCcTZi3jOrr3"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">0.6</ix:nonFraction></span>
million shares of common stock under the 2022 Purchase Agreement with Lincoln Park for net proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoKIuXTVpvAb"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million.</p>

</ix:nonNumeric><p id="xdx_813_zefK6Yp9hi3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="tnxp10ka014"></span>ITEM 9 - CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="tnxp10ka015"></span>ITEM 9A &#8211;
CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s evaluation of disclosure
controls and procedures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant
to Rule 13a-15 under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management recognizes that
any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired
control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints
and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their
costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on&#160;management&#8217;s
evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are designed
at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports
that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC
rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and
chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in internal control over financial
reporting.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our
internal control over financial reporting that occurred during the quarter ended December 31, 2022 that have materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s report on internal control
over financial reporting.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting for our company. Internal control over financial reporting
is defined in Rule&#160;13a-15(f)&#160;and 15d-15(f)&#160;promulgated under the Exchange Act, as a process designed by, or under the supervision
of, a company&#8217;s principal executive and principal financial officer and effected by the our board of directors, management and other
personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pertain to the maintenance of records that, in reasonable detail, accurately
        and fairly reflect the transactions and dispositions of the assets of the company;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide reasonable assurance that transactions are recorded as necessary to
        permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
        of the company are being made in accordance with authorizations of management and directors of the company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide reasonable assurance regarding prevention or timely detection of unauthorized
        acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate. Management recognizes that any controls and procedures, no matter how well designed and
operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating
the cost-benefit relationship of possible enhancements to controls and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted an evaluation
of the effectiveness of internal control over financial reporting based on the framework in Internal Control &#8212; Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our principal executive
officer and principal financial officer conclude that, at December&#160;31, 2022, our internal control over financial reporting was effective.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report does not
include an attestation report by EisnerAmper LLP, our independent registered public accounting firm regarding internal control over financial
reporting. As a smaller reporting company, our management&#8217;s report was not subject to attestation by our registered public accounting
firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management&#8217;s report in this annual
report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="tnxp10ka016"></span>ITEM 9B &#8211;
OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="tnxp10ka017"></span>ITEM 9C &#8211;
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 94; Options: NewSection; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b><span id="tnxp10ka018"></span>PART
III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="tnxp10ka019"></span>ITEM 10 &#8211; DIRECTORS, EXECUTIVE
OFFICERS AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors elects
our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director shall
be elected for the term of one year and until his successor is elected and qualified or until his earlier resignation or removal. Our
directors and executive officers are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 28%"><span style="font-size: 10pt">NAME</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 10%"><span style="font-size: 10pt">AGE</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 60%"><span style="font-size: 10pt">CURRENT POSITION</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Seth Lederman</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">65</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">President, CEO and Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Richard Bagger</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">62</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Margaret Smith Bell</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">63</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">David Grange</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">75</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Adeoye Olukotun</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">78</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Carolyn Taylor</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">63</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">James Treco</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">67</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Lead Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Jessica Morris</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">45</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Operating Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Bradley Saenger</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer and Treasurer</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Gregory Sullivan</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">57</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Medical Officer and Secretary</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following information
with respect to the principal occupation or employment of each nominee for director, the principal business of the corporation or other
organization in which such occupation or employment is carried on, and such nominee&#8217;s business experience during the past five years,
as well as the specific experiences, qualifications, attributes and skills that have led the Board to determine that such Board members
should serve on our Board, has been furnished to the Company by the respective director nominees:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Seth Lederman, MD&#160;</i></b>became our President, Chief Executive Officer, Chairman of the Board and
a Director in October 2011. Dr. Lederman founded Tonix Pharmaceuticals, Inc., a wholly-owned subsidiary of us (&#8220;Tonix Sub&#8221;)
in 2007 and has acted as its Chairman of the Board of Directors since its inception and as President since 2010. Dr. Lederman is an inventor
on key patents and patent applications underlying our programs including: TNX-102 SL&#8217;s eutectic composition; and TNX-102 SL&#8217;s
pharmacokinetic profile and related therapeutic properties. Dr. Lederman served as an Associate Professor at Columbia University, between
1996 and 2017. As an Assistant Professor at Columbia, Dr. Lederman discovered and characterized the CD40-ligand, or CD154 and invented
therapeutic candidates to treat autoimmune diseases and transplant rejection. TNX-1500 is a mAb directed against CD154 invented by Dr.
Lederman. Dr. Lederman has been a Manager of L&amp;L Technologies LLC, or L&amp;L, since 1996. In addition, Dr. Lederman has been the
Managing Member of Seth Lederman Co, LLC since 2007 and the Managing Member of Lederman &amp; Co, LLC, or Lederman &amp; Co, since 2002,
both of which are biopharmaceutical consulting and investing companies. Dr. Lederman has also been the Managing Member of Targent Pharmaceuticals,
LLC, or Targent, since 2000, and Managing Member of Plumbline LLC since 2002. Targent was a founder of Targent Pharmaceuticals Inc. on
which Board of Directors Dr. Lederman served from inception in 2001 until the sale of its assets to Spectrum Pharmaceuticals Inc. in 2006.
Between January 2007 and November 2008, Dr. Lederman was a Managing Partner of Konanda Pharma Partners, LLC, a Director of Konanda Pharma
Fund I, LP, and a Managing Partner of Konanda General Partner, LLC, which were related private growth equity fund entities. As well, between
2007 and 2008, Dr. Lederman was Chairman of Validus Pharmaceuticals, Inc. and Fontus Pharmaceuticals, Inc., which were portfolio companies
of the Konanda private growth equity funds. Since 2011, Dr. Lederman has served as CEO and Chairman of Leder Laboratories Inc., or Leder
Labs, and Starling Pharmaceuticals Inc., or Starling, which are biopharmaceutical development companies. Dr. Lederman was the chairman
of Leder Laboratories, Ltd., a wholly-owned subsidiary of Leder Laboratories Inc., between 2013 and 2018, when the entity was dissolved.
In 2015, Dr. Lederman served as a member of the US &#8211; Japan Business Council. Between 2006 and 2011, Dr. Lederman was a director
of Research Corporation, a New York-based non-profit organization. Dr. Lederman received his BA degree in Chemistry from Princeton University
in 1979 and his MD from Columbia University in 1983. Dr. Lederman&#8217;s significant experience with our patent portfolio and his experience
as an entrepreneur, seed capital investor, fund manager, and director of start-up biopharmaceutical companies were instrumental in his
selection as a member of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Richard Bagger </i></b><span style="font: normal 10pt Times New Roman, Times, Serif">became
a Director in June 2020. Mr. Bagger has been a Partner and Executive Director of Christie 55 Solutions, LLC, a New Jersey based consulting
firm, since January 2020. Mr. Bagger has also been an Adjunct Faculty member at the Rutgers University Eagleton Institute since 2018.
From 2012 through 2019, Mr. Bagger was Executive Vice President of Corporate Affairs and Market Access for Celgene Corporation (NASDAQ:
CELG), a global biopharmaceutical company, as well as a member of its Executive Committee. From 1993 to 2010, Mr. Bagger held roles of
increasing responsibility with Pfizer Inc. (NYSE: PFE), a global pharmaceutical company, and served as Senior Vice President, Worldwide
Public Affairs and Policy, from 2006 to 2009. Prior to joining Pfizer, Mr. Bagger was Assistant General Counsel of Blue Cross and Blue
Shield of New Jersey, a health insurer, and practiced law with the law firm of McCarter &amp; English. Mr. Bagger served as Board Chair
of the National Pharmaceutical Council for 2019 and is a member of the Board of Directors of the U.S. Chamber of Commerce. He is also
on the advisory board for the Lerner Center for the Study of Pharmaceutical Management Issues at Rutgers University Business School.
Mr. Bagger received an A.B. degree from Princeton University&#8217;s School of Public and International Affairs and a J.D. degree from
Rutgers University Law School. Mr. Bagger&#8217;s extensive healthcare and public policy experience were instrumental in his selection
as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Margaret Smith Bell</i></b>
became a Director in September 2017. Ms. Bell has been retired for the last ten years. Previously, Ms. Bell was a Vice President at Standard
Life Investments where she was a portfolio manager and health care equity analyst. Ms. Bell was also a Managing Director at Putnam Investments,
and served as a senior health care analyst and a portfolio manager of the Putnam Health Sciences Trust. Ms. Bell was an analyst and vice
president at State Street Research and a research analyst at Alex. Brown &amp; Sons, Inc. Ms. Bell is a past member of the Board of Overseers
at Beth Israel Deaconess Medical Center. Ms. Bell holds a B.A. from Wesleyan University and an M.B.A. from the Wharton School at the
University of Pennsylvania. Ms. Bell&#8217;s extensive healthcare and investment banking experience were instrumental in her selection
as a member of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Major General David Grange
(U.S. Army retired)</i></b>&#160;became a director in February 2018. MG Grange has been President and founder of Osprey Global Solutions,
LLC (&#8220;OGS&#8221;), a Service Disabled Veterans Organization, since 2011. MG Grange was Chief Executive Officer of Pharm-Olam International,
Ltd. (&#8220;Pharm-Olam&#8221;), a contract research organization, from April 2017 to October 2019. Prior to founding OGS, MG Grange
was a member of the Board of Pharmaceutical Product Development, Inc. (Nasdaq: PPDI), a contract research organization, from 2003 to
2009, and Chief Executive Officer from 2009 to 2011.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 95; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to PPDI he served
in the McCormick Tribune Foundation for 10 years most recently as Chief Executive Officer and President, where he also oversaw the
support of Veteran Programs. MG Grange served 30 years in the U.S. Army as a Ranger, Green Beret, Aviator, Infantryman and a member
of special operating units. At the Pentagon, he was Director of Army Current Operations, Readiness, and Mobilization. MG Grange
commanded the Ranger Regiment and the First Infantry Division (the Big Red One). MG Grange holds a master&#8217;s degree in Public
Service from Western Kentucky University. MG Grange&#8217;s extensive experience in the pharmaceutical industry and service with the
U.S. military was instrumental in his selection as a member of our Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Adeoye Olukotun, MD&#160;</i></b>became
a Director in September 2018. Dr. Olukotun is a board member of Arrowhead Pharmaceuticals. Dr Olukotun is a member of management of Genesis
Unicorn Corporation, a special acquisition company recently listed on Nasdaq (GENQU). Dr. Olukotun has been the Chief Executive Officer
of CR Strategies, LLC, a medical products consulting company, since 2000, and was the Chief Executive Officer of EpiGen Pharmaceuticals,
Inc., a pharmaceutical company, from 2014 to January of 2018. Dr. Olukotun served as Vice Chairman of CardoVax, Inc., a pharmaceutical
company, from 2012 to 2016, and as its Chief Executive Officer from 2006 to 2012. He is also co-founder of VIA Pharmaceuticals, Inc.,
a pharmaceutical company, and served as the company&#8217;s Chief Medical Officer from 2004 to 2008. Dr. Olukotun&#8217;s extensive medical
background and experience in the pharmaceutical industry was instrumental in his selection as a member of our Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Carolyn Taylor </i></b>became
a Director in July 2021. Ms. Taylor was general counsel of Strike Protocols Inc., a financial technology company, from 2019 to 2020, and
held positions of varying responsibility, including partner, and most recently, of counsel, at the law firm of Covington &amp; Burling
LLP from 1989 to 2000 and 2004 to 2015. From 2000 to 2003, Ms. Taylor served as Executive Vice President and General Counsel of Longitude,
Inc., a financial services company. Ms. Taylor graduated from Columbia Law School and earned a B.A. from Brown University. Ms. Taylor&#8217;s
broad transactional experience was instrumental in her selection as a member of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>James Treco&#160;</i></b>became
a director in February 2019 and has been our Lead Director since March 2020. Mr. Treco has been a Managing Partner at First Chicago Advisors,
Inc., a boutique financial advisory firm where he advises executives and boards of directors of a wide range of companies, from global,
large-cap companies to emerging companies, from 2009 to 2012 and from 2014 to the present. From 2012 to 2013 Mr. Treco was an investment
banker with Gleacher &amp; Company, a company that previously operated an investment banking business, providing corporate and institutional
clients with strategic and financial advisory services. Mr. Treco held various positions of increasing responsibility at Salomon Brothers/Citigroup
from 1984 to 2008, where he used his extensive experience in the global capital markets to advise a wide range of clients. Mr. Treco holds
a B.A. from Yale University and an M.B.A. from the Stanford University Graduate School of Business.&#160;Mr. Treco&#8217;s extensive healthcare
and investment banking experience were instrumental in his selection as a member of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Jessica Morris&#160;</i></b>is
our Chief Operating Officer and has worked for the Company since April 2013, first as a consultant (April 2013 &#8211; September 2013),
then as SVP of Finance (September 2013 &#8211; October 2015), followed by Chief Administrative Officer (October 2015 &#8211; January 2016),
Acting Chief Financial Officer (January 2016 &#8211; February 2016), and Executive Vice President, Operations (February 2016 &#8211; January
2018). Prior to joining the Company, Ms. Morris was a Vice President in investment management at Zhong Rong Group. Previously, Ms. Morris
was a Senior Associate in the Sponsor Finance Group at American Capital, a Vice President of the mezzanine debt fund at Calvert Street
Capital Partners, an Associate in the commercial finance department of Silicon Valley Bank, and a Financial Analyst in the investment
banking group at Deutsche Bank. Ms. Morris earned a B.S. in Commerce and a B.A. in Music from the University of Virginia, where she was
an Echols Scholar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Bradley Saenger, CPA</i></b>&#160;became
our Chief Financial Officer in February 2016. Mr. Saenger has worked for us since May 2014, as the Director of Accounting (May 2014 &#8211;
December 2015) and VP of Accounting (January 2016 &#8211; February 2016). Between June 2013 and March 2014, Mr. Saenger worked for Shire
Pharmaceuticals as a consultant in the financial analyst research and development group. Since November 2015, Mr. Saenger has been a director
of Tonix Pharma Holdings Limited. Between February 2013 and May 2013, Mr. Saenger worked for Stewart Health Care System as a financial
consultant. Between October 2011 and December 2012, Mr. Saenger was an Associate Director of Accounting at Vertex Pharmaceuticals, Inc.
Between January 2005 and September 2011, Mr. Saenger worked for Alere Inc., as a Manager of Corporate Accounting and Consolidations (2007
&#8211; 2011) and Manager of Financial Reporting (2005 &#8211; 2006). Mr. Saenger also worked for PricewaterhouseCoopers LLP, Shifren
Hirsowitz, public accountants and auditors in Johannesburg, South Africa, Investec Bank in Johannesburg, South Africa and Norman Sifris
and Company, public accountants and auditors in Johannesburg, South Africa. Mr. Saenger received his Bachelor&#8217;s and Honors&#8217;
degrees in Accounting Science from the University of South Africa. Mr. Saenger is a Chartered Accountant in South Africa and a Certified
Public Accountant in the Commonwealth of Massachusetts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Gregory Sullivan, MD&#160;</i></b>became
our Chief Medical Officer on June 3, 2014 and our Secretary in March 2017. Prior to becoming our Chief Medical Officer, he served on our
Scientific Advisory Board since October 2010, and had also provided&#160;<i>ad hoc&#160;</i>consulting services. Previously, Dr. Sullivan
had been a member of the faculty of Columbia University since July 1999, where he served as an Assistant Professor of Psychiatry in the
Department of Psychiatry at Columbia University Medical Center (CUMC) until June 2014. Between June 1997 and August 2014, Dr. Sullivan
maintained a part-time psychiatry practice. He served as a Research Scientist at the New York State Psychiatric Institute (NYSPI) from
December 2006 to June 2014. He also served as a member of the Institutional Review Board of the NYSPI from January 2009 to June 2014.
As Principal Investigator and Co-Investigator on several human studies of PTSD, Dr. Sullivan has administered the recruitment, biological
assessments, treatment, and safety of participants with PTSD in clinical trials of the disorder. He has published more than 50 articles
and chapters on research topics ranging from stress and anxiety disorders to abnormal serotonin receptor expression in depression, PTSD
and panic disorder. He is a recipient of grants from the National Institute of Mental Health (NIMH), the Anxiety Disorders Association
of America, NARSAD, the Dana Foundation, and the American Foundation for Suicide Prevention. Dr. Sullivan received a BA in Biology from
the University of California, Berkeley, and received his MD from the College of Physicians &amp; Surgeons at Columbia University. He completed
his residency training in psychiatry at CUMC, and then a two-year NIMH-sponsored research fellowship in anxiety and affective disorders
before joining the faculty at Columbia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors serve until the
next annual meeting of shareholders or until their successors are elected and qualified. Officers serve at the discretion of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 96; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has determined that
(i) Seth Lederman has a relationship which, in the opinion of the Board, would interfere with the exercise of independent judgment in
carrying out the responsibilities of a director and is not an &#8220;independent director&#8221; as defined in the Marketplace Rules of
The NASDAQ Stock Market and (ii) Richard Bagger, Margaret Smith Bell, David Grange, Adeoye Olukotun, Carolyn Taylor and James Treco are
each an independent director as defined in the Marketplace Rules of The NASDAQ Stock Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Leadership Structure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our CEO also serves as the
chairman of the Board. An&#160;independent director serves as the Board&#8217;s lead director. This structure allows one person to speak
for and lead&#160;both the Company and the Board, while also providing for effective&#160;independent board oversight through an independent
lead director.&#160;Having Dr. Lederman, our CEO, serve as Chairman creates clear and unambiguous authority, which is essential to effective
management. Our Board and management can respond more effectively to a clearer line of authority. By designating our CEO as its Chairman,
our Board also sends as an important signal to our employees and shareholders about who is accountable. Further, since Dr. Lederman is
the founder of our Company and is an inventor on key patents and patent applications underlying our programs, we believe that Dr. Lederman
is best-positioned to set our Board&#8217;s agenda and provide leadership.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established the position
of lead director, which is filled by Mr. Treco. The lead director has the following responsibilities, as detailed in the Lead Director
charter, adopted by the Board (and also performs any other functions the Board may request):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Board leadership</b>&#160;&#8212; provides leadership to the Board in&#160;any
        situation where the chairman&#8217;s role may be, or may be&#160;perceived to be, in conflict, and also chairs meetings when the&#160;chairman
        is absent;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Leadership of independent director meetings</b>&#160;&#8212; leads&#160;independent
        director meetings, which take place without any management directors or Tonix employees present;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Additional meetings</b>&#160;&#8212; calls additional independent&#160;director
        meetings as needed;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Chairman-independent director liaison</b>&#160;&#8212; regularly meets&#160;with
        the chairman and serves as liaison between the&#160;chairman and the independent directors;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Stockholder communications</b>&#160;&#8212; makes himself available for&#160;direct
        communication with our stockholders;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Board agenda, schedule &amp; information</b>&#160;&#8212; works with the
        chairman regarding meeting agendas, meeting schedules and information sent to directors for&#160;Board meetings, including the quality,
        quantity, appropriateness and timeliness of such information; and</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Advisors and consultants</b>&#160;&#8212; recommends to the Board the retention
        of outside advisors and consultants who report directly to the Board on Board-wide issues.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Role in Risk Oversight</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Risk is an integral part of
the Board and Board committee deliberations throughout the year. While the Board has the ultimate oversight responsibility for the risk
management process, various committees of the Board also have responsibility for risk management. In particular, the Audit Committee focuses
on financial risk, including internal controls, and receives financial risk assessment reports from management. Risks related to the compensation
programs are reviewed by the Compensation Committee. The Board is advised by these committees of significant risks and management&#8217;s
response through periodic updates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stockholder Communications with the Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s stockholders
may communicate with the Board, including non-executive directors or officers, by sending written communications addressed to such person
or persons in care of Tonix Pharmaceuticals Holding Corp., Attention: Secretary, 26 Main Street, Suite 101, Chatham, New Jersey 07928.
All communications will be compiled by the Secretary and submitted to the addressee. If the Board modifies this process, the revised process
will be posted on the Company&#8217;s website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Meetings and Committees of the Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal year ended
December 31, 2022, the Board held 10 meetings, the Audit Committee held eight meetings, the Compensation Committee held seven meetings
and the Nominating and Corporate Governance Committee held four meetings. The Board and Board committees also approved certain actions
by unanimous written consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Committees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has standing Audit,
Compensation, and Nominating and Corporate Governance Committees. Information concerning the membership and function of each committee
is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Board&#160;Committee&#160;Membership</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 51%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Audit</b></span> <span style="font-size: 10pt"><b>Committee</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Compensation</b></span>
        <span style="font-size: 10pt"><b>Committee&#160;</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Nominating&#160;and </b></span>
        <span style="font-size: 10pt"><b>Corporate&#160;</b></span> <span style="font-size: 10pt"><b>Governance Committee</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Richard Bagger </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">**</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Margaret Smith Bell </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">**</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">David Grange</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;*</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Adeoye Olukotun</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;*</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Carolyn Taylor</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;*</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">James Treco</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">**</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"></p>

<!-- Field: Page; Sequence: 97; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Member of Committee</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chairman of Committee</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit Committee
consists of James Treco, Chair of the Committee, Richard Bagger and Margaret Smith Bell. Our Board has determined each of the
members are &#8220;independent&#8221; as that term is defined under applicable SEC rules and under the current listing standards of
the NASDAQ Stock Market. Mr. Treco is our audit committee financial expert.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit Committee&#8217;s
responsibilities include: (i) reviewing the independence, qualifications, services, fees, and performance of the independent auditors,
(ii) appointing, replacing and discharging the independent auditor, (iii) pre-approving the professional services provided by the independent
auditor, (iv) reviewing the scope of the annual audit and reports and recommendations submitted by the independent auditor, and (v) reviewing
our financial reporting and accounting policies, including any significant changes, with management and the independent auditor. The Audit
Committee reviewed and discussed with management the Company&#8217;s audited financial statements for the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Compensation Committee consists of Margaret Smith Bell, Chair of the
Committee, David Grange, Adeoye Olukotun and Carolyn Taylor. Our Board has determined that all of the members are &#8220;independent&#8221;
under the current listing standards of the NASDAQ Stock Market. Our Board has adopted a written charter setting forth the authority and
responsibilities of the Compensation Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Compensation Committee
has responsibility for, among other things, evaluating and making decisions regarding the compensation of our executive officers, assuring
that the executive officers are compensated effectively in a manner consistent with our stated compensation strategy, producing an annual
report on executive compensation in accordance with the rules and regulations promulgated by the SEC and periodically evaluating and administering
the terms and administration of our incentive plans and benefit programs. In addition, our Compensation Committee reviews and makes recommendations
to the Board regarding incentive compensation plans that require shareholder approval, director compensation and the related executive compensation information for inclusion in the Company&#8217;s
Annual Report on Form 10-K and proxy statement, and employment and severance agreements relating to the chief executive officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nominating and Corporate Governance Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Nominating and Corporate Governance Committee consists of Richard Bagger,
Chair of the Committee, David Grange and James Treco. The Board has determined that all of the members are &#8220;independent&#8221; under
the current listing standards of the NASDAQ Stock Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Nominating and Corporate
Governance Committee has responsibility for assisting the Board in, among other things, effecting the organization, membership and function
of the Board and its committees. The Nominating and Corporate Governance Committee identifies and evaluates the qualifications of all
candidates for nomination for election as directors, and seeks director nominees that complement and enhance the effectiveness of the
existing Board to ensure that its members have varied and relevant backgrounds, skills, knowledge, perspectives and experiences. Our Board
currently includes two female directors and one director who contributes racial/ethnic diversity, and one who identifies as LGBTQ+. In addition, the Nominating and Corporate
Governance Committee is responsible for developing, recommending and evaluating corporate governance standards and a code of business
conduct and ethics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Nomination of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As provided in its charter
and our Company&#8217;s corporate governance principles, the Nominating and Corporate Governance Committee is responsible for identifying
individuals qualified to become directors. The Nominating and Corporate Governance Committee seeks to identify director candidates based
on input provided by a number of sources, including (1) the Nominating and Corporate Governance Committee members, (2) our other directors,
(3) our shareholders, (4) our Chief Executive Officer or Chairman, and (5) third parties such as professional search firms. In evaluating
potential candidates for director, the Nominating and Corporate Governance Committee considers the entirety of each candidate&#8217;s
credentials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Qualifications for consideration
as a director nominee may vary according to the particular areas of expertise being sought as a complement to the existing composition
of the Board. However, at a minimum, candidates for director must possess:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">high personal and professional ethics and integrity;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ability to exercise sound judgment;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ability to make independent analytical inquiries;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a willingness and ability to devote adequate time and resources to diligently
        perform Board and committee duties; and</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the appropriate and relevant business experience and acumen.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to these minimum
qualifications, the Nominating and Corporate Governance Committee also takes into account when considering whether to nominate a potential
director candidate the following factors:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether the person possesses specific industry expertise and familiarity with
        general issues affecting our business;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether the person&#8217;s nomination and election would enable the Board to
        have a member that qualifies as an &#8220;audit committee financial expert&#8221; as such term is defined by the SEC in Item 401 of Regulation
        S-K;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether the person would qualify as an &#8220;independent&#8221; director under
        the listing standards of the Nasdaq Stock Market;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 98; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the importance of continuity of the existing composition of the Board to provide
        long term stability and experienced oversight; and</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the importance of diversified Board membership, in terms of both the individuals
        involved and their various experiences and areas of expertise.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Nominating and Corporate
Governance Committee will consider director candidates recommended by shareholders provided such recommendations are submitted in accordance
with the procedures set forth below. In order to provide for an orderly and informed review and selection process for director candidates,
the Board has determined that shareholders who wish to recommend director candidates for consideration by the Nominating and Corporate
Governance Committee must comply with the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The recommendation must be made in writing to the Corporate Secretary at Tonix
        Pharmaceuticals Holding Corp.;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The recommendation must include the candidate&#8217;s name, home and business
        contact information, detailed biographical data and qualifications, information regarding any relationships between the candidate and
        the Company within the last three years and evidence of the recommending person&#8217;s ownership of the Company&#8217;s common stock;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The recommendation shall also contain a statement from the recommending shareholder
        in support of the candidate; professional references, particularly within the context of those relevant to board membership, including
        issues of character, judgment, diversity, age, independence, expertise, corporate experience, length of service, other commitments and
        the like; and personal references; and</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A statement from the shareholder nominee indicating that such nominee wants
        to serve on the Board and could be considered &#8220;independent&#8221; under the Rules and Regulations of the Nasdaq Stock Market and
        the SEC, as in effect at that time.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All candidates submitted by
shareholders will be evaluated by the Nominating and Corporate Governance Committee according to the criteria discussed above and in the
same manner as all other director candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Code of Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a Code of
Business Conduct and Ethics that applies to all of our directors, officers and employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Involvement in Certain Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as disclosed below,
our directors and executive officers have not been involved in any of the following events during the past ten years:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any bankruptcy petition filed by or against such person or any business of which
        such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any conviction in a criminal proceeding or being subject to a pending criminal
        proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">being subject to any order, judgment, or decree, not subsequently reversed,
        suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his
        involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities
        activities;&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">being found by a court of competent jurisdiction in a civil action, the Securities
        and Exchange Commission or the Commodity Futures Trading Commission to have violated a Federal or state securities or commodities law,
        and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">being subject of, or a party to, any Federal or state judicial or administrative
        order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or
        state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or
        any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">being subject of or party to any sanction or order, not subsequently reversed,
        suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization
        that has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="tnxp10ka020"></span>ITEM 11 - EXECUTIVE COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Compensation Philosophy&#160;and Practices</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the performance
of our executive officers significantly impacts our ability to achieve our corporate goals. We, therefore, place considerable importance
on the design and administration of our executive officer compensation program. This program is intended to enhance stockholder value
by attracting, motivating and retaining qualified individuals to perform at the highest levels and to contribute to our growth and success.
Our executive officer compensation program is designed to provide compensation opportunities that are tied to individual and corporate
performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation packages
are also designed to be competitive in our industry. The Compensation Committee from time-to-time consults with compensation consultants,
legal counsel and other advisors in designing our compensation program, including in evaluating the competitiveness of individual compensation
packages and in relation to our corporate goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 99; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our overall compensation philosophy
has been to pay our executive officers an annual base salary and to provide opportunities, through cash and equity incentives, to provide
higher compensation if certain key performance goals are satisfied. We believe that many of our key practices and programs demonstrate
good governance. The main principles of our fiscal year 2022 compensation strategy included the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt"><i>An emphasis on pay for performance</i>. A significant portion
        of our executive officers&#8217; total compensation is variable and at risk and tied directly to measurable performance, including pre-specified
        corporate, strategic or developmental goals, which aligns the interests of our executives with those of our stockholders;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt"><i>Performance results are linked to Company and individual performance</i>.
        &#160;When looking at performance over the year, we equally weigh individual performance as well as that of the Company as a whole.&#160;&#160;Target
        annual compensation is positioned to allow for above-median compensation to be earned through an executive officer&#8217;s and the Company&#8217;s
        extraordinary performance;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt"><i>Equity as a key component to align the interests of our executives
        with those of our stockholders.</i>&#160;Our Compensation Committee believes that keeping executives interests aligned with those of our
        stockholders is critical to driving toward achievement of long-term goals of both our stockholders and the Company. Accordingly, a significant
        portion of our executives&#8217; compensation are stock based, including stock options that are exercisable at a percentage above market
        value at the time of grant; and </span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt"><i>Peer group positioning</i>. &#160;While the Compensation Committee
        considers the level of compensation paid by the companies in our peer group as a reference point that provides a framework for its compensation
        decisions, in order to maintain competitiveness and flexibility, the Compensation Committee does not target compensation at a particular
        level relative to the peer group; nor does the Compensation Committee employ a formal benchmarking strategy or rely upon specific peer&#8211;derived
        targets.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, we also continued
practices that demonstrate good governance and careful stewardship of corporate assets, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt"><i>Limited personal benefits</i>. Our executive officers are eligible
        for the same benefits as our non-executive salaried employees, and they do not receive any additional perquisites.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt"><i>No retirement benefits</i>. We do not provide our executive officers
        with a traditional retirement plan, or with any supplemental deferred compensation or retirement benefits.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt"><i>No tax gross-ups</i>. We do not provide our executive officers
        with any tax gross-ups.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt"><i>No single-trigger cash change in control benefits</i>. We do
        not provide cash benefits to, or accelerate the vesting of unvested equity grants issued to, our executives upon a change in control,
        absent an actual termination of employment.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At our annual meeting in May
2022, we conducted our tri-annual advisory vote on executive compensation, commonly referred to as a &#8220;say-on-pay&#8221; vote. At
that time, a majority of the votes affirmatively cast on the advisory say-on-pay proposal were voted in favor of the compensation of our
named executive officers. The Compensation Committee understood this level of approval to indicate strong stockholder support for our
executive compensation policies and programs generally, and as a result, our Compensation Committee made no fundamental changes to our
executive compensation programs. We will hold our next say-on-pay vote at the 2025 annual meeting. Our Compensation Committee and our
Board will consider shareholder feedback through the say-on-pay vote and remains committed to engaging with shareholders and are open
to feedback from shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
certain summary information concerning compensation awarded to, earned by or paid to our Chief Executive Officer, and the two next most
highly paid executive officers for fiscal years 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Name&#160;&amp;&#160;Principal&#160;</b></span> <span style="font-size: 10pt"><b>Position</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Salary&#160;</b></span>
        <span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Bonus&#160;</b></span> <span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Stock&#160;</b></span> <span style="font-size: 10pt"><b>Awards&#160;</b></span>
        <span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Option&#160;</b></span>
        <span style="font-size: 10pt"><b>Awards&#160;</b></span> <span style="font-size: 10pt"><b>($)&#160;<sup>(1)</sup></b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Non-Equity&#160;</b></span>
        <span style="font-size: 10pt"><b>Incentive&#160;Plan&#160;</b></span> <span style="font-size: 10pt"><b>Compensation&#160;</b></span>
        <span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Non-Qualified&#160;</b></span>
        <span style="font-size: 10pt"><b>Deferred&#160;</b></span> <span style="font-size: 10pt"><b>Compensation&#160;</b></span>
        <span style="font-size: 10pt"><b>Earnings&#160;($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>All&#160;Other&#160;</b></span>
        <span style="font-size: 10pt"><b>Compensation&#160;</b></span> <span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span> <span style="font-size: 10pt"><b>($)</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%"><span style="font-size: 10pt">Seth&#160;Lederman</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 3%; text-align: right"><span style="font-size: 10pt">2022</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">675,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">355,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">3,550,167</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">4,580,167</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Chief&#160;Executive&#160;Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">675,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">506,250</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">6,527,139</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7,708,389</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Jessica Morris</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2022</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">455,175</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">155,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">781,037</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,391,212</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Chief&#160;Operations Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">425,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">170,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,174,885</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,769,885</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Bradley Saenger</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2022</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">445,400</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">152,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">639,030</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,236,430</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Chief&#160;Financial Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">425,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">170,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,174,885</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,769,885</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Gregory Sullivan</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2022</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">461,120</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">130,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">887,541</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,478,661</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Chief&#160;Medical Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">440,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">176,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,631,785</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,247,785</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 1%"><span style="font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="width: 99%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Represents the aggregate grant date fair value
        of options granted in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic
        718, &#8220;Stock Compensation.&#8221; For the relevant assumptions used in determining these amounts, refer to Note 14 to our audited
        financial statements.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 100; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Grants of Plan-Based Awards in Fiscal 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides information with regard
to each grant of plan-based award made to a named executive officer under any plan during the fiscal year ended December 31, 2022.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: white">
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Grant&#160;Date</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>All&#160;Other&#160;Option&#160;Awards:&#160;</b></span>
        <span style="font-size: 10pt"><b>Number&#160;of&#160;Securities&#160;</b></span> <span style="font-size: 10pt"><b>Underlying&#160;Options&#160;(#)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Exercise&#160;or</b></span>
        <span style="font-size: 10pt"><b>Base&#160;Price&#160;of</b></span> <span style="font-size: 10pt"><b>Option&#160;Awards&#160;($/Share)</b></span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Grant&#160;Date&#160;Fair&#160;Value&#160;of&#160;</b></span>
        <span style="font-size: 10pt"><b>Stock&#160;and&#160;Option&#160;Awards</b></span> <span style="font-size: 10pt"><b>($)&#160;<sup>(1)</sup></b></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2"><span style="font-size: 10pt">Seth Lederman</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">156,250</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6.62</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">931,630</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">156,250</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13.24</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">898,172</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">156,250</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">19.85</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">870,904</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">156,250</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">26.47</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">849,461</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom"><span style="font-size: 10pt">Bradley Saenger</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">28,125</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6.62</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">167,693</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">28,125</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13.24</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">161,671</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">28,125</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">19.85</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">156,763</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">28,125</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">26.47</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">152,903</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom"><span style="font-size: 10pt">Jessica Morris</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">34,375</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6.62</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">204,959</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">34,375</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13.24</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">197,598</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">34,375</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">19.85</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">191,599</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">34,375</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">26.47</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">186,882</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom"><span style="font-size: 10pt">Gregory Sullivan</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39,063</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6.62</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">232,907</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39,063</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13.24</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">224,543</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39,063</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">19.85</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">217,726</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39,063</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">26.47</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">212,365</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-bottom: 2pt"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td colspan="16" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-bottom: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td colspan="17" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the aggregate
        grant date fair value of options granted in accordance with FASB ASC Topic 718.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-bottom: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td colspan="17"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents an exercise price at a 200% premium
        of the closing price of the Company&#8217;s common stock on the grant date.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-bottom: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td colspan="17"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents an exercise price at a 300% premium
        of the closing price of the Company&#8217;s common stock on the grant date.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-bottom: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td colspan="17"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents an exercise price at a 400% premium
        of the closing price of the Company&#8217;s common stock on the grant date.</span></td></tr>
  <tr style="background-color: white">
    <td style="width: 3%; padding-bottom: 2pt"><span style="font-size: 1pt"><sup>&#160;</sup></span></td>
    <td style="width: 36%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 12%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 12%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 12%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-size: 1pt"><sup>&#160;</sup></span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 12%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 1pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Outstanding Equity Awards at December 31, 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
information regarding outstanding equity awards held by our named executive officers as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Number&#160;of&#160;</b></span>
        <span style="font-size: 10pt"><b>Securities&#160;</b></span> <span style="font-size: 10pt"><b>underlying&#160;</b></span>
        <span style="font-size: 10pt"><b>Unexercised&#160;</b></span> <span style="font-size: 10pt"><b>Options&#160;(#)&#160;</b></span>
        <span style="font-size: 10pt"><b>Exercisable</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Number&#160;of&#160;</b></span>
        <span style="font-size: 10pt"><b>Securities&#160;</b></span> <span style="font-size: 10pt"><b>underlying&#160;</b></span>
        <span style="font-size: 10pt"><b>Unexercised&#160;</b></span> <span style="font-size: 10pt"><b>Options&#160;(#)&#160;</b></span>
        <span style="font-size: 10pt"><b>Unexercisable</b></span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Option&#160;</b></span> <span style="font-size: 10pt"><b>Exercise&#160;</b></span>
        <span style="font-size: 10pt"><b>Price&#160;($/Sh)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Option</b></span> <span style="font-size: 10pt"><b>Expiration</b></span>
        <span style="font-size: 10pt"><b>Date</b></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 31%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 14%; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 16%; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; width: 2%; padding-bottom: 2pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 13%; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 13%; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Seth Lederman</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">326,400.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/12/2023</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">508,160.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/11/2024</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">315,840.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6/17/2024</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">213,760.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10/29/2024</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">190,400.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2025</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">190,400.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2025</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">160,960.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/9/2026</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">160,960.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/9/2026</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">17,600.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3/1/2027</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10,880.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/13/2028</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13,600.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/13/2028</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">73</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">604.80</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/26/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">73</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">755.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/26/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">406</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">656.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/6/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">406</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">819.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/6/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3,549</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">201</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">12.80</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3,549</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">201</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">16.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">53,827</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">8,673</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">24.64</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/4/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">53,827</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">8,673</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30.72</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/4/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">57,295</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">36,455</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39.04</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/23/2031</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">57,295</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">36,455</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">48.96</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/23/2031</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">156,250</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.62</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">156,250</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13.24</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">156,250</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19.85</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">156,250</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;26.47</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 101; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 31%"><span style="font-size: 10pt">Jessica Morris</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; width: 14%"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; width: 16%"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt; width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right; width: 13%"><span style="font-size: 10pt">508,160.00</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; width: 13%"><span style="font-size: 10pt">2/11/2024</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">315,840.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6/17/2024</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">213,760.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10/29/2024</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">190,400.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2025</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">160,960.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/9/2026</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">160,960.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/9/2026</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">17,600.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3/1/2027</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10,880.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/13/2028</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13,600.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/13/2028</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">17</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">604.80</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/26/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">17</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">755.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/26/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">91</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">656.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/6/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">91</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">819.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/6/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">712</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">38</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">12.80</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">712</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">38</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">16.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">9,688</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,562</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">24.64</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/4/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">9,687</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,563</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30.72</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/4/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10,315</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6,560</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39.04</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/23/2031</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10,315</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6,560</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">48.96</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/23/2031</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">34,375</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.62</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">34,375</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13.24</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">34,375</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19.85</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">34,375</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;26.47</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Bradley Saenger</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">315,840.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6/17/2024</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">213,760.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10/29/2024</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">190,400.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2025</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">160,960.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/9/2026</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">77,440.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/27/2026</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">77,440.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/27/2026</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">17,600.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3/1/2027</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10,880.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/13/2028</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13,600.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/13/2028</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">17</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">604.80</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/26/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">17</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">755.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/26/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">91</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">656.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/6/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">91</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">819.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/6/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">712</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">38</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">12.80</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">712</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">38</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">16.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">9,688</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,562</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">24.64</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/4/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">9,687</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,563</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30.72</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/4/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10,315</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6,560</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39.04</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/23/2031</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10,315</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6,560</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">48.96</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/23/2031</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">28,125</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.62</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">28,125</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13.24</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">28,125</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19.85</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">28,125</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;26.47</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Gregory Sullivan</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">315,840.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6/17/2024</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">213,760.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10/29/2024</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">190,400.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2025</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">160,960.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/9/2026</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">160,960.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/9/2026</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: top; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">17,600.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3/1/2027</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">19</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10,880.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/13/2028</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">19</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13,600.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/13/2028</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">25</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">604.80</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/26/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">25</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">755.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/26/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">136</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">656.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/6/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">136</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">819.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/6/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,155</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">64</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">12.80</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,154</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">65</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">16.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/25/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13,464</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2,161</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">24.64</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/4/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13,464</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2,161</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30.72</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5/4/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">14,328</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">9,110</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39.04</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/23/2031</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">14,328</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">9,110</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">48.96</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/23/2031</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39,063</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.62</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39,063</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13.24</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39,063</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19.85</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">39,063</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2pt"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;26.47</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2/15/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"></p>

<!-- Field: Page; Sequence: 102; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 1%"><span style="font-size: 10pt"><sup>(1)</sup>&#160;</span></td>
    <td style="width: 99%; text-align: justify"><span style="font-size: 10pt">The shares subject to this stock option vest 1/3rd upon the date(s)
        that certain stock price goals are achieved. The stock price goals are such date(s) when the Company&#8217;s common stock has an average
        closing sales price equal to or exceeding each of $192,000.00, $224,000.00 and $256,000.00 per share for 20 consecutive trading days,
        subject to a one year minimum service period prior to vesting.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt"><sup>(2)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The shares subject to this stock option vested as to 1/3 of the shares on February
        25, 2021, with the remaining shares vesting on an equal monthly basis over the following 24 months.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt"><sup>(3)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The shares subject to this stock option vested as to 1/3 of the shares on May
        4, 2021, with the remaining shares vesting on an equal monthly basis over the following 24 months.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt"><sup>(4)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The shares subject to this stock option vested as to 1/3 of the shares on February
        23, 2022, with the remaining shares vesting on an equal monthly basis over the following 24 months.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt"><sup>(5)</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The shares subject to this stock option vested as to 10% of the shares on February
        15, 2023, 10% of the shares on February 15, 2024, 40% of the shares on February 15, 2025 and 40% of the shares on February 15, 2026.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Option Exercises and Stock Vested</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No options were exercised by any of the named executive
officers and no named executive officers held restricted stock units during the fiscal year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Compensation Plan Information</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides certain information
with respect to our equity compensation plans in effect as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Plan Category</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of securities to be issued
        upon exercise of outstanding options,</b></span> <span style="font-size: 10pt"><b>warrants and rights</b></span> <span style="font-size: 10pt"><b>(A)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-average exercise price
        of outstanding options,</b></span> <span style="font-size: 10pt"><b>warrants and rights</b></span> <span style="font-size: 10pt"><b>(B)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of securities remaining
        available for future issuance under equity compensation plans (excluding securities reflected in column A)<sup>(2)</sup></b></span>
        <span style="font-size: 10pt"><b>(C)</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><span style="font-size: 10pt">Equity compensation plans approved by security holders<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">2,453,031</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">28.93</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">627,753</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Equity compensation plans not approved by security holders</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8212;&#160;&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;&#160;&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8212;&#160;&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,453,031</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">28.93</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">627,753</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 1%"><span style="font-size: 10pt"><sup>(1)</sup>&#160;</span></td>
    <td style="width: 99%"><span style="font-size: 10pt">Consists of the Company&#8217;s 2012 Amended and Restated Incentive Stock Option Plan,
        the 2014 Stock Incentive Plan, the 2016 Stock Incentive Plan, the 2017 Stock Incentive Plan, the 2018 Equity Incentive Plan, the 2019
        Stock Incentive Plan, the 2020 Stock Incentive Plan, the Amended and Restated 2020 Stock Incentive Plan and the 2019 Employee Stock Purchase
        Plan, the 2020 Employee Stock Purchase Plan, and the 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Consists of shares available for future issuance under the Amended and Restated
        2020 Plan and our ESPP. As of December 31, 2022, 627,744 shares of common stock were available for issuance under the Amended and Restated
        2020 Plan and 9 shares of common stock were available for issuance under the ESPP.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Contracts and Termination of Employment and Change-In-Control
Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Employment Agreement with Seth Lederman</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 11, 2014, the
Company entered into an employment agreement (the &#8220;Lederman Agreement&#8221;) with Dr. Seth Lederman to continue to serve as our
President, Chief Executive Officer and Chairman of the Board.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The base salary for Dr. Lederman
under the Lederman Agreement was $425,000 per annum and as of January 1, 2023, the base salary is $675,000.&#160;&#160;The Lederman Agreement
has an initial term of one year and automatically renew for successive one year terms unless either party delivers written notice not
to renew at least 60 days prior to the end of the current term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Lederman Agreement,
if the Company terminates Dr. Lederman&#8217;s employment without Cause (as defined in the Lederman Agreement) or Dr. Lederman resigns
for Good Reason (as defined in the Lederman Agreement), Dr. Lederman is entitled to the following payments and benefits: (1)&#160;his
fully earned but unpaid base salary through the date of termination at the rate then in effect, plus all other benefits, if any, under
any group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other group
benefit plan to which Dr. Lederman may be entitled to under the terms of such plans or agreements; (2)&#160;a lump sum cash payment in
an amount equal to 12&#160;months of his base salary as in effect immediately prior to the date of termination; (3)&#160;continuation
of health benefits for Dr. Lederman and his eligible dependents for a period of 12&#160;months following the date of termination; and
(4)&#160;the automatic acceleration of the vesting and exercisability of outstanding unvested stock awards as to the number of stock awards
that would have vested over the 12-month period following termination had Dr, Lederman remained continuously employed by the Company during
such period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Lederman Agreement,
if Dr. Lederman&#8217;s employment is terminated as a result of death or permanent disability, Dr. Lederman or his estate, as applicable,
is entitled to the following payments and benefits: (1)&#160;his fully earned but unpaid base salary through the date of termination at
the rate then in effect; (2)&#160;a lump sum cash payment in an amount equal to six months of his base salary as in effect immediately
prior to the date of termination; and (3)&#160;the automatic acceleration of the vesting and exercisability of outstanding unvested stock
awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Dr. Lederman is terminated
without Cause or resigns for Good Reason during the period commencing 90&#160;days prior to a Change in Control (as defined below) or
12&#160;months following a Change in Control, Dr. Lederman shall be entitled to receive, in lieu of the severance benefits described above,
the following payments and benefits: (1)&#160;a lump sum cash payment in an amount equal to 36&#160;months of his base salary as in effect
immediately prior to the date of termination, except that, if and while Dr. Dr. Lederman is still entitled to the Sale Bonus (as defined
below), it will only be 18 months; (2)&#160;continuation of health benefits for Dr. Lederman and his eligible dependents for a period
of 24&#160;months following the date of termination, except that, if and while Dr. Lederman is still entitled to the Sale Bonus it will
only be 12 months; and (3)&#160;the automatic acceleration of the vesting and exercisability of outstanding unvested stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 103; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If during the term of the
Lederman Agreement or within 120 days after Dr. Lederman is terminated without Cause or resigns for Good Reason, following a Change in
Control, the Company consummates a Change in Control transaction in which the Enterprise Value (as defined below) equals or exceeds $50
million, Dr. Lederman shall be entitled to receive a lump sum payment equal to 4.4% of the Enterprise Value (the &#8220;Sale Bonus&#8221;).&#160;&#160;The
Sale Bonus provision of the Lederman Agreement will terminate upon the Company granting Dr. Lederman long-term incentive compensation
mutually agreed to by the Board and Dr. Lederman.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Lederman
Agreement, &#8220;Cause&#8221; generally means (1)&#160;commission of an act of fraud, embezzlement or dishonesty or some other illegal
act that has a demonstrable material adverse impact on the Company or any successor or affiliate of the Company, (2)&#160;conviction of,
or entry into a plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony, (3)&#160;unauthorized use or disclosure of the
Company&#8217;s confidential information or trade secrets or any successor or affiliate of the Company that has, or may reasonably be
expected to have, a material adverse impact on any such entity; (4) gross negligence, failure to follow a material, lawful and reasonable
request of the Board or material violation of any duty of loyalty to the Company or any successor or affiliate of the Company, or any
other demonstrable material willful misconduct by Dr. Lederman, (5)&#160;ongoing and repeated failure or refusal to perform or neglect
of his duties as required by his employment agreement, which failure, refusal or neglect continues for 30&#160;days following Dr. Lederman&#8217;s
receipt of written notice from the Board stating with specificity the nature of such failure, refusal or neglect, provided that such failure
to perform is not as a result of illness, injury or medical incapacity, or (6)&#160;material breach of any Company policy or any material
provision of the&#160;Lederman Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Lederman
Agreement, &#8220;Good Reason&#8221; generally means (1)&#160;a material diminution in Dr. Lederman&#8217;s title, authority, duties or
responsibilities, (2)&#160;a material diminution in Dr. Lederman&#8217;s base compensation, unless such a reduction is imposed across-the-board
to the Company&#8217;s senior management, and such reduction is not greater than 15%, (3)&#160;a material change in the geographic location
at which Dr. Lederman must perform his duties, (4)&#160;any other action or inaction that constitutes a material breach by the Company
or any successor or affiliate of the Company&#8217;s obligations to Dr. Lederman under the&#160;Lederman Agreement, or (5) the Company
elects not to renew the&#160;Lederman Agreement&#160;for another term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Lederman
Agreement, &#8220;Change in Control&#8221; generally means:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt">A transaction or series of transactions (other than public offerings)
        that results in any person or entity or related group of persons or entities (other than the Company, its subsidiaries, an employee benefit
        plan maintained by the Company or any of its subsidiaries or a person or entity that, prior to such transaction, directly or indirectly
        controls, is controlled by, or is under common control with, the Company) of beneficial ownership (within the meaning of Rule 13d-3 under
        the Exchange Act) of more than 40% of the total combined voting power of the Company&#8217;s securities outstanding immediately after
        such acquisition;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 7%; text-align: justify">&#160;</td>
    <td style="width: 2%; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 91%; text-align: justify"><span style="font-size: 10pt">(1) a merger, consolidation, reorganization, or business combination
        or (2)&#160;the sale, exchange or transfer of all or substantially all of the Company&#8217;s assets in any single transaction or series
        of transactions or (3)&#160;the acquisition of assets or stock of another entity, in each case other than a transaction:</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 15%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9675;</span></td>
    <td style="width: 83%; text-align: justify"><span style="font-size: 10pt">which results in the Company&#8217;s voting securities outstanding
        immediately before the transaction continuing to represent, directly or indirectly, at least 60% of the combined voting power of the successor
        entity&#8217;s outstanding voting securities immediately after the transaction, and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 15%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt">&#9675;</span></td>
    <td style="width: 83%; text-align: justify"><span style="font-size: 10pt">after which no person or group beneficially owns voting securities
        representing 40% or more of the combined voting power of the Company or its successor; provided, however, that no person or group is treated
        as beneficially owning 40% or more of combined voting power of the Company or its successor solely as a result of the voting power held
        in the Company prior to the consummation of the transaction.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Lederman
Agreement, &#8220;Enterprise Value&#8221; generally means (1) in a Change in Control in which consideration is received by the Company,
the total cash and non-cash consideration, including debt assumed, received by the Company, net of any fees and expenses in connection
with the transaction and (2) in a Change in Control in which consideration is payable to the stockholders of the Company, the total cash
and non-cash consideration, including debt assumed, payable to the Company&#8217;s stockholders net of any fees and expenses in connection
with the transaction.&#160;&#160;Enterprise Value also includes any cash or non-cash consideration payable to the Company or to the Company&#8217;s
stockholders on a contingent, earnout or deferred basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Employment Agreement with Gregory Sullivan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 3, 2014, the Company
entered into an employment agreement (the &#8220;Sullivan Agreement&#8221;) with Dr. Gregory Sullivan to serve as our Chief Medical Officer.&#160;&#160;The
base salary for Dr. Sullivan under the Sullivan Agreement was $225,000 per annum and as of January 1, 2023, the base salary is $480,000.&#160;&#160;The
Sullivan Agreement had an initial term of one year and automatically renews for successive one year terms unless either party delivers
written notice not to renew at least 60 days prior to the end of the current term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Sullivan Agreement,
if the Company terminates Dr. Sullivan&#8217;s employment without Cause (as defined below) or Executive resigns for Good Reason (as defined
below), Dr. Sullivan is entitled to the following payments and benefits: (1)&#160;his fully earned but unpaid base salary through the
date of termination at the rate then in effect, plus all other benefits, if any, under&#160;any group retirement plan, nonqualified deferred
compensation plan, equity award plan or agreement, health benefits plan or other group benefit plan to which Dr. Sullivan may be entitled
to under the terms of such plans or agreements; (2)&#160;a lump sum cash payment in an amount equal to 12&#160;months of his base salary
as in effect immediately prior to the date of termination; (3)&#160;continuation of health benefits for Dr. Sullivan and his eligible
dependents for a period of 12&#160;months following the date of termination; and (4)&#160;the automatic acceleration of the vesting and
exercisability of outstanding unvested stock awards as to the number of stock awards that would have vested over the 12-month period following
termination had Dr. Sullivan remained continuously employed by the Company during such period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 104; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Sullivan Agreement,
if Dr. Sullivan&#8217;s employment is terminated as a result of death or permanent disability, Sullivan or his estate, as applicable,
is entitled to his fully earned but unpaid base salary through the end of the month in which termination occurs at the rate then in effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Sullivan
Agreement, &#8220;Cause&#8221; generally means (1)&#160;commission of an act of fraud, embezzlement or dishonesty or some other illegal
act that has a demonstrable material adverse impact on the Company or any successor or affiliate of the Company, (2)&#160;conviction of,
or entry into a plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony, (3)&#160;unauthorized use or disclosure of the
Company&#8217;s confidential information or trade secrets or any successor or affiliate of the Company that has, or may reasonably be
expected to have, a material adverse impact on any such entity, (4) gross negligence, failure to follow a material, lawful and reasonable
request of the Company or material violation of any duty of loyalty to the Company or any successor or affiliate of the Company, or any
other demonstrable material misconduct by Dr. Sullivan, (5)&#160;ongoing and repeated failure or refusal to perform or neglect of his
duties as required by his employment agreement, which failure, refusal or neglect continues for 30&#160;days following Dr. Sullivan&#8217;s
receipt of written notice from the Company stating with specificity the nature of such failure, refusal or neglect, or (6)&#160;material
breach of any Company policy or any material provision of the&#160;Sullivan Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Sullivan
Agreement, &#8220;Good Reason&#8221; generally means (1)&#160;a material diminution in Dr. Sullivan&#8217;s title, authority, duties or
responsibilities, (2)&#160;a material diminution in the executive officer&#8217;s base compensation, unless such a reduction is imposed
across-the-board to the Company&#8217;s senior management and such reduction is not greater than 15%, (3)&#160;a material change in the
geographic location at which the executive officer must perform his duties, (4)&#160;any other action or inaction that constitutes a material
breach by the Company or any successor or affiliate of the Company&#8217;s obligations to Dr. Sullivan under the&#160;Agreement, or (5)
the Company elects not to renew the&#160;Agreement&#160;for another term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Employment Agreement with Bradley Saenger</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2021, the
Company entered into an employment agreement (the &#8220;Saenger Agreement&#8221;) with Mr. Bradley Saenger to serve as our Chief Financial
Officer.&#160;&#160;The base salary for Saenger under the Saenger Agreement was $465,000 per annum as of January 1, 2023.&#160;&#160;The
Saenger Agreement has an initial term of one year and automatically renews for successive one year terms unless either party delivers
written notice not to renew at least 60 days prior to the end of the current term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Saenger Agreement,
if the Company terminates Mr. Saenger&#8217;s employment without Cause (as defined below) or Executive resigns for Good Reason (as defined
below), Saenger is entitled to the following payments and benefits: (1)&#160;his fully earned but unpaid base salary through the date
of termination at the rate then in effect, plus all other benefits, if any, under&#160;any group retirement plan, nonqualified deferred
compensation plan, equity award plan or agreement, health benefits plan or other group benefit plan to which Mr. Saenger may be entitled
to under the terms of such plans or agreements; (2)&#160;a lump sum cash payment in an amount equal to 12&#160;months of his base salary
as in effect immediately prior to the date of termination; (3)&#160;continuation of health benefits for Mr. Saenger and his eligible dependents
for a period of 12&#160;months following the date of termination; and (4)&#160;the automatic acceleration of the vesting and exercisability
of outstanding unvested stock awards as to the number of stock awards that would have vested over the 12-month period following termination
had Saenger remained continuously employed by the Company during such period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Saenger Agreement,
if Mr. Saenger&#8217;s employment is terminated as a result of death or permanent disability, Saenger or his estate, as applicable, is
entitled to his fully earned but unpaid base salary through the end of the month in which termination occurs at the rate then in effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Saenger
Agreement, &#8220;Cause&#8221; generally means (1)&#160;commission of an act of fraud, embezzlement or dishonesty or some other illegal
act that has a demonstrable material adverse impact on the Company or any successor or affiliate of the Company, (2)&#160;conviction of,
or entry into a plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony, (3)&#160;unauthorized use or disclosure of the
Company&#8217;s confidential information or trade secrets or any successor or affiliate of the Company that has, or may reasonably be
expected to have, a material adverse impact on any such entity, (4) gross negligence, failure to follow a material, lawful and reasonable
request of the Company or material violation of any duty of loyalty to the Company or any successor or affiliate of the Company, or any
other demonstrable material misconduct by Mr. Saenger, (5)&#160;ongoing and repeated failure or refusal to perform or neglect of his duties
as required by his employment agreement, which failure, refusal or neglect continues for 30&#160;days following Mr. Saenger&#8217;s receipt
of written notice from the Company stating with specificity the nature of such failure, refusal or neglect, or (6)&#160;material breach
of any Company policy or any material provision of the&#160;Saenger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Saenger
Agreement, &#8220;Good Reason&#8221; generally means (1)&#160;a material diminution in Mr. Saenger&#8217;s title, authority, duties or
responsibilities, (2)&#160;a material diminution in the executive officer&#8217;s base compensation, unless such a reduction is imposed
across-the-board to the Company&#8217;s senior management and such reduction is not greater than 15%, (3)&#160;a material change in the
geographic location at which the executive officer must perform his duties, (4)&#160;any other action or inaction that constitutes a material
breach by the Company or any successor or affiliate of the Company&#8217;s obligations to Mr. Saenger under the&#160;Agreement, or (5)
the Company elects not to renew the&#160;Agreement&#160;for another term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Employment Agreement with Jessica Morris</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2021, the
Company entered into an employment agreement (the &#8220;Morris Agreement&#8221;) with Ms. Jessica Morris to serve as our Chief Operations
Officer.&#160;&#160;The base salary for Morris under the Morris Agreement was $475,000 per annum as of January 1, 2023.&#160;&#160;The
Morris Agreement has an initial term of one year and automatically renews for successive one year terms unless either party delivers written
notice not to renew at least 60 days prior to the end of the current term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Morris Agreement,
if the Company terminates Ms. Morris&#8217;s employment without Cause (as defined below) or Executive resigns for Good Reason (as defined
below), Morris is entitled to the following payments and benefits: (1)&#160;her fully earned but unpaid base salary through the date of
termination at the rate then in effect, plus all other benefits, if any, under&#160;any group retirement plan, nonqualified deferred compensation
plan, equity award plan or agreement, health benefits plan or other group benefit plan to which Ms. Morris may be entitled to under the
terms of such plans or agreements; (2)&#160;a lump sum cash payment in an amount equal to 12&#160;months of her base salary as in effect
immediately prior to the date of termination; (3)&#160;continuation of health benefits for Ms. Morris and her eligible dependents for
a period of 12&#160;months following the date of termination; and (4)&#160;the automatic acceleration of the vesting and exercisability
of outstanding unvested stock awards as to the number of stock awards that would have vested over the 12-month period following termination
had Morris remained continuously employed by the Company during such period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 105; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Morris Agreement,
if Ms. Morris&#8217;s employment is terminated as a result of death or permanent disability, Morris or her estate, as applicable, is entitled
to her fully earned but unpaid base salary through the end of the month in which termination occurs at the rate then in effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Morris
Agreement, &#8220;Cause&#8221; generally means (1)&#160;commission of an act of fraud, embezzlement or dishonesty or some other illegal
act that has a demonstrable material adverse impact on the Company or any successor or affiliate of the Company, (2)&#160;conviction of,
or entry into a plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony, (3)&#160;unauthorized use or disclosure of the
Company&#8217;s confidential information or trade secrets or any successor or affiliate of the Company that has, or may reasonably be
expected to have, a material adverse impact on any such entity, (4) gross negligence, failure to follow a material, lawful and reasonable
request of the Company or material violation of any duty of loyalty to the Company or any successor or affiliate of the Company, or any
other demonstrable material misconduct by Ms. Morris, (5)&#160;ongoing and repeated failure or refusal to perform or neglect of her duties
as required by her employment agreement, which failure, refusal or neglect continues for 30&#160;days following Ms. Morris&#8217;s receipt
of written notice from the Company stating with specificity the nature of such failure, refusal or neglect, or (6)&#160;material breach
of any Company policy or any material provision of the&#160;Morris Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the&#160;Morris
Agreement, &#8220;Good Reason&#8221; generally means (1)&#160;a material diminution in Ms. Morris&#8217;s title, authority, duties or
responsibilities, (2)&#160;a material diminution in the executive officer&#8217;s base compensation, unless such a reduction is imposed
across-the-board to the Company&#8217;s senior management and such reduction is not greater than 15%, (3)&#160;a material change in the
geographic location at which the executive officer must perform her duties, (4)&#160;any other action or inaction that constitutes a material
breach by the Company or any successor or affiliate of the Company&#8217;s obligations to Ms. Morris under the&#160;Agreement, or (5)
the Company elects not to renew the&#160;Agreement&#160;for another term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Directors Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of February 2023, each
of our non-employee directors, other than the lead director, receives an annual cash retainer of $55,000; the retainer for the lead director
is $70,000. In addition, during 2022, each of our non-employee directors received stock options to purchase shares of our common stock
valued at $250,000 as determined by the Black Scholes method on the date of grant, which vest on the next annual meeting of stockholders.
The following table sets forth summary information concerning the total compensation paid to our non-employee directors in 2022 for services
to our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Cash </b></span>
        <span style="font-size: 10pt"><b>Compensation&#160;($)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Option</b></span>
        <span style="font-size: 10pt"><b>Awards&#160;($)<sup>(1)</sup></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Total&#160;($)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 54%"><span style="font-size: 10pt">Richard Bagger</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 13%; text-align: right"><span style="font-size: 10pt">50,000</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-size: 10pt">250,000</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-size: 10pt">300,000</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Margaret Smith Bell</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">50,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">250,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">300,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">David Grange</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">50,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">250,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">300,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Adeoye Olukotun</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">50,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">250,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">300,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Carolyn Taylor</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">50,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">250,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">300,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">James Treco <sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">70,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">250,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">320,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; padding-left: 9pt"><span style="font-size: 10pt"><b>Total:</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.5pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">320,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.5pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,500,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.5pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,820,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 3px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents the aggregate grant date fair value of stock options granted in accordance
        with FASB ASC Topic 718. For the relevant assumptions used in determining these amounts, refer to Note 14 to our audited financial statements.
        These amounts do not necessarily correspond to the actual value that may be recognized from the stock option grant.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mr. Treco received additional cash compensation for serving as lead director.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.25in"></p>

<!-- Field: Page; Sequence: 106; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="tnxp10ka021"></span>ITEM 12- SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
certain information regarding beneficial ownership of our common stock as of March 13, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">by each person who is known by us to beneficially own more than 5% of our common
        stock;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">by each of our officers and directors; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">by all of our officers and directors as a group.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in the footnotes to the following table, each person named in the table has sole voting and investment power and that person&#8217;s address
is c/o Tonix Pharmaceuticals Holding Corp., 26 Main Street, Suite 101, Chatham, New Jersey 07928.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt">NAME OF OWNER</span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt">TITLE OF
CLASS</span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt">NUMBER OF
SHARES OWNED (1)</span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt">PERCENTAGE OF
COMMON STOCK (2)</span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt"><i>5% Stockholders</i></span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Tang Capital Partners, LP</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,280,916</span></td>
    <td><span style="font-size: 10pt">(3)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">6.85</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 43%"><span style="font-size: 10pt"><i>Directors and Executive Officers</i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; padding-left: 10pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Seth Lederman</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">404,404</span></td>
    <td><span style="font-size: 10pt">(4)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Jessica Morris</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">72,315</span></td>
    <td><span style="font-size: 10pt">(5)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Bradley Saenger</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">68,622</span></td>
    <td><span style="font-size: 10pt">(6)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Gregory Sullivan</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">97,937</span></td>
    <td><span style="font-size: 10pt">(7)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Richard Bagger</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">77,538</span></td>
    <td><span style="font-size: 10pt">(8)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Margaret Smith Bell</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">77,697</span></td>
    <td><span style="font-size: 10pt">(9)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">David Grange</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">77,524</span></td>
    <td><span style="font-size: 10pt">(10)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Adeoye Olukotun</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">77,682</span></td>
    <td><span style="font-size: 10pt">(11)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Carolyn Taylor</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">74,030</span></td>
    <td><span style="font-size: 10pt">(12)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">James Treco</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">79,187</span></td>
    <td><span style="font-size: 10pt">(13)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Officers and Directors as a Group (10 persons)</span></td>
    <td>&#160;</td>
    <td style="padding-left: 10pt; text-align: center"><span style="font-size: 10pt">Common Stock</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,106,936</span></td>
    <td><span style="font-size: 10pt">(14)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1.74</span></td>
    <td><span style="font-size: 10pt">%&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Denotes less than 1%</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Beneficial Ownership is determined in accordance
with the rules of the SEC and generally includes voting or investment power with respect to securities. Shares of common stock subject
to options or warrants currently exercisable or convertible, or exercisable or convertible within 60 days of March 13, 2023 are deemed
outstanding for computing the percentage of the person holding such option or warrant but are not deemed outstanding for computing the
percentage of any other person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Percentage based upon 62,539,497 shares
of common stock issued and outstanding as of March 13, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Based solely on information contained in a
Schedule 13G filed with the SEC on December 16, 2022. The mailing address of this beneficial owner is 4747 Executive Drive, Suite 210,
San Diego, CA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Includes 376,650 shares of common stock underlying
options which are currently exercisable or become exercisable within 60 days, 7 shares of common stock owned by Lederman &amp; Co, 2 shares
of common stock owned by L&amp;L, 2 shares of common stock owned by Targent, 1 share of common stock owned by Leder Laboratories, Inc.
(Leder Labs), 1 share of common stock owned by Starling, 24,235 shares owned through an IRA account and 1 share owned by Dr. Lederman&#8217;s
spouse. Seth Lederman, as the Managing Member of Lederman &amp; Co and Targent, the Manager of L&amp;L and the Chairman of Leder Labs
and Starling, has investment and voting control over the shares held by these entities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Includes 72,314 shares of common stock underlying
options which are currently exercisable or become exercisable within 60 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Includes 68,008 shares of common stock underlying
options which are currently exercisable or become exercisable within 60 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Includes 94,836 shares of common stock underlying
options which are currently exercisable or become exercisable within 60 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) Includes 77,225 shares of common stock underlying
options and restricted stock units which are currently exercisable or vested or become exercisable within 60 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Includes 77,528 shares of common stock underlying
options and restricted stock units which are currently exercisable or vested or become exercisable within 60 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(10) Includes 77,524 shares of common stock underlying
options and restricted stock units which are currently exercisable or vested or become exercisable within 60 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(11) Includes 77,514 shares of common stock underlying
options and restricted stock units which are currently exercisable or vested or become exercisable within 60 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.25in"></p>

<!-- Field: Page; Sequence: 107; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12) Includes 74,030 shares of common stock underlying
options which are currently exercisable or become exercisable within 60 days</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(13) Includes 78,874 shares of common stock underlying
options which are currently exercisable or become exercisable within 60 days</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(14) Includes 1,074,503 shares of common stock
underlying options which are currently exercisable or vested or become exercisable within 60 days, 7 shares of common stock owned by
Lederman &amp; Co, 2 shares of common stock owned by L&amp;L, 2 shares of common stock owned by Targent, 1 share of common stock owned
by Leder Labs, 1 share of common stock owned by Starling, 24,235 shares owned through an IRA account of Dr. Lederman, and 1 share owned
by Dr. Lederman&#8217;s spouse.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="tnxp10ka022"></span><b>ITEM 13 - CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and
oversight of &#8220;related-party transactions.&#8221; For purposes of our policy only, a &#8220;related-party transaction&#8221; is a
transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related
party&#8221; are participants involving an amount that <span style="background-color: white">exceeds the lesser of $120,000 of $120,000
or one percent of the average of our total assets at year end for the last two completed fiscal years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> A related party is any executive
officer, director or a holder of more than five percent of our common stock, including any of their immediate family members and any entity
owned or controlled by such persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Where a transaction has been
identified as a related-party transaction, our Chief Compliance Officer must present information regarding the proposed related-party
transaction to our Nominating and Corporate Governance Committee for review. The presentation must include a description of, among other
things, the material facts, the direct and indirect interests of the related parties, the benefits of the transaction to us and whether
any alternative transactions are available. To identify related-party transactions in advance, we rely on information supplied by our
executive officers, directors and certain significant stockholders. In considering related-party transactions, our Nominating and Corporate
Governance Committee will take into account the relevant available facts and circumstances including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether the transaction was undertaken in the ordinary course of our business;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether the related party transaction was initiated by us or the related party;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether the transaction with the related party is proposed to be, or was, entered
        into on terms no less favorable to us than terms that could have been reached with an unrelated third party;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the purpose of, and the potential benefits to us from the related party transaction;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the approximate dollar value of the amount involved in the related party transaction,
        particularly as it relates to the related party;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the related party&#8217;s interest in the related party transaction, and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any other information regarding the related party transaction or the related
        party that would be material to investors in light of the circumstances of the particular transaction.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Nominating and Corporate
Governance Committee shall then make a recommendation to the Board, who will determine whether or not to approve of the related party
transaction, and if so, upon what terms and conditions. In the event a director has an interest in the proposed transaction, the director
must recuse himself or herself from the deliberations and approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the last two fiscal
years, there have been no related party transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="tnxp10ka023"></span>ITEM 14 &#8211;
PRINCIPAL ACCOUNTING FEES AND SERVICES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our independent registered public accounting firm
is <span id="xdx_902_edei--AuditorName_c20220101__20221231_zweytzohB9qk" class="xdx_phnt_RG9jdW1lbnQgLSBDb3ZlcgA_"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">EisnerAmper LLP</ix:nonNumeric></span>,
<span id="xdx_904_edei--AuditorLocation_c20220101__20221231_zoAVun4Cmfa5" class="xdx_phnt_RG9jdW1lbnQgLSBDb3ZlcgA_"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Iselin, New Jersey</ix:nonNumeric></span>,
PCAOB ID: <span id="xdx_90B_edei--AuditorFirmId_c20220101__20221231_zeF2xRjCYfkd" class="xdx_phnt_RG9jdW1lbnQgLSBDb3ZlcgA_"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">274</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>(1) Audit Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate fees billed
by our independent registered public accounting firm, for professional services rendered for the audit of our annual financial statements
for the years ended December 31, 2022 and 2021, including review of our interim financial statements as well as registration statement
filings with the SEC and comfort letters issued to underwriters were $383,880 and $312,291, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(2) Audit-Related Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not incur fees to our
independent registered public accounting firm for audit related fees during the fiscal years ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(3) Tax Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not incur fees to our
independent registered public accounting firm for tax services during the fiscal years ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><i>(4) All Other Fees</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt; background-color: white">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 108; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pre-Approval Policies and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consistent with SEC policies
and guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and permissible non-audit
services provided by our principal accountants on a case-by-case basis. Our Audit Committee has established a policy regarding approval
of all audit and permissible non-audit services provided by our principal accountants. Our Audit Committee pre-approves these services
by category and service. Our Audit Committee has pre-approved all of the services provided by our principal accountants.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="tnxp10ka024"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="tnxp10ka025"></span><b>ITEM 15 &#8211; EXHIBITS, FINANCIAL
STATEMENT SCHEDULES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt"><i>(c)</i></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Index to Exhibits</i></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Exhibits listed below
are identified by numbers corresponding to the Exhibit Table of Item 601 of Regulation S-K. The Exhibits designated by an asterisk (*)
are management contracts or compensatory plans or arrangements required to be filed pursuant to Item 15.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT INDEX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 7%"><span style="font-size: 10pt"><b>Exhibit</b></span> <span style="font-size: 10pt"><b>No.</b></span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 93%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000116552708000188/ex3-1.txt"><span style="font-size: 10pt">3.01</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Articles of Incorporation, filed as an exhibit to the Registration Statement
        on Form S-1, filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on April 9, 2008 and incorporated herein
        by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000101376211002735/ex31.pdf"><span style="font-size: 10pt">3.02</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Articles of Merger between Tamandare Explorations Inc. and Tonix Pharmaceuticals
        Holding Corp., effective October 11, 2011, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on October
        17, 2011 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000114420416106631/v441599_ex3-01.htm"><span style="font-size: 10pt">3.03</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Third Amended and Restated Bylaws, filed as an exhibit to the Current Report
        on Form 8-K, filed with the Commission on June 3, 2016 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000161577417001073/s105580_ex3-1.htm"><span style="font-size: 10pt">3.04</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certificate of Change of Tonix Pharmaceuticals Holding Corp., dated March 13,
        2017 and effective March 17, 2017, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on March 16, 2017
        and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000161577417003222/s106582_ex3-1.htm"><span style="font-size: 10pt">3.05</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certificate of Amendment to Articles of Incorporation, effective June 16, 2017,
        filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on June 16, 2017 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000161577418004308/s110252_ex4-1.htm"><span style="font-size: 10pt">3.06</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Specimen Common Stock Certificate, filed as an exhibit to the Current Report
        on Form 8-K, filed with the Commission on May 24, 2018 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119004459/ex3-07.htm"><span style="font-size: 10pt">3.07</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certificate of Amendment to Tonix Pharmaceuticals Holding Corp.&#8217;s Articles
        of Incorporation, as amended, filed with the Secretary of State of the State of Nevada on May 3, 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119008807/ex3-01.htm"><span style="font-size: 10pt">3.08</span></a></td>
    <td><span style="font-size: 10pt">Form of Certificate of Designation of Series A Convertible Preferred Stock, filed as an exhibit to the Current
        Report on Form 8-K, filed with the Commission on October 25, 2022 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713120000350/ex3-09.htm"><span style="font-size: 10pt">3.09</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Form of Certificate of Designation of Series B Convertible Preferred Stock,
        filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on October 25, 2022 and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 7%">&#160;</td>
    <td style="width: 93%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713122006187/ex3-01.htm">3.10</a></td>
    <td style="text-align: justify">
        <p style="margin: 0">Certificate of Amendment to Tonix Pharmaceuticals Holding Corp.&#8217;s Articles of Incorporation, filed as an exhibit
        to the Current Report on Form 8-K, filed with the Commission on May 16, 2022 and incorporated herein by reference.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000161577418004308/s110252_ex4-1.htm"><span style="font-size: 10pt">4.01</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Specimen Common Stock Certificate of the Registrant, filed as an exhibit to
        the Current Report on Form 8-K, filed with the Commission on May 24, 2018 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119008666/ex4-02.htm"><span style="font-size: 10pt">4.02</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Form of Warrant, filed as an exhibit to the Registration Statement on Form S-1,
        filed with the Commission on November 14, 2019 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119008666/ex4-04.htm"><span style="font-size: 10pt">4.03</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Form of Warrant Agency Agreement, filed as an exhibit to the Registration Statement
        on Form S-1, filed with the Commission on November 14, 2019 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713120001063/ex4-04.htm"><span style="font-size: 10pt">4.04</span></a></td>
    <td><span style="font-size: 10pt">Form of Warrant, filed as an exhibit to the Registration Statement on Form S-1, filed with the Commission
        on February 6, 2020 and incorporated herein by reference</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713120001063/ex4-05.htm"><span style="font-size: 10pt">4.05</span></a></td>
    <td><span style="font-size: 10pt">Form of Warrant Agency Agreement, filed as an exhibit to the Registration Statement on Form S-1, filed with
        the Commission on February 6, 2020 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="ex4-06.htm"><span style="font-size: 10pt">4.06</span></a></td>
    <td><span style="font-size: 10pt">Description of Registrant&#8217;s Securities, filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000114420413019920/v340300_def14a.htm"><span style="font-size: 10pt">10.01</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. 2012 Amended and Restated Incentive Stock
        Option Plan, incorporated herein by reference to Appendix B to our Definitive Proxy Statement on Schedule 14A (File No. 000-54879), filed
        with the Commission on April 3, 2013.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000114420414009883/v368866_ex10-1.htm"><span style="font-size: 10pt">10.02</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Employment Agreement, between Tonix Pharmaceuticals Holding Corp. and Seth Lederman,
        dated February 11, 2014, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on February 14, 2014 and incorporated
        herein by reference.*</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 109; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 7%"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1430306/000114420414027207/v377105_def14a.htm">10.03</a></span></td>
    <td style="text-align: justify; width: 93%"><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. 2014 Stock Incentive Plan, incorporated
        herein by reference to Annex A to our Definitive Proxy Statement on Schedule 14A (File No. 001-36019), filed with the Commission on May
        2, 2014.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000114420415012769/v402310_ex10-16.htm"><span style="font-size: 10pt">10.04</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lease Amendment and Expansion Agreement, dated February 11, 2014, by and between
        509 Madison Avenue Associates, L.P. and Tonix Pharmaceuticals, Inc., filed as an exhibit to the Annual Report on Form 10-K filed with
        the Commission on February 27, 2015 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt; color: blue"><span style="text-decoration: underline">10.05</span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Employment Agreement, between Tonix Pharmaceuticals Holding Corp. and Gregory
        Sullivan, dated June 3, 2014, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on June 3, 2014 and incorporated
        herein by reference.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000114420416090303/v435283_def14a.htm"><span style="font-size: 10pt">10.06</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. 2016 Stock Incentive Plan, incorporated
        herein by reference to Annex A to our Definitive Proxy Statement on Schedule 14A (File No. 001-36019), filed with the Commission on March
        25, 2016.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000161577417002003/s106006_def14a.htm"><span style="font-size: 10pt">10.07</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. 2017 Stock Incentive Plan, incorporated
        herein by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A (File No. 001-36019), filed with the Commission on
        May 2, 2017.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000161577418002736/s109689_def14a.htm"><span style="font-size: 10pt">10.08</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. 2018 Equity Incentive Plan, incorporated
        herein by reference to our Definitive Proxy Statement on Schedule 14A (File No. 001-36019), filed with the Commission on April 19, 2018.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000161577418011277/s113412_ex10-1.htm"><span style="font-size: 10pt">10.09</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Purchase Agreement, dated October 18, 2018, between Tonix Pharmaceuticals Holding
        Corp. and Lincoln Park Capital Fund, LLC, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on October 24,
        2018 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119002014/tnxp-def14a_051319.htm#a049_v1"><span style="font-size: 10pt">10.10</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. 2019 Stock Incentive Plan, incorporated
        herein by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A (File No. 001-36019), filed with the Commission on
        March 18, 2019.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119002014/tnxp-def14a_051319.htm#a050_v1"><span style="font-size: 10pt">10.11</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. 2019 Employee Stock Purchase Plan, incorporated
        herein by reference to Appendix B to our Definitive Proxy Statement on Schedule 14A (File No. 001-36019), filed with the Commission on
        March 18, 2019.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119005974/ex1-01.htm"><span style="font-size: 10pt">10.12</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">License Agreement, dated May 20, 2019, between Tonix Pharmaceuticals Holding
        Corp. and The Trustees of Columbia University in the City of New York, filed as an exhibit to the Quarterly Report on Form 10-Q filed
        with the Commission on August 12, 2019 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 7%"><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119006371/ex10-01.htm"><span style="font-size: 10pt">10.13</span></a></td>
    <td style="text-align: justify; width: 93%"><span style="font-size: 10pt">Purchase Agreement, dated August 20, 2019, between Tonix Pharmaceuticals
        Holding Corp. and Lincoln Park Capital Fund, LLC, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on August
        23, 2019 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119008474/ex10-01.htm"><span style="font-size: 10pt">10.14</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Asset Purchase Agreement, dated August 19, 2019, between Tonix Pharmaceuticals
        Holding Corp. and TRImaran Pharma, Inc., filed as an exhibit to the Quarterly Report on Form 10-Q filed with the Commission on November
        8, 2019 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119008474/ex10-02.htm"><span style="font-size: 10pt">10.15</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">First Amended and Restated Exclusive License Agreement, dated August 19, 2019,
        between Tonix Pharmaceuticals Holding Corp. and Wayne State University, filed as an exhibit to the Quarterly Report on Form 10-Q filed
        with the Commission on November 8, 2019 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119008474/ex10-03.htm"><span style="font-size: 10pt">10.16</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Exclusive License Agreement, dated September 16, 2019, between Tonix Pharmaceuticals
        Holding Corp. and The Trustees of Columbia University in the City of New York, filed as an exhibit to the Quarterly Report on Form 10-Q
        filed with the Commission on November 8, 2019 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713119009537/tnxp-def14a_011620.htm#tnxppre14a_a007"><span style="font-size: 10pt">10.17</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. 2020 Stock Incentive Plan, incorporated
        herein by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A (File No. 001-36019), filed with the Commission on
        December 13, 2019.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713120003189/ex10-18.htm"><span style="font-size: 10pt">10.18</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research Collaboration Agreement between Tonix Pharmaceutical, Inc. and Southern
        Research Institute, dated November 7, 2018, filed as an exhibit to the Annual Report on Form 10-K, filed with the Commission on March
        24, 2020 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713120004639/ex10-1.htm"><span style="font-size: 10pt">10.19</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">License Agreement, dated May 5, 2020, between Tonix Pharmaceuticals (Canada)
        Inc. and The Governors of the University of Alberta, filed as an exhibit to the Quarterly Report on Form 10-Q, filed with the Commission
        on August 10, 2020 and incorporated herein by reference. &#8224;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713120007238/ex10-02.htm"><span style="font-size: 10pt">10.20</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Asset Purchase Agreement, dated June 11, 2020, between Tonix Pharmaceuticals,
        Inc. and Trigemina, Inc., filed as an exhibit to the Quarterly Report on Form 10-Q, filed with the Commission on May 12, 2020 and incorporated
        herein by reference. &#8224;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713120007238/ex10-03.htm"><span style="font-size: 10pt">10.21</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Amended and Restated Exclusive License Agreement, dated June 11, 2020, between
        Tonix Pharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University, filed as an exhibit to the Quarterly Report
        on Form 10-Q, filed with the Commission on August 10, 2020 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713120007238/ex10-04.htm"><span style="font-size: 10pt">10.22</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Assignment and Agreement, dated June 11, 2020, between Tonix Pharmaceuticals,
        Inc. and The Board of Trustees of the Leland Stanford Junior University, filed as an exhibit to the Quarterly Report on Form 10-Q, filed
        with the Commission on August 10, 2020 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713120007238/ex10-01.htm"><span style="font-size: 10pt">10.23</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Purchase and Sale Agreement, dated July 1, 2020, between Tonix Pharmaceuticals
        Holding Corp. and Seller named therein, filed as an exhibit to the Quarterly Report on Form 10-Q, filed with the Commission on August
        10, 2020 and incorporated herein by reference. &#8224;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713120009688/ex10-01.htm"><span style="font-size: 10pt">10.24</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Real Property Purchase and Sale Agreement, dated October 14, 2020, between Tonix
        Pharmaceuticals Holding Corp. and the Seller named therein, filed as an exhibit to the Quarterly Report on Form 10-Q, filed with the Commission
        on November 9, 2020 and incorporated herein by reference. &#8224;</span></td></tr>
  </table>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 110; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"></td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713120003461/tnxp-def14a_050120.htm#tnxpa040"><span style="font-size: 10pt">10.25</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. Amended and Restated 2020 Stock Incentive
        Plan, incorporated herein by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A (File No. 001-36019), filed with
        the Commission on March 30, 2020.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713121002979/ex10-01.htm"><span style="font-size: 10pt">10.26</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Employment Agreement, between Tonix Pharmaceuticals Holding Corp. and Jessica
        Morris, dated February 23, 2021, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on February 26, 2021
        and incorporated herein by reference.*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 7%">&#160;</td>
    <td style="width: 93%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713121002979/ex10-02.htm"><span style="font-size: 10pt">10.27</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Employment Agreement, between Tonix Pharmaceuticals Holding Corp. and Bradley
        Saenger, dated February 23, 2021, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on February 26, 2021
        and incorporated herein by reference.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713121003550/ex10-28.htm"><span style="font-size: 10pt">10.28</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Purchase and Sale Agreement, dated March 5, 2021, between Tonix Pharmaceuticals
        Holding Corp. and the Seller named therein, filed as an exhibit to the Annual Report on Form 10-K, filed with the Commission on March
        15, 2021 and incorporated herein by reference. &#8224;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713121005464/ex10-01.htm"><span style="font-size: 10pt">10.29</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">License Agreement, dated April 14, 2021, between the Company and OyaGen, Inc.,
        filed as an exhibit to the Quarterly Report on Form 10-Q filed with the Commission on May 10, 2021 and incorporated herein by reference
        &#8224;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713121005684/ex10-01.htm"><span style="font-size: 10pt">10.30</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Purchase Agreement, dated May 14, 2021, by and between Tonix Pharmaceuticals
        Holding Corp. and Lincoln Park Capital Fund, LLC, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on
        May 14, 2021 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001430306/000138713121008266/ex10-01.htm"><span style="font-size: 10pt">10.31</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Purchase and Sale Agreement, dated July 26, 2021, between the Company and Southern
        Research, filed as an exhibit to the Quarterly Report on Form 10-Q filed with the Commission on August 9, 2021 and incorporated herein
        by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713122008839/ex10-01.htm"><span style="font-size: 10pt">10.32</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Purchase Agreement, dated August 16, 2022, by and between Tonix Pharmaceuticals
        Holding Corp. and Lincoln Park Capital Fund, LLC, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on August
        17, 2022 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713122003793/tnxp-def14a_050622.htm">10.33</a></span></td>
    <td><span style="font-size: 10pt">Tonix Pharmaceuticals Holding Corp. 2022 Employee Stock Purchase Plan, incorporated herein by reference
        to Appendix A to our Definitive Proxy Statement on Schedule 14A, filed with the Commission on March 18, 2022.*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713122010661/ex10-01.htm">10.34</a></span></td>
    <td><span style="font-size: 10pt">Form of Securities Purchase Agreement between Tonix Pharmaceuticals Holding Corp. and the investors thereto,
        dated October 25, 2022, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on October 25, 2022 and incorporated
        herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713122010661/ex10-03.htm">10.35</a></span></td>
    <td><span style="font-size: 10pt">Form of Side Letter between Tonix Pharmaceuticals Holding Corp. and the investors thereto, dated October
        25, 2022, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on October 25, 2022 and incorporated herein
        by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1430306/000138713122010661/ex10-02.htm">10.36</a></span></td>
    <td><span style="font-size: 10pt">Form of Registration Agreement between Tonix Pharmaceuticals Holding Corp. and the investors thereto, dated
        October 25, 2022, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on October 25, 2022 and incorporated
        herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 7%">&#160;</td>
    <td style="text-align: justify; width: 93%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1430306/000114420416081960/v431927_ex14-01.htm"><span style="font-size: 10pt">14.01</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Code of Business Conduct and Ethics for Employees, Executive Officers and Directors,
        filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on February 16, 2016 and incorporated herein by reference.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="ex21-01.htm"><span style="font-size: 10pt">21.01</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">List of Subsidiaries.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="ex23-01.htm"><span style="font-size: 10pt">23.01</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Consent of Independent Registered Public Accounting Firm, filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="ex31-01.htm"><span style="font-size: 10pt">31.01</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a)
        and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="ex31-02.htm"><span style="font-size: 10pt">31.02</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a)
        and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="ex32-01.htm"><span style="font-size: 10pt">32.01</span></a></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certifications of Chief Executive Officer and Chief Financial Officer pursuant
        to 18&#160;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">101</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The following materials from Tonix Pharmaceuticals Holding Corp.&#8217;s Annual
        Report on Form 10-K for the year ended December 31, 2022, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated
        Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Loss, (iv) the Consolidated
        Statements of Stockholders&#8217; Equity, (v) the Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">104</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The cover page from this Annual Report on Form 10-K, formatted as Inline XBRL.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8224; Certain portions of this exhibit, that
        are not material and would likely cause competitive harm to the registrant if publicly disclosed, have been redacted pursuant to Item
        601(b)(10) of Regulation S-K.&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Denotes a management compensatory agreement
        or arrangement.&#160;</p></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 111; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="tnxp10ka026"></span><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 52%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: March 13, 2023</span></td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ SETH LEDERMAN</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Seth Lederman</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer (Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: March 13, 2023</span></td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ BRADLEY SAENGER</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Bradley Saenger</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>POWER OF ATTORNEY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS BY THESE
PRESENTS, that each person whose signature appears below constitutes and appoints Seth Lederman and Bradley Saenger, jointly and severally,
his or her attorney-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to this
Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities
and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes,
may do or cause to be done by virtue hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 28%"><span style="font-size: 10pt">Name</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 47%"><span style="font-size: 10pt">Position</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 23%"><span style="font-size: 10pt">Date</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/ SETH LEDERMAN</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chief Executive Officer, President and Director </span> <span style="font-size: 10pt">(Principal
        Executive Officer)</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">March 13, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Seth Lederman</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/ BRADLEY SAENGER</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chief Financial Officer </span> <span style="font-size: 10pt">(Principal
        Financial Officer and Principal Accounting Officer)</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">March 13, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Bradley Saenger</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ RICHARD BAGGER</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 13, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Richard Bagger</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ MARGARET SMITH BELL</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 13, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Margaret Smith Bell</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ DAVID GRANGE&#160;</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 13, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">David Grange</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ ADEOYE OLUKOTUN</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 13, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adeoye Olukotun</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ CAROLYN TAYLOR</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 13, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carolyn Taylor</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ JAMES TRECO</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 13, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">James Treco</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 112; Value: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->&#160;</p></div>
    <!-- Field: /Page --> </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.04
<SEQUENCE>2
<FILENAME>ex4-06.htm
<DESCRIPTION>DESCRIPTION OF REGISTRANT'S SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="tnxp-10k_123122.htm">Tonix Pharmaceuticals Holding Corp. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.06</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF THE REGISTRANT&rsquo;S
SECURITIES REGISTERED PURSUANT<BR>
TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following is
a summary of all material characteristics of our common stock as set forth in our articles of incorporation and bylaws. The summary
does not purport to be complete and is qualified in its entirety by reference to our articles of incorporation and bylaws, each
as amended, and to the provisions of Chapter 78 of the Nevada Revised Statutes, as amended (&ldquo;NRS&rdquo;).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to
issue up to 1,000,000,000 shares of our common stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of our common stock are entitled
to one vote for each share on all matters submitted to a stockholder vote. Holders of our common stock do not have cumulative voting
rights. Therefore, holders of a majority of the shares of our common stock voting for the election of directors can elect all of
the directors. Holders of our common stock representing a majority of the voting power of our capital stock issued, outstanding
and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of stockholders. A
vote by the holders of a majority of our outstanding shares is required to effectuate certain fundamental corporate changes such
as dissolution, merger or an amendment to our articles of incorporation. However, a two-thirds vote is required for stockholders
to amend our bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the rights
of holders of shares of our preferred stock, if any, the holders of our common stock are entitled to share in all dividends that
our Board of Directors, in its discretion, declares on our common stock from legally available funds. In the event of a liquidation,
dissolution or winding up, each outstanding share of our common stock entitles its holder to participate pro rata in all assets
that remain after payment of liabilities and after providing for each class of stock, if any, having preference over our common
stock. Our common stock has no pre-emptive, subscription or conversion rights and there are no redemption provisions applicable
to our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Transfer Agent
and Registrar for our common stock is vStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following is
a summary of all material characteristics of our preferred stock as set forth in our articles of incorporation and bylaws. The
summary does not purport to be complete and is qualified in its entirety by reference to our articles of incorporation and bylaws,
each as amended, and to the provisions of Chapter 78 of the Nevada Revised Statutes, as amended (&ldquo;NRS&rdquo;).</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to
issue up to 5,000,000 shares of preferred stock, par value $0.001 per share, none of which are currently outstanding. The shares
of preferred stock may be issued in series, and shall have such voting powers, full or limited, or no voting powers, and such designations,
preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof,
as shall be stated and expressed in the resolution or resolutions providing for the issuance of such stock adopted from time to
time by the board of directors. The board of directors is expressly vested with the authority to determine and fix in the resolution
or resolutions providing for the issuances of preferred stock the voting powers, designations, preferences and rights, and the
qualifications, limitations or restrictions thereof, of each such series to the full extent now or hereafter permitted by the laws
of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Terms of the Preferred Stock That We May&nbsp;Offer and
Sell to You</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We summarize below
some of the provisions that will apply to the preferred stock that we may offer to you unless the applicable prospectus supplement
provides otherwise. This summary may not contain all information that is important to you. You should read the prospectus supplement,
which will contain additional information and which may update or change some of the information below. Prior to the issuance of
a new series of preferred stock, we will further amend our articles of incorporation, as amended, designating the stock of that
series and the terms of that series. We will file a copy of the certificate of designation that contains the terms of each new
series of preferred stock with the Nevada Secretary of State and the SEC each time we issue a new series of preferred stock. Each
certificate of designation will establish the number of shares included in a designated series and fix the designation, powers,
privileges, preferences and rights of the shares of each series as well as any applicable qualifications, limitations or restrictions.
You should refer to the applicable certificate of designation as well as our articles of incorporation, as amended, before deciding
to buy shares of our preferred stock as described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has the authority, without further action by the stockholders, to issue preferred stock in one or more series and to fix the number
of shares, dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking funds, and any
other rights, preferences, privileges and restrictions applicable to each such series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of any
preferred stock could adversely affect the rights of the holders of common stock and, therefore, reduce the value of the common
stock. The ability of our board of directors to issue preferred stock could discourage, delay or prevent a takeover or other corporate
action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 89 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="font: normal 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of any particular
series of preferred stock will be described in the prospectus supplement relating to that particular series of preferred stock,
including, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the designation, stated value and liquidation preference of such preferred stock;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of shares within the series;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the offering price;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the dividend rate or rates (or method of calculation), the date or dates from which dividends shall accrue, and whether such dividends shall be cumulative or noncumulative and, if cumulative, the dates from which dividends shall commence to cumulate;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any redemption or sinking fund provisions;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the amount that shares of such series shall be entitled to receive in the event of our liquidation, dissolution or winding-up;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the terms and conditions, if any, on which shares of such series shall be convertible or exchangeable for shares of our stock of any other class or classes, or other series of the same class;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the voting rights, if any, of shares of such series; the status as to reissuance or sale of shares of such series redeemed, purchased or otherwise reacquired, or surrendered to us on conversion or exchange;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the conditions and restrictions, if any, on the payment of dividends or on the making of other distributions on, or the purchase, redemption or other acquisition by us or any subsidiary, of the common stock or of any other class of our shares ranking junior to the shares of such series as to dividends or upon liquidation;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the conditions and restrictions, if any, on the creation of indebtedness by us or by any subsidiary, or on the issuance of any additional stock ranking on a parity with or prior to the shares of such series as to dividends or upon liquidation; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any additional dividend, liquidation, redemption, sinking or retirement fund and other rights, preferences, privileges, limitations and restrictions of such preferred stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description of
the terms of a particular series of preferred stock in the applicable prospectus supplement will not be complete. You should refer
to the applicable amendment to our articles of incorporation, as amended, for complete information regarding a series of preferred
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preferred stock
will, when issued against payment of the consideration payable therefore, be fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="font: normal 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.01
<SEQUENCE>3
<FILENAME>ex21-01.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="tnxp-10k_123122.htm">Tonix Pharmaceuticals Holding Corp. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.01</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSIDIARIES OF THE COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Subsidiary Name</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 64%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">State/ Jurisdiction of Incorporation/Formation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tonix Pharmaceuticals, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Krele, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tonix Pharmaceuticals (Canada), Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">New Brunswick, Canada</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tonix Pharma Holdings Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Ireland</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tonix Pharma Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Ireland</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Jenner LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tonix R&amp;D Center, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tonix Medicines, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="font: normal 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 91; Name: PageNo -->91<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.01
<SEQUENCE>4
<FILENAME>ex23-01.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="tnxp-10k_123122.htm">Tonix Pharmaceuticals Holding Corp. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.01</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="color: Black">We </font>consent
to the incorporation by reference in the Registration Statements of Tonix Pharmaceuticals Holding Corp. on Form S-3 (Nos.
333-237610, 333-251500, 333-254975, and 333-266982) and Form S-8 (Nos. 333-202006, 333-212300, 333-219928, 333-226776, 333-232137,
333-239152, 333-257437, and 333-265705) of our report dated March 13, 2023, on our audits of the consolidated financial statements
as of December 31, 2022 and 2021 and for each of the years then ended, which report is included in this Annual Report on Form 10-K.
Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue
as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ EisnerAmper LLP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EISNERAMPER LLP&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Iselin, New Jersey&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 13, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 92; Name: PageNo -->92<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.01
<SEQUENCE>5
<FILENAME>ex31-01.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="tnxp-10k_123122.htm">Tonix Pharmaceuticals Holding Corp. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.01</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Seth Lederman, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 10-K of Tonix Pharmaceuticals Holding Corp.;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal controls over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: March 13, 2023</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ SETH LEDERMAN</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Seth Lederman&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 92 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Value: 93; Name: PageNo -->93<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.02
<SEQUENCE>6
<FILENAME>ex31-02.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="tnxp-10k_123122.htm">Tonix Pharmaceuticals Holding Corp. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.02</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Bradley Saenger, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 10-K of Tonix Pharmaceuticals Holding Corp.;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal controls over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 13, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ BRADLEY SAENGER</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Bradley Saenger</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 93 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Value: 94; Name: PageNo -->94<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.01
<SEQUENCE>7
<FILENAME>ex32-01.htm
<DESCRIPTION>CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="tnxp-10k_123122.htm">Tonix Pharmaceuticals Holding Corp. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.01</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER</B>&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B>&nbsp;<B>18 U.S.C. SECTION
1350,</B>&nbsp;<B>AS ADOPTED PURSUANT TO</B>&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">I, Seth Lederman,
certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that
the Annual Report of Tonix Pharmaceuticals Holding Corp. on Form 10-K for the fiscal year ended December 31, 2022 fully complies
with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this
Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Tonix
Pharmaceuticals Holding Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ SETH LEDERMAN</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Date: March 13, 2023</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Seth Lederman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Chief&nbsp;Executive&nbsp;Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">I, Bradley Saenger,
certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that
the Annual Report of Tonix Pharmaceuticals Holding Corp. on Form 10-K for the fiscal year ended December 31, 2022 fully complies
with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this
Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Tonix
Pharmaceuticals Holding Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ BRADLEY SAENGER</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Date: March 13, 2023</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Bradley Saenger</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Financial Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 95; Name: PageNo -->95<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>tnxp-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaaOGbP9w5dzeelBtm91HWn6PyYhVTLWAyHBz7MWQTwN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:tnxp="http://tonixpharma.com/20221231" elementFormDefault="qualified" targetNamespace="http://tonixpharma.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://tonixpharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" id="ConsolidatedStatementsOfStockholdersEquityParenthetical">
	  <link:definition>00000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
	  <link:definition>00000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/Business" id="Business">
	  <link:definition>00000010 - Disclosure - BUSINESS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
	  <link:definition>00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformation" id="OtherBalanceSheetInformation">
	  <link:definition>00000013 - Disclosure - OTHER BALANCE SHEET INFORMATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000014 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/TemporaryEquity" id="TemporaryEquity">
	  <link:definition>00000016 - Disclosure - TEMPORARY EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana" id="AssetPurchaseAgreementWithKatana">
	  <link:definition>00000017 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina" id="AssetPurchaseAgreementWithTrigemina">
	  <link:definition>00000018 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran" id="AssetPurchaseAgreementWithTrimaran">
	  <link:definition>00000019 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LicenseAgreementWithCuria" id="LicenseAgreementWithCuria">
	  <link:definition>00000020 - Disclosure - LICENSE AGREEMENT WITH CURIA</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta" id="LicenseAgreementWithUniversityOfAlberta">
	  <link:definition>00000021 - Disclosure - LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LicenseAgreementWithOyagen" id="LicenseAgreementWithOyagen">
	  <link:definition>00000022 - Disclosure - LICENSE AGREEMENT WITH OYAGEN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LicenseAgreementWithInserm" id="LicenseAgreementWithInserm">
	  <link:definition>00000023 - Disclosure - LICENSE AGREEMENT WITH INSERM</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity" id="LicenseAgreementsWithColumbiaUniversity">
	  <link:definition>00000024 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SaleOfCommonStock" id="SaleOfCommonStock">
	  <link:definition>00000025 - Disclosure - SALE OF COMMON STOCK</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000026 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStock" id="WarrantsToPurchaseCommonStock">
	  <link:definition>00000027 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/Leases" id="Leases">
	  <link:definition>00000028 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/Commitments" id="Commitments">
	  <link:definition>00000029 - Disclosure - COMMITMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000030 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000031 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
	  <link:definition>00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformationTables" id="OtherBalanceSheetInformationTables">
	  <link:definition>00000035 - Disclosure - OTHER BALANCE SHEET INFORMATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/TemporaryEquityTables" id="TemporaryEquityTables">
	  <link:definition>00000036 - Disclosure - TEMPORARY EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables" id="WarrantsToPurchaseCommonStockTables">
	  <link:definition>00000038 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000039 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000040 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/BusinessDetailsNarrative" id="BusinessDetailsNarrative">
	  <link:definition>00000041 - Disclosure - BUSINESS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" id="FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails">
	  <link:definition>00000042 - Disclosure - The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" id="PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails">
	  <link:definition>00000043 - Disclosure - Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" id="PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails">
	  <link:definition>00000045 - Disclosure - Property and equipment, net consisted of the following (in thousands): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
	  <link:definition>00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" id="ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails">
	  <link:definition>00000047 - Disclosure - Components of selected captions in the consolidated balance sheets consist of: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
	  <link:definition>00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000049 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" id="SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails">
	  <link:definition>00000050 - Disclosure - The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/TemporaryEquityDetailsNarrative" id="TemporaryEquityDetailsNarrative">
	  <link:definition>00000051 - Disclosure - TEMPORARY EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative" id="AssetPurchaseAgreementWithKatanaDetailsNarrative">
	  <link:definition>00000052 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative" id="AssetPurchaseAgreementWithTrigeminaDetailsNarrative">
	  <link:definition>00000053 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative" id="AssetPurchaseAgreementWithTrimaranDetailsNarrative">
	  <link:definition>00000054 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative" id="LicenseAgreementWithCuriaDetailsNarrative">
	  <link:definition>00000055 - Disclosure - LICENSE AGREEMENT WITH CURIA (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative" id="LicenseAgreementWithOyagenDetailsNarrative">
	  <link:definition>00000056 - Disclosure - LICENSE AGREEMENT WITH OYAGEN (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative" id="LicenseAgreementWithInsermDetailsNarrative">
	  <link:definition>00000057 - Disclosure - LICENSE AGREEMENT WITH INSERM (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative" id="LicenseAgreementsWithColumbiaUniversityDetailsNarrative">
	  <link:definition>00000058 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative" id="SaleOfCommonStockDetailsNarrative">
	  <link:definition>00000059 - Disclosure - SALE OF COMMON STOCK (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" id="SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails">
	  <link:definition>00000060 - Disclosure -  A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" id="AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails">
	  <link:definition>00000061 - Disclosure - The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000062 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" id="FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details">
	  <link:definition>00000063 - Disclosure - The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative" id="WarrantsToPurchaseCommonStockDetailsNarrative">
	  <link:definition>00000064 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" id="AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails">
	  <link:definition>00000065 - Disclosure - At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails" id="OtherInformationRelatedToLeasesWasAsFollowsDetails">
	  <link:definition>00000066 - Disclosure - Other information related to leases was as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000067 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
	  <link:definition>00000068 - Disclosure - COMMITMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails" id="ComponentsOfNetLossConsistOfFollowingInThousandsDetails">
	  <link:definition>00000069 - Disclosure - Components of the net loss consist of the following (in thousands): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" id="ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails">
	  <link:definition>00000070 - Disclosure - A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company&#8217;s income tax provision is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" id="DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails">
	  <link:definition>00000071 - Disclosure - Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000072 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tonixpharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="tnxp_StockIssuanceNineMember" name="StockIssuanceNineMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuanceJanuary2021Member" name="StockIssuanceJanuary2021Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuanceFebruary2021Member" name="StockIssuanceFebruary2021Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuanceTwoMember" name="StockIssuanceTwoMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_LandImprovementsAndLabEquipmentMember" name="LandImprovementsAndLabEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_FurnitureAndAllOtherEquipmentMember" name="FurnitureAndAllOtherEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_FurnitureAndEquipmentMember" name="FurnitureAndEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" name="OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_KatanaPharmaceuticalsIncMember" name="KatanaPharmaceuticalsIncMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_TrigeminaIncMember" name="TrigeminaIncMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AssignmentAndAssumptionAgreementMember" name="AssignmentAndAssumptionAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_TRImaranPharmaIncMember" name="TRImaranPharmaIncMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_WSULicenseAgreementMember" name="WSULicenseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_LicenseAgreementMember" name="LicenseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_CuriaMember" name="CuriaMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_OyaGenIncMember" name="OyaGenIncMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_InsermLicenseAgreementMember" name="InsermLicenseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_InsermMember" name="InsermMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_OxytocinBasedTherapeuticsMember" name="OxytocinBasedTherapeuticsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_TrusteesOfColumbiaUniversityMember" name="TrusteesOfColumbiaUniversityMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_TFF2ProductMember" name="TFF2ProductMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PurchaseAgreementWithLincolnPark2022Member" name="PurchaseAgreementWithLincolnPark2022Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PurchaseAgreementWithLincolnParkMember" name="PurchaseAgreementWithLincolnParkMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PurchaseAgreementWithLincolnPark2021Member" name="PurchaseAgreementWithLincolnPark2021Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PurchaseAgreement2021Member" name="PurchaseAgreement2021Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_UnderwritingAgreementMember" name="UnderwritingAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AllianceGlobalPartnersMember" name="AllianceGlobalPartnersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_SalesAgreementMember" name="SalesAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IncentiveStockOptionsPlan2019Member" name="IncentiveStockOptionsPlan2019Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IncentiveStockOptionsPlan2020Member" name="IncentiveStockOptionsPlan2020Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AmendedAndRestated2020PlanMember" name="AmendedAndRestated2020PlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_TenPercentOrMoreShareholderMember" name="TenPercentOrMoreShareholderMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_EmployeeStockPurchasePlan2022Member" name="EmployeeStockPurchasePlan2022Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_EmployeeStockPurchasePlansMember" name="EmployeeStockPurchasePlansMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_EmployeeStockPurchasePlan2020Member" name="EmployeeStockPurchasePlan2020Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_Warrant1Member" name="Warrant1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_Warrant2Member" name="Warrant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_Warrant3Member" name="Warrant3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_WarrantsFromFeb2020FinancingMember" name="WarrantsFromFeb2020FinancingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_NewLeaseArrangementMember" name="NewLeaseArrangementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ResearchOrganizationsMember" name="ResearchOrganizationsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ConstructionContractMember" name="ConstructionContractMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DefinedContributionPlan401KPlanMember" name="DefinedContributionPlan401KPlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ExistingShareRepurchaseProgramMember" name="ExistingShareRepurchaseProgramMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_NewShareRepurchaseProgramMember" name="NewShareRepurchaseProgramMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_HealionBioIncMember" name="HealionBioIncMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_EmployeeStockOption1Member" name="EmployeeStockOption1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_SalesAgreementWithAGPMember" name="SalesAgreementWithAGPMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PreferredStockSharesDesignated" name="PreferredStockSharesDesignated" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodValueNewIssues7" name="StockIssuedDuringPeriodValueNewIssues7" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodSharesNewIssues7" name="StockIssuedDuringPeriodSharesNewIssues7" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4" name="IssuanceOfCommonStockUnderPurchaseAgreement4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4" name="IssuanceOfCommonStockUnderPurchaseAgreementInShares4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2" name="IssuanceOfCommonStockUnderPurchaseAgreement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2" name="IssuanceOfCommonStockUnderPurchaseAgreementInShares2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement" name="IssuanceOfCommitmentSharesUnderPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" name="IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PreferredStockDeemedDividend" name="PreferredStockDeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodValueNewIssues14" name="StockIssuedDuringPeriodValueNewIssues14" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodSharesNewIssues14" name="StockIssuedDuringPeriodSharesNewIssues14" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodValueNewIssues15" name="StockIssuedDuringPeriodValueNewIssues15" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodSharesNewIssues15" name="StockIssuedDuringPeriodSharesNewIssues15" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodValueNewIssues19" name="StockIssuedDuringPeriodValueNewIssues19" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodSharesNewIssues19" name="StockIssuedDuringPeriodSharesNewIssues19" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3" name="IssuanceOfCommonStockUnderPurchaseAgreement3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3" name="IssuanceOfCommonStockUnderPurchaseAgreementInShares3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1" name="IssuanceOfCommonStockUnderPurchaseAgreement1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1" name="IssuanceOfCommonStockUnderPurchaseAgreementInShares1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodValueNewIssues21" name="StockIssuedDuringPeriodValueNewIssues21" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockIssuedDuringPeriodSharesNewIssues21" name="StockIssuedDuringPeriodSharesNewIssues21" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" name="IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" name="IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_WarrantsExercisedPrice" name="WarrantsExercisedPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_CommonStockIssuedToAcquireResearchAndDevelopment" name="CommonStockIssuedToAcquireResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureOtherBalanceSheetInformationAbstract" name="DisclosureOtherBalanceSheetInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_OtherBalanceSheetInformationDiclosureTextBlock" name="OtherBalanceSheetInformationDiclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureTemporaryEquityAbstract" name="DisclosureTemporaryEquityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_TemporaryEquityTextBlock" name="TemporaryEquityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract" name="DisclosureAssetPurchaseAgreementWithKatanaAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AssetPurchaseAgreementWithKatanaTextBlock" name="AssetPurchaseAgreementWithKatanaTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract" name="DisclosureAssetPurchaseAgreementWithTrigeminaAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock" name="AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureLicenseAgreementWithCuriaAbstract" name="DisclosureLicenseAgreementWithCuriaAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_LicenseAgreementCuriaTextBlock" name="LicenseAgreementCuriaTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract" name="DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_LicenseAgreementUniversityOfAlbertaTextBlock" name="LicenseAgreementUniversityOfAlbertaTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureLicenseAgreementWithOyagenAbstract" name="DisclosureLicenseAgreementWithOyagenAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_LicenseAgreementOyagenTextBlock" name="LicenseAgreementOyagenTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureLicenseAgreementWithInsermAbstract" name="DisclosureLicenseAgreementWithInsermAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_LicenseAgreementWithInsermTextBlock" name="LicenseAgreementWithInsermTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureSaleOfCommonStockAbstract" name="DisclosureSaleOfCommonStockAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_SaleOfCommonStockTextBlock" name="SaleOfCommonStockTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract" name="DisclosureWarrantsToPurchaseCommonStockAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StockWarrantsTextBlock" name="StockWarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" name="SummaryOfOtherInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ContractRelatedPrepaidExpenseCurrent" name="ContractRelatedPrepaidExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent" name="ProfessionalFeesAndOtherPrepaidExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ContractRelatedAccruedLiabilitiesCurrent" name="ContractRelatedAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" name="CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ConstructionInProgressAccruedLiabilitiesCurrent" name="ConstructionInProgressAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" name="ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_CashEquivalentsFairValue" name="CashEquivalentsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_GrossProceeds" name="GrossProceeds" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PreferredStockIssuanceCosts" name="PreferredStockIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AccretionOfCarryingValueToRedemptionValue" name="AccretionOfCarryingValueToRedemptionValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PercentageOfIssueDiscount" name="PercentageOfIssueDiscount" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_StatedValuePerShare" name="StatedValuePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_TemporaryEquityRedemptionPricePercentage" name="TemporaryEquityRedemptionPricePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_EscrowDepositForOriginalIssueDiscount" name="EscrowDepositForOriginalIssueDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_CommonStockValuePerShares" name="CommonStockValuePerShares" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AchievementPaymentsPayable" name="AchievementPaymentsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ReimbursementOfPatentExpenses" name="ReimbursementOfPatentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ContingentMilestonePaymentObligation" name="ContingentMilestonePaymentObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" name="PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_MaximumPercentageReductionOfRoyaltiesPayable" name="MaximumPercentageReductionOfRoyaltiesPayable" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_SalesMilestones" name="SalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PercentagePadOfConsideration" name="PercentagePadOfConsideration" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_CommitmentToPurchaseSharesUnderAgreement" name="CommitmentToPurchaseSharesUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_PercentageOfIssuanceByIssuerOfCommonStock" name="PercentageOfIssuanceByIssuerOfCommonStock" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval" name="MaximumNumberOfSharesIssuedWIthoutShareholderApproval" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_CashFeePercentage" name="CashFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_UnderwritingDiscount" name="UnderwritingDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_OfferingPricePerAgreement" name="OfferingPricePerAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_SalesAgentCommissionPercentage" name="SalesAgentCommissionPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AmountReturnToEmployee1" name="AmountReturnToEmployee1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_AccumulatedEmployeePayrollDeductions" name="AccumulatedEmployeePayrollDeductions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ClassOfWarrantsOrRightExpirationDate" name="ClassOfWarrantsOrRightExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ExercisePriceOfWarrantsExpired" name="ExercisePriceOfWarrantsExpired" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" name="EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent" name="OperatingLossCarryforwardsLimitationsOnUsePercent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_MinimumBidRequirementPerShare" name="MinimumBidRequirementPerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tnxp_ConsecutiveBusinessDaysForMinimumBidPrice" name="ConsecutiveBusinessDaysForMinimumBidPrice" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>tnxp-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tonixpharma.com/role/Cover" xlink:href="tnxp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedBalanceSheets" xlink:href="tnxp-20221231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="tnxp-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfOperations" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Business" xlink:href="tnxp-20221231.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPolicies" xlink:href="tnxp-20221231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNet" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformation" xlink:href="tnxp-20221231.xsd#OtherBalanceSheetInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FairValueMeasurements" xlink:href="tnxp-20221231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/StockholdersEquity" xlink:href="tnxp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/TemporaryEquity" xlink:href="tnxp-20221231.xsd#TemporaryEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithKatana" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrigemina" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrimaran" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithCuria" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithCuria" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithUniversityOfAlberta" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithOyagen" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithOyagen" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithInserm" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithInserm" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity" xlink:href="tnxp-20221231.xsd#LicenseAgreementsWithColumbiaUniversity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SaleOfCommonStock" xlink:href="tnxp-20221231.xsd#SaleOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Stock-basedCompensation" xlink:href="tnxp-20221231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStock" xlink:href="tnxp-20221231.xsd#WarrantsToPurchaseCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Leases" xlink:href="tnxp-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Commitments" xlink:href="tnxp-20221231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/IncomeTaxes" xlink:href="tnxp-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SubsequentEvents" xlink:href="tnxp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="tnxp-20221231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesTables" xlink:href="tnxp-20221231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetTables" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformationTables" xlink:href="tnxp-20221231.xsd#OtherBalanceSheetInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/TemporaryEquityTables" xlink:href="tnxp-20221231.xsd#TemporaryEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Stock-basedCompensationTables" xlink:href="tnxp-20221231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables" xlink:href="tnxp-20221231.xsd#WarrantsToPurchaseCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LeasesTables" xlink:href="tnxp-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/IncomeTaxesTables" xlink:href="tnxp-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/BusinessDetailsNarrative" xlink:href="tnxp-20221231.xsd#BusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" xlink:href="tnxp-20221231.xsd#FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" xlink:href="tnxp-20221231.xsd#PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="tnxp-20221231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:href="tnxp-20221231.xsd#ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="tnxp-20221231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="tnxp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" xlink:href="tnxp-20221231.xsd#SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/TemporaryEquityDetailsNarrative" xlink:href="tnxp-20221231.xsd#TemporaryEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithKatanaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrigeminaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrimaranDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithCuriaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithOyagenDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithInsermDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementsWithColumbiaUniversityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative" xlink:href="tnxp-20221231.xsd#SaleOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" xlink:href="tnxp-20221231.xsd#SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" xlink:href="tnxp-20221231.xsd#AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tnxp-20221231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" xlink:href="tnxp-20221231.xsd#FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative" xlink:href="tnxp-20221231.xsd#WarrantsToPurchaseCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:href="tnxp-20221231.xsd#AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="tnxp-20221231.xsd#OtherInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LeasesDetailsNarrative" xlink:href="tnxp-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/CommitmentsDetailsNarrative" xlink:href="tnxp-20221231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails" xlink:href="tnxp-20221231.xsd#ComponentsOfNetLossConsistOfFollowingInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" xlink:href="tnxp-20221231.xsd#ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" xlink:href="tnxp-20221231.xsd#DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="tnxp-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="tnxp-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaapRedeemablePreferredStockDividends" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapRedeemablePreferredStockDividends" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CommonStockIssuedToAcquireResearchAndDevelopment" xlink:label="loc_tnxpCommonStockIssuedToAcquireResearchAndDevelopment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tnxpCommonStockIssuedToAcquireResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="00000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Business" xlink:title="00000010 - Disclosure - BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPolicies" xlink:title="00000011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNet" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherBalanceSheetInformation" xlink:title="00000013 - Disclosure - OTHER BALANCE SHEET INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FairValueMeasurements" xlink:title="00000014 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/TemporaryEquity" xlink:title="00000016 - Disclosure - TEMPORARY EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana" xlink:title="00000017 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina" xlink:title="00000018 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran" xlink:title="00000019 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithCuria" xlink:title="00000020 - Disclosure - LICENSE AGREEMENT WITH CURIA" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta" xlink:title="00000021 - Disclosure - LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithOyagen" xlink:title="00000022 - Disclosure - LICENSE AGREEMENT WITH OYAGEN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithInserm" xlink:title="00000023 - Disclosure - LICENSE AGREEMENT WITH INSERM" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity" xlink:title="00000024 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SaleOfCommonStock" xlink:title="00000025 - Disclosure - SALE OF COMMON STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensation" xlink:title="00000026 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStock" xlink:title="00000027 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Leases" xlink:title="00000028 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Commitments" xlink:title="00000029 - Disclosure - COMMITMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IncomeTaxes" xlink:title="00000030 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SubsequentEvents" xlink:title="00000031 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetTables" xlink:title="00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherBalanceSheetInformationTables" xlink:title="00000035 - Disclosure - OTHER BALANCE SHEET INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/TemporaryEquityTables" xlink:title="00000036 - Disclosure - TEMPORARY EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensationTables" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables" xlink:title="00000038 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LeasesTables" xlink:title="00000039 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IncomeTaxesTables" xlink:title="00000040 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/BusinessDetailsNarrative" xlink:title="00000041 - Disclosure - BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" xlink:title="00000042 - Disclosure - The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" xlink:title="00000043 - Disclosure - Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:title="00000045 - Disclosure - Property and equipment, net consisted of the following (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:title="00000047 - Disclosure - Components of selected captions in the consolidated balance sheets consist of: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContractRelatedPrepaidExpenseCurrent" xlink:label="loc_tnxpContractRelatedPrepaidExpenseCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_tnxpContractRelatedPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent" xlink:label="loc_tnxpProfessionalFeesAndOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_tnxpProfessionalFeesAndOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContractRelatedAccruedLiabilitiesCurrent" xlink:label="loc_tnxpContractRelatedAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_tnxpContractRelatedAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" xlink:label="loc_tnxpCompensationAndCompensationRelatedAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_tnxpCompensationAndCompensationRelatedAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ConstructionInProgressAccruedLiabilitiesCurrent" xlink:label="loc_tnxpConstructionInProgressAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_tnxpConstructionInProgressAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_tnxpProfessionalFeesAndOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_tnxpProfessionalFeesAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000049 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" xlink:title="00000050 - Disclosure - The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_GrossProceeds" xlink:label="loc_tnxpGrossProceeds" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:to="loc_tnxpGrossProceeds" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockIssuanceCosts" xlink:label="loc_tnxpPreferredStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:to="loc_tnxpPreferredStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_tnxpAccretionOfCarryingValueToRedemptionValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:to="loc_tnxpAccretionOfCarryingValueToRedemptionValue" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/TemporaryEquityDetailsNarrative" xlink:title="00000051 - Disclosure - TEMPORARY EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative" xlink:title="00000052 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative" xlink:title="00000053 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative" xlink:title="00000054 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative" xlink:title="00000055 - Disclosure - LICENSE AGREEMENT WITH CURIA (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative" xlink:title="00000056 - Disclosure - LICENSE AGREEMENT WITH OYAGEN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative" xlink:title="00000057 - Disclosure - LICENSE AGREEMENT WITH INSERM (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative" xlink:title="00000058 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative" xlink:title="00000059 - Disclosure - SALE OF COMMON STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" xlink:title="00000060 - Disclosure -  A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" xlink:title="00000061 - Disclosure - The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000062 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" xlink:title="00000063 - Disclosure - The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative" xlink:title="00000064 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:title="00000065 - Disclosure - At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000066 - Disclosure - Other information related to leases was as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LeasesDetailsNarrative" xlink:title="00000067 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CommitmentsDetailsNarrative" xlink:title="00000068 - Disclosure - COMMITMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails" xlink:title="00000069 - Disclosure - Components of the net loss consist of the following (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" xlink:title="00000070 - Disclosure - A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company&#8217;s income tax provision is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" xlink:label="loc_tnxpEffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_tnxpEffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" xlink:title="00000071 - Disclosure - Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000072 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>tnxp-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tonixpharma.com/role/Cover" xlink:href="tnxp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedBalanceSheets" xlink:href="tnxp-20221231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="tnxp-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfOperations" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Business" xlink:href="tnxp-20221231.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPolicies" xlink:href="tnxp-20221231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNet" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformation" xlink:href="tnxp-20221231.xsd#OtherBalanceSheetInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FairValueMeasurements" xlink:href="tnxp-20221231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/StockholdersEquity" xlink:href="tnxp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/TemporaryEquity" xlink:href="tnxp-20221231.xsd#TemporaryEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithKatana" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrigemina" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrimaran" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithCuria" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithCuria" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithUniversityOfAlberta" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithOyagen" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithOyagen" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithInserm" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithInserm" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity" xlink:href="tnxp-20221231.xsd#LicenseAgreementsWithColumbiaUniversity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SaleOfCommonStock" xlink:href="tnxp-20221231.xsd#SaleOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Stock-basedCompensation" xlink:href="tnxp-20221231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStock" xlink:href="tnxp-20221231.xsd#WarrantsToPurchaseCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Leases" xlink:href="tnxp-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Commitments" xlink:href="tnxp-20221231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/IncomeTaxes" xlink:href="tnxp-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SubsequentEvents" xlink:href="tnxp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="tnxp-20221231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesTables" xlink:href="tnxp-20221231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetTables" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformationTables" xlink:href="tnxp-20221231.xsd#OtherBalanceSheetInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/TemporaryEquityTables" xlink:href="tnxp-20221231.xsd#TemporaryEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Stock-basedCompensationTables" xlink:href="tnxp-20221231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables" xlink:href="tnxp-20221231.xsd#WarrantsToPurchaseCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LeasesTables" xlink:href="tnxp-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/IncomeTaxesTables" xlink:href="tnxp-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/BusinessDetailsNarrative" xlink:href="tnxp-20221231.xsd#BusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" xlink:href="tnxp-20221231.xsd#FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" xlink:href="tnxp-20221231.xsd#PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="tnxp-20221231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:href="tnxp-20221231.xsd#ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="tnxp-20221231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="tnxp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" xlink:href="tnxp-20221231.xsd#SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/TemporaryEquityDetailsNarrative" xlink:href="tnxp-20221231.xsd#TemporaryEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithKatanaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrigeminaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrimaranDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithCuriaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithOyagenDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithInsermDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementsWithColumbiaUniversityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative" xlink:href="tnxp-20221231.xsd#SaleOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" xlink:href="tnxp-20221231.xsd#SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" xlink:href="tnxp-20221231.xsd#AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tnxp-20221231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" xlink:href="tnxp-20221231.xsd#FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative" xlink:href="tnxp-20221231.xsd#WarrantsToPurchaseCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:href="tnxp-20221231.xsd#AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="tnxp-20221231.xsd#OtherInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LeasesDetailsNarrative" xlink:href="tnxp-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/CommitmentsDetailsNarrative" xlink:href="tnxp-20221231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails" xlink:href="tnxp-20221231.xsd#ComponentsOfNetLossConsistOfFollowingInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" xlink:href="tnxp-20221231.xsd#ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" xlink:href="tnxp-20221231.xsd#DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="tnxp-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="tnxp-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockSharesDesignated" xlink:label="loc_tnxpPreferredStockSharesDesignated_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpPreferredStockSharesDesignated_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues7" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues7_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues7_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues7" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues7_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues7_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement4_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement4_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares4_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares4_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement2_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares2_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement" xlink:label="loc_tnxpIssuanceOfCommitmentSharesUnderPurchaseAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommitmentSharesUnderPurchaseAgreement_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" xlink:label="loc_tnxpIssuanceOfCommitmentSharesUnderPurchaseAgreementInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommitmentSharesUnderPurchaseAgreementInShares_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockDeemedDividend" xlink:label="loc_tnxpPreferredStockDeemedDividend_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpPreferredStockDeemedDividend_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues14" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues14_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues14_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues14" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues14_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues14_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues1_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues1_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues15" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues15_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues15_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues15" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues15_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues15_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues19" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues19_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues19_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues19" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues19_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues19_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement3_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares3_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement1_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares1_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues21" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues21_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues21_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues21" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues21_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues21_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" xlink:label="loc_tnxpIssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" xlink:label="loc_tnxpIssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceNineMember" xlink:label="loc_tnxpStockIssuanceNineMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_tnxpStockIssuanceNineMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceJanuary2021Member" xlink:label="loc_tnxpStockIssuanceJanuary2021Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_tnxpStockIssuanceJanuary2021Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceFebruary2021Member" xlink:label="loc_tnxpStockIssuanceFebruary2021Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_tnxpStockIssuanceFebruary2021Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceTwoMember" xlink:label="loc_tnxpStockIssuanceTwoMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_tnxpStockIssuanceTwoMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WarrantsExercisedPrice" xlink:label="loc_tnxpWarrantsExercisedPrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_tnxpWarrantsExercisedPrice_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="00000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaapRedeemableConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapRedeemableConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Business" xlink:title="00000010 - Disclosure - BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPolicies" xlink:title="00000011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNet" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherBalanceSheetInformation" xlink:title="00000013 - Disclosure - OTHER BALANCE SHEET INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FairValueMeasurements" xlink:title="00000014 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/TemporaryEquity" xlink:title="00000016 - Disclosure - TEMPORARY EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana" xlink:title="00000017 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina" xlink:title="00000018 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran" xlink:title="00000019 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithCuria" xlink:title="00000020 - Disclosure - LICENSE AGREEMENT WITH CURIA" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta" xlink:title="00000021 - Disclosure - LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithOyagen" xlink:title="00000022 - Disclosure - LICENSE AGREEMENT WITH OYAGEN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithInserm" xlink:title="00000023 - Disclosure - LICENSE AGREEMENT WITH INSERM" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity" xlink:title="00000024 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SaleOfCommonStock" xlink:title="00000025 - Disclosure - SALE OF COMMON STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensation" xlink:title="00000026 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStock" xlink:title="00000027 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Leases" xlink:title="00000028 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Commitments" xlink:title="00000029 - Disclosure - COMMITMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IncomeTaxes" xlink:title="00000030 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SubsequentEvents" xlink:title="00000031 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetTables" xlink:title="00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherBalanceSheetInformationTables" xlink:title="00000035 - Disclosure - OTHER BALANCE SHEET INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/TemporaryEquityTables" xlink:title="00000036 - Disclosure - TEMPORARY EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensationTables" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables" xlink:title="00000038 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LeasesTables" xlink:title="00000039 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IncomeTaxesTables" xlink:title="00000040 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/BusinessDetailsNarrative" xlink:title="00000041 - Disclosure - BUSINESS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" xlink:title="00000042 - Disclosure - The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" xlink:title="00000043 - Disclosure - Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LandImprovementsAndLabEquipmentMember" xlink:label="loc_tnxpLandImprovementsAndLabEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpLandImprovementsAndLabEquipmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_FurnitureAndAllOtherEquipmentMember" xlink:label="loc_tnxpFurnitureAndAllOtherEquipmentMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpFurnitureAndAllOtherEquipmentMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRestrictedCash_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:title="00000045 - Disclosure - Property and equipment, net consisted of the following (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember" xlink:label="loc_us-gaapLandImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_FurnitureAndEquipmentMember" xlink:label="loc_tnxpFurnitureAndEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpFurnitureAndEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LaboratoryEquipmentMember" xlink:label="loc_tnxpLaboratoryEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpLaboratoryEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MD" xlink:label="loc_stprMD_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMD_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="loc_stprMA_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMA_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MT" xlink:label="loc_stprMT_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMT_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" xlink:label="loc_tnxpOfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpOfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAreaOfLand_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAdditions_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAdditions_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="loc_us-gaapPaymentsForConstructionInProcess_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForConstructionInProcess_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_140" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:title="00000047 - Disclosure - Components of selected captions in the consolidated balance sheets consist of: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CashEquivalentsFairValue" xlink:label="loc_tnxpCashEquivalentsFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_tnxpCashEquivalentsFairValue_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000049 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" xlink:title="00000050 - Disclosure - The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_GrossProceeds" xlink:label="loc_tnxpGrossProceeds_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpGrossProceeds_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockIssuanceCosts" xlink:label="loc_tnxpPreferredStockIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpPreferredStockIssuanceCosts_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_tnxpAccretionOfCarryingValueToRedemptionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpAccretionOfCarryingValueToRedemptionValue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/TemporaryEquityDetailsNarrative" xlink:title="00000051 - Disclosure - TEMPORARY EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaapRedeemableConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapRedeemableConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfIssueDiscount" xlink:label="loc_tnxpPercentageOfIssueDiscount_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpPercentageOfIssueDiscount_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StatedValuePerShare" xlink:label="loc_tnxpStatedValuePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStatedValuePerShare_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TemporaryEquityRedemptionPricePercentage" xlink:label="loc_tnxpTemporaryEquityRedemptionPricePercentage_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpTemporaryEquityRedemptionPricePercentage_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEscrowDeposit_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EscrowDepositForOriginalIssueDiscount" xlink:label="loc_tnxpEscrowDepositForOriginalIssueDiscount_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpEscrowDepositForOriginalIssueDiscount_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_250" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_250" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative" xlink:title="00000052 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementMember" xlink:label="loc_tnxpAssetPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssetPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_KatanaPharmaceuticalsIncMember" xlink:label="loc_tnxpKatanaPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpKatanaPharmaceuticalsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative" xlink:title="00000053 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementMember" xlink:label="loc_tnxpAssetPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssetPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssignmentAndAssumptionAgreementMember" xlink:label="loc_tnxpAssignmentAndAssumptionAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssignmentAndAssumptionAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TrigeminaIncMember" xlink:label="loc_tnxpTrigeminaIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpTrigeminaIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CommonStockValuePerShares" xlink:label="loc_tnxpCommonStockValuePerShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpCommonStockValuePerShares_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative" xlink:title="00000054 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementMember" xlink:label="loc_tnxpAssetPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssetPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WSULicenseAgreementMember" xlink:label="loc_tnxpWSULicenseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpWSULicenseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TRImaranPharmaIncMember" xlink:label="loc_tnxpTRImaranPharmaIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpTRImaranPharmaIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredLiabilitiesIncurred_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredLiabilitiesIncurred_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AchievementPaymentsPayable" xlink:label="loc_tnxpAchievementPaymentsPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpAchievementPaymentsPayable_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ReimbursementOfPatentExpenses" xlink:label="loc_tnxpReimbursementOfPatentExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpReimbursementOfPatentExpenses_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContingentMilestonePaymentObligation" xlink:label="loc_tnxpContingentMilestonePaymentObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpContingentMilestonePaymentObligation_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:label="loc_tnxpPercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpPercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MaximumPercentageReductionOfRoyaltiesPayable" xlink:label="loc_tnxpMaximumPercentageReductionOfRoyaltiesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpMaximumPercentageReductionOfRoyaltiesPayable_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative" xlink:title="00000055 - Disclosure - LICENSE AGREEMENT WITH CURIA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementMember" xlink:label="loc_tnxpLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CuriaMember" xlink:label="loc_tnxpCuriaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpCuriaMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative" xlink:title="00000056 - Disclosure - LICENSE AGREEMENT WITH OYAGEN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementMember" xlink:label="loc_tnxpLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OyaGenIncMember" xlink:label="loc_tnxpOyaGenIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpOyaGenIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative" xlink:title="00000057 - Disclosure - LICENSE AGREEMENT WITH INSERM (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_InsermLicenseAgreementMember" xlink:label="loc_tnxpInsermLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpInsermLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_InsermMember" xlink:label="loc_tnxpInsermMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpInsermMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OxytocinBasedTherapeuticsMember" xlink:label="loc_tnxpOxytocinBasedTherapeuticsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_tnxpOxytocinBasedTherapeuticsMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesMilestones" xlink:label="loc_tnxpSalesMilestones_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpSalesMilestones_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative" xlink:title="00000058 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementMember" xlink:label="loc_tnxpLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TrusteesOfColumbiaUniversityMember" xlink:label="loc_tnxpTrusteesOfColumbiaUniversityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_tnxpTrusteesOfColumbiaUniversityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TFF2ProductMember" xlink:label="loc_tnxpTFF2ProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_tnxpTFF2ProductMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:label="loc_tnxpPercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpPercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MaximumPercentageReductionOfRoyaltiesPayable" xlink:label="loc_tnxpMaximumPercentageReductionOfRoyaltiesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpMaximumPercentageReductionOfRoyaltiesPayable_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContingentMilestonePaymentObligation" xlink:label="loc_tnxpContingentMilestonePaymentObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpContingentMilestonePaymentObligation_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentagePadOfConsideration" xlink:label="loc_tnxpPercentagePadOfConsideration_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpPercentagePadOfConsideration_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative" xlink:title="00000059 - Disclosure - SALE OF COMMON STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnPark2022Member" xlink:label="loc_tnxpPurchaseAgreementWithLincolnPark2022Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreementWithLincolnPark2022Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnParkMember" xlink:label="loc_tnxpPurchaseAgreementWithLincolnParkMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreementWithLincolnParkMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnPark2021Member" xlink:label="loc_tnxpPurchaseAgreementWithLincolnPark2021Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreementWithLincolnPark2021Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreement2021Member" xlink:label="loc_tnxpPurchaseAgreement2021Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreement2021Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_UnderwritingAgreementMember" xlink:label="loc_tnxpUnderwritingAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpUnderwritingAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesAgreementMember" xlink:label="loc_tnxpSalesAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpSalesAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LincolnParkCapitalFundLLCMember" xlink:label="loc_tnxpLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_tnxpLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AllianceGlobalPartnersMember" xlink:label="loc_tnxpAllianceGlobalPartnersMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_tnxpAllianceGlobalPartnersMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AllianceGlobalPartnersMember" xlink:label="loc_tnxpAllianceGlobalPartnersMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_tnxpAllianceGlobalPartnersMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CommitmentToPurchaseSharesUnderAgreement" xlink:label="loc_tnxpCommitmentToPurchaseSharesUnderAgreement_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpCommitmentToPurchaseSharesUnderAgreement_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfIssuanceByIssuerOfCommonStock" xlink:label="loc_tnxpPercentageOfIssuanceByIssuerOfCommonStock_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpPercentageOfIssuanceByIssuerOfCommonStock_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval" xlink:label="loc_tnxpMaximumNumberOfSharesIssuedWIthoutShareholderApproval_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpMaximumNumberOfSharesIssuedWIthoutShareholderApproval_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CashFeePercentage" xlink:label="loc_tnxpCashFeePercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpCashFeePercentage_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_UnderwritingDiscount" xlink:label="loc_tnxpUnderwritingDiscount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpUnderwritingDiscount_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OfferingPricePerAgreement" xlink:label="loc_tnxpOfferingPricePerAgreement_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpOfferingPricePerAgreement_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesAgentCommissionPercentage" xlink:label="loc_tnxpSalesAgentCommissionPercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpSalesAgentCommissionPercentage_170" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" xlink:title="00000060 - Disclosure -  A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" xlink:title="00000061 - Disclosure - The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000062 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IncentiveStockOptionsPlan2019Member" xlink:label="loc_tnxpIncentiveStockOptionsPlan2019Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpIncentiveStockOptionsPlan2019Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IncentiveStockOptionsPlan2020Member" xlink:label="loc_tnxpIncentiveStockOptionsPlan2020Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpIncentiveStockOptionsPlan2020Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AmendedAndRestated2020PlanMember" xlink:label="loc_tnxpAmendedAndRestated2020PlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpAmendedAndRestated2020PlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockPurchasePlan2022Member" xlink:label="loc_tnxpEmployeeStockPurchasePlan2022Member_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpEmployeeStockPurchasePlan2022Member_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockPurchasePlansMember" xlink:label="loc_tnxpEmployeeStockPurchasePlansMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpEmployeeStockPurchasePlansMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockPurchasePlan2020Member" xlink:label="loc_tnxpEmployeeStockPurchasePlan2020Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpEmployeeStockPurchasePlan2020Member_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TenPercentOrMoreShareholderMember" xlink:label="loc_tnxpTenPercentOrMoreShareholderMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_tnxpTenPercentOrMoreShareholderMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srtExecutiveOfficerMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtExecutiveOfficerMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:label="loc_tnxpShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_tnxpShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_280" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_280" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_280" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_280" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_280" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_280" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_280" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_280" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_280" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_280" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_280" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_280" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_280" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AmountReturnToEmployee1" xlink:label="loc_tnxpAmountReturnToEmployee1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_tnxpAmountReturnToEmployee1_280" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AccumulatedEmployeePayrollDeductions" xlink:label="loc_tnxpAccumulatedEmployeePayrollDeductions_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_tnxpAccumulatedEmployeePayrollDeductions_280" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" xlink:title="00000063 - Disclosure - The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant1Member" xlink:label="loc_tnxpWarrant1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tnxpWarrant1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant2Member" xlink:label="loc_tnxpWarrant2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tnxpWarrant2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant3Member" xlink:label="loc_tnxpWarrant3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tnxpWarrant3Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ClassOfWarrantsOrRightExpirationDate" xlink:label="loc_tnxpClassOfWarrantsOrRightExpirationDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_tnxpClassOfWarrantsOrRightExpirationDate_80" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative" xlink:title="00000064 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WarrantsFromFeb2020FinancingMember" xlink:label="loc_tnxpWarrantsFromFeb2020FinancingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tnxpWarrantsFromFeb2020FinancingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant1Member" xlink:label="loc_tnxpWarrant1Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_tnxpWarrant1Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ExercisePriceOfWarrantsExpired" xlink:label="loc_tnxpExercisePriceOfWarrantsExpired_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_tnxpExercisePriceOfWarrantsExpired_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:title="00000065 - Disclosure - At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000066 - Disclosure - Other information related to leases was as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LeasesDetailsNarrative" xlink:title="00000067 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_NewLeaseArrangementMember" xlink:label="loc_tnxpNewLeaseArrangementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_tnxpNewLeaseArrangementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CommitmentsDetailsNarrative" xlink:title="00000068 - Disclosure - COMMITMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ResearchOrganizationsMember" xlink:label="loc_tnxpResearchOrganizationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_tnxpResearchOrganizationsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ConstructionContractMember" xlink:label="loc_tnxpConstructionContractMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_tnxpConstructionContractMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DefinedContributionPlan401KPlanMember" xlink:label="loc_tnxpDefinedContributionPlan401KPlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpDefinedContributionPlan401KPlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitment_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="loc_us-gaapDefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:label="loc_us-gaapDefinedContributionPlanAdministrativeExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDefinedContributionPlanAdministrativeExpenses_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails" xlink:title="00000069 - Disclosure - Components of the net loss consist of the following (in thousands): (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" xlink:title="00000070 - Disclosure - A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company&#8217;s income tax provision is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" xlink:title="00000071 - Disclosure - Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands): (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000072 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE" xlink:label="loc_countryIE_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIE_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BM" xlink:label="loc_countryBM_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBM_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ" xlink:label="loc_stprNJ_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprNJ_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="loc_stprMA_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMA_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent" xlink:label="loc_tnxpOperatingLossCarryforwardsLimitationsOnUsePercent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_tnxpOperatingLossCarryforwardsLimitationsOnUsePercent_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_130" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaapShareRepurchaseProgramAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapShareRepurchaseProgramAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaapShareRepurchaseProgramDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareRepurchaseProgramAxis" xlink:to="loc_us-gaapShareRepurchaseProgramDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaapShareRepurchaseProgramDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareRepurchaseProgramAxis" xlink:to="loc_us-gaapShareRepurchaseProgramDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ExistingShareRepurchaseProgramMember" xlink:label="loc_tnxpExistingShareRepurchaseProgramMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareRepurchaseProgramDomain" xlink:to="loc_tnxpExistingShareRepurchaseProgramMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_NewShareRepurchaseProgramMember" xlink:label="loc_tnxpNewShareRepurchaseProgramMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareRepurchaseProgramDomain" xlink:to="loc_tnxpNewShareRepurchaseProgramMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementMember" xlink:label="loc_tnxpAssetPurchaseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssetPurchaseAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesAgreementWithAGPMember" xlink:label="loc_tnxpSalesAgreementWithAGPMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpSalesAgreementWithAGPMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnPark2022Member" xlink:label="loc_tnxpPurchaseAgreementWithLincolnPark2022Member_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreementWithLincolnPark2022Member_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_HealionBioIncMember" xlink:label="loc_tnxpHealionBioIncMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpHealionBioIncMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockOption1Member" xlink:label="loc_tnxpEmployeeStockOption1Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_tnxpEmployeeStockOption1Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaapStockRepurchaseProgramAuthorizedAmount1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchaseProgramAuthorizedAmount1_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaapTreasuryStockAcquiredAverageCostPerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapTreasuryStockAcquiredAverageCostPerShare_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MinimumBidRequirementPerShare" xlink:label="loc_tnxpMinimumBidRequirementPerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_tnxpMinimumBidRequirementPerShare_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ConsecutiveBusinessDaysForMinimumBidPrice" xlink:label="loc_tnxpConsecutiveBusinessDaysForMinimumBidPrice_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_tnxpConsecutiveBusinessDaysForMinimumBidPrice_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_180" xlink:type="arc" order="13" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>tnxp-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceNineMember" xlink:label="tnxp_StockIssuanceNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuanceNineMember" xlink:to="tnxp_StockIssuanceNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuanceNineMember_lbl" xml:lang="en-US">Issuance of common stock under At-the-market offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceJanuary2021Member" xlink:label="tnxp_StockIssuanceJanuary2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuanceJanuary2021Member" xlink:to="tnxp_StockIssuanceJanuary2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuanceJanuary2021Member_lbl" xml:lang="en-US">Issuance of common stock in January 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceFebruary2021Member" xlink:label="tnxp_StockIssuanceFebruary2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuanceFebruary2021Member" xlink:to="tnxp_StockIssuanceFebruary2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuanceFebruary2021Member_lbl" xml:lang="en-US">Issuance of common stock in February 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceTwoMember" xlink:label="tnxp_StockIssuanceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuanceTwoMember" xlink:to="tnxp_StockIssuanceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuanceTwoMember_lbl" xml:lang="en-US">Issuance of common stock under 2021 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LandImprovementsAndLabEquipmentMember" xlink:label="tnxp_LandImprovementsAndLabEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LandImprovementsAndLabEquipmentMember" xlink:to="tnxp_LandImprovementsAndLabEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_LandImprovementsAndLabEquipmentMember_lbl" xml:lang="en-US">Land Improvements and Lab Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_FurnitureAndAllOtherEquipmentMember" xlink:label="tnxp_FurnitureAndAllOtherEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_FurnitureAndAllOtherEquipmentMember" xlink:to="tnxp_FurnitureAndAllOtherEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_FurnitureAndAllOtherEquipmentMember_lbl" xml:lang="en-US">Furniture and All Other Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember" xlink:label="us-gaap_LandImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovementsMember" xlink:to="us-gaap_LandImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandImprovementsMember_lbl" xml:lang="en-US">Land Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_FurnitureAndEquipmentMember" xlink:label="tnxp_FurnitureAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_FurnitureAndEquipmentMember" xlink:to="tnxp_FurnitureAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_FurnitureAndEquipmentMember_lbl" xml:lang="en-US">Furniture and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LaboratoryEquipmentMember" xlink:label="tnxp_LaboratoryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LaboratoryEquipmentMember" xlink:to="tnxp_LaboratoryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MD" xlink:label="stpr_MD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MD" xlink:to="stpr_MD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_MD_lbl" xml:lang="en-US">MARYLAND</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" xlink:label="tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" xlink:to="tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment and Laboratory equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_MA_lbl" xml:lang="en-US">MASSACHUSETTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MT" xlink:label="stpr_MT" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MT" xlink:to="stpr_MT_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_MT_lbl" xml:lang="en-US">MONTANA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementMember" xlink:label="tnxp_AssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AssetPurchaseAgreementMember" xlink:to="tnxp_AssetPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_KatanaPharmaceuticalsIncMember" xlink:label="tnxp_KatanaPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_KatanaPharmaceuticalsIncMember" xlink:to="tnxp_KatanaPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_KatanaPharmaceuticalsIncMember_lbl" xml:lang="en-US">Katana Pharmaceuticals, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TrigeminaIncMember" xlink:label="tnxp_TrigeminaIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TrigeminaIncMember" xlink:to="tnxp_TrigeminaIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_TrigeminaIncMember_lbl" xml:lang="en-US">Trigemina, Inc.[Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssignmentAndAssumptionAgreementMember" xlink:label="tnxp_AssignmentAndAssumptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AssignmentAndAssumptionAgreementMember" xlink:to="tnxp_AssignmentAndAssumptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AssignmentAndAssumptionAgreementMember_lbl" xml:lang="en-US">Assignment and Assumption Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TRImaranPharmaIncMember" xlink:label="tnxp_TRImaranPharmaIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TRImaranPharmaIncMember" xlink:to="tnxp_TRImaranPharmaIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_TRImaranPharmaIncMember_lbl" xml:lang="en-US">TRImaran Pharma Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WSULicenseAgreementMember" xlink:label="tnxp_WSULicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_WSULicenseAgreementMember" xlink:to="tnxp_WSULicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_WSULicenseAgreementMember_lbl" xml:lang="en-US">WSU License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementMember" xlink:label="tnxp_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementMember" xlink:to="tnxp_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CuriaMember" xlink:label="tnxp_CuriaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CuriaMember" xlink:to="tnxp_CuriaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_CuriaMember_lbl" xml:lang="en-US">Curia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OyaGenIncMember" xlink:label="tnxp_OyaGenIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OyaGenIncMember" xlink:to="tnxp_OyaGenIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_OyaGenIncMember_lbl" xml:lang="en-US">Oya Gen Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_InsermLicenseAgreementMember" xlink:label="tnxp_InsermLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_InsermLicenseAgreementMember" xlink:to="tnxp_InsermLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tnxp_InsermLicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_InsermMember" xlink:label="tnxp_InsermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_InsermMember" xlink:to="tnxp_InsermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_InsermMember_lbl" xml:lang="en-US">Inserm [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OxytocinBasedTherapeuticsMember" xlink:label="tnxp_OxytocinBasedTherapeuticsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OxytocinBasedTherapeuticsMember" xlink:to="tnxp_OxytocinBasedTherapeuticsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_OxytocinBasedTherapeuticsMember_lbl" xml:lang="en-US">Oxytocin-based Therapeutics [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TrusteesOfColumbiaUniversityMember" xlink:label="tnxp_TrusteesOfColumbiaUniversityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TrusteesOfColumbiaUniversityMember" xlink:to="tnxp_TrusteesOfColumbiaUniversityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_TrusteesOfColumbiaUniversityMember_lbl" xml:lang="en-US">Trustees Of Columbia University [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TFF2ProductMember" xlink:label="tnxp_TFF2ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TFF2ProductMember" xlink:to="tnxp_TFF2ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_TFF2ProductMember_lbl" xml:lang="en-US">TFF2 Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnPark2022Member" xlink:label="tnxp_PurchaseAgreementWithLincolnPark2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PurchaseAgreementWithLincolnPark2022Member" xlink:to="tnxp_PurchaseAgreementWithLincolnPark2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PurchaseAgreementWithLincolnPark2022Member_lbl" xml:lang="en-US">Purchase Agreement with Lincoln Park 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LincolnParkCapitalFundLLCMember" xlink:label="tnxp_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LincolnParkCapitalFundLLCMember" xlink:to="tnxp_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnParkMember" xlink:label="tnxp_PurchaseAgreementWithLincolnParkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PurchaseAgreementWithLincolnParkMember" xlink:to="tnxp_PurchaseAgreementWithLincolnParkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PurchaseAgreementWithLincolnParkMember_lbl" xml:lang="en-US">Purchase Agreement With Lincoln Park [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnPark2021Member" xlink:label="tnxp_PurchaseAgreementWithLincolnPark2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PurchaseAgreementWithLincolnPark2021Member" xlink:to="tnxp_PurchaseAgreementWithLincolnPark2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PurchaseAgreementWithLincolnPark2021Member_lbl" xml:lang="en-US">Purchase Agreement with Lincoln Park 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreement2021Member" xlink:label="tnxp_PurchaseAgreement2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PurchaseAgreement2021Member" xlink:to="tnxp_PurchaseAgreement2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PurchaseAgreement2021Member_lbl" xml:lang="en-US">Purchase Agreement 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_UnderwritingAgreementMember" xlink:label="tnxp_UnderwritingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_UnderwritingAgreementMember" xlink:to="tnxp_UnderwritingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AllianceGlobalPartnersMember" xlink:label="tnxp_AllianceGlobalPartnersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AllianceGlobalPartnersMember" xlink:to="tnxp_AllianceGlobalPartnersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AllianceGlobalPartnersMember_lbl" xml:lang="en-US">Alliance Global Partners [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesAgreementMember" xlink:label="tnxp_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SalesAgreementMember" xlink:to="tnxp_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IncentiveStockOptionsPlan2019Member" xlink:label="tnxp_IncentiveStockOptionsPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IncentiveStockOptionsPlan2019Member" xlink:to="tnxp_IncentiveStockOptionsPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IncentiveStockOptionsPlan2019Member_lbl" xml:lang="en-US">2019 Incentive Stock Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IncentiveStockOptionsPlan2020Member" xlink:label="tnxp_IncentiveStockOptionsPlan2020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IncentiveStockOptionsPlan2020Member" xlink:to="tnxp_IncentiveStockOptionsPlan2020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IncentiveStockOptionsPlan2020Member_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AmendedAndRestated2020PlanMember" xlink:label="tnxp_AmendedAndRestated2020PlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AmendedAndRestated2020PlanMember" xlink:to="tnxp_AmendedAndRestated2020PlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AmendedAndRestated2020PlanMember_lbl" xml:lang="en-US">Amended and Restated 2020 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TenPercentOrMoreShareholderMember" xlink:label="tnxp_TenPercentOrMoreShareholderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TenPercentOrMoreShareholderMember" xlink:to="tnxp_TenPercentOrMoreShareholderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_TenPercentOrMoreShareholderMember_lbl" xml:lang="en-US">10% or more Shareholder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockPurchasePlan2022Member" xlink:label="tnxp_EmployeeStockPurchasePlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EmployeeStockPurchasePlan2022Member" xlink:to="tnxp_EmployeeStockPurchasePlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_EmployeeStockPurchasePlan2022Member_lbl" xml:lang="en-US">Employee Stock Purchase Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockPurchasePlansMember" xlink:label="tnxp_EmployeeStockPurchasePlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EmployeeStockPurchasePlansMember" xlink:to="tnxp_EmployeeStockPurchasePlansMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_EmployeeStockPurchasePlansMember_lbl" xml:lang="en-US">Employee Stock Purchase Plans [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockPurchasePlan2020Member" xlink:label="tnxp_EmployeeStockPurchasePlan2020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EmployeeStockPurchasePlan2020Member" xlink:to="tnxp_EmployeeStockPurchasePlan2020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant1Member" xlink:label="tnxp_Warrant1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_Warrant1Member" xlink:to="tnxp_Warrant1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_Warrant1Member_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant2Member" xlink:label="tnxp_Warrant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_Warrant2Member" xlink:to="tnxp_Warrant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_Warrant2Member_lbl" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant3Member" xlink:label="tnxp_Warrant3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_Warrant3Member" xlink:to="tnxp_Warrant3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_Warrant3Member_lbl" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WarrantsFromFeb2020FinancingMember" xlink:label="tnxp_WarrantsFromFeb2020FinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_WarrantsFromFeb2020FinancingMember" xlink:to="tnxp_WarrantsFromFeb2020FinancingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_WarrantsFromFeb2020FinancingMember_lbl" xml:lang="en-US">Warrants from Feb 2020 Financing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_NewLeaseArrangementMember" xlink:label="tnxp_NewLeaseArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_NewLeaseArrangementMember" xlink:to="tnxp_NewLeaseArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_NewLeaseArrangementMember_lbl" xml:lang="en-US">New Operating Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ResearchOrganizationsMember" xlink:label="tnxp_ResearchOrganizationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ResearchOrganizationsMember" xlink:to="tnxp_ResearchOrganizationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ResearchOrganizationsMember_lbl" xml:lang="en-US">Research Organizations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ConstructionContractMember" xlink:label="tnxp_ConstructionContractMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ConstructionContractMember" xlink:to="tnxp_ConstructionContractMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ConstructionContractMember_lbl" xml:lang="en-US">Construction Contract [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DefinedContributionPlan401KPlanMember" xlink:label="tnxp_DefinedContributionPlan401KPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DefinedContributionPlan401KPlanMember" xlink:to="tnxp_DefinedContributionPlan401KPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DefinedContributionPlan401KPlanMember_lbl" xml:lang="en-US">Qualified Defined Contribution Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE" xlink:label="country_IE" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IE" xlink:to="country_IE_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IE_lbl" xml:lang="en-US">IRELAND</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BM" xlink:label="country_BM" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BM" xlink:to="country_BM_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BM_lbl" xml:lang="en-US">BERMUDA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ" xlink:label="stpr_NJ" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NJ" xlink:to="stpr_NJ_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_NJ_lbl" xml:lang="en-US">NEW JERSEY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareRepurchaseProgramAxis_lbl" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ExistingShareRepurchaseProgramMember" xlink:label="tnxp_ExistingShareRepurchaseProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ExistingShareRepurchaseProgramMember" xlink:to="tnxp_ExistingShareRepurchaseProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ExistingShareRepurchaseProgramMember_lbl" xml:lang="en-US">Existing Share Repurchase Program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_NewShareRepurchaseProgramMember" xlink:label="tnxp_NewShareRepurchaseProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_NewShareRepurchaseProgramMember" xlink:to="tnxp_NewShareRepurchaseProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_NewShareRepurchaseProgramMember_lbl" xml:lang="en-US">New Share Repurchase Program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_HealionBioIncMember" xlink:label="tnxp_HealionBioIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_HealionBioIncMember" xlink:to="tnxp_HealionBioIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_HealionBioIncMember_lbl" xml:lang="en-US">Healion Bio Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockOption1Member" xlink:label="tnxp_EmployeeStockOption1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EmployeeStockOption1Member" xlink:to="tnxp_EmployeeStockOption1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_EmployeeStockOption1Member_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesAgreementWithAGPMember" xlink:label="tnxp_SalesAgreementWithAGPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SalesAgreementWithAGPMember" xlink:to="tnxp_SalesAgreementWithAGPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_SalesAgreementWithAGPMember_lbl" xml:lang="en-US">Sales Agreement with AGP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City area code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local phone number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity public float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-to-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, short term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, long term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized Series B Convertible Preferred stock, 0 shares designated as of both December 31, 2022 and 2021; issued and outstanding - None Series A Convertible Preferred stock, 0 shares designated as of both December 31, 2022 and 2021; issued and outstanding - None</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 and 25,000,000&#160;shares authorized as of December 31, 2022 and 2021, respectively; 76,478,656 and 15,638,274 shares issued and&#160;outstanding as of December 31, 2022 and 2021, respectively and 93,741 and 4,033 shares to be issued as of December 31, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockSharesDesignated" xlink:label="tnxp_PreferredStockSharesDesignated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PreferredStockSharesDesignated" xlink:to="tnxp_PreferredStockSharesDesignated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PreferredStockSharesDesignated_lbl" xml:lang="en-US">Preferred stock, designated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock, to be issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">COSTS AND EXPENSES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="us-gaap_RedeemablePreferredStockDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl" xml:lang="en-US">Preferred stock deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, at beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues7" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues7" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues7" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues7_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues7_lbl" xml:lang="en-US">Issuance of common stock under At-the-market offering, net of transactional expenses of $3,078</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues7" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues7" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues7" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues7_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues7_lbl" xml:lang="en-US">Issuance of common stock under At-the-market offering, net of transactional expenses of $3,078 (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4_lbl" xml:lang="en-US">Issuance of common stock under 2022 Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4_lbl" xml:lang="en-US">Issuance of common stock under 2022 Purchase Agreement (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2_lbl" xml:lang="en-US">Issuance of common stock under 2021 Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2_lbl" xml:lang="en-US">Issuance of common stock under 2021 Purchase Agreement (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement" xlink:to="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement_lbl" xml:lang="en-US">Issuance of commitment shares under 2022 Purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" xlink:to="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares_lbl" xml:lang="en-US">Issuance of commitment shares under 2022 Purchase agreement (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockDeemedDividend" xlink:label="tnxp_PreferredStockDeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PreferredStockDeemedDividend" xlink:to="tnxp_PreferredStockDeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tnxp_PreferredStockDeemedDividend_lbl" xml:lang="en-US">Preferred stock deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues14" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues14" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues14" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues14_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues14_lbl" xml:lang="en-US">Issuance of common stock in January 2021 ($25.60 per share), net of transactional expenses of $3,096</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues14" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues14" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues14" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues14_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues14_lbl" xml:lang="en-US">Issuance of common stock in January 2021 ($25.60 per share), net of transactional expenses of $3,096 (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues1" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues1" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Issuance of common stock in exchange for exercise of warrants in March 2021 ($18.24 per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Issuance of common stock in exchange for exercise of warrants in March 2021 ($18.24 per share) (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues15" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues15" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues15" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues15_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues15_lbl" xml:lang="en-US">Issuance of common stock in February 2021 ($38.40 per share), net of transactional expenses of $5,002</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues15" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues15" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues15" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues15_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues15_lbl" xml:lang="en-US">Issuance of common stock in February 2021 ($38.40 per share), net of transactional expenses of $5,002 (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues19" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues19" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues19" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues19_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues19_lbl" xml:lang="en-US">Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues19" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues19" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues19" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues19_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues19_lbl" xml:lang="en-US">Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332 (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3_lbl" xml:lang="en-US">Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3_lbl" xml:lang="en-US">Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75 (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1_lbl" xml:lang="en-US">Issuance of commitment shares under 2021 Purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1_lbl" xml:lang="en-US">Issuance of commitment shares under 2021 Purchase agreement (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues21" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues21" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues21" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues21_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues21_lbl" xml:lang="en-US">Issuance of common stock in the acquisition of the OyaGen license</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues21" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues21" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues21" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues21_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues21_lbl" xml:lang="en-US">Issuance of common stock in the acquisition of the OyaGen license (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" xlink:to="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement_lbl" xml:lang="en-US">Issuance of commitment shares under Lincoln park Purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" xlink:to="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares_lbl" xml:lang="en-US">Issuance of commitment shares under Lincoln park Purchase agreement (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Employee stock purchase plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Employee stock purchase plan (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Foreign currency transaction loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, at end (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Transactional expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WarrantsExercisedPrice" xlink:label="tnxp_WarrantsExercisedPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_WarrantsExercisedPrice" xlink:to="tnxp_WarrantsExercisedPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_WarrantsExercisedPrice_lbl" xml:lang="en-US">Warrants exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CommonStockIssuedToAcquireResearchAndDevelopment" xlink:label="tnxp_CommonStockIssuedToAcquireResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CommonStockIssuedToAcquireResearchAndDevelopment" xlink:to="tnxp_CommonStockIssuedToAcquireResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_CommonStockIssuedToAcquireResearchAndDevelopment_lbl" xml:lang="en-US">Common stock issued to acquire in-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liabilities and ROU asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from ESPP</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds, net of $6,659 expenses, from sale of convertible redeemable preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Redemption of convertible redeemable preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds, net of $3,078 and $10,505 expenses, from sale of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of currency rate change on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash beginning of the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US">Preferred stock deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Expenses from sale of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureOtherBalanceSheetInformationAbstract" xlink:label="tnxp_DisclosureOtherBalanceSheetInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureOtherBalanceSheetInformationAbstract" xlink:to="tnxp_DisclosureOtherBalanceSheetInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureOtherBalanceSheetInformationAbstract_lbl" xml:lang="en-US">Other Balance Sheet Information</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OtherBalanceSheetInformationDiclosureTextBlock" xlink:label="tnxp_OtherBalanceSheetInformationDiclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OtherBalanceSheetInformationDiclosureTextBlock" xlink:to="tnxp_OtherBalanceSheetInformationDiclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_OtherBalanceSheetInformationDiclosureTextBlock_lbl" xml:lang="en-US">OTHER BALANCE SHEET INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureTemporaryEquityAbstract" xlink:label="tnxp_DisclosureTemporaryEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureTemporaryEquityAbstract" xlink:to="tnxp_DisclosureTemporaryEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureTemporaryEquityAbstract_lbl" xml:lang="en-US">Temporary Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TemporaryEquityTextBlock" xlink:label="tnxp_TemporaryEquityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TemporaryEquityTextBlock" xlink:to="tnxp_TemporaryEquityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_TemporaryEquityTextBlock_lbl" xml:lang="en-US">TEMPORARY EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract" xlink:label="tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract" xlink:to="tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract_lbl" xml:lang="en-US">Asset Purchase Agreement With Katana</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementWithKatanaTextBlock" xlink:label="tnxp_AssetPurchaseAgreementWithKatanaTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AssetPurchaseAgreementWithKatanaTextBlock" xlink:to="tnxp_AssetPurchaseAgreementWithKatanaTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AssetPurchaseAgreementWithKatanaTextBlock_lbl" xml:lang="en-US">ASSET PURCHASE AGREEMENT WITH KATANA</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract" xlink:label="tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract" xlink:to="tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract_lbl" xml:lang="en-US">Asset Purchase Agreement With Trigemina</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock" xlink:label="tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock" xlink:to="tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock_lbl" xml:lang="en-US">ASSET PURCHASE AGREEMENT WITH TRIGEMINA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">ASSET PURCHASE AGREEMENT WITH TRIMARAN</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithCuriaAbstract" xlink:label="tnxp_DisclosureLicenseAgreementWithCuriaAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureLicenseAgreementWithCuriaAbstract" xlink:to="tnxp_DisclosureLicenseAgreementWithCuriaAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureLicenseAgreementWithCuriaAbstract_lbl" xml:lang="en-US">License Agreement With Curia</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementCuriaTextBlock" xlink:label="tnxp_LicenseAgreementCuriaTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementCuriaTextBlock" xlink:to="tnxp_LicenseAgreementCuriaTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_LicenseAgreementCuriaTextBlock_lbl" xml:lang="en-US">LICENSE AGREEMENT WITH CURIA</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract" xlink:label="tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract" xlink:to="tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract_lbl" xml:lang="en-US">License Agreement With University Of Alberta</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementUniversityOfAlbertaTextBlock" xlink:label="tnxp_LicenseAgreementUniversityOfAlbertaTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementUniversityOfAlbertaTextBlock" xlink:to="tnxp_LicenseAgreementUniversityOfAlbertaTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_LicenseAgreementUniversityOfAlbertaTextBlock_lbl" xml:lang="en-US">LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithOyagenAbstract" xlink:label="tnxp_DisclosureLicenseAgreementWithOyagenAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureLicenseAgreementWithOyagenAbstract" xlink:to="tnxp_DisclosureLicenseAgreementWithOyagenAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureLicenseAgreementWithOyagenAbstract_lbl" xml:lang="en-US">License Agreement With Oyagen</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementOyagenTextBlock" xlink:label="tnxp_LicenseAgreementOyagenTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementOyagenTextBlock" xlink:to="tnxp_LicenseAgreementOyagenTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_LicenseAgreementOyagenTextBlock_lbl" xml:lang="en-US">LICENSE AGREEMENT WITH OYAGEN</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithInsermAbstract" xlink:label="tnxp_DisclosureLicenseAgreementWithInsermAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureLicenseAgreementWithInsermAbstract" xlink:to="tnxp_DisclosureLicenseAgreementWithInsermAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureLicenseAgreementWithInsermAbstract_lbl" xml:lang="en-US">License Agreement With Inserm</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementWithInsermTextBlock" xlink:label="tnxp_LicenseAgreementWithInsermTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementWithInsermTextBlock" xlink:to="tnxp_LicenseAgreementWithInsermTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_LicenseAgreementWithInsermTextBlock_lbl" xml:lang="en-US">LICENSE AGREEMENT WITH INSERM</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureSaleOfCommonStockAbstract" xlink:label="tnxp_DisclosureSaleOfCommonStockAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureSaleOfCommonStockAbstract" xlink:to="tnxp_DisclosureSaleOfCommonStockAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureSaleOfCommonStockAbstract_lbl" xml:lang="en-US">Sale Of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SaleOfCommonStockTextBlock" xlink:label="tnxp_SaleOfCommonStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SaleOfCommonStockTextBlock" xlink:to="tnxp_SaleOfCommonStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_SaleOfCommonStockTextBlock_lbl" xml:lang="en-US">SALE OF COMMON STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract" xlink:label="tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract" xlink:to="tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract_lbl" xml:lang="en-US">Warrants To Purchase Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockWarrantsTextBlock" xlink:label="tnxp_StockWarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockWarrantsTextBlock" xlink:to="tnxp_StockWarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StockWarrantsTextBlock_lbl" xml:lang="en-US">WARRANTS TO PURCHASE COMMON STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLeasesAbstract" xlink:label="tnxp_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureLeasesAbstract" xlink:to="tnxp_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_lbl" xml:lang="en-US">Intangible assets with indefinite lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US">Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xml:lang="en-US">Government Grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Per Share Data</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property and equipment, net consisted of the following (in thousands):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Components of selected captions in the consolidated balance sheets consist of:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US">The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands):</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" xlink:label="tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US">Other information related to leases was as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Components of the net loss consist of the following (in thousands):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company&#8217;s income tax provision is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands):</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WorkingCapital" xlink:label="tnxp_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_WorkingCapital" xlink:to="tnxp_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities excluded from the computation of basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market funds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of facility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xml:lang="en-US">Facility purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="us-gaap_PaymentsForConstructionInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForConstructionInProcess" xlink:to="us-gaap_PaymentsForConstructionInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForConstructionInProcess_lbl" xml:lang="en-US">Costs incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Total costs incurred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureOtherBalanceSheetInformationAbstract" xlink:to="tnxp_DisclosureOtherBalanceSheetInformationAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tnxp_DisclosureOtherBalanceSheetInformationAbstract_2_lbl" xml:lang="en-US">Components Of Selected Captions In Consolidated Balance Sheets Consist Of</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid expenses and other:</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContractRelatedPrepaidExpenseCurrent" xlink:label="tnxp_ContractRelatedPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ContractRelatedPrepaidExpenseCurrent" xlink:to="tnxp_ContractRelatedPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ContractRelatedPrepaidExpenseCurrent_lbl" xml:lang="en-US">Contract-related</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent" xlink:label="tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent" xlink:to="tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accrued expenses and other current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContractRelatedAccruedLiabilitiesCurrent" xlink:label="tnxp_ContractRelatedAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ContractRelatedAccruedLiabilitiesCurrent" xlink:to="tnxp_ContractRelatedAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tnxp_ContractRelatedAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Contract-related</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" xlink:label="tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" xlink:to="tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Compensation and compensation-related</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ConstructionInProgressAccruedLiabilitiesCurrent" xlink:label="tnxp_ConstructionInProgressAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ConstructionInProgressAccruedLiabilitiesCurrent" xlink:to="tnxp_ConstructionInProgressAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ConstructionInProgressAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Construction in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" xlink:label="tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" xlink:to="tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Professional fees and other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CashEquivalentsFairValue" xlink:label="tnxp_CashEquivalentsFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CashEquivalentsFairValue" xlink:to="tnxp_CashEquivalentsFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_CashEquivalentsFairValue_lbl" xml:lang="en-US">Cash equivalents - fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_GrossProceeds" xlink:label="tnxp_GrossProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_GrossProceeds" xlink:to="tnxp_GrossProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_GrossProceeds_lbl" xml:lang="en-US">Gross Proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockIssuanceCosts" xlink:label="tnxp_PreferredStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PreferredStockIssuanceCosts" xlink:to="tnxp_PreferredStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tnxp_PreferredStockIssuanceCosts_lbl" xml:lang="en-US">Preferred stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AccretionOfCarryingValueToRedemptionValue" xlink:label="tnxp_AccretionOfCarryingValueToRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AccretionOfCarryingValueToRedemptionValue" xlink:to="tnxp_AccretionOfCarryingValueToRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AccretionOfCarryingValueToRedemptionValue_lbl" xml:lang="en-US">Accretion of carrying value to redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Preferred stock subject to possible redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfIssueDiscount" xlink:label="tnxp_PercentageOfIssueDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PercentageOfIssueDiscount" xlink:to="tnxp_PercentageOfIssueDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PercentageOfIssueDiscount_lbl" xml:lang="en-US">Percentage of issue discount</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StatedValuePerShare" xlink:label="tnxp_StatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StatedValuePerShare" xlink:to="tnxp_StatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_StatedValuePerShare_lbl" xml:lang="en-US">Stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xml:lang="en-US">Preferred stock voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TemporaryEquityRedemptionPricePercentage" xlink:label="tnxp_TemporaryEquityRedemptionPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TemporaryEquityRedemptionPricePercentage" xlink:to="tnxp_TemporaryEquityRedemptionPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_TemporaryEquityRedemptionPricePercentage_lbl" xml:lang="en-US">Temporary equity redemption price percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Escrow Deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EscrowDepositForOriginalIssueDiscount" xlink:label="tnxp_EscrowDepositForOriginalIssueDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EscrowDepositForOriginalIssueDiscount" xlink:to="tnxp_EscrowDepositForOriginalIssueDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_EscrowDepositForOriginalIssueDiscount_lbl" xml:lang="en-US">Escrow Deposit for Original Issue Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xml:lang="en-US">Temporary equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_2_lbl" xml:lang="en-US">Redemption amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US">Asset Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Consideration paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payment for purchase of assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CommonStockValuePerShares" xlink:label="tnxp_CommonStockValuePerShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CommonStockValuePerShares" xlink:to="tnxp_CommonStockValuePerShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_CommonStockValuePerShares_lbl" xml:lang="en-US">Common stock value (per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US">Liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AchievementPaymentsPayable" xlink:label="tnxp_AchievementPaymentsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AchievementPaymentsPayable" xlink:to="tnxp_AchievementPaymentsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AchievementPaymentsPayable_lbl" xml:lang="en-US">Contingent milestone payment obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ReimbursementOfPatentExpenses" xlink:label="tnxp_ReimbursementOfPatentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ReimbursementOfPatentExpenses" xlink:to="tnxp_ReimbursementOfPatentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ReimbursementOfPatentExpenses_lbl" xml:lang="en-US">Reimbursement of patent expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContingentMilestonePaymentObligation" xlink:label="tnxp_ContingentMilestonePaymentObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ContingentMilestonePaymentObligation" xlink:to="tnxp_ContingentMilestonePaymentObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tnxp_ContingentMilestonePaymentObligation_lbl" xml:lang="en-US">Contingent milestone payment obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:label="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:to="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_lbl" xml:lang="en-US">Percentage of royalties payable to any third party for intellectual property rights</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MaximumPercentageReductionOfRoyaltiesPayable" xlink:label="tnxp_MaximumPercentageReductionOfRoyaltiesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_MaximumPercentageReductionOfRoyaltiesPayable" xlink:to="tnxp_MaximumPercentageReductionOfRoyaltiesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_MaximumPercentageReductionOfRoyaltiesPayable_lbl" xml:lang="en-US">Maximum percentage reduction of royalties payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Value of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesMilestones" xlink:label="tnxp_SalesMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SalesMilestones" xlink:to="tnxp_SalesMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_SalesMilestones_lbl" xml:lang="en-US">Sale MIlestones</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:to="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_2_lbl" xml:lang="en-US">Percentage of third party royalties payable for reduction in royalties payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentagePadOfConsideration" xlink:label="tnxp_PercentagePadOfConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PercentagePadOfConsideration" xlink:to="tnxp_PercentagePadOfConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PercentagePadOfConsideration_lbl" xml:lang="en-US">Percentage of pay for consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CommitmentToPurchaseSharesUnderAgreement" xlink:label="tnxp_CommitmentToPurchaseSharesUnderAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CommitmentToPurchaseSharesUnderAgreement" xlink:to="tnxp_CommitmentToPurchaseSharesUnderAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_CommitmentToPurchaseSharesUnderAgreement_lbl" xml:lang="en-US">Commitment to purchase shares under agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from equity offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfIssuanceByIssuerOfCommonStock" xlink:label="tnxp_PercentageOfIssuanceByIssuerOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PercentageOfIssuanceByIssuerOfCommonStock" xlink:to="tnxp_PercentageOfIssuanceByIssuerOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PercentageOfIssuanceByIssuerOfCommonStock_lbl" xml:lang="en-US">Percentage of issuance by issuer of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval" xlink:label="tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval" xlink:to="tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval_lbl" xml:lang="en-US">Maximum number of shares issued wIthout shareholder approval</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CashFeePercentage" xlink:label="tnxp_CashFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CashFeePercentage" xlink:to="tnxp_CashFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_CashFeePercentage_lbl" xml:lang="en-US">Cash fee</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_UnderwritingDiscount" xlink:label="tnxp_UnderwritingDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_UnderwritingDiscount" xlink:to="tnxp_UnderwritingDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_UnderwritingDiscount_lbl" xml:lang="en-US">Underwriting discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Expenses from sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OfferingPricePerAgreement" xlink:label="tnxp_OfferingPricePerAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OfferingPricePerAgreement" xlink:to="tnxp_OfferingPricePerAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_OfferingPricePerAgreement_lbl" xml:lang="en-US">Offering price per agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesAgentCommissionPercentage" xlink:label="tnxp_SalesAgentCommissionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SalesAgentCommissionPercentage" xlink:to="tnxp_SalesAgentCommissionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_SalesAgentCommissionPercentage_lbl" xml:lang="en-US">Commission to agent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Beginning, Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Forfeitures or expirations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeitures or expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate - Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate - Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term of option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected stock price volatility - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected stock price volatility - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:label="tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:to="tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Percentage of additional shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percent of fair value of common stock at grant date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of shares available for future grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Service period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized compensation cost, recognition period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Transfer to additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AmountReturnToEmployee1" xlink:label="tnxp_AmountReturnToEmployee1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AmountReturnToEmployee1" xlink:to="tnxp_AmountReturnToEmployee1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AmountReturnToEmployee1_lbl" xml:lang="en-US">ESPP withholdings returned to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AccumulatedEmployeePayrollDeductions" xlink:label="tnxp_AccumulatedEmployeePayrollDeductions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AccumulatedEmployeePayrollDeductions" xlink:to="tnxp_AccumulatedEmployeePayrollDeductions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_AccumulatedEmployeePayrollDeductions_lbl" xml:lang="en-US">Accumulated Employee Payroll Deductions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ClassOfWarrantsOrRightExpirationDate" xlink:label="tnxp_ClassOfWarrantsOrRightExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ClassOfWarrantsOrRightExpirationDate" xlink:to="tnxp_ClassOfWarrantsOrRightExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ClassOfWarrantsOrRightExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of exercised warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ExercisePriceOfWarrantsExpired" xlink:label="tnxp_ExercisePriceOfWarrantsExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ExercisePriceOfWarrantsExpired" xlink:to="tnxp_ExercisePriceOfWarrantsExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ExercisePriceOfWarrantsExpired_lbl" xml:lang="en-US">Exercise price of warrants expired (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureLeasesAbstract" xlink:to="tnxp_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tnxp_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">At December 31 2022 Future Minimum Lease Payments For Operating Leases With Non-cancelable Terms Of More Than One Year Were As Follows In Thousands</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Included interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">&#160;</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DisclosureLeasesAbstract" xlink:to="tnxp_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tnxp_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Other Information Related To Leases Was As Follows</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Lease liability, net of current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Lease liability, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Outstanding commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xml:lang="en-US">Employer matching contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Maximum annual contributions per employee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Maximum annual contributions per employer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xml:lang="en-US">Administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory federal income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign loss not subject to income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" xlink:label="tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" xlink:to="tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange_lbl" xml:lang="en-US">Attribute reduction from control change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income Tax Provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets/(liabilities):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2_lbl" xml:lang="en-US">Foreign losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent" xlink:label="tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent" xlink:to="tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent_lbl" xml:lang="en-US">Utilization NOL (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Operating loss carryforwards expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Increase in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Number of shares repurchased (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US">Repurchase program amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="us-gaap_TreasuryStockAcquiredAverageCostPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare_lbl" xml:lang="en-US">Price of shares repurchased (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xml:lang="en-US">Value of shares repurchased</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MinimumBidRequirementPerShare" xlink:label="tnxp_MinimumBidRequirementPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_MinimumBidRequirementPerShare" xlink:to="tnxp_MinimumBidRequirementPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_MinimumBidRequirementPerShare_lbl" xml:lang="en-US">Minimum bid price requirements NASDAQ</link:label>
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ConsecutiveBusinessDaysForMinimumBidPrice" xlink:label="tnxp_ConsecutiveBusinessDaysForMinimumBidPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ConsecutiveBusinessDaysForMinimumBidPrice" xlink:to="tnxp_ConsecutiveBusinessDaysForMinimumBidPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ConsecutiveBusinessDaysForMinimumBidPrice_lbl" xml:lang="en-US">Consecutive business days for minimum bid price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of options granted (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price of options granted (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2_lbl" xml:lang="en-US">Options term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AssignmentAndAssumptionAgreementMember" xlink:to="tnxp_AssignmentAndAssumptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AssignmentAndAssumptionAgreementMember_doc" xml:lang="en-US">Assignment and assumption agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CashEquivalentsFairValue" xlink:to="tnxp_CashEquivalentsFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_CashEquivalentsFairValue_doc" xml:lang="en-US">Fair value portion of demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CashFeePercentage" xlink:to="tnxp_CashFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_CashFeePercentage_doc" xml:lang="en-US">The amount of cash fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ClassOfWarrantsOrRightExpirationDate" xlink:to="tnxp_ClassOfWarrantsOrRightExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ClassOfWarrantsOrRightExpirationDate_doc" xml:lang="en-US">Expiration date of warrants or rights outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CommitmentToPurchaseSharesUnderAgreement" xlink:to="tnxp_CommitmentToPurchaseSharesUnderAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_CommitmentToPurchaseSharesUnderAgreement_doc" xml:lang="en-US">The amount represents commitment to purchase shares under agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CommonStockIssuedToAcquireResearchAndDevelopment" xlink:to="tnxp_CommonStockIssuedToAcquireResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_CommonStockIssuedToAcquireResearchAndDevelopment_doc" xml:lang="en-US">The amount represents common stock issued to acquire research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ContingentMilestonePaymentObligation" xlink:to="tnxp_ContingentMilestonePaymentObligation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ContingentMilestonePaymentObligation_doc" xml:lang="en-US">The amount of obligation to make contingent milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_DefinedContributionPlan401KPlanMember" xlink:to="tnxp_DefinedContributionPlan401KPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_DefinedContributionPlan401KPlanMember_doc" xml:lang="en-US">Information relating to defined contribution plan 401K during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_FurnitureAndAllOtherEquipmentMember" xlink:to="tnxp_FurnitureAndAllOtherEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_FurnitureAndAllOtherEquipmentMember_doc" xml:lang="en-US">The member represent furniture and all other equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IncentiveStockOptionsPlan2019Member" xlink:to="tnxp_IncentiveStockOptionsPlan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IncentiveStockOptionsPlan2019Member_doc" xml:lang="en-US">2019 Stock Incentive Plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IncentiveStockOptionsPlan2020Member" xlink:to="tnxp_IncentiveStockOptionsPlan2020Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IncentiveStockOptionsPlan2020Member_doc" xml:lang="en-US">2020 Stock Incentive Plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_InsermLicenseAgreementMember" xlink:to="tnxp_InsermLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_InsermLicenseAgreementMember_doc" xml:lang="en-US">The member represent inserm license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_InsermMember" xlink:to="tnxp_InsermMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_InsermMember_doc" xml:lang="en-US">The member represent inserm.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_KatanaPharmaceuticalsIncMember" xlink:to="tnxp_KatanaPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_KatanaPharmaceuticalsIncMember_doc" xml:lang="en-US">Represents member related to katana pharmaceutical.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementMember" xlink:to="tnxp_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_LicenseAgreementMember_doc" xml:lang="en-US">License agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementOyagenTextBlock" xlink:to="tnxp_LicenseAgreementOyagenTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_LicenseAgreementOyagenTextBlock_doc" xml:lang="en-US">This entire disclosure of the license agreement with Oyagen.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementWithInsermTextBlock" xlink:to="tnxp_LicenseAgreementWithInsermTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_LicenseAgreementWithInsermTextBlock_doc" xml:lang="en-US">This entire disclosure of the license agreement with Inserm.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LincolnParkCapitalFundLLCMember" xlink:to="tnxp_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Represents member related to Lincoln Park Capital Fund.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_MaximumPercentageReductionOfRoyaltiesPayable" xlink:to="tnxp_MaximumPercentageReductionOfRoyaltiesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_MaximumPercentageReductionOfRoyaltiesPayable_doc" xml:lang="en-US">The maximum percentage by which royalties payable may be reduced.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OfferingPricePerAgreement" xlink:to="tnxp_OfferingPricePerAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_OfferingPricePerAgreement_doc" xml:lang="en-US">Value of common shares agreed to be offered under the sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OxytocinBasedTherapeuticsMember" xlink:to="tnxp_OxytocinBasedTherapeuticsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_OxytocinBasedTherapeuticsMember_doc" xml:lang="en-US">The member represent oxytocin based therapeutics.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OyaGenIncMember" xlink:to="tnxp_OyaGenIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_OyaGenIncMember_doc" xml:lang="en-US">The member represent oya gen inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PercentageOfIssuanceByIssuerOfCommonStock" xlink:to="tnxp_PercentageOfIssuanceByIssuerOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PercentageOfIssuanceByIssuerOfCommonStock_doc" xml:lang="en-US">The amount represents percentage of issuance by issuer of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:to="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_doc" xml:lang="en-US">The percentage of royalties payable to any third party for intellectual property rights which are necessary for the practice of the rights licensed which may reduce royalties payable on net sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PercentagePadOfConsideration" xlink:to="tnxp_PercentagePadOfConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PercentagePadOfConsideration_doc" xml:lang="en-US">The percentage of pay for consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PreferredStockSharesDesignated" xlink:to="tnxp_PreferredStockSharesDesignated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PreferredStockSharesDesignated_doc" xml:lang="en-US">The number of designated shares of preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PurchaseAgreement2021Member" xlink:to="tnxp_PurchaseAgreement2021Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PurchaseAgreement2021Member_doc" xml:lang="en-US">This member stands for purchase agreement 2021.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ReimbursementOfPatentExpenses" xlink:to="tnxp_ReimbursementOfPatentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ReimbursementOfPatentExpenses_doc" xml:lang="en-US">The amount paid for reimbursement of patent expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SaleOfCommonStockTextBlock" xlink:to="tnxp_SaleOfCommonStockTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_SaleOfCommonStockTextBlock_doc" xml:lang="en-US">The entire disclosure related to sale of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SalesAgreementMember" xlink:to="tnxp_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_SalesAgreementMember_doc" xml:lang="en-US">Represents member sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SalesMilestones" xlink:to="tnxp_SalesMilestones_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_SalesMilestones_doc" xml:lang="en-US">Sales milestones specified in license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuanceFebruary2021Member" xlink:to="tnxp_StockIssuanceFebruary2021Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuanceFebruary2021Member_doc" xml:lang="en-US">Issuance of common stock in February 2021</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuanceJanuary2021Member" xlink:to="tnxp_StockIssuanceJanuary2021Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuanceJanuary2021Member_doc" xml:lang="en-US">Issuance of common stock in January 2021</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues1_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues14" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues14_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues14_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues15" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues15_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues15_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues19" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues19_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues19_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues21" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues21_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues21_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodSharesNewIssues7" xlink:to="tnxp_StockIssuedDuringPeriodSharesNewIssues7_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodSharesNewIssues7_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues1" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues1_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues15" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues15_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues15_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues19" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues19_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues19_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues21" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues21_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues21_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues7" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues7_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues7_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockWarrantsTextBlock" xlink:to="tnxp_StockWarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockWarrantsTextBlock_doc" xml:lang="en-US">The entire disclosure for stock warrants or rights issued during the given period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock_doc" xml:lang="en-US">A summary of information related to leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TFF2ProductMember" xlink:to="tnxp_TFF2ProductMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_TFF2ProductMember_doc" xml:lang="en-US">Information pertaining to TFF2 product.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TRImaranPharmaIncMember" xlink:to="tnxp_TRImaranPharmaIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_TRImaranPharmaIncMember_doc" xml:lang="en-US">Represents member related to TRImaran Pharma.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TrigeminaIncMember" xlink:to="tnxp_TrigeminaIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_TrigeminaIncMember_doc" xml:lang="en-US">Represents member trigemina inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TrusteesOfColumbiaUniversityMember" xlink:to="tnxp_TrusteesOfColumbiaUniversityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_TrusteesOfColumbiaUniversityMember_doc" xml:lang="en-US">Trustees of Columbia University.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_UnderwritingAgreementMember" xlink:to="tnxp_UnderwritingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_UnderwritingAgreementMember_doc" xml:lang="en-US">The member represent underwriting agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_UnderwritingDiscount" xlink:to="tnxp_UnderwritingDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_UnderwritingDiscount_doc" xml:lang="en-US">Refers to the underwriting discount incurred during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_WSULicenseAgreementMember" xlink:to="tnxp_WSULicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_WSULicenseAgreementMember_doc" xml:lang="en-US">Represents member related to WSU license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_Warrant1Member" xlink:to="tnxp_Warrant1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_Warrant1Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_Warrant2Member" xlink:to="tnxp_Warrant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_Warrant2Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_Warrant3Member" xlink:to="tnxp_Warrant3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_Warrant3Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_WarrantsExercisedPrice" xlink:to="tnxp_WarrantsExercisedPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_WarrantsExercisedPrice_doc" xml:lang="en-US">Price at which warrant holders acquired shares when converting their warrants into shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_WarrantsFromFeb2020FinancingMember" xlink:to="tnxp_WarrantsFromFeb2020FinancingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_WarrantsFromFeb2020FinancingMember_doc" xml:lang="en-US">Represents information related to warrants from feb 2020 financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_WorkingCapital" xlink:to="tnxp_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_WorkingCapital_doc" xml:lang="en-US">Amount of working capital as of reporting date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:to="tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_doc" xml:lang="en-US">Percentage of additional shares authorized for issuance under share-based payment arrangement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TenPercentOrMoreShareholderMember" xlink:to="tnxp_TenPercentOrMoreShareholderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_TenPercentOrMoreShareholderMember_doc" xml:lang="en-US">10% or more Shareholder.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EmployeeStockPurchasePlan2020Member" xlink:to="tnxp_EmployeeStockPurchasePlan2020Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_EmployeeStockPurchasePlan2020Member_doc" xml:lang="en-US">2020 Employee Stock Purchase Plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SalesAgentCommissionPercentage" xlink:to="tnxp_SalesAgentCommissionPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_SalesAgentCommissionPercentage_doc" xml:lang="en-US">Sales agent commission percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CommonStockValuePerShares" xlink:to="tnxp_CommonStockValuePerShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_CommonStockValuePerShares_doc" xml:lang="en-US">Common stock value per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_NewLeaseArrangementMember" xlink:to="tnxp_NewLeaseArrangementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_NewLeaseArrangementMember_doc" xml:lang="en-US">New Operating Lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ConsecutiveBusinessDaysForMinimumBidPrice" xlink:to="tnxp_ConsecutiveBusinessDaysForMinimumBidPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ConsecutiveBusinessDaysForMinimumBidPrice_doc" xml:lang="en-US">Consecutive business days for minimum bid price under NASDAQ rule.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuanceTwoMember" xlink:to="tnxp_StockIssuanceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuanceTwoMember_doc" xml:lang="en-US">Issuance of common stock under 2021 Purchase Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" xlink:to="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement_doc" xml:lang="en-US">Value of Issuance of commitment shares under Lincoln Park Purchase Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuanceNineMember" xlink:to="tnxp_StockIssuanceNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuanceNineMember_doc" xml:lang="en-US">Issuance of common stock under At-the-market offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" xlink:to="tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange_doc" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations related to attribute reduction from control change.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OtherBalanceSheetInformationDiclosureTextBlock" xlink:to="tnxp_OtherBalanceSheetInformationDiclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_OtherBalanceSheetInformationDiclosureTextBlock_doc" xml:lang="en-US">The entire disclosure of other balance sheet information.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ContractRelatedPrepaidExpenseCurrent" xlink:to="tnxp_ContractRelatedPrepaidExpenseCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ContractRelatedPrepaidExpenseCurrent_doc" xml:lang="en-US">Amount of asset related to contarct within one year or the normal operating cycle, if longer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent" xlink:to="tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent_doc" xml:lang="en-US">Amount of professional fees and other within one year or the normal operating cycle, if longer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ContractRelatedAccruedLiabilitiesCurrent" xlink:to="tnxp_ContractRelatedAccruedLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ContractRelatedAccruedLiabilitiesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of contract reltaed expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" xlink:to="tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of compensation and compensation-related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" xlink:to="tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of Professional fees and other reltaed expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AllianceGlobalPartnersMember" xlink:to="tnxp_AllianceGlobalPartnersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AllianceGlobalPartnersMember_doc" xml:lang="en-US">Alliance Global Partners</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PurchaseAgreementWithLincolnParkMember" xlink:to="tnxp_PurchaseAgreementWithLincolnParkMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PurchaseAgreementWithLincolnParkMember_doc" xml:lang="en-US">Purchase Agreement With Lincoln Park</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AchievementPaymentsPayable" xlink:to="tnxp_AchievementPaymentsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AchievementPaymentsPayable_doc" xml:lang="en-US">The amount upon the achievement of specified development, regulatory and sales milestones, Tonix also agreed to pay TRImaran and the Selling Shareholders, in restricted stock or cash, at Tonix's option per agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AssetPurchaseAgreementMember" xlink:to="tnxp_AssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AssetPurchaseAgreementMember_doc" xml:lang="en-US">Asset Purchase Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock" xlink:to="tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock_doc" xml:lang="en-US">The entire disclosure of asset purchase agreement with Trigemina.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AmountReturnToEmployee1" xlink:to="tnxp_AmountReturnToEmployee1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AmountReturnToEmployee1_doc" xml:lang="en-US">The amount returned to employees of their withholdings under the ESPP.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LaboratoryEquipmentMember" xlink:to="tnxp_LaboratoryEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_LaboratoryEquipmentMember_doc" xml:lang="en-US">Laboratory Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PreferredStockDeemedDividend" xlink:to="tnxp_PreferredStockDeemedDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PreferredStockDeemedDividend_doc" xml:lang="en-US">Amount of deemed dividend for preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AssetPurchaseAgreementWithKatanaTextBlock" xlink:to="tnxp_AssetPurchaseAgreementWithKatanaTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AssetPurchaseAgreementWithKatanaTextBlock_doc" xml:lang="en-US">The entire disclosure asset purchase agreement with Katana.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EmployeeStockOption1Member" xlink:to="tnxp_EmployeeStockOption1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_EmployeeStockOption1Member_doc" xml:lang="en-US">Share-based Payment Arrangement, Option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" xlink:to="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares_doc" xml:lang="en-US">Issuance of commitment shares under Lincoln Park Purchase Agreement, number of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StockIssuedDuringPeriodValueNewIssues14" xlink:to="tnxp_StockIssuedDuringPeriodValueNewIssues14_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StockIssuedDuringPeriodValueNewIssues14_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AmendedAndRestated2020PlanMember" xlink:to="tnxp_AmendedAndRestated2020PlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AmendedAndRestated2020PlanMember_doc" xml:lang="en-US">Amended and Restated 2020 Plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" xlink:to="tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember_doc" xml:lang="en-US">Office furniture and equipment and Laboratory equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ConstructionInProgressAccruedLiabilitiesCurrent" xlink:to="tnxp_ConstructionInProgressAccruedLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ConstructionInProgressAccruedLiabilitiesCurrent_doc" xml:lang="en-US">Amount of accrued liabilities related to construction in progress.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ResearchOrganizationsMember" xlink:to="tnxp_ResearchOrganizationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ResearchOrganizationsMember_doc" xml:lang="en-US">Research Organizations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ConstructionContractMember" xlink:to="tnxp_ConstructionContractMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ConstructionContractMember_doc" xml:lang="en-US">Construction Contract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement" xlink:to="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement_doc" xml:lang="en-US">Issuance of commitment shares under Purchase Agreement, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" xlink:to="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares_doc" xml:lang="en-US">Issuance of commitment shares under Purchase Agreement, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LandImprovementsAndLabEquipmentMember" xlink:to="tnxp_LandImprovementsAndLabEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_LandImprovementsAndLabEquipmentMember_doc" xml:lang="en-US">Land Improvements and Lab Equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_MinimumBidRequirementPerShare" xlink:to="tnxp_MinimumBidRequirementPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_MinimumBidRequirementPerShare_doc" xml:lang="en-US">The minimum bid price requirement per share for continued listing on the NASDAQ Capital Market.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TemporaryEquityTextBlock" xlink:to="tnxp_TemporaryEquityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_TemporaryEquityTextBlock_doc" xml:lang="en-US">The entire disclosure of temporary equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PercentageOfIssueDiscount" xlink:to="tnxp_PercentageOfIssueDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PercentageOfIssueDiscount_doc" xml:lang="en-US">Percentage of original issue discount to stated value per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_StatedValuePerShare" xlink:to="tnxp_StatedValuePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_StatedValuePerShare_doc" xml:lang="en-US">Stated value per share of covertible redeemable preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_TemporaryEquityRedemptionPricePercentage" xlink:to="tnxp_TemporaryEquityRedemptionPricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_TemporaryEquityRedemptionPricePercentage_doc" xml:lang="en-US">Percentage of stated value of temporary equity required for redemption of shares,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EscrowDepositForOriginalIssueDiscount" xlink:to="tnxp_EscrowDepositForOriginalIssueDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_EscrowDepositForOriginalIssueDiscount_doc" xml:lang="en-US">Amount held in escrow account for original issue discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_GrossProceeds" xlink:to="tnxp_GrossProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_GrossProceeds_doc" xml:lang="en-US">The gross proceeds from stock issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PreferredStockIssuanceCosts" xlink:to="tnxp_PreferredStockIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PreferredStockIssuanceCosts_doc" xml:lang="en-US">Amount of preferred stock issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AccretionOfCarryingValueToRedemptionValue" xlink:to="tnxp_AccretionOfCarryingValueToRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AccretionOfCarryingValueToRedemptionValue_doc" xml:lang="en-US">Accretion of Carrying Value to Redemption Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementUniversityOfAlbertaTextBlock" xlink:to="tnxp_LicenseAgreementUniversityOfAlbertaTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_LicenseAgreementUniversityOfAlbertaTextBlock_doc" xml:lang="en-US">The entire disclosure of the license agreement with University of Alberta.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_LicenseAgreementCuriaTextBlock" xlink:to="tnxp_LicenseAgreementCuriaTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_LicenseAgreementCuriaTextBlock_doc" xml:lang="en-US">The entire disclosure of the license agreement with Curia.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_CuriaMember" xlink:to="tnxp_CuriaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_CuriaMember_doc" xml:lang="en-US">Curia.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PurchaseAgreementWithLincolnPark2022Member" xlink:to="tnxp_PurchaseAgreementWithLincolnPark2022Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PurchaseAgreementWithLincolnPark2022Member_doc" xml:lang="en-US">Purchase Agreement with Lincoln Park 2022.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval" xlink:to="tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval_doc" xml:lang="en-US">Maximum number of shares issued wIthout shareholder approval.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PurchaseAgreementWithLincolnPark2021Member" xlink:to="tnxp_PurchaseAgreementWithLincolnPark2021Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_PurchaseAgreementWithLincolnPark2021Member_doc" xml:lang="en-US">Purchase Agreement with Lincoln Park 2021.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EmployeeStockPurchasePlan2022Member" xlink:to="tnxp_EmployeeStockPurchasePlan2022Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_EmployeeStockPurchasePlan2022Member_doc" xml:lang="en-US">Employee Stock Purchase Plan 2022.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_EmployeeStockPurchasePlansMember" xlink:to="tnxp_EmployeeStockPurchasePlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_EmployeeStockPurchasePlansMember_doc" xml:lang="en-US">Employee Stock Purchase Plans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_AccumulatedEmployeePayrollDeductions" xlink:to="tnxp_AccumulatedEmployeePayrollDeductions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_AccumulatedEmployeePayrollDeductions_doc" xml:lang="en-US">Accumulated employee payroll deductions related to stock purchase plan as of balance sheet date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ExistingShareRepurchaseProgramMember" xlink:to="tnxp_ExistingShareRepurchaseProgramMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ExistingShareRepurchaseProgramMember_doc" xml:lang="en-US">Existing Share Repurchase Program.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_NewShareRepurchaseProgramMember" xlink:to="tnxp_NewShareRepurchaseProgramMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_NewShareRepurchaseProgramMember_doc" xml:lang="en-US">New Share Repurchase Program.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_HealionBioIncMember" xlink:to="tnxp_HealionBioIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_HealionBioIncMember_doc" xml:lang="en-US">Healion Bio Inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_SalesAgreementWithAGPMember" xlink:to="tnxp_SalesAgreementWithAGPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_SalesAgreementWithAGPMember_doc" xml:lang="en-US">Sales Agreement with AGP.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4" xlink:to="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ExercisePriceOfWarrantsExpired" xlink:to="tnxp_ExercisePriceOfWarrantsExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_ExercisePriceOfWarrantsExpired_doc" xml:lang="en-US">The exercise price of expired warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_FurnitureAndEquipmentMember" xlink:to="tnxp_FurnitureAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_FurnitureAndEquipmentMember_doc" xml:lang="en-US">Furniture and Equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent" xlink:to="tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent_doc" xml:lang="en-US">Percent limitations on the use of all operating loss carryforwards available to reduce future taxable income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_InsermLicenseAgreementMember" xlink:to="tnxp_InsermLicenseAgreementMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_InsermLicenseAgreementMember_3_lbl" xml:lang="en-US">License Agreement [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PreferredStockDeemedDividend" xlink:to="tnxp_PreferredStockDeemedDividend_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PreferredStockDeemedDividend_3_lbl" xml:lang="en-US">Preferred Stock Deemed Dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_2_lbl" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ContractRelatedAccruedLiabilitiesCurrent" xlink:to="tnxp_ContractRelatedAccruedLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ContractRelatedAccruedLiabilitiesCurrent_3_lbl" xml:lang="en-US">Contract Related Accrued Liabilities Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_PreferredStockIssuanceCosts" xlink:to="tnxp_PreferredStockIssuanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_PreferredStockIssuanceCosts_3_lbl" xml:lang="en-US">Preferred Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tnxp_ContingentMilestonePaymentObligation" xlink:to="tnxp_ContingentMilestonePaymentObligation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tnxp_ContingentMilestonePaymentObligation_3_lbl" xml:lang="en-US">Contingent milestone payment obligation [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>tnxp-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tonixpharma.com/role/Cover" xlink:href="tnxp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedBalanceSheets" xlink:href="tnxp-20221231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="tnxp-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfOperations" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="tnxp-20221231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Business" xlink:href="tnxp-20221231.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPolicies" xlink:href="tnxp-20221231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNet" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformation" xlink:href="tnxp-20221231.xsd#OtherBalanceSheetInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FairValueMeasurements" xlink:href="tnxp-20221231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/StockholdersEquity" xlink:href="tnxp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/TemporaryEquity" xlink:href="tnxp-20221231.xsd#TemporaryEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithKatana" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrigemina" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrimaran" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithCuria" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithCuria" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithUniversityOfAlberta" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithOyagen" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithOyagen" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithInserm" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithInserm" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity" xlink:href="tnxp-20221231.xsd#LicenseAgreementsWithColumbiaUniversity" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SaleOfCommonStock" xlink:href="tnxp-20221231.xsd#SaleOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Stock-basedCompensation" xlink:href="tnxp-20221231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStock" xlink:href="tnxp-20221231.xsd#WarrantsToPurchaseCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Leases" xlink:href="tnxp-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Commitments" xlink:href="tnxp-20221231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/IncomeTaxes" xlink:href="tnxp-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SubsequentEvents" xlink:href="tnxp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="tnxp-20221231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesTables" xlink:href="tnxp-20221231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetTables" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformationTables" xlink:href="tnxp-20221231.xsd#OtherBalanceSheetInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/TemporaryEquityTables" xlink:href="tnxp-20221231.xsd#TemporaryEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Stock-basedCompensationTables" xlink:href="tnxp-20221231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables" xlink:href="tnxp-20221231.xsd#WarrantsToPurchaseCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LeasesTables" xlink:href="tnxp-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/IncomeTaxesTables" xlink:href="tnxp-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/BusinessDetailsNarrative" xlink:href="tnxp-20221231.xsd#BusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" xlink:href="tnxp-20221231.xsd#FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" xlink:href="tnxp-20221231.xsd#PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="tnxp-20221231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="tnxp-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:href="tnxp-20221231.xsd#ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="tnxp-20221231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="tnxp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" xlink:href="tnxp-20221231.xsd#SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/TemporaryEquityDetailsNarrative" xlink:href="tnxp-20221231.xsd#TemporaryEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithKatanaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrigeminaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative" xlink:href="tnxp-20221231.xsd#AssetPurchaseAgreementWithTrimaranDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithCuriaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithOyagenDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementWithInsermDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative" xlink:href="tnxp-20221231.xsd#LicenseAgreementsWithColumbiaUniversityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative" xlink:href="tnxp-20221231.xsd#SaleOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" xlink:href="tnxp-20221231.xsd#SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" xlink:href="tnxp-20221231.xsd#AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tnxp-20221231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" xlink:href="tnxp-20221231.xsd#FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative" xlink:href="tnxp-20221231.xsd#WarrantsToPurchaseCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:href="tnxp-20221231.xsd#AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="tnxp-20221231.xsd#OtherInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/LeasesDetailsNarrative" xlink:href="tnxp-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/CommitmentsDetailsNarrative" xlink:href="tnxp-20221231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails" xlink:href="tnxp-20221231.xsd#ComponentsOfNetLossConsistOfFollowingInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" xlink:href="tnxp-20221231.xsd#ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" xlink:href="tnxp-20221231.xsd#DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="tnxp-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tonixpharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="tnxp-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockSharesDesignated" xlink:label="loc_tnxpPreferredStockSharesDesignated" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpPreferredStockSharesDesignated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaapRedeemablePreferredStockDividends" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRedeemablePreferredStockDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues7" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues7" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues7" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues7" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues7" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues7" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement4" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares4" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement" xlink:label="loc_tnxpIssuanceOfCommitmentSharesUnderPurchaseAgreement" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommitmentSharesUnderPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" xlink:label="loc_tnxpIssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommitmentSharesUnderPurchaseAgreementInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockDeemedDividend" xlink:label="loc_tnxpPreferredStockDeemedDividend" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpPreferredStockDeemedDividend" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues14" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues14" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues14" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues14" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues14" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues14" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues15" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues15" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues15" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues15" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues15" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues15" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues19" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues19" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues19" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues19" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues19" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues19" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement3" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares3" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1" xlink:label="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommonStockUnderPurchaseAgreementInShares1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodValueNewIssues21" xlink:label="loc_tnxpStockIssuedDuringPeriodValueNewIssues21" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodValueNewIssues21" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuedDuringPeriodSharesNewIssues21" xlink:label="loc_tnxpStockIssuedDuringPeriodSharesNewIssues21" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStockIssuedDuringPeriodSharesNewIssues21" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" xlink:label="loc_tnxpIssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" xlink:label="loc_tnxpIssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpIssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceNineMember" xlink:label="loc_tnxpStockIssuanceNineMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_tnxpStockIssuanceNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceJanuary2021Member" xlink:label="loc_tnxpStockIssuanceJanuary2021Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_tnxpStockIssuanceJanuary2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceFebruary2021Member" xlink:label="loc_tnxpStockIssuanceFebruary2021Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_tnxpStockIssuanceFebruary2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockIssuanceTwoMember" xlink:label="loc_tnxpStockIssuanceTwoMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_tnxpStockIssuanceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WarrantsExercisedPrice" xlink:label="loc_tnxpWarrantsExercisedPrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_tnxpWarrantsExercisedPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CommonStockIssuedToAcquireResearchAndDevelopment" xlink:label="loc_tnxpCommonStockIssuedToAcquireResearchAndDevelopment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tnxpCommonStockIssuedToAcquireResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="00000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaapRedeemableConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapRedeemableConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Business" xlink:title="00000010 - Disclosure - BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPolicies" xlink:title="00000011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNet" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherBalanceSheetInformation" xlink:title="00000013 - Disclosure - OTHER BALANCE SHEET INFORMATION">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureOtherBalanceSheetInformationAbstract" xlink:label="loc_tnxpDisclosureOtherBalanceSheetInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OtherBalanceSheetInformationDiclosureTextBlock" xlink:label="loc_tnxpOtherBalanceSheetInformationDiclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureOtherBalanceSheetInformationAbstract" xlink:to="loc_tnxpOtherBalanceSheetInformationDiclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FairValueMeasurements" xlink:title="00000014 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/TemporaryEquity" xlink:title="00000016 - Disclosure - TEMPORARY EQUITY">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureTemporaryEquityAbstract" xlink:label="loc_tnxpDisclosureTemporaryEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TemporaryEquityTextBlock" xlink:label="loc_tnxpTemporaryEquityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureTemporaryEquityAbstract" xlink:to="loc_tnxpTemporaryEquityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana" xlink:title="00000017 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract" xlink:label="loc_tnxpDisclosureAssetPurchaseAgreementWithKatanaAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementWithKatanaTextBlock" xlink:label="loc_tnxpAssetPurchaseAgreementWithKatanaTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureAssetPurchaseAgreementWithKatanaAbstract" xlink:to="loc_tnxpAssetPurchaseAgreementWithKatanaTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina" xlink:title="00000018 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract" xlink:label="loc_tnxpDisclosureAssetPurchaseAgreementWithTrigeminaAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock" xlink:label="loc_tnxpAssetPurchaseAgreementWithTrigeminaDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureAssetPurchaseAgreementWithTrigeminaAbstract" xlink:to="loc_tnxpAssetPurchaseAgreementWithTrigeminaDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran" xlink:title="00000019 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaapAssetAcquisitionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithCuria" xlink:title="00000020 - Disclosure - LICENSE AGREEMENT WITH CURIA">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithCuriaAbstract" xlink:label="loc_tnxpDisclosureLicenseAgreementWithCuriaAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementCuriaTextBlock" xlink:label="loc_tnxpLicenseAgreementCuriaTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLicenseAgreementWithCuriaAbstract" xlink:to="loc_tnxpLicenseAgreementCuriaTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta" xlink:title="00000021 - Disclosure - LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract" xlink:label="loc_tnxpDisclosureLicenseAgreementWithUniversityOfAlbertaAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementUniversityOfAlbertaTextBlock" xlink:label="loc_tnxpLicenseAgreementUniversityOfAlbertaTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLicenseAgreementWithUniversityOfAlbertaAbstract" xlink:to="loc_tnxpLicenseAgreementUniversityOfAlbertaTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithOyagen" xlink:title="00000022 - Disclosure - LICENSE AGREEMENT WITH OYAGEN">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithOyagenAbstract" xlink:label="loc_tnxpDisclosureLicenseAgreementWithOyagenAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementOyagenTextBlock" xlink:label="loc_tnxpLicenseAgreementOyagenTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLicenseAgreementWithOyagenAbstract" xlink:to="loc_tnxpLicenseAgreementOyagenTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithInserm" xlink:title="00000023 - Disclosure - LICENSE AGREEMENT WITH INSERM">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithInsermAbstract" xlink:label="loc_tnxpDisclosureLicenseAgreementWithInsermAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementWithInsermTextBlock" xlink:label="loc_tnxpLicenseAgreementWithInsermTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLicenseAgreementWithInsermAbstract" xlink:to="loc_tnxpLicenseAgreementWithInsermTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity" xlink:title="00000024 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SaleOfCommonStock" xlink:title="00000025 - Disclosure - SALE OF COMMON STOCK">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureSaleOfCommonStockAbstract" xlink:label="loc_tnxpDisclosureSaleOfCommonStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SaleOfCommonStockTextBlock" xlink:label="loc_tnxpSaleOfCommonStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureSaleOfCommonStockAbstract" xlink:to="loc_tnxpSaleOfCommonStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensation" xlink:title="00000026 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStock" xlink:title="00000027 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract" xlink:label="loc_tnxpDisclosureWarrantsToPurchaseCommonStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StockWarrantsTextBlock" xlink:label="loc_tnxpStockWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureWarrantsToPurchaseCommonStockAbstract" xlink:to="loc_tnxpStockWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Leases" xlink:title="00000028 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLeasesAbstract" xlink:label="loc_tnxpDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Commitments" xlink:title="00000029 - Disclosure - COMMITMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IncomeTaxes" xlink:title="00000030 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SubsequentEvents" xlink:title="00000031 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaapStockholdersEquityPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStockholdersEquityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaapStockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="loc_us-gaapGovernmentAssistancePolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGovernmentAssistancePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetTables" xlink:title="00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherBalanceSheetInformationTables" xlink:title="00000035 - Disclosure - OTHER BALANCE SHEET INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureOtherBalanceSheetInformationAbstract" xlink:label="loc_tnxpDisclosureOtherBalanceSheetInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srtScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureOtherBalanceSheetInformationAbstract" xlink:to="loc_srtScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/TemporaryEquityTables" xlink:title="00000036 - Disclosure - TEMPORARY EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureTemporaryEquityAbstract" xlink:label="loc_tnxpDisclosureTemporaryEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaapTemporaryEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureTemporaryEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensationTables" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables" xlink:title="00000038 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Tables)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract" xlink:label="loc_tnxpDisclosureWarrantsToPurchaseCommonStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureWarrantsToPurchaseCommonStockAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LeasesTables" xlink:title="00000039 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLeasesAbstract" xlink:label="loc_tnxpDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" xlink:label="loc_tnxpSummaryOfOtherInformationRelatedToLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_tnxpSummaryOfOtherInformationRelatedToLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IncomeTaxesTables" xlink:title="00000040 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/BusinessDetailsNarrative" xlink:title="00000041 - Disclosure - BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WorkingCapital" xlink:label="loc_tnxpWorkingCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_tnxpWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails" xlink:title="00000042 - Disclosure - The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails" xlink:title="00000043 - Disclosure - Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LandImprovementsAndLabEquipmentMember" xlink:label="loc_tnxpLandImprovementsAndLabEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpLandImprovementsAndLabEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_FurnitureAndAllOtherEquipmentMember" xlink:label="loc_tnxpFurnitureAndAllOtherEquipmentMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpFurnitureAndAllOtherEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:title="00000045 - Disclosure - Property and equipment, net consisted of the following (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember" xlink:label="loc_us-gaapLandImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_FurnitureAndEquipmentMember" xlink:label="loc_tnxpFurnitureAndEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LaboratoryEquipmentMember" xlink:label="loc_tnxpLaboratoryEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpLaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MD" xlink:label="loc_stprMD" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="loc_stprMA" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MT" xlink:label="loc_stprMT" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMT" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" xlink:label="loc_tnxpOfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_tnxpOfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAdditions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAdditions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="loc_us-gaapPaymentsForConstructionInProcess" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForConstructionInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:title="00000047 - Disclosure - Components of selected captions in the consolidated balance sheets consist of: (Details)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureOtherBalanceSheetInformationAbstract" xlink:label="loc_tnxpDisclosureOtherBalanceSheetInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureOtherBalanceSheetInformationAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContractRelatedPrepaidExpenseCurrent" xlink:label="loc_tnxpContractRelatedPrepaidExpenseCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_tnxpContractRelatedPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent" xlink:label="loc_tnxpProfessionalFeesAndOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_tnxpProfessionalFeesAndOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureOtherBalanceSheetInformationAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContractRelatedAccruedLiabilitiesCurrent" xlink:label="loc_tnxpContractRelatedAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAbstract" xlink:to="loc_tnxpContractRelatedAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" xlink:label="loc_tnxpCompensationAndCompensationRelatedAccruedLiabilitiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAbstract" xlink:to="loc_tnxpCompensationAndCompensationRelatedAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ConstructionInProgressAccruedLiabilitiesCurrent" xlink:label="loc_tnxpConstructionInProgressAccruedLiabilitiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAbstract" xlink:to="loc_tnxpConstructionInProgressAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_tnxpProfessionalFeesAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAbstract" xlink:to="loc_tnxpProfessionalFeesAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureOtherBalanceSheetInformationAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CashEquivalentsFairValue" xlink:label="loc_tnxpCashEquivalentsFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_tnxpCashEquivalentsFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000049 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails" xlink:title="00000050 - Disclosure - The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value (Details)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureTemporaryEquityAbstract" xlink:label="loc_tnxpDisclosureTemporaryEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureTemporaryEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_GrossProceeds" xlink:label="loc_tnxpGrossProceeds" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpGrossProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PreferredStockIssuanceCosts" xlink:label="loc_tnxpPreferredStockIssuanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpPreferredStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_tnxpAccretionOfCarryingValueToRedemptionValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpAccretionOfCarryingValueToRedemptionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/TemporaryEquityDetailsNarrative" xlink:title="00000051 - Disclosure - TEMPORARY EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureTemporaryEquityAbstract" xlink:label="loc_tnxpDisclosureTemporaryEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureTemporaryEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaapRedeemableConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapRedeemableConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfIssueDiscount" xlink:label="loc_tnxpPercentageOfIssueDiscount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpPercentageOfIssueDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_StatedValuePerShare" xlink:label="loc_tnxpStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TemporaryEquityRedemptionPricePercentage" xlink:label="loc_tnxpTemporaryEquityRedemptionPricePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpTemporaryEquityRedemptionPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EscrowDepositForOriginalIssueDiscount" xlink:label="loc_tnxpEscrowDepositForOriginalIssueDiscount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tnxpEscrowDepositForOriginalIssueDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative" xlink:title="00000052 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementMember" xlink:label="loc_tnxpAssetPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_KatanaPharmaceuticalsIncMember" xlink:label="loc_tnxpKatanaPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpKatanaPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative" xlink:title="00000053 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementMember" xlink:label="loc_tnxpAssetPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssignmentAndAssumptionAgreementMember" xlink:label="loc_tnxpAssignmentAndAssumptionAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssignmentAndAssumptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TrigeminaIncMember" xlink:label="loc_tnxpTrigeminaIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpTrigeminaIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CommonStockValuePerShares" xlink:label="loc_tnxpCommonStockValuePerShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpCommonStockValuePerShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative" xlink:title="00000054 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementMember" xlink:label="loc_tnxpAssetPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WSULicenseAgreementMember" xlink:label="loc_tnxpWSULicenseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpWSULicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TRImaranPharmaIncMember" xlink:label="loc_tnxpTRImaranPharmaIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpTRImaranPharmaIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AchievementPaymentsPayable" xlink:label="loc_tnxpAchievementPaymentsPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpAchievementPaymentsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ReimbursementOfPatentExpenses" xlink:label="loc_tnxpReimbursementOfPatentExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpReimbursementOfPatentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContingentMilestonePaymentObligation" xlink:label="loc_tnxpContingentMilestonePaymentObligation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpContingentMilestonePaymentObligation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:label="loc_tnxpPercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpPercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MaximumPercentageReductionOfRoyaltiesPayable" xlink:label="loc_tnxpMaximumPercentageReductionOfRoyaltiesPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_tnxpMaximumPercentageReductionOfRoyaltiesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative" xlink:title="00000055 - Disclosure - LICENSE AGREEMENT WITH CURIA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithCuriaAbstract" xlink:label="loc_tnxpDisclosureLicenseAgreementWithCuriaAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLicenseAgreementWithCuriaAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementMember" xlink:label="loc_tnxpLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CuriaMember" xlink:label="loc_tnxpCuriaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpCuriaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative" xlink:title="00000056 - Disclosure - LICENSE AGREEMENT WITH OYAGEN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithOyagenAbstract" xlink:label="loc_tnxpDisclosureLicenseAgreementWithOyagenAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLicenseAgreementWithOyagenAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementMember" xlink:label="loc_tnxpLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OyaGenIncMember" xlink:label="loc_tnxpOyaGenIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpOyaGenIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative" xlink:title="00000057 - Disclosure - LICENSE AGREEMENT WITH INSERM (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLicenseAgreementWithInsermAbstract" xlink:label="loc_tnxpDisclosureLicenseAgreementWithInsermAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLicenseAgreementWithInsermAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_InsermLicenseAgreementMember" xlink:label="loc_tnxpInsermLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpInsermLicenseAgreementMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_InsermMember" xlink:label="loc_tnxpInsermMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpInsermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OxytocinBasedTherapeuticsMember" xlink:label="loc_tnxpOxytocinBasedTherapeuticsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_tnxpOxytocinBasedTherapeuticsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesMilestones" xlink:label="loc_tnxpSalesMilestones" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpSalesMilestones" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative" xlink:title="00000058 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LicenseAgreementMember" xlink:label="loc_tnxpLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TrusteesOfColumbiaUniversityMember" xlink:label="loc_tnxpTrusteesOfColumbiaUniversityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_tnxpTrusteesOfColumbiaUniversityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtProductOrServiceAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TFF2ProductMember" xlink:label="loc_tnxpTFF2ProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_tnxpTFF2ProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:label="loc_tnxpPercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpPercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MaximumPercentageReductionOfRoyaltiesPayable" xlink:label="loc_tnxpMaximumPercentageReductionOfRoyaltiesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpMaximumPercentageReductionOfRoyaltiesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ContingentMilestonePaymentObligation" xlink:label="loc_tnxpContingentMilestonePaymentObligation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpContingentMilestonePaymentObligation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentagePadOfConsideration" xlink:label="loc_tnxpPercentagePadOfConsideration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_tnxpPercentagePadOfConsideration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative" xlink:title="00000059 - Disclosure - SALE OF COMMON STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnPark2022Member" xlink:label="loc_tnxpPurchaseAgreementWithLincolnPark2022Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreementWithLincolnPark2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnParkMember" xlink:label="loc_tnxpPurchaseAgreementWithLincolnParkMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreementWithLincolnParkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnPark2021Member" xlink:label="loc_tnxpPurchaseAgreementWithLincolnPark2021Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreementWithLincolnPark2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreement2021Member" xlink:label="loc_tnxpPurchaseAgreement2021Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreement2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_UnderwritingAgreementMember" xlink:label="loc_tnxpUnderwritingAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesAgreementMember" xlink:label="loc_tnxpSalesAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_LincolnParkCapitalFundLLCMember" xlink:label="loc_tnxpLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_tnxpLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AllianceGlobalPartnersMember" xlink:label="loc_tnxpAllianceGlobalPartnersMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_tnxpAllianceGlobalPartnersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AllianceGlobalPartnersMember" xlink:label="loc_tnxpAllianceGlobalPartnersMember_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_tnxpAllianceGlobalPartnersMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CommitmentToPurchaseSharesUnderAgreement" xlink:label="loc_tnxpCommitmentToPurchaseSharesUnderAgreement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpCommitmentToPurchaseSharesUnderAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PercentageOfIssuanceByIssuerOfCommonStock" xlink:label="loc_tnxpPercentageOfIssuanceByIssuerOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpPercentageOfIssuanceByIssuerOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval" xlink:label="loc_tnxpMaximumNumberOfSharesIssuedWIthoutShareholderApproval" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpMaximumNumberOfSharesIssuedWIthoutShareholderApproval" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_CashFeePercentage" xlink:label="loc_tnxpCashFeePercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpCashFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_UnderwritingDiscount" xlink:label="loc_tnxpUnderwritingDiscount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpUnderwritingDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OfferingPricePerAgreement" xlink:label="loc_tnxpOfferingPricePerAgreement" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpOfferingPricePerAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesAgentCommissionPercentage" xlink:label="loc_tnxpSalesAgentCommissionPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_tnxpSalesAgentCommissionPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails" xlink:title="00000060 - Disclosure -  A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails" xlink:title="00000061 - Disclosure - The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000062 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IncentiveStockOptionsPlan2019Member" xlink:label="loc_tnxpIncentiveStockOptionsPlan2019Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpIncentiveStockOptionsPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_IncentiveStockOptionsPlan2020Member" xlink:label="loc_tnxpIncentiveStockOptionsPlan2020Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpIncentiveStockOptionsPlan2020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AmendedAndRestated2020PlanMember" xlink:label="loc_tnxpAmendedAndRestated2020PlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpAmendedAndRestated2020PlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockPurchasePlan2022Member" xlink:label="loc_tnxpEmployeeStockPurchasePlan2022Member" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpEmployeeStockPurchasePlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockPurchasePlansMember" xlink:label="loc_tnxpEmployeeStockPurchasePlansMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpEmployeeStockPurchasePlansMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockPurchasePlan2020Member" xlink:label="loc_tnxpEmployeeStockPurchasePlan2020Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpEmployeeStockPurchasePlan2020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_TenPercentOrMoreShareholderMember" xlink:label="loc_tnxpTenPercentOrMoreShareholderMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_tnxpTenPercentOrMoreShareholderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srtExecutiveOfficerMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:label="loc_tnxpShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_tnxpShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AmountReturnToEmployee1" xlink:label="loc_tnxpAmountReturnToEmployee1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_tnxpAmountReturnToEmployee1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AccumulatedEmployeePayrollDeductions" xlink:label="loc_tnxpAccumulatedEmployeePayrollDeductions" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_tnxpAccumulatedEmployeePayrollDeductions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details" xlink:title="00000063 - Disclosure - The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022: (Details)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract" xlink:label="loc_tnxpDisclosureWarrantsToPurchaseCommonStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureWarrantsToPurchaseCommonStockAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant1Member" xlink:label="loc_tnxpWarrant1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tnxpWarrant1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant2Member" xlink:label="loc_tnxpWarrant2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tnxpWarrant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant3Member" xlink:label="loc_tnxpWarrant3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tnxpWarrant3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ClassOfWarrantsOrRightExpirationDate" xlink:label="loc_tnxpClassOfWarrantsOrRightExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_tnxpClassOfWarrantsOrRightExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative" xlink:title="00000064 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract" xlink:label="loc_tnxpDisclosureWarrantsToPurchaseCommonStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureWarrantsToPurchaseCommonStockAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_WarrantsFromFeb2020FinancingMember" xlink:label="loc_tnxpWarrantsFromFeb2020FinancingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tnxpWarrantsFromFeb2020FinancingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_Warrant1Member" xlink:label="loc_tnxpWarrant1Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_tnxpWarrant1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ExercisePriceOfWarrantsExpired" xlink:label="loc_tnxpExercisePriceOfWarrantsExpired" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_tnxpExercisePriceOfWarrantsExpired" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:title="00000065 - Disclosure - At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLeasesAbstract" xlink:label="loc_tnxpDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000066 - Disclosure - Other information related to leases was as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLeasesAbstract" xlink:label="loc_tnxpDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LeasesDetailsNarrative" xlink:title="00000067 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DisclosureLeasesAbstract" xlink:label="loc_tnxpDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tnxpDisclosureLeasesAbstract" xlink:to="loc_us-gaapOtherCommitmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_NewLeaseArrangementMember" xlink:label="loc_tnxpNewLeaseArrangementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_tnxpNewLeaseArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CommitmentsDetailsNarrative" xlink:title="00000068 - Disclosure - COMMITMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ResearchOrganizationsMember" xlink:label="loc_tnxpResearchOrganizationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_tnxpResearchOrganizationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ConstructionContractMember" xlink:label="loc_tnxpConstructionContractMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_tnxpConstructionContractMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_DefinedContributionPlan401KPlanMember" xlink:label="loc_tnxpDefinedContributionPlan401KPlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tnxpDefinedContributionPlan401KPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="loc_us-gaapDefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:label="loc_us-gaapDefinedContributionPlanAdministrativeExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDefinedContributionPlanAdministrativeExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails" xlink:title="00000069 - Disclosure - Components of the net loss consist of the following (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails" xlink:title="00000070 - Disclosure - A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company&#8217;s income tax provision is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" xlink:label="loc_tnxpEffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_tnxpEffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails" xlink:title="00000071 - Disclosure - Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000072 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE" xlink:label="loc_countryIE" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIE" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BM" xlink:label="loc_countryBM" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBM" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ" xlink:label="loc_stprNJ" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprNJ" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="loc_stprMA" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent" xlink:label="loc_tnxpOperatingLossCarryforwardsLimitationsOnUsePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_tnxpOperatingLossCarryforwardsLimitationsOnUsePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaapShareRepurchaseProgramAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapShareRepurchaseProgramAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaapShareRepurchaseProgramDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareRepurchaseProgramAxis" xlink:to="loc_us-gaapShareRepurchaseProgramDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ExistingShareRepurchaseProgramMember" xlink:label="loc_tnxpExistingShareRepurchaseProgramMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareRepurchaseProgramDomain" xlink:to="loc_tnxpExistingShareRepurchaseProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_NewShareRepurchaseProgramMember" xlink:label="loc_tnxpNewShareRepurchaseProgramMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareRepurchaseProgramDomain" xlink:to="loc_tnxpNewShareRepurchaseProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_AssetPurchaseAgreementMember" xlink:label="loc_tnxpAssetPurchaseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_SalesAgreementWithAGPMember" xlink:label="loc_tnxpSalesAgreementWithAGPMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpSalesAgreementWithAGPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_PurchaseAgreementWithLincolnPark2022Member" xlink:label="loc_tnxpPurchaseAgreementWithLincolnPark2022Member" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_tnxpPurchaseAgreementWithLincolnPark2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_HealionBioIncMember" xlink:label="loc_tnxpHealionBioIncMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tnxpHealionBioIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_EmployeeStockOption1Member" xlink:label="loc_tnxpEmployeeStockOption1Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_tnxpEmployeeStockOption1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapVestingAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaapStockRepurchaseProgramAuthorizedAmount1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaapTreasuryStockAcquiredAverageCostPerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapTreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_MinimumBidRequirementPerShare" xlink:label="loc_tnxpMinimumBidRequirementPerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_tnxpMinimumBidRequirementPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20221231.xsd#tnxp_ConsecutiveBusinessDaysForMinimumBidPrice" xlink:label="loc_tnxpConsecutiveBusinessDaysForMinimumBidPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_tnxpConsecutiveBusinessDaysForMinimumBidPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088933094288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TONIX
PHARMACEUTICALS HOLDING CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001430306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1434750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26
        Main Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chatham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City area code</a></td>
<td class="text">(862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local phone number</a></td>
<td class="text">799-8599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
        Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TNXP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,022,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,539,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EisnerAmper LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088932334208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,229<span></span>
</td>
<td class="nump">$ 178,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">10,548<span></span>
</td>
<td class="nump">10,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">130,777<span></span>
</td>
<td class="nump">189,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">93,814<span></span>
</td>
<td class="nump">50,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-to-use assets</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">225,690<span></span>
</td>
<td class="nump">240,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,068<span></span>
</td>
<td class="nump">13,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,680<span></span>
</td>
<td class="nump">7,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, short term</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,180<span></span>
</td>
<td class="nump">21,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, long term</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,508<span></span>
</td>
<td class="nump">22,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized Series B Convertible Preferred stock, 0 shares designated as of both December 31, 2022 and 2021; issued and outstanding - None Series A Convertible Preferred stock, 0 shares designated as of both December 31, 2022 and 2021; issued and outstanding - None</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 and 25,000,000&#160;shares authorized as of December 31, 2022 and 2021, respectively; 76,478,656 and 15,638,274 shares issued and&#160;outstanding as of December 31, 2022 and 2021, respectively and 93,741 and 4,033 shares to be issued as of December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">677,311<span></span>
</td>
<td class="nump">578,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(470,038)<span></span>
</td>
<td class="num">(359,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">207,182<span></span>
</td>
<td class="nump">218,717<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 225,690<span></span>
</td>
<td class="nump">$ 240,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140089040002336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">76,478,656<span></span>
</td>
<td class="nump">15,638,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">76,478,656<span></span>
</td>
<td class="nump">15,638,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, to be issued</a></td>
<td class="nump">93,741<span></span>
</td>
<td class="nump">4,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PreferredStockSharesDesignated', window );">Preferred stock, designated</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PreferredStockSharesDesignated', window );">Preferred stock, designated</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of designated shares of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140089039976912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>COSTS AND EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 81,876<span></span>
</td>
<td class="nump">$ 68,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">30,215<span></span>
</td>
<td class="nump">23,474<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">&#160;</a></td>
<td class="nump">112,091<span></span>
</td>
<td class="nump">92,312<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(112,091)<span></span>
</td>
<td class="num">(92,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,873<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(110,218)<span></span>
</td>
<td class="num">(92,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Preferred stock deemed dividend</a></td>
<td class="nump">6,659<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (116,877)<span></span>
</td>
<td class="num">$ (92,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (3.27)<span></span>
</td>
<td class="num">$ (8.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (3.27)<span></span>
</td>
<td class="num">$ (8.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">35,739,057<span></span>
</td>
<td class="nump">11,387,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">35,739,057<span></span>
</td>
<td class="nump">11,387,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemablePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemablePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088933259856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (110,218)<span></span>
</td>
<td class="num">$ (92,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (110,293)<span></span>
</td>
<td class="num">$ (92,317)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931813136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 355,237<span></span>
</td>
<td class="num">$ (62)<span></span>
</td>
<td class="num">$ (267,533)<span></span>
</td>
<td class="nump">$ 87,648<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, at beginning (in shares) at Dec. 31, 2020</a></td>
<td class="nump">6,568,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodValueNewIssues14', window );">Issuance of common stock in January 2021 ($25.60 per share), net of transactional expenses of $3,096</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodSharesNewIssues14', window );">Issuance of common stock in January 2021 ($25.60 per share), net of transactional expenses of $3,096 (in shares)</a></td>
<td class="nump">1,562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodValueNewIssues1', window );">Issuance of common stock in exchange for exercise of warrants in March 2021 ($18.24 per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodSharesNewIssues1', window );">Issuance of common stock in exchange for exercise of warrants in March 2021 ($18.24 per share) (in shares)</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodValueNewIssues15', window );">Issuance of common stock in February 2021 ($38.40 per share), net of transactional expenses of $5,002</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">64,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">64,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodSharesNewIssues15', window );">Issuance of common stock in February 2021 ($38.40 per share), net of transactional expenses of $5,002 (in shares)</a></td>
<td class="nump">1,822,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodValueNewIssues19', window );">Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">69,288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">69,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodSharesNewIssues19', window );">Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332 (in shares)</a></td>
<td class="nump">3,445,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3', window );">Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">41,194<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">41,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3', window );">Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75 (in shares)</a></td>
<td class="nump">2,016,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1', window );">Issuance of commitment shares under 2021 Purchase agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1', window );">Issuance of commitment shares under 2021 Purchase agreement (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodValueNewIssues21', window );">Issuance of common stock in the acquisition of the OyaGen license</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodSharesNewIssues21', window );">Issuance of common stock in the acquisition of the OyaGen license (in shares)</a></td>
<td class="nump">86,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement', window );">Issuance of commitment shares under Lincoln park Purchase agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares', window );">Issuance of commitment shares under Lincoln park Purchase agreement (in shares)</a></td>
<td class="nump">90,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="nump">5,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,899<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency transaction loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(92,287)<span></span>
</td>
<td class="num">(92,287)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">578,613<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="num">(359,820)<span></span>
</td>
<td class="nump">218,717<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, at end (in shares) at Dec. 31, 2021</a></td>
<td class="nump">15,638,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodValueNewIssues7', window );">Issuance of common stock under At-the-market offering, net of transactional expenses of $3,078</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">85,237<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">85,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockIssuedDuringPeriodSharesNewIssues7', window );">Issuance of common stock under At-the-market offering, net of transactional expenses of $3,078 (in shares)</a></td>
<td class="nump">56,357,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4', window );">Issuance of common stock under 2022 Purchase Agreement</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4', window );">Issuance of common stock under 2022 Purchase Agreement (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2', window );">Issuance of common stock under 2021 Purchase Agreement</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">8,679<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2', window );">Issuance of common stock under 2021 Purchase Agreement (in shares)</a></td>
<td class="nump">2,853,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement', window );">Issuance of commitment shares under 2022 Purchase agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares', window );">Issuance of commitment shares under 2022 Purchase agreement (in shares)</a></td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PreferredStockDeemedDividend', window );">Preferred stock deemed dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,659)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="nump">4,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,914<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency transaction loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(110,218)<span></span>
</td>
<td class="num">(110,218)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 677,311<span></span>
</td>
<td class="num">$ (167)<span></span>
</td>
<td class="num">$ (470,038)<span></span>
</td>
<td class="nump">$ 207,182<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, at end (in shares) at Dec. 31, 2022</a></td>
<td class="nump">76,478,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of Issuance of commitment shares under Lincoln Park Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of commitment shares under Lincoln Park Purchase Agreement, number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of commitment shares under Purchase Agreement, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of commitment shares under Purchase Agreement, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_PreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deemed dividend for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_PreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodSharesNewIssues14">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodSharesNewIssues14</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodSharesNewIssues15">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodSharesNewIssues15</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodSharesNewIssues19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodSharesNewIssues19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodSharesNewIssues21">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodSharesNewIssues21</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodSharesNewIssues7">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodSharesNewIssues7</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodValueNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodValueNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodValueNewIssues14">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodValueNewIssues14</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodValueNewIssues15">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodValueNewIssues15</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodValueNewIssues19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodValueNewIssues19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodValueNewIssues21">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodValueNewIssues21</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockIssuedDuringPeriodValueNewIssues7">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockIssuedDuringPeriodValueNewIssues7</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088933037248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_WarrantsExercisedPrice', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceNineMember', window );">Issuance of common stock under At-the-market offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Transactional expenses</a></td>
<td class="nump">$ 3,078<span></span>
</td>
<td class="nump">$ 2,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceJanuary2021Member', window );">Issuance of common stock in January 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Transactional expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceFebruary2021Member', window );">Issuance of common stock in February 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Transactional expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceTwoMember', window );">Issuance of common stock under 2021 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Transactional expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_WarrantsExercisedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price at which warrant holders acquired shares when converting their warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_WarrantsExercisedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceJanuary2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceJanuary2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceFebruary2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceFebruary2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tnxp_StockIssuanceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088941344752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (110,218)<span></span>
</td>
<td class="num">$ (92,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_CommonStockIssuedToAcquireResearchAndDevelopment', window );">Common stock issued to acquire in-process research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,914<span></span>
</td>
<td class="nump">7,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="num">(164)<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(1,045)<span></span>
</td>
<td class="nump">3,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities and ROU asset, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(98,053)<span></span>
</td>
<td class="num">(75,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(48,147)<span></span>
</td>
<td class="num">(35,307)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(48,147)<span></span>
</td>
<td class="num">(35,307)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from ESPP</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds, net of $6,659 expenses, from sale of convertible redeemable preferred stock</a></td>
<td class="nump">40,591<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock', window );">Redemption of convertible redeemable preferred stock</a></td>
<td class="num">(47,250)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds, net of $3,078 and $10,505 expenses, from sale of common stock and warrants</a></td>
<td class="nump">94,463<span></span>
</td>
<td class="nump">212,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">87,844<span></span>
</td>
<td class="nump">212,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of currency rate change on cash</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(58,430)<span></span>
</td>
<td class="nump">101,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash beginning of the period</a></td>
<td class="nump">178,900<span></span>
</td>
<td class="nump">77,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash end of period</a></td>
<td class="nump">120,470<span></span>
</td>
<td class="nump">178,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">3,092<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Preferred stock deemed dividend</a></td>
<td class="nump">$ 6,659<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_CommonStockIssuedToAcquireResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount represents common stock issued to acquire research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_CommonStockIssuedToAcquireResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088935912672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Expenses from sale of common stock and warrants</a></td>
<td class="nump">$ 3,078<span></span>
</td>
<td class="nump">$ 10,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Expenses from sale of common stock and warrants</a></td>
<td class="nump">$ 6,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936786944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">BUSINESS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--NatureOfOperations_zlvvG1OMgiy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8211;
<span id="xdx_821_zacOZmUYMm59">BUSINESS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tonix Pharmaceuticals Holding
Corp., through its wholly owned subsidiary Tonix Pharmaceuticals, Inc. (&#8220;Tonix Sub&#8221;), is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing therapeutics and vaccines to treat and prevent human disease and alleviate
suffering. The therapeutics include both small molecules and biologics. All drug product and vaccine candidates are still in development
and none are approved or marketed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements include the accounts of Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiaries, Tonix Sub, Krele LLC, Tonix
Pharmaceuticals (Canada), Inc., Tonix Medicines, Inc., Jenner LLC, Tonix R&amp;D Center LLC, Tonix Pharma Holdings Limited and Tonix Pharma
Limited (collectively hereafter referred to as the &#8220;Company&#8221; or &#8220;Tonix&#8221;). All intercompany balances and transactions
have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Going
Concern</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization
of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses
from operations and negative cash flows from operating activities. At December 31, 2022, the Company had working capital of approximately
$<span id="xdx_909_ecustom--WorkingCapital_iI_pn5n6_c20221231_zMAchNvNO0be" title="Working capital">112.6</span> million. At December
31, 2022, the Company had an accumulated deficit of approximately $<span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3n3_dxL_c20221231_zFcvc05qocU6" title="Accumulated deficit::XDX::-470038"><span style="-sec-ix-hidden: xdx2ixbrl0523">470.0
million</span></span>. The Company held cash and cash equivalents of approximately $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dxL_c20221231_ziIbKtPDeCDk" title="Cash and cash equivalents::XDX::120229"><span style="-sec-ix-hidden: xdx2ixbrl0525">120.2
million</span></span> as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company believes that
its cash resources at December 31, 2022 and the proceeds that it raised from equity offerings in the first quarter of 2023, net of amounts
paid to repurchase shares in the first quarter of 2023 (See Note 22), will meet its operating and capital expenditure requirements into
the fourth quarter of 2023, but not beyond.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;These factors raise
substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company faces significant challenges and uncertainties
and, as a result, its available capital resources may be consumed more rapidly than currently expected due to changes it may make in its
research and development spending plans. The Company believes that it has the ability to obtain additional funding through public and
private financing and collaborative arrangements with strategic partners to increase the funds available to fund operations. However,
the Company may not be able to raise capital on terms acceptable to the Company. Without additional funds, it may be forced to delay,
scale back or eliminate some of its research and development activities, or other operations and potentially delay product development
in an effort to provide sufficient funds to continue operations. If any of these events occurs, the Company&#8217;s ability to achieve
its development and commercialization goals would be adversely affected. The financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140089024264656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zm9kn7So8Ni6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
2 &#8211; <span id="xdx_824_z4KJEYWVH121">SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--StockholdersEquityPolicyTextBlock_zOZ3iJLnegD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Reverse
Stock Split</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 16, 2022, the Company
filed a Certificate of Change with the Nevada Secretary of State, effective May 17, 2022. Pursuant to the Certificate of Change, the Company
effected a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20220515__20220516_zaVAYh85aOi5" title="Reverse stock split">1-for-32</span>
reverse stock split of its issued and outstanding shares of common stock. The Company accounted for the reverse stock split on a retrospective
basis pursuant to ASC 260, Earnings Per Share. All authorized, issued and outstanding common stock, common stock warrants, stock option
awards, exercise prices and per share data have been adjusted in these consolidated financial statements, on a retroactive basis, to reflect
the reverse stock split for all periods presented. Authorized preferred stock was not adjusted because of the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z85bylyw235c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Risks
and uncertainties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s primary
efforts are devoted to conducting research and development of innovative pharmaceutical and biological products to address public health
challenges. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions
to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated
revenues, and there is no assurance that if its products are approved for sale, that the Company will be able to generate cash flow to
fund operations. In addition, there can be no assurance that the Company&#8217;s research and development will be successfully completed
or that any product will be approved or commercially viable. Moreover, the extent to which COVID-19 impacts the Company&#8217;s operations
will depend on future developments, which are highly uncertain and cannot be predicted with confidence at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_847_eus-gaap--UseOfEstimates_zycH3ZaWPaDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Use
of estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in accordance with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date
of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates. Significant estimates include the assumptions used in the fair value of stock-based compensation and other equity instruments,
and the percent of completion of research and development contracts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeCsYv2kOrg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Cash
Equivalents and Restricted Cash</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers cash
equivalents to be those investments which are highly liquid, readily convertible to cash and have an original maturity of three months
or less when purchased. At December 31, 2022 and December 31, 2021, cash equivalents, which consisted of money market funds, amounted
to $<span id="xdx_90E_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20221231_z94GNFrnaeJl" title="Money market funds">116.3</span> million
and $<span id="xdx_90F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20211231_zgwX3aBLcKJ4">120.4</span> million, respectively.&#160;Restricted
cash, which is included in Other non-current assets on the consolidated balance sheet at December 31, 2022 and December 31, 2021 of approximately
$<span id="xdx_90E_eus-gaap--RestrictedCash_iI_pn3p0_c20221231_znWvNSUUBPEe">241,000</span> and $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn3p0_c20211231_z9QJnmrt7PY9">240,000</span>,
respectively, collateralizes a letter of credit issued in connection with the lease of office space in Chatham, New Jersey and New York
City (see Note 19).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_893_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zm4EC9tOs0H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets
that sum to the total of the same amounts shown in the consolidated statement of cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zOZh4WPjT098" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December
        31, </b></span> <span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z8H3ZnL15rCj" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December
        31, </b></span> <span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzAEg_zJ9wBtsQLBPj" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Cash and cash equivalents</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">120,229</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">178,660</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzAEg_z6lDGQL9tM9h" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Restricted cash</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">241</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">240</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzAEg_z21OclPlbmq2" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">120,470</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">178,900</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zASRSTfMjLX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfbFUYyyXE0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Property
and equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#8217;s estimated
useful life, which ranges from <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MinimumMember_zvv78dahWPi9" title="Estimated useful life of property and equipment">20</span>
to <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MaximumMember_zKg1zF1o4gDi" title="Estimated useful life of property and equipment">30</span>
years for buildings, <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LandImprovementsAndLabEquipmentMember_z3pJHCpx5zxj" title="Estimated useful life of property and equipment">15</span>
years for land improvements, and laboratory equipment, <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKWRPzNxpR49" title="Estimated useful life of property and equipment">three
years</span> for computer assets, <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndAllOtherEquipmentMember_zwoae7YmI5vb" title="Estimated useful life of property and equipment">five
years</span> for furniture and all other equipment and term of lease for leasehold improvements. Depreciation on assets begin when the
asset is available for its intended use. Depreciation and amortization expense for the years ended December 31, 2022, and 2021 was $<span id="xdx_90B_eus-gaap--DepreciationAndAmortization_pp0p0_c20220101__20221231_zXgSwU9KAhij" title="Depreciation and amortization expense">1,253,000</span>&#160;and
$<span id="xdx_90A_eus-gaap--DepreciationAndAmortization_pp0p0_c20210101__20211231_z4wIiMThVXRl" title="Depreciation and amortization expense">50,000</span>,
respectively. The Company&#8217;s property and equipment is located in the United States.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84C_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_zPuPuWvi2DZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Intangible
assets with indefinite lives</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2015, the Company purchased certain internet domain rights, which were determined to have an indefinite life. Identifiable intangibles
with indefinite lives, which are included in Other non-current assets on the consolidated balance sheet, are not amortized but are tested
for impairment annually or whenever events or changes in circumstances indicate that their carrying amount may be less than fair value.
As of December 31, 2022, and 2021, the Company believed that no impairment existed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zSRdMtHSVd58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets, lease liability, short term and lease liability, long term in the Company&#8217;s consolidated balance sheets. ROU assets represent
the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental
borrowing rate based on the information available at the transition date and subsequent lease commencement dates in determining the present
value of lease payments. This is the rate the Company would have to pay if borrowing on a collateralized basis over a similar term to
each lease. The operating lease ROU asset excludes lease incentives. The Company&#8217;s lease terms may include options to extend or
terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments made under
operating leases is recognized on a straight-line basis over the lease term.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zmlnMQJvq0Cg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Convertible
Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preferred shares subject to
mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity (&#8220;mezzanine&#8221;)
until such time as the conditions are removed or lapse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2B4gU2l2Br9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Research
and Development Costs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company outsources certain
of its research and development efforts and expenses these costs as incurred, including the cost of manufacturing products for testing,
as well as licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual
property acquired has been expensed as research and development costs, as such property is related to particular research and development
projects and had no alternative future uses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company estimates its
expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical
site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which
vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided
under such contracts. The Company accounts for trial expenses according to the timing of various aspects of the trial. The Company determines
accrual estimates taking into account discussion with applicable personnel and outside service providers as to the progress or state of
consummation of trials, or the services completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the course of a clinical
trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of
its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#8217;s
clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party
vendors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_843_eus-gaap--GovernmentAssistancePolicyTextBlock_zN6kPx5OpuP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Government
Grants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may enter into
arrangements with governmental entities for the purpose of obtaining funding for research and development activities. The Company is reimbursed
for costs incurred that are associated with specified research and development activities included in the grant application approved by
the government authority. The Company classifies government grants&#160;received under these arrangements as a reduction to the related
research and development expense in the same period as the relevant expenses are incurred. In August 2022, the Company announced that
it received a Cooperative Agreement grant from the National Institute on Drug Abuse (&#8220;NIDA&#8221;), part of the National Institutes
of Health, to support the development of its TNX-1300 product candidate for the treatment of cocaine intoxication. No funding was received
during 2022.</p>

<p id="xdx_856_zD4GjP9ASqW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwWpE0uggAn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Stock-based
compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All stock-based payments to
employees and to nonemployees for their services, including grants of restricted stock units (&#8220;RSUs&#8221;), and stock options,
are measured at fair value on the grant date and recognized in the consolidated statements of operations as compensation or other expense
over the requisite service period. The Company accounts for share-based awards in accordance with the provisions of the Accounting Standards
Codification (&#8220;ASC&#8221;) 718, Compensation &#8211; Stock Compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84A_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzyMnbsscSmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Foreign
Currency Translation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operations of the Company&#8217;s
Canadian subsidiary, Tonix Pharmaceuticals (Canada), Inc., are conducted in local currency, which represents its functional currency.
The U.S. dollar is the functional currency of the other foreign subsidiaries. Balance sheet accounts of the Canadian subsidiary were translated
from foreign currency into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated
at the average rate of exchange prevailing during the period. Translation adjustments resulting from this process were included in accumulated
other comprehensive loss on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_842_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zIX4YsfLpDx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Comprehensive
Income (Loss)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Comprehensive income (loss)
is defined as the change in equity of a business during a period from transactions and other events and circumstances from non-owners
sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Other comprehensive income (loss) represents foreign currency translation adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zhcIfHS6aHh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Income
Taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred income tax assets
and liabilities are determined based on the estimated future tax effects of net operating loss and credit carryforwards and temporary
differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted
tax rates. The Company records a valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred
income tax assets will be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes a
tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination
by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements
from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate
settlement. As of December 31, 2022, the Company has not recorded any unrecognized tax benefits. The Company&#8217;s policy is to recognize
interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zFQaNokTE3O3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Per
Share Data</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The computation of basic and
diluted loss per share for the years ended December 31, 2022 and 2021 excludes potentially dilutive securities when their inclusion would
be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All warrants issued participate
on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors, on the Company&#8217;s
common stock. For purposes of computing EPS, these warrants are considered to participate with common stock in earnings of the Company.
Therefore, the Company calculates basic and diluted EPS using the two-class method. Under the two-class method, net income for the period
is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed
earnings. No income was allocated to the warrants for the years ended December 31, 2022 and 2021, as results of operations were a loss
for the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2Jg2M9UU6Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Potentially
dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 74%"><span style="font-size: 10pt">Warrants to purchase common stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zlJ8KJutPM95" style="width: 10%; text-align: right" title="Potentially dilutive securities excluded from the computation of basic and diluted net loss per share"><span style="font-size: 10pt">19,970</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuPWz6Kcp2Wh" style="width: 10%; text-align: right"><span style="font-size: 10pt">19,970</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Options to purchase common stock</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6EUYcfN9HVe" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2,453,031</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgD9NCZtwzCj" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">805,762</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2pt"><span style="font-size: 10pt">Totals</span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231_zHAwQlRmET47" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,473,001</span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231_zIa3f0mUJkf5" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">825,732</span></td>
    <td style="padding-bottom: 2pt">&#160;</td></tr>
  </table> &#160;

<p id="xdx_8A1_zDCKA9a5gOAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z95j2sM0cFcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Recently
Issued Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB issued
ASU No. 2020-06,&#160;<i>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>,
which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also
removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and
it also simplifies the diluted earnings per share calculation in certain areas. The Company will adopt ASU 2020-06 on January 1, 2023,
under the modified retrospective method of transition. The Company does not anticipate the adoption of ASU 2020-06 to impact the Company&#8217;s
financial position, results of operations or cash flows.</p>

<p id="xdx_85E_zpPf80juRY08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140089029944960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zQaOV5iXQO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
3 &#8211; <span id="xdx_823_zP24ztM0VfCf">PROPERTY AND EQUIPMENT, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zOf7u8D41vZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property
and equipment, net consisted of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>December 31</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>December 31</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Property and equipment, net:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Land</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zHMLFED0vKZ" style="width: 10%; text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">8,011</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zd62r56k6sPe" style="width: 10%; text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">7,911</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Land improvements</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandImprovementsMember_zuUm2uRmrLD4" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;79</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Buildings</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zlx4e3nScrYb" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;65,644</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Office furniture and equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_z3peqzBoilr7" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">1,893</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_zIYvvdnZcc4e" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">756</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zk1KcjNgjrci" style="text-align: right"><span style="font-size: 10pt">18,440</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zoDllnstNj0f" style="text-align: right"><span style="font-size: 10pt">347</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt">Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUvRUMMWnSLa" style="text-align: right">34&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWTM21u71Ard" style="text-align: right">23&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt">Construction in progress</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z898pzOA0HUa" style="border-bottom: Black 1pt solid; text-align: right">1,366</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z5mGqFX9ses" style="border-bottom: Black 1pt solid; text-align: right">41,921</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20221231_zlVxml4RMZP1" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">95,467</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20211231_zp28qnw1pEgd" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">50,958</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Less: Accumulated depreciation and
        amortization</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20221231_zO3QDuaVS8sj" style="border-bottom: black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"><span style="font-size: 10pt">(1,653</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20211231_zskr3FQ6LApg" style="border-bottom: black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"><span style="font-size: 10pt">(400</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20221231_z5ehXejrwQZe" style="border-bottom: black 2.5pt double; text-align: right" title="Property and equipment, net"><span style="font-size: 10pt">93,814</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20211231_zZ8F6JpaaKi3" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">50,558</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zTrF2efF0RR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 1, 2021, the Company
completed the acquisition of its approximately <span id="xdx_907_eus-gaap--AreaOfLand_iI_uSquareFoot_c20211001__srt--StatementGeographicalAxis__stpr--MD_zJhEfFlX47J3">45,000</span>
square foot research and development facility in Frederick, Maryland totaling $<span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__srt--StatementGeographicalAxis__stpr--MD_zGTnNphCZUne" title="Facility purchase">17.5</span>
million, to process development activities. Of the total purchase price, $<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zqQMALPhZ0G5">2.1</span>
million was allocated to the value of land acquired, and $<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__srt--StatementGeographicalAxis__stpr--MD__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zL3PHz4OELl6">13.9</span>
million was allocated to buildings, and approximately $<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__srt--StatementGeographicalAxis__stpr--MD__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember_zYMDqvGEkVS6">1.5</span>
million was allocated to Office furniture and equipment and Laboratory equipment. During the year ended December 31, 2022, the
assets became ready for the intended use and were placed in service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 28, 2020, the
Company completed the purchase of its approximately <span id="xdx_90E_eus-gaap--AreaOfLand_iI_uSquareFoot_c20200928__srt--StatementGeographicalAxis__stpr--MA_z5FNmA5cl1ek" title="Area of facility">45,000</span>
square foot facility in Dartmouth, Massachusetts for $<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pdn6_c20200927__20200928__srt--StatementGeographicalAxis__stpr--MA_zfeAhKq37Bxg">4</span>.0
million, to house its new Advanced Development Center for the development and manufacturing of vaccines. Of the total purchase price,
$<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20200927__20200928__srt--StatementGeographicalAxis__stpr--MA__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zDQthcN0c6I">1.2</span>
million was allocated to the value of land acquired, and $<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20200927__20200928__srt--StatementGeographicalAxis__stpr--MA__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zf78cHURNsDa">2.8</span>
million was allocated to buildings. Additionally, the Company incurred approximately $<span id="xdx_90D_eus-gaap--PaymentsForConstructionInProcess_pn5n6_c20220101__20221231__srt--StatementGeographicalAxis__stpr--MA_zt9VFH98OS19" title="Costs incurred">38.8</span>
million of costs during the year ended December 31, 2022, bringing total costs incurred-to-date to $<span id="xdx_90D_eus-gaap--PaymentsToAcquireProductiveAssets_pn5n6_c20200929__20221231__srt--StatementGeographicalAxis__stpr--MA_zMg8c8uITYSl" title="Total costs incurred">61.6</span>
million, of which the majority relates to the build-out of the facility. During the year ended December 31, 2022, the assets became
ready for the intended use and were placed in service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 23, 2020, the
Company completed the purchase of its approximately <span id="xdx_90A_eus-gaap--AreaOfLand_iI_uAcre_c20201223__srt--StatementGeographicalAxis__stpr--MT_zjpm3F5q37Dh">44</span>-acre
site in Hamilton, Montana for $<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20201221__20201223__srt--StatementGeographicalAxis__stpr--MT_z3ffXCrIbzU7">4.5</span>
million, for the construction of a vaccine development and commercial scale manufacturing facility. As of December 31, 2022, the
asset was not ready for its intended use.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088939659056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureOtherBalanceSheetInformationAbstract', window );"><strong>Other Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_OtherBalanceSheetInformationDiclosureTextBlock', window );">OTHER BALANCE SHEET INFORMATION</a></td>
<td class="text"><p id="xdx_804_ecustom--OtherBalanceSheetInformationDiclosureTextBlock_zEexXqbesbWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
4 &#8211; <span id="xdx_829_ztlsn9Wh5Ni1">OTHER BALANCE SHEET INFORMATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_894_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zZmjN0MMISXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Components
of selected captions in the consolidated balance sheets consist of:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20221231_zpaDHLoBqmvl" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zQQsSctglemb" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2022</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2021</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zpjLBKcG4czh" style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Prepaid expenses and other:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--ContractRelatedPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zgztWqrGeFUg" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Contract-related</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt">8,043</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt">7,726</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidInsurance_i01I_pn3n3_maPEAOAzN1F_zeeRZKyz8ONi" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Insurance</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,275</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,482</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--ProfessionalFeesAndOtherPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zTsWJ0dIya5d" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,230</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,181</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_mtPEAOAzN1F_zoIUDXhnGTW6" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">10,548</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">10,389</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrentAbstract_iB_zTyJXsT5VeN3" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Accrued expenses and other current liabilities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--ContractRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zhTVZS7AmCv3" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Contract-related</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">3,273</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">2,832</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--CompensationAndCompensationRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_ziUVNyyjNLO9" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Compensation and compensation-related</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,645</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,868</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ConstructionInProgressAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zpUJBdKzASj5" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Construction in progress</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,103</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,572</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProfessionalFeesAndOtherAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zaYPfZCqCLr2" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Professional fees and other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">659</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">673</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzLWJ_zGSMNqABDbh8" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">9,680</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">7,945</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zmfAn5zuV5Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureOtherBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureOtherBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_OtherBalanceSheetInformationDiclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of other balance sheet information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_OtherBalanceSheetInformationDiclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936012176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zInqEP7JQoh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
5 &#8211; <span id="xdx_828_zOtIFkQMnyNe">FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value measurements affect
the Company&#8217;s accounting for certain of its financial assets. Fair value is defined as the price that would be received to sell
an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and is measured
according to a hierarchy that includes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 15%">&#160;</td>
    <td style="width: 7%"><span style="font-size: 10pt">Level 1:</span></td>
    <td style="width: 78%; text-align: justify"><span style="font-size: 10pt">Observable inputs, such as quoted prices in active markets.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 15%">&#160;</td>
    <td style="width: 7%"><span style="font-size: 10pt">Level 2:</span></td>
    <td style="width: 78%; text-align: justify"><span style="font-size: 10pt">Inputs, other than quoted prices in active markets, that are observable
        either directly or indirectly. Level&#160;2 assets and liabilities include debt securities with quoted market prices that are traded less
        frequently than exchange-traded instruments. This category includes U.S. government agency-backed debt securities and corporate-debt securities.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 15%">&#160;</td>
    <td style="width: 7%"><span style="font-size: 10pt">Level 3:</span></td>
    <td style="width: 78%; text-align: justify"><span style="font-size: 10pt">Unobservable inputs in which there is little or no market data.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, and
December 31, 2021, the Company used Level 1 quoted prices in active markets to value cash equivalents of $<span id="xdx_907_ecustom--CashEquivalentsFairValue_iI_pn5n6_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zCAZ5TxA8Qog">116.3</span>
million and $<span id="xdx_90B_ecustom--CashEquivalentsFairValue_iI_pn5n6_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z391b4fVOVs9">120.4</span>
million, respectively. The Company did not have any Level 2 or Level 3 assets or liabilities as of both December 31, 2022 and 2021.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942840576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zhdwEFEgeQc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
6 &#8211; <span id="xdx_820_zFd27WXyjVs4">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 16, 2022, the Company
filed a Certificate of Change with the Nevada Secretary of State, effective May 17, 2022. Pursuant to the Certificate of Change, the
Company effected a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpkxzitroKGl">1-for-32
</span>reverse stock split of its issued and outstanding shares of common stock, whereby <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwxnIZSeZmD5">599,679,596
</span>outstanding shares of the Company&#8217;s common stock were exchanged for <span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQHkNULtF9tl">18,740,141
</span>shares of the Company&#8217;s common stock. In connection with the reverse stock split, the Company issued an additional <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSLijTjcsNG">130,462
</span>shares of the Company&#8217;s common stock due to fractional shares. Furthermore, pursuant to the Certificate of Change, the number
of authorized shares of common stock was reduced from <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pdn6_c20220514_zjgzFxhLOTf6">800
</span>million to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pdn6_c20220516_zryjIfEHzX95">50</span> million. All per
share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect
the reverse stock split.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 5, 2022, the Company
filed an amendment to its articles of incorporation, as amended, to increase the number of shares of common stock authorized from <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220803_zKrHID5DV68h">50,000,000</span>
to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220805_z3EF34Sb6rW5">150,000,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 13, 2022, the
Company filed an amendment to its articles of incorporation, as amended, to increase the number of shares of common stock authorized from
<span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221211_zwNTcHPxbibi">150,000,000</span> to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221213_zUa29GK8TY0f">1,000,000,000</span>.</p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942911328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TEMPORARY EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureTemporaryEquityAbstract', window );"><strong>Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_TemporaryEquityTextBlock', window );">TEMPORARY EQUITY</a></td>
<td class="text"><p id="xdx_80D_ecustom--TemporaryEquityTextBlock_zwifcfc9Yy3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
7 &#8211; <span id="xdx_821_zR793VlTLTGe">TEMPORARY EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 26, 2022, the Company
closed on an offering (&#8220;the October offering&#8221;) with certain institutional investors (the &#8220;Investors&#8221;), pursuant
to which the Company issued and sold, in a private placement, <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z04GH2GpG4b" title="Number of shares issued">1,400,000</span>
shares of the Company&#8217;s Series A Convertible Redeemable Preferred Stock, par value $<span id="xdx_900_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNnTTED6aR6" title="Preferred stock, par value (in dollars per share)">0.001</span>
per share (the &#8220;Series A Preferred Stock&#8221;), and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGeWZ3Flloc8">100,000</span>
shares of the Company&#8217;s Series B Convertible Redeemable Preferred Stock, par value $<span id="xdx_902_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zu3eBO1UzpX3">0.001</span>
per share (the &#8220;Series B Preferred Stock,&#8221; and together with the Series A Preferred Stock, the &#8220;Preferred Stock&#8221;),
at an offering price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zcEmoZMgCnT9" title="Price per share">9.50</span>
per share, representing a <span id="xdx_90C_ecustom--PercentageOfIssueDiscount_uPure_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zySYYQ7ayvYc">5%</span>
original issue discount (&#8220;OID) to the stated value of $<span id="xdx_904_ecustom--StatedValuePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zRpWwqUDk3Cd">10.00</span>
per share, for gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pdn6_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zdhIaxaCdMUh">14.3</span>
million in the aggregate for the October offering, before the deduction of fees and offering expenses. The shares of Preferred Stock
were convertible, at a conversion price of $<span id="xdx_900_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zhKZu136wo7h">1.00</span>
per share (subject in certain circumstances to adjustments), into shares of the Company&#8217;s common stock, at the option of the holders
and, in certain circumstances, by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 13, 2022, an amendment
(the &#8220;December Amendment&#8221;) to the Company&#8217;s Articles of Incorporation, as amended, to increase the Company&#8217;s authorized
shares of common stock from <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221211_z7a8HV52cPE">150,000,000</span>
to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221213_zVBNhpl4oOt8">1,000,000,000</span>, was approved at
a special meeting of shareholders. The Series A Preferred Stock had the right to vote on such December Amendment on an as-converted to
common stock basis. The shares of the Series B Preferred Stock were automatically voted in a manner that &#8220;mirrored&#8221; the proportions
on which the shares of Common Stock (excluding any shares of Common Stock that were not voted) and Series A Preferred Stock were voted
to increase the Authorized Shares. The December Amendment required the approval of the majority of the votes associated with the Company&#8217;s
outstanding stock entitled to vote on the proposal. Because the Series B Preferred Stock were automatically and without further action
of the purchaser voted in a manner that &#8220;mirrored&#8221; the proportions on which the shares of Common Stock (excluding any shares
of Common Stock that were not voted) and Series A Preferred Stock were voted on the December Amendment, abstentions by common stockholders
did not have any effect on the votes cast by the holders of the Series B Preferred Stock. The Certificates of Designation for the Preferred
Stock provides that the <span id="xdx_908_eus-gaap--PreferredStockVotingRights_pid_c20221212__20221213__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zXBrgMzGr4o4" title="Preferred stock voting rights">Preferred
Stock have no voting rights other than the right to vote on the December Amendment and as a class on certain other specified matters</span>,
and, with respect to the Series B Certificate of Designation, <span id="xdx_907_eus-gaap--PreferredStockVotingRights_pid_c20221212__20221213__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ze0InPxbVT93">the
right to cast 2,500 votes per share of Series B Preferred Stock on the December Amendment</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Preferred Stock
were entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred
Stock was convertible, at the option of the holders and, in certain circumstances, by the Company, into shares of Common Stock at a conversion
price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zKSalTY1j1x9">1.00</span>
per share. The holders of the Preferred Stock had the right to require the Company to redeem their shares of preferred stock for cash
at <span id="xdx_901_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z2wHG7OPvr87">105%</span>
of the stated value of such shares through January 23, 2023. The Company had the option to redeem the Preferred Stock for cash at <span id="xdx_90A_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zDEx3N2TXe71">105%</span>
of the stated value, subject to the holders&#8217; rights to convert the shares prior to such redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The $<span id="xdx_908_eus-gaap--EscrowDeposit_iI_pdn6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zJ0VcZjiZjW8">14.3</span>
million in gross proceeds of the October offering was held in an escrow account, along with an additional $<span id="xdx_90B_ecustom--EscrowDepositForOriginalIssueDiscount_iI_pdn6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z0wKypglidcg">1.5</span>
million deposited by the Company to cover the aggregate OID as well as the additional amount that would be necessary to fund the <span id="xdx_903_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zI2WveX3oCO8">105%</span>
redemption price until the expiration of the redemption period for the Preferred Stock, as applicable, subject to the earlier payment
to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in the escrow account would be disbursed to the
Company.</p>

<p id="xdx_89E_eus-gaap--TemporaryEquityTableTextBlock_gL3TETTB-XKNNU_zqJ8jD81ImIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. <span id="xdx_8B6_zFvQt5F2N4C3">The
Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value</span> of approximately $<span id="xdx_905_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIKIp2nesvT2" title="Temporary equity">14.7</span>
million and $<span id="xdx_901_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbHhRLhVAnnb">1.1</span>
million, respectively, as calculated in the following table (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWowwR0zsiRa" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        A</b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrDSnUVt6Mkc" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        B </b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--GrossProceeds_iI_pn3n3_maTECAAzHsD_zECCzRrLMIui" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Gross Proceeds</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">13,300</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">950</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Less:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_msTECAAzHsD_zdXwooGT29Fb" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in"><span style="font-size: 10pt">Preferred stock issuance costs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(844</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(60</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Plus:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_maTECAAzHsD_zSMJovDY5Wai" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 0.25in"><span style="font-size: 10pt">Accretion of carrying value to redemption value</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2,244</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">160</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_mtTECAAzHsD_zyXeIpUafxLf" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Preferred stock subject to possible redemption</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">14,700</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,050</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zJKAXSk3404a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During December 2022, the
Company received redemption notices for all outstanding shares of Preferred Stock. The Preferred Stock was redeemed during December 2022
at <span id="xdx_904_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221201__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zIOZlaOpZHEc">105%</span>
of the $<span id="xdx_907_ecustom--StatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zCUBH8qmTzK8">10.00</span>
stated value of the Preferred Stock, or $<span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_pn5n6_c20221201__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zVBcEWGOQizj" title="Redemption amount">15.8</span>
million in the aggregate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 24, 2022, the Company
closed on an offering (&#8220;the Offering&#8221;) with certain institutional investors (the &#8220;Investors&#8221;), pursuant to which
the Company issued and sold, in a private placement, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbqrFVoBuex4" title="Number of shares issued">2,500,000</span>
shares of the Company&#8217;s Series A Convertible Redeemable Preferred Stock, par value $<span id="xdx_90B_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGqWfR96jLX7" title="Preferred stock, par value (in dollars per share)">0.001</span>
per share (the &#8220;Series A Preferred Stock&#8221;), and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zcmHaHvyzr01">500,000</span>
shares of the Company&#8217;s Series B Convertible Redeemable Preferred Stock, par value $<span id="xdx_909_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKb2fc2jPVc7">0.001</span>
per share (the &#8220;Series B Preferred Stock,&#8221; and together with the Series A Preferred Stock, the &#8220;Preferred Stock&#8221;),
at an offering price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zKO3jsVXNM46" title="Price per share">9.50</span>
per share, representing a <span id="xdx_906_ecustom--PercentageOfIssueDiscount_uPure_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z2oyMKrlOVYa">5%</span>
original issue discount (&#8220;OID) to the stated value of $<span id="xdx_908_ecustom--StatedValuePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zqjPkKS30xwd">10.00</span>
per share, for gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pdn6_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zTlpLtNvrwN4">28.5</span>
million in the aggregate for the Offering, before the deduction of fees and offering expenses. The shares of Preferred Stock were convertible,
at a conversion price of $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zJZBczYqnYch">4.00</span>
per share (subject in certain circumstances to adjustments), into shares of the Company&#8217;s common stock, at the option of the holders
and, in certain circumstances, by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 5, 2022, an amendment
(the &#8220;Amendment&#8221;) to the Company&#8217;s Articles of Incorporation, as amended, to increase the Company&#8217;s authorized
shares of common stock from <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220803_zsfgb17q9jp4">50,000,000</span>
to <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220805_zI3KSp6dOAV4" title="Common stock, authorized">150,000,000</span>,
was approved at a special meeting of shareholders. The Series A Preferred Stock had the right to vote on such Amendment on an as-converted
to common stock basis. The shares of the Series B Preferred Stock were automatically voted in a manner that &#8220;mirrored&#8221; the
proportions on which the shares of Common Stock (excluding any shares of Common Stock that were not voted) and Series A Preferred Stock
were voted to increase the Authorized Shares. The Amendment required the approval of the majority of the votes associated with the Company&#8217;s
outstanding stock entitled to vote on the proposal. Because the Series B Preferred Stock were automatically and without further action
of the purchaser voted in a manner that &#8220;mirrored&#8221; the proportions on which the shares of Common Stock (excluding any shares
of Common Stock that were not voted) and Series A Preferred Stock were voted on the Amendment, abstentions by common stockholders did
not have any effect on the votes cast by the holders of the Series B Preferred Stock. The Certificates of Designation for the Preferred
Stock provides that the <span id="xdx_902_eus-gaap--PreferredStockVotingRights_pid_c20220804__20220805__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zWywwEPeKVoj" title="Preferred stock voting rights">Preferred
Stock have no voting rights other than the right to vote on the Amendment and as a class on certain other specified matters</span>, and,
with respect to the Series B Certificate of Designation, <span id="xdx_900_eus-gaap--PreferredStockVotingRights_pid_c20220804__20220805__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zi99hxHRFDM1">the
right to cast 2,500 votes per share of Series B Preferred Stock on the Amendment</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Preferred Stock
were entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred
Stock was convertible, at the option of the holders and, in certain circumstances, by the Company, into shares of Common Stock at a conversion
price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zKHivVUHoRsh">4.00</span>
per share. The holders of the Preferred Stock had the right to require the Company to redeem their shares of preferred stock for cash
at <span id="xdx_90B_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zHJ9oJRpS2l8">105%</span>
of the stated value of such shares through September 22, 2022. The Company had the option to redeem the Preferred Stock for cash at <span id="xdx_90E_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zW8DSiTZCkGa">105%</span>
of the stated value, subject to the holders&#8217; rights to convert the shares prior to such redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The $<span id="xdx_90D_eus-gaap--EscrowDeposit_iI_pdn6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zjg8euac2WMg">28.5</span>
million in gross proceeds of the Offering was held in an escrow account, along with an additional $<span id="xdx_905_ecustom--EscrowDepositForOriginalIssueDiscount_iI_pdn6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z307uZsMNVTj">3</span>.0
million deposited by the Company to cover the aggregate OID as well as the additional amount that would be necessary to fund the <span id="xdx_90B_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zpi0UDFLYqRl">105%</span>
redemption price until the expiration of the redemption period for the Preferred Stock, as applicable, subject to the earlier payment
to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in the escrow account would be disbursed to the
Company.</p>

<div id="xdx_C07_gL3TETTB-XKNNU_zTyLjOQtmuR">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. The Series A Preferred
Stock and Series B Preferred Stock was recorded at redemption value of approximately $<span id="xdx_902_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbkIMJNKWRmc" title="Temporary equity">26.3</span>
million and $<span id="xdx_903_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zba28qKJdj4l" title="Temporary equity">5.2</span>
million, respectively, as calculated in the following table (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfcNMrfrQp33" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        A</b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLYnqqg39TC6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        B </b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_406_ecustom--GrossProceeds_iI_pn3n3_zhzRGGwpa5R4" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Gross Proceeds</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">23,750</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">4,750</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Less:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_40D_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_zMP4L2SK3nB2" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in"><span style="font-size: 10pt">Preferred stock issuance costs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(1,046</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(209</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Plus:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_407_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_zl7uAw1F24X7" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 0.25in"><span style="font-size: 10pt">Accretion of carrying value to redemption value</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">3,546</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">709</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_409_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_zPI5MPtcZL8c" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Preferred stock subject to possible redemption</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">26,250</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">5,250</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During August 2022, the Company
received redemption notices for all outstanding shares of Preferred Stock. The Preferred Stock was redeemed during August 2022 at <span id="xdx_907_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z7bzPZfcWpQc">105%</span>
of the $<span id="xdx_90D_ecustom--StatedValuePerShare_iI_c20220831__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zw4PVYWUdo26">10.00</span>
stated value of the Preferred Stock, or $<span id="xdx_907_eus-gaap--PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_pn5n6_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zNknnffvM9f8" title="Redemption amount">31.5</span>
million in the aggregate.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureTemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureTemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088935909136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT WITH KATANA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract', window );"><strong>Asset Purchase Agreement With Katana</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_AssetPurchaseAgreementWithKatanaTextBlock', window );">ASSET PURCHASE AGREEMENT WITH KATANA</a></td>
<td class="text"><p id="xdx_800_ecustom--AssetPurchaseAgreementWithKatanaTextBlock_zIrFlKhMGfdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
8 &#8211; <span id="xdx_82B_zH2t5F1eHu13">ASSET PURCHASE AGREEMENT WITH KATANA</span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 22, 2020, the
Company entered into an asset purchase agreement (the &#8220;Katana Asset Purchase Agreement&#8221;) with Katana Pharmaceuticals, Inc.
(&#8220;Katana&#8221;) pursuant to which Tonix acquired Katana assets related to insulin resistance and related syndromes, including obesity
(the &#8220;Katana Assets&#8221;). In connection with the acquisition of the Katana Assets, Tonix assumed Katana&#8217;s rights and obligations
under that certain Exclusive License Agreement by and between Katana and The University of Geneva (&#8220;Geneva&#8221;) (the &#8220;Geneva
License &#8220;Agreement&#8221;) pursuant to an Assignment and Assumption Agreement with Geneva (&#8220;Geneva Assignment and Assumption
Agreement&#8221;), dated December 22, 2020. As consideration for entering into the Katana Asset Purchase Agreement, Tonix paid $<span id="xdx_90F_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20201221__20201222__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--KatanaPharmaceuticalsIncMember_znJOZG6yVgdf" title="Consideration paid">0.7</span>
million to Katana. The costs associated with the cash payments were recorded to research and development expenses in the statement
of operations for the year ended December 31, 2020. Because the Katana intellectual property was acquired prior to U.S. Food and Drug
Administration (FDA) approval, the cash consideration totaling $<span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20201221__20201222__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--KatanaPharmaceuticalsIncMember_zlmQY2SG61Y1" title="Research and development costs">0.7</span>
million, was expensed as research and development costs since there is no alternative future use and the acquired intellectual
property does not constitute a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
Geneva Assignment and Assumption Agreement, Geneva has granted to Tonix an exclusive license, with the right to sublicense, certain patents
related to the Katana Assets. Tonix is obligated to use commercially reasonable efforts to diligently develop, manufacture, and sell products
claimed or covered by the patent and will use commercially reasonable efforts to diligently develop markets for such products. The Geneva
License Agreement specifies developmental milestones and the period of time during which such milestones must be completed and provides
for an annual maintenance fee payable to Geneva. As of December 31, 2022, no milestone payments have been accrued or paid in relation
to this agreement.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_AssetPurchaseAgreementWithKatanaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure asset purchase agreement with Katana.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_AssetPurchaseAgreementWithKatanaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936669472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT WITH TRIGEMINA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract', window );"><strong>Asset Purchase Agreement With Trigemina</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock', window );">ASSET PURCHASE AGREEMENT WITH TRIGEMINA</a></td>
<td class="text"><p id="xdx_80C_ecustom--AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock_zDppIBS9jo4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
9 &#8211; <span id="xdx_820_zpjak9qwOSZg">ASSET PURCHASE AGREEMENT WITH TRIGEMINA</span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 11, 2020, the Company
entered into an asset purchase agreement (the &#8220;Trigemina Asset Purchase Agreement&#8221;) with Trigemina, Inc. (&#8220;Trigemina&#8221;)
and certain shareholders named therein (the &#8220;Executive Shareholders&#8221;) pursuant to which Tonix acquired Trigemina assets related
to migraine and pain treatment technologies (the &#8220;Trigemina Assets&#8221;). In connection with the acquisition of the Trigemina
Assets, Tonix assumed Trigemina&#8217;s rights and obligations under that certain Amended and Restated Exclusive License Agreement, dated
November 30, 2007, as amended, by and between Trigemina and The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;)
(the &#8220;Stanford License &#8220;Agreement&#8221;) pursuant to an Assignment and Assumption Agreement with Stanford (&#8220;Assignment
and Assumption Agreement&#8221;), dated June 11, 2020. As consideration for entering into the Asset Purchase Agreement, Tonix paid $<span id="xdx_900_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_zYOqrO5cZNci" title="Payment for purchase of assets">824,759</span>
to Trigemina and issued to Trigemina <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_z4kJXPnGfLul" title="Number of shares issued (in shares)">62,500</span>
shares of the Company&#8217;s common stock, valued at $<span id="xdx_907_ecustom--CommonStockValuePerShares_pip0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_zfJzmjmG9Rrb" title="Common stock value (per share)">21.76</span>
per share, based on the closing stock price on June 11, 2020, and paid Stanford $<span id="xdx_905_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssignmentAndAssumptionAgreementMember_zaC2ibO4oHj7" title="Payment for purchase of assets">250,241</span>
pursuant to the terms of the Assignment and Assumption Agreement. The common stock is unregistered and subject to a 12-month lock-up and
a Shareholder Voting Agreement, dated June 11, 2020, pursuant to which Trigemina and the Executive Shareholders have agreed to vote the
common stock on any matter put to a vote of the shareholders of the Company in accordance with management&#8217;s recommendations. Both
the costs associated with the cash payments and share issuance, totaling $<span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_zFOhi0ISYZsa" title="Research and development costs">2.4</span>
million, were recorded to research and development expenses in the statement of operations for the year ended December 31, 2020.
Because the Trigemina intellectual property was acquired prior to FDA approval, the cash and stock consideration, was expensed as research
and development costs since there is no alternative future use and the acquired intellectual property does not constitute a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
Assignment and Assumption Agreement, Stanford has granted to Tonix an exclusive license, with the right to sublicense, certain patents
related to the Trigemina Assets. Stanford has reserved for itself the right to practice under the patents for academic research and educational
purposes. Tonix is obligated to use commercially reasonable efforts to diligently develop, manufacture, and sell products claimed or covered
by the patent and will use commercially reasonable efforts to diligently develop markets for such products. The Trigemina License Agreement
specifies developmental milestones and the period of time during which such milestones must be completed and provides for an annual maintenance
fee payable to Stanford. As of December 31, 2022, other than the annual maintenance fee, no milestone payments have been accrued or paid
in relation to this agreement.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of asset purchase agreement with Trigemina.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942911328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT WITH TRIMARAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">ASSET PURCHASE AGREEMENT WITH TRIMARAN</a></td>
<td class="text"><p id="xdx_803_eus-gaap--AssetAcquisitionTextBlock_ztjIp2a21GYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
10 &#8211; <span id="xdx_82A_zzfBSoQFeikl">ASSET PURCHASE AGREEMENT WITH TRIMARAN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 19, 2019, the Company
entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with TRImaran Pharma, Inc. (&#8220;TRImaran&#8221;)
and the selling shareholders named therein (the &#8220;Selling Shareholders&#8221;) pursuant to which Tonix acquired TRImaran&#8217;s
assets related to certain pyran-based compounds (the &#8220;Assets&#8221;). In connection with the acquisition of the Assets, Tonix entered
into a First Amended and Restated Exclusive License Agreement (the &#8220;WSU License Agreement&#8221;) with Wayne State University (&#8220;WSU&#8221;)
on August 19, 2019, as subsequently amended. As consideration for entering into the Asset Purchase Agreement, Tonix paid $<span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_z2oMKhoZZKUc" title="Payment for purchase of assets">100,000</span>
to TRImaran and has assumed certain liabilities of TRImaran totaling $<span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_zsiM8nTtqfV1" title="Liabilities assumed">68,500</span>.
The $<span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_zNGJWpnbILR2" title="Research and development costs">168,500</span>
was previously recorded to research and development expenses in the statement of operations. Upon the achievement of specified development,
regulatory and sales milestones, Tonix also agreed to pay TRImaran and the Selling Shareholders, in restricted stock or cash, at Our option,
a total of approximately $<span id="xdx_909_ecustom--AchievementPaymentsPayable_iI_pn5n6_c20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_zmDTMzUmQ1z5" title="Contingent milestone payment obligation">3.4</span>
million. Pursuant to the terms of the Asset Purchase Agreement, TRImaran and the Selling Shareholders are prohibited from disclosing
confidential information related to the Assets and are restricted from engaging, for a period of three years, in the development or commercialization
of any therapeutic containing any pyran-based drug compound for the treatment of post-traumatic stress disorder, attention deficit hyperactivity
disorder or major depressive disorder. Also for a period of three years, if TRImaran or any Selling Shareholder engage in the research
or development of any potential therapeutic compound for the treatment of any central nervous system disorder, TRImaran or such Selling
Shareholder is obliged to provide notice and opportunity to Tonix to make an offer to acquire or license rights with respect to such product
candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
WSU License Agreement, WSU has granted to Tonix an exclusive license, with the right to sublicense, certain patents, technical information
and material (collectively, the &#8220;Technology&#8221;) related to the Assets. WSU has reserved for itself the right to practice the
Technology for academic research and educational purposes. Tonix is obligated to use commercially reasonable efforts to obtain regulatory
approval for one or more products utilizing the Technology (&#8220;WSU Products&#8221;) and to use commercially reasonable marketing efforts
throughout the term of the WSU License Agreement. The WSU License Agreement specifies developmental milestones and the period of time
during which such milestones must be completed and provides for an annual maintenance fee payable to WSU. Tonix is obligated to substantially
manufacture WSU Products in the United States if WSU Products will be sold in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the WSU License
Agreement, Tonix paid $<span id="xdx_905_ecustom--ReimbursementOfPatentExpenses_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zMbUHTlrnkc" title="Reimbursement of patent expenses">75,000</span>
to WSU as reimbursement of certain patent expenses, and, upon the achievement of specified development, regulatory and sales milestones,
the Company also agreed to pay WSU, milestone payments totaling approximately $<span id="xdx_905_ecustom--ContingentMilestonePaymentObligation_iI_pn5n6_c20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zzuL0bQa1O5e">3.4</span>
million. Tonix has also agreed to pay WSU single-digit royalties on net sales of WSU Products sold by Tonix or a sublicensee on
a tiered basis based on net sales, and additional sublicense fees on certain consideration received from sublicensees. Royalties on each
particular WSU Product are payable on a country-by-country and Product-by-Product basis until the date of expiration of the last valid
claim in the last to expire of the issued patents covered by the WSU License Agreement. Royalties payable on net sales of WSU Products
may be reduced by <span id="xdx_903_ecustom--PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_pip0_dp_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zQUD7VdYEra1">50</span>%
of the royalties payable by Tonix to any third party for intellectual property rights which are necessary for the practice of the rights
licensed to Tonix under the WSU License Agreement, provided that the royalty payable on a WSU Product may not be reduced by more than
<span id="xdx_90D_ecustom--MaximumPercentageReductionOfRoyaltiesPayable_pip0_dp_uPure_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zJ92oUJDlrRc" title="Maximum percentage reduction of royalties payable">50</span>%.
Each party also has the right to terminate the agreement for customary reasons such as material breach and bankruptcy. The WSU License
Agreement contains provisions relating to termination, indemnification, confidentiality and other customary matters for an agreement of
this kind. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936688848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENT WITH CURIA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureLicenseAgreementWithCuriaAbstract', window );"><strong>License Agreement With Curia</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_LicenseAgreementCuriaTextBlock', window );">LICENSE AGREEMENT WITH CURIA</a></td>
<td class="text"><p id="xdx_807_ecustom--LicenseAgreementCuriaTextBlock_zmVMdNiVDNxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
11 &#8211; <span id="xdx_824_zk8ewTuFmCM1">LICENSE AGREEMENT WITH CURIA</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 12, 2022,
the Company entered into an exclusive license agreement with Curia for the development of three humanized murine mAbs for the
treatment or prophylaxis of SARS-CoV-2 infection. We believe that the licensing of these mAbs strengthens our pipeline of
next-generation therapeutics to treat COVID-19, which is caused by SARS-CoV-2. As consideration for entering into the License
Agreement, we paid a license fee of approximately $<span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20201221__20201222__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--CuriaMember_znz5GLmHjf63" title="Payment for purchase of assets">0.4</span>
million to Curia. The License Agreement also provides for single-digit royalties and contingent milestone payments. As of
December 31, 2022, other than the upfront fee, no payments have been accrued or paid in relation to this agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureLicenseAgreementWithCuriaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureLicenseAgreementWithCuriaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_LicenseAgreementCuriaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the license agreement with Curia.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_LicenseAgreementCuriaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936676832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract', window );"><strong>License Agreement With University Of Alberta</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_LicenseAgreementUniversityOfAlbertaTextBlock', window );">LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA</a></td>
<td class="text"><p id="xdx_80A_ecustom--LicenseAgreementUniversityOfAlbertaTextBlock_zPO8BKylQcNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
12 &#8211; <span id="xdx_827_znrREsD4ZjT4">LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 18, 2022, the
Company entered into an exclusive License Agreement with the University of Alberta focused on identifying and testing broad-spectrum
antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses. As consideration for entering into the License
Agreement, Tonix paid a low-five digit license fee to University of Alberta. The License Agreement also provides for single-digit
royalties and contingent milestone payments. As of December 31, 2022, other than the upfront fee, no milestone payments have been
accrued or paid in relation to this agreement.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_LicenseAgreementUniversityOfAlbertaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the license agreement with University of Alberta.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_LicenseAgreementUniversityOfAlbertaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942851344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENT WITH OYAGEN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureLicenseAgreementWithOyagenAbstract', window );"><strong>License Agreement With Oyagen</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_LicenseAgreementOyagenTextBlock', window );">LICENSE AGREEMENT WITH OYAGEN</a></td>
<td class="text"><p id="xdx_805_ecustom--LicenseAgreementOyagenTextBlock_zk6ikIDYblvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
13 &#8211; <span id="xdx_824_z9Ivl92pT0I9">LICENSE AGREEMENT WITH OYAGEN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 14, 2021, the Company
and OyaGen, Inc. (&#8220;OyaGen&#8221;) entered into an exclusive License Agreement (the &#8220;OyaGen License Agreement&#8221;) pursuant
to which OyaGen granted to Tonix an exclusive license to certain patents and technical information related to an antiviral inhibitor of
SARS-CoV-2, sangivamycin, and to develop and commercialize products thereunder, and to acquire rights to any technology based thereon
for the prevention or treatment of COVID-19 developed by OyaGen during the term of the License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As consideration for entering
into the License Agreement, Tonix paid a low-seven digit license fee to OyaGen, and issued to OyaGen and an affiliated entity an aggregate
of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210413__20210414__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--OyaGenIncMember_z0FEluzy5aza" title="Number of shares issued (in shares)">86,010
</span>shares of the Company&#8217;s common stock. The shares were valued at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210413__20210414__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--OyaGenIncMember_zFH5CW9x6IDe" title="Value of shares issued">3</span>.0
million, which was recorded as research and development expense. The OyaGen License also provided for single-digit royalties and contingent
milestone payments.&#160;In July 2022, the Company notified OyaGen of its intent to terminate the OyaGen License Agreement, and the agreement
was terminated effective September 20, 2022.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureLicenseAgreementWithOyagenAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureLicenseAgreementWithOyagenAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_LicenseAgreementOyagenTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This entire disclosure of the license agreement with Oyagen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_LicenseAgreementOyagenTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936844624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENT WITH INSERM<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureLicenseAgreementWithInsermAbstract', window );"><strong>License Agreement With Inserm</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_LicenseAgreementWithInsermTextBlock', window );">LICENSE AGREEMENT WITH INSERM</a></td>
<td class="text"><p id="xdx_80F_ecustom--LicenseAgreementWithInsermTextBlock_z9vTIhWRIYki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
14 &#8211; <span id="xdx_825_zuH0EoTXRfQ8">LICENSE AGREEMENT WITH INSERM</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 11, 2021,
the Company entered into a license agreement (the &#8220;Inserm License Agreement&#8221;) pursuant to which it licensed technology
using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from Inserm
(the French National Institute of Health and Medical Research), Aix-Marseille Universit&#233; and Centre Hospitalier Universitaire
of Toulouse. The Inserm License Agreement provides for the payment of annual fees and milestone payments upon the occurrence of
specified sales milestones totaling approximately $<span id="xdx_905_ecustom--SalesMilestones_pn5n6_c20210207__20210211__us-gaap--TypeOfArrangementAxis__custom--InsermLicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--InsermMember__us-gaap--BusinessAcquisitionAxis__custom--OxytocinBasedTherapeuticsMember_ze9LYZdlwqa">0.4</span>
million, as well royalties on net sales of products based on the licensed technology, and assignment/transfer and sublicense
royalties. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureLicenseAgreementWithInsermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureLicenseAgreementWithInsermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_LicenseAgreementWithInsermTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This entire disclosure of the license agreement with Inserm.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_LicenseAgreementWithInsermTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942911328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_z18pYIUDsTjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
15 &#8211; <span id="xdx_82C_zUPdDVsYYye">LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 16, 2019, the
Company entered into an exclusive License Agreement (the &#8220;Columbia License Agreement&#8221;) with the Trustees of Columbia University
in the City of New York (&#8220;Columbia&#8221;), as subsequently amended, pursuant to which Columbia granted to Tonix an exclusive license,
with the right to sublicense, certain patents and technical information (collectively, the &#8220;TFF2 Technology&#8221;) related to a
recombinant Trefoil Family Factor 2 (TFF2), and to develop and commercialize products thereunder (each, a &#8220;TFF2 Product&#8221;).
Pursuant to the terms of the Columbia License Agreement, Columbia reserved for itself the right to practice the TFF2 Technology for academic
research and educational purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company paid a five-digit
license fee to Columbia as consideration for entering into the Columbia License Agreement, which was recorded to research and development
expenses in the statement of operations for the year ended December 31, 2019. The Company is obligated to use Commercially Reasonable
Efforts, as defined in the Columbia License Agreement, to develop and commercialize the TFF2 Product, and to achieve specified developmental
milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is obligated to
pay Columbia single-digit royalties on net sales of (i) TFF2 Products sold by Tonix or a sublicensee and (ii) any other products that
involve material or technical information related to the TFF2 Product and transferred to Tonix pursuant to the Columbia License Agreement
(&#8220;Other Products&#8221;) sold by Tonix or a sublicensee. Royalties on each particular TFF2 Product are payable on a country-by-country
and Product-by-Product basis until the latest of (i) the date of expiration of the last valid claim in the last to expire of the issued
patents covered by the Columbia License Agreement, and (ii) a specified period of time after the first commercial sale of a TFF2 Product
in the country in question. Royalties on each particular Other Product are payable on a country-by-country and product-by-product basis
until a specified period of time after the first commercial sale of such particular Other Product in such country. Royalties payable on
net sales of the TFF2 Product and Other Products may be reduced by <span id="xdx_907_ecustom--PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_pii_dp_uPure_c20190915__20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_zEa5slyh3Gbb" title="Percentage of third party royalties payable for reduction in royalties payable">50</span>%
of the royalties payable by Tonix to any third party for intellectual property rights which are necessary for the practice of the rights
licensed to Tonix under the Columbia License Agreement, provided that the royalty payable on a Product or Other Product may not be reduced
by more than <span id="xdx_904_ecustom--MaximumPercentageReductionOfRoyaltiesPayable_pid_dp_c20190915__20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_z6EHqMRDJbT4">50</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also
obligated to make contingent milestone payments to Columbia totaling $<span id="xdx_907_ecustom--ContingentMilestonePaymentObligation_iI_pn5n6_c20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_zSmiqv9VEsBj">4.1</span>
million on a Product-by-Product basis upon the achievement of certain development, approval and sales milestones related to a
TFF2 Product. In addition, the Company shall pay Columbia <span id="xdx_906_ecustom--PercentagePadOfConsideration_pii_dp_uPure_c20190915__20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_zeYxuX7xrI93">5</span>%
of consideration, other than royalty payments and certain other categories of consideration, payable to the Company by a
sublicensee. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 20, 2019, the Company
entered into an exclusive License Agreement (the &#8220;License Agreement&#8221;) with Columbia pursuant to which Columbia, for itself
and on behalf of the University of Kentucky and the University of Michigan (collectively, the &#8220;Institutions&#8221;) granted to the
Company an exclusive license, with the right to sublicense, certain patents, technical information and material (collectively, the &#8220;Technology&#8221;)
related to a double-mutant cocaine esterase, and to develop and commercialize products thereunder (each, a &#8220;Product&#8221;). Pursuant
to the terms of the License Agreement, Columbia has reserved for itself and the Institutions the right to practice the Technology for
academic research and educational purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company paid a six-digit
license fee to Columbia as consideration for entering into the License Agreement. The Company is obligated to use Commercially Reasonable
Efforts, as defined in the License Agreement, to develop and commercialize the Product, and to achieve specified developmental milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agreed to pay
Columbia single-digit royalties on net sales of (i) Products sold by the Company or a sublicensee and (ii) any other products that involve
material or technical information related to the Product and transferred to the Company pursuant to the License Agreement (&#8220;Other
Products&#8221;) sold by the Company or a sublicensee. Royalties on each particular Product are payable on a country-by-country and Product-by-Product
basis until the latest of (i) the date of expiration of the last valid claim in the last to expire of the issued patents covered by the
License Agreement, (ii) a specified period of time after the first commercial sale of a Product in the country in question, or (iii) expiration
of any market exclusivity period granted by a regulatory agency. Royalties on each particular Other Product are payable on a country-by-country
and product-by-product basis until the later of (i) a specified period of time after the first commercial sale of such particular Other
Product in such country or (ii) expiration of any market exclusivity period granted by a regulatory agency. Royalties payable on net sales
of the Product and Other Products may be reduced by <span id="xdx_90E_ecustom--PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_pii_dp_uPure_c20190519__20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z3Ah1vyNKzfa" title="Percentage of third party royalties payable for reduction in royalties payable">50</span>%
of the royalties payable by the Company to any third party for intellectual property rights which are necessary for the practice of the
rights licensed to the Company under the License Agreement, provided that the royalty payable on a Product or Other Product may not be
reduced by more than <span id="xdx_909_ecustom--MaximumPercentageReductionOfRoyaltiesPayable_pii_dp_uPure_c20190519__20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zLBjcBcHGDdf">50</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also
obligated to make contingent milestone payments to Columbia totaling $<span id="xdx_900_ecustom--ContingentMilestonePaymentObligation_iI_pn6n6_c20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zETW1gpFSL7l">3 </span>million
on a Product-by-Product basis upon the achievement of certain development, approval and sales milestones related to a Product. In
addition, the Company shall pay Columbia <span id="xdx_90D_ecustom--PercentagePadOfConsideration_pii_dp_c20190519__20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zmkLfTqx8ti4">5</span>%
of consideration, other than royalty payments and certain other categories of consideration, payable to the Company by a
sublicensee. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936704784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SALE OF COMMON STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureSaleOfCommonStockAbstract', window );"><strong>Sale Of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_SaleOfCommonStockTextBlock', window );">SALE OF COMMON STOCK</a></td>
<td class="text"><p id="xdx_801_ecustom--SaleOfCommonStockTextBlock_zkqgYm651y81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
16 &#8211; <span id="xdx_829_znZ5hxBTWOm2">SALE OF COMMON STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">2022
Lincoln Park Transaction</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2022, the Company
entered into a purchase agreement (the &#8220;2022 Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;2022 Registration
Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). Pursuant to the terms of the 2022 Purchase
Agreement, Lincoln Park has agreed to purchase from the Company up to $<span id="xdx_906_ecustom--CommitmentToPurchaseSharesUnderAgreement_c20220815__20220816__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z50KXIyDKuF7">50,000,000</span>
of the Company&#8217;s common stock (subject to certain limitations) from time to time during the term of the 2022 Purchase Agreement.
Pursuant to the terms of the 2022 Registration Rights Agreement, the Company filed with the SEC a registration statement to register for
resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the 2022 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
2022 Purchase Agreement, at the time the Company signed the 2022 Purchase Agreement and the 2022 Registration Rights Agreement, the Company
issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20220815__20220816__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z4LIr3qQQrQ3">625,000</span>
shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of the Company&#8217;s common stock under
the 2022 Purchase Agreement. The commitment shares were valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220815__20220816__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zRzFBi8lXsde">1,000,000</span>
and recorded as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost of capital to
be raised under the 2022 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, the Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pin6_uShares_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member_z8bNL6UaqGfg">1</span>.0
million shares of common stock under the 2022 Purchase Agreement, for net proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member_zIUrLx7pxS47">0.5</span> million.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to December
31, 2022, the Company sold <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWWQp9yQGgZe">0.6</span>
million shares of common stock under the 2022 Purchase Agreement with Lincoln Park for net proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zk9p11hapJT7">0.4</span>
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Purchase
Agreement with Lincoln Park</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 3, 2021, the Company
entered into a purchase agreement (the &#8220;Purchase Agreement with Lincoln Park&#8221;) and a registration rights agreement (the &#8220;Lincoln
Park Registration Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). Pursuant to the terms of
the Purchase Agreement with Lincoln Park, Lincoln Park agreed to purchase from the Company up to $<span id="xdx_904_ecustom--CommitmentToPurchaseSharesUnderAgreement_pp0p0_c20211202__20211203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zf4X4ncK4tSk" title="Commitment to purchase shares under agreement">80,000,000</span>
of the Company&#8217;s common stock (subject to certain limitations) from time to time during the term of the Purchase Agreement with
Lincoln Park. Pursuant to the terms of the Lincoln Park Registration Rights Agreement, the Company filed with the SEC a registration statement
to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase Agreement
with Lincoln Park.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
Purchase Agreement with Lincoln Park, at the time the Company signed the Purchase Agreement with Lincoln Park and the Lincoln Park Registration
Rights Agreement, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20211202__20211203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuyjH4acUWUh" title="Number of shares issued (in shares)">90,910</span>
shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under the Purchase Agreement
with Lincoln Park. The commitment shares were valued at $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20211202__20211203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zrMlS9NSOZ25" title="Number of shares issued, value">1.6</span>
million and recorded as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost
of capital to be raised under the Purchase Agreement with Lincoln Park.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, the Company sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_zpe0SyFDZCo2" title="Number of shares issued (in shares)">2.9</span>
million shares of common stock under the Purchase Agreement with Lincoln Park, for net proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_z39QCFnChULi" title="Proceeds from equity offerings">8.7</span>
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules of
the NASDAQ Global Market, the Company could not issue or sell more than <span id="xdx_90B_ecustom--PercentageOfIssuanceByIssuerOfCommonStock_pid_dp_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_zXHHpWeJzW2c" title="Percentage of issuance by issuer of common stock">19.99</span>%
of the shares of its common stock outstanding immediately prior to the execution of the Purchase Agreement with Lincoln Park (approximately
<span id="xdx_907_ecustom--MaximumNumberOfSharesIssuedWIthoutShareholderApproval_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_zQLTeK74SRu">2.9
million</span> shares) to Lincoln Park under the Purchase Agreement with Lincoln Park without stockholder approval, unless the average
price of all applicable sales of its common stock to Lincoln Park under the Purchase Agreement with Lincoln Park equals or exceeds a threshold
amount. As the Company has issued approximately <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_ztTVAweLUA45" title="Number of shares issued (in shares)">2.9</span>
million shares to Lincoln Park, by December 31, 2022, under the Purchase Agreement with Lincoln Park at less than the threshold
amount, the Company will not sell any additional shares under the Purchase Agreement with Lincoln Park without shareholder approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">2021
Lincoln Park Transaction</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 14, 2021, the Company
entered into a purchase agreement (the &#8220;2021 Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;2021 Registration
Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). Pursuant to the terms of the 2021 Purchase
Agreement, Lincoln Park agreed to purchase from the Company up to $<span id="xdx_904_ecustom--CommitmentToPurchaseSharesUnderAgreement_pp0p0_c20210513__20210514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2021Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zj5xIMcex5x6" title="Commitment to purchase shares under agreement">80,000,000</span>
of the Company&#8217;s common stock (subject to certain limitations) from time to time during the term of the 2021 Purchase Agreement.
Pursuant to the terms of the 2021 Registration Rights Agreement, the Company filed with the SEC a registration statement to register for
resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the 2021 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the
2021 Purchase Agreement, at the time the Company signed the 2021 Purchase Agreement and the 2021 Registration Rights Agreement, the Company
issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210513__20210514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2021Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z4BxbODE4YOc" title="Number of shares issued (in shares)">40,000</span>
shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under the 2021 Purchase
Agreement. The commitment shares were valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210513__20210514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2021Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zdPJYy0Cz8k4" title="Number of shares issued, value">1.6</span>
million and recorded as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost
of capital to be raised under the 2021 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">During
the year ended December 31, 2021, the Company sold an aggregate of approximately <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zi9nt3a3jY88">2</span>.0
million shares of common stock under the 2021 Purchase Agreement, for gross proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zpceiXFLrtJb">41.3</span>
million. During the year ended December 31, 2022, no shares of common stock were sold under the 2021 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules of
the NASDAQ Global Market, the Company could not issue or sell more than <span id="xdx_90B_ecustom--PercentageOfIssuanceByIssuerOfCommonStock_pid_dp_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zemlrmf9tmQl">19.99</span>%
of the shares of its common stock outstanding immediately prior to the execution of the 2021 Purchase Agreement (approximately <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zkIKkhByQBRj">2</span>.0
million shares) to Lincoln Park under the 2021 Purchase Agreement without stockholder approval, unless the average price of all applicable
sales of its common stock to Lincoln Park under the 20121 Purchase Agreement equals or exceeds a threshold amount. As the Company has
issued approximately <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zyovP8OIVAh8">2</span>.0
million shares to Lincoln Park under the 2021 Purchase Agreement, at less than the threshold amount, the Company will not sell any additional
shares under the 2021 Purchase Agreement without shareholder approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">February
2021 Financing</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 8, 2021, the Company
entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210206__20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zTbIrfm3ncvf" title="Number of shares issued (in shares)">1.8</span>
million shares of its common stock, in a registered direct public offering (the &#8220;February 2021 Financing&#8221;), with A.G.P/Alliance
Global Partners (&#8220;AGP&#8221;), acting as placement agent. The public offering price for each share of common stock was $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pii_uUSDPShares_c20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zhAvZ68ejCpi" title="Sale of stock, price (in dollars per share)">38.40</span>.
The February 2021 Financing closed on February 9, 2021. AGP received a cash fee of <span id="xdx_904_ecustom--CashFeePercentage_pii_dp_uPure_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zhnRVLhBCvsc" title="Cash fee">7</span>%
of the gross proceeds, for an aggregate amount of $<span id="xdx_901_ecustom--UnderwritingDiscount_pn5n6_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zWDUMiZTt4Tj" title="Underwriting discount">4.9</span>
million. The Company incurred other offering expenses of approximately $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zHiesFvN8xk1" title="Expenses from sale of stock">0.1</span>
million. The Company received net proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0n6_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zx5bIdqVzCw6" title="Proceeds from equity offerings">65</span>.0
million, after deducting the fees and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">January
2021 Financing</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 11, 2021, the Company
entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zS8vPSSFQpv1" title="Number of shares issued (in shares)">1.6</span>
million shares of its common stock in a registered direct public offering (the &#8220;January 2021 Financing&#8221;), with AGP as placement
agent. The public offering price for each share of common stock was $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pii_uUSDPShares_c20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zjRo6y7SNWOe" title="Sale of stock, price (in dollars per share)">25.60</span>.
The January 2021 Financing closed on January 13, 2021. AGP received a cash fee of <span id="xdx_90F_ecustom--CashFeePercentage_pii_dp_uPure_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zaXicIi3WK54" title="Cash fee">7</span>%
of the gross proceeds, for an aggregate of $<span id="xdx_903_ecustom--UnderwritingDiscount_pn5n6_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zlBSWUVvau65" title="Underwriting discount">2.8</span>
million. The Company incurred other offering expenses of approximately $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z5Rja3KLIdZ" title="Expenses from sale of stock">0.3</span>
million. The Company received net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zE2vi2vmdGP5" title="Proceeds from equity offerings">36.9</span>
million, after deducting the fees and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">At-the-Market Offerings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;On April 8, 2020, the
Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with AGP pursuant to which the Company may issue and sell,
from time to time, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<span id="xdx_902_ecustom--OfferingPricePerAgreement_pp0n6_c20200407__20200408__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember_zbR37rECCVK9" title="Offering price per agreement">320</span>.0
million in at-the-market offerings (&#8220;ATM&#8221;) sales. AGP will act as sales agent and will be paid a <span id="xdx_908_ecustom--SalesAgentCommissionPercentage_pid_dp_c20200407__20200408__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember_zhNEkmYMNiEd" title="Commission to agent">3</span>%
commission on each sale under the Sales Agreement. The Company&#8217;s common stock will be sold at prevailing market prices at the time
of the sale, and, as a result, prices will vary. During the year ended December 31, 2022, the Company sold approximately <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zofP0hjxw8yg" title="Number of shares sold">56.4</span>
million shares of common stock under the Sales Agreement, for net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zQRFYB55csR2" title="Proceeds from equity offerings">85.3</span>
million. During the year ended December 31, 2021, the Company sold approximately <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zEhdmqnIEhFi" title="Number of shares sold">3.5</span>
million shares of common stock under the Sales Agreement, for net proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z9OLykwE979j" title="Proceeds from equity offerings">69.3</span>
million. Subsequent to December 31, 2022, the Company has sold <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP35eL8qUe99" title="Number of shares issued (in shares)">2.1</span>
million shares of common stock under the Sales Agreement, for net proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuctuwBxR2N3" title="Proceeds from equity offerings">1.4</span>
million.&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureSaleOfCommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureSaleOfCommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_SaleOfCommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_SaleOfCommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936680560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z714NrcDyBge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
17 &#8211; <span id="xdx_823_ziwiO9BYfRr6">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Stock
Incentive Plans</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 3, 2019, the Company&#8217;s
stockholders approved the Tonix Pharmaceuticals Holding Corp. 2019 Stock Incentive Plan (the &#8220;2019 Plan&#8221;). The 2019 Plan provided
for the issuance of up to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20190503__us-gaap--PlanNameAxis__custom--IncentiveStockOptionsPlan2019Member_zaL8suJWocxf">4,375</span>
shares of common stock. With the adoption of the 2020 Plan (as defined below), no further grants may be made under the 2019 Plan. On January
16, 2020, the Company&#8217;s stockholders approved the Tonix Pharmaceuticals Holding Corp. 2020 Stock Incentive Plan (the &#8220;2020
Plan&#8221;). The 2020 Plan provided for the issuance of up to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200116__us-gaap--PlanNameAxis__custom--IncentiveStockOptionsPlan2020Member_zam1TCfr9Ipc" title="Number of shares authorized">18,750</span>
shares of common stock. With the adoption of the Amended and Restated 2020 Plan (as defined below), no further grants may be made under
the 2020 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2020, the Company&#8217;s
stockholders approved the Tonix Pharmaceuticals Holding Corp. Amended and Restated 2020 Stock Incentive Plan (&#8220;Amended and Restated
2020 Plan&#8221;), and together with the 2020 Plan and the 2019 Plan, the &#8220;Plans&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the Amended
and Restated 2020 Plan, the Company may issue (1) stock options (incentive and nonstatutory), (2) restricted stock, (3) stock appreciation
rights (&#8220;SARs&#8221;), (4) RSUs, (5) other stock-based awards, and (6) cash-based awards. The Amended and Restated 2020 Plan initially
provided for the issuance of up to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_uShares_c20200501__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_zrXzoHb7MVYc" title="Percentage of additional shares authorized">312,500
</span>shares of common stock, which amount&#160;will be increased to the extent that awards granted under the Plans are forfeited, expire
or are settled for cash (except as otherwise provided in the Amended and Restated 2020 Plan). In addition, the Amended and Restated 2020
Plan contains an &#8220;evergreen provision&#8221; providing for an annual increase in the number of shares of our common stock available
for issuance under the Amended and Restated 2020 Plan on January 1 of each year for a period of ten years, commencing on January 1, 2021
and ending on (and including) January 1, 2030, in an amount equal to the difference between (x) twenty percent (<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_z5JN5TZDMruc" title="Percentage of additional shares authorized">20</span>%)
of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, and (y) the total number of
shares of common stock reserved under the Amended and Restated 2020 Plan on December 31<sup>st</sup> of such preceding calendar year
(including shares subject to outstanding awards, issued pursuant to awards or available for future awards). The Board of Directors determines
the exercise price, vesting and expiration period of the grants under the Amended and Restated 2020 Plan. However, the exercise price
of an incentive stock option may not be less than <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TenPercentOrMoreShareholderMember_zKhcrQyZ8KO4">110</span>%
of fair value of the common stock at the date of the grant for a 10% or more shareholder and <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_zH1a80XjbmUk">100</span>%
of fair value for a grantee who is not a 10% shareholder. The fair value of the common stock is determined based on quoted market price
or in absence of such quoted market price, by the Board of Directors in good faith. Additionally, the expiration period of grants under
the Amended and Restated 2020 Plan may not be more than <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dt_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_zogx3eLsmzri" title="Expiration period">ten
years</span>. As of December 31, 2022, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_z0dC6IryuFB">627,744
</span>options were available for future grants under the Amended and Restated 2020 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/>

<div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhcqcmcrSy7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;A
summary of the stock option&#160;activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted- Average</b></span>
        <span style="font-size: 10pt"><b>Exercise&#160;Price</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span>
        <span style="font-size: 10pt"><b>Remaining&#160;</b></span> <span style="font-size: 10pt"><b>Contractual&#160;Term</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Aggregate</b></span> <span style="font-size: 10pt"><b>Intrinsic</b></span>
        <span style="font-size: 10pt"><b>Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Outstanding at December 31, 2020</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_z8QEF9Ldn2Ae" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="font-size: 10pt">319,179</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zXwgtIPhAWm4" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="font-size: 10pt">2.93</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zCCVNJiiNH67" style="width: 15%; text-align: right" title="Weighted average remaining contractual term"><span style="font-size: 10pt">9.26</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zV7Y3IVFQpma" style="width: 12%; text-align: right" title="Beginning, Aggregate Intrinsic Value"><span style="font-size: 10pt">131,558</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Grants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zfiIfBvbsM0j" style="text-align: right" title="Grants"><span style="font-size: 10pt">486,639</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zOG86dylxtf8" style="text-align: right" title="Grants"><span style="font-size: 10pt">40.85</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Forfeitures or expirations</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_zKjEzdjLrTjf" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"><span style="font-size: 10pt">(56)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zYFeC7ZW3OO8" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"><span style="font-size: 10pt">149,713.14</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Outstanding at December 31, 2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_z9MNdSsWT9Cj" style="text-align: right" title="Outstanding at end"><span style="font-size: 10pt">805,762</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231_zx8pJKNcryj5" style="text-align: right" title="Outstanding at end"><span style="font-size: 10pt">78.02</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zqr2cpE1k0G6" style="text-align: right" title="Weighted average remaining contractual term"><span style="font-size: 10pt">8.83</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Grants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zVwtcF2kU1L3" style="text-align: right" title="Grants"><span style="font-size: 10pt">1,695,608</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zHGKSimzqy61" style="text-align: right" title="Grants"><span style="font-size: 10pt">12.06</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Forfeitures or expirations</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_zJlazzscnvEb" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"><span style="font-size: 10pt">(48,339</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zeyG8JWfNyvf" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"><span style="font-size: 10pt">255.40</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Outstanding at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_z7anQ9MzTHXe" style="border-bottom: black 2.5pt double; text-align: right" title="Outstanding at end"><span style="font-size: 10pt">2,453,031</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231_z3zk9WvoIDZj" style="border-bottom: black 2.5pt double; text-align: right" title="Outstanding at end"><span style="font-size: 10pt">28.93</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zZDC6CBOJOH2" style="border-bottom: black 2.5pt double; text-align: right" title="Weighted average remaining contractual term"><span style="font-size: 10pt">8.70</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Exercisable at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zctTAL3gFE74" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"><span style="font-size: 10pt">590,582</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231_zmQTYImGOZde" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"><span style="font-size: 10pt">70.82</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zvIpaX7vLUkj" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"><span style="font-size: 10pt">7.64</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zkfAKwaYTs56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value
in the preceding table represents the total pretax intrinsic value, based on options with an exercise price less than the Company&#8217;s
closing stock price at the respective dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The weighted average grant
date fair value of options granted during the years ended December 31, 2022 and 2021, was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231_zmAM6aMsywm9" title="Weighted average grant date fair value of options (in dollars per share)">5.25</span>
and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231_zsA6nSKoDZpe" title="Weighted average grant date fair value of options (in dollars per share)">33.78</span>
per share, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company measures the
fair value of stock options on the date of grant, based on the Black Scholes option pricing model using certain assumptions
discussed below, and the closing market price of the Company&#8217;s common stock on the date of the grant. The fair value of the
award is measured on the grant date. <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4p0_dxL_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z1VA1CI012M9" title="Vesting percentage::XDX::0.3333"><span style="-sec-ix-hidden: xdx2ixbrl1020">One-third </span></span>of
most stock options granted pursuant to the Plans vest 12 months from the date of grant and <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4p0_dxL_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zUk6ZZi0p1V7" title="::XDX::0.0278"><span style="-sec-ix-hidden: xdx2ixbrl1021">1/36</span><sup>th </sup></span>each
month thereafter for 24 months and expire <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNkgTBl1Gks5">ten
years</span> from the date of grant. In addition, the Company issues options to directors which vest over a <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zzdHhXaHRwG1" title="Vesting period::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1024">one-year</span></span> period. The Company also issues premium options to executive officers which have an exercise price greater than the grant
date fair value and has issued performance-based options which vest when target parameters are met or probable of being met, subject
in each case to a <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dt_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_z3rvzDOnmCZg" title="Service period">one
year</span> minimum service period prior to vesting. Stock-based compensation expense related to awards is amortized over the
applicable service period using the straight-line method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zohZPBPNS2ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows:&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20220101__20221231_zEHr2YtfTD2g" title="Risk-free interest rate - Minimum">1.67</span>%
        to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20220101__20221231_zj83l5FCbyFi" title="Risk-free interest rate - Maximum">3.05</span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20210101__20211231_z7zgsb62MYJj" title="Risk-free interest rate - Minimum">0.79</span>%
        to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20210101__20211231_zSZG5dwWmFo" title="Risk-free interest rate - Maximum">1.63</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Expected term of option</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zsSuL8lrJP0d" title="Expected term of option">5.5</span>
        to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zXqxUtnnjALi" title="Expected term of option">10</span>
        years</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zzSShwBZa0ci" title="Expected term of option">5.5</span>
        to <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zPPZOPlezia2" title="Expected term of option">6</span>
        years</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Expected stock price volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20220101__20221231_zWx2tt7XZ9ke" title="Expected stock price volatility - minimum">120.32</span>%
        - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20220101__20221231_zw8PbQelsC11" title="Expected stock price volatility - maximum">133.22</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20210101__20211231_zTRrTh3rQWWa" title="Expected stock price volatility - minimum">124.37</span>%
        to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20210101__20211231_ztMZAIvH0p67" title="Expected stock price volatility - maximum">137.73</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 64%"><span style="font-size: 10pt">Expected dividend yield</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20220101__20221231_zptWT381s0ac" title="Expected dividend yield">0.0</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20210101__20211231_zelPGnsdwk4c" title="Expected dividend yield">0.0</span>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table>

<p id="xdx_8AB_ziP5tLr2ywr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risk-free interest rate
is based on the yield of Daily U.S. Treasury Yield Curve Rates with terms equal to the expected term of the options as of the grant date.&#160;The
expected term of options is determined using the simplified method, as provided in an SEC Staff Accounting Bulletin,&#160;and the expected
stock price volatility is based on the Company&#8217; historical stock price volatility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation expense
relating to options granted of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQoO2M336M3e" title="Stock-based compensation expense">10.9</span>
million, of which $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEMYASB0chNh" title="General and administrative">7.9</span>
million and $<span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_pp0n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0fuFMSWg6Be" title="Research and development costs">3</span>.0
million, related to General and Administration and Research and Development, respectively was recognized for the year ended December 31,
2022.&#160;Stock-based compensation expense relating to options granted of $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSRCOiVD7Omh" title="Stock-based compensation expense">7.9</span>
million, of which $<span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zql36sCXS7L6" title="General and administrative">5.5</span>
million and $<span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcqkGMlVgnv7" title="Research and development costs">2.4</span>
million, related to General and Administration and Research and Development, respectively was recognized for the year ended December
31, 2021.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, the
Company had approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV3X3Kgj2xLe" title="Unrecognized compensation cost">11.6</span>
million of unrecognized compensation cost related to non-vested awards granted under the Plans, which the Company expects to recognize
over a weighted average period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoo7X38FIeY7" title="Unrecognized compensation cost, recognition period">1.73</span>
years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Employee
Stock Purchase Plans</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 3, 2019, the Company&#8217;s
stockholders approved the Tonix Pharmaceuticals Holdings Corp. 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;). As a result
of adoption of the 2020 ESPP, as defined below, by the stockholders, no further grants may be made under the 2019 ESPP Plan. On May 1,
2020, the Company&#8217;s stockholders approved the Tonix Pharmaceuticals Holdings Corp. 2020 Employee Stock Purchase Plan (the &#8220;2020
ESPP&#8221;). No further grants may be made under the 2020 ESPP Plan. On May 6, 2022, the Company&#8217;s stockholders approved the Tonix
Pharmaceuticals Holdings Corp. 2022 Employee Stock Purchase Plan (the &#8220;2022 ESPP&#8221;, and together with the 2019 ESPP and the
2020 ESPP, the &#8220;ESPP Plans&#8221;)).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2022 ESPP allows eligible
employees to purchase up to&#160;an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_uShares_c20190503__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member_zuHNaliqJsC7" title="Number of shares authorized">93,750</span>&#160;shares
of the Company&#8217;s common stock. Under the 2022 ESPP, on the first day of each offering period, each eligible employee for that offering
period has the option to enroll for that offering period, which allows the eligible employees to purchase shares of the Company&#8217;s
common stock at the end of the offering period. Each offering period under the 2022 ESPP is for six months, which can be modified from
time-to-time. Subject to limitations, each participant will be permitted to purchase a number of shares determined by dividing the employee&#8217;s
accumulated payroll deductions for the offering period by the applicable purchase price, which is equal to&#160;<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20190502__20190503__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member_zbU14m199Yc7" title="Percent of fair value of common stock at grant date">85</span>
percent&#160;of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. A participant
must designate in his or her enrollment package the percentage (if any) of compensation to be deducted during that offering period for
the purchase of stock under the 2022 ESPP, subject to the statutory limit under the Code. As of December 31, 2022, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member_zbGVUGmtuH09" title="Number of shares available for future grants">9</span>
shares were available for future sales under the 2022 ESPP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;The 2022 and 2020 ESPP
are considered compensatory plans with the related compensation cost expensed over the six-month offering period. For the year ended December
31, 2022 and 2021, $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlansMember_zVMq5N5BQDj4" title="Stock-based compensation expense">46,000</span>
and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlansMember_zdYaFxp6sHc" title="Stock-based compensation expense">89,000</span>,
respectively were expensed. In January 2021, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20210101__20210131__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zO9nldlnmN38" title="Employee stock purchase plan (in shares)">1,703</span>
shares that were purchased as of December 31, 2020, under the 2020 ESPP, were issued. Accordingly, during the first quarter of 2021, approximately
$<span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c20210101__20210331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zP09K8f98sZe" title="Transfer to additional paid in capital">28,000</span>
of employee payroll deductions accumulated at December 31, 2020, related to acquiring such shares, was transferred from accrued expenses
to additional paid in capital. The remaining $<span id="xdx_90F_ecustom--AmountReturnToEmployee1_c20210101__20210331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_ztRDzRWV6EO3" title="ESPP withholdings returned to employees">4,000</span>
was returned to the employees. In January 2022, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20220101__20220131__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zC3r7Sdrw2N2" title="Employee stock purchase plan (in shares)">4,033</span>
shares that were purchased as of December 31, 2021, under the 2020 ESPP, were issued. Accordingly, during the first quarter of 2022, approximately
$<span id="xdx_90B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c20220101__20220331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zmzm71UeSVqd" title="Transfer to additional paid in capital">40,000</span>
of employee payroll deductions accumulated at December 31, 2021, related to acquiring such shares, was transferred from accrued expenses
to additional paid in capital. The remaining $<span id="xdx_901_ecustom--AmountReturnToEmployee1_c20220101__20220331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zcfoyQVTHzKb" title="ESPP withholdings returned to employees">30,000</span>
was returned to the employees. As of December 31, 2022, approximately $<span id="xdx_90E_ecustom--AccumulatedEmployeePayrollDeductions_iI_pp0p0_c20221231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlansMember_zoiDGqcXI7Lb">43,000</span>
of employee payroll deductions have accumulated and have been recorded in accrued expenses.&#160;In January 2023, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20230101__20230131__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1acdjwTc82i" title="Employee stock purchase plan (in shares)">93,741</span>
shares that were purchased as of December 31, 2022, under the 2022 ESPP, were issued. Accordingly, during the first quarter of 2023, approximately
$<span id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c20230101__20230331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvgE3ZgVcE2k" title="Transfer to additional paid in capital">29,000</span>
of employee payroll deductions accumulated at December 31, 2023, related to acquiring such shares, was transferred from accrued expenses
to additional paid in capital. The remaining $<span id="xdx_90D_ecustom--AmountReturnToEmployee1_c20230101__20230331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zujTIrYagfg3" title="ESPP withholdings returned to employees">14,000</span>
was returned to the employees.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942915920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS TO PURCHASE COMMON STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract', window );"><strong>Warrants To Purchase Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StockWarrantsTextBlock', window );">WARRANTS TO PURCHASE COMMON STOCK</a></td>
<td class="text"><p id="xdx_80C_ecustom--StockWarrantsTextBlock_zjKWOHygrJTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
18 &#8211; <span id="xdx_82D_zMDxE7PHHdh1">WARRANTS TO PURCHASE COMMON STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zj70aoJ5PEa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zPJrhweMGqxe">The
following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Expiration</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Price</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Outstanding</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zCRzvyBA0lhg" title="Exercise price (in dollars per share)">16.00</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z3WDRbN4k58d" title="Number Outstanding">779</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 52%; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zwvsV3Q0zeg8" title="Expiration date">November
        2024</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zP7p8O46Jl69" title="Exercise price (in dollars per share)">18.24</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zKYtXM5JYcAk" title="Number Outstanding">3,860</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z59AAoLC2HR9" title="Expiration date">February
        2025</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zUzJwgpiox7d" title="Exercise price (in dollars per share)">1,120.00</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zJScLaqvFVii" title="Number Outstanding">15,331</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zgKKtWuc4mU2" title="Expiration Date">December
        2023</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231_z3Ravt8OtHy6" style="border-bottom: black 2.5pt double; text-align: right" title="Number Outstanding"><span style="font-size: 10pt">19,970</span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>

<p id="xdx_8A1_zKAb5nBoRudc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No warrants were exercised
during the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2021, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromFeb2020FinancingMember_zI7auKdDr2Ra" title="Number of exercised warrants">107</span>
warrants from the February 2020 Financing, with an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromFeb2020FinancingMember_zACUVUYqijqe" title="Exercise price (in dollars per share)">18.24</span>,
were exercised for proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromFeb2020FinancingMember_zUN48XedUuba" title="Proceeds from exercise of warrants">2,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2021, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTpnxnGDpZM7" title="Number of warrants expired">5,441</span>
and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--Warrant1Member_zBRLV7oD9KP9" title="Number of warrants expired">474</span>
warrants with a per share exercise price of $<span id="xdx_906_ecustom--ExercisePriceOfWarrantsExpired_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvNiuFlMtzk6" title="Exercise price of warrants expired (in dollars per share)">630.00</span>
and $<span id="xdx_902_ecustom--ExercisePriceOfWarrantsExpired_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--Warrant1Member_zq5LKyxh6HY9" title="Exercise price of warrants expired (in dollars per share)">687.50</span>,
respectively, expired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StockWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for stock warrants or rights issued during the given period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StockWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936769872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zOLPMTwxzxyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE
19 &#8211; <span id="xdx_82D_znOKrZPwTda7">LEASES</span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has various operating
lease agreements, which are primarily for office space. These agreements frequently include one or more renewal options and require the
Company to pay for utilities, taxes, insurance and maintenance expense. No lease agreement imposes a restriction on the Company&#8217;s
ability to engage in financing transactions or enter into further lease agreements. At December 31, 2022, the Company has right-of-use
assets of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_dxL_c20221231_zmW3UlGEQsZ4" title="Right-of-use assets, net::XDX::715"><span style="-sec-ix-hidden: xdx2ixbrl1146">0.7
million</span></span> and a total lease liability for operating leases of $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_pn3n3_dxL_c20221231_zQAOQYVs8pS7" title="Total lease liability::XDX::760"><span style="-sec-ix-hidden: xdx2ixbrl1148">0.7
million</span></span> of which $<span id="xdx_90E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_dxL_c20221231_zqDQBdfx97E7" title="Lease liability, net of current portion::XDX::328"><span style="-sec-ix-hidden: xdx2ixbrl1150">0.3
million</span></span> is included in long-term lease liabilities and $<span id="xdx_905_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_dxL_c20221231_zSuqWCRq4M8k" title="Lease liability, current::XDX::432"><span style="-sec-ix-hidden: xdx2ixbrl1152">0.4
million</span></span> is included in current lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zEJCFisgJnFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zIwIJWsuho85">At
December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 88%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b><span style="text-decoration: underline">Year&#160;Ending&#160;December&#160;31,</span></b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zCCQaPJv0y3" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1eV_zLp5OcVo0Bvg" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 85%"><span style="font-size: 10pt">2023</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">441</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1eV_zDZtryDitfu1" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">164</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1eV_zYuUd8SsbYG3" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">159</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1eV_zxMdw3u8PkT5" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2026</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1eV_zPrq8T8ost92" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">2027</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1eV_zqeTNpUY4Efd" style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">775</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z6yd4QrARzZ" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Included interest</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(15</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zbSFKU1qEcEh" style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">760</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zOZ4gWu8uiJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, the Company entered into new operating leases and lease amendments, resulting in the Company recognizing an additional operating
lease liability of approximately $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zUsqH7eY7eD3" title="Total lease liability">386,000</span>
based on the present value of the minimum rental payments. The Company also recognized a corresponding increase to ROU assets of approximately
$<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zUoVpP096WXc" title="Right-of-use assets, net">386,000</span>,
which represents a non-cash investing and financing activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2021, the Company entered into lease amendments, resulting in the Company recognizing an operating lease liability of approximately
$<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20211231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zsShrMUBfFH7" title="Total lease liability">467,000</span>
based on the present value of the future minimum rental payments. The Company also recognized corresponding ROU assets of approximately
$<span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zS67rRsgacx7" title="Right-of-use assets, net">467,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating lease expense was
$<span id="xdx_90C_eus-gaap--OperatingLeaseExpense_pp0n6_c20220101__20221231_zFxoeT3Zq08d" title="Operating lease expense"><span id="xdx_90A_eus-gaap--OperatingLeaseExpense_pp0n6_c20210101__20211231_zpUd512ddby8" title="Operating lease expense">0.6</span></span>
million for both years ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_890_ecustom--SummaryOfOtherInformationRelatedToLeasesTableTextBlock_zZQ884hZvyXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span id="xdx_8B7_z6iTv0Mk00qk">Other
information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Cash paid for amounts included in the
        measurement of lease liabilities:</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31,  2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31,  2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Operating cash flow from operating leases (in
        thousands)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220101__20221231_zPTNP0tOFsq6" title="Operating cash flow from operating leases">598</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--OperatingLeasePayments_c20210101__20211231_zxA2Wr6ED0pj" title="Operating cash flow from operating leases">632</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Weighted Average Remaining Lease Term</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Operating leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_z3HNyxEj2II" title="Weighted average remaining lease term operating leases">2.20</span>
        years</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_znQeP7VQh7pi" title="Weighted average remaining lease term operating leases">2.71</span>
        years</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Weighted Average Discount Rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Operating leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20221231_zWKb6FI3X5N2" title="Weighted average discount rate operating leases">2.19</span></span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20211231_zpE9w2mRcp3" title="Weighted average discount rate operating leases">1.34</span></span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>

<p id="xdx_8AA_zn30dbCnzhv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936682992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsDisclosureTextBlock_zEYp0uEbb6u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
20 &#8211; <span id="xdx_82B_zf5jgiyywzp5">COMMITMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Contractual
agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered into
contracts with various contract research organizations with outstanding commitments aggregating approximately $<span id="xdx_905_eus-gaap--OtherCommitment_iI_pn5n6_c20221231__us-gaap--OtherCommitmentsAxis__custom--ResearchOrganizationsMember_z7pGx69zPL2j" title="Outstanding commitments">58.6</span>
million at December 31, 2022 for future work to be performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a
construction contract with outstanding commitments aggregating approximately $<span id="xdx_902_eus-gaap--OtherCommitment_iI_pn5n6_c20221231__us-gaap--OtherCommitmentsAxis__custom--ConstructionContractMember_ztsNR34Q3Sw8">2</span>.0
million at December 31, 2022 for future work to be performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Defined
contribution plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a qualified
defined contribution plan (the &#8220;401(k) Plan&#8221;) pursuant to Section 401(k) of the Code, whereby all eligible employees may&#160;participate.
Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) Plan, subject to defined limitations. The
Company is required to make contributions to the 401(k) Plan equal to <span id="xdx_907_eus-gaap--DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_pp2p2_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_z0nrLLNDcYh3" title="Employer matching contribution">100</span>
percent of each participant&#8217;s pretax contributions of up to <span id="xdx_905_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pp2p2_dc_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_zm6o3kA1C7nf" title="Maximum annual contributions per employee">six</span>
percent of his or her eligible compensation, and the Company is also required to make a contribution equal to <span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pp2p2_dc_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_zTjULTFvkAH1" title="Maximum annual contributions per employer">three</span>
percent of each participant&#8217;s salary, on an annual basis, subject to limitations under the Code. The Company charged operations
$<span id="xdx_90D_eus-gaap--DefinedContributionPlanAdministrativeExpenses_pn5n6_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_zEkwjy1H6Hb1" title="Administrative expenses">0.9</span>
million and $<span id="xdx_900_eus-gaap--DefinedContributionPlanAdministrativeExpenses_pn5n6_c20210101__20211231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_z3isMgXWhtil" title="Administrative expenses">0.4</span>
million for the year ended December 31, 2022, and 2021, respectively, for contributions under the 401(k) Plan.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936722672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zK67rGSS6ckc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
21 &#8211; <span id="xdx_822_zsxHdSaWNw33">INCOME TAXES</span> &#8211; </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_899_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zjEhisVJR1K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span id="xdx_8BA_zkrsWCnn7Dhg">Components
of the net loss consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20220101__20221231_ztWF3FRkKBc5" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20211231_zwJljXzTgmm9" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_maNILz5B4_zjwSRzlxvSb8" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><span style="font-size: 10pt">Foreign</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(88,478</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(73,689</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maNILz5B4_zD5HtakXfWIb" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Domestic</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(21,740</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(18,598</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_mtNILz5B4_zWli3YAq4N52" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(110,218</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(92,287</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>

<p id="xdx_8A0_zM55ZPdKQFB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, the foreign losses
are primarily comprised of $<span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn5n6_di_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--IE_zMk3XEm5QkTc" title="Foreign losses">86.7</span>
million related to the Irish operations and $<span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn5n6_di_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--BM_zw0XCZZd7wSa">1.5</span>
million related to the Bermudan operations of Tonix International Holding. In 2021, the foreign losses were primarily comprised
of $<span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn5n6_di_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--BM_zmMsXvvDnXfk">71.9</span>
million related to the Bermudan operations of Tonix International Holding.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zKciEbcJCate" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zfk7VEREzlRg">A
reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate
the Company&#8217;s income tax provision is as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_499_20220101__20221231_zahNZGVzxMBh" style="text-align: center">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49C_20210101__20211231_zCeZkwzAOsSl" style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Year Ended December&#160;31,</b></span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maITP_zISccJzeiwI7" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 46%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Statutory federal income tax</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(21.0</span></td>
    <td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">)%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(21.0</span></td>
    <td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_msITP_zkI4qy92Ybmg" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.6</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">15.0</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_msITP_zPoyg7cYdzSa" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Foreign loss not subject to income tax</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7.0</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7.0</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange_pid_dp_uPure_msITP_zeJ7uWoD4SBb" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Attribute reduction from control change</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4.0</span></td>
    <td style="white-space: nowrap">%<span style="font-size: 10pt"/></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(1.2</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_msITP_zz24AVYh3qHg" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">0.4</span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">%</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">0.2</span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtITP_zBwqkK0JoRN3" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Income Tax Provision</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">0.0</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><span style="font-size: 10pt">%</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">0.0</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><span style="font-size: 10pt">%</span></td></tr>
  </table>

<p id="xdx_8A9_z65NfV8SQWCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyovoei5FTde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zdnJIiIjnKH8">Deferred
tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands):</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_494_20221231_zhQ3rRxBmsW" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49F_20211231_ztCNS99boig2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsNetAbstract_iB_pn3n3_zR96kMS6Cvmf" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Deferred tax assets/(liabilities):</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGz7el_zqoraYjYLR0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%"><span style="font-size: 10pt">Net operating loss carryforward</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">21,642</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">13,297</span></td>
    <td style="width: 3%">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3n3_maDTAGz7el_zAo1RF4kaHck" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Stock-based compensation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7,353</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5,832</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGz7el_zxFVpCJ1aaFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,997</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2,285</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGz7el_maDTALNzDL0_zZVByPplpQI9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Total deferred assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">30,992</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">21,414</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzDL0_zwdP8L1COg83" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Valuation allowance</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(30,992</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(21,414</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzDL0_zoryXsKDhVnj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Net deferred tax assets</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1270">&#8212;</span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8212;</span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zSI8MIp4vITj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has incurred research
and development (&#8220;R&amp;D&#8221;) expenses, a portion of which qualifies for tax credits. The Company conducted an R&amp;D credit
study to quantify the amount of credits and has claimed an R&amp;D credit on its 2014-2017 tax returns. A portion of these R&amp;D credit
carryforwards are subject to annual limitations in their use in accordance with Internal Revenue Service Code (&#8220;IRC&#8221;) section
383. The R&amp;D credit carryforwards at December 31, 2022 have been reduced to $<span id="xdx_90C_eus-gaap--TaxCreditCarryforwardAmount_iI_pdn6_c20221231__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zBiyqVopiSZ7" title="Credit carryforwards">0</span>.0
million to reflect IRC section 383 ownership changes through December 31, 2022 and the resulting inability to utilize a portion of the
R&amp;D credit prior to its expiration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, 2022, the
Company has $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--IE_zBr2As3oyQvi" title="Operating loss carryforwards">165.5
</span>million of Ireland net operating loss (&#8220;NOL&#8221;) carryforwards that do not expire. As of December 31, 2022, the Company's
Federal NOL carryforwards of $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfHfIEDMvfCg">3.6
</span>million, which do
not expire, but their utilization is limited to <span id="xdx_908_ecustom--OperatingLossCarryforwardsLimitationsOnUsePercent_dp_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZv5YtHAjuI7" title="Utilization NOL (percent)">80%</span> of taxable income. Additionally, the Company has New Jersey NOL carryforwards
of $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__srt--StatementGeographicalAxis__stpr--NJ_zyetk2emhH13">2.3
</span>million and Massachusetts NOL carryforwards of $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__srt--StatementGeographicalAxis__stpr--MA_zP3srFVf1vm9">0.3
</span>million, which both <span id="xdx_906_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z9tvvqbEUZci" title="Operating loss carryforwards expiration">expire
in 20 years</span>. The NOL carryforwards at December 31, 2022 have been reduced to reflect IRC section 382 ownership changes through December
31, 2022 and the resultant inability due to annual limitations, to utilize a portion of the NOL prior to its expiration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management assesses the available
positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets.
A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December
31, 2022. Such objective evidence limits the ability to consider other subjective evidence such as our projections for future growth.
As such, the Company has determined that it is not more likely than not that the deferred tax assets will be realized and accordingly,
has provided a full valuation allowance against its gross deferred tax assets. The increase in the valuation allowance for the years ended
December 31, 2022 and 2021 were $<span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20220101__20221231_zQjexi6KaKtf" title="Increase in valuation allowance">9.5</span>
million, and $<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20210101__20211231_zmzO8o1zst3i">15.3</span>
million respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognizes interest
accrued related to unrecognized tax benefits and penalties as income tax expense. However, as of December 31, 2022 there are no unrecognized
tax benefits recorded. The Company is subject to taxation in the United States and various states and foreign jurisdictions. As of December
31, 2022, the Company&#8217;s tax returns remain open and subject to examination by the tax authorities for the tax years 2019 and after.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088933157952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zebVu2qqZbLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE
22 &#8211; <span id="xdx_829_zXhDsNlEwME9">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Since
January 1, 2023, the Company has repurchased </span><span id="xdx_90B_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pip0_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember_zAxJF3HrGrV2">15,700,269</span><span>
of its shares of common stock outstanding under its $<span id="xdx_90D_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn5n6_c20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember_zrwdihlIrRoc">12.5 </span>million
s</span>hare repurchase program at prices ranging from $<span id="xdx_90E_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember__srt--RangeAxis__srt--MinimumMember_zrTqGdx6zKVi" title="Price of shares repurchased (in dollars per share)">0.44 </span>to
$<span id="xdx_900_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember__srt--RangeAxis__srt--MaximumMember_z7wuixmg6nj9">1.38</span><span style="background-color: white">
per share for a gross aggregate cost of approximately $<span id="xdx_908_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn5n6_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember_zw9qmPv0oxf4" title="Value of shares repurchased">12.5</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
January 2023, the <span style="background-color: white">Board of Directors approved </span>a new share&#160;repurchase
program&#160;pursuant to which the Company may&#160;repurchase&#160;up to $<span id="xdx_903_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn5n6_c20230102__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeoFBUU0My89" title="Repurchase program amount">12.5</span>
million in value of its outstanding common stock from time to time on the open market and in privately negotiated transactions
subject to market conditions, share price and other factors.&#160;<span style="background-color: white">Since January 1, 2023, the
Company has repurchased </span><span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pip0_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember_zECEdf3vV2xf" title="Number of shares repurchased (in shares)">1,000,000</span> <span style="background-color: white">of
its shares of common stock outstanding under the new share repurchase program at $<span id="xdx_90A_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_pid_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember_zam0u8T1YMQl">1.14</span>
per share for a gross aggregate cost of $<span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn5n6_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember_zHus7B20ow9c">1.1</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
timing and amount of any shares</span>&#160;repurchased&#160;<span style="background-color: white">will be determined based on the Company&#8217;s
evaluation of market conditions and other factors and the</span>&#160;New Share Repurchase Program&#160;<span style="background-color: white">may
be discontinued or suspended at any time.&#160;</span>Repurchases&#160;<span style="background-color: white">will be made in accordance
with the rules and regulations promulgated by the Securities and Exchange Commission and certain other legal requirements to which the
Company may be subject.&#160;</span>Repurchases&#160;<span style="background-color: white">may be made, in part, under a Rule 10b5-1 plan,
which allows stock&#160;</span>repurchases&#160;<span style="background-color: white">when the Company might otherwise be precluded from
doing so. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Subsequent
to December 31, 2022, <span style="background-color: white">the Company regained compliance with the minimum bid price requirement for
continued listing on The Nasdaq Capital Market because the Company&#8217;s shares had a closing bid price at or above $<span id="xdx_907_ecustom--MinimumBidRequirementPerShare_iI_c20230102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGYiIz2QN2oi" title="Minimum bid price requirements NASDAQ">1.00</span>
per share for a minimum of <span id="xdx_90E_ecustom--ConsecutiveBusinessDaysForMinimumBidPrice_dtD_c20230101__20230102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6i1jkwSBmo8" title="Consecutive business days for minimum bid price">10</span>
consecutive business days, as set forth in Nasdaq Listing Rule 5550(a)(2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
February 2, 2023, the Company entered into an asset purchase agreement </span>(the &#8220;Asset Purchase Agreement&#8221;) with Healion
Bio Inc., <span style="background-color: white">pursuant to which the Company acquired all the pre-clinical infectious disease assets
of Healion, including its portfolio of next-generation antiviral technology assets. Healion&#8217;s drug portfolio includes a class of
broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action, including TNX-3900, formerly
known as HB-121. </span>As consideration for entering into the Asset Purchase Agreement, the Company paid $<span id="xdx_909_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20230201__20230202__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--HealionBioIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z66gS0EEifMi" title="Consideration paid">1.2</span>
million to Healion. Because the Healion intellectual property was acquired prior to FDA approval, the cash consideration totaling
$<span id="xdx_903_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20230201__20230202__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--HealionBioIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv1HhJC88a9a" title="Research and development costs">1.2</span>
million, is expected to be expensed as research and development costs since there is no alternative future use and the acquired
intellectual property does not constitute a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 13, 2023, the
Company announced that it exercised an option to obtain an exclusive license from Columbia for the development of a portfolio of both
fully human and murine mAbs for the treatment or prophylaxis of SARS-CoV-2 infection, including the Company&#8217;s TNX-3600 and TNX-4100
product candidates, respectively. The licensed mAbs were developed as part of a research collaboration and option agreement between the
Company and Columbia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2023, the
Company granted options to purchase an aggregate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4xieYygDOzj" title="Number of options granted (in shares)">4,394,303
</span>shares of the Company&#8217;s common stock to employees with an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zo56V5eVzWG8" title="Exercise price of options granted (in dollars per share)">0.73</span>,
with a term of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZnnpm2YCgR2" title="Options term">ten
years</span>, vesting <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zsMewqp61N04" title="Vesting percentage::XDX::0.3333"><span style="-sec-ix-hidden: xdx2ixbrl1316">1/3
</span></span>on the first anniversary and <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z5PUZMxXm7df" title="::XDX::0.0278"><span style="-sec-ix-hidden: xdx2ixbrl1317">1/36</span></span><sup>th
</sup>each month thereafter for 24 months. Additionally, the Company granted options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHMOmNAyB7Xb">1,327,500
</span>shares of the Company&#8217;s common stock to certain employees with an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhjkoXv2l6o5">0.91</span>,
with a term of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znxmrHMTDbF4">ten
years</span>, vesting <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zNskKi4uIm9c" title="::XDX::0.3333"><span style="-sec-ix-hidden: xdx2ixbrl1321">1/3
</span></span>on the first anniversary and <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z5OtPNl1UTgb" title="::XDX::0.0278"><span style="-sec-ix-hidden: xdx2ixbrl1322">1/36</span></span><sup>th
</sup>each month thereafter for 24 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to December 31,
2022, the Company sold <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementWithAGPMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znFI14KGqBka" title="Number of shares issued (in shares)">2.1</span>
million shares of common stock under the Sales Agreement with AGP for net proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementWithAGPMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoNSnEIa5xG2" title="Number of shares issued, value">1.4</span>
million.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to December 31,
2022, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCcTZi3jOrr3">0.6</span>
million shares of common stock under the 2022 Purchase Agreement with Lincoln Park for net proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoKIuXTVpvAb">0.4</span>
million.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088932235408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p id="xdx_849_eus-gaap--StockholdersEquityPolicyTextBlock_zOZ3iJLnegD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Reverse
Stock Split</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 16, 2022, the Company
filed a Certificate of Change with the Nevada Secretary of State, effective May 17, 2022. Pursuant to the Certificate of Change, the Company
effected a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20220515__20220516_zaVAYh85aOi5" title="Reverse stock split">1-for-32</span>
reverse stock split of its issued and outstanding shares of common stock. The Company accounted for the reverse stock split on a retrospective
basis pursuant to ASC 260, Earnings Per Share. All authorized, issued and outstanding common stock, common stock warrants, stock option
awards, exercise prices and per share data have been adjusted in these consolidated financial statements, on a retroactive basis, to reflect
the reverse stock split for all periods presented. Authorized preferred stock was not adjusted because of the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and uncertainties</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z85bylyw235c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Risks
and uncertainties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s primary
efforts are devoted to conducting research and development of innovative pharmaceutical and biological products to address public health
challenges. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions
to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated
revenues, and there is no assurance that if its products are approved for sale, that the Company will be able to generate cash flow to
fund operations. In addition, there can be no assurance that the Company&#8217;s research and development will be successfully completed
or that any product will be approved or commercially viable. Moreover, the extent to which COVID-19 impacts the Company&#8217;s operations
will depend on future developments, which are highly uncertain and cannot be predicted with confidence at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_847_eus-gaap--UseOfEstimates_zycH3ZaWPaDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Use
of estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in accordance with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date
of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates. Significant estimates include the assumptions used in the fair value of stock-based compensation and other equity instruments,
and the percent of completion of research and development contracts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeCsYv2kOrg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Cash
Equivalents and Restricted Cash</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers cash
equivalents to be those investments which are highly liquid, readily convertible to cash and have an original maturity of three months
or less when purchased. At December 31, 2022 and December 31, 2021, cash equivalents, which consisted of money market funds, amounted
to $<span id="xdx_90E_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20221231_z94GNFrnaeJl" title="Money market funds">116.3</span> million
and $<span id="xdx_90F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20211231_zgwX3aBLcKJ4">120.4</span> million, respectively.&#160;Restricted
cash, which is included in Other non-current assets on the consolidated balance sheet at December 31, 2022 and December 31, 2021 of approximately
$<span id="xdx_90E_eus-gaap--RestrictedCash_iI_pn3p0_c20221231_znWvNSUUBPEe">241,000</span> and $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn3p0_c20211231_z9QJnmrt7PY9">240,000</span>,
respectively, collateralizes a letter of credit issued in connection with the lease of office space in Chatham, New Jersey and New York
City (see Note 19).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_893_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zm4EC9tOs0H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets
that sum to the total of the same amounts shown in the consolidated statement of cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zOZh4WPjT098" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December
        31, </b></span> <span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z8H3ZnL15rCj" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December
        31, </b></span> <span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzAEg_zJ9wBtsQLBPj" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Cash and cash equivalents</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">120,229</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">178,660</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzAEg_z6lDGQL9tM9h" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Restricted cash</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">241</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">240</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzAEg_z21OclPlbmq2" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">120,470</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">178,900</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zASRSTfMjLX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfbFUYyyXE0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Property
and equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#8217;s estimated
useful life, which ranges from <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MinimumMember_zvv78dahWPi9" title="Estimated useful life of property and equipment">20</span>
to <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MaximumMember_zKg1zF1o4gDi" title="Estimated useful life of property and equipment">30</span>
years for buildings, <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LandImprovementsAndLabEquipmentMember_z3pJHCpx5zxj" title="Estimated useful life of property and equipment">15</span>
years for land improvements, and laboratory equipment, <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKWRPzNxpR49" title="Estimated useful life of property and equipment">three
years</span> for computer assets, <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndAllOtherEquipmentMember_zwoae7YmI5vb" title="Estimated useful life of property and equipment">five
years</span> for furniture and all other equipment and term of lease for leasehold improvements. Depreciation on assets begin when the
asset is available for its intended use. Depreciation and amortization expense for the years ended December 31, 2022, and 2021 was $<span id="xdx_90B_eus-gaap--DepreciationAndAmortization_pp0p0_c20220101__20221231_zXgSwU9KAhij" title="Depreciation and amortization expense">1,253,000</span>&#160;and
$<span id="xdx_90A_eus-gaap--DepreciationAndAmortization_pp0p0_c20210101__20211231_z4wIiMThVXRl" title="Depreciation and amortization expense">50,000</span>,
respectively. The Company&#8217;s property and equipment is located in the United States.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Intangible assets with indefinite lives</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_zPuPuWvi2DZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Intangible
assets with indefinite lives</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2015, the Company purchased certain internet domain rights, which were determined to have an indefinite life. Identifiable intangibles
with indefinite lives, which are included in Other non-current assets on the consolidated balance sheet, are not amortized but are tested
for impairment annually or whenever events or changes in circumstances indicate that their carrying amount may be less than fair value.
As of December 31, 2022, and 2021, the Company believed that no impairment existed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zSRdMtHSVd58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets, lease liability, short term and lease liability, long term in the Company&#8217;s consolidated balance sheets. ROU assets represent
the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental
borrowing rate based on the information available at the transition date and subsequent lease commencement dates in determining the present
value of lease payments. This is the rate the Company would have to pay if borrowing on a collateralized basis over a similar term to
each lease. The operating lease ROU asset excludes lease incentives. The Company&#8217;s lease terms may include options to extend or
terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments made under
operating leases is recognized on a straight-line basis over the lease term.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Convertible Preferred Stock</a></td>
<td class="text"><p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zmlnMQJvq0Cg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Convertible
Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preferred shares subject to
mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity (&#8220;mezzanine&#8221;)
until such time as the conditions are removed or lapse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2B4gU2l2Br9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Research
and Development Costs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company outsources certain
of its research and development efforts and expenses these costs as incurred, including the cost of manufacturing products for testing,
as well as licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual
property acquired has been expensed as research and development costs, as such property is related to particular research and development
projects and had no alternative future uses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company estimates its
expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical
site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which
vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided
under such contracts. The Company accounts for trial expenses according to the timing of various aspects of the trial. The Company determines
accrual estimates taking into account discussion with applicable personnel and outside service providers as to the progress or state of
consummation of trials, or the services completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the course of a clinical
trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of
its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#8217;s
clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party
vendors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><p id="xdx_843_eus-gaap--GovernmentAssistancePolicyTextBlock_zN6kPx5OpuP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Government
Grants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may enter into
arrangements with governmental entities for the purpose of obtaining funding for research and development activities. The Company is reimbursed
for costs incurred that are associated with specified research and development activities included in the grant application approved by
the government authority. The Company classifies government grants&#160;received under these arrangements as a reduction to the related
research and development expense in the same period as the relevant expenses are incurred. In August 2022, the Company announced that
it received a Cooperative Agreement grant from the National Institute on Drug Abuse (&#8220;NIDA&#8221;), part of the National Institutes
of Health, to support the development of its TNX-1300 product candidate for the treatment of cocaine intoxication. No funding was received
during 2022.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwWpE0uggAn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Stock-based
compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All stock-based payments to
employees and to nonemployees for their services, including grants of restricted stock units (&#8220;RSUs&#8221;), and stock options,
are measured at fair value on the grant date and recognized in the consolidated statements of operations as compensation or other expense
over the requisite service period. The Company accounts for share-based awards in accordance with the provisions of the Accounting Standards
Codification (&#8220;ASC&#8221;) 718, Compensation &#8211; Stock Compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzyMnbsscSmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Foreign
Currency Translation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operations of the Company&#8217;s
Canadian subsidiary, Tonix Pharmaceuticals (Canada), Inc., are conducted in local currency, which represents its functional currency.
The U.S. dollar is the functional currency of the other foreign subsidiaries. Balance sheet accounts of the Canadian subsidiary were translated
from foreign currency into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated
at the average rate of exchange prevailing during the period. Translation adjustments resulting from this process were included in accumulated
other comprehensive loss on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zIX4YsfLpDx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Comprehensive
Income (Loss)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Comprehensive income (loss)
is defined as the change in equity of a business during a period from transactions and other events and circumstances from non-owners
sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Other comprehensive income (loss) represents foreign currency translation adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zhcIfHS6aHh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Income
Taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred income tax assets
and liabilities are determined based on the estimated future tax effects of net operating loss and credit carryforwards and temporary
differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted
tax rates. The Company records a valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred
income tax assets will be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes a
tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination
by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements
from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate
settlement. As of December 31, 2022, the Company has not recorded any unrecognized tax benefits. The Company&#8217;s policy is to recognize
interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per Share Data</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zFQaNokTE3O3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Per
Share Data</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The computation of basic and
diluted loss per share for the years ended December 31, 2022 and 2021 excludes potentially dilutive securities when their inclusion would
be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All warrants issued participate
on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors, on the Company&#8217;s
common stock. For purposes of computing EPS, these warrants are considered to participate with common stock in earnings of the Company.
Therefore, the Company calculates basic and diluted EPS using the two-class method. Under the two-class method, net income for the period
is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed
earnings. No income was allocated to the warrants for the years ended December 31, 2022 and 2021, as results of operations were a loss
for the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2Jg2M9UU6Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Potentially
dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 74%"><span style="font-size: 10pt">Warrants to purchase common stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zlJ8KJutPM95" style="width: 10%; text-align: right" title="Potentially dilutive securities excluded from the computation of basic and diluted net loss per share"><span style="font-size: 10pt">19,970</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuPWz6Kcp2Wh" style="width: 10%; text-align: right"><span style="font-size: 10pt">19,970</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Options to purchase common stock</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6EUYcfN9HVe" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2,453,031</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgD9NCZtwzCj" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">805,762</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2pt"><span style="font-size: 10pt">Totals</span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231_zHAwQlRmET47" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,473,001</span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231_zIa3f0mUJkf5" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">825,732</span></td>
    <td style="padding-bottom: 2pt">&#160;</td></tr>
  </table> &#160;

<p id="xdx_8A1_zDCKA9a5gOAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z95j2sM0cFcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Recently
Issued Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB issued
ASU No. 2020-06,&#160;<i>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>,
which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also
removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and
it also simplifies the diluted earnings per share calculation in certain areas. The Company will adopt ASU 2020-06 on January 1, 2023,
under the modified retrospective method of transition. The Company does not anticipate the adoption of ASU 2020-06 to impact the Company&#8217;s
financial position, results of operations or cash flows.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342957-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126960819&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088933126512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows:</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zm4EC9tOs0H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets
that sum to the total of the same amounts shown in the consolidated statement of cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zOZh4WPjT098" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December
        31, </b></span> <span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z8H3ZnL15rCj" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December
        31, </b></span> <span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzAEg_zJ9wBtsQLBPj" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Cash and cash equivalents</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">120,229</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">178,660</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzAEg_z6lDGQL9tM9h" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Restricted cash</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">241</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">240</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzAEg_z21OclPlbmq2" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">120,470</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">178,900</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2Jg2M9UU6Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Potentially
dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 74%"><span style="font-size: 10pt">Warrants to purchase common stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zlJ8KJutPM95" style="width: 10%; text-align: right" title="Potentially dilutive securities excluded from the computation of basic and diluted net loss per share"><span style="font-size: 10pt">19,970</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuPWz6Kcp2Wh" style="width: 10%; text-align: right"><span style="font-size: 10pt">19,970</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Options to purchase common stock</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6EUYcfN9HVe" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2,453,031</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgD9NCZtwzCj" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">805,762</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2pt"><span style="font-size: 10pt">Totals</span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231_zHAwQlRmET47" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">2,473,001</span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231_zIa3f0mUJkf5" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">825,732</span></td>
    <td style="padding-bottom: 2pt">&#160;</td></tr>
  </table> &#160;

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088935990000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment, net consisted of the following (in thousands):</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zOf7u8D41vZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property
and equipment, net consisted of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>December 31</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>December 31</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Property and equipment, net:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Land</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zHMLFED0vKZ" style="width: 10%; text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">8,011</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zd62r56k6sPe" style="width: 10%; text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">7,911</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Land improvements</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandImprovementsMember_zuUm2uRmrLD4" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;79</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Buildings</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zlx4e3nScrYb" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;65,644</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Office furniture and equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_z3peqzBoilr7" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">1,893</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_zIYvvdnZcc4e" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">756</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zk1KcjNgjrci" style="text-align: right"><span style="font-size: 10pt">18,440</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zoDllnstNj0f" style="text-align: right"><span style="font-size: 10pt">347</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt">Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUvRUMMWnSLa" style="text-align: right">34&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWTM21u71Ard" style="text-align: right">23&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt">Construction in progress</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z898pzOA0HUa" style="border-bottom: Black 1pt solid; text-align: right">1,366</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z5mGqFX9ses" style="border-bottom: Black 1pt solid; text-align: right">41,921</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20221231_zlVxml4RMZP1" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">95,467</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20211231_zp28qnw1pEgd" style="text-align: right" title="Property and equipment gross"><span style="font-size: 10pt">50,958</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Less: Accumulated depreciation and
        amortization</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20221231_zO3QDuaVS8sj" style="border-bottom: black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"><span style="font-size: 10pt">(1,653</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20211231_zskr3FQ6LApg" style="border-bottom: black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"><span style="font-size: 10pt">(400</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20221231_z5ehXejrwQZe" style="border-bottom: black 2.5pt double; text-align: right" title="Property and equipment, net"><span style="font-size: 10pt">93,814</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20211231_zZ8F6JpaaKi3" style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">50,558</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942271360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureOtherBalanceSheetInformationAbstract', window );"><strong>Other Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Components of selected captions in the consolidated balance sheets consist of:</a></td>
<td class="text"><p id="xdx_894_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zZmjN0MMISXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Components
of selected captions in the consolidated balance sheets consist of:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20221231_zpaDHLoBqmvl" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zQQsSctglemb" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2022</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2021</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>(in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zpjLBKcG4czh" style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Prepaid expenses and other:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--ContractRelatedPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zgztWqrGeFUg" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Contract-related</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt">8,043</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt">7,726</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidInsurance_i01I_pn3n3_maPEAOAzN1F_zeeRZKyz8ONi" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Insurance</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,275</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,482</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--ProfessionalFeesAndOtherPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zTsWJ0dIya5d" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,230</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,181</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_mtPEAOAzN1F_zoIUDXhnGTW6" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">10,548</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">10,389</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrentAbstract_iB_zTyJXsT5VeN3" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Accrued expenses and other current liabilities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--ContractRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zhTVZS7AmCv3" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Contract-related</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">3,273</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">2,832</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--CompensationAndCompensationRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_ziUVNyyjNLO9" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Compensation and compensation-related</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,645</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,868</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ConstructionInProgressAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zpUJBdKzASj5" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Construction in progress</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,103</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,572</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProfessionalFeesAndOtherAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zaYPfZCqCLr2" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Professional fees and other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">659</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">673</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzLWJ_zGSMNqABDbh8" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">9,680</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">7,945</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureOtherBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureOtherBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942866432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TEMPORARY EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureTemporaryEquityAbstract', window );"><strong>Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--TemporaryEquityTableTextBlock_gL3TETTB-XKNNU_zqJ8jD81ImIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. <span id="xdx_8B6_zFvQt5F2N4C3">The
Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value</span> of approximately $<span id="xdx_905_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIKIp2nesvT2" title="Temporary equity">14.7</span>
million and $<span id="xdx_901_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbHhRLhVAnnb">1.1</span>
million, respectively, as calculated in the following table (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWowwR0zsiRa" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        A</b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrDSnUVt6Mkc" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        B </b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--GrossProceeds_iI_pn3n3_maTECAAzHsD_zECCzRrLMIui" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Gross Proceeds</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">13,300</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">950</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Less:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_msTECAAzHsD_zdXwooGT29Fb" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in"><span style="font-size: 10pt">Preferred stock issuance costs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(844</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(60</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Plus:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_maTECAAzHsD_zSMJovDY5Wai" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 0.25in"><span style="font-size: 10pt">Accretion of carrying value to redemption value</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2,244</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">160</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_mtTECAAzHsD_zyXeIpUafxLf" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Preferred stock subject to possible redemption</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">14,700</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,050</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. The Series A Preferred
Stock and Series B Preferred Stock was recorded at redemption value of approximately $<span id="xdx_902_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbkIMJNKWRmc" title="Temporary equity">26.3</span>
million and $<span id="xdx_903_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zba28qKJdj4l" title="Temporary equity">5.2</span>
million, respectively, as calculated in the following table (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfcNMrfrQp33" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        A</b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLYnqqg39TC6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Series
        B </b></span> <span style="font-size: 10pt"><b>Preferred Stock</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_406_ecustom--GrossProceeds_iI_pn3n3_zhzRGGwpa5R4" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Gross Proceeds</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">23,750</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">4,750</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Less:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_40D_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_zMP4L2SK3nB2" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in"><span style="font-size: 10pt">Preferred stock issuance costs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(1,046</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(209</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Plus:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_407_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_zl7uAw1F24X7" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 0.25in"><span style="font-size: 10pt">Accretion of carrying value to redemption value</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">3,546</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">709</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_409_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_zPI5MPtcZL8c" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Preferred stock subject to possible redemption</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">26,250</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">5,250</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureTemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureTemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088933091296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows:</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhcqcmcrSy7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;A
summary of the stock option&#160;activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted- Average</b></span>
        <span style="font-size: 10pt"><b>Exercise&#160;Price</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span>
        <span style="font-size: 10pt"><b>Remaining&#160;</b></span> <span style="font-size: 10pt"><b>Contractual&#160;Term</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Aggregate</b></span> <span style="font-size: 10pt"><b>Intrinsic</b></span>
        <span style="font-size: 10pt"><b>Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Outstanding at December 31, 2020</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_z8QEF9Ldn2Ae" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="font-size: 10pt">319,179</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zXwgtIPhAWm4" style="width: 12%; text-align: right" title="Outstanding at beginning"><span style="font-size: 10pt">2.93</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zCCVNJiiNH67" style="width: 15%; text-align: right" title="Weighted average remaining contractual term"><span style="font-size: 10pt">9.26</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zV7Y3IVFQpma" style="width: 12%; text-align: right" title="Beginning, Aggregate Intrinsic Value"><span style="font-size: 10pt">131,558</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Grants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zfiIfBvbsM0j" style="text-align: right" title="Grants"><span style="font-size: 10pt">486,639</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zOG86dylxtf8" style="text-align: right" title="Grants"><span style="font-size: 10pt">40.85</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Forfeitures or expirations</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_zKjEzdjLrTjf" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"><span style="font-size: 10pt">(56)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zYFeC7ZW3OO8" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"><span style="font-size: 10pt">149,713.14</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Outstanding at December 31, 2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_z9MNdSsWT9Cj" style="text-align: right" title="Outstanding at end"><span style="font-size: 10pt">805,762</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231_zx8pJKNcryj5" style="text-align: right" title="Outstanding at end"><span style="font-size: 10pt">78.02</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zqr2cpE1k0G6" style="text-align: right" title="Weighted average remaining contractual term"><span style="font-size: 10pt">8.83</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Grants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zVwtcF2kU1L3" style="text-align: right" title="Grants"><span style="font-size: 10pt">1,695,608</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zHGKSimzqy61" style="text-align: right" title="Grants"><span style="font-size: 10pt">12.06</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Forfeitures or expirations</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_zJlazzscnvEb" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"><span style="font-size: 10pt">(48,339</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zeyG8JWfNyvf" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"><span style="font-size: 10pt">255.40</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Outstanding at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_z7anQ9MzTHXe" style="border-bottom: black 2.5pt double; text-align: right" title="Outstanding at end"><span style="font-size: 10pt">2,453,031</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231_z3zk9WvoIDZj" style="border-bottom: black 2.5pt double; text-align: right" title="Outstanding at end"><span style="font-size: 10pt">28.93</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zZDC6CBOJOH2" style="border-bottom: black 2.5pt double; text-align: right" title="Weighted average remaining contractual term"><span style="font-size: 10pt">8.70</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Exercisable at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zctTAL3gFE74" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"><span style="font-size: 10pt">590,582</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231_zmQTYImGOZde" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"><span style="font-size: 10pt">70.82</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zvIpaX7vLUkj" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"><span style="font-size: 10pt">7.64</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows:</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zohZPBPNS2ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows:&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20220101__20221231_zEHr2YtfTD2g" title="Risk-free interest rate - Minimum">1.67</span>%
        to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20220101__20221231_zj83l5FCbyFi" title="Risk-free interest rate - Maximum">3.05</span>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20210101__20211231_z7zgsb62MYJj" title="Risk-free interest rate - Minimum">0.79</span>%
        to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20210101__20211231_zSZG5dwWmFo" title="Risk-free interest rate - Maximum">1.63</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Expected term of option</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zsSuL8lrJP0d" title="Expected term of option">5.5</span>
        to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zXqxUtnnjALi" title="Expected term of option">10</span>
        years</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zzSShwBZa0ci" title="Expected term of option">5.5</span>
        to <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zPPZOPlezia2" title="Expected term of option">6</span>
        years</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Expected stock price volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20220101__20221231_zWx2tt7XZ9ke" title="Expected stock price volatility - minimum">120.32</span>%
        - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20220101__20221231_zw8PbQelsC11" title="Expected stock price volatility - maximum">133.22</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20210101__20211231_zTRrTh3rQWWa" title="Expected stock price volatility - minimum">124.37</span>%
        to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20210101__20211231_ztMZAIvH0p67" title="Expected stock price volatility - maximum">137.73</span>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 64%"><span style="font-size: 10pt">Expected dividend yield</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20220101__20221231_zptWT381s0ac" title="Expected dividend yield">0.0</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20210101__20211231_zelPGnsdwk4c" title="Expected dividend yield">0.0</span>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942866432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS TO PURCHASE COMMON STOCK (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract', window );"><strong>Warrants To Purchase Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zj70aoJ5PEa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zPJrhweMGqxe">The
following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Expiration</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Price</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Outstanding</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zCRzvyBA0lhg" title="Exercise price (in dollars per share)">16.00</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z3WDRbN4k58d" title="Number Outstanding">779</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 52%; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zwvsV3Q0zeg8" title="Expiration date">November
        2024</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zP7p8O46Jl69" title="Exercise price (in dollars per share)">18.24</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zKYtXM5JYcAk" title="Number Outstanding">3,860</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z59AAoLC2HR9" title="Expiration date">February
        2025</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zUzJwgpiox7d" title="Exercise price (in dollars per share)">1,120.00</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zJScLaqvFVii" title="Number Outstanding">15,331</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zgKKtWuc4mU2" title="Expiration Date">December
        2023</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231_z3Ravt8OtHy6" style="border-bottom: black 2.5pt double; text-align: right" title="Number Outstanding"><span style="font-size: 10pt">19,970</span></td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 2pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936011392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands):</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zEJCFisgJnFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zIwIJWsuho85">At
December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 88%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b><span style="text-decoration: underline">Year&#160;Ending&#160;December&#160;31,</span></b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zCCQaPJv0y3" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1eV_zLp5OcVo0Bvg" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 85%"><span style="font-size: 10pt">2023</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">441</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1eV_zDZtryDitfu1" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">164</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1eV_zYuUd8SsbYG3" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">159</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1eV_zxMdw3u8PkT5" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2026</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1eV_zPrq8T8ost92" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">2027</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1eV_zqeTNpUY4Efd" style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">775</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z6yd4QrARzZ" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Included interest</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(15</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zbSFKU1qEcEh" style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">760</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock', window );">Other information related to leases was as follows:</a></td>
<td class="text"><p id="xdx_890_ecustom--SummaryOfOtherInformationRelatedToLeasesTableTextBlock_zZQ884hZvyXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span id="xdx_8B7_z6iTv0Mk00qk">Other
information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Cash paid for amounts included in the
        measurement of lease liabilities:</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31,  2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31,  2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Operating cash flow from operating leases (in
        thousands)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220101__20221231_zPTNP0tOFsq6" title="Operating cash flow from operating leases">598</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--OperatingLeasePayments_c20210101__20211231_zxA2Wr6ED0pj" title="Operating cash flow from operating leases">632</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Weighted Average Remaining Lease Term</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Operating leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_z3HNyxEj2II" title="Weighted average remaining lease term operating leases">2.20</span>
        years</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_znQeP7VQh7pi" title="Weighted average remaining lease term operating leases">2.71</span>
        years</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Weighted Average Discount Rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Operating leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20221231_zWKb6FI3X5N2" title="Weighted average discount rate operating leases">2.19</span></span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20211231_zpE9w2mRcp3" title="Weighted average discount rate operating leases">1.34</span></span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A summary of information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088942864576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of the net loss consist of the following (in thousands):</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zjEhisVJR1K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span id="xdx_8BA_zkrsWCnn7Dhg">Components
of the net loss consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20220101__20221231_ztWF3FRkKBc5" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20211231_zwJljXzTgmm9" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_maNILz5B4_zjwSRzlxvSb8" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><span style="font-size: 10pt">Foreign</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(88,478</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(73,689</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maNILz5B4_zD5HtakXfWIb" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Domestic</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(21,740</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(18,598</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_mtNILz5B4_zWli3YAq4N52" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(110,218</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">(92,287</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company&#8217;s income tax provision is as follows:</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zKciEbcJCate" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zfk7VEREzlRg">A
reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate
the Company&#8217;s income tax provision is as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_499_20220101__20221231_zahNZGVzxMBh" style="text-align: center">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49C_20210101__20211231_zCeZkwzAOsSl" style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>Year Ended December&#160;31,</b></span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maITP_zISccJzeiwI7" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 46%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Statutory federal income tax</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(21.0</span></td>
    <td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">)%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">(21.0</span></td>
    <td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_msITP_zkI4qy92Ybmg" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.6</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">15.0</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_msITP_zPoyg7cYdzSa" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Foreign loss not subject to income tax</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7.0</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7.0</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange_pid_dp_uPure_msITP_zeJ7uWoD4SBb" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Attribute reduction from control change</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4.0</span></td>
    <td style="white-space: nowrap">%<span style="font-size: 10pt"/></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(1.2</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_msITP_zz24AVYh3qHg" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">0.4</span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">%</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">0.2</span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtITP_zBwqkK0JoRN3" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Income Tax Provision</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">0.0</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><span style="font-size: 10pt">%</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt">0.0</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><span style="font-size: 10pt">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands):</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyovoei5FTde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zdnJIiIjnKH8">Deferred
tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands):</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_494_20221231_zhQ3rRxBmsW" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49F_20211231_ztCNS99boig2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><span style="font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsNetAbstract_iB_pn3n3_zR96kMS6Cvmf" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Deferred tax assets/(liabilities):</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGz7el_zqoraYjYLR0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%"><span style="font-size: 10pt">Net operating loss carryforward</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">21,642</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">13,297</span></td>
    <td style="width: 3%">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3n3_maDTAGz7el_zAo1RF4kaHck" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Stock-based compensation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7,353</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5,832</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGz7el_zxFVpCJ1aaFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Other</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,997</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2,285</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGz7el_maDTALNzDL0_zZVByPplpQI9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Total deferred assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">30,992</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">21,414</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzDL0_zwdP8L1COg83" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Valuation allowance</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(30,992</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(21,414</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzDL0_zoryXsKDhVnj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Net deferred tax assets</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1270">&#8212;</span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8212;</span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140089039977600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_WorkingCapital', window );">Working capital</a></td>
<td class="nump">$ 112,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(470,038)<span></span>
</td>
<td class="num">$ (359,820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,229<span></span>
</td>
<td class="nump">$ 178,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of working capital as of reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088932323424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows: (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,229<span></span>
</td>
<td class="nump">$ 178,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">$ 120,470<span></span>
</td>
<td class="nump">$ 178,900<span></span>
</td>
<td class="nump">$ 77,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931577008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows: (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of basic and diluted net loss per share</a></td>
<td class="nump">2,473,001<span></span>
</td>
<td class="nump">825,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of basic and diluted net loss per share</a></td>
<td class="nump">19,970<span></span>
</td>
<td class="nump">19,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of basic and diluted net loss per share</a></td>
<td class="nump">2,453,031<span></span>
</td>
<td class="nump">805,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088941783232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,300,000<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,253,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_LandImprovementsAndLabEquipmentMember', window );">Land Improvements and Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_FurnitureAndAllOtherEquipmentMember', window );">Furniture and All Other Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_LandImprovementsAndLabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_LandImprovementsAndLabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_FurnitureAndAllOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_FurnitureAndAllOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931617200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net consisted of the following (in thousands): (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">$ 95,467<span></span>
</td>
<td class="nump">$ 50,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">93,814<span></span>
</td>
<td class="nump">50,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">8,011<span></span>
</td>
<td class="nump">7,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember', window );">Land Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">65,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_FurnitureAndEquipmentMember', window );">Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">18,440<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">$ 1,366<span></span>
</td>
<td class="nump">$ 41,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_FurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_FurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931987504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 23, 2020 </div>
<div>USD ($) </div>
<div>a</div>
</th>
<th class="th">
<div>Sep. 28, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">MARYLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of facility | ft&#178;</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">MARYLAND | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">MARYLAND | Office furniture and equipment and Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">MASSACHUSETTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of facility | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForConstructionInProcess', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">MASSACHUSETTS | Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">MASSACHUSETTS | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MT', window );">MONTANA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of facility | a</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForConstructionInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForConstructionInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931610896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Components of selected captions in the consolidated balance sheets consist of: (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ContractRelatedPrepaidExpenseCurrent', window );">Contract-related</a></td>
<td class="nump">$ 8,043<span></span>
</td>
<td class="nump">$ 7,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">&#160;</a></td>
<td class="nump">10,548<span></span>
</td>
<td class="nump">10,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ContractRelatedAccruedLiabilitiesCurrent', window );">Contract-related</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">2,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent', window );">Compensation and compensation-related</a></td>
<td class="nump">3,645<span></span>
</td>
<td class="nump">2,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ConstructionInProgressAccruedLiabilitiesCurrent', window );">Construction in progress</a></td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">1,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent', window );">Professional fees and other</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">&#160;</a></td>
<td class="nump">$ 9,680<span></span>
</td>
<td class="nump">$ 7,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of compensation and compensation-related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ConstructionInProgressAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities related to construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ConstructionInProgressAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ContractRelatedAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of contract reltaed expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ContractRelatedAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ContractRelatedPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to contarct within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ContractRelatedPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Professional fees and other reltaed expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of professional fees and other within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936976512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_CashEquivalentsFairValue', window );">Cash equivalents - fair value</a></td>
<td class="nump">$ 116.3<span></span>
</td>
<td class="nump">$ 120.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_CashEquivalentsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_CashEquivalentsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931623888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 13, 2022</div></th>
<th class="th"><div>Dec. 11, 2022</div></th>
<th class="th"><div>Aug. 05, 2022</div></th>
<th class="th"><div>Aug. 03, 2022</div></th>
<th class="th"><div>May 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">1-for-32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">1-for-32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="nump">599,679,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="nump">18,740,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock Issued During Period, Shares, Reverse Stock Splits</a></td>
<td class="nump">130,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088941878816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 26, 2022</div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_GrossProceeds', window );">Gross Proceeds</a></td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="nump">$ 23,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PreferredStockIssuanceCosts', window );">Preferred stock issuance costs</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_AccretionOfCarryingValueToRedemptionValue', window );">Accretion of carrying value to redemption value</a></td>
<td class="nump">2,244<span></span>
</td>
<td class="nump">3,546<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock subject to possible redemption</a></td>
<td class="nump">14,700<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_GrossProceeds', window );">Gross Proceeds</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PreferredStockIssuanceCosts', window );">Preferred stock issuance costs</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_AccretionOfCarryingValueToRedemptionValue', window );">Accretion of carrying value to redemption value</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock subject to possible redemption</a></td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="nump">$ 5,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_AccretionOfCarryingValueToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of Carrying Value to Redemption Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_AccretionOfCarryingValueToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_PreferredStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred stock issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_PreferredStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088928038224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TEMPORARY EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 13, 2022</div></th>
<th class="th"><div>Oct. 26, 2022</div></th>
<th class="th"><div>Aug. 05, 2022</div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 11, 2022</div></th>
<th class="th"><div>Aug. 03, 2022</div></th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>May 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">the
right to cast 2,500 votes per share of Series B Preferred Stock on the December Amendment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
right to cast 2,500 votes per share of Series B Preferred Stock on the Amendment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PercentageOfIssueDiscount', window );">Percentage of issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_StatedValuePerShare', window );">Stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">Preferred
Stock have no voting rights other than the right to vote on the December Amendment and as a class on certain other specified matters<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Preferred
Stock have no voting rights other than the right to vote on the Amendment and as a class on certain other specified matters<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_TemporaryEquityRedemptionPricePercentage', window );">Temporary equity redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_EscrowDepositForOriginalIssueDiscount', window );">Escrow Deposit for Original Issue Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,800,000<span></span>
</td>
<td class="nump">$ 31,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_EscrowDepositForOriginalIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount held in escrow account for original issue discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_EscrowDepositForOriginalIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_PercentageOfIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of original issue discount to stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_PercentageOfIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_StatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated value per share of covertible redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_StatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_TemporaryEquityRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of stated value of temporary equity required for redemption of shares,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_TemporaryEquityRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936973968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative) - Asset Purchase Agreement [Member] - Katana Pharmaceuticals, Inc [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 22, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Consideration paid</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tnxp_KatanaPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tnxp_KatanaPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088941767888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Jun. 11, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member] | Trigemina, Inc.[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment for purchase of assets</a></td>
<td class="nump">$ 824,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_CommonStockValuePerShares', window );">Common stock value (per share) | $ / shares</a></td>
<td class="nump">$ 21.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_AssignmentAndAssumptionAgreementMember', window );">Assignment and Assumption Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment for purchase of assets</a></td>
<td class="nump">$ 250,241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_CommonStockValuePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_CommonStockValuePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tnxp_TrigeminaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tnxp_TrigeminaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_AssignmentAndAssumptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_AssignmentAndAssumptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088941879328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Aug. 19, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member] | TRImaran Pharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment for purchase of assets</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities assumed</a></td>
<td class="nump">68,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">168,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_AchievementPaymentsPayable', window );">Contingent milestone payment obligation</a></td>
<td class="nump">3,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_WSULicenseAgreementMember', window );">WSU License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ReimbursementOfPatentExpenses', window );">Reimbursement of patent expenses</a></td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ContingentMilestonePaymentObligation', window );">Contingent milestone payment obligation</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable', window );">Percentage of royalties payable to any third party for intellectual property rights</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_MaximumPercentageReductionOfRoyaltiesPayable', window );">Maximum percentage reduction of royalties payable</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_AchievementPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount upon the achievement of specified development, regulatory and sales milestones, Tonix also agreed to pay TRImaran and the Selling Shareholders, in restricted stock or cash, at Tonix's option per agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_AchievementPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ContingentMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of obligation to make contingent milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ContingentMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_MaximumPercentageReductionOfRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage by which royalties payable may be reduced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_MaximumPercentageReductionOfRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalties payable to any third party for intellectual property rights which are necessary for the practice of the rights licensed which may reduce royalties payable on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ReimbursementOfPatentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid for reimbursement of patent expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ReimbursementOfPatentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tnxp_TRImaranPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tnxp_TRImaranPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_WSULicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_WSULicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088935834640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LICENSE AGREEMENT WITH CURIA (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 22, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_LicenseAgreementMember', window );">License Agreement [Member] | Curia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment for purchase of assets</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tnxp_CuriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tnxp_CuriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088936789584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LICENSE AGREEMENT WITH OYAGEN (Details Narrative) - License Agreement [Member] - Oya Gen Inc [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 14, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">86,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued | $</a></td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tnxp_OyaGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tnxp_OyaGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931453232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LICENSE AGREEMENT WITH INSERM (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 11, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_InsermLicenseAgreementMember', window );">License Agreement [Member] | Inserm [Member] | Oxytocin-based Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_SalesMilestones', window );">Sale MIlestones</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_SalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestones specified in license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_SalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_InsermLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_InsermLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tnxp_InsermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tnxp_InsermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tnxp_OxytocinBasedTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tnxp_OxytocinBasedTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088927955888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative) - License Agreement [Member] - Trustees Of Columbia University [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 16, 2019</div></th>
<th class="th"><div>May 20, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_LicenseAgreementMember', window );">TFF2 Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable', window );">Percentage of third party royalties payable for reduction in royalties payable</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_MaximumPercentageReductionOfRoyaltiesPayable', window );">Maximum percentage reduction of royalties payable</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ContingentMilestonePaymentObligation', window );">Contingent milestone payment obligation</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PercentagePadOfConsideration', window );">Percentage of pay for consideration</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_LicenseAgreementMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable', window );">Percentage of third party royalties payable for reduction in royalties payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_MaximumPercentageReductionOfRoyaltiesPayable', window );">Maximum percentage reduction of royalties payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ContingentMilestonePaymentObligation', window );">Contingent milestone payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PercentagePadOfConsideration', window );">Percentage of pay for consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ContingentMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of obligation to make contingent milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ContingentMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_MaximumPercentageReductionOfRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage by which royalties payable may be reduced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_MaximumPercentageReductionOfRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalties payable to any third party for intellectual property rights which are necessary for the practice of the rights licensed which may reduce royalties payable on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_PercentagePadOfConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of pay for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_PercentagePadOfConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tnxp_TrusteesOfColumbiaUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tnxp_TrusteesOfColumbiaUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tnxp_TFF2ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tnxp_TFF2ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088927333872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SALE OF COMMON STOCK (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 16, 2022</div></th>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Feb. 08, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Apr. 08, 2020</div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2022Member', window );">Purchase Agreement with Lincoln Park 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2022Member', window );">Purchase Agreement with Lincoln Park 2022 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2022Member', window );">Purchase Agreement with Lincoln Park 2022 [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_CommitmentToPurchaseSharesUnderAgreement', window );">Commitment to purchase shares under agreement</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnParkMember', window );">Purchase Agreement With Lincoln Park [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PercentageOfIssuanceByIssuerOfCommonStock', window );">Percentage of issuance by issuer of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval', window );">Maximum number of shares issued wIthout shareholder approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnParkMember', window );">Purchase Agreement With Lincoln Park [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_CommitmentToPurchaseSharesUnderAgreement', window );">Commitment to purchase shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2021Member', window );">Purchase Agreement with Lincoln Park 2021 [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_CommitmentToPurchaseSharesUnderAgreement', window );">Commitment to purchase shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreement2021Member', window );">Purchase Agreement 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_PercentageOfIssuanceByIssuerOfCommonStock', window );">Percentage of issuance by issuer of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Alliance Global Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.40<span></span>
</td>
<td class="nump">$ 25.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_CashFeePercentage', window );">Cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_UnderwritingDiscount', window );">Underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Expenses from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_SalesAgreementMember', window );">Sales Agreement [Member] | Alliance Global Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_OfferingPricePerAgreement', window );">Offering price per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_SalesAgentCommissionPercentage', window );">Commission to agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_SalesAgreementMember', window );">Sales Agreement [Member] | Alliance Global Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,400,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,300,000<span></span>
</td>
<td class="nump">$ 69,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_SalesAgreementMember', window );">Sales Agreement [Member] | Alliance Global Partners [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_CashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_CashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_CommitmentToPurchaseSharesUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount represents commitment to purchase shares under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_CommitmentToPurchaseSharesUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares issued wIthout shareholder approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_OfferingPricePerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares agreed to be offered under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_OfferingPricePerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_PercentageOfIssuanceByIssuerOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount represents percentage of issuance by issuer of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_PercentageOfIssuanceByIssuerOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_SalesAgentCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales agent commission percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_SalesAgentCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_UnderwritingDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the underwriting discount incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_UnderwritingDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tnxp_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tnxp_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tnxp_AllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tnxp_AllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tnxp_AllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tnxp_AllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931913520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows: (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning</a></td>
<td class="nump">805,762<span></span>
</td>
<td class="nump">319,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 78.02<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 9 months 29 days<span></span>
</td>
<td class="text">9 years 3 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Beginning, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants</a></td>
<td class="nump">1,695,608<span></span>
</td>
<td class="nump">486,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Grants</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="nump">$ 40.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeitures or expirations</a></td>
<td class="num">(48,339)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeitures or expirations</a></td>
<td class="nump">$ 255.40<span></span>
</td>
<td class="nump">$ 149,713.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end</a></td>
<td class="nump">2,453,031<span></span>
</td>
<td class="nump">805,762<span></span>
</td>
<td class="nump">319,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end</a></td>
<td class="nump">$ 28.93<span></span>
</td>
<td class="nump">$ 78.02<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end</a></td>
<td class="nump">590,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end</a></td>
<td class="nump">$ 70.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end</a></td>
<td class="text">7 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088941520192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows: (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate - Minimum</a></td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate - Maximum</a></td>
<td class="nump">3.05%<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility - minimum</a></td>
<td class="nump">120.32%<span></span>
</td>
<td class="nump">124.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility - maximum</a></td>
<td class="nump">133.22%<span></span>
</td>
<td class="nump">137.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of option</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of option</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088925998336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>May 03, 2019</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Jan. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 33.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,215,000<span></span>
</td>
<td class="nump">$ 23,474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">2.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tnxp_IncentiveStockOptionsPlan2019Member', window );">2019 Incentive Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tnxp_IncentiveStockOptionsPlan2020Member', window );">2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tnxp_AmendedAndRestated2020PlanMember', window );">Amended and Restated 2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized', window );">Percentage of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value of common stock at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tnxp_AmendedAndRestated2020PlanMember', window );">Amended and Restated 2020 Plan [Member] | 10% or more Shareholder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value of common stock at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlan2022Member', window );">Employee Stock Purchase Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value of common stock at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlan2022Member', window );">Employee Stock Purchase Plan 2022 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Transfer to additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_AmountReturnToEmployee1', window );">ESPP withholdings returned to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlansMember', window );">Employee Stock Purchase Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_AccumulatedEmployeePayrollDeductions', window );">Accumulated Employee Payroll Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlan2020Member', window );">2020 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,033<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Transfer to additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_AmountReturnToEmployee1', window );">ESPP withholdings returned to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_AccumulatedEmployeePayrollDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated employee payroll deductions related to stock purchase plan as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_AccumulatedEmployeePayrollDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_AmountReturnToEmployee1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount returned to employees of their withholdings under the ESPP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_AmountReturnToEmployee1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tnxp_IncentiveStockOptionsPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tnxp_IncentiveStockOptionsPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tnxp_IncentiveStockOptionsPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tnxp_IncentiveStockOptionsPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tnxp_AmendedAndRestated2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tnxp_AmendedAndRestated2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tnxp_TenPercentOrMoreShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tnxp_TenPercentOrMoreShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tnxp_EmployeeStockPurchasePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088932285520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022: (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number Outstanding</a></td>
<td class="nump">19,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tnxp_Warrant1Member', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number Outstanding</a></td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="text">2024-11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tnxp_Warrant2Member', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number Outstanding</a></td>
<td class="nump">3,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="text">2025-02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tnxp_Warrant3Member', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,120.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number Outstanding</a></td>
<td class="nump">15,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ClassOfWarrantsOrRightExpirationDate', window );">Expiration Date</a></td>
<td class="text">2023-12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ClassOfWarrantsOrRightExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ClassOfWarrantsOrRightExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tnxp_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tnxp_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tnxp_Warrant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tnxp_Warrant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tnxp_Warrant3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tnxp_Warrant3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088927982736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS TO PURCHASE COMMON STOCK (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ExercisePriceOfWarrantsExpired', window );">Exercise price of warrants expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tnxp_Warrant1Member', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ExercisePriceOfWarrantsExpired', window );">Exercise price of warrants expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 687.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tnxp_WarrantsFromFeb2020FinancingMember', window );">Warrants from Feb 2020 Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of exercised warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ExercisePriceOfWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of expired warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ExercisePriceOfWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=tnxp_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=tnxp_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tnxp_WarrantsFromFeb2020FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tnxp_WarrantsFromFeb2020FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088941524240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">&#160;</a></td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Included interest</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">&#160;</a></td>
<td class="nump">$ 760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931551648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other information related to leases was as follows: (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow from operating leases</a></td>
<td class="nump">$ 598<span></span>
</td>
<td class="nump">$ 632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term operating leases</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate operating leases</a></td>
<td class="nump">2.19%<span></span>
</td>
<td class="nump">1.34%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088941504480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">$ 715,000<span></span>
</td>
<td class="nump">$ 914,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">328,000<span></span>
</td>
<td class="nump">467,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">432,000<span></span>
</td>
<td class="nump">489,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=tnxp_NewLeaseArrangementMember', window );">New Operating Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">386,000<span></span>
</td>
<td class="nump">467,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 386,000<span></span>
</td>
<td class="nump">$ 467,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=tnxp_NewLeaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=tnxp_NewLeaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931461312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tnxp_DefinedContributionPlan401KPlanMember', window );">Qualified Defined Contribution Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Employer matching contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Maximum annual contributions per employer</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAdministrativeExpenses', window );">Administrative expenses</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=tnxp_ResearchOrganizationsMember', window );">Research Organizations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Outstanding commitments</a></td>
<td class="nump">58.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=tnxp_ConstructionContractMember', window );">Construction Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Outstanding commitments</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of administrative expense incurred by defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tnxp_DefinedContributionPlan401KPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tnxp_DefinedContributionPlan401KPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=tnxp_ResearchOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=tnxp_ResearchOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=tnxp_ConstructionContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=tnxp_ConstructionContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931551648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of the net loss consist of the following (in thousands): (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">$ (88,478)<span></span>
</td>
<td class="num">$ (73,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">(21,740)<span></span>
</td>
<td class="num">(18,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total</a></td>
<td class="num">$ (110,218)<span></span>
</td>
<td class="num">$ (92,287)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931549840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company&#8217;s income tax provision is as follows: (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign loss not subject to income tax</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange', window );">Attribute reduction from control change</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income Tax Provision</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations related to attribute reduction from control change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088925927328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands): (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets/(liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 21,642<span></span>
</td>
<td class="nump">$ 13,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">7,353<span></span>
</td>
<td class="nump">5,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">2,285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred assets</a></td>
<td class="nump">30,992<span></span>
</td>
<td class="nump">21,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(30,992)<span></span>
</td>
<td class="num">(21,414)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088931817872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign losses</a></td>
<td class="nump">$ 88,478,000<span></span>
</td>
<td class="nump">$ 73,689,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="nump">15,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member] | IRELAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign losses</a></td>
<td class="nump">86,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">165,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member] | BERMUDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign losses</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 71,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent', window );">Utilization NOL (percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Operating loss carryforwards expiration</a></td>
<td class="text">expire
in 20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | NEW JERSEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | MASSACHUSETTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140088928417776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Jan. 02, 2023</div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695,608<span></span>
</td>
<td class="nump">486,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="nump">$ 40.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2022Member', window );">Purchase Agreement with Lincoln Park 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_MinimumBidRequirementPerShare', window );">Minimum bid price requirements NASDAQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tnxp_ConsecutiveBusinessDaysForMinimumBidPrice', window );">Consecutive business days for minimum bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="nump">4,394,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted (in dollars per share)</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">2.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="nump">1,327,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted (in dollars per share)</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">2.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Asset Purchase Agreement [Member] | Healion Bio Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sales Agreement with AGP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement with Lincoln Park 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Existing Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase program amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Existing Share Repurchase Program [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Price of shares repurchased (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Existing Share Repurchase Program [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Price of shares repurchased (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | New Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase program amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Price of shares repurchased (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_ConsecutiveBusinessDaysForMinimumBidPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consecutive business days for minimum bid price under NASDAQ rule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_ConsecutiveBusinessDaysForMinimumBidPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tnxp_MinimumBidRequirementPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum bid price requirement per share for continued listing on the NASDAQ Capital Market.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tnxp_MinimumBidRequirementPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tnxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementWithLincolnPark2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tnxp_EmployeeStockOption1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tnxp_EmployeeStockOption1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tnxp_HealionBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tnxp_HealionBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tnxp_SalesAgreementWithAGPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tnxp_SalesAgreementWithAGPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=tnxp_ExistingShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=tnxp_ExistingShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=tnxp_NewShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=tnxp_NewShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>tnxp-10k_123122_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:tnxp="http://tonixpharma.com/20221231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tnxp-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockIssuanceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockIssuanceJanuary2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceJanuary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockIssuanceJanuary2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceJanuary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockIssuanceFebruary2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceFebruary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockIssuanceFebruary2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceFebruary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockIssuanceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockIssuanceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tnxp:StockIssuanceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-05-152022-05-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <startDate>2022-05-15</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_BuildingMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_BuildingMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LandImprovementsAndLabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:LandImprovementsAndLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FurnitureAndAllOtherEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:FurnitureAndAllOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LandImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_FurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_FurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-10-01_stpr_MD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="From2021-09-222021-10-01_stpr_MD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-22</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="From2021-09-222021-10-01_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-22</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="From2021-09-222021-10-01_stpr_MD_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-22</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="From2021-09-222021-10-01_stpr_MD_custom_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tnxp:OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-22</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-28_stpr_MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-28</instant>
        </period>
    </context>
    <context id="From2020-09-272020-09-28_stpr_MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-27</startDate>
            <endDate>2020-09-28</endDate>
        </period>
    </context>
    <context id="From2020-09-272020-09-28_stpr_MA_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-27</startDate>
            <endDate>2020-09-28</endDate>
        </period>
    </context>
    <context id="From2020-09-272020-09-28_stpr_MA_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-27</startDate>
            <endDate>2020-09-28</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_stpr_MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-09-292022-12-31_stpr_MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-23_stpr_MT">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="From2020-12-212020-12-23_stpr_MT">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-21</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-05-152022-05-16_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-15</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2022-05-14</instant>
        </period>
    </context>
    <context id="AsOf2022-05-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2022-05-16</instant>
        </period>
    </context>
    <context id="AsOf2022-08-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="AsOf2022-08-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2022-08-05</instant>
        </period>
    </context>
    <context id="AsOf2022-12-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2022-12-11</instant>
        </period>
    </context>
    <context id="AsOf2022-12-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <instant>2022-12-13</instant>
        </period>
    </context>
    <context id="From2022-10-242022-10-26_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-26</instant>
        </period>
    </context>
    <context id="From2022-10-242022-10-26_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-26</instant>
        </period>
    </context>
    <context id="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-26</instant>
        </period>
    </context>
    <context id="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="From2022-12-122022-12-13_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="From2022-12-122022-12-13_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="From2022-12-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-06-232022-06-24_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-24</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="From2022-06-232022-06-24_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-24</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-24</endDate>
        </period>
    </context>
    <context id="From2022-08-042022-08-05_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-04</startDate>
            <endDate>2022-08-05</endDate>
        </period>
    </context>
    <context id="From2022-08-042022-08-05_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-04</startDate>
            <endDate>2022-08-05</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2020-12-212020-12-22_custom_AssetPurchaseAgreementMember_custom_KatanaPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:KatanaPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-21</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:TrigeminaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-10</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="From2020-06-102020-06-11_custom_AssignmentAndAssumptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssignmentAndAssumptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-10</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:TRImaranPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-17</startDate>
            <endDate>2019-08-19</endDate>
        </period>
    </context>
    <context id="AsOf2019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:TRImaranPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-19</instant>
        </period>
    </context>
    <context id="From2019-08-172019-08-19_custom_WSULicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:WSULicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-17</startDate>
            <endDate>2019-08-19</endDate>
        </period>
    </context>
    <context id="AsOf2019-08-19_custom_WSULicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:WSULicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-19</instant>
        </period>
    </context>
    <context id="From2020-12-212020-12-22_custom_LicenseAgreementMember_custom_CuriaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:CuriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-21</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="From2021-04-132021-04-14_custom_LicenseAgreementMember_custom_OyaGenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:OyaGenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-14</endDate>
        </period>
    </context>
    <context id="From2021-02-072021-02-11_custom_InsermLicenseAgreementMember_custom_InsermMember_custom_OxytocinBasedTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tnxp:OxytocinBasedTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:InsermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:InsermLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-07</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tnxp:TFF2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:TrusteesOfColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-15</startDate>
            <endDate>2019-09-16</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tnxp:TFF2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:TrusteesOfColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-16</instant>
        </period>
    </context>
    <context id="From2019-05-192019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:TrusteesOfColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-19</startDate>
            <endDate>2019-05-20</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:TrusteesOfColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-20</instant>
        </period>
    </context>
    <context id="From2022-08-152022-08-16_custom_PurchaseAgreementWithLincolnPark2022Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnPark2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-16</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnPark2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnPark2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnPark2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="From2021-12-022021-12-03_custom_PurchaseAgreementWithLincolnParkMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-05-132021-05-14_custom_PurchaseAgreementWithLincolnPark2021Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreementWithLincolnPark2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:PurchaseAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-02-062021-02-08_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-06</startDate>
            <endDate>2021-02-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-08_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-08</instant>
        </period>
    </context>
    <context id="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-07</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-10</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="From2020-04-072020-04-08_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-07</startDate>
            <endDate>2020-04-08</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-13_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tnxp:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-03_custom_IncentiveStockOptionsPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:IncentiveStockOptionsPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-03</instant>
        </period>
    </context>
    <context id="AsOf2020-01-16_custom_IncentiveStockOptionsPlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:IncentiveStockOptionsPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="AsOf2020-05-01_custom_AmendedAndRestated2020PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:AmendedAndRestated2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:AmendedAndRestated2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember_custom_TenPercentOrMoreShareholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:AmendedAndRestated2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tnxp:TenPercentOrMoreShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AmendedAndRestated2020PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:AmendedAndRestated2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_srt_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-05-03_custom_EmployeeStockPurchasePlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-03</instant>
        </period>
    </context>
    <context id="From2019-05-022019-05-03_custom_EmployeeStockPurchasePlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-02</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeeStockPurchasePlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeeStockPurchasePlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-31_custom_EmployeeStockPurchasePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_EmployeeStockPurchasePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_EmployeeStockPurchasePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeeStockPurchasePlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:EmployeeStockPurchasePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_Warrant1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_Warrant1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_Warrant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_Warrant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_Warrant3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_Warrant3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:Warrant3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_WarrantsFromFeb2020FinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:WarrantsFromFeb2020FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_WarrantsFromFeb2020FinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tnxp:WarrantsFromFeb2020FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember964078343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_Warrant1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tnxp:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NewLeaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tnxp:NewLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_NewLeaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tnxp:NewLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ResearchOrganizationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tnxp:ResearchOrganizationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ConstructionContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tnxp:ConstructionContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:DefinedContributionPlan401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DefinedContributionPlan401KPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tnxp:DefinedContributionPlan401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_country_IE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_country_BM">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ForeignCountryMember_country_BM">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ForeignCountryMember_country_IE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_stpr_NJ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_stpr_MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-02_custom_NewShareRepurchaseProgramMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-02</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_NewShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">tnxp:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-02_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-02</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-02_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-02</endDate>
        </period>
    </context>
    <context id="From2023-02-012023-02-02_custom_AssetPurchaseAgreementMember_custom_HealionBioIncMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tnxp:HealionBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tnxp:EmployeeStockOption1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tnxp:EmployeeStockOption1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tnxp:EmployeeStockOption1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-13_custom_SalesAgreementWithAGPMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tnxp:SalesAgreementWithAGPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Acre">
        <measure>utr:acre</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001430306</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0121"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0134"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RedeemablePreferredStockDividends
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues7
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues7
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreement
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:PreferredStockDeemedDividend
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:PreferredStockDeemedDividend
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:PreferredStockDeemedDividend
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues14
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues14
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues15
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues15
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues19
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues19
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement1
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues21
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues21
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:StockIssuedDuringPeriodValueNewIssues21
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <tnxp:CommonStockIssuedToAcquireResearchAndDevelopment
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="xdx2ixbrl0523"
      unitRef="USD">-470038000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="xdx2ixbrl0525"
      unitRef="USD">120229000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="4"
      id="xdx2ixbrl1020"
      unitRef="Pure">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="4"
      id="xdx2ixbrl1021"
      unitRef="Pure">0.0278</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_srt_DirectorMember"
      id="xdx2ixbrl1024">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="xdx2ixbrl1146"
      unitRef="USD">715000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="xdx2ixbrl1148"
      unitRef="USD">760000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="xdx2ixbrl1150"
      unitRef="USD">328000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="xdx2ixbrl1152"
      unitRef="USD">432000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="4"
      id="xdx2ixbrl1316"
      unitRef="Pure">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="4"
      id="xdx2ixbrl1317"
      unitRef="Pure">0.0278</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="4"
      id="xdx2ixbrl1321"
      unitRef="Pure">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="4"
      id="xdx2ixbrl1322"
      unitRef="Pure">0.0278</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-36019</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">TONIX PHARMACEUTICALS HOLDING CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">26-1434750</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">26         Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Chatham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">07928</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">(862)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">799-8599</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common         Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">TNXP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">50022154</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-13" decimals="INF" unitRef="Shares">62539497</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">120229000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">178660000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">10548000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">10389000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">130777000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">189049000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">93814000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">50558000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">715000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">914000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">384000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">379000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">225690000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">240900000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">8068000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">13282000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">9680000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">7945000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">432000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">489000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">18180000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">21716000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">328000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">467000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">18508000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">22183000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <tnxp:PreferredStockSharesDesignated
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</tnxp:PreferredStockSharesDesignated>
    <tnxp:PreferredStockSharesDesignated
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</tnxp:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <tnxp:PreferredStockSharesDesignated
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</tnxp:PreferredStockSharesDesignated>
    <tnxp:PreferredStockSharesDesignated
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</tnxp:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">76478656</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">76478656</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">15638274</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">15638274</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">93741</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">4033</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">76000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">677311000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">578613000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-470038000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-359820000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-167000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-92000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">207182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">218717000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">225690000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">240900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">81876000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">68838000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">30215000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">23474000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">112091000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">92312000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-112091000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-92312000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1873000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">25000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-110218000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-92287000</us-gaap:NetIncomeLoss>
    <us-gaap:RedeemablePreferredStockDividends
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">6659000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-116877000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-92287000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="2"
      unitRef="USDPShares">-3.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-01to2022-12-31"
      decimals="2"
      unitRef="USDPShares">-3.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="2"
      unitRef="USDPShares">-8.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-12-31"
      decimals="2"
      unitRef="USDPShares">-8.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="Shares">35739057</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="Shares">35739057</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="Shares">11387308</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="Shares">11387308</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-110218000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-92287000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-75000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-30000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-110293000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-92317000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15638274</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">578613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-92000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-359820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">218717000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_StockIssuanceNineMember"
      decimals="-3"
      unitRef="USD">3078000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <tnxp:StockIssuedDuringPeriodSharesNewIssues7
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">56357869</tnxp:StockIssuedDuringPeriodSharesNewIssues7>
    <tnxp:StockIssuedDuringPeriodValueNewIssues7
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">56000</tnxp:StockIssuedDuringPeriodValueNewIssues7>
    <tnxp:StockIssuedDuringPeriodValueNewIssues7
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">85237000</tnxp:StockIssuedDuringPeriodValueNewIssues7>
    <tnxp:StockIssuedDuringPeriodValueNewIssues7
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">85293000</tnxp:StockIssuedDuringPeriodValueNewIssues7>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares4
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1000000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares4>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">487000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">488000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreement4>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares2
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2853480</tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares2>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">3000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">8679000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">8682000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreement2>
    <tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">625000</tnxp:IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares>
    <tnxp:PreferredStockDeemedDividend
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">6659000</tnxp:PreferredStockDeemedDividend>
    <tnxp:PreferredStockDeemedDividend
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">6659000</tnxp:PreferredStockDeemedDividend>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4033</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">40000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">40000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">10914000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">10914000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-75000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-75000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-110218000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-110218000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">76478656</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">677311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-470038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">207182000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6568335</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">355237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-267533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">87648000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-12-31_custom_StockIssuanceJanuary2021Member"
      decimals="INF"
      unitRef="USDPShares">25.60</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_custom_StockIssuanceJanuary2021Member"
      decimals="-3"
      unitRef="USD">3096000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <tnxp:StockIssuedDuringPeriodSharesNewIssues14
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1562500</tnxp:StockIssuedDuringPeriodSharesNewIssues14>
    <tnxp:StockIssuedDuringPeriodValueNewIssues14
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</tnxp:StockIssuedDuringPeriodValueNewIssues14>
    <tnxp:StockIssuedDuringPeriodValueNewIssues14
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">36902000</tnxp:StockIssuedDuringPeriodValueNewIssues14>
    <tnxp:StockIssuedDuringPeriodValueNewIssues14
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">36904000</tnxp:StockIssuedDuringPeriodValueNewIssues14>
    <tnxp:WarrantsExercisedPrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">18.24</tnxp:WarrantsExercisedPrice>
    <tnxp:StockIssuedDuringPeriodSharesNewIssues1
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">107</tnxp:StockIssuedDuringPeriodSharesNewIssues1>
    <tnxp:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2000</tnxp:StockIssuedDuringPeriodValueNewIssues1>
    <tnxp:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2000</tnxp:StockIssuedDuringPeriodValueNewIssues1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-12-31_custom_StockIssuanceFebruary2021Member"
      decimals="INF"
      unitRef="USDPShares">38.40</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_custom_StockIssuanceFebruary2021Member"
      decimals="-3"
      unitRef="USD">5002000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <tnxp:StockIssuedDuringPeriodSharesNewIssues15
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1822917</tnxp:StockIssuedDuringPeriodSharesNewIssues15>
    <tnxp:StockIssuedDuringPeriodValueNewIssues15
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</tnxp:StockIssuedDuringPeriodValueNewIssues15>
    <tnxp:StockIssuedDuringPeriodValueNewIssues15
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">64995000</tnxp:StockIssuedDuringPeriodValueNewIssues15>
    <tnxp:StockIssuedDuringPeriodValueNewIssues15
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">64997000</tnxp:StockIssuedDuringPeriodValueNewIssues15>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_custom_StockIssuanceNineMember"
      decimals="-3"
      unitRef="USD">2332000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <tnxp:StockIssuedDuringPeriodSharesNewIssues19
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3445297</tnxp:StockIssuedDuringPeriodSharesNewIssues19>
    <tnxp:StockIssuedDuringPeriodValueNewIssues19
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">4000</tnxp:StockIssuedDuringPeriodValueNewIssues19>
    <tnxp:StockIssuedDuringPeriodValueNewIssues19
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">69288000</tnxp:StockIssuedDuringPeriodValueNewIssues19>
    <tnxp:StockIssuedDuringPeriodValueNewIssues19
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">69292000</tnxp:StockIssuedDuringPeriodValueNewIssues19>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_custom_StockIssuanceTwoMember"
      decimals="-3"
      unitRef="USD">75000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares3
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2016855</tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares3>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">41194000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">41196000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreement3>
    <tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares1
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">40000</tnxp:IssuanceOfCommonStockUnderPurchaseAgreementInShares1>
    <tnxp:StockIssuedDuringPeriodSharesNewIssues21
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">86010</tnxp:StockIssuedDuringPeriodSharesNewIssues21>
    <tnxp:StockIssuedDuringPeriodValueNewIssues21
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">3000000</tnxp:StockIssuedDuringPeriodValueNewIssues21>
    <tnxp:StockIssuedDuringPeriodValueNewIssues21
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">3000000</tnxp:StockIssuedDuringPeriodValueNewIssues21>
    <tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">90909</tnxp:IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5344</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">7899000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">7899000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-30000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-30000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-92287000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-92287000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">578613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-92000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-359820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">218717000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-110218000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-92287000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1253000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">50000</us-gaap:DepreciationDepletionAndAmortization>
    <tnxp:CommonStockIssuedToAcquireResearchAndDevelopment
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">3000000</tnxp:CommonStockIssuedToAcquireResearchAndDevelopment>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">10914000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">7899000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">164000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-518000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-1045000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">3526000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-11000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1205000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1748000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-98053000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-75557000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">48147000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">35307000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-48147000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-35307000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">40000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">96000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">6659000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">40591000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">47250000</us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">3078000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">10505000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">94463000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">212389000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">87844000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">212487000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-74000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-31000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-58430000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">101592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">178900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">77308000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">120470000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">178900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3092000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">6730000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">6659000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NatureOfOperations contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--NatureOfOperations_zlvvG1OMgiy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 &#x2013;
&lt;span id="xdx_821_zacOZmUYMm59"&gt;BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Tonix Pharmaceuticals Holding
Corp., through its wholly owned subsidiary Tonix Pharmaceuticals, Inc. (&#x201c;Tonix Sub&#x201d;), is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing therapeutics and vaccines to treat and prevent human disease and alleviate
suffering. The therapeutics include both small molecules and biologics. All drug product and vaccine candidates are still in development
and none are approved or marketed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The consolidated financial
statements include the accounts of Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiaries, Tonix Sub, Krele LLC, Tonix
Pharmaceuticals (Canada), Inc., Tonix Medicines, Inc., Jenner LLC, Tonix R&amp;amp;D Center LLC, Tonix Pharma Holdings Limited and Tonix Pharma
Limited (collectively hereafter referred to as the &#x201c;Company&#x201d; or &#x201c;Tonix&#x201d;). All intercompany balances and transactions
have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Going
Concern&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying financial
statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization
of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses
from operations and negative cash flows from operating activities. At December 31, 2022, the Company had working capital of approximately
$&lt;span id="xdx_909_ecustom--WorkingCapital_iI_pn5n6_c20221231_zMAchNvNO0be" title="Working capital"&gt;112.6&lt;/span&gt; million. At December
31, 2022, the Company had an accumulated deficit of approximately $&lt;span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3n3_dxL_c20221231_zFcvc05qocU6" title="Accumulated deficit::XDX::-470038"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0523"&gt;470.0
million&lt;/span&gt;&lt;/span&gt;. The Company held cash and cash equivalents of approximately $&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dxL_c20221231_ziIbKtPDeCDk" title="Cash and cash equivalents::XDX::120229"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0525"&gt;120.2
million&lt;/span&gt;&lt;/span&gt; as of December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company believes that
its cash resources at December 31, 2022 and the proceeds that it raised from equity offerings in the first quarter of 2023, net of amounts
paid to repurchase shares in the first quarter of 2023 (See Note 22), will meet its operating and capital expenditure requirements into
the fourth quarter of 2023, but not beyond.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;These factors raise
substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company faces significant challenges and uncertainties
and, as a result, its available capital resources may be consumed more rapidly than currently expected due to changes it may make in its
research and development spending plans. The Company believes that it has the ability to obtain additional funding through public and
private financing and collaborative arrangements with strategic partners to increase the funds available to fund operations. However,
the Company may not be able to raise capital on terms acceptable to the Company. Without additional funds, it may be forced to delay,
scale back or eliminate some of its research and development activities, or other operations and potentially delay product development
in an effort to provide sufficient funds to continue operations. If any of these events occurs, the Company&#x2019;s ability to achieve
its development and commercialization goals would be adversely affected. The financial statements do not include any adjustments that
might result from the outcome of this uncertainty.&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <tnxp:WorkingCapital contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">112600000</tnxp:WorkingCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zm9kn7So8Ni6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
2 &#x2013; &lt;span id="xdx_824_z4KJEYWVH121"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--StockholdersEquityPolicyTextBlock_zOZ3iJLnegD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 16, 2022, the Company
filed a Certificate of Change with the Nevada Secretary of State, effective May 17, 2022. Pursuant to the Certificate of Change, the Company
effected a &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20220515__20220516_zaVAYh85aOi5" title="Reverse stock split"&gt;1-for-32&lt;/span&gt;
reverse stock split of its issued and outstanding shares of common stock. The Company accounted for the reverse stock split on a retrospective
basis pursuant to ASC 260, Earnings Per Share. All authorized, issued and outstanding common stock, common stock warrants, stock option
awards, exercise prices and per share data have been adjusted in these consolidated financial statements, on a retroactive basis, to reflect
the reverse stock split for all periods presented. Authorized preferred stock was not adjusted because of the reverse stock split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z85bylyw235c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Risks
and uncertainties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s primary
efforts are devoted to conducting research and development of innovative pharmaceutical and biological products to address public health
challenges. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions
to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated
revenues, and there is no assurance that if its products are approved for sale, that the Company will be able to generate cash flow to
fund operations. In addition, there can be no assurance that the Company&#x2019;s research and development will be successfully completed
or that any product will be approved or commercially viable. Moreover, the extent to which COVID-19 impacts the Company&#x2019;s operations
will depend on future developments, which are highly uncertain and cannot be predicted with confidence at this time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zycH3ZaWPaDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Use
of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of financial
statements in accordance with Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date
of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates. Significant estimates include the assumptions used in the fair value of stock-based compensation and other equity instruments,
and the percent of completion of research and development contracts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeCsYv2kOrg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Cash
Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company considers cash
equivalents to be those investments which are highly liquid, readily convertible to cash and have an original maturity of three months
or less when purchased. At December 31, 2022 and December 31, 2021, cash equivalents, which consisted of money market funds, amounted
to $&lt;span id="xdx_90E_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20221231_z94GNFrnaeJl" title="Money market funds"&gt;116.3&lt;/span&gt; million
and $&lt;span id="xdx_90F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20211231_zgwX3aBLcKJ4"&gt;120.4&lt;/span&gt; million, respectively.&#160;Restricted
cash, which is included in Other non-current assets on the consolidated balance sheet at December 31, 2022 and December 31, 2021 of approximately
$&lt;span id="xdx_90E_eus-gaap--RestrictedCash_iI_pn3p0_c20221231_znWvNSUUBPEe"&gt;241,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn3p0_c20211231_z9QJnmrt7PY9"&gt;240,000&lt;/span&gt;,
respectively, collateralizes a letter of credit issued in connection with the lease of office space in Chatham, New Jersey and New York
City (see Note 19).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zm4EC9tOs0H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets
that sum to the total of the same amounts shown in the consolidated statement of cash flows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zOZh4WPjT098" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December
        31, &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_z8H3ZnL15rCj" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December
        31, &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzAEg_zJ9wBtsQLBPj" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,229&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;178,660&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzAEg_z6lDGQL9tM9h" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;241&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;240&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzAEg_z21OclPlbmq2" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,470&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;178,900&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zASRSTfMjLX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfbFUYyyXE0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Property
and equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment are
stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#x2019;s estimated
useful life, which ranges from &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MinimumMember_zvv78dahWPi9" title="Estimated useful life of property and equipment"&gt;20&lt;/span&gt;
to &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MaximumMember_zKg1zF1o4gDi" title="Estimated useful life of property and equipment"&gt;30&lt;/span&gt;
years for buildings, &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LandImprovementsAndLabEquipmentMember_z3pJHCpx5zxj" title="Estimated useful life of property and equipment"&gt;15&lt;/span&gt;
years for land improvements, and laboratory equipment, &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKWRPzNxpR49" title="Estimated useful life of property and equipment"&gt;three
years&lt;/span&gt; for computer assets, &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndAllOtherEquipmentMember_zwoae7YmI5vb" title="Estimated useful life of property and equipment"&gt;five
years&lt;/span&gt; for furniture and all other equipment and term of lease for leasehold improvements. Depreciation on assets begin when the
asset is available for its intended use. Depreciation and amortization expense for the years ended December 31, 2022, and 2021 was $&lt;span id="xdx_90B_eus-gaap--DepreciationAndAmortization_pp0p0_c20220101__20221231_zXgSwU9KAhij" title="Depreciation and amortization expense"&gt;1,253,000&lt;/span&gt;&#160;and
$&lt;span id="xdx_90A_eus-gaap--DepreciationAndAmortization_pp0p0_c20210101__20211231_z4wIiMThVXRl" title="Depreciation and amortization expense"&gt;50,000&lt;/span&gt;,
respectively. The Company&#x2019;s property and equipment is located in the United States.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_zPuPuWvi2DZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Intangible
assets with indefinite lives&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2015, the Company purchased certain internet domain rights, which were determined to have an indefinite life. Identifiable intangibles
with indefinite lives, which are included in Other non-current assets on the consolidated balance sheet, are not amortized but are tested
for impairment annually or whenever events or changes in circumstances indicate that their carrying amount may be less than fair value.
As of December 31, 2022, and 2021, the Company believed that no impairment existed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zSRdMtHSVd58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determines if
an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;)
assets, lease liability, short term and lease liability, long term in the Company&#x2019;s consolidated balance sheets. ROU assets represent
the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses an incremental
borrowing rate based on the information available at the transition date and subsequent lease commencement dates in determining the present
value of lease payments. This is the rate the Company would have to pay if borrowing on a collateralized basis over a similar term to
each lease. The operating lease ROU asset excludes lease incentives. The Company&#x2019;s lease terms may include options to extend or
terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments made under
operating leases is recognized on a straight-line basis over the lease term.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zmlnMQJvq0Cg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Convertible
Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Preferred shares subject to
mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity (&#x201c;mezzanine&#x201d;)
until such time as the conditions are removed or lapse.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2B4gU2l2Br9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Research
and Development Costs&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company outsources certain
of its research and development efforts and expenses these costs as incurred, including the cost of manufacturing products for testing,
as well as licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual
property acquired has been expensed as research and development costs, as such property is related to particular research and development
projects and had no alternative future uses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company estimates its
expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical
site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which
vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided
under such contracts. The Company accounts for trial expenses according to the timing of various aspects of the trial. The Company determines
accrual estimates taking into account discussion with applicable personnel and outside service providers as to the progress or state of
consummation of trials, or the services completed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the course of a clinical
trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of
its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#x2019;s
clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party
vendors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--GovernmentAssistancePolicyTextBlock_zN6kPx5OpuP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Government
Grants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the Company may enter into
arrangements with governmental entities for the purpose of obtaining funding for research and development activities. The Company is reimbursed
for costs incurred that are associated with specified research and development activities included in the grant application approved by
the government authority. The Company classifies government grants&#160;received under these arrangements as a reduction to the related
research and development expense in the same period as the relevant expenses are incurred. In August 2022, the Company announced that
it received a Cooperative Agreement grant from the National Institute on Drug Abuse (&#x201c;NIDA&#x201d;), part of the National Institutes
of Health, to support the development of its TNX-1300 product candidate for the treatment of cocaine intoxication. No funding was received
during 2022.&lt;/p&gt;

&lt;p id="xdx_856_zD4GjP9ASqW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwWpE0uggAn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Stock-based
compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All stock-based payments to
employees and to nonemployees for their services, including grants of restricted stock units (&#x201c;RSUs&#x201d;), and stock options,
are measured at fair value on the grant date and recognized in the consolidated statements of operations as compensation or other expense
over the requisite service period. The Company accounts for share-based awards in accordance with the provisions of the Accounting Standards
Codification (&#x201c;ASC&#x201d;) 718, Compensation &#x2013; Stock Compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzyMnbsscSmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Operations of the Company&#x2019;s
Canadian subsidiary, Tonix Pharmaceuticals (Canada), Inc., are conducted in local currency, which represents its functional currency.
The U.S. dollar is the functional currency of the other foreign subsidiaries. Balance sheet accounts of the Canadian subsidiary were translated
from foreign currency into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated
at the average rate of exchange prevailing during the period. Translation adjustments resulting from this process were included in accumulated
other comprehensive loss on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zIX4YsfLpDx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Comprehensive
Income (Loss)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Comprehensive income (loss)
is defined as the change in equity of a business during a period from transactions and other events and circumstances from non-owners
sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Other comprehensive income (loss) represents foreign currency translation adjustments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zhcIfHS6aHh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Income
Taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred income tax assets
and liabilities are determined based on the estimated future tax effects of net operating loss and credit carryforwards and temporary
differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted
tax rates. The Company records a valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred
income tax assets will be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes a
tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination
by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements
from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate
settlement. As of December 31, 2022, the Company has not recorded any unrecognized tax benefits. The Company&#x2019;s policy is to recognize
interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zFQaNokTE3O3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Per
Share Data&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The computation of basic and
diluted loss per share for the years ended December 31, 2022 and 2021 excludes potentially dilutive securities when their inclusion would
be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All warrants issued participate
on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors, on the Company&#x2019;s
common stock. For purposes of computing EPS, these warrants are considered to participate with common stock in earnings of the Company.
Therefore, the Company calculates basic and diluted EPS using the two-class method. Under the two-class method, net income for the period
is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed
earnings. No income was allocated to the warrants for the years ended December 31, 2022 and 2021, as results of operations were a loss
for the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2Jg2M9UU6Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Potentially
dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%"&gt;&lt;span style="font-size: 10pt"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zlJ8KJutPM95" style="width: 10%; text-align: right" title="Potentially dilutive securities excluded from the computation of basic and diluted net loss per share"&gt;&lt;span style="font-size: 10pt"&gt;19,970&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuPWz6Kcp2Wh" style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;19,970&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6EUYcfN9HVe" style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,453,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgD9NCZtwzCj" style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;805,762&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&lt;span style="font-size: 10pt"&gt;Totals&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231_zHAwQlRmET47" style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,473,001&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231_zIa3f0mUJkf5" style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;825,732&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt; &#160;

&lt;p id="xdx_8A1_zDCKA9a5gOAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z95j2sM0cFcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the FASB issued
ASU No. 2020-06,&#160;&lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;,
which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also
removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and
it also simplifies the diluted earnings per share calculation in certain areas. The Company will adopt ASU 2020-06 on January 1, 2023,
under the modified retrospective method of transition. The Company does not anticipate the adoption of ASU 2020-06 to impact the Company&#x2019;s
financial position, results of operations or cash flows.&lt;/p&gt;

&lt;p id="xdx_85E_zpPf80juRY08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--StockholdersEquityPolicyTextBlock_zOZ3iJLnegD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 16, 2022, the Company
filed a Certificate of Change with the Nevada Secretary of State, effective May 17, 2022. Pursuant to the Certificate of Change, the Company
effected a &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20220515__20220516_zaVAYh85aOi5" title="Reverse stock split"&gt;1-for-32&lt;/span&gt;
reverse stock split of its issued and outstanding shares of common stock. The Company accounted for the reverse stock split on a retrospective
basis pursuant to ASC 260, Earnings Per Share. All authorized, issued and outstanding common stock, common stock warrants, stock option
awards, exercise prices and per share data have been adjusted in these consolidated financial statements, on a retroactive basis, to reflect
the reverse stock split for all periods presented. Authorized preferred stock was not adjusted because of the reverse stock split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-05-152022-05-16">1-for-32</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z85bylyw235c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Risks
and uncertainties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s primary
efforts are devoted to conducting research and development of innovative pharmaceutical and biological products to address public health
challenges. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions
to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated
revenues, and there is no assurance that if its products are approved for sale, that the Company will be able to generate cash flow to
fund operations. In addition, there can be no assurance that the Company&#x2019;s research and development will be successfully completed
or that any product will be approved or commercially viable. Moreover, the extent to which COVID-19 impacts the Company&#x2019;s operations
will depend on future developments, which are highly uncertain and cannot be predicted with confidence at this time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zycH3ZaWPaDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Use
of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of financial
statements in accordance with Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date
of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates. Significant estimates include the assumptions used in the fair value of stock-based compensation and other equity instruments,
and the percent of completion of research and development contracts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeCsYv2kOrg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Cash
Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company considers cash
equivalents to be those investments which are highly liquid, readily convertible to cash and have an original maturity of three months
or less when purchased. At December 31, 2022 and December 31, 2021, cash equivalents, which consisted of money market funds, amounted
to $&lt;span id="xdx_90E_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20221231_z94GNFrnaeJl" title="Money market funds"&gt;116.3&lt;/span&gt; million
and $&lt;span id="xdx_90F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_uUSD_c20211231_zgwX3aBLcKJ4"&gt;120.4&lt;/span&gt; million, respectively.&#160;Restricted
cash, which is included in Other non-current assets on the consolidated balance sheet at December 31, 2022 and December 31, 2021 of approximately
$&lt;span id="xdx_90E_eus-gaap--RestrictedCash_iI_pn3p0_c20221231_znWvNSUUBPEe"&gt;241,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn3p0_c20211231_z9QJnmrt7PY9"&gt;240,000&lt;/span&gt;,
respectively, collateralizes a letter of credit issued in connection with the lease of office space in Chatham, New Jersey and New York
City (see Note 19).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zm4EC9tOs0H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets
that sum to the total of the same amounts shown in the consolidated statement of cash flows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zOZh4WPjT098" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December
        31, &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_z8H3ZnL15rCj" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December
        31, &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzAEg_zJ9wBtsQLBPj" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,229&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;178,660&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzAEg_z6lDGQL9tM9h" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;241&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;240&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzAEg_z21OclPlbmq2" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,470&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;178,900&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zASRSTfMjLX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">116300000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">120400000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">241000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">240000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zm4EC9tOs0H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets
that sum to the total of the same amounts shown in the consolidated statement of cash flows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zOZh4WPjT098" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December
        31, &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_z8H3ZnL15rCj" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December
        31, &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzAEg_zJ9wBtsQLBPj" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,229&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;178,660&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzAEg_z6lDGQL9tM9h" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;241&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;240&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzAEg_z21OclPlbmq2" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,470&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;178,900&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">120229000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">178660000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">241000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">240000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">120470000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">178900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfbFUYyyXE0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Property
and equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment are
stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#x2019;s estimated
useful life, which ranges from &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MinimumMember_zvv78dahWPi9" title="Estimated useful life of property and equipment"&gt;20&lt;/span&gt;
to &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember__srt--RangeAxis__srt--MaximumMember_zKg1zF1o4gDi" title="Estimated useful life of property and equipment"&gt;30&lt;/span&gt;
years for buildings, &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LandImprovementsAndLabEquipmentMember_z3pJHCpx5zxj" title="Estimated useful life of property and equipment"&gt;15&lt;/span&gt;
years for land improvements, and laboratory equipment, &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKWRPzNxpR49" title="Estimated useful life of property and equipment"&gt;three
years&lt;/span&gt; for computer assets, &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndAllOtherEquipmentMember_zwoae7YmI5vb" title="Estimated useful life of property and equipment"&gt;five
years&lt;/span&gt; for furniture and all other equipment and term of lease for leasehold improvements. Depreciation on assets begin when the
asset is available for its intended use. Depreciation and amortization expense for the years ended December 31, 2022, and 2021 was $&lt;span id="xdx_90B_eus-gaap--DepreciationAndAmortization_pp0p0_c20220101__20221231_zXgSwU9KAhij" title="Depreciation and amortization expense"&gt;1,253,000&lt;/span&gt;&#160;and
$&lt;span id="xdx_90A_eus-gaap--DepreciationAndAmortization_pp0p0_c20210101__20211231_z4wIiMThVXRl" title="Depreciation and amortization expense"&gt;50,000&lt;/span&gt;,
respectively. The Company&#x2019;s property and equipment is located in the United States.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_BuildingMember_srt_MinimumMember">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_BuildingMember_srt_MaximumMember">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_custom_LandImprovementsAndLabEquipmentMember">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_custom_FurnitureAndAllOtherEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1253000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">50000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_zPuPuWvi2DZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Intangible
assets with indefinite lives&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2015, the Company purchased certain internet domain rights, which were determined to have an indefinite life. Identifiable intangibles
with indefinite lives, which are included in Other non-current assets on the consolidated balance sheet, are not amortized but are tested
for impairment annually or whenever events or changes in circumstances indicate that their carrying amount may be less than fair value.
As of December 31, 2022, and 2021, the Company believed that no impairment existed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zSRdMtHSVd58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determines if
an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;)
assets, lease liability, short term and lease liability, long term in the Company&#x2019;s consolidated balance sheets. ROU assets represent
the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses an incremental
borrowing rate based on the information available at the transition date and subsequent lease commencement dates in determining the present
value of lease payments. This is the rate the Company would have to pay if borrowing on a collateralized basis over a similar term to
each lease. The operating lease ROU asset excludes lease incentives. The Company&#x2019;s lease terms may include options to extend or
terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments made under
operating leases is recognized on a straight-line basis over the lease term.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zmlnMQJvq0Cg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Convertible
Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Preferred shares subject to
mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity (&#x201c;mezzanine&#x201d;)
until such time as the conditions are removed or lapse.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2B4gU2l2Br9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Research
and Development Costs&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company outsources certain
of its research and development efforts and expenses these costs as incurred, including the cost of manufacturing products for testing,
as well as licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual
property acquired has been expensed as research and development costs, as such property is related to particular research and development
projects and had no alternative future uses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company estimates its
expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical
site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which
vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided
under such contracts. The Company accounts for trial expenses according to the timing of various aspects of the trial. The Company determines
accrual estimates taking into account discussion with applicable personnel and outside service providers as to the progress or state of
consummation of trials, or the services completed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the course of a clinical
trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of
its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#x2019;s
clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party
vendors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_843_eus-gaap--GovernmentAssistancePolicyTextBlock_zN6kPx5OpuP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Government
Grants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the Company may enter into
arrangements with governmental entities for the purpose of obtaining funding for research and development activities. The Company is reimbursed
for costs incurred that are associated with specified research and development activities included in the grant application approved by
the government authority. The Company classifies government grants&#160;received under these arrangements as a reduction to the related
research and development expense in the same period as the relevant expenses are incurred. In August 2022, the Company announced that
it received a Cooperative Agreement grant from the National Institute on Drug Abuse (&#x201c;NIDA&#x201d;), part of the National Institutes
of Health, to support the development of its TNX-1300 product candidate for the treatment of cocaine intoxication. No funding was received
during 2022.&lt;/p&gt;

</us-gaap:GovernmentAssistancePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwWpE0uggAn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Stock-based
compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All stock-based payments to
employees and to nonemployees for their services, including grants of restricted stock units (&#x201c;RSUs&#x201d;), and stock options,
are measured at fair value on the grant date and recognized in the consolidated statements of operations as compensation or other expense
over the requisite service period. The Company accounts for share-based awards in accordance with the provisions of the Accounting Standards
Codification (&#x201c;ASC&#x201d;) 718, Compensation &#x2013; Stock Compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzyMnbsscSmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Operations of the Company&#x2019;s
Canadian subsidiary, Tonix Pharmaceuticals (Canada), Inc., are conducted in local currency, which represents its functional currency.
The U.S. dollar is the functional currency of the other foreign subsidiaries. Balance sheet accounts of the Canadian subsidiary were translated
from foreign currency into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated
at the average rate of exchange prevailing during the period. Translation adjustments resulting from this process were included in accumulated
other comprehensive loss on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zIX4YsfLpDx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Comprehensive
Income (Loss)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Comprehensive income (loss)
is defined as the change in equity of a business during a period from transactions and other events and circumstances from non-owners
sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Other comprehensive income (loss) represents foreign currency translation adjustments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zhcIfHS6aHh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Income
Taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred income tax assets
and liabilities are determined based on the estimated future tax effects of net operating loss and credit carryforwards and temporary
differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted
tax rates. The Company records a valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred
income tax assets will be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes a
tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination
by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements
from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate
settlement. As of December 31, 2022, the Company has not recorded any unrecognized tax benefits. The Company&#x2019;s policy is to recognize
interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zFQaNokTE3O3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Per
Share Data&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The computation of basic and
diluted loss per share for the years ended December 31, 2022 and 2021 excludes potentially dilutive securities when their inclusion would
be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All warrants issued participate
on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors, on the Company&#x2019;s
common stock. For purposes of computing EPS, these warrants are considered to participate with common stock in earnings of the Company.
Therefore, the Company calculates basic and diluted EPS using the two-class method. Under the two-class method, net income for the period
is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed
earnings. No income was allocated to the warrants for the years ended December 31, 2022 and 2021, as results of operations were a loss
for the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2Jg2M9UU6Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Potentially
dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%"&gt;&lt;span style="font-size: 10pt"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zlJ8KJutPM95" style="width: 10%; text-align: right" title="Potentially dilutive securities excluded from the computation of basic and diluted net loss per share"&gt;&lt;span style="font-size: 10pt"&gt;19,970&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuPWz6Kcp2Wh" style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;19,970&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6EUYcfN9HVe" style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,453,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgD9NCZtwzCj" style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;805,762&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&lt;span style="font-size: 10pt"&gt;Totals&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231_zHAwQlRmET47" style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,473,001&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231_zIa3f0mUJkf5" style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;825,732&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt; &#160;

&lt;p id="xdx_8A1_zDCKA9a5gOAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2Jg2M9UU6Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Potentially
dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%"&gt;&lt;span style="font-size: 10pt"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zlJ8KJutPM95" style="width: 10%; text-align: right" title="Potentially dilutive securities excluded from the computation of basic and diluted net loss per share"&gt;&lt;span style="font-size: 10pt"&gt;19,970&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuPWz6Kcp2Wh" style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;19,970&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6EUYcfN9HVe" style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,453,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgD9NCZtwzCj" style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;805,762&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&lt;span style="font-size: 10pt"&gt;Totals&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20221231_zHAwQlRmET47" style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,473,001&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231_zIa3f0mUJkf5" style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;825,732&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt; &#160;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">19970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">19970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2453031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">805762</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">2473001</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">825732</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z95j2sM0cFcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the FASB issued
ASU No. 2020-06,&#160;&lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;,
which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also
removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and
it also simplifies the diluted earnings per share calculation in certain areas. The Company will adopt ASU 2020-06 on January 1, 2023,
under the modified retrospective method of transition. The Company does not anticipate the adoption of ASU 2020-06 to impact the Company&#x2019;s
financial position, results of operations or cash flows.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zQaOV5iXQO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_823_zP24ztM0VfCf"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zOf7u8D41vZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property
and equipment, net consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Property and equipment, net:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Land&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zHMLFED0vKZ" style="width: 10%; text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;8,011&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zd62r56k6sPe" style="width: 10%; text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;7,911&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandImprovementsMember_zuUm2uRmrLD4" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;79&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Buildings&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zlx4e3nScrYb" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;65,644&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_z3peqzBoilr7" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;1,893&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_zIYvvdnZcc4e" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;756&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zk1KcjNgjrci" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;18,440&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zoDllnstNj0f" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;347&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUvRUMMWnSLa" style="text-align: right"&gt;34&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWTM21u71Ard" style="text-align: right"&gt;23&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"&gt;Construction in progress&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z898pzOA0HUa" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,366&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z5mGqFX9ses" style="border-bottom: Black 1pt solid; text-align: right"&gt;41,921&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20221231_zlVxml4RMZP1" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;95,467&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20211231_zp28qnw1pEgd" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;50,958&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: Accumulated depreciation and
        amortization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20221231_zO3QDuaVS8sj" style="border-bottom: black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"&gt;&lt;span style="font-size: 10pt"&gt;(1,653&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20211231_zskr3FQ6LApg" style="border-bottom: black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"&gt;&lt;span style="font-size: 10pt"&gt;(400&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20221231_z5ehXejrwQZe" style="border-bottom: black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;&lt;span style="font-size: 10pt"&gt;93,814&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20211231_zZ8F6JpaaKi3" style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;50,558&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zTrF2efF0RR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On October 1, 2021, the Company
completed the acquisition of its approximately &lt;span id="xdx_907_eus-gaap--AreaOfLand_iI_uSquareFoot_c20211001__srt--StatementGeographicalAxis__stpr--MD_zJhEfFlX47J3"&gt;45,000&lt;/span&gt;
square foot research and development facility in Frederick, Maryland totaling $&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__srt--StatementGeographicalAxis__stpr--MD_zGTnNphCZUne" title="Facility purchase"&gt;17.5&lt;/span&gt;
million, to process development activities. Of the total purchase price, $&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zqQMALPhZ0G5"&gt;2.1&lt;/span&gt;
million was allocated to the value of land acquired, and $&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__srt--StatementGeographicalAxis__stpr--MD__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zL3PHz4OELl6"&gt;13.9&lt;/span&gt;
million was allocated to buildings, and approximately $&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210922__20211001__srt--StatementGeographicalAxis__stpr--MD__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember_zYMDqvGEkVS6"&gt;1.5&lt;/span&gt;
million was allocated to Office furniture and equipment and Laboratory equipment. During the year ended December 31, 2022, the
assets became ready for the intended use and were placed in service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On September 28, 2020, the
Company completed the purchase of its approximately &lt;span id="xdx_90E_eus-gaap--AreaOfLand_iI_uSquareFoot_c20200928__srt--StatementGeographicalAxis__stpr--MA_z5FNmA5cl1ek" title="Area of facility"&gt;45,000&lt;/span&gt;
square foot facility in Dartmouth, Massachusetts for $&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pdn6_c20200927__20200928__srt--StatementGeographicalAxis__stpr--MA_zfeAhKq37Bxg"&gt;4&lt;/span&gt;.0
million, to house its new Advanced Development Center for the development and manufacturing of vaccines. Of the total purchase price,
$&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20200927__20200928__srt--StatementGeographicalAxis__stpr--MA__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zDQthcN0c6I"&gt;1.2&lt;/span&gt;
million was allocated to the value of land acquired, and $&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20200927__20200928__srt--StatementGeographicalAxis__stpr--MA__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zf78cHURNsDa"&gt;2.8&lt;/span&gt;
million was allocated to buildings. Additionally, the Company incurred approximately $&lt;span id="xdx_90D_eus-gaap--PaymentsForConstructionInProcess_pn5n6_c20220101__20221231__srt--StatementGeographicalAxis__stpr--MA_zt9VFH98OS19" title="Costs incurred"&gt;38.8&lt;/span&gt;
million of costs during the year ended December 31, 2022, bringing total costs incurred-to-date to $&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquireProductiveAssets_pn5n6_c20200929__20221231__srt--StatementGeographicalAxis__stpr--MA_zMg8c8uITYSl" title="Total costs incurred"&gt;61.6&lt;/span&gt;
million, of which the majority relates to the build-out of the facility. During the year ended December 31, 2022, the assets became
ready for the intended use and were placed in service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 23, 2020, the
Company completed the purchase of its approximately &lt;span id="xdx_90A_eus-gaap--AreaOfLand_iI_uAcre_c20201223__srt--StatementGeographicalAxis__stpr--MT_zjpm3F5q37Dh"&gt;44&lt;/span&gt;-acre
site in Hamilton, Montana for $&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20201221__20201223__srt--StatementGeographicalAxis__stpr--MT_z3ffXCrIbzU7"&gt;4.5&lt;/span&gt;
million, for the construction of a vaccine development and commercial scale manufacturing facility. As of December 31, 2022, the
asset was not ready for its intended use.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zOf7u8D41vZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property
and equipment, net consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Property and equipment, net:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Land&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zHMLFED0vKZ" style="width: 10%; text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;8,011&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zd62r56k6sPe" style="width: 10%; text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;7,911&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandImprovementsMember_zuUm2uRmrLD4" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;79&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Buildings&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zlx4e3nScrYb" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;65,644&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_z3peqzBoilr7" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;1,893&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndEquipmentMember_zIYvvdnZcc4e" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;756&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zk1KcjNgjrci" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;18,440&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zoDllnstNj0f" style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;347&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUvRUMMWnSLa" style="text-align: right"&gt;34&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWTM21u71Ard" style="text-align: right"&gt;23&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"&gt;Construction in progress&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z898pzOA0HUa" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,366&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z5mGqFX9ses" style="border-bottom: Black 1pt solid; text-align: right"&gt;41,921&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20221231_zlVxml4RMZP1" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;95,467&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPE_c20211231_zp28qnw1pEgd" style="text-align: right" title="Property and equipment gross"&gt;&lt;span style="font-size: 10pt"&gt;50,958&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: Accumulated depreciation and
        amortization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20221231_zO3QDuaVS8sj" style="border-bottom: black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"&gt;&lt;span style="font-size: 10pt"&gt;(1,653&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPE_c20211231_zskr3FQ6LApg" style="border-bottom: black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"&gt;&lt;span style="font-size: 10pt"&gt;(400&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20221231_z5ehXejrwQZe" style="border-bottom: black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;&lt;span style="font-size: 10pt"&gt;93,814&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPE_c20211231_zZ8F6JpaaKi3" style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;50,558&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LandMember"
      decimals="-3"
      unitRef="USD">8011000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LandMember"
      decimals="-3"
      unitRef="USD">7911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LandImprovementsMember"
      decimals="-3"
      unitRef="USD">79000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_BuildingMember"
      decimals="-3"
      unitRef="USD">65644000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_FurnitureAndEquipmentMember"
      decimals="-3"
      unitRef="USD">1893000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_FurnitureAndEquipmentMember"
      decimals="-3"
      unitRef="USD">756000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_LaboratoryEquipmentMember"
      decimals="-3"
      unitRef="USD">18440000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentMember"
      decimals="-3"
      unitRef="USD">347000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      unitRef="USD">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      unitRef="USD">23000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      unitRef="USD">1366000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      unitRef="USD">41921000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">95467000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">50958000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1653000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">93814000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">50558000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AreaOfLand
      contextRef="AsOf2021-10-01_stpr_MD"
      decimals="INF"
      unitRef="SquareFoot">45000</us-gaap:AreaOfLand>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="From2021-09-222021-10-01_stpr_MD"
      decimals="-5"
      unitRef="USD">17500000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="From2021-09-222021-10-01_us-gaap_LandMember"
      decimals="-5"
      unitRef="USD">2100000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="From2021-09-222021-10-01_stpr_MD_us-gaap_BuildingMember"
      decimals="-5"
      unitRef="USD">13900000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="From2021-09-222021-10-01_stpr_MD_custom_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember"
      decimals="-5"
      unitRef="USD">1500000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:AreaOfLand
      contextRef="AsOf2020-09-28_stpr_MA"
      decimals="INF"
      unitRef="SquareFoot">45000</us-gaap:AreaOfLand>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="From2020-09-272020-09-28_stpr_MA"
      decimals="0"
      unitRef="USD">4000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="From2020-09-272020-09-28_stpr_MA_us-gaap_LandMember"
      decimals="-5"
      unitRef="USD">1200000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="From2020-09-272020-09-28_stpr_MA_us-gaap_BuildingMember"
      decimals="-5"
      unitRef="USD">2800000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PaymentsForConstructionInProcess
      contextRef="From2022-01-012022-12-31_stpr_MA"
      decimals="-5"
      unitRef="USD">38800000</us-gaap:PaymentsForConstructionInProcess>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2020-09-292022-12-31_stpr_MA"
      decimals="-5"
      unitRef="USD">61600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AreaOfLand
      contextRef="AsOf2020-12-23_stpr_MT"
      decimals="INF"
      unitRef="Acre">44</us-gaap:AreaOfLand>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="From2020-12-212020-12-23_stpr_MT"
      decimals="-5"
      unitRef="USD">4500000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <tnxp:OtherBalanceSheetInformationDiclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_804_ecustom--OtherBalanceSheetInformationDiclosureTextBlock_zEexXqbesbWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_829_ztlsn9Wh5Ni1"&gt;OTHER BALANCE SHEET INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zZmjN0MMISXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Components
of selected captions in the consolidated balance sheets consist of:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20221231_zpaDHLoBqmvl" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zQQsSctglemb" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zpjLBKcG4czh" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Prepaid expenses and other:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ContractRelatedPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zgztWqrGeFUg" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Contract-related&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,043&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,726&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidInsurance_i01I_pn3n3_maPEAOAzN1F_zeeRZKyz8ONi" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Insurance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,275&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,482&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ProfessionalFeesAndOtherPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zTsWJ0dIya5d" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,230&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,181&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_mtPEAOAzN1F_zoIUDXhnGTW6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,548&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,389&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrentAbstract_iB_zTyJXsT5VeN3" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Accrued expenses and other current liabilities:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zhTVZS7AmCv3" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Contract-related&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,273&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,832&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--CompensationAndCompensationRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_ziUVNyyjNLO9" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Compensation and compensation-related&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,645&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,868&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ConstructionInProgressAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zpUJBdKzASj5" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,103&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,572&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProfessionalFeesAndOtherAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zaYPfZCqCLr2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Professional fees and other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;659&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;673&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzLWJ_zGSMNqABDbh8" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,680&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,945&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zmfAn5zuV5Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"&gt;&#160;&lt;/p&gt;

</tnxp:OtherBalanceSheetInformationDiclosureTextBlock>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zZmjN0MMISXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Components
of selected captions in the consolidated balance sheets consist of:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20221231_zpaDHLoBqmvl" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zQQsSctglemb" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrentAbstract_iB_zpjLBKcG4czh" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Prepaid expenses and other:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ContractRelatedPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zgztWqrGeFUg" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Contract-related&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,043&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,726&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidInsurance_i01I_pn3n3_maPEAOAzN1F_zeeRZKyz8ONi" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Insurance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,275&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,482&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ProfessionalFeesAndOtherPrepaidExpenseCurrent_i01I_pn3n3_maPEAOAzN1F_zTsWJ0dIya5d" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,230&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,181&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_mtPEAOAzN1F_zoIUDXhnGTW6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,548&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,389&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrentAbstract_iB_zTyJXsT5VeN3" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Accrued expenses and other current liabilities:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zhTVZS7AmCv3" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Contract-related&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,273&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,832&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--CompensationAndCompensationRelatedAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_ziUVNyyjNLO9" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Compensation and compensation-related&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,645&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,868&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ConstructionInProgressAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zpUJBdKzASj5" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,103&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,572&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProfessionalFeesAndOtherAccruedLiabilitiesCurrent_i01I_pn3n3_maAPAOAzLWJ_zaYPfZCqCLr2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Professional fees and other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;659&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;673&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzLWJ_zGSMNqABDbh8" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,680&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,945&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <tnxp:ContractRelatedPrepaidExpenseCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">8043000</tnxp:ContractRelatedPrepaidExpenseCurrent>
    <tnxp:ContractRelatedPrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">7726000</tnxp:ContractRelatedPrepaidExpenseCurrent>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1275000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1482000</us-gaap:PrepaidInsurance>
    <tnxp:ProfessionalFeesAndOtherPrepaidExpenseCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1230000</tnxp:ProfessionalFeesAndOtherPrepaidExpenseCurrent>
    <tnxp:ProfessionalFeesAndOtherPrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1181000</tnxp:ProfessionalFeesAndOtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">10548000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">10389000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <tnxp:ContractRelatedAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3273000</tnxp:ContractRelatedAccruedLiabilitiesCurrent>
    <tnxp:ContractRelatedAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2832000</tnxp:ContractRelatedAccruedLiabilitiesCurrent>
    <tnxp:CompensationAndCompensationRelatedAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3645000</tnxp:CompensationAndCompensationRelatedAccruedLiabilitiesCurrent>
    <tnxp:CompensationAndCompensationRelatedAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2868000</tnxp:CompensationAndCompensationRelatedAccruedLiabilitiesCurrent>
    <tnxp:ConstructionInProgressAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2103000</tnxp:ConstructionInProgressAccruedLiabilitiesCurrent>
    <tnxp:ConstructionInProgressAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1572000</tnxp:ConstructionInProgressAccruedLiabilitiesCurrent>
    <tnxp:ProfessionalFeesAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">659000</tnxp:ProfessionalFeesAndOtherAccruedLiabilitiesCurrent>
    <tnxp:ProfessionalFeesAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">673000</tnxp:ProfessionalFeesAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">9680000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">7945000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zInqEP7JQoh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_828_zOtIFkQMnyNe"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Fair value measurements affect
the Company&#x2019;s accounting for certain of its financial assets. Fair value is defined as the price that would be received to sell
an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and is measured
according to a hierarchy that includes:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 15%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7%"&gt;&lt;span style="font-size: 10pt"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Observable inputs, such as quoted prices in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 15%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7%"&gt;&lt;span style="font-size: 10pt"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inputs, other than quoted prices in active markets, that are observable
        either directly or indirectly. Level&#160;2 assets and liabilities include debt securities with quoted market prices that are traded less
        frequently than exchange-traded instruments. This category includes U.S. government agency-backed debt securities and corporate-debt securities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 15%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7%"&gt;&lt;span style="font-size: 10pt"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Unobservable inputs in which there is little or no market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2022, and
December 31, 2021, the Company used Level 1 quoted prices in active markets to value cash equivalents of $&lt;span id="xdx_907_ecustom--CashEquivalentsFairValue_iI_pn5n6_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zCAZ5TxA8Qog"&gt;116.3&lt;/span&gt;
million and $&lt;span id="xdx_90B_ecustom--CashEquivalentsFairValue_iI_pn5n6_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z391b4fVOVs9"&gt;120.4&lt;/span&gt;
million, respectively. The Company did not have any Level 2 or Level 3 assets or liabilities as of both December 31, 2022 and 2021.&lt;/p&gt;

</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <tnxp:CashEquivalentsFairValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-5"
      unitRef="USD">116300000</tnxp:CashEquivalentsFairValue>
    <tnxp:CashEquivalentsFairValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-5"
      unitRef="USD">120400000</tnxp:CashEquivalentsFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zhdwEFEgeQc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_820_zFd27WXyjVs4"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 16, 2022, the Company
filed a Certificate of Change with the Nevada Secretary of State, effective May 17, 2022. Pursuant to the Certificate of Change, the
Company effected a &lt;span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpkxzitroKGl"&gt;1-for-32
&lt;/span&gt;reverse stock split of its issued and outstanding shares of common stock, whereby &lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwxnIZSeZmD5"&gt;599,679,596
&lt;/span&gt;outstanding shares of the Company&#x2019;s common stock were exchanged for &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQHkNULtF9tl"&gt;18,740,141
&lt;/span&gt;shares of the Company&#x2019;s common stock. In connection with the reverse stock split, the Company issued an additional &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20220515__20220516__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSLijTjcsNG"&gt;130,462
&lt;/span&gt;shares of the Company&#x2019;s common stock due to fractional shares. Furthermore, pursuant to the Certificate of Change, the number
of authorized shares of common stock was reduced from &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pdn6_c20220514_zjgzFxhLOTf6"&gt;800
&lt;/span&gt;million to &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pdn6_c20220516_zryjIfEHzX95"&gt;50&lt;/span&gt; million. All per
share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect
the reverse stock split.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 5, 2022, the Company
filed an amendment to its articles of incorporation, as amended, to increase the number of shares of common stock authorized from &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220803_zKrHID5DV68h"&gt;50,000,000&lt;/span&gt;
to &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220805_z3EF34Sb6rW5"&gt;150,000,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 13, 2022, the
Company filed an amendment to its articles of incorporation, as amended, to increase the number of shares of common stock authorized from
&lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221211_zwNTcHPxbibi"&gt;150,000,000&lt;/span&gt; to &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221213_zUa29GK8TY0f"&gt;1,000,000,000&lt;/span&gt;.&lt;/p&gt;


</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-05-152022-05-16_us-gaap_CommonStockMember">1-for-32</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-05-152022-05-16_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">599679596</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-05-152022-05-16_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18740141</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2022-05-152022-05-16_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">130462</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-05-14" decimals="INF" unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-05-16" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-08-03" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-08-05" decimals="INF" unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-11" decimals="INF" unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-13" decimals="INF" unitRef="Shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <tnxp:TemporaryEquityTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_ecustom--TemporaryEquityTextBlock_zwifcfc9Yy3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_821_zR793VlTLTGe"&gt;TEMPORARY EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On October 26, 2022, the Company
closed on an offering (&#x201c;the October offering&#x201d;) with certain institutional investors (the &#x201c;Investors&#x201d;), pursuant
to which the Company issued and sold, in a private placement, &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z04GH2GpG4b" title="Number of shares issued"&gt;1,400,000&lt;/span&gt;
shares of the Company&#x2019;s Series A Convertible Redeemable Preferred Stock, par value $&lt;span id="xdx_900_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNnTTED6aR6" title="Preferred stock, par value (in dollars per share)"&gt;0.001&lt;/span&gt;
per share (the &#x201c;Series A Preferred Stock&#x201d;), and &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGeWZ3Flloc8"&gt;100,000&lt;/span&gt;
shares of the Company&#x2019;s Series B Convertible Redeemable Preferred Stock, par value $&lt;span id="xdx_902_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zu3eBO1UzpX3"&gt;0.001&lt;/span&gt;
per share (the &#x201c;Series B Preferred Stock,&#x201d; and together with the Series A Preferred Stock, the &#x201c;Preferred Stock&#x201d;),
at an offering price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zcEmoZMgCnT9" title="Price per share"&gt;9.50&lt;/span&gt;
per share, representing a &lt;span id="xdx_90C_ecustom--PercentageOfIssueDiscount_uPure_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zySYYQ7ayvYc"&gt;5%&lt;/span&gt;
original issue discount (&#x201c;OID) to the stated value of $&lt;span id="xdx_904_ecustom--StatedValuePerShare_iI_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zRpWwqUDk3Cd"&gt;10.00&lt;/span&gt;
per share, for gross proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pdn6_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zdhIaxaCdMUh"&gt;14.3&lt;/span&gt;
million in the aggregate for the October offering, before the deduction of fees and offering expenses. The shares of Preferred Stock
were convertible, at a conversion price of $&lt;span id="xdx_900_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zhKZu136wo7h"&gt;1.00&lt;/span&gt;
per share (subject in certain circumstances to adjustments), into shares of the Company&#x2019;s common stock, at the option of the holders
and, in certain circumstances, by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 13, 2022, an amendment
(the &#x201c;December Amendment&#x201d;) to the Company&#x2019;s Articles of Incorporation, as amended, to increase the Company&#x2019;s authorized
shares of common stock from &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221211_z7a8HV52cPE"&gt;150,000,000&lt;/span&gt;
to &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221213_zVBNhpl4oOt8"&gt;1,000,000,000&lt;/span&gt;, was approved at
a special meeting of shareholders. The Series A Preferred Stock had the right to vote on such December Amendment on an as-converted to
common stock basis. The shares of the Series B Preferred Stock were automatically voted in a manner that &#x201c;mirrored&#x201d; the proportions
on which the shares of Common Stock (excluding any shares of Common Stock that were not voted) and Series A Preferred Stock were voted
to increase the Authorized Shares. The December Amendment required the approval of the majority of the votes associated with the Company&#x2019;s
outstanding stock entitled to vote on the proposal. Because the Series B Preferred Stock were automatically and without further action
of the purchaser voted in a manner that &#x201c;mirrored&#x201d; the proportions on which the shares of Common Stock (excluding any shares
of Common Stock that were not voted) and Series A Preferred Stock were voted on the December Amendment, abstentions by common stockholders
did not have any effect on the votes cast by the holders of the Series B Preferred Stock. The Certificates of Designation for the Preferred
Stock provides that the &lt;span id="xdx_908_eus-gaap--PreferredStockVotingRights_pid_c20221212__20221213__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zXBrgMzGr4o4" title="Preferred stock voting rights"&gt;Preferred
Stock have no voting rights other than the right to vote on the December Amendment and as a class on certain other specified matters&lt;/span&gt;,
and, with respect to the Series B Certificate of Designation, &lt;span id="xdx_907_eus-gaap--PreferredStockVotingRights_pid_c20221212__20221213__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ze0InPxbVT93"&gt;the
right to cast 2,500 votes per share of Series B Preferred Stock on the December Amendment&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The holders of Preferred Stock
were entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred
Stock was convertible, at the option of the holders and, in certain circumstances, by the Company, into shares of Common Stock at a conversion
price of $&lt;span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zKSalTY1j1x9"&gt;1.00&lt;/span&gt;
per share. The holders of the Preferred Stock had the right to require the Company to redeem their shares of preferred stock for cash
at &lt;span id="xdx_901_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z2wHG7OPvr87"&gt;105%&lt;/span&gt;
of the stated value of such shares through January 23, 2023. The Company had the option to redeem the Preferred Stock for cash at &lt;span id="xdx_90A_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zDEx3N2TXe71"&gt;105%&lt;/span&gt;
of the stated value, subject to the holders&#x2019; rights to convert the shares prior to such redemption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The $&lt;span id="xdx_908_eus-gaap--EscrowDeposit_iI_pdn6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zJ0VcZjiZjW8"&gt;14.3&lt;/span&gt;
million in gross proceeds of the October offering was held in an escrow account, along with an additional $&lt;span id="xdx_90B_ecustom--EscrowDepositForOriginalIssueDiscount_iI_pdn6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z0wKypglidcg"&gt;1.5&lt;/span&gt;
million deposited by the Company to cover the aggregate OID as well as the additional amount that would be necessary to fund the &lt;span id="xdx_903_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221024__20221026__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zI2WveX3oCO8"&gt;105%&lt;/span&gt;
redemption price until the expiration of the redemption period for the Preferred Stock, as applicable, subject to the earlier payment
to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in the escrow account would be disbursed to the
Company.&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--TemporaryEquityTableTextBlock_gL3TETTB-XKNNU_zqJ8jD81ImIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. &lt;span id="xdx_8B6_zFvQt5F2N4C3"&gt;The
Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value&lt;/span&gt; of approximately $&lt;span id="xdx_905_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIKIp2nesvT2" title="Temporary equity"&gt;14.7&lt;/span&gt;
million and $&lt;span id="xdx_901_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbHhRLhVAnnb"&gt;1.1&lt;/span&gt;
million, respectively, as calculated in the following table (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWowwR0zsiRa" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Series
        A&lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrDSnUVt6Mkc" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Series
        B &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--GrossProceeds_iI_pn3n3_maTECAAzHsD_zECCzRrLMIui" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="font-size: 10pt"&gt;Gross Proceeds&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,300&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;950&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Less:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_msTECAAzHsD_zdXwooGT29Fb" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock issuance costs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(844&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(60&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Plus:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_maTECAAzHsD_zSMJovDY5Wai" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accretion of carrying value to redemption value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,244&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;160&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_mtTECAAzHsD_zyXeIpUafxLf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock subject to possible redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;14,700&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,050&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zJKAXSk3404a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During December 2022, the
Company received redemption notices for all outstanding shares of Preferred Stock. The Preferred Stock was redeemed during December 2022
at &lt;span id="xdx_904_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20221201__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zIOZlaOpZHEc"&gt;105%&lt;/span&gt;
of the $&lt;span id="xdx_907_ecustom--StatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zCUBH8qmTzK8"&gt;10.00&lt;/span&gt;
stated value of the Preferred Stock, or $&lt;span id="xdx_90C_eus-gaap--PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_pn5n6_c20221201__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zVBcEWGOQizj" title="Redemption amount"&gt;15.8&lt;/span&gt;
million in the aggregate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 24, 2022, the Company
closed on an offering (&#x201c;the Offering&#x201d;) with certain institutional investors (the &#x201c;Investors&#x201d;), pursuant to which
the Company issued and sold, in a private placement, &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbqrFVoBuex4" title="Number of shares issued"&gt;2,500,000&lt;/span&gt;
shares of the Company&#x2019;s Series A Convertible Redeemable Preferred Stock, par value $&lt;span id="xdx_90B_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGqWfR96jLX7" title="Preferred stock, par value (in dollars per share)"&gt;0.001&lt;/span&gt;
per share (the &#x201c;Series A Preferred Stock&#x201d;), and &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zcmHaHvyzr01"&gt;500,000&lt;/span&gt;
shares of the Company&#x2019;s Series B Convertible Redeemable Preferred Stock, par value $&lt;span id="xdx_909_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKb2fc2jPVc7"&gt;0.001&lt;/span&gt;
per share (the &#x201c;Series B Preferred Stock,&#x201d; and together with the Series A Preferred Stock, the &#x201c;Preferred Stock&#x201d;),
at an offering price of $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zKO3jsVXNM46" title="Price per share"&gt;9.50&lt;/span&gt;
per share, representing a &lt;span id="xdx_906_ecustom--PercentageOfIssueDiscount_uPure_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z2oyMKrlOVYa"&gt;5%&lt;/span&gt;
original issue discount (&#x201c;OID) to the stated value of $&lt;span id="xdx_908_ecustom--StatedValuePerShare_iI_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zqjPkKS30xwd"&gt;10.00&lt;/span&gt;
per share, for gross proceeds of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pdn6_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zTlpLtNvrwN4"&gt;28.5&lt;/span&gt;
million in the aggregate for the Offering, before the deduction of fees and offering expenses. The shares of Preferred Stock were convertible,
at a conversion price of $&lt;span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zJZBczYqnYch"&gt;4.00&lt;/span&gt;
per share (subject in certain circumstances to adjustments), into shares of the Company&#x2019;s common stock, at the option of the holders
and, in certain circumstances, by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 5, 2022, an amendment
(the &#x201c;Amendment&#x201d;) to the Company&#x2019;s Articles of Incorporation, as amended, to increase the Company&#x2019;s authorized
shares of common stock from &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220803_zsfgb17q9jp4"&gt;50,000,000&lt;/span&gt;
to &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220805_zI3KSp6dOAV4" title="Common stock, authorized"&gt;150,000,000&lt;/span&gt;,
was approved at a special meeting of shareholders. The Series A Preferred Stock had the right to vote on such Amendment on an as-converted
to common stock basis. The shares of the Series B Preferred Stock were automatically voted in a manner that &#x201c;mirrored&#x201d; the
proportions on which the shares of Common Stock (excluding any shares of Common Stock that were not voted) and Series A Preferred Stock
were voted to increase the Authorized Shares. The Amendment required the approval of the majority of the votes associated with the Company&#x2019;s
outstanding stock entitled to vote on the proposal. Because the Series B Preferred Stock were automatically and without further action
of the purchaser voted in a manner that &#x201c;mirrored&#x201d; the proportions on which the shares of Common Stock (excluding any shares
of Common Stock that were not voted) and Series A Preferred Stock were voted on the Amendment, abstentions by common stockholders did
not have any effect on the votes cast by the holders of the Series B Preferred Stock. The Certificates of Designation for the Preferred
Stock provides that the &lt;span id="xdx_902_eus-gaap--PreferredStockVotingRights_pid_c20220804__20220805__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zWywwEPeKVoj" title="Preferred stock voting rights"&gt;Preferred
Stock have no voting rights other than the right to vote on the Amendment and as a class on certain other specified matters&lt;/span&gt;, and,
with respect to the Series B Certificate of Designation, &lt;span id="xdx_900_eus-gaap--PreferredStockVotingRights_pid_c20220804__20220805__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zi99hxHRFDM1"&gt;the
right to cast 2,500 votes per share of Series B Preferred Stock on the Amendment&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The holders of Preferred Stock
were entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred
Stock was convertible, at the option of the holders and, in certain circumstances, by the Company, into shares of Common Stock at a conversion
price of $&lt;span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zKHivVUHoRsh"&gt;4.00&lt;/span&gt;
per share. The holders of the Preferred Stock had the right to require the Company to redeem their shares of preferred stock for cash
at &lt;span id="xdx_90B_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zHJ9oJRpS2l8"&gt;105%&lt;/span&gt;
of the stated value of such shares through September 22, 2022. The Company had the option to redeem the Preferred Stock for cash at &lt;span id="xdx_90E_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zW8DSiTZCkGa"&gt;105%&lt;/span&gt;
of the stated value, subject to the holders&#x2019; rights to convert the shares prior to such redemption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The $&lt;span id="xdx_90D_eus-gaap--EscrowDeposit_iI_pdn6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zjg8euac2WMg"&gt;28.5&lt;/span&gt;
million in gross proceeds of the Offering was held in an escrow account, along with an additional $&lt;span id="xdx_905_ecustom--EscrowDepositForOriginalIssueDiscount_iI_pdn6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z307uZsMNVTj"&gt;3&lt;/span&gt;.0
million deposited by the Company to cover the aggregate OID as well as the additional amount that would be necessary to fund the &lt;span id="xdx_90B_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220623__20220624__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zpi0UDFLYqRl"&gt;105%&lt;/span&gt;
redemption price until the expiration of the redemption period for the Preferred Stock, as applicable, subject to the earlier payment
to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in the escrow account would be disbursed to the
Company.&lt;/p&gt;

&lt;div id="xdx_C07_gL3TETTB-XKNNU_zTyLjOQtmuR"&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. The Series A Preferred
Stock and Series B Preferred Stock was recorded at redemption value of approximately $&lt;span id="xdx_902_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbkIMJNKWRmc" title="Temporary equity"&gt;26.3&lt;/span&gt;
million and $&lt;span id="xdx_903_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zba28qKJdj4l" title="Temporary equity"&gt;5.2&lt;/span&gt;
million, respectively, as calculated in the following table (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfcNMrfrQp33" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Series
        A&lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLYnqqg39TC6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Series
        B &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_406_ecustom--GrossProceeds_iI_pn3n3_zhzRGGwpa5R4" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="font-size: 10pt"&gt;Gross Proceeds&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;23,750&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,750&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Less:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_40D_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_zMP4L2SK3nB2" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock issuance costs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,046&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(209&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Plus:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_407_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_zl7uAw1F24X7" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accretion of carrying value to redemption value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,546&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;709&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_409_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_zPI5MPtcZL8c" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock subject to possible redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;26,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During August 2022, the Company
received redemption notices for all outstanding shares of Preferred Stock. The Preferred Stock was redeemed during August 2022 at &lt;span id="xdx_907_ecustom--TemporaryEquityRedemptionPricePercentage_pid_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z7bzPZfcWpQc"&gt;105%&lt;/span&gt;
of the $&lt;span id="xdx_90D_ecustom--StatedValuePerShare_iI_c20220831__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zw4PVYWUdo26"&gt;10.00&lt;/span&gt;
stated value of the Preferred Stock, or $&lt;span id="xdx_907_eus-gaap--PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_pn5n6_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zNknnffvM9f8" title="Redemption amount"&gt;31.5&lt;/span&gt;
million in the aggregate.&lt;/p&gt;

</tnxp:TemporaryEquityTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-242022-10-26_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-242022-10-26_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">9.50</us-gaap:SharesIssuedPricePerShare>
    <tnxp:PercentageOfIssueDiscount
      contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.05</tnxp:PercentageOfIssueDiscount>
    <tnxp:StatedValuePerShare
      contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">10.00</tnxp:StatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">14300000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-11" decimals="INF" unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-13" decimals="INF" unitRef="Shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockVotingRights contextRef="From2022-12-122022-12-13_us-gaap_RedeemableConvertiblePreferredStockMember">Preferred
Stock have no voting rights other than the right to vote on the December Amendment and as a class on certain other specified matters</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockVotingRights contextRef="From2022-12-122022-12-13_us-gaap_SeriesBPreferredStockMember">the
right to cast 2,500 votes per share of Series B Preferred Stock on the December Amendment</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <tnxp:TemporaryEquityRedemptionPricePercentage
      contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">1.05</tnxp:TemporaryEquityRedemptionPricePercentage>
    <tnxp:TemporaryEquityRedemptionPricePercentage
      contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">1.05</tnxp:TemporaryEquityRedemptionPricePercentage>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">14300000</us-gaap:EscrowDeposit>
    <tnxp:EscrowDepositForOriginalIssueDiscount
      contextRef="AsOf2022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1500000</tnxp:EscrowDepositForOriginalIssueDiscount>
    <tnxp:TemporaryEquityRedemptionPricePercentage
      contextRef="From2022-10-242022-10-26_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">1.05</tnxp:TemporaryEquityRedemptionPricePercentage>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--TemporaryEquityTableTextBlock_gL3TETTB-XKNNU_zqJ8jD81ImIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. &lt;span id="xdx_8B6_zFvQt5F2N4C3"&gt;The
Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value&lt;/span&gt; of approximately $&lt;span id="xdx_905_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIKIp2nesvT2" title="Temporary equity"&gt;14.7&lt;/span&gt;
million and $&lt;span id="xdx_901_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbHhRLhVAnnb"&gt;1.1&lt;/span&gt;
million, respectively, as calculated in the following table (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWowwR0zsiRa" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Series
        A&lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221026__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrDSnUVt6Mkc" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Series
        B &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--GrossProceeds_iI_pn3n3_maTECAAzHsD_zECCzRrLMIui" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="font-size: 10pt"&gt;Gross Proceeds&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,300&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;950&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Less:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_msTECAAzHsD_zdXwooGT29Fb" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock issuance costs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(844&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(60&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Plus:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_maTECAAzHsD_zSMJovDY5Wai" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accretion of carrying value to redemption value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,244&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;160&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_mtTECAAzHsD_zyXeIpUafxLf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock subject to possible redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;14,700&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,050&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;Since
the Preferred Stock had a redemption feature at the option of the holder, it was classified as temporary equity. The Series A Preferred
Stock and Series B Preferred Stock was recorded at redemption value of approximately $&lt;span id="xdx_902_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbkIMJNKWRmc" title="Temporary equity"&gt;26.3&lt;/span&gt;
million and $&lt;span id="xdx_903_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn5n6_c20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zba28qKJdj4l" title="Temporary equity"&gt;5.2&lt;/span&gt;
million, respectively, as calculated in the following table (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfcNMrfrQp33" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Series
        A&lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLYnqqg39TC6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Series
        B &lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_406_ecustom--GrossProceeds_iI_pn3n3_zhzRGGwpa5R4" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="font-size: 10pt"&gt;Gross Proceeds&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;23,750&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,750&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Less:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_40D_ecustom--PreferredStockIssuanceCosts_iNI_pn3n3_di_zMP4L2SK3nB2" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock issuance costs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,046&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(209&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Plus:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_407_ecustom--AccretionOfCarryingValueToRedemptionValue_iI_pn3n3_zl7uAw1F24X7" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accretion of carrying value to redemption value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,546&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;709&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIFRoZSBTZXJpZXMgQSBQcmVmZXJyZWQgU3RvY2sgYW5kIFNlcmllcyBCIFByZWZlcnJlZCBTdG9jayB3YXMgcmVjb3JkZWQgYXQgcmVkZW1wdGlvbiB2YWx1ZSAoRGV0YWlscykA" id="xdx_409_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iTI_pn3n3_zPI5MPtcZL8c" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Preferred stock subject to possible redemption&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;26,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember"
      decimals="-5"
      unitRef="USD">14700000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tnxp:GrossProceeds
      contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      unitRef="USD">13300000</tnxp:GrossProceeds>
    <tnxp:GrossProceeds
      contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      unitRef="USD">950000</tnxp:GrossProceeds>
    <tnxp:PreferredStockIssuanceCosts
      contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      unitRef="USD">844000</tnxp:PreferredStockIssuanceCosts>
    <tnxp:PreferredStockIssuanceCosts
      contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      unitRef="USD">60000</tnxp:PreferredStockIssuanceCosts>
    <tnxp:AccretionOfCarryingValueToRedemptionValue
      contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      unitRef="USD">2244000</tnxp:AccretionOfCarryingValueToRedemptionValue>
    <tnxp:AccretionOfCarryingValueToRedemptionValue
      contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      unitRef="USD">160000</tnxp:AccretionOfCarryingValueToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      unitRef="USD">14700000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-10-26_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      unitRef="USD">1050000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tnxp:TemporaryEquityRedemptionPricePercentage
      contextRef="From2022-12-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">1.05</tnxp:TemporaryEquityRedemptionPricePercentage>
    <tnxp:StatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">10.00</tnxp:StatedValuePerShare>
    <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
      contextRef="From2022-12-012022-12-31_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="-5"
      unitRef="USD">15800000</us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-06-232022-06-24_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-06-232022-06-24_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">9.50</us-gaap:SharesIssuedPricePerShare>
    <tnxp:PercentageOfIssueDiscount
      contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.05</tnxp:PercentageOfIssueDiscount>
    <tnxp:StatedValuePerShare
      contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">10.00</tnxp:StatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">28500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-08-03" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-08-05" decimals="INF" unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockVotingRights contextRef="From2022-08-042022-08-05_us-gaap_RedeemableConvertiblePreferredStockMember">Preferred
Stock have no voting rights other than the right to vote on the Amendment and as a class on certain other specified matters</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockVotingRights contextRef="From2022-08-042022-08-05_us-gaap_SeriesBPreferredStockMember">the
right to cast 2,500 votes per share of Series B Preferred Stock on the Amendment</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <tnxp:TemporaryEquityRedemptionPricePercentage
      contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">1.05</tnxp:TemporaryEquityRedemptionPricePercentage>
    <tnxp:TemporaryEquityRedemptionPricePercentage
      contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">1.05</tnxp:TemporaryEquityRedemptionPricePercentage>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">28500000</us-gaap:EscrowDeposit>
    <tnxp:EscrowDepositForOriginalIssueDiscount
      contextRef="AsOf2022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3000000</tnxp:EscrowDepositForOriginalIssueDiscount>
    <tnxp:TemporaryEquityRedemptionPricePercentage
      contextRef="From2022-06-232022-06-24_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">1.05</tnxp:TemporaryEquityRedemptionPricePercentage>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember"
      decimals="-5"
      unitRef="USD">26300000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      unitRef="USD">5200000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tnxp:GrossProceeds
      contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      unitRef="USD">23750000</tnxp:GrossProceeds>
    <tnxp:GrossProceeds
      contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      unitRef="USD">4750000</tnxp:GrossProceeds>
    <tnxp:PreferredStockIssuanceCosts
      contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      unitRef="USD">1046000</tnxp:PreferredStockIssuanceCosts>
    <tnxp:PreferredStockIssuanceCosts
      contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      unitRef="USD">209000</tnxp:PreferredStockIssuanceCosts>
    <tnxp:AccretionOfCarryingValueToRedemptionValue
      contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      unitRef="USD">3546000</tnxp:AccretionOfCarryingValueToRedemptionValue>
    <tnxp:AccretionOfCarryingValueToRedemptionValue
      contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      unitRef="USD">709000</tnxp:AccretionOfCarryingValueToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-06-24_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      unitRef="USD">26250000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-06-24_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      unitRef="USD">5250000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tnxp:TemporaryEquityRedemptionPricePercentage
      contextRef="From2022-08-012022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">1.05</tnxp:TemporaryEquityRedemptionPricePercentage>
    <tnxp:StatedValuePerShare
      contextRef="AsOf2022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">10.00</tnxp:StatedValuePerShare>
    <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
      contextRef="From2022-08-012022-08-31_us-gaap_RedeemableConvertiblePreferredStockMember"
      decimals="-5"
      unitRef="USD">31500000</us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock>
    <tnxp:AssetPurchaseAgreementWithKatanaTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_ecustom--AssetPurchaseAgreementWithKatanaTextBlock_zIrFlKhMGfdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_82B_zH2t5F1eHu13"&gt;ASSET PURCHASE AGREEMENT WITH KATANA&lt;/span&gt;&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 22, 2020, the
Company entered into an asset purchase agreement (the &#x201c;Katana Asset Purchase Agreement&#x201d;) with Katana Pharmaceuticals, Inc.
(&#x201c;Katana&#x201d;) pursuant to which Tonix acquired Katana assets related to insulin resistance and related syndromes, including obesity
(the &#x201c;Katana Assets&#x201d;). In connection with the acquisition of the Katana Assets, Tonix assumed Katana&#x2019;s rights and obligations
under that certain Exclusive License Agreement by and between Katana and The University of Geneva (&#x201c;Geneva&#x201d;) (the &#x201c;Geneva
License &#x201c;Agreement&#x201d;) pursuant to an Assignment and Assumption Agreement with Geneva (&#x201c;Geneva Assignment and Assumption
Agreement&#x201d;), dated December 22, 2020. As consideration for entering into the Katana Asset Purchase Agreement, Tonix paid $&lt;span id="xdx_90F_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20201221__20201222__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--KatanaPharmaceuticalsIncMember_znJOZG6yVgdf" title="Consideration paid"&gt;0.7&lt;/span&gt;
million to Katana. The costs associated with the cash payments were recorded to research and development expenses in the statement
of operations for the year ended December 31, 2020. Because the Katana intellectual property was acquired prior to U.S. Food and Drug
Administration (FDA) approval, the cash consideration totaling $&lt;span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20201221__20201222__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--KatanaPharmaceuticalsIncMember_zlmQY2SG61Y1" title="Research and development costs"&gt;0.7&lt;/span&gt;
million, was expensed as research and development costs since there is no alternative future use and the acquired intellectual
property does not constitute a business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the terms of the
Geneva Assignment and Assumption Agreement, Geneva has granted to Tonix an exclusive license, with the right to sublicense, certain patents
related to the Katana Assets. Tonix is obligated to use commercially reasonable efforts to diligently develop, manufacture, and sell products
claimed or covered by the patent and will use commercially reasonable efforts to diligently develop markets for such products. The Geneva
License Agreement specifies developmental milestones and the period of time during which such milestones must be completed and provides
for an annual maintenance fee payable to Geneva. As of December 31, 2022, no milestone payments have been accrued or paid in relation
to this agreement.&lt;/p&gt;

</tnxp:AssetPurchaseAgreementWithKatanaTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-12-212020-12-22_custom_AssetPurchaseAgreementMember_custom_KatanaPharmaceuticalsIncMember"
      decimals="-5"
      unitRef="USD">700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2020-12-212020-12-22_custom_AssetPurchaseAgreementMember_custom_KatanaPharmaceuticalsIncMember"
      decimals="-5"
      unitRef="USD">700000</us-gaap:OtherResearchAndDevelopmentExpense>
    <tnxp:AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80C_ecustom--AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock_zDppIBS9jo4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_820_zpjak9qwOSZg"&gt;ASSET PURCHASE AGREEMENT WITH TRIGEMINA&lt;/span&gt;&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 11, 2020, the Company
entered into an asset purchase agreement (the &#x201c;Trigemina Asset Purchase Agreement&#x201d;) with Trigemina, Inc. (&#x201c;Trigemina&#x201d;)
and certain shareholders named therein (the &#x201c;Executive Shareholders&#x201d;) pursuant to which Tonix acquired Trigemina assets related
to migraine and pain treatment technologies (the &#x201c;Trigemina Assets&#x201d;). In connection with the acquisition of the Trigemina
Assets, Tonix assumed Trigemina&#x2019;s rights and obligations under that certain Amended and Restated Exclusive License Agreement, dated
November 30, 2007, as amended, by and between Trigemina and The Board of Trustees of the Leland Stanford Junior University (&#x201c;Stanford&#x201d;)
(the &#x201c;Stanford License &#x201c;Agreement&#x201d;) pursuant to an Assignment and Assumption Agreement with Stanford (&#x201c;Assignment
and Assumption Agreement&#x201d;), dated June 11, 2020. As consideration for entering into the Asset Purchase Agreement, Tonix paid $&lt;span id="xdx_900_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_zYOqrO5cZNci" title="Payment for purchase of assets"&gt;824,759&lt;/span&gt;
to Trigemina and issued to Trigemina &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_z4kJXPnGfLul" title="Number of shares issued (in shares)"&gt;62,500&lt;/span&gt;
shares of the Company&#x2019;s common stock, valued at $&lt;span id="xdx_907_ecustom--CommonStockValuePerShares_pip0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_zfJzmjmG9Rrb" title="Common stock value (per share)"&gt;21.76&lt;/span&gt;
per share, based on the closing stock price on June 11, 2020, and paid Stanford $&lt;span id="xdx_905_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssignmentAndAssumptionAgreementMember_zaC2ibO4oHj7" title="Payment for purchase of assets"&gt;250,241&lt;/span&gt;
pursuant to the terms of the Assignment and Assumption Agreement. The common stock is unregistered and subject to a 12-month lock-up and
a Shareholder Voting Agreement, dated June 11, 2020, pursuant to which Trigemina and the Executive Shareholders have agreed to vote the
common stock on any matter put to a vote of the shareholders of the Company in accordance with management&#x2019;s recommendations. Both
the costs associated with the cash payments and share issuance, totaling $&lt;span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20200610__20200611__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TrigeminaIncMember_zFOhi0ISYZsa" title="Research and development costs"&gt;2.4&lt;/span&gt;
million, were recorded to research and development expenses in the statement of operations for the year ended December 31, 2020.
Because the Trigemina intellectual property was acquired prior to FDA approval, the cash and stock consideration, was expensed as research
and development costs since there is no alternative future use and the acquired intellectual property does not constitute a business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the terms of the
Assignment and Assumption Agreement, Stanford has granted to Tonix an exclusive license, with the right to sublicense, certain patents
related to the Trigemina Assets. Stanford has reserved for itself the right to practice under the patents for academic research and educational
purposes. Tonix is obligated to use commercially reasonable efforts to diligently develop, manufacture, and sell products claimed or covered
by the patent and will use commercially reasonable efforts to diligently develop markets for such products. The Trigemina License Agreement
specifies developmental milestones and the period of time during which such milestones must be completed and provides for an annual maintenance
fee payable to Stanford. As of December 31, 2022, other than the annual maintenance fee, no milestone payments have been accrued or paid
in relation to this agreement.&lt;/p&gt;

</tnxp:AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember"
      decimals="0"
      unitRef="USD">824759</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember"
      decimals="INF"
      unitRef="Shares">62500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <tnxp:CommonStockValuePerShares
      contextRef="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember"
      decimals="INF"
      unitRef="USDPShares">21.76</tnxp:CommonStockValuePerShares>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-06-102020-06-11_custom_AssignmentAndAssumptionAgreementMember"
      decimals="0"
      unitRef="USD">250241</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember"
      decimals="-5"
      unitRef="USD">2400000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:AssetAcquisitionTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--AssetAcquisitionTextBlock_ztjIp2a21GYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_82A_zzfBSoQFeikl"&gt;ASSET PURCHASE AGREEMENT WITH TRIMARAN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 19, 2019, the Company
entered into an asset purchase agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with TRImaran Pharma, Inc. (&#x201c;TRImaran&#x201d;)
and the selling shareholders named therein (the &#x201c;Selling Shareholders&#x201d;) pursuant to which Tonix acquired TRImaran&#x2019;s
assets related to certain pyran-based compounds (the &#x201c;Assets&#x201d;). In connection with the acquisition of the Assets, Tonix entered
into a First Amended and Restated Exclusive License Agreement (the &#x201c;WSU License Agreement&#x201d;) with Wayne State University (&#x201c;WSU&#x201d;)
on August 19, 2019, as subsequently amended. As consideration for entering into the Asset Purchase Agreement, Tonix paid $&lt;span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_z2oMKhoZZKUc" title="Payment for purchase of assets"&gt;100,000&lt;/span&gt;
to TRImaran and has assumed certain liabilities of TRImaran totaling $&lt;span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_zsiM8nTtqfV1" title="Liabilities assumed"&gt;68,500&lt;/span&gt;.
The $&lt;span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_zNGJWpnbILR2" title="Research and development costs"&gt;168,500&lt;/span&gt;
was previously recorded to research and development expenses in the statement of operations. Upon the achievement of specified development,
regulatory and sales milestones, Tonix also agreed to pay TRImaran and the Selling Shareholders, in restricted stock or cash, at Our option,
a total of approximately $&lt;span id="xdx_909_ecustom--AchievementPaymentsPayable_iI_pn5n6_c20190819__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--TRImaranPharmaIncMember_zmDTMzUmQ1z5" title="Contingent milestone payment obligation"&gt;3.4&lt;/span&gt;
million. Pursuant to the terms of the Asset Purchase Agreement, TRImaran and the Selling Shareholders are prohibited from disclosing
confidential information related to the Assets and are restricted from engaging, for a period of three years, in the development or commercialization
of any therapeutic containing any pyran-based drug compound for the treatment of post-traumatic stress disorder, attention deficit hyperactivity
disorder or major depressive disorder. Also for a period of three years, if TRImaran or any Selling Shareholder engage in the research
or development of any potential therapeutic compound for the treatment of any central nervous system disorder, TRImaran or such Selling
Shareholder is obliged to provide notice and opportunity to Tonix to make an offer to acquire or license rights with respect to such product
candidate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the terms of the
WSU License Agreement, WSU has granted to Tonix an exclusive license, with the right to sublicense, certain patents, technical information
and material (collectively, the &#x201c;Technology&#x201d;) related to the Assets. WSU has reserved for itself the right to practice the
Technology for academic research and educational purposes. Tonix is obligated to use commercially reasonable efforts to obtain regulatory
approval for one or more products utilizing the Technology (&#x201c;WSU Products&#x201d;) and to use commercially reasonable marketing efforts
throughout the term of the WSU License Agreement. The WSU License Agreement specifies developmental milestones and the period of time
during which such milestones must be completed and provides for an annual maintenance fee payable to WSU. Tonix is obligated to substantially
manufacture WSU Products in the United States if WSU Products will be sold in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the WSU License
Agreement, Tonix paid $&lt;span id="xdx_905_ecustom--ReimbursementOfPatentExpenses_pp0p0_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zMbUHTlrnkc" title="Reimbursement of patent expenses"&gt;75,000&lt;/span&gt;
to WSU as reimbursement of certain patent expenses, and, upon the achievement of specified development, regulatory and sales milestones,
the Company also agreed to pay WSU, milestone payments totaling approximately $&lt;span id="xdx_905_ecustom--ContingentMilestonePaymentObligation_iI_pn5n6_c20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zzuL0bQa1O5e"&gt;3.4&lt;/span&gt;
million. Tonix has also agreed to pay WSU single-digit royalties on net sales of WSU Products sold by Tonix or a sublicensee on
a tiered basis based on net sales, and additional sublicense fees on certain consideration received from sublicensees. Royalties on each
particular WSU Product are payable on a country-by-country and Product-by-Product basis until the date of expiration of the last valid
claim in the last to expire of the issued patents covered by the WSU License Agreement. Royalties payable on net sales of WSU Products
may be reduced by &lt;span id="xdx_903_ecustom--PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_pip0_dp_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zQUD7VdYEra1"&gt;50&lt;/span&gt;%
of the royalties payable by Tonix to any third party for intellectual property rights which are necessary for the practice of the rights
licensed to Tonix under the WSU License Agreement, provided that the royalty payable on a WSU Product may not be reduced by more than
&lt;span id="xdx_90D_ecustom--MaximumPercentageReductionOfRoyaltiesPayable_pip0_dp_uPure_c20190817__20190819__us-gaap--TypeOfArrangementAxis__custom--WSULicenseAgreementMember_zJ92oUJDlrRc" title="Maximum percentage reduction of royalties payable"&gt;50&lt;/span&gt;%.
Each party also has the right to terminate the agreement for customary reasons such as material breach and bankruptcy. The WSU License
Agreement contains provisions relating to termination, indemnification, confidentiality and other customary matters for an agreement of
this kind. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.&lt;/p&gt;

</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember"
      decimals="0"
      unitRef="USD">68500</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember"
      decimals="0"
      unitRef="USD">168500</us-gaap:OtherResearchAndDevelopmentExpense>
    <tnxp:AchievementPaymentsPayable
      contextRef="AsOf2019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember"
      decimals="-5"
      unitRef="USD">3400000</tnxp:AchievementPaymentsPayable>
    <tnxp:ReimbursementOfPatentExpenses
      contextRef="From2019-08-172019-08-19_custom_WSULicenseAgreementMember"
      decimals="0"
      unitRef="USD">75000</tnxp:ReimbursementOfPatentExpenses>
    <tnxp:ContingentMilestonePaymentObligation
      contextRef="AsOf2019-08-19_custom_WSULicenseAgreementMember"
      decimals="-5"
      unitRef="USD">3400000</tnxp:ContingentMilestonePaymentObligation>
    <tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable
      contextRef="From2019-08-172019-08-19_custom_WSULicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable>
    <tnxp:MaximumPercentageReductionOfRoyaltiesPayable
      contextRef="From2019-08-172019-08-19_custom_WSULicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</tnxp:MaximumPercentageReductionOfRoyaltiesPayable>
    <tnxp:LicenseAgreementCuriaTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_ecustom--LicenseAgreementCuriaTextBlock_zmVMdNiVDNxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE
11 &#x2013; &lt;span id="xdx_824_zk8ewTuFmCM1"&gt;LICENSE AGREEMENT WITH CURIA&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 12, 2022,
the Company entered into an exclusive license agreement with Curia for the development of three humanized murine mAbs for the
treatment or prophylaxis of SARS-CoV-2 infection. We believe that the licensing of these mAbs strengthens our pipeline of
next-generation therapeutics to treat COVID-19, which is caused by SARS-CoV-2. As consideration for entering into the License
Agreement, we paid a license fee of approximately $&lt;span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20201221__20201222__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--CuriaMember_znz5GLmHjf63" title="Payment for purchase of assets"&gt;0.4&lt;/span&gt;
million to Curia. The License Agreement also provides for single-digit royalties and contingent milestone payments. As of
December 31, 2022, other than the upfront fee, no payments have been accrued or paid in relation to this agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</tnxp:LicenseAgreementCuriaTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-12-212020-12-22_custom_LicenseAgreementMember_custom_CuriaMember"
      decimals="-5"
      unitRef="USD">400000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <tnxp:LicenseAgreementUniversityOfAlbertaTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_ecustom--LicenseAgreementUniversityOfAlbertaTextBlock_zPO8BKylQcNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE
12 &#x2013; &lt;span id="xdx_827_znrREsD4ZjT4"&gt;LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 18, 2022, the
Company entered into an exclusive License Agreement with the University of Alberta focused on identifying and testing broad-spectrum
antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses. As consideration for entering into the License
Agreement, Tonix paid a low-five digit license fee to University of Alberta. The License Agreement also provides for single-digit
royalties and contingent milestone payments. As of December 31, 2022, other than the upfront fee, no milestone payments have been
accrued or paid in relation to this agreement.&lt;/p&gt;

</tnxp:LicenseAgreementUniversityOfAlbertaTextBlock>
    <tnxp:LicenseAgreementOyagenTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_ecustom--LicenseAgreementOyagenTextBlock_zk6ikIDYblvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE
13 &#x2013; &lt;span id="xdx_824_z9Ivl92pT0I9"&gt;LICENSE AGREEMENT WITH OYAGEN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 14, 2021, the Company
and OyaGen, Inc. (&#x201c;OyaGen&#x201d;) entered into an exclusive License Agreement (the &#x201c;OyaGen License Agreement&#x201d;) pursuant
to which OyaGen granted to Tonix an exclusive license to certain patents and technical information related to an antiviral inhibitor of
SARS-CoV-2, sangivamycin, and to develop and commercialize products thereunder, and to acquire rights to any technology based thereon
for the prevention or treatment of COVID-19 developed by OyaGen during the term of the License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As consideration for entering
into the License Agreement, Tonix paid a low-seven digit license fee to OyaGen, and issued to OyaGen and an affiliated entity an aggregate
of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210413__20210414__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--OyaGenIncMember_z0FEluzy5aza" title="Number of shares issued (in shares)"&gt;86,010
&lt;/span&gt;shares of the Company&#x2019;s common stock. The shares were valued at $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210413__20210414__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--OyaGenIncMember_zFH5CW9x6IDe" title="Value of shares issued"&gt;3&lt;/span&gt;.0
million, which was recorded as research and development expense. The OyaGen License also provided for single-digit royalties and contingent
milestone payments.&#160;In July 2022, the Company notified OyaGen of its intent to terminate the OyaGen License Agreement, and the agreement
was terminated effective September 20, 2022.&lt;/p&gt;

</tnxp:LicenseAgreementOyagenTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-04-132021-04-14_custom_LicenseAgreementMember_custom_OyaGenIncMember"
      decimals="INF"
      unitRef="Shares">86010</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-04-132021-04-14_custom_LicenseAgreementMember_custom_OyaGenIncMember"
      decimals="-5"
      unitRef="USD">3000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <tnxp:LicenseAgreementWithInsermTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_ecustom--LicenseAgreementWithInsermTextBlock_z9vTIhWRIYki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
14 &#x2013; &lt;span id="xdx_825_zuH0EoTXRfQ8"&gt;LICENSE AGREEMENT WITH INSERM&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On February 11, 2021,
the Company entered into a license agreement (the &#x201c;Inserm License Agreement&#x201d;) pursuant to which it licensed technology
using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from Inserm
(the French National Institute of Health and Medical Research), Aix-Marseille Universit&#xe9; and Centre Hospitalier Universitaire
of Toulouse. The Inserm License Agreement provides for the payment of annual fees and milestone payments upon the occurrence of
specified sales milestones totaling approximately $&lt;span id="xdx_905_ecustom--SalesMilestones_pn5n6_c20210207__20210211__us-gaap--TypeOfArrangementAxis__custom--InsermLicenseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--InsermMember__us-gaap--BusinessAcquisitionAxis__custom--OxytocinBasedTherapeuticsMember_ze9LYZdlwqa"&gt;0.4&lt;/span&gt;
million, as well royalties on net sales of products based on the licensed technology, and assignment/transfer and sublicense
royalties. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.&lt;/p&gt;

</tnxp:LicenseAgreementWithInsermTextBlock>
    <tnxp:SalesMilestones
      contextRef="From2021-02-072021-02-11_custom_InsermLicenseAgreementMember_custom_InsermMember_custom_OxytocinBasedTherapeuticsMember"
      decimals="-5"
      unitRef="USD">400000</tnxp:SalesMilestones>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_z18pYIUDsTjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE
15 &#x2013; &lt;span id="xdx_82C_zUPdDVsYYye"&gt;LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On September 16, 2019, the
Company entered into an exclusive License Agreement (the &#x201c;Columbia License Agreement&#x201d;) with the Trustees of Columbia University
in the City of New York (&#x201c;Columbia&#x201d;), as subsequently amended, pursuant to which Columbia granted to Tonix an exclusive license,
with the right to sublicense, certain patents and technical information (collectively, the &#x201c;TFF2 Technology&#x201d;) related to a
recombinant Trefoil Family Factor 2 (TFF2), and to develop and commercialize products thereunder (each, a &#x201c;TFF2 Product&#x201d;).
Pursuant to the terms of the Columbia License Agreement, Columbia reserved for itself the right to practice the TFF2 Technology for academic
research and educational purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company paid a five-digit
license fee to Columbia as consideration for entering into the Columbia License Agreement, which was recorded to research and development
expenses in the statement of operations for the year ended December 31, 2019. The Company is obligated to use Commercially Reasonable
Efforts, as defined in the Columbia License Agreement, to develop and commercialize the TFF2 Product, and to achieve specified developmental
milestones.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is obligated to
pay Columbia single-digit royalties on net sales of (i) TFF2 Products sold by Tonix or a sublicensee and (ii) any other products that
involve material or technical information related to the TFF2 Product and transferred to Tonix pursuant to the Columbia License Agreement
(&#x201c;Other Products&#x201d;) sold by Tonix or a sublicensee. Royalties on each particular TFF2 Product are payable on a country-by-country
and Product-by-Product basis until the latest of (i) the date of expiration of the last valid claim in the last to expire of the issued
patents covered by the Columbia License Agreement, and (ii) a specified period of time after the first commercial sale of a TFF2 Product
in the country in question. Royalties on each particular Other Product are payable on a country-by-country and product-by-product basis
until a specified period of time after the first commercial sale of such particular Other Product in such country. Royalties payable on
net sales of the TFF2 Product and Other Products may be reduced by &lt;span id="xdx_907_ecustom--PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_pii_dp_uPure_c20190915__20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_zEa5slyh3Gbb" title="Percentage of third party royalties payable for reduction in royalties payable"&gt;50&lt;/span&gt;%
of the royalties payable by Tonix to any third party for intellectual property rights which are necessary for the practice of the rights
licensed to Tonix under the Columbia License Agreement, provided that the royalty payable on a Product or Other Product may not be reduced
by more than &lt;span id="xdx_904_ecustom--MaximumPercentageReductionOfRoyaltiesPayable_pid_dp_c20190915__20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_z6EHqMRDJbT4"&gt;50&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is also
obligated to make contingent milestone payments to Columbia totaling $&lt;span id="xdx_907_ecustom--ContingentMilestonePaymentObligation_iI_pn5n6_c20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_zSmiqv9VEsBj"&gt;4.1&lt;/span&gt;
million on a Product-by-Product basis upon the achievement of certain development, approval and sales milestones related to a
TFF2 Product. In addition, the Company shall pay Columbia &lt;span id="xdx_906_ecustom--PercentagePadOfConsideration_pii_dp_uPure_c20190915__20190916__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__custom--TFF2ProductMember_zeYxuX7xrI93"&gt;5&lt;/span&gt;%
of consideration, other than royalty payments and certain other categories of consideration, payable to the Company by a
sublicensee. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 20, 2019, the Company
entered into an exclusive License Agreement (the &#x201c;License Agreement&#x201d;) with Columbia pursuant to which Columbia, for itself
and on behalf of the University of Kentucky and the University of Michigan (collectively, the &#x201c;Institutions&#x201d;) granted to the
Company an exclusive license, with the right to sublicense, certain patents, technical information and material (collectively, the &#x201c;Technology&#x201d;)
related to a double-mutant cocaine esterase, and to develop and commercialize products thereunder (each, a &#x201c;Product&#x201d;). Pursuant
to the terms of the License Agreement, Columbia has reserved for itself and the Institutions the right to practice the Technology for
academic research and educational purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company paid a six-digit
license fee to Columbia as consideration for entering into the License Agreement. The Company is obligated to use Commercially Reasonable
Efforts, as defined in the License Agreement, to develop and commercialize the Product, and to achieve specified developmental milestones.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company agreed to pay
Columbia single-digit royalties on net sales of (i) Products sold by the Company or a sublicensee and (ii) any other products that involve
material or technical information related to the Product and transferred to the Company pursuant to the License Agreement (&#x201c;Other
Products&#x201d;) sold by the Company or a sublicensee. Royalties on each particular Product are payable on a country-by-country and Product-by-Product
basis until the latest of (i) the date of expiration of the last valid claim in the last to expire of the issued patents covered by the
License Agreement, (ii) a specified period of time after the first commercial sale of a Product in the country in question, or (iii) expiration
of any market exclusivity period granted by a regulatory agency. Royalties on each particular Other Product are payable on a country-by-country
and product-by-product basis until the later of (i) a specified period of time after the first commercial sale of such particular Other
Product in such country or (ii) expiration of any market exclusivity period granted by a regulatory agency. Royalties payable on net sales
of the Product and Other Products may be reduced by &lt;span id="xdx_90E_ecustom--PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable_pii_dp_uPure_c20190519__20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z3Ah1vyNKzfa" title="Percentage of third party royalties payable for reduction in royalties payable"&gt;50&lt;/span&gt;%
of the royalties payable by the Company to any third party for intellectual property rights which are necessary for the practice of the
rights licensed to the Company under the License Agreement, provided that the royalty payable on a Product or Other Product may not be
reduced by more than &lt;span id="xdx_909_ecustom--MaximumPercentageReductionOfRoyaltiesPayable_pii_dp_uPure_c20190519__20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zLBjcBcHGDdf"&gt;50&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is also
obligated to make contingent milestone payments to Columbia totaling $&lt;span id="xdx_900_ecustom--ContingentMilestonePaymentObligation_iI_pn6n6_c20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zETW1gpFSL7l"&gt;3 &lt;/span&gt;million
on a Product-by-Product basis upon the achievement of certain development, approval and sales milestones related to a Product. In
addition, the Company shall pay Columbia &lt;span id="xdx_90D_ecustom--PercentagePadOfConsideration_pii_dp_c20190519__20190520__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--TrusteesOfColumbiaUniversityMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zmkLfTqx8ti4"&gt;5&lt;/span&gt;%
of consideration, other than royalty payments and certain other categories of consideration, payable to the Company by a
sublicensee. As of December 31, 2022, no milestone payments have been accrued or paid in relation to this agreement.&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable
      contextRef="From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember"
      decimals="INF"
      unitRef="Pure">0.50</tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable>
    <tnxp:MaximumPercentageReductionOfRoyaltiesPayable
      contextRef="From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember"
      decimals="INF"
      unitRef="Pure">0.50</tnxp:MaximumPercentageReductionOfRoyaltiesPayable>
    <tnxp:ContingentMilestonePaymentObligation
      contextRef="AsOf2019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember"
      decimals="-5"
      unitRef="USD">4100000</tnxp:ContingentMilestonePaymentObligation>
    <tnxp:PercentagePadOfConsideration
      contextRef="From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember"
      decimals="INF"
      unitRef="Pure">0.05</tnxp:PercentagePadOfConsideration>
    <tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable
      contextRef="From2019-05-192019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember"
      decimals="INF"
      unitRef="Pure">0.50</tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable>
    <tnxp:MaximumPercentageReductionOfRoyaltiesPayable
      contextRef="From2019-05-192019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember"
      decimals="INF"
      unitRef="Pure">0.50</tnxp:MaximumPercentageReductionOfRoyaltiesPayable>
    <tnxp:ContingentMilestonePaymentObligation
      contextRef="AsOf2019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember"
      decimals="-6"
      unitRef="USD">3000000</tnxp:ContingentMilestonePaymentObligation>
    <tnxp:PercentagePadOfConsideration
      contextRef="From2019-05-192019-05-20_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_us-gaap_ProductMember"
      decimals="INF"
      unitRef="Pure">0.05</tnxp:PercentagePadOfConsideration>
    <tnxp:SaleOfCommonStockTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_801_ecustom--SaleOfCommonStockTextBlock_zkqgYm651y81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
16 &#x2013; &lt;span id="xdx_829_znZ5hxBTWOm2"&gt;SALE OF COMMON STOCK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;2022
Lincoln Park Transaction&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 16, 2022, the Company
entered into a purchase agreement (the &#x201c;2022 Purchase Agreement&#x201d;) and a registration rights agreement (the &#x201c;2022 Registration
Rights Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;). Pursuant to the terms of the 2022 Purchase
Agreement, Lincoln Park has agreed to purchase from the Company up to $&lt;span id="xdx_906_ecustom--CommitmentToPurchaseSharesUnderAgreement_c20220815__20220816__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z50KXIyDKuF7"&gt;50,000,000&lt;/span&gt;
of the Company&#x2019;s common stock (subject to certain limitations) from time to time during the term of the 2022 Purchase Agreement.
Pursuant to the terms of the 2022 Registration Rights Agreement, the Company filed with the SEC a registration statement to register for
resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the 2022 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the terms of the
2022 Purchase Agreement, at the time the Company signed the 2022 Purchase Agreement and the 2022 Registration Rights Agreement, the Company
issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20220815__20220816__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z4LIr3qQQrQ3"&gt;625,000&lt;/span&gt;
shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of the Company&#x2019;s common stock under
the 2022 Purchase Agreement. The commitment shares were valued at $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220815__20220816__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zRzFBi8lXsde"&gt;1,000,000&lt;/span&gt;
and recorded as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost of capital to
be raised under the 2022 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2022, the Company sold &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pin6_uShares_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member_z8bNL6UaqGfg"&gt;1&lt;/span&gt;.0
million shares of common stock under the 2022 Purchase Agreement, for net proceeds of approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member_zIUrLx7pxS47"&gt;0.5&lt;/span&gt; million.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Subsequent to December
31, 2022, the Company sold &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWWQp9yQGgZe"&gt;0.6&lt;/span&gt;
million shares of common stock under the 2022 Purchase Agreement with Lincoln Park for net proceeds of approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zk9p11hapJT7"&gt;0.4&lt;/span&gt;
million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Purchase
Agreement with Lincoln Park&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 3, 2021, the Company
entered into a purchase agreement (the &#x201c;Purchase Agreement with Lincoln Park&#x201d;) and a registration rights agreement (the &#x201c;Lincoln
Park Registration Rights Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;). Pursuant to the terms of
the Purchase Agreement with Lincoln Park, Lincoln Park agreed to purchase from the Company up to $&lt;span id="xdx_904_ecustom--CommitmentToPurchaseSharesUnderAgreement_pp0p0_c20211202__20211203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zf4X4ncK4tSk" title="Commitment to purchase shares under agreement"&gt;80,000,000&lt;/span&gt;
of the Company&#x2019;s common stock (subject to certain limitations) from time to time during the term of the Purchase Agreement with
Lincoln Park. Pursuant to the terms of the Lincoln Park Registration Rights Agreement, the Company filed with the SEC a registration statement
to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase Agreement
with Lincoln Park.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the terms of the
Purchase Agreement with Lincoln Park, at the time the Company signed the Purchase Agreement with Lincoln Park and the Lincoln Park Registration
Rights Agreement, the Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20211202__20211203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuyjH4acUWUh" title="Number of shares issued (in shares)"&gt;90,910&lt;/span&gt;
shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under the Purchase Agreement
with Lincoln Park. The commitment shares were valued at $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20211202__20211203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zrMlS9NSOZ25" title="Number of shares issued, value"&gt;1.6&lt;/span&gt;
million and recorded as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost
of capital to be raised under the Purchase Agreement with Lincoln Park.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2022, the Company sold &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_zpe0SyFDZCo2" title="Number of shares issued (in shares)"&gt;2.9&lt;/span&gt;
million shares of common stock under the Purchase Agreement with Lincoln Park, for net proceeds of approximately $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_z39QCFnChULi" title="Proceeds from equity offerings"&gt;8.7&lt;/span&gt;
million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under applicable rules of
the NASDAQ Global Market, the Company could not issue or sell more than &lt;span id="xdx_90B_ecustom--PercentageOfIssuanceByIssuerOfCommonStock_pid_dp_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_zXHHpWeJzW2c" title="Percentage of issuance by issuer of common stock"&gt;19.99&lt;/span&gt;%
of the shares of its common stock outstanding immediately prior to the execution of the Purchase Agreement with Lincoln Park (approximately
&lt;span id="xdx_907_ecustom--MaximumNumberOfSharesIssuedWIthoutShareholderApproval_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_zQLTeK74SRu"&gt;2.9
million&lt;/span&gt; shares) to Lincoln Park under the Purchase Agreement with Lincoln Park without stockholder approval, unless the average
price of all applicable sales of its common stock to Lincoln Park under the Purchase Agreement with Lincoln Park equals or exceeds a threshold
amount. As the Company has issued approximately &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnParkMember_ztTVAweLUA45" title="Number of shares issued (in shares)"&gt;2.9&lt;/span&gt;
million shares to Lincoln Park, by December 31, 2022, under the Purchase Agreement with Lincoln Park at less than the threshold
amount, the Company will not sell any additional shares under the Purchase Agreement with Lincoln Park without shareholder approval.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;2021
Lincoln Park Transaction&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 14, 2021, the Company
entered into a purchase agreement (the &#x201c;2021 Purchase Agreement&#x201d;) and a registration rights agreement (the &#x201c;2021 Registration
Rights Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;). Pursuant to the terms of the 2021 Purchase
Agreement, Lincoln Park agreed to purchase from the Company up to $&lt;span id="xdx_904_ecustom--CommitmentToPurchaseSharesUnderAgreement_pp0p0_c20210513__20210514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2021Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zj5xIMcex5x6" title="Commitment to purchase shares under agreement"&gt;80,000,000&lt;/span&gt;
of the Company&#x2019;s common stock (subject to certain limitations) from time to time during the term of the 2021 Purchase Agreement.
Pursuant to the terms of the 2021 Registration Rights Agreement, the Company filed with the SEC a registration statement to register for
resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the 2021 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the terms of the
2021 Purchase Agreement, at the time the Company signed the 2021 Purchase Agreement and the 2021 Registration Rights Agreement, the Company
issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210513__20210514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2021Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z4BxbODE4YOc" title="Number of shares issued (in shares)"&gt;40,000&lt;/span&gt;
shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under the 2021 Purchase
Agreement. The commitment shares were valued at $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210513__20210514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2021Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zdPJYy0Cz8k4" title="Number of shares issued, value"&gt;1.6&lt;/span&gt;
million and recorded as an addition to equity for the issuance of the common stock and treated as a reduction to equity as a cost
of capital to be raised under the 2021 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;During
the year ended December 31, 2021, the Company sold an aggregate of approximately &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zi9nt3a3jY88"&gt;2&lt;/span&gt;.0
million shares of common stock under the 2021 Purchase Agreement, for gross proceeds of approximately $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zpceiXFLrtJb"&gt;41.3&lt;/span&gt;
million. During the year ended December 31, 2022, no shares of common stock were sold under the 2021 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under applicable rules of
the NASDAQ Global Market, the Company could not issue or sell more than &lt;span id="xdx_90B_ecustom--PercentageOfIssuanceByIssuerOfCommonStock_pid_dp_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zemlrmf9tmQl"&gt;19.99&lt;/span&gt;%
of the shares of its common stock outstanding immediately prior to the execution of the 2021 Purchase Agreement (approximately &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zkIKkhByQBRj"&gt;2&lt;/span&gt;.0
million shares) to Lincoln Park under the 2021 Purchase Agreement without stockholder approval, unless the average price of all applicable
sales of its common stock to Lincoln Park under the 20121 Purchase Agreement equals or exceeds a threshold amount. As the Company has
issued approximately &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2021Member_zyovP8OIVAh8"&gt;2&lt;/span&gt;.0
million shares to Lincoln Park under the 2021 Purchase Agreement, at less than the threshold amount, the Company will not sell any additional
shares under the 2021 Purchase Agreement without shareholder approval.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;February
2021 Financing&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On February 8, 2021, the Company
entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210206__20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zTbIrfm3ncvf" title="Number of shares issued (in shares)"&gt;1.8&lt;/span&gt;
million shares of its common stock, in a registered direct public offering (the &#x201c;February 2021 Financing&#x201d;), with A.G.P/Alliance
Global Partners (&#x201c;AGP&#x201d;), acting as placement agent. The public offering price for each share of common stock was $&lt;span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pii_uUSDPShares_c20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zhAvZ68ejCpi" title="Sale of stock, price (in dollars per share)"&gt;38.40&lt;/span&gt;.
The February 2021 Financing closed on February 9, 2021. AGP received a cash fee of &lt;span id="xdx_904_ecustom--CashFeePercentage_pii_dp_uPure_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zhnRVLhBCvsc" title="Cash fee"&gt;7&lt;/span&gt;%
of the gross proceeds, for an aggregate amount of $&lt;span id="xdx_901_ecustom--UnderwritingDiscount_pn5n6_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zWDUMiZTt4Tj" title="Underwriting discount"&gt;4.9&lt;/span&gt;
million. The Company incurred other offering expenses of approximately $&lt;span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zHiesFvN8xk1" title="Expenses from sale of stock"&gt;0.1&lt;/span&gt;
million. The Company received net proceeds of approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0n6_c20210207__20210209__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zx5bIdqVzCw6" title="Proceeds from equity offerings"&gt;65&lt;/span&gt;.0
million, after deducting the fees and other offering expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;January
2021 Financing&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On January 11, 2021, the Company
entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zS8vPSSFQpv1" title="Number of shares issued (in shares)"&gt;1.6&lt;/span&gt;
million shares of its common stock in a registered direct public offering (the &#x201c;January 2021 Financing&#x201d;), with AGP as placement
agent. The public offering price for each share of common stock was $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pii_uUSDPShares_c20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zjRo6y7SNWOe" title="Sale of stock, price (in dollars per share)"&gt;25.60&lt;/span&gt;.
The January 2021 Financing closed on January 13, 2021. AGP received a cash fee of &lt;span id="xdx_90F_ecustom--CashFeePercentage_pii_dp_uPure_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zaXicIi3WK54" title="Cash fee"&gt;7&lt;/span&gt;%
of the gross proceeds, for an aggregate of $&lt;span id="xdx_903_ecustom--UnderwritingDiscount_pn5n6_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zlBSWUVvau65" title="Underwriting discount"&gt;2.8&lt;/span&gt;
million. The Company incurred other offering expenses of approximately $&lt;span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z5Rja3KLIdZ" title="Expenses from sale of stock"&gt;0.3&lt;/span&gt;
million. The Company received net proceeds of approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210110__20210111__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zE2vi2vmdGP5" title="Proceeds from equity offerings"&gt;36.9&lt;/span&gt;
million, after deducting the fees and other offering expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;At-the-Market Offerings&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;On April 8, 2020, the
Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with AGP pursuant to which the Company may issue and sell,
from time to time, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $&lt;span id="xdx_902_ecustom--OfferingPricePerAgreement_pp0n6_c20200407__20200408__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember_zbR37rECCVK9" title="Offering price per agreement"&gt;320&lt;/span&gt;.0
million in at-the-market offerings (&#x201c;ATM&#x201d;) sales. AGP will act as sales agent and will be paid a &lt;span id="xdx_908_ecustom--SalesAgentCommissionPercentage_pid_dp_c20200407__20200408__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember_zhNEkmYMNiEd" title="Commission to agent"&gt;3&lt;/span&gt;%
commission on each sale under the Sales Agreement. The Company&#x2019;s common stock will be sold at prevailing market prices at the time
of the sale, and, as a result, prices will vary. During the year ended December 31, 2022, the Company sold approximately &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zofP0hjxw8yg" title="Number of shares sold"&gt;56.4&lt;/span&gt;
million shares of common stock under the Sales Agreement, for net proceeds of approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zQRFYB55csR2" title="Proceeds from equity offerings"&gt;85.3&lt;/span&gt;
million. During the year ended December 31, 2021, the Company sold approximately &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zEhdmqnIEhFi" title="Number of shares sold"&gt;3.5&lt;/span&gt;
million shares of common stock under the Sales Agreement, for net proceeds of approximately $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z9OLykwE979j" title="Proceeds from equity offerings"&gt;69.3&lt;/span&gt;
million. Subsequent to December 31, 2022, the Company has sold &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP35eL8qUe99" title="Number of shares issued (in shares)"&gt;2.1&lt;/span&gt;
million shares of common stock under the Sales Agreement, for net proceeds of approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuctuwBxR2N3" title="Proceeds from equity offerings"&gt;1.4&lt;/span&gt;
million.&#160;&lt;/p&gt;

</tnxp:SaleOfCommonStockTextBlock>
    <tnxp:CommitmentToPurchaseSharesUnderAgreement
      contextRef="From2022-08-152022-08-16_custom_PurchaseAgreementWithLincolnPark2022Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</tnxp:CommitmentToPurchaseSharesUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-08-152022-08-16_custom_PurchaseAgreementWithLincolnPark2022Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-08-152022-08-16_custom_PurchaseAgreementWithLincolnPark2022Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnPark2022Member"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnPark2022Member"
      decimals="-5"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="Shares">600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <tnxp:CommitmentToPurchaseSharesUnderAgreement
      contextRef="From2021-12-022021-12-03_custom_PurchaseAgreementWithLincolnParkMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">80000000</tnxp:CommitmentToPurchaseSharesUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-12-022021-12-03_custom_PurchaseAgreementWithLincolnParkMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">90910</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-12-022021-12-03_custom_PurchaseAgreementWithLincolnParkMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      unitRef="USD">1600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember"
      decimals="-5"
      unitRef="Shares">2900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember"
      decimals="-5"
      unitRef="USD">8700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <tnxp:PercentageOfIssuanceByIssuerOfCommonStock
      contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember"
      decimals="INF"
      unitRef="Pure">0.1999</tnxp:PercentageOfIssuanceByIssuerOfCommonStock>
    <tnxp:MaximumNumberOfSharesIssuedWIthoutShareholderApproval
      contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember"
      decimals="-5"
      unitRef="Shares">2900000</tnxp:MaximumNumberOfSharesIssuedWIthoutShareholderApproval>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnParkMember"
      decimals="-5"
      unitRef="Shares">2900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <tnxp:CommitmentToPurchaseSharesUnderAgreement
      contextRef="From2021-05-132021-05-14_custom_PurchaseAgreementWithLincolnPark2021Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">80000000</tnxp:CommitmentToPurchaseSharesUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-05-132021-05-14_custom_PurchaseAgreementWithLincolnPark2021Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">40000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-05-132021-05-14_custom_PurchaseAgreementWithLincolnPark2021Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      unitRef="USD">1600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member"
      decimals="-5"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member"
      decimals="-5"
      unitRef="USD">41300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <tnxp:PercentageOfIssuanceByIssuerOfCommonStock
      contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member"
      decimals="INF"
      unitRef="Pure">0.1999</tnxp:PercentageOfIssuanceByIssuerOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member"
      decimals="-5"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_PurchaseAgreement2021Member"
      decimals="-5"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-02-062021-02-08_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="Shares">1800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-02-08_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      unitRef="USDPShares">38.40</us-gaap:SaleOfStockPricePerShare>
    <tnxp:CashFeePercentage
      contextRef="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      unitRef="Pure">0.07</tnxp:CashFeePercentage>
    <tnxp:UnderwritingDiscount
      contextRef="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="USD">4900000</tnxp:UnderwritingDiscount>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-02-072021-02-09_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="0"
      unitRef="USD">65000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="Shares">1600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      unitRef="USDPShares">25.60</us-gaap:SaleOfStockPricePerShare>
    <tnxp:CashFeePercentage
      contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      unitRef="Pure">0.07</tnxp:CashFeePercentage>
    <tnxp:UnderwritingDiscount
      contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="USD">2800000</tnxp:UnderwritingDiscount>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-01-102021-01-11_custom_UnderwritingAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="USD">36900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <tnxp:OfferingPricePerAgreement
      contextRef="From2020-04-072020-04-08_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="0"
      unitRef="USD">320000000</tnxp:OfferingPricePerAgreement>
    <tnxp:SalesAgentCommissionPercentage
      contextRef="From2020-04-072020-04-08_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      unitRef="Pure">0.03</tnxp:SalesAgentCommissionPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="Shares">56400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-01-012022-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="USD">85300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="Shares">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-01-012021-12-31_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      unitRef="USD">69300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-13_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="Shares">2100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-03-13_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">1400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z714NrcDyBge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
17 &#x2013; &lt;span id="xdx_823_ziwiO9BYfRr6"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Stock
Incentive Plans&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 3, 2019, the Company&#x2019;s
stockholders approved the Tonix Pharmaceuticals Holding Corp. 2019 Stock Incentive Plan (the &#x201c;2019 Plan&#x201d;). The 2019 Plan provided
for the issuance of up to &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20190503__us-gaap--PlanNameAxis__custom--IncentiveStockOptionsPlan2019Member_zaL8suJWocxf"&gt;4,375&lt;/span&gt;
shares of common stock. With the adoption of the 2020 Plan (as defined below), no further grants may be made under the 2019 Plan. On January
16, 2020, the Company&#x2019;s stockholders approved the Tonix Pharmaceuticals Holding Corp. 2020 Stock Incentive Plan (the &#x201c;2020
Plan&#x201d;). The 2020 Plan provided for the issuance of up to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200116__us-gaap--PlanNameAxis__custom--IncentiveStockOptionsPlan2020Member_zam1TCfr9Ipc" title="Number of shares authorized"&gt;18,750&lt;/span&gt;
shares of common stock. With the adoption of the Amended and Restated 2020 Plan (as defined below), no further grants may be made under
the 2020 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 1, 2020, the Company&#x2019;s
stockholders approved the Tonix Pharmaceuticals Holding Corp. Amended and Restated 2020 Stock Incentive Plan (&#x201c;Amended and Restated
2020 Plan&#x201d;), and together with the 2020 Plan and the 2019 Plan, the &#x201c;Plans&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the terms of the Amended
and Restated 2020 Plan, the Company may issue (1) stock options (incentive and nonstatutory), (2) restricted stock, (3) stock appreciation
rights (&#x201c;SARs&#x201d;), (4) RSUs, (5) other stock-based awards, and (6) cash-based awards. The Amended and Restated 2020 Plan initially
provided for the issuance of up to &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_uShares_c20200501__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_zrXzoHb7MVYc" title="Percentage of additional shares authorized"&gt;312,500
&lt;/span&gt;shares of common stock, which amount&#160;will be increased to the extent that awards granted under the Plans are forfeited, expire
or are settled for cash (except as otherwise provided in the Amended and Restated 2020 Plan). In addition, the Amended and Restated 2020
Plan contains an &#x201c;evergreen provision&#x201d; providing for an annual increase in the number of shares of our common stock available
for issuance under the Amended and Restated 2020 Plan on January 1 of each year for a period of ten years, commencing on January 1, 2021
and ending on (and including) January 1, 2030, in an amount equal to the difference between (x) twenty percent (&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_z5JN5TZDMruc" title="Percentage of additional shares authorized"&gt;20&lt;/span&gt;%)
of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, and (y) the total number of
shares of common stock reserved under the Amended and Restated 2020 Plan on December 31&lt;sup&gt;st&lt;/sup&gt; of such preceding calendar year
(including shares subject to outstanding awards, issued pursuant to awards or available for future awards). The Board of Directors determines
the exercise price, vesting and expiration period of the grants under the Amended and Restated 2020 Plan. However, the exercise price
of an incentive stock option may not be less than &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TenPercentOrMoreShareholderMember_zKhcrQyZ8KO4"&gt;110&lt;/span&gt;%
of fair value of the common stock at the date of the grant for a 10% or more shareholder and &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_zH1a80XjbmUk"&gt;100&lt;/span&gt;%
of fair value for a grantee who is not a 10% shareholder. The fair value of the common stock is determined based on quoted market price
or in absence of such quoted market price, by the Board of Directors in good faith. Additionally, the expiration period of grants under
the Amended and Restated 2020 Plan may not be more than &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dt_c20220101__20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_zogx3eLsmzri" title="Expiration period"&gt;ten
years&lt;/span&gt;. As of December 31, 2022, &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestated2020PlanMember_z0dC6IryuFB"&gt;627,744
&lt;/span&gt;options were available for future grants under the Amended and Restated 2020 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;

&lt;div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt; width: 100%"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhcqcmcrSy7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;A
summary of the stock option&#160;activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted- Average&lt;/b&gt;&lt;/span&gt;
        &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&#160;Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;/span&gt;
        &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Remaining&#160;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Contractual&#160;Term&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;
        &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 37%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_z8QEF9Ldn2Ae" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;319,179&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zXwgtIPhAWm4" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;2.93&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zCCVNJiiNH67" style="width: 15%; text-align: right" title="Weighted average remaining contractual term"&gt;&lt;span style="font-size: 10pt"&gt;9.26&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zV7Y3IVFQpma" style="width: 12%; text-align: right" title="Beginning, Aggregate Intrinsic Value"&gt;&lt;span style="font-size: 10pt"&gt;131,558&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Grants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zfiIfBvbsM0j" style="text-align: right" title="Grants"&gt;&lt;span style="font-size: 10pt"&gt;486,639&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zOG86dylxtf8" style="text-align: right" title="Grants"&gt;&lt;span style="font-size: 10pt"&gt;40.85&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeitures or expirations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_zKjEzdjLrTjf" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"&gt;&lt;span style="font-size: 10pt"&gt;(56)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zYFeC7ZW3OO8" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"&gt;&lt;span style="font-size: 10pt"&gt;149,713.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_z9MNdSsWT9Cj" style="text-align: right" title="Outstanding at end"&gt;&lt;span style="font-size: 10pt"&gt;805,762&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231_zx8pJKNcryj5" style="text-align: right" title="Outstanding at end"&gt;&lt;span style="font-size: 10pt"&gt;78.02&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zqr2cpE1k0G6" style="text-align: right" title="Weighted average remaining contractual term"&gt;&lt;span style="font-size: 10pt"&gt;8.83&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Grants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zVwtcF2kU1L3" style="text-align: right" title="Grants"&gt;&lt;span style="font-size: 10pt"&gt;1,695,608&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zHGKSimzqy61" style="text-align: right" title="Grants"&gt;&lt;span style="font-size: 10pt"&gt;12.06&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeitures or expirations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_zJlazzscnvEb" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"&gt;&lt;span style="font-size: 10pt"&gt;(48,339&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zeyG8JWfNyvf" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"&gt;&lt;span style="font-size: 10pt"&gt;255.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_z7anQ9MzTHXe" style="border-bottom: black 2.5pt double; text-align: right" title="Outstanding at end"&gt;&lt;span style="font-size: 10pt"&gt;2,453,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231_z3zk9WvoIDZj" style="border-bottom: black 2.5pt double; text-align: right" title="Outstanding at end"&gt;&lt;span style="font-size: 10pt"&gt;28.93&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zZDC6CBOJOH2" style="border-bottom: black 2.5pt double; text-align: right" title="Weighted average remaining contractual term"&gt;&lt;span style="font-size: 10pt"&gt;8.70&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zctTAL3gFE74" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"&gt;&lt;span style="font-size: 10pt"&gt;590,582&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231_zmQTYImGOZde" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"&gt;&lt;span style="font-size: 10pt"&gt;70.82&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zvIpaX7vLUkj" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"&gt;&lt;span style="font-size: 10pt"&gt;7.64&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zkfAKwaYTs56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The aggregate intrinsic value
in the preceding table represents the total pretax intrinsic value, based on options with an exercise price less than the Company&#x2019;s
closing stock price at the respective dates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The weighted average grant
date fair value of options granted during the years ended December 31, 2022 and 2021, was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231_zmAM6aMsywm9" title="Weighted average grant date fair value of options (in dollars per share)"&gt;5.25&lt;/span&gt;
and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231_zsA6nSKoDZpe" title="Weighted average grant date fair value of options (in dollars per share)"&gt;33.78&lt;/span&gt;
per share, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company measures the
fair value of stock options on the date of grant, based on the Black Scholes option pricing model using certain assumptions
discussed below, and the closing market price of the Company&#x2019;s common stock on the date of the grant. The fair value of the
award is measured on the grant date. &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4p0_dxL_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z1VA1CI012M9" title="Vesting percentage::XDX::0.3333"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1020"&gt;One-third &lt;/span&gt;&lt;/span&gt;of
most stock options granted pursuant to the Plans vest 12 months from the date of grant and &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4p0_dxL_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zUk6ZZi0p1V7" title="::XDX::0.0278"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;1/36&lt;/span&gt;&lt;sup&gt;th &lt;/sup&gt;&lt;/span&gt;each
month thereafter for 24 months and expire &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNkgTBl1Gks5"&gt;ten
years&lt;/span&gt; from the date of grant. In addition, the Company issues options to directors which vest over a &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zzdHhXaHRwG1" title="Vesting period::XDX::P1Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;one-year&lt;/span&gt;&lt;/span&gt; period. The Company also issues premium options to executive officers which have an exercise price greater than the grant
date fair value and has issued performance-based options which vest when target parameters are met or probable of being met, subject
in each case to a &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dt_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_z3rvzDOnmCZg" title="Service period"&gt;one
year&lt;/span&gt; minimum service period prior to vesting. Stock-based compensation expense related to awards is amortized over the
applicable service period using the straight-line method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zohZPBPNS2ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The
assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows:&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20220101__20221231_zEHr2YtfTD2g" title="Risk-free interest rate - Minimum"&gt;1.67&lt;/span&gt;%
        to &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20220101__20221231_zj83l5FCbyFi" title="Risk-free interest rate - Maximum"&gt;3.05&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20210101__20211231_z7zgsb62MYJj" title="Risk-free interest rate - Minimum"&gt;0.79&lt;/span&gt;%
        to &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20210101__20211231_zSZG5dwWmFo" title="Risk-free interest rate - Maximum"&gt;1.63&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expected term of option&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zsSuL8lrJP0d" title="Expected term of option"&gt;5.5&lt;/span&gt;
        to &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zXqxUtnnjALi" title="Expected term of option"&gt;10&lt;/span&gt;
        years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zzSShwBZa0ci" title="Expected term of option"&gt;5.5&lt;/span&gt;
        to &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zPPZOPlezia2" title="Expected term of option"&gt;6&lt;/span&gt;
        years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20220101__20221231_zWx2tt7XZ9ke" title="Expected stock price volatility - minimum"&gt;120.32&lt;/span&gt;%
        - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20220101__20221231_zw8PbQelsC11" title="Expected stock price volatility - maximum"&gt;133.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20210101__20211231_zTRrTh3rQWWa" title="Expected stock price volatility - minimum"&gt;124.37&lt;/span&gt;%
        to &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20210101__20211231_ztMZAIvH0p67" title="Expected stock price volatility - maximum"&gt;137.73&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-size: 10pt"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20220101__20221231_zptWT381s0ac" title="Expected dividend yield"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20210101__20211231_zelPGnsdwk4c" title="Expected dividend yield"&gt;0.0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_ziP5tLr2ywr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The risk-free interest rate
is based on the yield of Daily U.S. Treasury Yield Curve Rates with terms equal to the expected term of the options as of the grant date.&#160;The
expected term of options is determined using the simplified method, as provided in an SEC Staff Accounting Bulletin,&#160;and the expected
stock price volatility is based on the Company&#x2019; historical stock price volatility.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Stock-based compensation expense
relating to options granted of $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQoO2M336M3e" title="Stock-based compensation expense"&gt;10.9&lt;/span&gt;
million, of which $&lt;span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEMYASB0chNh" title="General and administrative"&gt;7.9&lt;/span&gt;
million and $&lt;span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_pp0n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0fuFMSWg6Be" title="Research and development costs"&gt;3&lt;/span&gt;.0
million, related to General and Administration and Research and Development, respectively was recognized for the year ended December 31,
2022.&#160;Stock-based compensation expense relating to options granted of $&lt;span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSRCOiVD7Omh" title="Stock-based compensation expense"&gt;7.9&lt;/span&gt;
million, of which $&lt;span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zql36sCXS7L6" title="General and administrative"&gt;5.5&lt;/span&gt;
million and $&lt;span id="xdx_900_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcqkGMlVgnv7" title="Research and development costs"&gt;2.4&lt;/span&gt;
million, related to General and Administration and Research and Development, respectively was recognized for the year ended December
31, 2021.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2022, the
Company had approximately $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV3X3Kgj2xLe" title="Unrecognized compensation cost"&gt;11.6&lt;/span&gt;
million of unrecognized compensation cost related to non-vested awards granted under the Plans, which the Company expects to recognize
over a weighted average period of &lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoo7X38FIeY7" title="Unrecognized compensation cost, recognition period"&gt;1.73&lt;/span&gt;
years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Employee
Stock Purchase Plans&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 3, 2019, the Company&#x2019;s
stockholders approved the Tonix Pharmaceuticals Holdings Corp. 2019 Employee Stock Purchase Plan (the &#x201c;2019 ESPP&#x201d;). As a result
of adoption of the 2020 ESPP, as defined below, by the stockholders, no further grants may be made under the 2019 ESPP Plan. On May 1,
2020, the Company&#x2019;s stockholders approved the Tonix Pharmaceuticals Holdings Corp. 2020 Employee Stock Purchase Plan (the &#x201c;2020
ESPP&#x201d;). No further grants may be made under the 2020 ESPP Plan. On May 6, 2022, the Company&#x2019;s stockholders approved the Tonix
Pharmaceuticals Holdings Corp. 2022 Employee Stock Purchase Plan (the &#x201c;2022 ESPP&#x201d;, and together with the 2019 ESPP and the
2020 ESPP, the &#x201c;ESPP Plans&#x201d;)).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The 2022 ESPP allows eligible
employees to purchase up to&#160;an aggregate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_uShares_c20190503__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member_zuHNaliqJsC7" title="Number of shares authorized"&gt;93,750&lt;/span&gt;&#160;shares
of the Company&#x2019;s common stock. Under the 2022 ESPP, on the first day of each offering period, each eligible employee for that offering
period has the option to enroll for that offering period, which allows the eligible employees to purchase shares of the Company&#x2019;s
common stock at the end of the offering period. Each offering period under the 2022 ESPP is for six months, which can be modified from
time-to-time. Subject to limitations, each participant will be permitted to purchase a number of shares determined by dividing the employee&#x2019;s
accumulated payroll deductions for the offering period by the applicable purchase price, which is equal to&#160;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20190502__20190503__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member_zbU14m199Yc7" title="Percent of fair value of common stock at grant date"&gt;85&lt;/span&gt;
percent&#160;of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. A participant
must designate in his or her enrollment package the percentage (if any) of compensation to be deducted during that offering period for
the purchase of stock under the 2022 ESPP, subject to the statutory limit under the Code. As of December 31, 2022, &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member_zbGVUGmtuH09" title="Number of shares available for future grants"&gt;9&lt;/span&gt;
shares were available for future sales under the 2022 ESPP.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;The 2022 and 2020 ESPP
are considered compensatory plans with the related compensation cost expensed over the six-month offering period. For the year ended December
31, 2022 and 2021, $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlansMember_zVMq5N5BQDj4" title="Stock-based compensation expense"&gt;46,000&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlansMember_zdYaFxp6sHc" title="Stock-based compensation expense"&gt;89,000&lt;/span&gt;,
respectively were expensed. In January 2021, &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20210101__20210131__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zO9nldlnmN38" title="Employee stock purchase plan (in shares)"&gt;1,703&lt;/span&gt;
shares that were purchased as of December 31, 2020, under the 2020 ESPP, were issued. Accordingly, during the first quarter of 2021, approximately
$&lt;span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c20210101__20210331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zP09K8f98sZe" title="Transfer to additional paid in capital"&gt;28,000&lt;/span&gt;
of employee payroll deductions accumulated at December 31, 2020, related to acquiring such shares, was transferred from accrued expenses
to additional paid in capital. The remaining $&lt;span id="xdx_90F_ecustom--AmountReturnToEmployee1_c20210101__20210331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_ztRDzRWV6EO3" title="ESPP withholdings returned to employees"&gt;4,000&lt;/span&gt;
was returned to the employees. In January 2022, &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20220101__20220131__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zC3r7Sdrw2N2" title="Employee stock purchase plan (in shares)"&gt;4,033&lt;/span&gt;
shares that were purchased as of December 31, 2021, under the 2020 ESPP, were issued. Accordingly, during the first quarter of 2022, approximately
$&lt;span id="xdx_90B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c20220101__20220331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zmzm71UeSVqd" title="Transfer to additional paid in capital"&gt;40,000&lt;/span&gt;
of employee payroll deductions accumulated at December 31, 2021, related to acquiring such shares, was transferred from accrued expenses
to additional paid in capital. The remaining $&lt;span id="xdx_901_ecustom--AmountReturnToEmployee1_c20220101__20220331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2020Member_zcfoyQVTHzKb" title="ESPP withholdings returned to employees"&gt;30,000&lt;/span&gt;
was returned to the employees. As of December 31, 2022, approximately $&lt;span id="xdx_90E_ecustom--AccumulatedEmployeePayrollDeductions_iI_pp0p0_c20221231__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlansMember_zoiDGqcXI7Lb"&gt;43,000&lt;/span&gt;
of employee payroll deductions have accumulated and have been recorded in accrued expenses.&#160;In January 2023, &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_uShares_c20230101__20230131__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1acdjwTc82i" title="Employee stock purchase plan (in shares)"&gt;93,741&lt;/span&gt;
shares that were purchased as of December 31, 2022, under the 2022 ESPP, were issued. Accordingly, during the first quarter of 2023, approximately
$&lt;span id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c20230101__20230331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvgE3ZgVcE2k" title="Transfer to additional paid in capital"&gt;29,000&lt;/span&gt;
of employee payroll deductions accumulated at December 31, 2023, related to acquiring such shares, was transferred from accrued expenses
to additional paid in capital. The remaining $&lt;span id="xdx_90D_ecustom--AmountReturnToEmployee1_c20230101__20230331__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlan2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zujTIrYagfg3" title="ESPP withholdings returned to employees"&gt;14,000&lt;/span&gt;
was returned to the employees.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2019-05-03_custom_IncentiveStockOptionsPlan2019Member"
      decimals="INF"
      unitRef="Shares">4375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-01-16_custom_IncentiveStockOptionsPlan2020Member"
      decimals="INF"
      unitRef="Shares">18750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-05-01_custom_AmendedAndRestated2020PlanMember"
      decimals="INF"
      unitRef="Shares">312500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <tnxp:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized
      contextRef="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember"
      decimals="INF"
      unitRef="Pure">0.20</tnxp:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember_custom_TenPercentOrMoreShareholderMember"
      decimals="INF"
      unitRef="Pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2022-01-012022-12-31_custom_AmendedAndRestated2020PlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_AmendedAndRestated2020PlanMember"
      decimals="INF"
      unitRef="Shares">627744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhcqcmcrSy7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;A
summary of the stock option&#160;activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted- Average&lt;/b&gt;&lt;/span&gt;
        &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&#160;Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;/span&gt;
        &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Remaining&#160;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Contractual&#160;Term&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt; &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;
        &lt;span style="font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 37%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_z8QEF9Ldn2Ae" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;319,179&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zXwgtIPhAWm4" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;2.93&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zCCVNJiiNH67" style="width: 15%; text-align: right" title="Weighted average remaining contractual term"&gt;&lt;span style="font-size: 10pt"&gt;9.26&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zV7Y3IVFQpma" style="width: 12%; text-align: right" title="Beginning, Aggregate Intrinsic Value"&gt;&lt;span style="font-size: 10pt"&gt;131,558&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Grants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zfiIfBvbsM0j" style="text-align: right" title="Grants"&gt;&lt;span style="font-size: 10pt"&gt;486,639&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zOG86dylxtf8" style="text-align: right" title="Grants"&gt;&lt;span style="font-size: 10pt"&gt;40.85&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeitures or expirations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_zKjEzdjLrTjf" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"&gt;&lt;span style="font-size: 10pt"&gt;(56)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zYFeC7ZW3OO8" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"&gt;&lt;span style="font-size: 10pt"&gt;149,713.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_z9MNdSsWT9Cj" style="text-align: right" title="Outstanding at end"&gt;&lt;span style="font-size: 10pt"&gt;805,762&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231_zx8pJKNcryj5" style="text-align: right" title="Outstanding at end"&gt;&lt;span style="font-size: 10pt"&gt;78.02&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zqr2cpE1k0G6" style="text-align: right" title="Weighted average remaining contractual term"&gt;&lt;span style="font-size: 10pt"&gt;8.83&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Grants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zVwtcF2kU1L3" style="text-align: right" title="Grants"&gt;&lt;span style="font-size: 10pt"&gt;1,695,608&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zHGKSimzqy61" style="text-align: right" title="Grants"&gt;&lt;span style="font-size: 10pt"&gt;12.06&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeitures or expirations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_zJlazzscnvEb" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"&gt;&lt;span style="font-size: 10pt"&gt;(48,339&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zeyG8JWfNyvf" style="border-bottom: black 1pt solid; text-align: right" title="Forfeitures or expirations"&gt;&lt;span style="font-size: 10pt"&gt;255.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_z7anQ9MzTHXe" style="border-bottom: black 2.5pt double; text-align: right" title="Outstanding at end"&gt;&lt;span style="font-size: 10pt"&gt;2,453,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231_z3zk9WvoIDZj" style="border-bottom: black 2.5pt double; text-align: right" title="Outstanding at end"&gt;&lt;span style="font-size: 10pt"&gt;28.93&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zZDC6CBOJOH2" style="border-bottom: black 2.5pt double; text-align: right" title="Weighted average remaining contractual term"&gt;&lt;span style="font-size: 10pt"&gt;8.70&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zctTAL3gFE74" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"&gt;&lt;span style="font-size: 10pt"&gt;590,582&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231_zmQTYImGOZde" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"&gt;&lt;span style="font-size: 10pt"&gt;70.82&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zvIpaX7vLUkj" style="border-bottom: black 2.5pt double; text-align: right" title="Exercisable at end"&gt;&lt;span style="font-size: 10pt"&gt;7.64&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">319179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">2.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31">P9Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">131558000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">486639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">40.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">149713.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">805762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">78.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31">P8Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">1695608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">12.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">48339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">255.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2453031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">28.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-12-31">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">590582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">70.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-12-31">P7Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">33.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_srt_ExecutiveOfficerMember">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zohZPBPNS2ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The
assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows:&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20220101__20221231_zEHr2YtfTD2g" title="Risk-free interest rate - Minimum"&gt;1.67&lt;/span&gt;%
        to &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20220101__20221231_zj83l5FCbyFi" title="Risk-free interest rate - Maximum"&gt;3.05&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pip0_dp_uPure_c20210101__20211231_z7zgsb62MYJj" title="Risk-free interest rate - Minimum"&gt;0.79&lt;/span&gt;%
        to &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pip0_dp_uPure_c20210101__20211231_zSZG5dwWmFo" title="Risk-free interest rate - Maximum"&gt;1.63&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expected term of option&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zsSuL8lrJP0d" title="Expected term of option"&gt;5.5&lt;/span&gt;
        to &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zXqxUtnnjALi" title="Expected term of option"&gt;10&lt;/span&gt;
        years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zzSShwBZa0ci" title="Expected term of option"&gt;5.5&lt;/span&gt;
        to &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zPPZOPlezia2" title="Expected term of option"&gt;6&lt;/span&gt;
        years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20220101__20221231_zWx2tt7XZ9ke" title="Expected stock price volatility - minimum"&gt;120.32&lt;/span&gt;%
        - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20220101__20221231_zw8PbQelsC11" title="Expected stock price volatility - maximum"&gt;133.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip0_dp_uPure_c20210101__20211231_zTRrTh3rQWWa" title="Expected stock price volatility - minimum"&gt;124.37&lt;/span&gt;%
        to &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip0_dp_uPure_c20210101__20211231_ztMZAIvH0p67" title="Expected stock price volatility - maximum"&gt;137.73&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-size: 10pt"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20220101__20221231_zptWT381s0ac" title="Expected dividend yield"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20210101__20211231_zelPGnsdwk4c" title="Expected dividend yield"&gt;0.0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1.2032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1.3322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">1.2437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">1.3773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="USD">10900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="USD">7900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="USD">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="USD">5500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="USD">2400000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="USD">11600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">P1Y8M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2019-05-03_custom_EmployeeStockPurchasePlan2022Member"
      decimals="INF"
      unitRef="Shares">93750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2019-05-022019-05-03_custom_EmployeeStockPurchasePlan2022Member"
      decimals="INF"
      unitRef="Pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_EmployeeStockPurchasePlan2022Member"
      decimals="INF"
      unitRef="Shares">9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_custom_EmployeeStockPurchasePlansMember"
      decimals="0"
      unitRef="USD">46000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlansMember"
      decimals="0"
      unitRef="USD">89000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2021-01-012021-01-31_custom_EmployeeStockPurchasePlan2020Member"
      decimals="INF"
      unitRef="Shares">1703</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_custom_EmployeeStockPurchasePlan2020Member"
      decimals="0"
      unitRef="USD">28000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <tnxp:AmountReturnToEmployee1
      contextRef="From2021-01-012021-03-31_custom_EmployeeStockPurchasePlan2020Member"
      decimals="0"
      unitRef="USD">4000</tnxp:AmountReturnToEmployee1>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2022-01-012022-01-31_custom_EmployeeStockPurchasePlan2020Member"
      decimals="INF"
      unitRef="Shares">4033</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlan2020Member"
      decimals="0"
      unitRef="USD">40000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <tnxp:AmountReturnToEmployee1
      contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlan2020Member"
      decimals="0"
      unitRef="USD">30000</tnxp:AmountReturnToEmployee1>
    <tnxp:AccumulatedEmployeePayrollDeductions
      contextRef="AsOf2022-12-31_custom_EmployeeStockPurchasePlansMember"
      decimals="0"
      unitRef="USD">43000</tnxp:AccumulatedEmployeePayrollDeductions>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2023-01-012023-01-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">93741</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">29000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <tnxp:AmountReturnToEmployee1
      contextRef="From2023-01-012023-03-31_custom_EmployeeStockPurchasePlan2022Member_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">14000</tnxp:AmountReturnToEmployee1>
    <tnxp:StockWarrantsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80C_ecustom--StockWarrantsTextBlock_zjKWOHygrJTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
18 &#x2013; &lt;span id="xdx_82D_zMDxE7PHHdh1"&gt;WARRANTS TO PURCHASE COMMON STOCK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zj70aoJ5PEa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zPJrhweMGqxe"&gt;The
following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zCRzvyBA0lhg" title="Exercise price (in dollars per share)"&gt;16.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z3WDRbN4k58d" title="Number Outstanding"&gt;779&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 52%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zwvsV3Q0zeg8" title="Expiration date"&gt;November
        2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zP7p8O46Jl69" title="Exercise price (in dollars per share)"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zKYtXM5JYcAk" title="Number Outstanding"&gt;3,860&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z59AAoLC2HR9" title="Expiration date"&gt;February
        2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zUzJwgpiox7d" title="Exercise price (in dollars per share)"&gt;1,120.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zJScLaqvFVii" title="Number Outstanding"&gt;15,331&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zgKKtWuc4mU2" title="Expiration Date"&gt;December
        2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231_z3Ravt8OtHy6" style="border-bottom: black 2.5pt double; text-align: right" title="Number Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;19,970&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;

&lt;p id="xdx_8A1_zKAb5nBoRudc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;No warrants were exercised
during the year ended December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2021, &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromFeb2020FinancingMember_zI7auKdDr2Ra" title="Number of exercised warrants"&gt;107&lt;/span&gt;
warrants from the February 2020 Financing, with an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromFeb2020FinancingMember_zACUVUYqijqe" title="Exercise price (in dollars per share)"&gt;18.24&lt;/span&gt;,
were exercised for proceeds of approximately $&lt;span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsFromFeb2020FinancingMember_zUN48XedUuba" title="Proceeds from exercise of warrants"&gt;2,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2021, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTpnxnGDpZM7" title="Number of warrants expired"&gt;5,441&lt;/span&gt;
and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--Warrant1Member_zBRLV7oD9KP9" title="Number of warrants expired"&gt;474&lt;/span&gt;
warrants with a per share exercise price of $&lt;span id="xdx_906_ecustom--ExercisePriceOfWarrantsExpired_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvNiuFlMtzk6" title="Exercise price of warrants expired (in dollars per share)"&gt;630.00&lt;/span&gt;
and $&lt;span id="xdx_902_ecustom--ExercisePriceOfWarrantsExpired_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--Warrant1Member_zq5LKyxh6HY9" title="Exercise price of warrants expired (in dollars per share)"&gt;687.50&lt;/span&gt;,
respectively, expired.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</tnxp:StockWarrantsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zj70aoJ5PEa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zPJrhweMGqxe"&gt;The
following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zCRzvyBA0lhg" title="Exercise price (in dollars per share)"&gt;16.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z3WDRbN4k58d" title="Number Outstanding"&gt;779&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 52%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zwvsV3Q0zeg8" title="Expiration date"&gt;November
        2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zP7p8O46Jl69" title="Exercise price (in dollars per share)"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zKYtXM5JYcAk" title="Number Outstanding"&gt;3,860&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z59AAoLC2HR9" title="Expiration date"&gt;February
        2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zUzJwgpiox7d" title="Exercise price (in dollars per share)"&gt;1,120.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zJScLaqvFVii" title="Number Outstanding"&gt;15,331&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantsOrRightExpirationDate_dd_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant3Member_zgKKtWuc4mU2" title="Expiration Date"&gt;December
        2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20221231_z3Ravt8OtHy6" style="border-bottom: black 2.5pt double; text-align: right" title="Number Outstanding"&gt;&lt;span style="font-size: 10pt"&gt;19,970&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_Warrant1Member"
      decimals="INF"
      unitRef="USDPShares">16.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_Warrant1Member"
      decimals="INF"
      unitRef="Shares">779</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tnxp:ClassOfWarrantsOrRightExpirationDate contextRef="From2022-01-012022-12-31_custom_Warrant1Member">2024-11</tnxp:ClassOfWarrantsOrRightExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_Warrant2Member"
      decimals="INF"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_Warrant2Member"
      decimals="INF"
      unitRef="Shares">3860</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tnxp:ClassOfWarrantsOrRightExpirationDate contextRef="From2022-01-012022-12-31_custom_Warrant2Member">2025-02</tnxp:ClassOfWarrantsOrRightExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_Warrant3Member"
      decimals="INF"
      unitRef="USDPShares">1120.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_Warrant3Member"
      decimals="INF"
      unitRef="Shares">15331</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tnxp:ClassOfWarrantsOrRightExpirationDate contextRef="From2022-01-012022-12-31_custom_Warrant3Member">2023-12</tnxp:ClassOfWarrantsOrRightExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">19970</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_custom_WarrantsFromFeb2020FinancingMember"
      decimals="INF"
      unitRef="Shares">107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_WarrantsFromFeb2020FinancingMember"
      decimals="INF"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-12-31_custom_WarrantsFromFeb2020FinancingMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember964078343"
      decimals="INF"
      unitRef="Shares">5441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-12-31_custom_Warrant1Member"
      decimals="INF"
      unitRef="Shares">474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <tnxp:ExercisePriceOfWarrantsExpired
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember964078343"
      decimals="INF"
      unitRef="USDPShares">630.00</tnxp:ExercisePriceOfWarrantsExpired>
    <tnxp:ExercisePriceOfWarrantsExpired
      contextRef="From2021-01-012021-12-31_custom_Warrant1Member"
      decimals="INF"
      unitRef="USDPShares">687.50</tnxp:ExercisePriceOfWarrantsExpired>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zOLPMTwxzxyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE
19 &#x2013; &lt;span id="xdx_82D_znOKrZPwTda7"&gt;LEASES&lt;/span&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has various operating
lease agreements, which are primarily for office space. These agreements frequently include one or more renewal options and require the
Company to pay for utilities, taxes, insurance and maintenance expense. No lease agreement imposes a restriction on the Company&#x2019;s
ability to engage in financing transactions or enter into further lease agreements. At December 31, 2022, the Company has right-of-use
assets of $&lt;span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_dxL_c20221231_zmW3UlGEQsZ4" title="Right-of-use assets, net::XDX::715"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1146"&gt;0.7
million&lt;/span&gt;&lt;/span&gt; and a total lease liability for operating leases of $&lt;span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_pn3n3_dxL_c20221231_zQAOQYVs8pS7" title="Total lease liability::XDX::760"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;0.7
million&lt;/span&gt;&lt;/span&gt; of which $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_dxL_c20221231_zqDQBdfx97E7" title="Lease liability, net of current portion::XDX::328"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1150"&gt;0.3
million&lt;/span&gt;&lt;/span&gt; is included in long-term lease liabilities and $&lt;span id="xdx_905_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_dxL_c20221231_zSuqWCRq4M8k" title="Lease liability, current::XDX::432"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1152"&gt;0.4
million&lt;/span&gt;&lt;/span&gt; is included in current lease liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zEJCFisgJnFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_zIwIJWsuho85"&gt;At
December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 88%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Year&#160;Ending&#160;December&#160;31,&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zCCQaPJv0y3" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1eV_zLp5OcVo0Bvg" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 85%"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;441&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1eV_zDZtryDitfu1" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;164&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1eV_zYuUd8SsbYG3" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;159&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1eV_zxMdw3u8PkT5" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1eV_zPrq8T8ost92" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1eV_zqeTNpUY4Efd" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;775&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z6yd4QrARzZ" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Included interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(15&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zbSFKU1qEcEh" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;760&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zOZ4gWu8uiJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2022, the Company entered into new operating leases and lease amendments, resulting in the Company recognizing an additional operating
lease liability of approximately $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zUsqH7eY7eD3" title="Total lease liability"&gt;386,000&lt;/span&gt;
based on the present value of the minimum rental payments. The Company also recognized a corresponding increase to ROU assets of approximately
$&lt;span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zUoVpP096WXc" title="Right-of-use assets, net"&gt;386,000&lt;/span&gt;,
which represents a non-cash investing and financing activity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2021, the Company entered into lease amendments, resulting in the Company recognizing an operating lease liability of approximately
$&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20211231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zsShrMUBfFH7" title="Total lease liability"&gt;467,000&lt;/span&gt;
based on the present value of the future minimum rental payments. The Company also recognized corresponding ROU assets of approximately
$&lt;span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231__us-gaap--OtherCommitmentsAxis__custom--NewLeaseArrangementMember_zS67rRsgacx7" title="Right-of-use assets, net"&gt;467,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Operating lease expense was
$&lt;span id="xdx_90C_eus-gaap--OperatingLeaseExpense_pp0n6_c20220101__20221231_zFxoeT3Zq08d" title="Operating lease expense"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseExpense_pp0n6_c20210101__20211231_zpUd512ddby8" title="Operating lease expense"&gt;0.6&lt;/span&gt;&lt;/span&gt;
million for both years ended December 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--SummaryOfOtherInformationRelatedToLeasesTableTextBlock_zZQ884hZvyXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_z6iTv0Mk00qk"&gt;Other
information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Cash paid for amounts included in the
        measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31,  2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31,  2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Operating cash flow from operating leases (in
        thousands)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220101__20221231_zPTNP0tOFsq6" title="Operating cash flow from operating leases"&gt;598&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeasePayments_c20210101__20211231_zxA2Wr6ED0pj" title="Operating cash flow from operating leases"&gt;632&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_z3HNyxEj2II" title="Weighted average remaining lease term operating leases"&gt;2.20&lt;/span&gt;
        years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_znQeP7VQh7pi" title="Weighted average remaining lease term operating leases"&gt;2.71&lt;/span&gt;
        years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20221231_zWKb6FI3X5N2" title="Weighted average discount rate operating leases"&gt;2.19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20211231_zpE9w2mRcp3" title="Weighted average discount rate operating leases"&gt;1.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zn30dbCnzhv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zEJCFisgJnFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_zIwIJWsuho85"&gt;At
December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 88%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Year&#160;Ending&#160;December&#160;31,&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zCCQaPJv0y3" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1eV_zLp5OcVo0Bvg" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 85%"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;441&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1eV_zDZtryDitfu1" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;164&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1eV_zYuUd8SsbYG3" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;159&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1eV_zxMdw3u8PkT5" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1eV_zPrq8T8ost92" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1eV_zqeTNpUY4Efd" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;775&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z6yd4QrARzZ" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Included interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(15&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zbSFKU1qEcEh" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;760&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">441000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">164000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">159000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">9000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">775000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">15000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">760000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31_custom_NewLeaseArrangementMember"
      decimals="0"
      unitRef="USD">386000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31_custom_NewLeaseArrangementMember"
      decimals="0"
      unitRef="USD">386000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-12-31_custom_NewLeaseArrangementMember"
      decimals="0"
      unitRef="USD">467000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31_custom_NewLeaseArrangementMember"
      decimals="0"
      unitRef="USD">467000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">600000</us-gaap:OperatingLeaseExpense>
    <tnxp:SummaryOfOtherInformationRelatedToLeasesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_ecustom--SummaryOfOtherInformationRelatedToLeasesTableTextBlock_zZQ884hZvyXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_z6iTv0Mk00qk"&gt;Other
information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Cash paid for amounts included in the
        measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31,  2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31,  2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Operating cash flow from operating leases (in
        thousands)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220101__20221231_zPTNP0tOFsq6" title="Operating cash flow from operating leases"&gt;598&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeasePayments_c20210101__20211231_zxA2Wr6ED0pj" title="Operating cash flow from operating leases"&gt;632&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_z3HNyxEj2II" title="Weighted average remaining lease term operating leases"&gt;2.20&lt;/span&gt;
        years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_znQeP7VQh7pi" title="Weighted average remaining lease term operating leases"&gt;2.71&lt;/span&gt;
        years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20221231_zWKb6FI3X5N2" title="Weighted average discount rate operating leases"&gt;2.19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_uPure_c20211231_zpE9w2mRcp3" title="Weighted average discount rate operating leases"&gt;1.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</tnxp:SummaryOfOtherInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">598000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">632000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2021-12-31">P2Y8M15D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.0219</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-12-31" decimals="INF" unitRef="Pure">0.0134</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--CommitmentsDisclosureTextBlock_zEYp0uEbb6u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
20 &#x2013; &lt;span id="xdx_82B_zf5jgiyywzp5"&gt;COMMITMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Contractual
agreements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has entered into
contracts with various contract research organizations with outstanding commitments aggregating approximately $&lt;span id="xdx_905_eus-gaap--OtherCommitment_iI_pn5n6_c20221231__us-gaap--OtherCommitmentsAxis__custom--ResearchOrganizationsMember_z7pGx69zPL2j" title="Outstanding commitments"&gt;58.6&lt;/span&gt;
million at December 31, 2022 for future work to be performed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company entered into a
construction contract with outstanding commitments aggregating approximately $&lt;span id="xdx_902_eus-gaap--OtherCommitment_iI_pn5n6_c20221231__us-gaap--OtherCommitmentsAxis__custom--ConstructionContractMember_ztsNR34Q3Sw8"&gt;2&lt;/span&gt;.0
million at December 31, 2022 for future work to be performed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Defined
contribution plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has a qualified
defined contribution plan (the &#x201c;401(k) Plan&#x201d;) pursuant to Section 401(k) of the Code, whereby all eligible employees may&#160;participate.
Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) Plan, subject to defined limitations. The
Company is required to make contributions to the 401(k) Plan equal to &lt;span id="xdx_907_eus-gaap--DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_pp2p2_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_z0nrLLNDcYh3" title="Employer matching contribution"&gt;100&lt;/span&gt;
percent of each participant&#x2019;s pretax contributions of up to &lt;span id="xdx_905_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pp2p2_dc_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_zm6o3kA1C7nf" title="Maximum annual contributions per employee"&gt;six&lt;/span&gt;
percent of his or her eligible compensation, and the Company is also required to make a contribution equal to &lt;span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pp2p2_dc_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_zTjULTFvkAH1" title="Maximum annual contributions per employer"&gt;three&lt;/span&gt;
percent of each participant&#x2019;s salary, on an annual basis, subject to limitations under the Code. The Company charged operations
$&lt;span id="xdx_90D_eus-gaap--DefinedContributionPlanAdministrativeExpenses_pn5n6_c20220101__20221231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_zEkwjy1H6Hb1" title="Administrative expenses"&gt;0.9&lt;/span&gt;
million and $&lt;span id="xdx_900_eus-gaap--DefinedContributionPlanAdministrativeExpenses_pn5n6_c20210101__20211231__us-gaap--PlanNameAxis__custom--DefinedContributionPlan401KPlanMember_z3isMgXWhtil" title="Administrative expenses"&gt;0.4&lt;/span&gt;
million for the year ended December 31, 2022, and 2021, respectively, for contributions under the 401(k) Plan.&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:OtherCommitment
      contextRef="AsOf2022-12-31_custom_ResearchOrganizationsMember"
      decimals="-5"
      unitRef="USD">58600000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2022-12-31_custom_ConstructionContractMember"
      decimals="-5"
      unitRef="USD">2000000</us-gaap:OtherCommitment>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember"
      decimals="2"
      unitRef="Pure">1</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember"
      decimals="2"
      unitRef="Pure">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember"
      decimals="2"
      unitRef="Pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember"
      decimals="-5"
      unitRef="USD">900000</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="From2021-01-012021-12-31_custom_DefinedContributionPlan401KPlanMember"
      decimals="-5"
      unitRef="USD">400000</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zK67rGSS6ckc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
21 &#x2013; &lt;span id="xdx_822_zsxHdSaWNw33"&gt;INCOME TAXES&lt;/span&gt; &#x2013; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zjEhisVJR1K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zkrsWCnn7Dhg"&gt;Components
of the net loss consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20220101__20221231_ztWF3FRkKBc5" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210101__20211231_zwJljXzTgmm9" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_maNILz5B4_zjwSRzlxvSb8" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(88,478&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(73,689&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maNILz5B4_zD5HtakXfWIb" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Domestic&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21,740&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(18,598&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_mtNILz5B4_zWli3YAq4N52" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(110,218&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(92,287&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zM55ZPdKQFB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In 2022, the foreign losses
are primarily comprised of $&lt;span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn5n6_di_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--IE_zMk3XEm5QkTc" title="Foreign losses"&gt;86.7&lt;/span&gt;
million related to the Irish operations and $&lt;span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn5n6_di_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--BM_zw0XCZZd7wSa"&gt;1.5&lt;/span&gt;
million related to the Bermudan operations of Tonix International Holding. In 2021, the foreign losses were primarily comprised
of $&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn5n6_di_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--BM_zmMsXvvDnXfk"&gt;71.9&lt;/span&gt;
million related to the Bermudan operations of Tonix International Holding.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zKciEbcJCate" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_zfk7VEREzlRg"&gt;A
reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate
the Company&#x2019;s income tax provision is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20220101__20221231_zahNZGVzxMBh" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20210101__20211231_zCeZkwzAOsSl" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maITP_zISccJzeiwI7" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 46%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Statutory federal income tax&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_msITP_zkI4qy92Ybmg" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_msITP_zPoyg7cYdzSa" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Foreign loss not subject to income tax&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange_pid_dp_uPure_msITP_zeJ7uWoD4SBb" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Attribute reduction from control change&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;%&lt;span style="font-size: 10pt"/&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_msITP_zz24AVYh3qHg" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtITP_zBwqkK0JoRN3" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Income Tax Provision&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z65NfV8SQWCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyovoei5FTde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zdnJIiIjnKH8"&gt;Deferred
tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20221231_zhQ3rRxBmsW" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20211231_ztCNS99boig2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsNetAbstract_iB_pn3n3_zR96kMS6Cvmf" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Deferred tax assets/(liabilities):&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGz7el_zqoraYjYLR0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font-size: 10pt"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,642&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,297&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3n3_maDTAGz7el_zAo1RF4kaHck" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,353&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,832&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGz7el_zxFVpCJ1aaFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,997&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,285&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGz7el_maDTALNzDL0_zZVByPplpQI9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Total deferred assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,992&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,414&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzDL0_zwdP8L1COg83" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(30,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21,414&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzDL0_zoryXsKDhVnj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1270"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zSI8MIp4vITj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has incurred research
and development (&#x201c;R&amp;amp;D&#x201d;) expenses, a portion of which qualifies for tax credits. The Company conducted an R&amp;amp;D credit
study to quantify the amount of credits and has claimed an R&amp;amp;D credit on its 2014-2017 tax returns. A portion of these R&amp;amp;D credit
carryforwards are subject to annual limitations in their use in accordance with Internal Revenue Service Code (&#x201c;IRC&#x201d;) section
383. The R&amp;amp;D credit carryforwards at December 31, 2022 have been reduced to $&lt;span id="xdx_90C_eus-gaap--TaxCreditCarryforwardAmount_iI_pdn6_c20221231__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zBiyqVopiSZ7" title="Credit carryforwards"&gt;0&lt;/span&gt;.0
million to reflect IRC section 383 ownership changes through December 31, 2022 and the resulting inability to utilize a portion of the
R&amp;amp;D credit prior to its expiration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At December 31, 2022, the
Company has $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--StatementGeographicalAxis__country--IE_zBr2As3oyQvi" title="Operating loss carryforwards"&gt;165.5
&lt;/span&gt;million of Ireland net operating loss (&#x201c;NOL&#x201d;) carryforwards that do not expire. As of December 31, 2022, the Company's
Federal NOL carryforwards of $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfHfIEDMvfCg"&gt;3.6
&lt;/span&gt;million, which do
not expire, but their utilization is limited to &lt;span id="xdx_908_ecustom--OperatingLossCarryforwardsLimitationsOnUsePercent_dp_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZv5YtHAjuI7" title="Utilization NOL (percent)"&gt;80%&lt;/span&gt; of taxable income. Additionally, the Company has New Jersey NOL carryforwards
of $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__srt--StatementGeographicalAxis__stpr--NJ_zyetk2emhH13"&gt;2.3
&lt;/span&gt;million and Massachusetts NOL carryforwards of $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__srt--StatementGeographicalAxis__stpr--MA_zP3srFVf1vm9"&gt;0.3
&lt;/span&gt;million, which both &lt;span id="xdx_906_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z9tvvqbEUZci" title="Operating loss carryforwards expiration"&gt;expire
in 20 years&lt;/span&gt;. The NOL carryforwards at December 31, 2022 have been reduced to reflect IRC section 382 ownership changes through December
31, 2022 and the resultant inability due to annual limitations, to utilize a portion of the NOL prior to its expiration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Management assesses the available
positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets.
A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December
31, 2022. Such objective evidence limits the ability to consider other subjective evidence such as our projections for future growth.
As such, the Company has determined that it is not more likely than not that the deferred tax assets will be realized and accordingly,
has provided a full valuation allowance against its gross deferred tax assets. The increase in the valuation allowance for the years ended
December 31, 2022 and 2021 were $&lt;span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20220101__20221231_zQjexi6KaKtf" title="Increase in valuation allowance"&gt;9.5&lt;/span&gt;
million, and $&lt;span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20210101__20211231_zmzO8o1zst3i"&gt;15.3&lt;/span&gt;
million respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes interest
accrued related to unrecognized tax benefits and penalties as income tax expense. However, as of December 31, 2022 there are no unrecognized
tax benefits recorded. The Company is subject to taxation in the United States and various states and foreign jurisdictions. As of December
31, 2022, the Company&#x2019;s tax returns remain open and subject to examination by the tax authorities for the tax years 2019 and after.&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zjEhisVJR1K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zkrsWCnn7Dhg"&gt;Components
of the net loss consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20220101__20221231_ztWF3FRkKBc5" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210101__20211231_zwJljXzTgmm9" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_maNILz5B4_zjwSRzlxvSb8" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(88,478&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(73,689&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maNILz5B4_zD5HtakXfWIb" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Domestic&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21,740&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(18,598&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_mtNILz5B4_zWli3YAq4N52" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(110,218&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(92,287&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-88478000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-73689000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-21740000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-18598000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-110218000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-92287000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_country_IE"
      decimals="-5"
      unitRef="USD">-86700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_country_BM"
      decimals="-5"
      unitRef="USD">-1500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2021-01-012021-12-31_us-gaap_ForeignCountryMember_country_BM"
      decimals="-5"
      unitRef="USD">-71900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zKciEbcJCate" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_zfk7VEREzlRg"&gt;A
reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate
the Company&#x2019;s income tax provision is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20220101__20221231_zahNZGVzxMBh" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20210101__20211231_zCeZkwzAOsSl" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maITP_zISccJzeiwI7" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 46%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Statutory federal income tax&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_msITP_zkI4qy92Ybmg" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_msITP_zPoyg7cYdzSa" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Foreign loss not subject to income tax&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange_pid_dp_uPure_msITP_zeJ7uWoD4SBb" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Attribute reduction from control change&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;%&lt;span style="font-size: 10pt"/&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_msITP_zz24AVYh3qHg" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtITP_zBwqkK0JoRN3" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Income Tax Provision&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.096</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.150</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <tnxp:EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.040</tnxp:EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange>
    <tnxp:EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.012</tnxp:EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyovoei5FTde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zdnJIiIjnKH8"&gt;Deferred
tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20221231_zhQ3rRxBmsW" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20211231_ztCNS99boig2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsNetAbstract_iB_pn3n3_zR96kMS6Cvmf" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Deferred tax assets/(liabilities):&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGz7el_zqoraYjYLR0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font-size: 10pt"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,642&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,297&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3n3_maDTAGz7el_zAo1RF4kaHck" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,353&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,832&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGz7el_zxFVpCJ1aaFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,997&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,285&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGz7el_maDTALNzDL0_zZVByPplpQI9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Total deferred assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,992&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,414&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzDL0_zwdP8L1COg83" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(30,992&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(21,414&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzDL0_zoryXsKDhVnj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1270"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">21642000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">13297000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">7353000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5832000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1997000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2285000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">30992000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">21414000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">30992000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">21414000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2022-12-31_us-gaap_ResearchMember"
      decimals="0"
      unitRef="USD">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember_country_IE"
      decimals="-5"
      unitRef="USD">165500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      unitRef="USD">3600000</us-gaap:OperatingLossCarryforwards>
    <tnxp:OperatingLossCarryforwardsLimitationsOnUsePercent
      contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember"
      decimals="INF"
      unitRef="Pure">0.80</tnxp:OperatingLossCarryforwardsLimitationsOnUsePercent>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_stpr_NJ"
      decimals="-5"
      unitRef="USD">2300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_stpr_MA"
      decimals="-5"
      unitRef="USD">300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">expire
in 20 years</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">9500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-012021-12-31"
      decimals="-5"
      unitRef="USD">15300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zebVu2qqZbLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE
22 &#x2013; &lt;span id="xdx_829_zXhDsNlEwME9"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="background-color: white"&gt;Since
January 1, 2023, the Company has repurchased &lt;/span&gt;&lt;span id="xdx_90B_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pip0_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember_zAxJF3HrGrV2"&gt;15,700,269&lt;/span&gt;&lt;span&gt;
of its shares of common stock outstanding under its $&lt;span id="xdx_90D_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn5n6_c20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember_zrwdihlIrRoc"&gt;12.5 &lt;/span&gt;million
s&lt;/span&gt;hare repurchase program at prices ranging from $&lt;span id="xdx_90E_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember__srt--RangeAxis__srt--MinimumMember_zrTqGdx6zKVi" title="Price of shares repurchased (in dollars per share)"&gt;0.44 &lt;/span&gt;to
$&lt;span id="xdx_900_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember__srt--RangeAxis__srt--MaximumMember_z7wuixmg6nj9"&gt;1.38&lt;/span&gt;&lt;span style="background-color: white"&gt;
per share for a gross aggregate cost of approximately $&lt;span id="xdx_908_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn5n6_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--ExistingShareRepurchaseProgramMember_zw9qmPv0oxf4" title="Value of shares repurchased"&gt;12.5&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;In
January 2023, the &lt;span style="background-color: white"&gt;Board of Directors approved &lt;/span&gt;a new share&#160;repurchase
program&#160;pursuant to which the Company may&#160;repurchase&#160;up to $&lt;span id="xdx_903_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn5n6_c20230102__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeoFBUU0My89" title="Repurchase program amount"&gt;12.5&lt;/span&gt;
million in value of its outstanding common stock from time to time on the open market and in privately negotiated transactions
subject to market conditions, share price and other factors.&#160;&lt;span style="background-color: white"&gt;Since January 1, 2023, the
Company has repurchased &lt;/span&gt;&lt;span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pip0_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember_zECEdf3vV2xf" title="Number of shares repurchased (in shares)"&gt;1,000,000&lt;/span&gt; &lt;span style="background-color: white"&gt;of
its shares of common stock outstanding under the new share repurchase program at $&lt;span id="xdx_90A_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_pid_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember_zam0u8T1YMQl"&gt;1.14&lt;/span&gt;
per share for a gross aggregate cost of $&lt;span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pn5n6_c20230101__20230313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShareRepurchaseProgramAxis__custom--NewShareRepurchaseProgramMember_zHus7B20ow9c"&gt;1.1&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
timing and amount of any shares&lt;/span&gt;&#160;repurchased&#160;&lt;span style="background-color: white"&gt;will be determined based on the Company&#x2019;s
evaluation of market conditions and other factors and the&lt;/span&gt;&#160;New Share Repurchase Program&#160;&lt;span style="background-color: white"&gt;may
be discontinued or suspended at any time.&#160;&lt;/span&gt;Repurchases&#160;&lt;span style="background-color: white"&gt;will be made in accordance
with the rules and regulations promulgated by the Securities and Exchange Commission and certain other legal requirements to which the
Company may be subject.&#160;&lt;/span&gt;Repurchases&#160;&lt;span style="background-color: white"&gt;may be made, in part, under a Rule 10b5-1 plan,
which allows stock&#160;&lt;/span&gt;repurchases&#160;&lt;span style="background-color: white"&gt;when the Company might otherwise be precluded from
doing so. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;Subsequent
to December 31, 2022, &lt;span style="background-color: white"&gt;the Company regained compliance with the minimum bid price requirement for
continued listing on The Nasdaq Capital Market because the Company&#x2019;s shares had a closing bid price at or above $&lt;span id="xdx_907_ecustom--MinimumBidRequirementPerShare_iI_c20230102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGYiIz2QN2oi" title="Minimum bid price requirements NASDAQ"&gt;1.00&lt;/span&gt;
per share for a minimum of &lt;span id="xdx_90E_ecustom--ConsecutiveBusinessDaysForMinimumBidPrice_dtD_c20230101__20230102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6i1jkwSBmo8" title="Consecutive business days for minimum bid price"&gt;10&lt;/span&gt;
consecutive business days, as set forth in Nasdaq Listing Rule 5550(a)(2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;On
February 2, 2023, the Company entered into an asset purchase agreement &lt;/span&gt;(the &#x201c;Asset Purchase Agreement&#x201d;) with Healion
Bio Inc., &lt;span style="background-color: white"&gt;pursuant to which the Company acquired all the pre-clinical infectious disease assets
of Healion, including its portfolio of next-generation antiviral technology assets. Healion&#x2019;s drug portfolio includes a class of
broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action, including TNX-3900, formerly
known as HB-121. &lt;/span&gt;As consideration for entering into the Asset Purchase Agreement, the Company paid $&lt;span id="xdx_909_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20230201__20230202__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--HealionBioIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z66gS0EEifMi" title="Consideration paid"&gt;1.2&lt;/span&gt;
million to Healion. Because the Healion intellectual property was acquired prior to FDA approval, the cash consideration totaling
$&lt;span id="xdx_903_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20230201__20230202__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--HealionBioIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv1HhJC88a9a" title="Research and development costs"&gt;1.2&lt;/span&gt;
million, is expected to be expensed as research and development costs since there is no alternative future use and the acquired
intellectual property does not constitute a business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On February 13, 2023, the
Company announced that it exercised an option to obtain an exclusive license from Columbia for the development of a portfolio of both
fully human and murine mAbs for the treatment or prophylaxis of SARS-CoV-2 infection, including the Company&#x2019;s TNX-3600 and TNX-4100
product candidates, respectively. The licensed mAbs were developed as part of a research collaboration and option agreement between the
Company and Columbia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On February 23, 2023, the
Company granted options to purchase an aggregate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4xieYygDOzj" title="Number of options granted (in shares)"&gt;4,394,303
&lt;/span&gt;shares of the Company&#x2019;s common stock to employees with an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zo56V5eVzWG8" title="Exercise price of options granted (in dollars per share)"&gt;0.73&lt;/span&gt;,
with a term of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZnnpm2YCgR2" title="Options term"&gt;ten
years&lt;/span&gt;, vesting &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zsMewqp61N04" title="Vesting percentage::XDX::0.3333"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1316"&gt;1/3
&lt;/span&gt;&lt;/span&gt;on the first anniversary and &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z5PUZMxXm7df" title="::XDX::0.0278"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;1/36&lt;/span&gt;&lt;/span&gt;&lt;sup&gt;th
&lt;/sup&gt;each month thereafter for 24 months. Additionally, the Company granted options to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHMOmNAyB7Xb"&gt;1,327,500
&lt;/span&gt;shares of the Company&#x2019;s common stock to certain employees with an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhjkoXv2l6o5"&gt;0.91&lt;/span&gt;,
with a term of &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znxmrHMTDbF4"&gt;ten
years&lt;/span&gt;, vesting &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zNskKi4uIm9c" title="::XDX::0.3333"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1321"&gt;1/3
&lt;/span&gt;&lt;/span&gt;on the first anniversary and &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pp4d_dxL_c20230222__20230223__us-gaap--AwardTypeAxis__custom--EmployeeStockOption1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z5OtPNl1UTgb" title="::XDX::0.0278"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;1/36&lt;/span&gt;&lt;/span&gt;&lt;sup&gt;th
&lt;/sup&gt;each month thereafter for 24 months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Subsequent to December 31,
2022, the Company sold &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementWithAGPMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znFI14KGqBka" title="Number of shares issued (in shares)"&gt;2.1&lt;/span&gt;
million shares of common stock under the Sales Agreement with AGP for net proceeds of approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementWithAGPMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoNSnEIa5xG2" title="Number of shares issued, value"&gt;1.4&lt;/span&gt;
million.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Subsequent to December 31,
2022, the Company sold &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_uShares_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCcTZi3jOrr3"&gt;0.6&lt;/span&gt;
million shares of common stock under the 2022 Purchase Agreement with Lincoln Park for net proceeds of approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230313__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementWithLincolnPark2022Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoKIuXTVpvAb"&gt;0.4&lt;/span&gt;
million.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember"
      decimals="INF"
      unitRef="Shares">15700269</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AsOf2023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember"
      decimals="-5"
      unitRef="USD">12500000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.44</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">1.38</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_ExistingShareRepurchaseProgramMember"
      decimals="-5"
      unitRef="USD">12500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AsOf2023-01-02_custom_NewShareRepurchaseProgramMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">12500000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_NewShareRepurchaseProgramMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_NewShareRepurchaseProgramMember"
      decimals="INF"
      unitRef="USDPShares">1.14</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2023-01-012023-03-13_us-gaap_SubsequentEventMember_custom_NewShareRepurchaseProgramMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <tnxp:MinimumBidRequirementPerShare
      contextRef="AsOf2023-01-02_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">1.00</tnxp:MinimumBidRequirementPerShare>
    <tnxp:ConsecutiveBusinessDaysForMinimumBidPrice contextRef="From2023-01-012023-01-02_us-gaap_SubsequentEventMember">P10D</tnxp:ConsecutiveBusinessDaysForMinimumBidPrice>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-02-012023-02-02_custom_AssetPurchaseAgreementMember_custom_HealionBioIncMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">1200000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-02-012023-02-02_custom_AssetPurchaseAgreementMember_custom_HealionBioIncMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">1200000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">4394303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">0.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2023-02-222023-02-23_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">1327500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">0.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2023-02-222023-02-23_custom_EmployeeStockOption1Member_us-gaap_SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-13_custom_SalesAgreementWithAGPMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="Shares">2100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-03-13_custom_SalesAgreementWithAGPMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">1400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="Shares">600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-03-13_custom_PurchaseAgreementWithLincolnPark2022Member_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">EisnerAmper LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Iselin, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">274</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^P:G*'".+>@6!=V<S+8I.8<Q4VQX)<6&R.QL4,LV<IAY-30_B+._^UQ)^#2
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MS4$QC.7^#9@RD-=7E(J'B=HAU#O"R5]02P,$%     @ )8MM5@A2)E/K P
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MSLS7=F] F +A,+75CCI4O1U+WL]GJ2]B/3EB74(\W(U:;5>&1BTD6  )QH#
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M<<%#L9.L"HC?G[*L?+VH7GBT>^?6U1]02P,$%     @ )8MM5I%=ZX43!
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M+C8UOC;RO8;7J*RVR#<J\HV#Y.\Q15TGQYITE[,%"I6;^5 7%Q0"TS=<Y,$
M[[W(#P+;RD58Y2+\WQ<9OKJC,&R<O[C(@RS>J]'=J(44Q=2V"*E9SYDJBTBU
M6W6AMBV^+_8[NCN5S>0?3-G:^D1,<R:AP(F&]$Y.M3Y1MHMRH?C,5MPQ5[I^
MVVFF.RP*8Z#/)YRK]<($J'IV]!=02P,$%     @ )8MM5FH@^TM&!P  4A
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M.J=QQ3XO34AB@5:RAS-NGDVKG..4,$7#Q0BD^Y('_*5K/#.T;,-P:")C07_
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M&C*,;]T\%L[I&Z\VKB0 HW6L:[S2S@ (;BTM"2IR6Q=MSO9%\M4N7RE:&$.
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M@4WL)MD61=$'6J)M8B522U)QW*_O4+)=ITT,%'WA93ASSES(X6@KU7>]8<S
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MJ1)K;;9]?N$^OHUAK9_1J% K>D<4WQ[FC#\2PFN"7@B5K=:&@ Y?[>[2/)K
MO=*OJ^4SNRD%%<QG+IQ>RH:C?<J=TCN]=%98# OK.X#N+ZQR2O/N#COP! :O
ME],#V.LL:"P1[T[-[XKKSU[;3)S9$BB=@J:A9RG^7Y"FQ_$(TFP8C]^ZCI*]
M9Z-"LPZ/(V79=W3[@O2K_?N[:)^=_\S;Q_N*F375BPJ[(M=A_.4H M,^B.W$
MZ3H\0KEV]*2%84G_(=!X ]I?:5+:37R _E_)_!=02P,$%     @ )8MM5F10
M2K$, P  %P<  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULQ57?;],P
M$'[/7W'*))["\J,_M[65MJX(!&-CW4 (\> FE\9:8@?;61E_/6>G#47:*O'$
M@Y.S???==T[N\V0CU8,N$ W\K$JAIWYA3'T:ACHML&+Z6-8H:">7JF*&IFH=
MZEHARUQ0589)% W#BG'ASR9N[4;-)K(Q)1=XHT W5<74TP66<C/U8W^W<,O7
MA;$+X6Q2LS4NT=S7-XIF88>2\0J%YE* PGSJG\>G%WWK[QP^<]SH/1ML)2LI
M'^SD73;U(TL(2TR-16#T>L0YEJ4%(AH_MIA^E](&[ML[]#>N=JIEQ33.9?F%
M9Z:8^F,?,LQ94YI;N7F+VWH&%B^5I79/V+2^"65,&VUDM0VF><5%^V8_M^>P
M%S".7@A(M@&)X]TF<BPOF6&SB9(;4-:;T*SA2G711(X+^U&61M$NIS@S6]Y=
MS]^_O?YPN;A=OCH:)_'H#!:?[M_=?9V$AO"M5YANL2Y:K.0%K#B!*RE,H6$A
M,LS^!@B)6,<NV;&[2 XB7F)Z#+TX@"1*D@-XO:[:GL/KO8"W^-%P\P3?SE?:
M*/HAOC]79 O1?Q["-LFIKEF*4Y^Z0*-Z1'_VZB@>1F<'"/8[@OU#Z/_X.0YC
M?;R^6WA#<##Q&;P,#=<"KM@3Q,/VH ,P!<)<5C433U[.2\R P1R5X3E/F4&0
M.<P+)M9(?ZLIG/M'?&09@R6F"@VUM_59&G(. /,<7?.U649MEF.X:91NF#!@
M9)OQN0R.C+<ELX5R?.+7)$FO>XDW.#D)AJ.38' R].)Q,.I'0=R/O;@7!?UA
MXHVCR!M$ML;S9DT-!8,#59),D.)D-!PK;C0P(I66J"TE+E*I:JF8590 F&[=
M,0N<MZ#:22$<L&BJ%2H;I NFVO!45A4I$35U^@"L,854_!>ES96L8! %4>0&
MQ'LV\:8N0 <6]_:H=V?RWZE[^WSCG67'<QT1[HE5A6KM)%E3@D:85K>ZU4[U
MSUNQ^^/>7AE73*VYT%!B3J'1\6C@@VIEN)T863OI6TE#0NK,@FXN5-:!]G,I
MS6YB$W1WX>PW4$L#!!0    ( "6+;59(=1[^P@4  & 2   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;.U837/;-A"]\U?L*&['F5$EDA(M?\_(CMNZ
MT]2N[;23(TQ"%AN28 !0BOOK^Q8D9=JRW3233'+H121 [,/;Q>X^BOM+I=^9
MN926/N1980YZ<VO+W>'0Q'.9"S-0I2SP9*9T+BR&^F9H2BU%XHSR;!CZ_M8P
M%VG1.]QW<^?Z<%]5-DL+>:[)5'DN].V1S-3RH!?TVHF+]&9N>6)XN%^*&WDI
M[9OR7&,T7*$D:2X+DZJ"M)P=]*;![M&8U[L%?Z1R:3KWQ)Y<*_6.!Z?)0<]G
M0C*3L64$@<M"'LLL8R#0>-]@]E9;LF'WOD7_T?D.7ZZ%D<<J^S--[/R@M]VC
M1,Y$E=D+M?Q9-OY$C!>KS+A?6M9K@TF/XLI8E3?&8)"G17T5'YHX= RV_2<,
MPL8@=+SKC1S+5\**PWVMEJ1Y-=#XQKGJK$$N+?A0+JW&TQ1V]O#JY/7YV<7T
MXBV=_/[F].KM_M "E9\-XP;AJ$8(GT (0GJM"CLW=%(D,KD/, 2=%:>PY704
M/HOX2L8#&@5]"OTP? 9OM/)QY/!&3_DH\U)II!R=O*]2>_N8CS7"^'$$KHQ=
M4XI8'O20^D;JA>P=?O\BV/+WGN$W7O$;/X?^46?P/,)O9U<GWH2^?[$=!L$>
M/02DLX+.8JNNI:9PJXYKG^Q<TK'*2U'<>G&FC$R(RZ0@-9M)G18WM,F H;_'
M*UO[]J%[%.R]1+[:.<526W0 2@MC4UMQP8D,HX5$!FM#FPS1H)VVLRU$G\I*
MFTH4UK.*EO,TGG?)46I,!7*B2,BH+.D#EP25.ET(*ZG,<"YH$[9/07_L^WW?
M]\D?^'Y P;W1SB#R*?H.LQA2,!Z,*. [! <9)W/V+ABUT4$<!% 31O:Z]%=K
MI^WC52C OL/;G<9DS]!4VS3.I$'LZ+2(E>9LY!!A%U/O(N$5K-,B1F<U\E$8
M4=FYTNG?,O',7.@:+U9YCE-#/.-W--,JIR!R3CO'@_;.C<[1\*36L+]TR^=B
M(:E0M%"63UMS P,H]M8@@  P"S?+W+!*<H+PY'H,W.FP-Q1GPAA>V.9$#6A*
M&:>S%.>(5FHE<@+3W@H]%L92V(] DS<R5+(-N\E>7B+E,'=TYP+5+CS-YPK3
M<V0+[P2$!X;>4@(9ZU*;80X$DG21)C V_:8*A/DAY?@B6[7%&O3^% _E^PJ9
MW35@9<%<=DNE2#D[9S"_=3!WYW1<GY/;?.#(/3R-):+7[)9>9Q*Y89UOJG3R
M!0S;<0GA=G70!CE.=5SEQHHBEF!Y?=M-(5X)QH^SX7U$LS-+K8?"BEW4-^KZ
M"'Q7-/AAVAMMY43UW"5R5GJVZQ"UZ86,@' G:+_.A9D4MD+8GW$,3&T="<ZB
M.E\PLJL.+ET'=Q'TFJR8KNW,N?ADRC"ZEJC"A+%ME^!"9)5D_R;P+VCPO77\
MYL$:MO>35LC]<ZUB*9$8&]Q/1@CA!NU$OO>K-&;7N[.IBY:[&Y\:CL"@_#:W
MQV-Z29M;/KWTSK,*%M,87:&-52RTON5RK<GB6-<<"/LA,"!.:WN9ZOHOO ZQ
M50FFG&==<S[;_L3Q1>= MWQ5.1U8E==*.+RV-R.2$J]521>F0#]!%A)>&0EU
M07@7Y,1,&.HN!Q_$[D%1W#NL1*+!)Y0\PL;#"38)ZG(U&FQS0_^E*A"'\2=*
MW9>4.&HESOLDB7,MLB-JT3,2%VZC2,>-Q$VK&[Q-4O2O^O:-REI7U:(OH6G?
MB)3]KV"?5<'&CRF8*XR1F_&^GG[1NGYYGT._0$B4I58?4J2GQ*'"X2U(=C0(
M/X>DA:/^)&*)&//U(T4-<C+>8ED+_9U/UK51/P+(Q-_Y[[J&?SVA(QVY:Z-K
M34]<UXBOH&H=+G1?TT9XUWKL7^:P\Z\_E_K&?=O@"JP*6W\ 6,VN/I],ZZ\&
M=\OK;R^OA;Z!KE$F9S#U!Y.H5S?)=F!5Z;XA7"MK5>YNYU(@X7D!GL\4.ETS
MX U6'Y4._P%02P,$%     @ )8MM5B[DBL>Q!   + L  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&ULG5;;;MLX$'WW5Q#JHN@"AB]*V@2);<!)O6W1
M;6LDSO:9IL8648I422J._WX/J4N<YK*+/B26J)DS9V8.AYSLC/WA<B+/[@JE
MW33)O2_/AD,G<BJX&YB2-+YLC"VXQZO=#EUIB6?1J5##=#1Z-RRXU,EL$M>6
M=C8QE5=2T](R5Q4%M_L+4F8W3<9)NW EM[D/"\/9I.1;NB9_4RXMWH8=2B8+
MTDX:S2QMILE\?'9Q'.RCP3^2=N[@F85,UL;\""^?LFDR"H1(D? !@>/GEBY)
MJ0 $&C\;S*0+&1P/GUOTOV+NR&7-'5T:]5UF/I\FIPG+:,,KY:_,[B,U^;P-
M>,(H%_^S76U[=)(P43EOBL89# JIZU]^U]3AP.%T](Q#VCBDD7<=*+)\SSV?
M3:S9,1NL@18>8JK1&^2D#DVY]A9?)?S\;'Y]O5BQY<W5Y<?Y]8+-/UPM%E\6
M7U?L^Z?51_9YOII_G4^&'I&"_5 TJ!<U:OH,ZCAE7XSVN6,+G5'V$& (BAW/
MM.5YD;Z(^)[$@!V-^RP=I>D+>$==WD<1[^BYO)V#XI>5%3EZRN9;2P2M>?9=
M^IQ]1BDU?RKO&O7X:=2P@\Y<R05-$VP11_:6DMGK5^-WH_,7.!]WG(]?0O_M
M7KV,^O7;:M$[9:]?G:;C\3G[/T'8-\W0$"K69%F:QJ:,^LSGU+LT1<GUGJ&4
M9"EC4GO#.'9?K'?9UIMW]7X#KQ@\'9W796?/]29:C<__Q!;I>L26.<?F%%1Y
M*;AR??9)BT'OS0/$SA'Q7<41%:1VN10Y6QDM[S ;?E8RT&U (UN'H:.XQRJL
MI785*H<E)QUL!'+066?A]CJSIB#$EUJH*I-ZR\P:QG[?>RY%U_(:@#031NMF
M5,7\@E/D!8RP:#9QZ0% O^7O,%0[^K&5)^?@'T:2BT3-6LDM#T"N5V%/6H!Q
MSP19C\G-%G<@[3 ?V=]28.0>[HCU/B*LR>^(=%<B+*W YT;#RX8\ \,/I.F6
ML[;\]6M7_L-"U)]Z;;AF]7&O#UL&'2%ON=615V P#XF7L3[WA&/YGF3RO'OO
M4>0^RV)K'PE] +?0+2=1QEA2AL.Q5GQH>Y3\KZUZ0LYM\THN,_8'&PU.XM_R
M(.&  M3"-=WO_5<:A^B-+8*RK05@+>1&,)I1UW)5]Z!_K[LHG&#MJG7WM=5*
MB;)H[WH'N^.1, =-'.E:Y=6&%0H@3%&0%9(KM<<&XLYHOE;$:(,R0JXPRR1\
M$ 0&&=WBYE#V<>CI:H-#O++@$K+&T:Y8:4U6"; 1BLNP!= )86[C[(%P [&:
M;W392;C\-@=0L#_"7 CM=A6F1QM]$+?"+Y*^%Z0K2<B-)-<BA56N<)XKP@FO
MJ=ZCD2PT9++8;J3#LBI*JIY5,>2!3X'K ;9E2*94%"H<4,#I%LITO< R3%ZM
MJQ +K4,=XN3:4*C*/F:,3&O>4=:(V^F]/6W[3)O[L,$QT'<0%K2S#B.!"V&K
MNO91S'%.JK@U>E$=D$$W\0=/G83#@QL,&K.-][2PRRKMZ\M,M]I=!>?U#>C>
MO+Y'?N%VBVG-%&W@BAWU-JGUW+YX4\;[T-IXW*[B8X[K+-E@@.\;8WS[$@)T
M%^39OU!+ P04    "  EBVU6I(.P?E,%  ",#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6RE5]MNVS@0??=7#-Q%T04$7Q3GTB8QX*3>-HLF#6)W
M^TQ+8XNH1*HD%2=_OX?4Q4[;!,7N2Z(+Y\R9,Q>-S[;:?+,9LZ.'(E?VO)\Y
M5[X;#FV2<2'L0)>L\&:M32$<;LUF:$O#(@U&13Z,1Z.C82&DZD_/PK-;,SW3
ME<NEXEM#MBH*81XO.-?;\_ZXWSZXDYO,^0?#Z5DI-KQ@]Z6\-;@;=BBI+%A9
MJ1497I_W9^-W%Q-_/ASX1_+6[EV3CV2E]3=_<Y6>]T>>$.><.(\@\.^>+SG/
M/1!H?&\P^YU+;[A_W:+_%6)'+"MA^5+G7V7JLO/^29]27HLJ=W=Z^Y&;> X]
M7J)S&_[2MCX[&?4IJ:S316,,!H54]7_QT.BP9W#RG$'<&,2!=^THL'POG)B>
M&;TEXT\#S5^$4(,UR$GED[)P!F\E[-QTMEC,EW3[Y>[RXVPQI]F'N_G\>GZS
MI*]7RX^TO+OZ,+^^NIF=#1V<>9-AT@!?U,#Q,\#CF*ZU<IFEN4HY?0HP!,N.
M:MQ2O8A?1'S/R8 .QA'%HSA^ >^@"_T@X!T\%[JU*/K;RB09TDJSC6%&N3GZ
M*EU&2R,W#,'%KT*O@2>_!O9]],Z6(N'S/AK%LKGG_O3UJ_'1Z/0%VI..]N0E
M]/^3L9>!;SXOY[VW]/K523P>G])O^J'/BOZN%-.XSLPH(I<Q7>JB%.JQ!SW9
M<$I2.4T"71A$+UO112?Z&V_E?<>CTTY[>BY'X>#X]$]TRWZN(KI2*)(W/^*T
MQWM"I92P<9A69#-A.--YRL:2$@58@H-AO-HG,W_@I/*C@Q9[!AT!A&(K@0 0
MWS:3"=AH)1\P;KY7TD>^"R;$;C'*<N$X[<&@D!L#*M !O$I/RF&RNB"(XR13
M.M<;R?8E=3HJ P1/B5:J&7A!&F\7J%@9'NIU>-1A]&J,J&5M,9WW28=J.#X%
M:S_>;""J5[G<" ]GJ4)S&T *U^DZ WUT?#AZQ];Y8&G^D.25]2I^D@EF^EXN
M(TJ#'C?ZGHL5T Y&OI)&QQ'HD*C1(EH]!L05NRVSVI<53Y>(Z4(+D_H EP9S
MDZ%:$^PG"(XS"R<4OF*I+U>I#7U1H&.@RV-7,.V1KE[V=>_LVPB:YS\7Y7Y-
MH.8AL=RHD%3/8^8U+D,V=C,G)*OST/+96?:>LVR=-BH^[<4!3'Q)6(DLA8P1
M\"DTI52;NBM]B,_U65L7J,V4_J"3>!(='[ZEHS@Z'(TH'@^.CR@^'$7Q9$SQ
M8.(1NL@]+OP4;1YZOZ%#M-, 1 C=H7Q00&OJ4Q%WE937>8AVE1Z*U)^VU:I[
MV]9E"7V4L[VF_UJ*/[;3X"F%9H"G03CIL$^LG[HJC=\L$NY:@5M/P40D(@5\
M$H $] VQ<UHE(1\B[Z%:2FT9CNL8I6T[K"99(2&)+@HVB11Y_@@D86&YRIEX
M#1_PA&.IA W<XD#*]]BVR@B+@JK6H%<9Z.#]@GX.QAKN897D0OIN!\T$S8=I
MU4.7[2(()EL)D__, 13,-VZTL!7";[T/0M/NU/]I+O1LR8E<^_'7@/FG(L?4
MS#%6M.)Z' 6^J&<=FM\A(DJK4-[U/ Y>]VP*3 >,$1]/F;-K)A5HW:-+FJ3A
M0Z54Y7VA<B"%4 GWUNR%>0Q!(]BV3$*3P3/VDV9^-3M*1-I_4/QT5/4@_@F3
M@!F1TCM^WD,1JB<3J/&5GW4B24Q5Y\DW8D^J^B/B6R=4,4JF^Y(.?K5C#/<V
M1"1Q$_9@/QHJY>IEL7O:K=JS>L/<':_W]&MA-A*3/^<U3$>#X\-^W0SMC=-E
MV#=7VF%[#9<9?BZP\0?P?JVU:V^\@^X'R/1?4$L#!!0    ( "6+;5;UYLN\
M)@4  / +   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;*566V_;-A1^
M]Z\@W*'H ,^6G:3-FL2 D[EK@*4U[&1Y&/9 2\<648E422J.]^OW'>H2!76"
M 0,,2R+/Y?O.C3S?&?O-I41>/.:9=A?]U/OBXVCDXI1RZ8:F((V=C;&Y]/BT
MVY$K+,DD*.79:!)%[T>Y5+H_/0]K"SL]-Z7/E*:%%:[,<VGWEY29W45_W&\6
MEFJ;>EX83<\+N:45^;MB8?$U:JTD*B?ME-'"TN:B/QM_O#QF^2#PIZ*=Z[P+
M9K(VYAM_7"<7_8@!44:Q9PL2CP>ZHBQC0X#QO;;9;UVR8O>]L?XI< >7M71T
M9;)[E?CTHG_:%PEM9)GYI=E]IIK/"=N+3>;"O]A5LB?'?1&7SIN\5@:"7.GJ
M*1_K.'043J,7%":UPB3@KAP%E+])+Z?GUNR$96E8XY= -6@#G-*<E)6WV%70
M\]/9:C6_%8N[Y=7GV6HN9K\OY_.;^9=;<7]]^UG<+J]O9LO9E_.1AR_6&,6U
MW<O*[N0%N^.)N#':IT[,=4+)<P,C@&R13AJDEY-7+?Y&\5 <C0=B$DTFK]@[
M:ID?!7M'+]B[+!U6G!-7)E\K+:LBT8F8.8=FF,7?2^546/UKMG;>HH#^/A2(
MRLWQ83?<5!]=(6.ZZ*-K'-D'ZD_?OAF_C\Y>(7'<DCA^S?K_2-_K=K]\O9WW
MQI%X^^9T,AZ?B?_F1WS58E9N4;5B_"LGBO]]2ASB0NI]C[0G2XE0VAO$6L@0
MZJ*T<8K.$G)KB=#Q7KQC+78^B<ZJ?"P:H5DC%+;'9S^C8WS*&#!58'.12G3K
M0%QKU,N[VD:SV^CT.-'L _,!W+?"08M2DR5DG= RI[!M2>EG6%:U^*HCWN(
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M@K9;WRX\4)4Q5A,C"V=&2VG(VMPPI7\)*AM ^RLIS7YB$]1_I\$?4$L#!!0
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M<QHW%/V^O^(.Z632&;+L+@]#;#.#L9T^[.":I/TLE@MHO"MM)*V)_WVOM(^
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M@6!H Z[/M:[;"1W0?;J]^"]02P,$%     @ )8MM5GITNG,- P  U 8  !D
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M9KOOA>[&FR:<T=&_./&'RPJ?6,+2 +R?&^,W-[1 _]%V_@]02P,$%     @
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M.+1#GQDAQ?S,CP%4QZ<+-2+NLRCNLW%QY^Z'4[K,5%.FX (05T-!AD0^2NB
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ML'GS67)H!6<^):DFN4/(#R0(EV+F.U5?)(.!K O98%^';'^!Z/2Q71T#7&+
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M<.6&5_E*! +N@UEH\#"B?K'RTRD(C#;!F+O.](]V_>8SSN=[SV)$2:PB\.@
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M5%ET=)RFCC5#PI^4!XZSO&A(MQC9=L9G#S%QE2FL_BQ2?UR2QEO:EO#.4O]
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MFQA6(K#2A=:0@3I4< K26/I0>=LC5]B1;^;Z5-S/1N9TW"E<P0\2KN#_#%=
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MH&[;=SNQJO8M<ZLL-6 _+.C%@]HID'RGZ/RZB=N@?T/-_P)02P,$%     @
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M76&>-_7HBWE3U6^YVHI20XX;<@W[XZ$'JJF4S<#(RE6GM314ZUPWHY\+5-:
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ME7C3IQ7M&--N5%6;T6%1*1I$S')-DQ\*;4#GRZI2NXV^H)LE)S\!4$L#!!0
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M]5K]K@.B'&3E1O',#H\=5WH4V66L9S\*XZ#M>\[5:6,2U/\FX]]02P,$%
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M70-G@>X@T'4TS'&U:C<MU8NK06GULF"J0.'S" Z-M* KD)K07,T4:(5PA\S
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M84VO-QIO0/N5UNY^X@-T_P?F/P%02P,$%     @ )8MM5D_%_TA"!   00L
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M0-D O#Z7:'<]L3=HOF4F?P!02P,$%     @ )8MM5@1?_/RL!   KQT  !D
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MJ9K.S#Z,]L$A3H(&<,8VR71__=I (1#JELJ\)$#N/9Q[?$*.G.F!LI]\2X@
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M_'Q-J7@Z47OZU7\X\_\!4$L#!!0    ( "6+;59E?4X]$ 8  +$Z   9
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M*E[GP?H(UD&T^_1^Y"=B+X"^%4#S /HRH/-&0#L/:!^:H9,'=%X&T#<"NGE
M]]" 7A[0R\[][F1E9]KUE#<:ROB1R'1O34L7,KFR:'V"@RCM63,E];>!CE.C
MZ<WUE-W,OY#QE4O87[>?IY?L:OZ!7+$Y>><*Y05A0JX\*;VT![P?-I5.FH8V
M_3P!VR6@;R1P*+F,([5*"(L68E$!X'8 [5L 3=W<HLWTN<T3:B5>^^J$M)P/
MA+:H0VYG+GGW^WNR5'_\YO0'?U8<X;F=YPK_A-!VQFL5/*\"Y-I!,['1H,$+
MD.7 V $'UMXUE#[SJA3X98RA0[OH>^V,VWF#>^%%"_+U4JSOA/RWXK FUO"T
MYGY,-IXOSAJZJ"9"/HC&2)^J7JM20R3,1<(8$L9!,$/03B%H)Z.WWRHF4H]X
M4CU](-/0BQ1)]67?M\%&#T6*?+W0NY//2JR32K4[2+61,!<)8T@8!\$,M;N%
MVEWKY<L]/P@#]40V6^FO].A>)>H.T<T0Z5W.PX@ZK?1OV'S8U\N:JJY>2!A#
MPC@(9NC5*_3J6?6Z'-]\N=##?)5,ULBZUQX2YB)A# GC()BA9;_0LG_$2MM'
MJHV$N4@80\(X"&:H/2C4'EBOW+%^9B3QDBR?*^Y_MIO"R0[6VZNYG>[KBFM-
M65<W)(PA81P$,W0[+70[_?41\O35".GTNU5#I#577<&0,(:$<1#,$,QIE8_#
MK8,&27V)3;9!N BB>^LCBAU7MY9":2Z4QJ TCJ*9,N^Y'LX1Q\\<CA(=27.A
M- :E<13-%)V6HM-?+\<Y8W_T=-JG5?78GJVV;D@:@](XBF;J5MI$CMTGVJO)
MU\MEX NRW,HH4%LIL@M7%!=NNG;AW<724[%\VOO"6L*A-A.4YD)I#$KC*)K9
M*TJOR3FFV>1 W28HS872&)3&4313]-)R<@">D_/:='(J[ZCMR6K+!K6=H#2.
MHIFRE<Z3\S/K:38;GW^ZG;'Y?%8I&=2 @M)<*(U!:1Q%,W4M72CGF#:4 _6A
MH#072F-0&D?13-%+,\J!NE%V6FV5H;:5<Y!5QJ!).8IFRE=Z4@[ E+(S:HL&
MM:Z<UXY9IU4QO#-H6HZBF:\LE,84M1M3YW&B$A)$_E;*RM<H)G9 7<V@-!=*
M8SEMOP>T!X.*+L!1>4W12IN)6AV-T3Q67DC\GTL'-92@-!=*8U :SVG[':&G
M]S4Z@BE=:191NUEDW++J(>ZG+ZO8>;4UA)I+4!J#TCB*9NI<FDNT?<1;6 KU
MCJ T%TIC4!I'T4S12^^(6FV*P^Z![(S:VD(MHIQFN-2TZAX(FI:C:*9LI?M#
M[>[/RYI\T"]T=F9M&:&6$93&H#2.HIE:EY81[1VS+D/])"C-A=(8E,91-%/T
MTD^B5NOBP+H,M8V@-#>G&>\[5CV8,&A:CJ*9LI6.$+4[0I?75_/QU;A2+*C[
M Z6Y4!J#TCB*9BI:FD3T])C5%^H>06DNE,:@-(ZBF;,Q2HNI;;>8*HS=JDDL
M$SNF]KR,UFL/MF-62Q>:D4%I'$4S12LMIK;=8CIHR+0S:BOVVG7I5/V^ZD+3
M,BB-HV@[V9I[,_#60MYG<R43XL?;2.TFXQ5;B_F8XVP68K/<?3>9\]*3]T&4
MD% L=6CKI*_/L]S-C]RMJ'B3S>>[BY6*U]GB2G@+(=,=]/?+.%;/*VF"8I;J
MZ']02P,$%     @ )8MM5DO5L3)3 P  8 L  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&ULK99M;]HP$,>_BI554R>MS1-Y@ %22S6M+Z:A=@^O37*
M-2?.;%.Z;[]SDJ8!#)LTWH =W__RN[,OOO%6R)]J#:#)<\%+-7'66E<CUU79
M&@JJKD4%):XLA2RHQJE<N:J20/-:5' W\+S8+2@KG>FX?C:7T['8:,Y*F$NB
M-D5!Y>];X&([<7SGY<$#6ZVU>>!.QQ5=P2/H;]5<XLSMO.2L@%(Q41()RXES
MXX]F?F $M<5W!EO5&Q,3RD*(GV9RGT\<SQ !ATP;%Q3_GF &G!M/R/&K=>IT
M[S3"_OC%^\<Z> QF017,!/_!<KV>.*E#<EC2#=</8OL)VH BXR\37-6_9-O:
M>@[)-DJ+HA4C0<'*YI\^MXGH"?S!$4'0"H)_%82M(*P#;<CJL.ZHIM.Q%%LB
MC35Z,X,Z-[4:HV&EV<9'+7&5H4Y/9Z*H1 FE5D0L29->R$E&*Y-E15A)]!I(
MAF/!64[-XH)R6F9 ZK>J>HTIC?H1N;P#31E7[\@5^?9X1RXOWI$+X^3K6FP4
M+7,U=C5BFY>[68MXVR &1Q#O(+LFH?^>!%X06.2S?Y?[NW(7D]5E+.@R%M3^
MPB/^YA(JRG("SUA*"A3!J(C ),F1+;;&V<#NS!3I2%4T@XF#5:A /H$S??O&
MC[T/MDC/Y&PG[K"+.SSE'4]*J256W94$;HZ!+=C&0U1[,!^0IVGJ#<*Q^]0/
MXM H28*X,]J!&W1P@Y-P]Z7:2',H;52--.Z]T ^2:(_*8C1( SM5U%%%)ZF^
MF%-A(XHL1*&W1V0Q\E/?3A1W1/$9S]MM?(C@18-T#]1F%:9#.VG2D28GR^PF
MR^0&;&6&GT4I\8M%.*,+QIEFH*REEYRS],[D;"<7:9>+]+]++SW8A#!(]DOO
MT"A(PR.'?-C!#?\"5Y@=HLVMC)N4]1Z<(AX>$L>#_;(\- K2.+43^][KI>?]
M+:%*RTW32>#M5$FQPFVS7T[>(0*>[SU.BY4?)4=2Z_=N9_\DZ%R*)7(A)N5D
M"?TRL++Z!Q1Q--Q'M1CU3LHNZ>NMZ)_S)KMMO?5O@6&<[G\"+5;)L'=&&E:W
MU_Z8WO,SE2N&O0N')<J\ZP3ULFGGFHD65=T1+83&_JH>KK$%!FD,<'TIA'Z9
MF":K:ZJG?P!02P,$%     @ )8MM5KMIVTZ% @  5@8  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&ULK55=;]HP%/TK5UDUM1(E7[3;NA") M60H*I@
M= _5'DRX@%7'3FTG=/]^MI-&5*)5'_I"?.U[SKWG!-\D>R$?U0Y1PW/.N.I[
M.ZV+*]]7V0YSHKJB0&Y.-D+F1)M0;GU52"1K!\J9'P7!I9\3RKTT<7MW,DU$
MJ1GE>"=!E7E.Y+]K9&+?]T+O96-.MSMM-_PT*<@6%ZB7Q9TTD=^RK&F.7%'!
M0>*F[PW"JV'/YKN$>XI[=; &JV0EQ*,-)NN^%]B&D&&F+0,QCPJ'R)@E,FT\
M-9Q>6]("#]<O[#=.N]&R(@J'@OVA:[WK>]\]6..&E$S/Q?X7-GHN+%\FF'*_
ML&]R P^R4FF1-V#304YY_23/C0\'@+#W!B!J -%' 7$#B)W0NC,G:T0T21,I
M]B!MMF&S"^>-0QLUE-NWN-#2G%*#T^G-8#*'^\%T.8;9>+!8SL>S\>WO!9R.
M4!/*%-P2*8FU^@S.8;D8P>G)&9P Y3"CC)DWH1)?FT8LG9\U1:_KHM$;14>8
M=2$..Q %470$/OPX/'P-]XW\UH.H]2!R?+VW/"!4PCUA)79@PHM2JPY,L4(&
M(3S,,%^A_'M,Y+NL]OI=J8)DV/?,_5(H*_32KU_"R^#G,<F?1/;*@+@U(';L
M\0<,&"B%6@'A:YA2LJ*,:HH*9DA4*7$-YNK-,2NEI'SKLFX%E^W&-5%4P</4
M%(")QEP=-2[^3.,^B>R5<;W6N-Z[_YPA43O IY)6A"$WMIW#QGI962^/*:_I
M?C@Z.V"K- PONW'B5X>2CF1%0;?79M6]^@>WWD[<&9%;RA4PW!A<T/UVX8&L
MIU@=:%&X0; 2VHP5M]R9P8_2)ICSC1#Z);"SI?V4I/\!4$L#!!0    ( "6+
M;5:3?'\W/00  -T=   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;+V9
M[V_:.!C'_Q4KDW:;U#8_@  =('4E(=&UUZYL=SI-]\(-AD1-8F8[L-Y??W:2
M9@5"%D[/'2\@CI_OY['CKY*'>+2E[(F'A CT/8E3/M9"(=:7NLZ#D"287] U
M267/DK($"]ED*YVO&<&+7)3$NF48MI[@*-4FH_S</9N,:";B*"7W#/$L23![
M_DABNAUKIO9RXB%:A4*=T">C-5Z1.1%?UO=,MO2*LH@2DO*(IHB1Y5B[,B]]
MTU""/.+WB&SYJV.DIO)(Z9-J^(NQ9J@1D9@$0B&P_-F0:Q+'BB3'\:V$:E5.
M)7Q]_$)W\\G+R3QB3JYI_$>T$.%8&VAH098XB\4#W7JDG%!/\0(:\_P;;8O8
MWE!#0<8%34JQ'$$2I<4O_EY>B%<"LW-$8)4":U_0/2+HE().6T&W%'3;"GJE
MH-=68)<"NZV@7PKZ;:_2H!0,VF88EH)A;H=B_?+%GV*!)R-&MXBI:$E3![F#
M<K5<\RA59I\+)GLCJ1.3^>>[ZU^]NYNI\S!_^V9@F?T/R/GTQ?_\)WHW)0)'
M,4>_8<:P\N1[=(YXB!GA(UW(Y JA!V6BCT4BZTBB6_R,3/L,689EU:BOF]53
M$ER@CGE4/FTA-SM'Y4X;^?'L;K/\*EM=(*-W5#YK(S\^>*_%A>\>5?OM+[RY
M*]>EU2J_697?K)S7.3:9(,B2+,:"+-"=" E#US21M^E0W3\W!/EI0!."WMU0
MSM^CKS=2CGQ!$OY7G>6*7-WZ7.HY<<G7."!C36;@A&V(-GG[QK2-#W4.A(1-
M(6$.),R%A,T@81XDS >"[9B\4YF\TT2?S 4-GD(:+PCCOR#G6Q:)YS/T0#:R
M35#>B^;K.!)UGFY&F^>RP#GOU-Y"&Y6G&A@2YD#"7$C8#!+F0<)\(-B.@;N5
M@;N-+I/WY$16HKE3S] \?^2CJTR$E$5_DT6=;0N@G0-5A;V9](SB,](WKUUZ
M&&@:1FWHM'VH4Q-:G]]M'3EK.R7O,'!0/TS_,-+J[07N+%BO6K!>ZP5#7V])
M\DA8[1.S$7/J$Q,2-H6$.9 P%Q(V@X1YD# ?"+;C7[ORK_T_EH4VI,DA85-(
MF ,)<R%A,TB8!PGS@6 [)N]7)N__=V5A,[JI+&Q4GFI@2)@#"7,A83-(F <)
M\X%@.P8>5 8>_*3*2)57U4M*NMRK#HL^45\<#@XKJ>'0[@][0WNO.FP<P*EF
MA80YD# 7$C:#A'F0,!\(MF/68676X;\VJ\]Y5N_4X>&_@T&_:YA=<\^HC<E/
M-2HDS(&$N9"P&23,@X3Y0+ =HYK&CW?PQL\+@]*4:)JQ*%VA>\(BNGAQ;&V9
M4/\6WCAT<,?HVM:>?YN'=*J!06D.*,T%I<U :1XHS8>B%3;67^TJJ8W/6\Q6
M4<I13)82;USTY1]&5NPE%@U!U_E&TR,5@B;Y84BPK'95@.Q?4BI>&FKOJMK1
MG?P#4$L#!!0    ( "6+;5:6L,KC&P,  "H+   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;+56:V^;,!3]*Q:KIE9:RYLD78+4A_:2JD5-NWV8]L&!
MF^ 5,+--TO[[V0ZAI$#4:NV7Q(][+N=<<\P=KRF[XPF 0/=9FO.)D0A1G)HF
MCQ+(,#^A!>1R9T%9AH6<LJ7)"P8XUJ L-1W+"LP,D]P(QWIMRL(Q+45*<I@R
MQ,LLP^SA'%*ZGABVL5VX)LM$J 4S'!=X"3,0M\64R9E99XE)!CDG-$<,%A/C
MS#Z]L#5 1_P@L.:-,5)2YI3>J<G7>&)8BA&D$ F5 LN_%5Q FJI,DL??*JE1
M/U,!F^-M]D]:O!0SQQPN:/J3Q"*9&$,#Q;# 92JNZ?H+5()\E2^B*=>_:%W%
M6@:*2BYH5H$E@XSDFW]\7Q6B ;"]'H!3 9SG MP*X&JA&V9:UB46.!PSND9,
M1<ML:J!KH]%2#<G5,<X$D[M$XD1XDP": 2/ T1F:RA("8Q"CF:#1'<)YO-T\
M;VVN,9?G&%$6RR4LY#B&K-!GL\)I">CP$@0F*3]"Q^AV=HD.#X[0 2(YNDEH
MR65N/C:%E*"(F%%%]WQ#U^FA^ST2)\@)/B#'<IP.^,5^^+<REW"O"V[*PM75
M<^KJ.3J?UY.OMW*_KB"; _O=I7!O2F7;4U[@"":&]"4'M@(C?/_.#JR/77I?
M*=F.>K=6[^Y5_YE1SJ5T&@%T'^8&[VN\NE!6H>VZEC4V5TT-[2C''?B/43OD
MO)J<MY?<XXEP?2*$\Q+G$:"(<M%)=I,O:- X'GK>$ZX=0;;E!=U<_9JKOY?K
M610QT,ZA"Q1AQAY(OJQ<)&C+65WD_18OQVF1;P>Y?A_WH.8>O*C.O)S_D5>T
MXEW(UX/,4V@(Z*(>M%C9WJ#UDK2CG,#I>TD&-?G!<_S;OMSV^7=ORI?Z]Y62
M[:@?UNJ'_^G?8:OH(__IP;1CO%[SCFIFHU<V[ZCMR^ ITXX8QQIU,[6MQP^H
M]=;FK9ZP8X$6^XZ@02_[QN???F/[5@_8N>2MUEO2$>6W[6LV&AG515YAMB0Y
M1RDL),PZ&4@\VS1FFXF@A>YMYE3(3DD/$]G, E,!<G]!J=A.5+M4M\?A/U!+
M P04    "  EBVU6R'MZ]IP(   "7   &0   'AL+W=O<FMS:&5E=',O<VAE
M970U,2YX;6R]G&MOX[@9A;_OKR#<HI@%9F-+OL1)DP!)K+NTDTUF6BR*?F!D
M)A9&%Z\D)SO[ZTM=?)%-<:3V= ?(Q%+X/D>T>,2+7O#J/4F_9BO&<O)[%,;9
M]6"5Y^O+X3#S5RRBV5FR9C'_RTN21C3GA^GK,%NGC"[+H"@<JJ/1;!C1(![<
M7)7G'M*;JV23AT','E*2;:*(IM_N6)B\7P^4P?;$8_"ZRHL3PYNK-7UE3RS_
MLGY(^=%P1UD&$8NS((E)REZN![?*I:=.BH"RQ#\"]IX=?"9%59Z3Y&MQ8"VO
M!Z/BBEC(_+Q 4/[KC=VS,"Q(_#I^JZ&#G681>/AY2]?+RO/*/-.,W2?A/X-E
MOKH>S =DR5[H)LP?DW>3U16:%CP_";/R?_)>E9U.!L3?9'D2U<'\"J(@KG[3
MW^LOXB!@/FH)4.L ]2A :5,8UP'CK@J3.F#256%:!TR/ Z8M ;,Z8-95X;P.
M.#\.F+4$S.N >5>%BSK@HFN ,MK>N5'GD-W-/K[;RK@M9'N[E9/[W1JRO>%*
M><>'55LL&_*"YO3F*DW>25J4Y[SB0^F&,IZWWR NC/N4I_RO 8_+;SYKWL.G
MQ]O'7XGVRQ?K\Z_DPX+E- @S\C--4UJXZD?R$_GRM" ?_OKCU3#GFD7DT*_Y
M>L576_@*\9(X7V5$BY=L*8@WOQ.O2@!#7ME=C=5MC>]4*7'!_#.BC#\2=:2J
M@@NZEX=_\O,SHLY:PQ?R\-O-ZQD935O#-7FXO8FY^J0U7.]0]['2&FYTN'A)
MN/F_J5O=PQ5!N-WEOK>K.UUN7'NS<>7A'OU&E/96XW6(%M[UA@7&.]./2]RD
M!7>?1!'O-/GCQ?_ZD=!-ODK2X ^A/>\JTJPD%:. MQMEM/UW-7P[-(Y4M!B!
M7&9KZK/K 1]B9"Q]8X.;O_U%F8W^+K*10'<JE-60LGKWZAI(7;.[KG5:5)V*
M"MJ=OT+GM*2XH-NUH'=:<'Y2G4;;G>S:[D3:=A_9DD7K:M 7)9LX%S5:*:+G
MK;E'PA9(F(:$Z4B8@829%6QZT)8FYU63/W+&?Z%*1!T)\NH=),Q%PCP0K&'C
MZ<[&4ZF-GU@:L(S<D@<^46-IRI;DJ>B.R+\\%CVS]-\B6TN1?6V-A"V0, T)
MTY$P PDSD3 +";.1, <)<Y$P#P1K^'^V\_],ZO^?-X7+2?)"LA7E>!)DV48\
M I6"^KI^=CHFF@C&+PNDJ'8J6H_8FJ(Z4M1 PDPDS$+";"3,0<)<),P#P1I>
M/=]Y]5SJU7T77<\8US0E;S3<,/(AB,DR"4.:9F3-_5R:6;1,=">5Z.OB"G9^
M8*C1V6BD''D8*:EUDM21D@829B)A%A)F(V$.$N8B81X(UG#P?.?@N=3!G_F4
M.4EI^HVPWS9!_DUD4"FAKT'G)U,V97(NZF>1JMJIJCH3311UI*J!A)E(F(6$
MV4B8@X2Y2)@'@C5L>K&SZ4672?%=KTFQ%-G7MTC8 @G3D# ="3.0,!,)LY P
M&PESD# 7"?- L(;_E='^;>P(-2V6D_H:OZ:=OH XZJ^AJII 53@QAJH:4)H)
MI5E0F@VE.5":"Z5Y*%K3MP=9%,K_?XHLU^CM:*73)!DJJG43U:&B!I1F0FD6
ME&9#:0Z4YD)I'HK6]+.Z][/:Q\_D+<F#^)6D11I@)O2NG)>OV ]E,,D3XM,L
M)^I'WM,57';P6"@Z_M9)0!(3CB$+YI>3 7(;L7C)?T1OP._EU]-W)/_GU4Y6
M*0U:*1U*,Z T$TJSH#0;2G.@-!=*\U"TYD-HGZ6ER-.TNJS:R1&]QPSCTW6[
MD6 !;0&5U02R4^&Z'536@-),*,V"TFPHS8'27"C-0]&:EMTGIRG2I)DR.XU%
M]#EDY#Z)WUB:!\7G/NMY<H7>CD;2%E":!J7I4)H!I9E0F@6EV5": Z6Y4)J'
MHC6?#?N,-T6>\O:0!C[;CX:%WH=FN-6T^4&W>G$V/>[)H:EK721UJ*0!I9E0
MF@6EV5": Z6Y4)J'HC6=NL]-4^3):0\L]?D4E+Z64]9R"9XL@\QO2S>7XWK;
MMJ(5*YJ'BV@GQH6FJ'43U:&B!I1F0FD6E&9#:0Z4YD)I'HK6M.X^54V1YZH]
MY33GP^QJZ5W>UT(STFI:<^9\[%AH0EH'1;U#&:-#&;-#&0M:.QM*<Z T%TKS
M4+2F8?:988H\->PA37S&EAEY29.(6+ROH[%?]GN2":S03] $,D640386OI&&
MII )=-6Y^)TT-(D,2C.A- M*LZ$T!TISH30/16LZ>Y],ILBSR8X\^_'0T-N#
M<O^-<F(JM#0TMZRF-2Q][&5HRIA <')L8F@F&)1F0FD6E&9#:0Z4YD)I'HK6
MW*MBGQ"FRA/">K^([LK[H5J)7M$W1N*DR25)ON)#YWQ%JY>RNW>[Q0O=]O?0
MA,9+0C-"B1_2+"L*^OQY0X.X!F9KY@<O :],1/.</WU$CPEY!?JN6/]I7P?V
M6]"@WX(.I1E0F@FE65":#:4Y4)H+I7DH6O,QM\^?4^7Y<\>ONDFZW^9AO5TW
MK]?DA$\]:.I<36LLABFG*W!04:V;J-ZMF-&MF FM@@6EV5": Z6Y4)J'HC7-
MMT]V4^7I6UKF%S$+MDZR0+C +0?TMI?:=6X/U=4$NBUS>ZBN :694)H%I=E0
MF@.EN5":AZ(U+;M/#5/EJ6%-RY*7)"6?^+ TB&E8KN'QX;GD?94<WMO.@J0Q
MD:L64%E-(#L6;46E0V4-*,V$TBPHS8;2'"C-A=(\%*UIYGW2F/K]I+'O;FDF
M9_3V+#0M#$K3H#2]IC6?3G/1?GZ"DF/A@\R$7J$%I=E0F@.EN5":AZ)5KAT>
M[*$;L?2UW$PZ(V4?6NVLN3N[V[#ZMMRV]^B\KEP:BN"\J5Q:U7;4>WRU.[9'
M4]YS9R1D+UQJ=';.FV!:;3A='>3)NMS!]SG)\R0J/ZX87;*T*,#__I(D^?:@
M$-AM^WWS'U!+ P04    "  EBVU6!$":36\"   "!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6R-5%%/VS 0_BNG#$T@,1)"81M+(X6V&Q4KJMHR
M'A /;G)M+)PXV$[+_OW.3L@ZJ:"])#[[[KOO.]\YVDKUI'-$ R^%*'7?RXVI
M+GU?ISD63)_("DLZ64E5,$.F6ONZ4L@R%U0(/PR""[]@O/3BR.U-51S)V@A>
MXE2!KHN"J=]7*.2V[YUZKQLSOLZ-W?#CJ&)KG*.YJZ:*++]#R7B!I>:R!(6K
MOI><7E[UK+]S^,5QJW?68)4LI7RRQCCK>X$EA )38Q$8_38X0"$L$-%X;C&]
M+J4-W%V_HG]WVDG+DFD<2''/,Y/WO2\>9+ABM3 SN;W&5L^YQ4NET.X+V]8W
M\""MM9%%&TP,"EXV?_;2UF$G( S?" C;@-#Q;A(YED-F6!PIN05EO0G-+IQ4
M%TWD>&DO96X4G7**,W$RGX\6,+V;#:Z3^0B2'[/1:#*Z7<#]>'$--\DBN4W@
M<(B&<:'AEBG%;!F/X!,D6E/33&N5YE062-8*D:[+P,,$BR6J1_*Y(4XE@VG.
MJ((IUH:G3.AC&)?I7[<#X"5,N!!T33KR#<FRY/RTE7#52 C?D##$] 3"\!C"
M( S@;CZ$PX.C?V%\JDI7FK K3>APS]XJC=.7I,\UU]RUT,-/<H&QP4(_[N/9
MX/7VX]GQNM055:'OT?QH5!OTXH\?3B^";^^P/>O8GKV''@^H=CQ#>SW$M&(\
MV\>PP?CJ,.R\;N+@Y'/D;_8D[G6)>^\FGI$41CT K,QH'C8TYY5K@U1JL_<Z
M>_]!PM]I:?LZ3)A:\U*#P!5%D?^Y!ZJ9N,8PLG)=OI2&9L8M<WJD4%D'.E])
M:5X-.SC=LQ?_ 5!+ P04    "  EBVU6'2I?,A0#  "["   &0   'AL+W=O
M<FMS:&5E=',O<VAE970U,RYX;6RUEFU/VS 0Q[_**4,32*AYH$^PME*!#CH-
M5+5EO$![8=)K:Y'$F>VT(.W#[^RDH8S021/T16,[OO_]SG>VTUD+^:"6B!H>
MXRA176>I=7KBNBI<8LQ43:28T)NYD#'3U)4+5Z42V<P:Q9$;>%[3C1E/G%['
MCHUDKR,R'?$$1Q)4%L=,/IUB)-9=QW<V V.^6&HSX/8Z*5O@!/5-.I+4<TN5
M&8\Q45PD(''>=?K^R:GO&0,[XP?'M=IJ@PGE7H@'TQG.NHYGB##"4!L)1H\5
MGF$4&27B^%6(.J5/8[C=WJA_M<%3,/=,X9F(;OE,+[M.VX$9SED6Z;%87V(1
M4,/HA2)2]A_6^=RFYT"8*2WBPI@(8I[D3_98+,260?TM@Z P""QW[LA2GC/-
M>ATIUB#-;%(S#1NJM28XGIBL3+2DMYSL=*\_F0RF,+H9GUWV)P/H7XP'@ZO!
M]11NA]-+F(Z'%X.KX74?]L]1,QXIN&92,K.2!QU7$X"1<</"V6GN+'C#V;<L
MJ8'O'T+@!1[<3,YA?^\ ]L %M6025?%X*>Q21&5801E68#W5WPI+*:KH42;#
M):4,^@N)2+6DX>X*XWN4/^$W3"5?("TI.X1A$M8V;ZK"VNG,;)P3E;(0NP[M
M#(5RA4[O\R>_Z7W9$<I1&<J153_:&4H__)5QQ6TEWWVG*3#4&*M*VJ,/H*V7
MM/6="S]B3W:=Z;R =+/\8@[,1*&J:'.]AM4S9\BJUP[JK<9QQUU5<#1*CL9.
MCNO,)--X+DJ+*Y7A#/9Y4HP<4 E4U5M.E:LWMZB:0</SJJ&:)51S)]29B&/*
M'VWJ\ %6+,H0]E.BM!B&YWDK5#'EXNTMIL"OM9K53*V2J;63:4PEP"A/P)(9
M'6<K.J=3F\%0J.J$M5XE+*A[YE<-TBY!VO_:LGR16-<&A;I9G-IZ?[U[J[!V
MJO]GU1^7[,?OO$>//X#6]YX/?>^==VDA^"+K#2^H^W\EW=VZBLRU?L7D@B<*
M(IR3H5=KD8+,;\J\HT5J;Z=[H>FNL\TE?5V@-!/H_5P(O>F8"Z_\7NG] 5!+
M P04    "  EBVU6!,_WIG0#  !S"@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U-"YX;6RU5FUOZC84_BM6-DUWTM2\4*!T$(FV;$4J%8)V_7"U#R8Y$.O:
M<:[M0)'VXW?LI"G:#=G5M/*!^.T\YSDO/C[C@U1?= 9@R*O@N9YXF3'%M>_K
M) -!]84L(,>=K52"&IRJG:\+!31U0H+[41 ,?$%9[L5CM[94\5B6AK,<EHKH
M4@BJCC? Y6'BA=[;PHKM,F,7_'A<T!VLP3P72X4SOT%)F8!<,YD3!=N)-PVO
M;\*>%7 G_F!PT"=C8DW92/G%3N;IQ LL(^"0& M!\;.'6^#<(B&/KS6HU^BT
M@J?C-_3?G/%HS(9JN)7\A:4FFWA7'DEA2TMN5O)P#[5!?8N72*[=/SG49P./
M)*4V4M3"R$"PO/K2U]H1)P)1=$8@J@4BQ[M2Y%C>44/CL9('HNQI1+,#9ZJ3
M1G(LMU%9&X6[#.5,/%VO9T]D^;RZO9^N9V3Z^VHV6\P>G\C+_.F>/*WFB^EJ
M^D@^W8&AC&OR2)6BUI$_CWV#^BV*G]2Z;BI=T3E=Y>Z"A*-?2!2$(_*\OB.?
M?OP'C(_T&QNBQH;(X5Z>P]4:TW=9JB3#^)#I3@%@XACR>0%B ^I/\I>U!+..
MYF2940PFF>=)L]UF2:=&>U6N=4$3F'AX%S2H/7CQ3S^$@^#7#GMZC3T]A][K
MM&>:?"V99BYW/S_@$3(W('0KV]X'L+ULV%YV>G])C\[96"%(\18#N2746J';
MV%9X?8=GJ\8^#@/[&_O[%A[]AD>_D\<#HQO&T5^@K>Y20-JFO (9G"@?7/7/
MZ1XTN@>=NE?H58JF$YJG6!/V6.P*YY1$ZG8?#+ZA$7;P&#8\AIT\;F5N6+ZS
MF@7C@-4#TZ:H R0WG.VHS:<V0L-O"/4N.Z)RU3"ZZF3TLGXF#RS!,MYV,=N(
M=.+]QUP>-6Q'__/-&WT VS!X+][!O^0=$YM2Z<JK>.D*:NP(7@OK\=;,JR%/
M(SWLGXUS>/*0A!^5>S5R_WN3+WQ_&<+NIV$)"G//8']AO:/DD7)7() 7W7 @
M1N*5/1*3,97BHC)'5\=8;K!/P,:AI)P4"GL@NZ/L"]_NTXJ%=6UC07#1/\/^
M_1T(.PMWO*"O3)2"%.]6*$C+JI]ILZ>56^][N/DG+81MQQ94[5BN"8<M2@47
M0PR.JCJ<:F)DX;J*C338H[AAAETA*'L ][=2FK>);52:/C/^&U!+ P04
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M93#F#$8AA2K-S7J[ZVAP ^_??8!WP$/H<2%HE77=-01II^I.4J#K!*AX &B
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M7-!M%Y7M0-]G4IJ7AKU/9??GYD]02P,$%     @ )8MM5BK8TYO%#   ++T
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M6W87RN8)N;4WR>;%YF_CKKGO:&!,UD69+9K!U2-8S);W_Z;?FA_$U@#3V3/
M:@98+QU@-P/LIP/L/0.<9H#STAG<9H#[T@'C9L#XI0,.F@$'+QUPV PX?#K
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M4\#S>FZ3>#N,NF&?.CWJ-NEKIW<I?7M/WW[/.8G6N9.VW5I(V_4<RZ%-XNW
M+@<1=<0U+,0QG[V!I%HO=2X?I[V,0>LTGW2$=3B#J OM$.R8RMZW4;UQ^_P*
M?!8+-DU 1Z5MQKS0\H*F?=$/]EY#>RVT8VGVYH[JW=V9TG08.ZR\-#SX:ZIT
M)0-7J?1_V$&Z]X-4[X_.5$D/TJ],5K^V:]9)XZ>'>K=Z5T(KU3,/KBI2X,OB
MRD>@,]YDLORY73^MKY7&Q65*X_F]NFXJKD#V,.5=U3?&T38*DL "(:U>'Y>?
ME]<_94?FZ^)"9)I+F:=%<P5L#EP%X/>+/)>[CAJ@OH0;_0=02P,$%     @
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M4-8 WR^D-&\/=H&V\YW\"U!+ P04    "  EBVU6:9R">SX1  "T%P$ &0
M 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6S%W5U3X\C9QO&OHN))GMJMV@%)
M?@$F#%4#:KWW#K7L)@>I' A;@&MMB\@RS*3RX2/9 KFQ:%NS_X0]F 6C_K7
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M;"]W;W)K<VAE971S+W-H965T-C0N>&ULO5A1;^(X$/XK5O:TZDIW) XAL%U
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MHS14CMVPH(:)RAK0?BZE64_L 5T+3GX#4$L#!!0    ( "6+;58<5](3. ,
M +\+   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;*V676_:,!2&_XJ5
M35,KM<T'$*"#2 4ZK5*_5-;MHMJ%"0=B-8DSVT#[[V<[(21-2->)&Q([Y[QY
M7F.?G,&&LF<>  CT$H4Q'QJ!$,FY:7(_@ CS,YI +)\L*(NPD$.V-'G" ,]U
M4A2:CF6Y9H1);'@#/7?/O %=B9#$<,\07T419J\C".EF:-C&=N*!+ .A)DQO
MD. E3$$\)O=,CLQ<94XBB#FA,6*P&!H7]OG8=E2"COA)8,,+]TA9F5'ZK 97
M\Z%A*2((P1=* LO+&L80ADI)<OS)1(W\G2JQ>+]5_Z;-2S,SS&%,PU]D+H*A
MT3/0'!9X%8H'NOD.F:&.TO-IR/4OVJ2Q;<M _HH+&F7)DB B<7K%+]E"%!)L
M=T^"DR4X;Q/:>Q):64)+&TW)M*T)%M@;,+I!3$5+-76CUT9G2S<D5G_C5##Y
ME,@\X5U?7DPOI^AH @*3D*-;S!A6*WN,3M'C=(*./A\/3"'?I.)-/U,=I:K.
M'E7;03<T%@%'E_$<YF4!4R+FG,Z6<^0T*D[ /T,M^P0YEN/4 (W_/=UNP&GE
MR];2>JT]>G<B (;&-(J(D)M:</1T+4/0E8"(_ZY;L%2O7:^G#NLY3[ /0T.>
M1@YL#8;WY9/M6E_KS!Y(K&2]G5MO-ZE[^J2?TL7IB@/"G(/@)R@&46<Z5>IH
M)550UE[7[EB6-3#713O5L+[=+H:50#LY:*<1] <5.$0AR$..0H)G)"3BM8XR
ME7&+E*Y5I6Q\VW\NNIM[<1N]7)==Z 5'="$K!&-R^Z&$,E45Z]RY%7<MIU=U
M5PUKN]V]_T$WY^Y^C#L#K@/M5@E:3A6T)JS7WPO:RT%[C:!W":BZ%R^S#0,O
M\D/)H8ZS5P'0N^4MY[MA)<Y^SMEOY+R5'\8=:[J\3S<0S8#5EIU&M8^6G0.)
ME8S;UNY+91VXYF:"!W)_*+6R_<*'VCY8W<VD2H>^YU;W:$U<TZFWG1VL<YC:
MF^ETWB6MQM62FH56* *VU!TB1SY=Q2+M-O+9O N]T+W7F_F1ZDYUB[6325O;
M&\R6).;2W4)*6F=="<72;C$=")KHAFM&A6S?]&T@.VQ@*D ^7U JM@/U@KQG
M]_X"4$L#!!0    ( "6+;58,XFCZC@,  -8.   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;*V7VV[C-A"&7X50%\4NT%H''W*H;2"Q4S1 O4F3W?9B
MT0M:&EO$2J27I.)LG[Y#2I$E5R::0#>V*'%^SC<:#3G3O9!?50J@R7.><37S
M4JUWE[ZOXA1RJ@9B!QR?;(3,J<:AW/IJ)X$FUBC/_"@()GY.&??F4WOO7LZG
MHM 9XW OB2KRG,KOUY")_<P+O9<;#VR;:G/#GT]W= N/H#_O[B6._%HE83EP
MQ00G$C8S[RJ\7(0C8V!G_,E@KQK7Q*"LA?AJ!K?)S N,1Y!!K(T$Q;\G6$"6
M&27TXULEZM5K&L/F]8OZKQ8>8=94P4)D?[%$IS/OW",);&B1Z0>Q_PTJH+'1
MBT6F["_9EW/'$X_$A=(BKXS1@YSQ\I\^5X%H&(2G#*+*(#HV&)TP&%8&0PM:
M>F:QEE33^52*/9%F-JJ9"QL;:XTTC)O7^*@E/F5HI^>+N]7J]M/JYN.G1_)^
M"9JR3)&/5$IJPON!_$P^/R[)^W<?R#O".%FQ+,/HJZFO<7$CX<?50M?E0M&)
MA<*(K 37J2(W/(&D+>"CU[7KT8OKUY%3<0GQ@ S#GT@41%&'0XO_;QXZW!G6
MD1Q:O=$)O3\*FK$-@X0L88//$K) 7LG6A<W7^XQR\F4%^1KDWUWA<ZJ;K_E2
M[6@,,P\_5P7R";SYCS^$D^"7+O2>Q%J!&-6!&%GUX8E W.D4),+G.=/XP6M%
MOOR.4\BMAEQUHH_Z1.])K(4^KM''SARXR7>9^([T6%_BE/$MB1LYT(5>ZH6!
M%30U]VF.R?C4!'(N^4:@20TT<0*MZ#/+BYQ0SC&]6S2*[! 42F+H8IO\ERT8
M!),C/*<#;\0[J_'.>L&377AGG7C#(SRG V_$.Z_QSIUX5PGN&$SILI@3>,;-
M7T%G\2Z%+EHL%T<H77-&]9R6AQ>UAQ=.#Q^0F<HX)7=R2SG[AY:A=]5)I^!K
MBT5/8BWV,#CLO4'/E;(2[(F^+[4V?N/H$3I?_EVAE:8\*>MD'81.[NH4$S62
M;WP^.*XE[@7?"A0=@"(G$&[X^+$5Y0'5[OYX2G4FLUOPU>^S)[4V_N$ % [[
M3N=>#SU]J;7Q#\>>T'FT>%4ZETKC1C9'QZG<ZSG&;W0(.<BM;9P4NEEP79ZX
MZ[MU<W9E6Y*C^]>F:;.=QT&F[/A65&X9UNX,-B@9#,Z03I9-5#G08F?[D+70
MV-78RQ0;3Y!F C[?"*%?!F:!NI6=_PM02P,$%     @ )8MM5I#^L56U @
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M^D< O0;0<T9K9<[6G!J:CI7<$F6SD<T.7&T<&MTP87?QT2C\RA!GTIDL*RE
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M=--WH//R8!8MED(]< >]%5Z0.1%WJQLF[]P2)8P2DO*(IH"1A[XSA&<CY*N
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MV2@_TZI@\B.V*6:+*.4@)@\2TCOM2(HL/[7*;P1=90<_]U0(FF272X)#PM0
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M2A(_ IC?011A"#R-.((Y  \8$D7V/;CW/@K7[ZEP\Y_!X1]02P,$%     @
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M[&T[O.2SZ7^DZS]02P$"% ,4    "  EBVU6!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "6+;59H
MU<L5[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( "6+;5:97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ )8MM5J5(0B)W!P
MK#   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( "6+;593-Z%/K@4  $X6   8              " @;H/
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  EBVU68&'.
M-F8#   =#@  &               @(&>%0  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ )8MM5@A2)E/K P  7@T  !@
M ("!.AD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "6+
M;5;4N@_9U0(  / '   8              " @5L=  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    "  EBVU6HDJ-GGX)  !_2P  &
M        @(%F(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ )8MM5I%=ZX43!   (!,  !@              ("!&BH  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( "6+;58\?9P_Q@8  !,<   8
M              " @6,N  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    "  EBVU6!E_Q];\"  "_!P  &               @(%?-0  >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ )8MM5FH@^TM&!P
M4A   !D              ("!5#@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    "  EBVU6X2ZI?6$4  "4-0  &0              @('1
M/P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "6+;5;'
M:M:UG ,  ,H'   9              " @6E4  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ )8MM5JE&_2,> P  N 8  !D
M     ("!/%@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "6+;5:D@[!^4P4  (P,   9              "
M@>%M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ )8MM
M5O7FR[PF!0  \ L  !D              ("!:W,  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    "  EBVU6 \9$\!4#  "I!@  &0
M        @('(>   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( "6+;5:,SP=G70,  %T'   9              " @11\  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ )8MM5JEKN^B& P  J0<
M !D              ("!J'\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    "  EBVU6V:QH\F(#   J!P  &0              @(%E@P
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( "6+;5:!$6OA
M( <  *,7   9              " @?Z&  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ )8MM5JG1$?D=!0  [!   !D
M ("!58X  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  E
MBVU6L3NZWW8(  #&%0  &0              @(&IDP  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( "6+;59Z=+IS#0,  -0&   9
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M970S,2YX;6Q02P$"% ,4    "  EBVU6[*9B-*H5  #7/@  &0
M    @('EM0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M "6+;5:,F_BRD@,  $\)   9              " @<;+  !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ )8MM5O8U#WHG P  P@8  !D
M             ("!C\\  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    "  EBVU6UP[+B1H#  #!!@  &0              @('MT@  >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( "6+;59,5ECO-@,
M +H(   9              " @3[6  !X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ )8MM5J:S=3P;!   5PH  !D              ("!
MJ]D  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  EBVU6
MNN("6\4"  !9!@  &0              @(']W0  >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( "6+;59+JI/!.P,  !L(   9
M      " @?G@  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ )8MM5D_%_TA"!   00L  !D              ("!:^0  'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  EBVU6TAJA IP"  "D!@
M&0              @('DZ   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( "6+;5;\"-@K\0(  (H(   9              " @;?K  !X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ )8MM5FFQ?ODU
M P  UPP  !D              ("!W^X  'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    "  EBVU6!%_\_*P$  "O'0  &0
M@(%+\@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( "6+
M;58K-+^?8@0  ,\9   9              " @2[W  !X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ )8MM5F5]3CT0!@  L3H  !D
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M=#4P+GAM;%!+ 0(4 Q0    ( "6+;5;(>WKVG @   )<   9
M  " @1H0 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
M)8MM5@1 FDUO @   @4  !D              ("![1@! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    "  EBVU6'2I?,A0#  "["   &0
M            @(&3&P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4
M Q0    ( "6+;58$S_>F= ,  ',*   9              " @=X> 0!X;"]W
M;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ )8MM5@7*(1Y9 @
M(@4  !D              ("!B2(! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX
M;6Q02P$"% ,4    "  EBVU6G]FJKW<"   R!0  &0              @($9
M)0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( "6+;5;G
M:$V<90(  #P%   9              " @<<G 0!X;"]W;W)K<VAE971S+W-H
M965T-3<N>&UL4$L! A0#%     @ )8MM5N-5:CNE P  2P\  !D
M     ("!8RH! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "6+;58D0^P9EP,  "\.   9              "
M@7Q5 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ )8MM
M5JM 8;?' P  [Q$  !D              ("!2ED! 'AL+W=O<FMS:&5E=',O
M<VAE970V-"YX;6Q02P$"% ,4    "  EBVU66X3)\;<"  "?!P  &0
M        @(%(70$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0
M   ( "6+;5:^R:CNOP(  (X'   9              " @39@ 0!X;"]W;W)K
M<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ )8MM5AQ7TA,X P  OPL
M !D              ("!+&,! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q0
M2P$"% ,4    "  EBVU6#.)H^HX#  #6#@  &0              @(&;9@$
M>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( "6+;5:0_K%5
MM0(  /T&   9              " @6!J 0!X;"]W;W)K<VAE971S+W-H965T
M-CDN>&UL4$L! A0#%     @ )8MM5H;+4B-A P  Z0D  !D
M ("!3&T! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    "  E
MBVU6KZ6(O_8"  #H"   &0              @('D< $ >&PO=V]R:W-H965T
M<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( "6+;58QA;"&TP0  $<<   9
M          " @1%T 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#
M%     @ )8MM5H[A'_5O#   $Z0  !D              ("!&WD! 'AL+W=O
M<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    "  EBVU6KVK;VD,#   F
M%   #0              @ '!A0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (
M "6+;5:7BKL<P    !,"   +              "  2^) 0!?<F5L<R\N<F5L
M<U!+ 0(4 Q0    ( "6+;59W+!A8%08  #HP   /              "  1B*
M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  EBVU6M\<#,$("  !"*P
M&@              @ %:D $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  EBVU6^,,"'08"  !/*@  $P              @ '4D@$
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     40!1 "X6   +E0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>205</ContextCount>
  <ElementCount>324</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>89</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/Business</Role>
      <ShortName>BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - OTHER BALANCE SHEET INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/OtherBalanceSheetInformation</Role>
      <ShortName>OTHER BALANCE SHEET INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - TEMPORARY EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/TemporaryEquity</Role>
      <ShortName>TEMPORARY EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana</Role>
      <ShortName>ASSET PURCHASE AGREEMENT WITH KATANA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina</Role>
      <ShortName>ASSET PURCHASE AGREEMENT WITH TRIGEMINA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran</Role>
      <ShortName>ASSET PURCHASE AGREEMENT WITH TRIMARAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - LICENSE AGREEMENT WITH CURIA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LicenseAgreementWithCuria</Role>
      <ShortName>LICENSE AGREEMENT WITH CURIA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta</Role>
      <ShortName>LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - LICENSE AGREEMENT WITH OYAGEN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LicenseAgreementWithOyagen</Role>
      <ShortName>LICENSE AGREEMENT WITH OYAGEN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - LICENSE AGREEMENT WITH INSERM</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LicenseAgreementWithInserm</Role>
      <ShortName>LICENSE AGREEMENT WITH INSERM</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity</Role>
      <ShortName>LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SALE OF COMMON STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SaleOfCommonStock</Role>
      <ShortName>SALE OF COMMON STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/WarrantsToPurchaseCommonStock</Role>
      <ShortName>WARRANTS TO PURCHASE COMMON STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/Commitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - OTHER BALANCE SHEET INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/OtherBalanceSheetInformationTables</Role>
      <ShortName>OTHER BALANCE SHEET INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/OtherBalanceSheetInformation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - TEMPORARY EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/TemporaryEquityTables</Role>
      <ShortName>TEMPORARY EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/TemporaryEquity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/Stock-basedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables</Role>
      <ShortName>WARRANTS TO PURCHASE COMMON STOCK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/WarrantsToPurchaseCommonStock</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/Leases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/BusinessDetailsNarrative</Role>
      <ShortName>BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/Business</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails</Role>
      <ShortName>The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails</Role>
      <ShortName>Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Property and equipment, net consisted of the following (in thousands): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails</Role>
      <ShortName>Property and equipment, net consisted of the following (in thousands): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Components of selected captions in the consolidated balance sheets consist of: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails</Role>
      <ShortName>Components of selected captions in the consolidated balance sheets consist of: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/StockholdersEquity</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails</Role>
      <ShortName>The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - TEMPORARY EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/TemporaryEquityDetailsNarrative</Role>
      <ShortName>TEMPORARY EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/TemporaryEquityTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative</Role>
      <ShortName>ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative</Role>
      <ShortName>ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative</Role>
      <ShortName>ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - LICENSE AGREEMENT WITH CURIA (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative</Role>
      <ShortName>LICENSE AGREEMENT WITH CURIA (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/LicenseAgreementWithCuria</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - LICENSE AGREEMENT WITH OYAGEN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative</Role>
      <ShortName>LICENSE AGREEMENT WITH OYAGEN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/LicenseAgreementWithOyagen</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - LICENSE AGREEMENT WITH INSERM (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative</Role>
      <ShortName>LICENSE AGREEMENT WITH INSERM (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/LicenseAgreementWithInserm</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative</Role>
      <ShortName>LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SALE OF COMMON STOCK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative</Role>
      <ShortName>SALE OF COMMON STOCK (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/SaleOfCommonStock</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure -  A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails</Role>
      <ShortName>A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails</Role>
      <ShortName>The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details</Role>
      <ShortName>The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative</Role>
      <ShortName>WARRANTS TO PURCHASE COMMON STOCK (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails</Role>
      <ShortName>At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - Other information related to leases was as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails</Role>
      <ShortName>Other information related to leases was as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/LeasesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - COMMITMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>COMMITMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/Commitments</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - Components of the net loss consist of the following (in thousands): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails</Role>
      <ShortName>Components of the net loss consist of the following (in thousands): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company???s income tax provision is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails</Role>
      <ShortName>A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company???s income tax provision is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails</Role>
      <ShortName>Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="tnxp-10k_123122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tonixpharma.com/role/SubsequentEvents</ParentRole>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 14 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:OperatingLeaseLiability, us-gaap:OperatingLeaseLiabilityCurrent, us-gaap:OperatingLeaseLiabilityNoncurrent, us-gaap:OperatingLeaseRightOfUseAsset, us-gaap:RetainedEarningsAccumulatedDeficit, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  tnxp-10k_123122.htm 29, 104, 105, 106, 107, 108, 109, 110, 111, 112, 115, 116, 117, 118</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="tnxp-10k_123122.htm">tnxp-10k_123122.htm</File>
    <File>ex21-01.htm</File>
    <File>ex23-01.htm</File>
    <File>ex31-01.htm</File>
    <File>ex31-02.htm</File>
    <File>ex32-01.htm</File>
    <File>ex4-06.htm</File>
    <File>tnxp-20221231.xsd</File>
    <File>tnxp-20221231_cal.xml</File>
    <File>tnxp-20221231_def.xml</File>
    <File>tnxp-20221231_lab.xml</File>
    <File>tnxp-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="579">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tnxp-10k_123122.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 579,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 205,
   "dts": {
    "calculationLink": {
     "local": [
      "tnxp-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tnxp-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tnxp-10k_123122.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tnxp-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tnxp-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tnxp-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 554,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 48,
    "http://tonixpharma.com/20221231": 39,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 92
   },
   "keyCustom": 78,
   "keyStandard": 246,
   "memberCustom": 51,
   "memberStandard": 35,
   "nsprefix": "tnxp",
   "nsuri": "http://tonixpharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://tonixpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - BUSINESS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://tonixpharma.com/role/Business",
     "shortName": "BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://tonixpharma.com/role/SignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://tonixpharma.com/role/PropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:OtherBalanceSheetInformationDiclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - OTHER BALANCE SHEET INFORMATION",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://tonixpharma.com/role/OtherBalanceSheetInformation",
     "shortName": "OTHER BALANCE SHEET INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:OtherBalanceSheetInformationDiclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://tonixpharma.com/role/FairValueMeasurements",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://tonixpharma.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - TEMPORARY EQUITY",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://tonixpharma.com/role/TemporaryEquity",
     "shortName": "TEMPORARY EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:AssetPurchaseAgreementWithKatanaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana",
     "shortName": "ASSET PURCHASE AGREEMENT WITH KATANA",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:AssetPurchaseAgreementWithKatanaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina",
     "shortName": "ASSET PURCHASE AGREEMENT WITH TRIGEMINA",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran",
     "shortName": "ASSET PURCHASE AGREEMENT WITH TRIMARAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://tonixpharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:LicenseAgreementCuriaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - LICENSE AGREEMENT WITH CURIA",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://tonixpharma.com/role/LicenseAgreementWithCuria",
     "shortName": "LICENSE AGREEMENT WITH CURIA",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:LicenseAgreementCuriaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:LicenseAgreementUniversityOfAlbertaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta",
     "shortName": "LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:LicenseAgreementUniversityOfAlbertaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:LicenseAgreementOyagenTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - LICENSE AGREEMENT WITH OYAGEN",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://tonixpharma.com/role/LicenseAgreementWithOyagen",
     "shortName": "LICENSE AGREEMENT WITH OYAGEN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:LicenseAgreementOyagenTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:LicenseAgreementWithInsermTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - LICENSE AGREEMENT WITH INSERM",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://tonixpharma.com/role/LicenseAgreementWithInserm",
     "shortName": "LICENSE AGREEMENT WITH INSERM",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:LicenseAgreementWithInsermTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity",
     "shortName": "LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:SaleOfCommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - SALE OF COMMON STOCK",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://tonixpharma.com/role/SaleOfCommonStock",
     "shortName": "SALE OF COMMON STOCK",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:SaleOfCommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://tonixpharma.com/role/Stock-basedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:StockWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://tonixpharma.com/role/WarrantsToPurchaseCommonStock",
     "shortName": "WARRANTS TO PURCHASE COMMON STOCK",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tnxp:StockWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://tonixpharma.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - COMMITMENTS",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://tonixpharma.com/role/Commitments",
     "shortName": "COMMITMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://tonixpharma.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://tonixpharma.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "32",
     "role": "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://tonixpharma.com/role/SignificantAccountingPoliciesTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://tonixpharma.com/role/PropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "tnxp:OtherBalanceSheetInformationDiclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - OTHER BALANCE SHEET INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://tonixpharma.com/role/OtherBalanceSheetInformationTables",
     "shortName": "OTHER BALANCE SHEET INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "tnxp:OtherBalanceSheetInformationDiclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "tnxp:TemporaryEquityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - TEMPORARY EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://tonixpharma.com/role/TemporaryEquityTables",
     "shortName": "TEMPORARY EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "tnxp:TemporaryEquityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://tonixpharma.com/role/Stock-basedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "tnxp:StockWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables",
     "shortName": "WARRANTS TO PURCHASE COMMON STOCK (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "tnxp:StockWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://tonixpharma.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://tonixpharma.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "tnxp:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - BUSINESS (Details Narrative)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://tonixpharma.com/role/BusinessDetailsNarrative",
     "shortName": "BUSINESS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "tnxp:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows: (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails",
     "shortName": "The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows: (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails",
     "shortName": "Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-05-152022-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Property and equipment, net consisted of the following (in thousands): (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails",
     "shortName": "Property and equipment, net consisted of the following (in thousands): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-09-222021-10-01_us-gaap_LandMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-09-222021-10-01_us-gaap_LandMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "tnxp:OtherBalanceSheetInformationDiclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tnxp:ContractRelatedPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Components of selected captions in the consolidated balance sheets consist of: (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails",
     "shortName": "Components of selected captions in the consolidated balance sheets consist of: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "tnxp:OtherBalanceSheetInformationDiclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tnxp:ContractRelatedPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "tnxp:CashEquivalentsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative",
     "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "tnxp:CashEquivalentsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-05-152022-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-05-152022-05-16_us-gaap_CommonStockMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "tnxp:TemporaryEquityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tnxp:GrossProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails",
     "shortName": "The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "tnxp:TemporaryEquityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-10-26_us-gaap_SeriesAPreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tnxp:GrossProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-13",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - TEMPORARY EQUITY (Details Narrative)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative",
     "shortName": "TEMPORARY EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:TemporaryEquityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-10-242022-10-26_us-gaap_SeriesAPreferredStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:AssetPurchaseAgreementWithKatanaTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2020-12-212020-12-22_custom_AssetPurchaseAgreementMember_custom_KatanaPharmaceuticalsIncMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
     "shortName": "ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:AssetPurchaseAgreementWithKatanaTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2020-12-212020-12-22_custom_AssetPurchaseAgreementMember_custom_KatanaPharmaceuticalsIncMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
     "shortName": "ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2020-06-102020-06-11_custom_AssetPurchaseAgreementMember_custom_TrigeminaIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
     "shortName": "ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2019-08-172019-08-19_custom_AssetPurchaseAgreementMember_custom_TRImaranPharmaIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:LicenseAgreementCuriaTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2020-12-212020-12-22_custom_LicenseAgreementMember_custom_CuriaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - LICENSE AGREEMENT WITH CURIA (Details Narrative)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative",
     "shortName": "LICENSE AGREEMENT WITH CURIA (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:LicenseAgreementCuriaTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2020-12-212020-12-22_custom_LicenseAgreementMember_custom_CuriaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:LicenseAgreementOyagenTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-04-132021-04-14_custom_LicenseAgreementMember_custom_OyaGenIncMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - LICENSE AGREEMENT WITH OYAGEN (Details Narrative)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
     "shortName": "LICENSE AGREEMENT WITH OYAGEN (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:LicenseAgreementOyagenTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-04-132021-04-14_custom_LicenseAgreementMember_custom_OyaGenIncMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:LicenseAgreementWithInsermTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-02-072021-02-11_custom_InsermLicenseAgreementMember_custom_InsermMember_custom_OxytocinBasedTherapeuticsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "tnxp:SalesMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - LICENSE AGREEMENT WITH INSERM (Details Narrative)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative",
     "shortName": "LICENSE AGREEMENT WITH INSERM (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:LicenseAgreementWithInsermTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-02-072021-02-11_custom_InsermLicenseAgreementMember_custom_InsermMember_custom_OxytocinBasedTherapeuticsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "tnxp:SalesMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative",
     "shortName": "LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2019-09-152019-09-16_custom_LicenseAgreementMember_custom_TrusteesOfColumbiaUniversityMember_custom_TFF2ProductMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tnxp:PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:SaleOfCommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-012022-12-31_custom_PurchaseAgreementWithLincolnPark2022Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - SALE OF COMMON STOCK (Details Narrative)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
     "shortName": "SALE OF COMMON STOCK (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:SaleOfCommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-08-152022-08-16_custom_PurchaseAgreementWithLincolnPark2022Member_custom_LincolnParkCapitalFundLLCMember",
      "decimals": "0",
      "lang": null,
      "name": "tnxp:CommitmentToPurchaseSharesUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure -  A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows: (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails",
     "shortName": "A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows: (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails",
     "shortName": "The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "tnxp:StockWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022: (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details",
     "shortName": "The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "tnxp:StockWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Details Narrative)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative",
     "shortName": "WARRANTS TO PURCHASE COMMON STOCK (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tnxp:StockWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-01-012021-12-31_us-gaap_WarrantMember964078343",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails",
     "shortName": "At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "tnxp:SummaryOfOtherInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - Other information related to leases was as follows: (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails",
     "shortName": "Other information related to leases was as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "tnxp:SummaryOfOtherInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - LEASES (Details Narrative)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://tonixpharma.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - COMMITMENTS (Details Narrative)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://tonixpharma.com/role/CommitmentsDetailsNarrative",
     "shortName": "COMMITMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-012022-12-31_custom_DefinedContributionPlan401KPlanMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000069 - Disclosure - Components of the net loss consist of the following (in thousands): (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails",
     "shortName": "Components of the net loss consist of the following (in thousands): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tnxp:WarrantsExercisedPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tnxp:WarrantsExercisedPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000070 - Disclosure - A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company\u2019s income tax provision is as follows: (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails",
     "shortName": "A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company\u2019s income tax provision is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000071 - Disclosure - Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands): (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails",
     "shortName": "Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000072 - Disclosure - INCOME TAXES (Details Narrative)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "AsOf2023-01-02_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "tnxp:MinimumBidRequirementPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tnxp-10k_123122.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 89,
   "tag": {
    "country_BM": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BERMUDA"
       }
      }
     },
     "localname": "BM",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r429",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r429",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r429",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City area code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r429",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity common stock, shares outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative",
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity public float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative",
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local phone number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of directors.",
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of executive officer.",
        "label": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r231",
      "r339",
      "r359",
      "r380",
      "r381",
      "r401",
      "r409",
      "r417",
      "r466",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r231",
      "r339",
      "r359",
      "r380",
      "r381",
      "r401",
      "r409",
      "r417",
      "r466",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r184",
      "r340",
      "r402",
      "r415",
      "r462",
      "r463",
      "r468",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r184",
      "r340",
      "r402",
      "r415",
      "r462",
      "r463",
      "r468",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r223",
      "r231",
      "r260",
      "r261",
      "r262",
      "r338",
      "r339",
      "r359",
      "r380",
      "r381",
      "r401",
      "r409",
      "r417",
      "r461",
      "r466",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r223",
      "r231",
      "r260",
      "r261",
      "r262",
      "r338",
      "r339",
      "r359",
      "r380",
      "r381",
      "r401",
      "r409",
      "r417",
      "r461",
      "r466",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "auth_ref": [
      "r452",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Components of selected captions in the consolidated balance sheets consist of:"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/OtherBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r403",
      "r416",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area."
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r383",
      "r384",
      "r403",
      "r416",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r458",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MARYLAND"
       }
      }
     },
     "localname": "MD",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MONTANA"
       }
      }
     },
     "localname": "MT",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_AccretionOfCarryingValueToRedemptionValue": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_TemporaryEquityCarryingAmountAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of Carrying Value to Redemption Value",
        "label": "Accretion of carrying value to redemption value"
       }
      }
     },
     "localname": "AccretionOfCarryingValueToRedemptionValue",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_AccumulatedEmployeePayrollDeductions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated employee payroll deductions related to stock purchase plan as of balance sheet date.",
        "label": "Accumulated Employee Payroll Deductions"
       }
      }
     },
     "localname": "AccumulatedEmployeePayrollDeductions",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_AchievementPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount upon the achievement of specified development, regulatory and sales milestones, Tonix also agreed to pay TRImaran and the Selling Shareholders, in restricted stock or cash, at Tonix's option per agreement.",
        "label": "Contingent milestone payment obligation"
       }
      }
     },
     "localname": "AchievementPaymentsPayable",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_AllianceGlobalPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance Global Partners",
        "label": "Alliance Global Partners [Member]"
       }
      }
     },
     "localname": "AllianceGlobalPartnersMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_AmendedAndRestated2020PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated 2020 Plan",
        "label": "Amended and Restated 2020 Plan [Member]"
       }
      }
     },
     "localname": "AmendedAndRestated2020PlanMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_AmountReturnToEmployee1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount returned to employees of their withholdings under the ESPP.",
        "label": "ESPP withholdings returned to employees"
       }
      }
     },
     "localname": "AmountReturnToEmployee1",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement",
        "label": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_AssetPurchaseAgreementWithKatanaTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure asset purchase agreement with Katana.",
        "label": "ASSET PURCHASE AGREEMENT WITH KATANA"
       }
      }
     },
     "localname": "AssetPurchaseAgreementWithKatanaTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatana"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of asset purchase agreement with Trigemina.",
        "label": "ASSET PURCHASE AGREEMENT WITH TRIGEMINA"
       }
      }
     },
     "localname": "AssetPurchaseAgreementWithTrigeminaDisclosureTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigemina"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_AssignmentAndAssumptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment and assumption agreement.",
        "label": "Assignment and Assumption Agreement [Member]"
       }
      }
     },
     "localname": "AssignmentAndAssumptionAgreementMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_CashEquivalentsFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash equivalents - fair value"
       }
      }
     },
     "localname": "CashEquivalentsFairValue",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_CashFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash fee percentage.",
        "label": "Cash fee"
       }
      }
     },
     "localname": "CashFeePercentage",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_ClassOfWarrantsOrRightExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of warrants or rights outstanding.",
        "label": "Expiration Date"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightExpirationDate",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "tnxp_CommitmentToPurchaseSharesUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents commitment to purchase shares under agreement.",
        "label": "Commitment to purchase shares under agreement"
       }
      }
     },
     "localname": "CommitmentToPurchaseSharesUnderAgreement",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_CommonStockIssuedToAcquireResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents common stock issued to acquire research and development.",
        "label": "Common stock issued to acquire in-process research and development"
       }
      }
     },
     "localname": "CommonStockIssuedToAcquireResearchAndDevelopment",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_CommonStockValuePerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock value per share.",
        "label": "Common stock value (per share)"
       }
      }
     },
     "localname": "CommonStockValuePerShares",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of compensation and compensation-related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Compensation and compensation-related"
       }
      }
     },
     "localname": "CompensationAndCompensationRelatedAccruedLiabilitiesCurrent",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_ConsecutiveBusinessDaysForMinimumBidPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consecutive business days for minimum bid price under NASDAQ rule.",
        "label": "Consecutive business days for minimum bid price"
       }
      }
     },
     "localname": "ConsecutiveBusinessDaysForMinimumBidPrice",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "tnxp_ConstructionContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction Contract",
        "label": "Construction Contract [Member]"
       }
      }
     },
     "localname": "ConstructionContractMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_ConstructionInProgressAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liabilities related to construction in progress.",
        "label": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressAccruedLiabilitiesCurrent",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_ContingentMilestonePaymentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of obligation to make contingent milestone payments.",
        "label": "Contingent milestone payment obligation [Default Label]",
        "verboseLabel": "Contingent milestone payment obligation"
       }
      }
     },
     "localname": "ContingentMilestonePaymentObligation",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_ContractRelatedAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of contract reltaed expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Contract Related Accrued Liabilities Current",
        "verboseLabel": "Contract-related"
       }
      }
     },
     "localname": "ContractRelatedAccruedLiabilitiesCurrent",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_ContractRelatedPrepaidExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to contarct within one year or the normal operating cycle, if longer.",
        "label": "Contract-related"
       }
      }
     },
     "localname": "ContractRelatedPrepaidExpenseCurrent",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_CuriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Curia.",
        "label": "Curia [Member]"
       }
      }
     },
     "localname": "CuriaMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_DefinedContributionPlan401KPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information relating to defined contribution plan 401K during the period.",
        "label": "Qualified Defined Contribution Plan [Member]"
       }
      }
     },
     "localname": "DefinedContributionPlan401KPlanMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_DisclosureAssetPurchaseAgreementWithKatanaAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Purchase Agreement With Katana"
       }
      }
     },
     "localname": "DisclosureAssetPurchaseAgreementWithKatanaAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureAssetPurchaseAgreementWithTrigeminaAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Purchase Agreement With Trigemina"
       }
      }
     },
     "localname": "DisclosureAssetPurchaseAgreementWithTrigeminaAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "terseLabel": "Other Information Related To Leases Was As Follows",
        "verboseLabel": "At December 31 2022 Future Minimum Lease Payments For Operating Leases With Non-cancelable Terms Of More Than One Year Were As Follows In Thousands"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureLicenseAgreementWithCuriaAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement With Curia"
       }
      }
     },
     "localname": "DisclosureLicenseAgreementWithCuriaAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureLicenseAgreementWithInsermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement With Inserm"
       }
      }
     },
     "localname": "DisclosureLicenseAgreementWithInsermAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureLicenseAgreementWithOyagenAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement With Oyagen"
       }
      }
     },
     "localname": "DisclosureLicenseAgreementWithOyagenAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement With University Of Alberta"
       }
      }
     },
     "localname": "DisclosureLicenseAgreementWithUniversityOfAlbertaAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureOtherBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Balance Sheet Information",
        "verboseLabel": "Components Of Selected Captions In Consolidated Balance Sheets Consist Of"
       }
      }
     },
     "localname": "DisclosureOtherBalanceSheetInformationAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureSaleOfCommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Common Stock"
       }
      }
     },
     "localname": "DisclosureSaleOfCommonStockAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureTemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity"
       }
      }
     },
     "localname": "DisclosureTemporaryEquityAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_DisclosureWarrantsToPurchaseCommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase Common Stock"
       }
      }
     },
     "localname": "DisclosureWarrantsToPurchaseCommonStockAbstract",
     "nsuri": "http://tonixpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tnxp_EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations related to attribute reduction from control change.",
        "label": "Attribute reduction from control change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAttributeReductionFromControlChange",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_EmployeeStockOption1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOption1Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_EmployeeStockPurchasePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan.",
        "label": "2020 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2020Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_EmployeeStockPurchasePlan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2022.",
        "label": "Employee Stock Purchase Plan 2022 [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2022Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_EmployeeStockPurchasePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plans.",
        "label": "Employee Stock Purchase Plans [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlansMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_EscrowDepositForOriginalIssueDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount held in escrow account for original issue discount.",
        "label": "Escrow Deposit for Original Issue Discount"
       }
      }
     },
     "localname": "EscrowDepositForOriginalIssueDiscount",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_ExercisePriceOfWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exercise price of expired warrants.",
        "label": "Exercise price of warrants expired (in dollars per share)"
       }
      }
     },
     "localname": "ExercisePriceOfWarrantsExpired",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "tnxp_ExistingShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Existing Share Repurchase Program.",
        "label": "Existing Share Repurchase Program [Member]"
       }
      }
     },
     "localname": "ExistingShareRepurchaseProgramMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_FurnitureAndAllOtherEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent furniture and all other equipment.",
        "label": "Furniture and All Other Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndAllOtherEquipmentMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_FurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and Equipment.",
        "label": "Furniture and Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndEquipmentMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_GrossProceeds": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TemporaryEquityCarryingAmountAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross proceeds from stock issued.",
        "label": "Gross Proceeds"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_HealionBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healion Bio Inc.",
        "label": "Healion Bio Inc. [Member]"
       }
      }
     },
     "localname": "HealionBioIncMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_IncentiveStockOptionsPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Stock Incentive Plan.",
        "label": "2019 Incentive Stock Option Plan [Member]"
       }
      }
     },
     "localname": "IncentiveStockOptionsPlan2019Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_IncentiveStockOptionsPlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Incentive Plan.",
        "label": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "IncentiveStockOptionsPlan2020Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_InsermLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent inserm license agreement.",
        "label": "License Agreement [Member] [Default Label]",
        "verboseLabel": "License Agreement [Member]"
       }
      }
     },
     "localname": "InsermLicenseAgreementMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_InsermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent inserm.",
        "label": "Inserm [Member]"
       }
      }
     },
     "localname": "InsermMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of Issuance of commitment shares under Lincoln Park Purchase Agreement.",
        "label": "Issuance of commitment shares under Lincoln park Purchase agreement"
       }
      }
     },
     "localname": "IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreement",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of commitment shares under Lincoln Park Purchase Agreement, number of shares.",
        "label": "Issuance of commitment shares under Lincoln park Purchase agreement (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommitmentSharesUnderLincolnParkPurchaseAgreementShares",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of commitment shares under Purchase Agreement, value.",
        "label": "Issuance of commitment shares under 2022 Purchase agreement"
       }
      }
     },
     "localname": "IssuanceOfCommitmentSharesUnderPurchaseAgreement",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of commitment shares under Purchase Agreement, shares.",
        "label": "Issuance of commitment shares under 2022 Purchase agreement (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommitmentSharesUnderPurchaseAgreementInShares",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_IssuanceOfCommonStockUnderPurchaseAgreement1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of commitment shares under 2021 Purchase agreement"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderPurchaseAgreement1",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_IssuanceOfCommonStockUnderPurchaseAgreement2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock under 2021 Purchase Agreement"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderPurchaseAgreement2",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_IssuanceOfCommonStockUnderPurchaseAgreement3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderPurchaseAgreement3",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_IssuanceOfCommonStockUnderPurchaseAgreement4": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock under 2022 Purchase Agreement"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderPurchaseAgreement4",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of commitment shares under 2021 Purchase agreement (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderPurchaseAgreementInShares1",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock under 2021 Purchase Agreement (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderPurchaseAgreementInShares2",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75 (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderPurchaseAgreementInShares3",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_IssuanceOfCommonStockUnderPurchaseAgreementInShares4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock under 2022 Purchase Agreement (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderPurchaseAgreementInShares4",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_KatanaPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member related to katana pharmaceutical.",
        "label": "Katana Pharmaceuticals, Inc [Member]"
       }
      }
     },
     "localname": "KatanaPharmaceuticalsIncMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_LandImprovementsAndLabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Land Improvements and Lab Equipment.",
        "label": "Land Improvements and Lab Equipment [Member]"
       }
      }
     },
     "localname": "LandImprovementsAndLabEquipmentMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_LicenseAgreementCuriaTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the license agreement with Curia.",
        "label": "LICENSE AGREEMENT WITH CURIA"
       }
      }
     },
     "localname": "LicenseAgreementCuriaTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithCuria"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_LicenseAgreementOyagenTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This entire disclosure of the license agreement with Oyagen.",
        "label": "LICENSE AGREEMENT WITH OYAGEN"
       }
      }
     },
     "localname": "LicenseAgreementOyagenTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithOyagen"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_LicenseAgreementUniversityOfAlbertaTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the license agreement with University of Alberta.",
        "label": "LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA"
       }
      }
     },
     "localname": "LicenseAgreementUniversityOfAlbertaTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithUniversityOfAlberta"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_LicenseAgreementWithInsermTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This entire disclosure of the license agreement with Inserm.",
        "label": "LICENSE AGREEMENT WITH INSERM"
       }
      }
     },
     "localname": "LicenseAgreementWithInsermTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithInserm"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member related to Lincoln Park Capital Fund.",
        "label": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_MaximumNumberOfSharesIssuedWIthoutShareholderApproval": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares issued wIthout shareholder approval.",
        "label": "Maximum number of shares issued wIthout shareholder approval"
       }
      }
     },
     "localname": "MaximumNumberOfSharesIssuedWIthoutShareholderApproval",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_MaximumPercentageReductionOfRoyaltiesPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage by which royalties payable may be reduced.",
        "label": "Maximum percentage reduction of royalties payable"
       }
      }
     },
     "localname": "MaximumPercentageReductionOfRoyaltiesPayable",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_MinimumBidRequirementPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum bid price requirement per share for continued listing on the NASDAQ Capital Market.",
        "label": "Minimum bid price requirements NASDAQ"
       }
      }
     },
     "localname": "MinimumBidRequirementPerShare",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "tnxp_NewLeaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Operating Lease.",
        "label": "New Operating Lease [Member]"
       }
      }
     },
     "localname": "NewLeaseArrangementMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_NewShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Share Repurchase Program.",
        "label": "New Share Repurchase Program [Member]"
       }
      }
     },
     "localname": "NewShareRepurchaseProgramMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_OfferingPricePerAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common shares agreed to be offered under the sales agreement.",
        "label": "Offering price per agreement"
       }
      }
     },
     "localname": "OfferingPricePerAgreement",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office furniture and equipment and Laboratory equipment",
        "label": "Office furniture and equipment and Laboratory equipment [Member]"
       }
      }
     },
     "localname": "OfficeFurnitureAndEquipmentAndLaboratoryEquipmentMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_OperatingLossCarryforwardsLimitationsOnUsePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Utilization NOL (percent)"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUsePercent",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_OtherBalanceSheetInformationDiclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of other balance sheet information.",
        "label": "OTHER BALANCE SHEET INFORMATION"
       }
      }
     },
     "localname": "OtherBalanceSheetInformationDiclosureTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/OtherBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_OxytocinBasedTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent oxytocin based therapeutics.",
        "label": "Oxytocin-based Therapeutics [Member]"
       }
      }
     },
     "localname": "OxytocinBasedTherapeuticsMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_OyaGenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent oya gen inc.",
        "label": "Oya Gen Inc [Member]"
       }
      }
     },
     "localname": "OyaGenIncMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_PercentageOfIssuanceByIssuerOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents percentage of issuance by issuer of common stock.",
        "label": "Percentage of issuance by issuer of common stock"
       }
      }
     },
     "localname": "PercentageOfIssuanceByIssuerOfCommonStock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_PercentageOfIssueDiscount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of original issue discount to stated value per share.",
        "label": "Percentage of issue discount"
       }
      }
     },
     "localname": "PercentageOfIssueDiscount",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalties payable to any third party for intellectual property rights which are necessary for the practice of the rights licensed which may reduce royalties payable on net sales.",
        "label": "Percentage of royalties payable to any third party for intellectual property rights",
        "verboseLabel": "Percentage of third party royalties payable for reduction in royalties payable"
       }
      }
     },
     "localname": "PercentageOfThirdPartyRoyaltiesPayableForReductionsInRoyaltiesPayable",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_PercentagePadOfConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of pay for consideration.",
        "label": "Percentage of pay for consideration"
       }
      }
     },
     "localname": "PercentagePadOfConsideration",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_PreferredStockDeemedDividend": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deemed dividend for preferred stock.",
        "label": "Preferred Stock Deemed Dividend",
        "negatedLabel": "Preferred stock deemed dividend"
       }
      }
     },
     "localname": "PreferredStockDeemedDividend",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_PreferredStockIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TemporaryEquityCarryingAmountAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of preferred stock issuance costs",
        "label": "Preferred Stock Issuance Costs",
        "negatedLabel": "Preferred stock issuance costs"
       }
      }
     },
     "localname": "PreferredStockIssuanceCosts",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_PreferredStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of designated shares of preferred stock.",
        "label": "Preferred stock, designated"
       }
      }
     },
     "localname": "PreferredStockSharesDesignated",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Professional fees and other reltaed expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Professional fees and other"
       }
      }
     },
     "localname": "ProfessionalFeesAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_ProfessionalFeesAndOtherPrepaidExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of professional fees and other within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "ProfessionalFeesAndOtherPrepaidExpenseCurrent",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_PurchaseAgreement2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for purchase agreement 2021.",
        "label": "Purchase Agreement 2021 [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement2021Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_PurchaseAgreementWithLincolnPark2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement with Lincoln Park 2021.",
        "label": "Purchase Agreement with Lincoln Park 2021 [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementWithLincolnPark2021Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_PurchaseAgreementWithLincolnPark2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement with Lincoln Park 2022.",
        "label": "Purchase Agreement with Lincoln Park 2022 [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementWithLincolnPark2022Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_PurchaseAgreementWithLincolnParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement With Lincoln Park",
        "label": "Purchase Agreement With Lincoln Park [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementWithLincolnParkMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_ReimbursementOfPatentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid for reimbursement of patent expenses.",
        "label": "Reimbursement of patent expenses"
       }
      }
     },
     "localname": "ReimbursementOfPatentExpenses",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_ResearchOrganizationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Organizations",
        "label": "Research Organizations [Member]"
       }
      }
     },
     "localname": "ResearchOrganizationsMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_SaleOfCommonStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to sale of common stock.",
        "label": "SALE OF COMMON STOCK"
       }
      }
     },
     "localname": "SaleOfCommonStockTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_SalesAgentCommissionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agent commission percentage.",
        "label": "Commission to agent"
       }
      }
     },
     "localname": "SalesAgentCommissionPercentage",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member sales agreement.",
        "label": "Sales Agreement [Member]"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_SalesAgreementWithAGPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement with AGP.",
        "label": "Sales Agreement with AGP [Member]"
       }
      }
     },
     "localname": "SalesAgreementWithAGPMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_SalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestones specified in license agreement.",
        "label": "Sale MIlestones"
       }
      }
     },
     "localname": "SalesMilestones",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Percentage of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_StatedValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated value per share of covertible redeemable preferred stock.",
        "label": "Stated value per share"
       }
      }
     },
     "localname": "StatedValuePerShare",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "tnxp_StockIssuanceFebruary2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in February 2021",
        "label": "Issuance of common stock in February 2021 [Member]"
       }
      }
     },
     "localname": "StockIssuanceFebruary2021Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_StockIssuanceJanuary2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in January 2021",
        "label": "Issuance of common stock in January 2021 [Member]"
       }
      }
     },
     "localname": "StockIssuanceJanuary2021Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_StockIssuanceNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock under At-the-market offering",
        "label": "Issuance of common stock under At-the-market offering [Member]"
       }
      }
     },
     "localname": "StockIssuanceNineMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_StockIssuanceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock under 2021 Purchase Agreement",
        "label": "Issuance of common stock under 2021 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockIssuanceTwoMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_StockIssuedDuringPeriodSharesNewIssues1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock in exchange for exercise of warrants in March 2021 ($18.24 per share) (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues1",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_StockIssuedDuringPeriodSharesNewIssues14": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock in January 2021 ($25.60 per share), net of transactional expenses of $3,096 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues14",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_StockIssuedDuringPeriodSharesNewIssues15": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock in February 2021 ($38.40 per share), net of transactional expenses of $5,002 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues15",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_StockIssuedDuringPeriodSharesNewIssues19": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues19",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_StockIssuedDuringPeriodSharesNewIssues21": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock in the acquisition of the OyaGen license (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues21",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_StockIssuedDuringPeriodSharesNewIssues7": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock under At-the-market offering, net of transactional expenses of $3,078 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues7",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tnxp_StockIssuedDuringPeriodValueNewIssues1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock in exchange for exercise of warrants in March 2021 ($18.24 per share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues1",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_StockIssuedDuringPeriodValueNewIssues14": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock in January 2021 ($25.60 per share), net of transactional expenses of $3,096"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues14",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_StockIssuedDuringPeriodValueNewIssues15": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock in February 2021 ($38.40 per share), net of transactional expenses of $5,002"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues15",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_StockIssuedDuringPeriodValueNewIssues19": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues19",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_StockIssuedDuringPeriodValueNewIssues21": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock in the acquisition of the OyaGen license"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues21",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_StockIssuedDuringPeriodValueNewIssues7": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock under At-the-market offering, net of transactional expenses of $3,078"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues7",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_StockWarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for stock warrants or rights issued during the given period.",
        "label": "WARRANTS TO PURCHASE COMMON STOCK"
       }
      }
     },
     "localname": "StockWarrantsTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_SummaryOfOtherInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of information related to leases.",
        "label": "Other information related to leases was as follows:"
       }
      }
     },
     "localname": "SummaryOfOtherInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_TFF2ProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to TFF2 product.",
        "label": "TFF2 Product [Member]"
       }
      }
     },
     "localname": "TFF2ProductMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_TRImaranPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member related to TRImaran Pharma.",
        "label": "TRImaran Pharma Inc [Member]"
       }
      }
     },
     "localname": "TRImaranPharmaIncMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_TemporaryEquityRedemptionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of stated value of temporary equity required for redemption of shares,",
        "label": "Temporary equity redemption price percentage"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPricePercentage",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "tnxp_TemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of temporary equity.",
        "label": "TEMPORARY EQUITY"
       }
      }
     },
     "localname": "TemporaryEquityTextBlock",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tnxp_TenPercentOrMoreShareholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "10% or more Shareholder.",
        "label": "10% or more Shareholder [Member]"
       }
      }
     },
     "localname": "TenPercentOrMoreShareholderMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_TrigeminaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member trigemina inc.",
        "label": "Trigemina, Inc.[Member]"
       }
      }
     },
     "localname": "TrigeminaIncMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_TrusteesOfColumbiaUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trustees of Columbia University.",
        "label": "Trustees Of Columbia University [Member]"
       }
      }
     },
     "localname": "TrusteesOfColumbiaUniversityMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_UnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent underwriting agreement.",
        "label": "Underwriting Agreement [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_UnderwritingDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the underwriting discount incurred during the period.",
        "label": "Underwriting discount"
       }
      }
     },
     "localname": "UnderwritingDiscount",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tnxp_WSULicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member related to WSU license agreement.",
        "label": "WSU License Agreement [Member]"
       }
      }
     },
     "localname": "WSULicenseAgreementMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_Warrant1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant One [Member]"
       }
      }
     },
     "localname": "Warrant1Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_Warrant2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant Two [Member]"
       }
      }
     },
     "localname": "Warrant2Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_Warrant3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant Three [Member]"
       }
      }
     },
     "localname": "Warrant3Member",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_WarrantsExercisedPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price at which warrant holders acquired shares when converting their warrants into shares.",
        "label": "Warrants exercise price (in dollars per share)"
       }
      }
     },
     "localname": "WarrantsExercisedPrice",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "tnxp_WarrantsFromFeb2020FinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to warrants from feb 2020 financing.",
        "label": "Warrants from Feb 2020 Financing [Member]"
       }
      }
     },
     "localname": "WarrantsFromFeb2020FinancingMember",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "tnxp_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of working capital as of reporting date.",
        "label": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://tonixpharma.com/20221231",
     "presentation": [
      "http://tonixpharma.com/role/BusinessDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": ""
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails",
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r414"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities:"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51",
      "r116"
     ],
     "calculation": {
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r122",
      "r356",
      "r364",
      "r365"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r129",
      "r130",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r16",
      "r19",
      "r95",
      "r329",
      "r360",
      "r361",
      "r443",
      "r444",
      "r445",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r453",
      "r454",
      "r455",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.",
        "label": "Transfer to additional paid in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r61",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Transactional expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Potentially dilutive securities excluded from the computation of basic and diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of facility"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative",
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "ASSET PURCHASE AGREEMENT WITH TRIMARAN"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaran"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r98",
      "r103",
      "r118",
      "r138",
      "r178",
      "r180",
      "r182",
      "r187",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r297",
      "r299",
      "r308",
      "r414",
      "r464",
      "r465",
      "r513"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r112",
      "r123",
      "r138",
      "r187",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r297",
      "r299",
      "r308",
      "r414",
      "r464",
      "r465",
      "r513"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r295",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r90",
      "r91",
      "r295",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Purchases of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r114",
      "r393"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/BusinessDetailsNarrative",
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets",
      "http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r29",
      "r34",
      "r39"
     ],
     "calculation": {
      "http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash beginning of the period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r29",
      "r97"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r138",
      "r157",
      "r158",
      "r161",
      "r163",
      "r167",
      "r168",
      "r187",
      "r194",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r204",
      "r205",
      "r209",
      "r213",
      "r220",
      "r308",
      "r382",
      "r438",
      "r449",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Number Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtDecember312022Details",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock, to be issued"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r453",
      "r454",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, authorized",
        "verboseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r414"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value; 1,000,000,000 and 25,000,000\u00a0shares authorized as of December 31, 2022 and 2021, respectively; 76,478,656 and 15,638,274 shares issued and\u00a0outstanding as of December 31, 2022 and 2021, respectively and 93,741 and 4,033 shares to be issued as of December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r20",
      "r125",
      "r127",
      "r132",
      "r353",
      "r357"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r102",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Risks and uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": ""
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COSTS AND EXPENSES:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r280"
     ],
     "calculation": {
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets/(liabilities):"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r89",
      "r499"
     ],
     "calculation": {
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r89",
      "r499"
     ],
     "calculation": {
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r89",
      "r499"
     ],
     "calculation": {
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/DeferredTaxAssetsLiabilitiesAndRelatedValuationAllowanceAsOfDecember312022And2021WereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanAdministrativeExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of administrative expense incurred by defined contribution plan.",
        "label": "Administrative expenses"
       }
      }
     },
     "localname": "DefinedContributionPlanAdministrativeExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Maximum annual contributions per employer"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.",
        "label": "Employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Maximum annual contributions per employee"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r32",
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r32",
      "r177"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r234",
      "r265",
      "r266",
      "r268",
      "r273",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r133",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r154",
      "r157",
      "r161",
      "r162",
      "r163",
      "r165",
      "r303",
      "r304",
      "r354",
      "r358",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per common share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r133",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r157",
      "r161",
      "r162",
      "r163",
      "r165",
      "r303",
      "r304",
      "r354",
      "r358",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per common share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Per Share Data"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of currency rate change on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income Tax Provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r140",
      "r276",
      "r290"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Statutory federal income tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r497",
      "r500"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r497",
      "r500"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Foreign loss not subject to income tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r497",
      "r500"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ReconciliationOfEffectOfApplyingFederalStatutoryRateToNetLossAndEffectiveIncomeTaxRateUsedToCalculateCompanysIncomeTaxProvisionIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r61",
      "r110",
      "r129",
      "r130",
      "r131",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r166",
      "r188",
      "r222",
      "r269",
      "r270",
      "r271",
      "r286",
      "r287",
      "r302",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r329",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r100",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r203",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r306",
      "r335",
      "r336",
      "r337",
      "r399",
      "r400",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r203",
      "r224",
      "r229",
      "r306",
      "r335",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r203",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r335",
      "r336",
      "r337",
      "r399",
      "r400",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Intangible assets with indefinite lives"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government assistance.",
        "label": "Government Grants"
       }
      }
     },
     "localname": "GovernmentAssistancePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r139",
      "r289"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r139",
      "r289"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Foreign",
        "negatedLabel": "Foreign losses"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails",
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r277",
      "r278",
      "r284",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r274",
      "r275",
      "r278",
      "r279",
      "r283",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r447",
      "r509"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Lease liabilities and ROU asset, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r24",
      "r176"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to real estate held.",
        "label": "Land Improvements [Member]"
       }
      }
     },
     "localname": "LandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "At December 31, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands):"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": ""
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Included interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r138",
      "r187",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r298",
      "r299",
      "r300",
      "r308",
      "r396",
      "r464",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r99",
      "r105",
      "r414",
      "r450",
      "r459",
      "r507"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r113",
      "r138",
      "r187",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r298",
      "r299",
      "r300",
      "r308",
      "r414",
      "r464",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r169",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r29",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r33",
      "r101",
      "r107",
      "r111",
      "r124",
      "r126",
      "r131",
      "r138",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r159",
      "r178",
      "r179",
      "r181",
      "r183",
      "r187",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r304",
      "r308",
      "r397",
      "r464"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfNetLossConsistOfFollowingInThousandsDetails",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r154",
      "r155",
      "r160",
      "r163",
      "r178",
      "r179",
      "r181",
      "r183",
      "r397"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss available to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r178",
      "r179",
      "r181",
      "r183",
      "r397"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "",
        "verboseLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AtDecember312022FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails",
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liability, short term",
        "verboseLabel": "Lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets",
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease liability, long term",
        "verboseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets",
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r322",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash flow from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-to-use assets",
        "verboseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets",
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r326",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r325",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/OtherInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Outstanding commitments"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative",
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation."
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative",
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative",
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative",
      "http://tonixpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation loss",
        "verboseLabel": "Foreign currency transaction loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Research and development costs"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForConstructionInProcess": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.",
        "label": "Costs incurred"
       }
      }
     },
     "localname": "PaymentsForConstructionInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.",
        "label": "Redemption amount",
        "negatedLabel": "Redemption of convertible redeemable preferred stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Expenses from sale of common stock and warrants",
        "verboseLabel": "Expenses from sale of stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Consideration paid",
        "verboseLabel": "Payment for purchase of assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r134",
      "r502",
      "r503",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Total costs incurred"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/CommitmentsDetailsNarrative",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock, Convertible, Conversion Price"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r41",
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "verboseLabel": "Preferred stock deemed dividend"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r3",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r3",
      "r414"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized Series B Convertible Preferred stock, 0 shares designated as of both December 31, 2022 and 2021; issued and outstanding - None Series A Convertible Preferred stock, 0 shares designated as of both December 31, 2022 and 2021; issued and outstanding - None"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockVotingRights": {
     "auth_ref": [
      "r3",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Preferred stock voting rights"
       }
      }
     },
     "localname": "PreferredStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other",
        "totalLabel": ""
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails",
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other:"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r394",
      "r398",
      "r460"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds, net of $3,078 and $10,505 expenses, from sale of common stock and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds, net of $6,659 expenses, from sale of convertible redeemable preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r26",
      "r82"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds from ESPP"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from equity offerings",
        "verboseLabel": "Number of shares issued, value"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Facility purchase"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r53",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r50",
      "r115"
     ],
     "calculation": {
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r52",
      "r106",
      "r355",
      "r414"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property and equipment, net consisted of the following (in thousands):"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Estimated useful life of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RedeemablePreferredStockDividends": {
     "auth_ref": [
      "r41",
      "r61",
      "r68"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.",
        "label": "Preferred stock deemed dividend"
       }
      }
     },
     "localname": "RedeemablePreferredStockDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r230",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r109",
      "r330",
      "r331",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r230",
      "r330",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r83",
      "r108",
      "r521"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r439",
      "r448",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash",
        "verboseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInConsolidatedStatementOfCashFlowsDetails",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r68",
      "r104",
      "r363",
      "r365",
      "r414"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/BusinessDetailsNarrative",
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r110",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r188",
      "r269",
      "r270",
      "r271",
      "r286",
      "r287",
      "r302",
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of stock, price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of December 31, 2022 and 2021, are as follows:"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows:"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2022 and 2021 were as follows (in thousands):"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company\u2019s income tax provision is as follows:"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Components of the net loss consist of the following (in thousands):"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails",
      "http://tonixpharma.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r74",
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "A summary of the stock option activity and related information for the Plans for the years ended December 31, 2022, and 2021 is as follows:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "The assumptions used in the valuation of stock options granted during the year ended December 31, 2022 and 2021 were as follows:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r55",
      "r58",
      "r60",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r119",
      "r120",
      "r121",
      "r167",
      "r204",
      "r205",
      "r207",
      "r209",
      "r213",
      "r218",
      "r220",
      "r401",
      "r438",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r440",
      "r441",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r440",
      "r441",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted average grant date fair value of options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock price volatility - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock price volatility - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate - Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate - Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Number of exercised warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Number of warrants expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Number of shares available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable at end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeitures or expirations"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Forfeitures or expirations"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Grants",
        "verboseLabel": "Number of options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative",
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "periodStartLabel": "Beginning, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Exercise price of options granted (in dollars per share)",
        "verboseLabel": "Grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative",
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r238",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Expiration period",
        "verboseLabel": "Options term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term of option"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringYearEndedDecember312022And2021WereAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForYearsEndedDecember312022And2021IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Percent of fair value of common stock at grant date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, at end (in shares)",
        "periodStartLabel": "Balance, at beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r40",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r138",
      "r157",
      "r158",
      "r161",
      "r163",
      "r167",
      "r168",
      "r187",
      "r194",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r204",
      "r205",
      "r209",
      "r213",
      "r220",
      "r308",
      "r382",
      "r438",
      "r449",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r61",
      "r110",
      "r129",
      "r130",
      "r131",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r166",
      "r188",
      "r222",
      "r269",
      "r270",
      "r271",
      "r286",
      "r287",
      "r302",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r329",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r166",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Value of shares issued",
        "verboseLabel": "Number of shares issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Repurchase program amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Number of shares repurchased (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Value of shares repurchased"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r47",
      "r414",
      "r450",
      "r459",
      "r507"
     ],
     "calculation": {
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets",
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r137",
      "r205",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r222",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r1",
      "r2",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Reverse stock split",
        "verboseLabel": "Stockholders' Equity, Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://tonixpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r316",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r316",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r316",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r316",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation related to use of the tax credit carryforward.",
        "label": "Operating loss carryforwards expiration"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r194",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202"
     ],
     "calculation": {
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary equity",
        "totalLabel": "Preferred stock subject to possible redemption"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SeriesPreferredStockAndSeriesBPreferredStockWasRecordedAtRedemptionValueDetails",
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r0",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r0",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "The Series A Preferred Stock and Series B Preferred Stock was recorded at redemption value"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/TemporaryEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Price of shares repurchased (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithKatanaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrigeminaDetailsNarrative",
      "http://tonixpharma.com/role/AssetPurchaseAgreementWithTrimaranDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithCuriaDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithInsermDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementWithOyagenDetailsNarrative",
      "http://tonixpharma.com/role/LicenseAgreementsWithColumbiaUniversityDetailsNarrative",
      "http://tonixpharma.com/role/SaleOfCommonStockDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r170",
      "r171",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tonixpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfDecember312022And2021AreAsFollowsDetails",
      "http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r156",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average common shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r154",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tonixpharma.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342957-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r419": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r426": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r427": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r428": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r429": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r431": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r432": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r433": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r434": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r435": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r436": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r437": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126960819&loc=d3e20905-112640",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001387131-23-003377-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-23-003377-xbrl.zip
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M?BAXAE&=GRD!:D>!\1"7N)!$,<%A?0!)-U12'FI1H;&@6Y:I2F&IB*().LA
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M0_#E9.6V6N&!BI88<M?:\M$JF^_Q7MOCR29<T=5(=U>2KE3^'U!+ P04
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MG  LE[)?KV?^N!VILH;\=I!]3)#?'/X!4$L#!!0    ( "6+;5;,+>Q\B0X
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M%$7'-7UZV-:V#VM\S="\8*M]=D&VF^[A7@-[/;O/_D#![;$W;VT/''4H C8
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M*E[[6;>?BF[[ '#Y>WU8%QT9$<38@%2H(/RRHH6%[M?N**MM/^XE/Z=XV-B
M!6*\,Z2.%+KM^R:ZB(=\UL='JH\UI<@EZ2WG "4>EIT&U%>#G?J$O90RHC;?
MJN%@N4-GI?M@0YVY?;^UK\=RRWSCU9&]_W'NR;W36UXGW>J:Y[;-1/;."3L4
M*V]NU)H/Q]CILMI"=?L769<[I<;T5IU[1Z3:9*C%A.O OHR\YF!Y^\,CN*+Z
MSOI0DVVS@4*CR[LX?QV 3[ YT51#)>>)P&D(]P8-/+0=/V7'R<BV8.,-I;3V
M'0-.8"*7XM"GQ^R[M'CL5EH\SCAP][FCX\$[.MYVOFM'QP-U1*#?P_^\C!P@
M_:=G_P%02P,$%     @ )8MM5HL;];#G+@0 ]X(E !,   !T;GAP+3$P:U\Q
M,C,Q,C(N:'1M['UI<]I8N^!W5_D_:'SGWDIN@0-XB9VD,T6\).Z.E]=VNM^>
MNE4I(1U '2'16K#I#_/;YUG.D8Y 8'"$ 5OOW$ECD,[Z[.N'_W/?<XV!"$+'
M]W[9JF_7M@SA6;[M>)U?MN*H73W8^C\?-S<^="-X#I[UPE^VNE'4?_?FS=W=
MW?;=SK8?=-[4#P\/W]SC,UO\T+O[W.<:M5K]S;_/O]Y87=$SJXX71J9GB>0E
MU_%^3!X??TT>;06NDWD4OU&3[+P9&QI^M=,7](?WW_"/F4>CW$?W^-%(/>J$
M_FZC_G;:.OB)Y(7[2<_6<<VP0_'O3]=?T\>C_.?31]]$@>F%;3_HF1'<(8ZT
M5ZTUJHU];9!J**S,0/#W=L<?/#C.076GKL89NYSL3O'GEADF)VZ+D>-6<\(/
M\$:CH1X,1'OBL/MOX%?U8!P%$Q\\? ._)@^&U8YI]I.'VV;8H@?E#YGIY7?5
M,.[W7=$37C3Q/7R&WOU[1[T=!M'4-^7O(V_!>('OBC!W)OHELT0["JK1L"_"
M_.W#SV_P9WRG5JW5JXWDSBP_]J)@F'\1\L?,5&'4#_*?QE^RCP;Y^\T\%'GW
MZ3U$ON?<][LFP-BVY??HP7H#((PHC#!M^*^!__L0.9$K/GYXP_^%7WLB,@T<
MIBK^CIW!+UM'OA?!B5=O8>-;AL5__;(5B?OH#1.B-_C>&SGLA_]5K1JGCG#M
M=\:-B-X;%V9/O#/N[?OWQMDQ??A>:^Q\_W;SGXWCS\WF%?P'E_<=MVU4J[,.
ML7/Z';?\?62KW]56YQAJ]X#>JM5K]<>\OO?INP!4@WW _YUX<)+#(SBBP'3/
M/%O<_R:&WVM CG=W:CNU_7G&/=3&;0+4VPCYIZ[9^=XVW5#,,U1=&^HH#@(<
MR DMT_U3F,&)9Q^;D?C./W^]J=V?.[5_SO_URR_S3%'3ICCVK;B7F>,4O@GI
M=.<9LSEQS"L1.+[-HY[^.<>8;W>___OXW]^O>-#_.7(=&#/\GUL$(^.*X,@2
M<>3 '*'QQ7>101M'?M#_'UC\SO_\W=B!UVJ-P_K^]^_U&GS^[?MW!^GZ_R X
MPM_UV@_X!4"HT=B&&>=9VO'WF\NG6UDXQ]+V/P'"'G^O?Y=LEM<(7\TS1N/[
M#>Q" !A\)ZF"!PGINWG&.<:U7,FQ=L:6]'.#'WZ_B@/Q?5<?I0_?S+? F[]C
MF/C4]Z/OM>_ ,.5J_FY'\XW3M& MV@BFE:RDY=M#(XR&KOAEJPU4^9U1K_4C
MX];IP88OQ)UQ[?=,K\)?5&"6P&D3_;>=@7K/=L*^:P[?&9[O"?K1N7^'A%P$
MR"'H+\>VA4?\ O^$!R\ #0/'8E9P'UVC5'$:^#U$;F2*M7KDT^=Z@X0:#[8&
M4PGG72YQW/J84L</;S)3%#-KAG1N?23:N9"))A'6K8]5?G@ALTZ@M5L?\?$G
MF%&CQ%L?3_^<,N-I8%HH\LJAI*SW[@HD3P$G9]]$OO7C=].-E9PA5]4,+]OZ
M2AS[ERU D(:#*%JKHQ 6>PX_"_@/$E'XSG-<D%$"&.JC6I&:OL EU2<MJ;&T
M)4TZI9V=E3NEG=W"EW0-\@(HO"U79!=W[ P<(&-VN)4'[W6&]RE+/=PO;*G(
MC-_1HL[",!;V<1P (V<LHC,$VDV_A&]S%]M(%BNO^KO</# +P,O8!8IC7T9=
M$1SYO7X@NL(+G8$X\T Z%N>BUQ+!Z/8:.X=KL+UKT$Q A[9/S,"#(<,)>]FM
M%;L77"P:."[;<)X]WZ.]?0/F%8"@8'5!$6]V D%:Z>Z37=ANP1>VP$W.>&U[
MR[NVQI-=V][;M=GDK-=VL,@=.1$NG27]_&W-N2OMF"9L:+\X/OD4&VK:MH-3
M@AQF.O:9=V3VG<AT)VVN.([[))M[-*+M[ZW51F=$MOV"I9 B=Y55%D877C#=
M&Q'N<'6V$O$*IPAOB],OBE[\XQ'D;<%DKL!-S8@,;XO7'J:)K2>]ONL/A:!G
M%&9<N:97/+P5ARQ/N;&?@,7BA-FGW/",<'I0G&"K=M>T_XI#HM;AK3]! B Z
M_@EV9N-%P"V0M_%:A%'@6)'$TV^PKO :'3VA$XD;$0P<2_!170O+[W@T<N$0
M?E <=UZ/(WD\;AP43PQ6^ZAFQ:KB] YU+I-NYJL?AJ=^()R.QQ9>:WB++GP>
MI.G9])=+)Y2>[86(+MNWYGWAR'-8O+ES)78^GR9S6+R%=25.84;P/RQ>^($%
MI_LM'FJ+IV,_L^ Y@:UX8O-3BW\T-SE<AIVWGF\Q'#.Z__S^=@IT!2UP?[/A
M^$Z!3J0Y-C/G7A[$_)V=I=S)DX%<@7ZUQ6UO1H@KT"$WQU[VGNRN=I=R5_/N
M;\;+VEW*91T^V67MK<7^9KRLO87:HZ<Z?G:>[,86ZSHI=),S7MMB_253=U0\
M(R[:CKW S<PEGN^\+5A06N3&'HU<11OL%[C)&9&K0 /^@G8TON2"R?A,/*FQ
M %*P##UP[GT\'ED.EJ%SS+V_&?'D8*'D;<SK^]6!DW6]*S/X,9L#^&< L4#S
M]A/O;3X65:"Y^JGW^7@D7&B,VB+W/"-B'BXT9&T!&QS?0?&^A.(\KS]#5PZ+
M]S ^Q<8>CVP+L*\_Q89GQ;3B#?"KX 7]"0C?K14?S[_:1_)HW-BM/<]P@Y_%
MJMU:<>&$2_"A_A3R%!]QM!([GTLHW:T7'YFT$J<P(_C7BP\A>-BK^S-06R^>
MCOW,@N<$MN*)S4\M_M'<I%ZPRJK=.PM;P% LX >! %8A3!"M #V.Q4"X?O]G
M@K!W"TSR2C, ?4L(.\15_&$&@,/1R;T(+"<44X,:IJZS0"-;WCI3+2M-%CSR
MO8$((F<L;_!Q>M5N@2:;9 OFD,0-H*+7HB\E[H7NH7B-8D).)L WX: F5#UN
MS7L%XF::49IE)AKA.!9MQW)&$')Z&NY> \1V6UA.SW3#7[:J\!?F4,-\^ FX
M(WPWLH6/NV]KM9V#1RS]R R1=N!_3K"6"\P#1]N,C@!3A["7N9.(]QI[DU>?
M733%+1T^1NM$J;DU*C4WD;9TR-3Q:9@^(I&B>6<&-OWS.TC7L+-KI].-0A"C
M+?C5[(AIM"@GP"JCW5[V<0',#)(G\F5[6@)*,E977'KY#*1>:]3T0]Q-SE"7
MQK &Q=;'VO8._.\%'^+MG3_I$.NS'V*M\78J^CQ<"6&N[85!]/T8V+<5^<&D
MU>]NY=W8^%F,W=BG:3?&>F-]Z^-5_1%U&"[[(C!QF*\")J';OVQ_"T4S#,4\
M1*Y>W]V?E4R\K>\]1LO(K/2K8[8<UXF&\ZWQ8.8U[M>*6^.%[UE<)F2NU>[5
M9EWM3N,QK&+":H\>L]3&K$O=W6D\8JG'4H8 O9 @,U2K=41X,1^@-MX6KP$_
M9GGYXDR]R,S#I^<,.U0<L9%\VIF',\2M4/P=P^@G _BG..:[4]\?X1OKQW*7
M>; 3&?(.BM[3#_8A-KR"!VN!/N+W\LZU_F00.R;I/ >(?;J#G0RQC<;C(1:_
M3"NCX3F3:BL\2X3\!%9I?1=2^5T8TZ":NN^Z 0Z/9I]J0Q::W+X/[2WY,]86
M_64K=.!4!)?5E%-E!^?I0C\.U&SP&)6K>R</G[8ZQ>2BRG^JUP059DN^3;Y'
M_3QRVHX(#-J*R*UM>W3V6[:(V^C+Z71O<N>3L_5)?!U?11B9082%U#ZFVU$C
MI;^-O2:X^MK'=-_I]';F%?5]9@'J2WFDD\\YD3%J^]6=VIJ=+9=OCCZF&TBF
MD+\4>DB _SO5^L[Z'I+<P$(/:3VQ- -)&71;R"'5U_V0ZD]P2*-&"RP"*L)/
M63NL9(_+.LB4S(L.BAC:#_(G&Q9SWW?1ULIK-6RGAYX:K*2?1JL 1<?WCUPS
MA-W3UIKW3KCU,7ED\NX_O,F=2%_DF_Q5KA.RE'"PPG"P/'K0?-%PD+O[%TD/
M2CA8)3A8*#V8Z%%=+W$JHQG6'Z,9UI] ,WPXTN>YX!BZF:,AFF)\CWS-&3P;
MV_=SQ:X)]SX]8.IEP,#4,WAI\#!S#-H+@8U9S^.%P<F$>-:7 13YFW_F$% K
M)8:5DQAJ2[CW4F)878EA*?!02@QK)S$L TY*B6&5)(8GA( UL]\\U2$]HH#I
MR\"5I0M8*Q[;\9.%9%\&$*V4A+;V %6*>.LAXJT[H)4RXM)EQ/4 H7E2UE\&
M]*R6U+1Z?L^?+!WP,H!H=:6F=02H4FI:0ZEI#0&ME)I62VI:/1":$&I9RDK+
M=^$]16AE:2!:<5%GV?!02BKK(:DL&4Y*06/I@L930<!$4YW,DDYJPV'9L@O'
M>RX$(FZ%CNV8P?#&=$4F,C];=#^[[=)(-RUF, ]D?C6]&$X9GWJ!D#.V^R62
MD:7D=)0PL7HPL1XZ[#0 .A6MX 5#T/CV2[)20L7RH6+%"<M<P%2*NB7P/!IX
MTKI/+PEVDEV7H#-O-,R#=;2?"3@]G \_\UF4JO@$(-NKUO>23_MK%I0]>LJX
MF7E/F?:])%3^%#L DUZ'@9'*,9\[GM.+>\\#@Z\"'TXN&F*[K:CIV6A*[7.]
MQMMA7V1Q.7L8#R/L+ N!$WUWC44B>2K\,W/ )5GX>8 U[TN 72C Z@=< NQ<
M_HBOIF>?]?J!/R!! OMW?#5;R:V^(* E 7RFXRA!;.Z$K'X<B> E0I46.I-W
M!B4HS46M3N/ <Z(X$'#<3=>E((.7"%5$JV8XC!*\YJ-4LN_9\X"D)HQK.VX<
M.0-Q(ZPXH+X5)_>6&]O"QK-@HD1EUB_;*C[C2@1<B7V8/T"6KF5.K 2W^0*0
M2W!;7W!;0[OH6"N1$N1F +FQ4RNIW'Q4K@2[]0>[U:-V$T)M48%_'E VEWJ9
M;GN)H2O+J'9=WO<S#56:@M^Z@>Z%WOWX$3QSO)_N9WE1]S^O5^59W'N. ; T
M_(T?PC.'AGH)#6L"#4\I&R2NS)8?F)$?#%\L+$P\@I=%%TI(6$E(6(J^@#W0
MN[[[XI6&R>?P0FA#"1'K !'+H!%'/LP2Q-02^LR#0^P$(GR)(#'M(%X8E2AA
M8K5AXHEZ]]2JM?KW,.H'W\^/U_7:,40VR13Y+. "S7[7L4Q71M#"[MZ='R_W
M+FN:<VE1*:^'U4:CO-6G=1KBF<_M--2!85&^ZA%@*-U)2W(GK2O 2.KQS/P1
M11&5A0'J<GT?ZPZLTCQVV6X[ELBU&W.^P_,RGJTL4).A[I&748)^?N<D7-B!
M!/CFLX;8YA(E=GG."Y78>8ZWY:T^(6++,Y\/L4> 82$\;2(P/"/)O2CX>.Y:
MPAH#Z0O2$I8)J"ND):PLL(ZGB93L==' L++)&PQPAR4P/#EE.%PA8-#;SS9V
M) C</FL0N%VJ$D7GO& E"N>HE[?ZI(A-9SXOR\\ PY/D2IV:3O"[Z<;BS.O'
M4?A5#(3[3"J])EO[-$P^?H%YS,#J#FFC68EQRE&\L,"'$BA6'"B>HD#T6-G#
MLO75LEM?K7@EQX3%X!R[:U8E,T-R:0,+);GK64IT[)#V%WU(!]7:SEH?$F[@
M"0YI;]T/:6_!AP0,LUY?YT.B#3S!(:TUNM$&%BP6U6O5QF[R*16+;F!8$39?
M:)'Q*;M?LIA$]S6WB0VO=M&:> D^JP@^68*BP\%2",JG%PT1N;LO"<KL!*4$
MGZ6#SU,1E EP4+9"68-6*"O#=$IH60-H67&&E (9_E^JF)5 MLY AO_WB$B%
M^H(<F@\"62G_K(C\LT: 5/:2>S[4:J6"[":$7Y2@M0:@]531&*GC?;_:V$D^
M[98FPE4S$8XZXO>UL*V9'?'[FM"^*$=\"3ZK"#Y9YZ<.!TLA**6(O'2(6&>"
M4H+/TL'GJ0C*!#@HI=AUDV*7R71*:%D#:%EQAI0"V4&UMIL&D95 MLY AG<Y
M-Y#IL8-/#&2E_+,B\L\Z 5)=?2K-@&M/K>:V,-.U+UI'*T%KW4!K-!I^P1;F
MT8S@AJH*UPQ#$5W%@=4U0]'L!$*DU<;4,[^9L"#SJFL&/=,2<82)M^&99ST/
M*,)"(I?M)G:8[=#FM3)MTT[G88B99Q77P@5@MJ^ J QO82FA2;67M;5,OX6E
MDL:?R'UN+)3_UE CJ=>23_5YP/XV<  @',\L0?V)07W\Y)<,W@1%\X(W =S2
MP-OI>'3#G@U_Q#UJ*3MRK<\<G&<X@1*L<L"J?H@"2?UM\NEP+JIY?=8SX4:8
M496D\ZE)9_[Q+Q/0%3S-!>@*]!:I.97@78+WSVIOHW"Z".UM,D'^X^;;5\>"
M8QR]E^<,CQ,W71*Y&8A<"3++!)FG)1R3S3[YIZ%^/8H#QWS^4/%8D"B6I6F'
M71IQ)G2VV*W6=Y)/N[,!\>70_"R\%R&AK08@CQSX4H%9PLQ\P"S!:]' W*C6
MWJI/J<GF#"XPZ$T':7YF!,SOAY%O.=XG$,[MVZX(S#X9AY])U\)I8#_MR)X:
M^/6K*7;N3W'H>"(,F];?L1,ZHT@W_?J7C80(ZW,C8>,)#%R'5.A0?MJ?C:/<
M!O!?(4"L/O+=N-=RS&^>,Q !7,IPY,G3T\95X-NQ]0*$ZT4BH"V<=U]%QW1/
MZ+PR/H*'+J.8%6#I87F5E\&-" :P6WT9HS>];"7T<-X*D0H'%JV$EGA6XMD:
MXUE6<S]<6"',E$7M5>N'ZE.C5ACJJ#"A$F^>.=YH3716ASWM:2:OF=D3PO^B
MV5.)8R6.K2F.95F3CBR+RO,Y2,K$'VA2W9B/\ \GZGYU/,MW/5"=?^ ;6532
M?CPR^TYDNJ>Q9W_]>O3\,6;VPUHT%CUP"4LU(4A8F\^$(,%RH7:\\49J<R-!
M"=VK %ZKV9IM)P$O^+2#-:[FI[%)SE+<"L7?,3Q[,G@1WMZG)JU)/D+VH,<[
M5.;>Q%(18.<Q""!!<L%^$JSGU$@^S8P I8 Q(Q:4PH6$L7G]$P2.JRE<E%"]
M F"ULD)%G<PO.\FGW3F$BGI)5V>7+F9N%_><:2O!VMR^W[TG","0M+7^ &U-
M+_)%@?,\\+M8 )J?BM:?AHIBH9/DTX$"H&^>+8*[P(D<KS/!=-QT7<?T+/'9
M]5NFB^$DG@A>0*3.E*-9-)&<=N3+!G"$HT=$Q]0.%ND,*<&Z!.O'^A]&X7,A
M_H>1$,K:80FI):0^F@ _)CRQMJ",'5U$I;1N_E0O ;P$\,>*T/,FF$N06[2$
M48)U"=:/E3#J"VN+F];5V&4)@S\ELO"-Z8JP!-$,B.:=2;%^M0G9%^&GH?[+
MBH+N:,F/W;E%#@F#R_$XE!#_E!"_'M1X;;P=^8;>$J1+D%Y/T_/$J*#'@O3+
MC1%:/X"?9^=E)%(!2*?G!J3Q1V=P@;#+@:#BL9=452Z\<DT/'WT>>(.[N3![
M>OK5#+M>GDZHKF@Q.J&T6=1([]R? 0P:M9<(!FK72S0-R"M:-!@ J*6%-F$'
MMK";GGTM0BQ';>,S>"+/%@8>VO)R 6!/XR&+RG[)UY1+4%@Z**R'8OIH"$H2
M$(5W)0*DQ)?!N1^(FZX9B*[OVB(H06TY%L<'KZ1$A6G-D4L2NBHD].D['X_0
M0F61..GU77\H=$ESU&:!.$9UCX[\7A_.VJ3:2'=F8"/.PKU?>N)Y  YO:DR+
MGWA&Q5+#WP$RT?^8M2#,?OHE[7MZT+^]\TO07QKH)Z=?@GY!H%^"<0DXCZ.9
M81!]/W8"847^,U&/ED,2L0C*K1.YXK)]YMG.P+%CT^45X$_9(R[!MTCP/;D7
M5HQFU\MVV[&>BY:_DF"<?]0E.,\685&R\55BXZL7QS!B]BG!9<G@\E36GGQ7
M>N885!ZJ]"8^DQI).1:_&7;]7%WI>FU3K.U2 L2* L1XU<XYRZ2,PM%3> ]*
MZ%D1Z%FZ#^$A@'@F ;WS0,,JQ-6ND2)30M!*0M#J:30Y$ 2?9F-*SS=.<(9=
MKR,<T<T^'1SME'#T3.%HYRDMS24]6GDX>J1DM'AZE(&CDAX]5SA:'#V:4U4O
MY>IGJJ1G4A=G94@OHI+YHFPZ\ZSA!>4++IQECB3IEI!>0OIR('WA2D8M@?0:
M<Y"E 6@!IUQ[S"G7EA(TA"%!YX[G].+>>A,&#+BYQN3\-/XFLZ]UE*67!A#F
M_?,$"'U?)4#,YKXH*<0*6_^6!A EA7AQ )%O?OG#Q)HXT3/I;G#DFB%L4V[J
M,KAV.EV]U$]VM\_<SC(Q&**\\U)LF(4H/)-(J1D!Y(5'2)5W7A*%68C"SHL"
MD)V2*)1W7A*%&>(CY>&%^-RI:*%%]-3Q3,]RO,Z+ I\I)U!JI/DM($I 6G%
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ML2X;7( ^L^I[78\;.?-L]*>"D- :&E97 !K ?#\,AP]>BVER0L,T[D#&K_X
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MI@QIXW>U2BOKQ.T/GAX*ZX]/6YH$A?O%06&QJ[L6H0@&6%^U!(EIAUZHKXA
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MBSUY@2P_M,G0S,(QX91$#]0*;<?F]J+8VQ6&T]8@KRF<?D4I#O=!GJC *N.
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ME(IQW?SZ]<_MS8U/R@W&;B2+^K'8C&C);IPD62Q"VZF)3-"!LT01!M]PHD@
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MV1GGL% (**_HKPBU\V!#GHL+AX,;P/3P%$R\N8%1,XDJ1EKQ )A>S&&QSO8
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M),UD?EJ7-@\ ;94K/[HT+-R@C9;,:BOB1Y4/,,8+CY8L19G)&2'C?A\%;R?
M+"]%ONX2"8NK+V2CIEUUKE*ER#O;I+HP'B[ "*%OWP1< M0J+N?SN:8<E+5
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MF7FJ=(EI88P++7A-8^,33V:4]M%)F51ZBF2( : YDKD*(#X;/C$\2 98<-W
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MWXN\O>)"7=J1KYDBT\R7"7=C;Y&[P4]FZ290#!N,*-)>M,Q'[Q=,_*62D$_
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MTO/"K+(&KMDA#@7*O_IBS.$6*P [QZZJY4(F:=L//FPD;1'913)!'D6?1D/
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MK&F=EVLBZ%TS[8^NO%"[>;/88H\#"<^/][4C[5\Q.:WW#L-27_,"$H79C+_
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MAGICF;X.LFM60RZ2%H@DC!;A,KY/XI2 _./ #0?:O([2;5S\[=TV7 [/U:V
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M]N)#(.J>+T7+&# NUV0EB_DX*L@"-158RH*N@.4\;'.$?^^2=H0 \:!5W[Y
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M-)91E'(>[>-J![.T-9@;AY-]\M<H1/P0(< 7RKWL+-,R\9N,DU3\"3JZ.8E
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MA.A:J2<@D08[,4?]%7Q=&#28WO.3Y]W@;>[O..[D)\.2W1/-;%I_W?*G.=I
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M#@JNE37],P9=O[GU_U+Q55EV!$=-*A9P52)M.#KU("" GYEF2";7D =.NJ:
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M[?PETW]L^""/QJQ],($KY9=? *)VLX?N1'OHU#=4J26Y#G8Q^,MR94;ET!O
M1MH?+$)L7.4NEC!)%03<[CJN;?!)!4ABCEFN5"E8M#&[GB!A<[=20&&<6DRY
MDC5";=@PKF&RF4P*N<#QK4_FJ%]>]YHM9FK*@)4B M_'G,LN3/&95ZJ^?5)C
M>^4=UP="/Z,XL,8Y%#$G4$:6ZRQ9R'E\_>/?SE^?O[D(SI*<.XVX3M"4#[%I
M_?KLY<U^X%4+B7LU6C;I/;=IVZTR+FZ3D>P/_]15;P.>Q<KE15V[!XVG^,%R
MVS*9>S9[*$JZRC^O]!4X%*_C88$B28-_S($:._.85EOJR[WR<X%0Y67)U<=+
MBC&OV3HXO7CG</8??'$G2Y# ]/A,."1!-I)!$;>94?QYR80CO!0):16@EM4>
M,XH6$K]E$YH%<K6ZA![E36-W[KZPG<'@[S[!5\P(!)$"QGW!<C\0Q-?K_8*O
M4^X')\C6^ZEY MP"K?-[9!6?5.1MX_;8WHW-=2_ +C>B=I$LA)">OID@33*3
ML*&,LG);H6!L50S+Q*>"+../YP0]TZ/<7)^%P>#LAS.5JX;,7B+*O6?PX1X:
M8(0#Y[J.IA&\5]02HL$4.H*1MF6T_J%,!S'RSCWE-T,Z,QEV.[(@DW059[]$
M)JSK%_3(B(?Z@E:=>7#S]L#JI<]JE^JC]=>3VJ\W;J GVHX1P<#='8?/5Z\W
M%+'N_*/78JE# [^[A7E#M_[WD^%VEMU]Z=URY342^R:?N'MB<C44V/FFE39D
MEK;"S&L-U.X5YG$O@RR&/X8N&;@Y&<<9$X&&2BWO15@U6#?=NHK-51F2:Y)9
MP.1,<1(X%GLN=*M;L=(H"M(8\OHD**W<>N,DFF8YM]]+#!5,\'$L"!KY$#UH
MAG<Z%EP<YV(R;R1C#'B)QY]1UQN_UYI?DFXQ."0LGP:H8E@]HWVY,UPE*8G9
M? [Y.&JWV"!H7)\&K]=?'K^2,"G=8R9YFN9W!O:1P0;&"+\E.9K:XLP^VSVU
MW7KXL1(_YF*2?&6S'Y@YIQ@TU))/)@@-%B;>PHDWWF2<>,T2]4S@G=-2<N]2
M8'<BLC'EL@P;UDQP!20P4,1</JV(C:3F1D4RE,X<,XV,9T'S-O-P4Z3U-V_/
MWU.OX"B25TQ#DQT#&B981BND6OC1MFM5"M!*9L(>I0B-*B=*I.4PKL"F*P!J
M$^YFLNM>V>3,(%&6!J_!>#PZDNT&KJRY0SYGC;^Y%/8%2&USRCLS!(=D-HSC
M2<QQ9%!/HI5IE7HEZNV6[6R[-*-<^J-<II&4"0TN#SF.$94.&8!W\SO$E=A<
MN49X:226]8TC6+L$?/-:?40ZGQTDW_A<3Q _]VM H^!]+%2E>::^7N6=)@PU
M!> -^]*E;02PT2HCKN@H(T\I:!QQ5<!X'C/L^:8%Q!1+-ZHKZZ>E" ,D<+@P
M!SAF;.QK4L?(7Z^^U?D2G)SW -!PK9P'WRUILFH<*,'."/FT30,L#2RIWE^B
M^>)%<.9)2&G?):_P['1_UP3PR1;^Z]G5)"^8*L>PJ#EBYZ,3+I4H44H%?R=?
M!O3530298T"O23Q 8KX/@PN2)2EX(S@?7;VP#"P*:"1-WI-\)$B.TG-0"VGY
MJ"8PE<!VQ)6(X@+6"N## *E#+;-7Q_\^"Z]TTQ-0R1RI&.8DTBU/,SI]>RT9
M/9/-6,N3M?NW_FZD5S0;(%GX?K#W\OH-"DE8$N+?ATZ,>S-PX;1XODASLM/Z
M3X&C-YEP00$ DUEACI@%>6GN0MY9;@A.#CJP\4I.922HJF2)"75C.78AV&70
M;3A$?VJY.P!0$@)Z31)WL).X7Z*LG)8Y2/.1W[F(&U[&8[3N!D-4Q,$@6@#
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MS:C8Z#\E')7(0E@D).SIW0KS3/J XW'\H>$[O8Q!$?X&YTN>L-5"^)MW3-X
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MA<2A4H)E!L+;7Z'<43J+GX"#5X:*CF*;:/D!C#CN,8O)X8+Q5>!D 0@$\7
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M^^:ES['YZOFYAEN-HJ^F 3P69QW49RTC6?M[>=74F CFB2,&NMD,K1_'?9%
M"N00_RQ1OT)9<OX_?32]".16";;-O-KC.,S'O8 U,YR*W+7C(ML)W_2O./FN
MBH>_H!\LJW)R9Q.C/@?]43#$/0F.-?OE'_!<WO\^K2/D']%+*Q$$N$V1J(2%
MTD7(6[2C&N3]K$A8,C$\OC3RW2^0+F@@77/$1 V,,@:Y4/F09PQ]T\5"'/U(
MF <PB4.PM(!C#?A"E_2*YRS\#G^:!9URM6:^0G-;U5C&Q>1-3S5U3]5M&>Y
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M6B$E!686 S-8K](IZEHPGR=D'$M>+H^^7':.XV\=0WE[<71Y_(["-12N:7,
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M,BVNJKE5J-?G[<=(L-'_>V-L.,U)]US5<5>T M[.6[\ LQWW@HA%63477/G
M4CXHK(2:S5X>?;GL',??.D8-U9N5%;Y/EI?SO)>F:[KFZNZ*7DFO]\YD*F$K
M[TSX#T ZVOJ*F.'KO;4[4Y^?]>(<LVOJMFJOBG.]WGMK,X<$<C,TS;1(K,T3
MF^C0$RFGH/Z$(>]G.0N5"XPR)]E4.4^&+ K^$HIP*R_VZ*)[@;TNC:ZF6Z9.
MU[OB>J7:"5>[H_>,XM(P''O57/I7?,-WY<T^Z[T5H_<,37=\W^C0[<W#Y]8)
M<\]Z=:;NFOZJ/MBO]\9NS[I]=B:)&;BN[YFK,G!?\<7=EC+ZW/=F^ :H+W1E
M"^F.+ WNF^[XO'>HN[JM:>ZJ7)A7?8EKY*P^.R'B*#33<HE]SJ==WC;QZUEO
M34[_,G3-L%:D8+[J6[M]R-7STIL/!MV*HKI7?&>W)C@_.X/LV+9N^"3FULG.
M?5[^*,8:&9IF.;I)U[;>])YGO;ERD@]Z-S7;(^_F/'QN'5CSK%?G^CJ8='1A
M:\]H>=XXD=81(L[53%/3Z?H6]CC)>V'0QP3M/^*$MY-KV@88 IIID*R;V^,E
MRP>!S#5MY\U)4>=[/MD$\U=WYSB53;;OW^$$W4L69NG^'C"H89AG+!O!#VIG
M$^7DON:<W/8U?F]SGFYKH=7BW-TGKPW3W:YE&:IAK[ -;Z7NW2Y46JK@A!E\
MFHQ%">%EY^V9JIQU!@'/1M.PSY(>&\?A-'Q77^HR(?&* =BZYH/P/\OW',)N
MPNXG2)5Z\AV9JFY:JN?2B G"[VVG)CT+]_8PZ=HQG /BX(3A6\[A>@8$=PW7
MM'WJ $+(_>2)4D^/[9[CFH3IA.G;SG!Y#D5%[]BV:ZP*&;VNVR'TWF8JT)/O
MQA')/[9EV2ZUY2;\W@  V]F.#W#<=2SG@ ;T$(YO'<<IVBZB[5<?/QK[>]F(
M)VS"<[B/.A&"0NT4:F]A\)A"[11J?W"HW3$]U75(P<#4ZW@07 =\H* (4":@
M3$SX) L&?'DJW"N#3@OCZ*;I^18U:B?4W;T@N6X;CD,A<D+=G8Q_N[KK>.25
M(/3=N>"VIVN.29A+F+OKD6O9UD-W#&M%B]S7=5V$S ]N=/+TN.MKODY9%X2U
M.Y=2871L'4PWFHI(N+M3^1*-IAN:89KD,B/\O0LZM[8A>?+MN)ZC:<1V"6WO
M@,X]FK$\B][0U4S3)G<OX>\=T+F[)\8S9:*9FN/8IGU V<2$PW= IYVIE(C
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MUWI@=FG.V2F>R%VGY\5-46&3IN[4YJS?TI!&.N_%AB)PL2Y+>(*R$M'&5G8
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MW118U]&,JU^1*._X_F>_@T//JQLKHHU&SY2> 5NO'5%IKT]LYW986\XQPU?
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MSHTY139:-5(U/^V%H2^1N="NY4TJO@.N2+-CHCF%['[=5[?^IUJ\AJFS'L
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MAU*.=3X<O_\V_IC^*@(I2G,D%5P)@+R^2/:4.>[E=(R_EITA)+P$>[. 3K*
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MUG"#UE(HRM;%+C=2=NY=8)(>N*AM5JZ9\JQW.8GFJJ;.J(VA%Y2FN7%TJ/R
MN,-B0+5L/>HEG1?(5[U G@T]AX&=J$QL-D.M:G-+:4QT8#T!YHD,@#87:OIN
MFE CG^+\5[8KQ@$Z[.ELB5^[)8*@INRCC?1&5<O  FE$&=OBZ_(J9$R\ GW
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M 5<=&D68 X)58=7;*D]FUI'94*_H-J5 P87R"P<MZIJF9KY<04+/Z(K9CE(
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MS6(],$,^>=J#T/HI#536DX_/P!4#6(40LURR&O2D'F %^%2A2I+["\8G?D5
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M:9R(Y!,[=NFS2;/\NL) I5"+G>T,,L(,"56ZEY039@I<0$9#+NJ_'56+OJ'
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M=<QG-ZO0RX & P;F_<3"( 40Y8SE1Z[":!+!T(JYD@PV12Y,>T'36DKXBUF
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M7:D2#"G=0&@-#BFK$=N6M6[*'M%Y"H%P-%N74-AP7,.IXVQ"O&@[N-_JW8*
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M+34MUL\6.5OD!W07K3KCO,5X)*\KRPPLUD6UD:[BV?YF^_L-0Y">B.T@T8G
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MX:.^W(^:(+OY<_AYVNU;G9'0]9LXAM&_84""Z[ESX%-/@OR'^(MEVUQV%=^
M#WB*9S;D%YT#A-$E58,B FG#O9,^Y$@SN2G[\V8Y+[IYT=V01=<'N51UI\B*
M$=G'%> H7X,GGRR%+^E%S<;^)1M[*U7]K%@V6]_XLK^IHT;;+()^3XW =#;T
MV=!O@*'O"94[HI2J[FAZHYD?:M4KB\7Y>'%\26]NMOXOU?K3-.*V6:.SC1.
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MD%9!0Z<3: "C.$I*GEE_XO';6 &&L8#HWA)1G[K-LJVR^QW%1*EF>QBQ1DK
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M@H$E[C"&M@1ZZV83*ZES.?0!D,#Y9A!S^5QB_LY+*&N'?S[)R3EBQT"B!AZ
MU :@(C\(^!W$<25FGXN-3L>1J:*@C%! 1!5KBQMF6*=Z.F0Z!R+EC5.M*3BX
M-BE@W*U* Z^= \8<:W_>U)?+V1">O76!/&Z9AX))M,?;CD(?W_B3<'W&/\&J
MAN3ILN<A$HX:K8IRHAS<$C!43,+@!@Y[,FZWIK\<$[3%4$UTWP4&EP9ASA0!
MZR@$R@ZSQ#DYZA1C_\_(.&/"6X6JSLZ#3-9YD\V[L08S[W@C>>-/ ,655<LV
M#J_.]E<1.Z#L&]8X6SAJ[/WD140EE^( :8'\+#]MU^TRG],)L6J:7-'SE$5'
MS2V&%7;EAT%JC<ZVUAC2==?RPYS2L.!%N;;)B15(JC]3CO&FJ$GQT\S]SC:4
MFI:M40P.S:A#/<0]J(>(O(UL*?BJ"GJ/D)JO@8 R=($2'VWG0W)IZ='@R#1U
MH!MC*#J\D]JEZ\-M7 L%\ML!!9)1(+_]C% @!R"60?T'.$!FZ(3!,S8&0XLH
MJ(73%$<>-%@J(83/YF><?<D;6$C>Q+X")VTX!H82UF'/OA=D'+E@+@:6^OA9
M!!HG*=@R%VJ^C"Y9C=D!*KR;)\ ZB[I=[OF86KMJ+G*RWMB55(60"#I\F^=O
MQ('$Q3'_G5">E.LKL,&&G3[L]&&G7V\((3M&,>? =!R3R,K@8(Z"3*G+NG'%
M$O9QNIV*4=/;;1I40UFHA1G>4*PP 6W84.A^ [E8+3#P##:1%^XB<T4;1IPL
MG*91OORMUH:% :JP9-C2E0-U_)TG)+C*)'^;CU<<X*R1.\B;D#;W3;X.(YM<
M+E@L)3Q=1\OHLZH:NU190?XIKR:>^,3G7)N<L\STH/F0F+B;DJ+NHK!-%;,G
M,LG,:J')3U/M=)2@NP E0K27'S7[=%O:\$_S2=[PP["V+TGQ<D4HR\+)K,BG
MR:D3KQ<B7D+YCCO\W.3GR @\HYN11BDN[#[RRV?YA 5-?[?/3[4',J)CS1HC
MKY+7=56\11DA?37.5RR@].9/JO$^V&(N9S4IK+WZLL)[K$8TR")KX"R2[(YA
M90)3VZ@2N8YR0B\*QAAZP*Q8N.1QH.>"C)TR.3*#Z259-$EFW(-,T(P6+/R^
M<D0W 4DAO];NCDT OQ>F&MYINWTV$AGYT<'A TU[-U+9@D7C>LKD*#E>GN(/
MK:643[].?GGQ_,4K^]!?CNK+DQ?_/'WU+RV438,OGCXY?=S[D^.G3_^EU;A6
MNN%_)<6<)Z=R 2U>W1H=5$><VF!E::IL-N@(TH(M]!]X_DO7W<8GA:D669S4
ME7"DMIP.8M6UJ7#U<:G#"18ETG>I07^2.2):2TJKH^@SJS"V8:8%37_P8YQK
M,8.25 HP^3;WY4GKP'B&FGYCY AS=&FWF,#&O[M3,QLW>(TUH89ILOG!&=HY
M33NZVEM8"(84 86L*ROW\CV<PW>;0:Y(SB2#(8E9!_]_"8;4I="$UHEK_PN:
M?#Q0F&XSRX1 !Z)432JCUU:BYN[=R:AJSP_)&=IOK(DG.+M-@IF +:A,3:9-
M/;>Z2N,B70TB=+<C?[Q"]U,#@M=4ZI8Z1AG+#A=6B27 Z6FN<]IR[(<*,FA@
MZOAG<1(\-O=V=Z199$I'R(Q.JS14H$'IDKL']X(%B3ITGU1M[HMV:V:F[E.^
M.JYUS+^IBEOJ(KSQ&?RLRC$[X$^>JNJ/%/ T[G5,GM'\P@9)-\;D;^D2D)U9
M<T3+=-J^H=5P"7D)7-%6)8% "2CMOUEQKKX5&27%&WS$YO,<;X O]Y.?<N;)
MDVVO):DZH-05#N7<S5E76A8YSP)2O^BD&K:K&_D-T,]RLW;L2,^XG\4+?:\!
MT2U1;4!9W>,Y2\'KK;E0G]R2W(FW= 'X]B5]ME'Z=(VU4Q9Y5W) V[3;FY &
MY9?G6F2$O6IIJ/1JCE%O(EK\S-=4I=J?.Y?N?>M$2D/"ELURK] H)$-R:8$
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M=W=$(3CL@_CQ:IN$N%%)"!J5&&94?ZNI50EU6M_RS3ZU5G9!B=M-2*FK$<\
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M=5G6EW)RAG>7Z@@ZG>KQ2F-WC!7,"%H8G-2A SL#23@$*J'.4:S)7P7%K/Z
M8W-,/.?"P$I-^TND;].$$T3,CNVGS@C.X,"ZZX?;[$*Z:P()]Y5B#1U?Q\EM
MV87N&W%TPG7R1V%CE<YMUT=2/ZOKR.LY+C4A?&H+.3-@@^B\?0=JT)# O-N1
M/VI6YXS#W@ET!7:=P:HZ\%RRO*JJ7M'FF41 NMXE$H<%]TY.!8^7M]YQ@(#"
MA41-\NCTV$+>C2!.2SR,-K?"!N-  :\WJ7JRO/(0AQPB.EZ&AK+BQ_;I *L
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MT';:XYFXL'6X_,9%LG$*"T@Q.962A/&PUB*HM!>US5<\R. L9!'?<AY.=2O
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M)ENF3LA6'S,6(T=Y\RZ:8M2E[5K%&5,XZBS0HW9D#[ ;:B;?_$>M*7*#L&9
MK>S<#"NWCDK%Z0Z.>W<X,:U0)JKKJSV?C127@J5)^JC8ZMO4L;TM_YVT4M1^
MSM52N2L#$:N&'V)6$'- H;Z]*<YK/L1<N0"=+S2'1:;('^&*3>K+ZC)KA!V!
ME[5V_<(!!8^+"&GAA>-?U'*_BH=AMB>#/D<%(2&^9C^8ID6+N'3?O5!FO51)
M='?/7HD;1UZ+<NGZ0\7U1G0+8OQ$]S7HJ?7/X[$DRDH?**T[5A[A2+J5$"Y%
M00WW35C>@Q,A E"Z43TQ5%U]G-R>YV-X_.@XLCJP29P"TNU'2UO@P!25L-E3
MA7N ?@%=[F[;]L79-W*YNSLQ'1;:DF ^AB.BI]J 5"NYN' T'KM\FC"=:M><
MBFZCM4KLV3EU@(1&*_!$:).F-ZMT>BX*&M.2I[7#Z!AD\$(7UU66LA<6Y%<B
M1>];;"U(F+*)UGVE2XR$M1=9Q*2GH/;U0!&?C;6CO%7?1$=J<S\Y"\\&]NQ[
M<?I=X&K@MWC7V_5AB5P!C_'%5IP1@'K<+J3(33SH/8%";O Q(3V@P6F21:W\
MT2/'_))/Q&WTQ=D13X29/== [QHDYGY+3! U].%.9NLE([R>; -PN^YJW,K,
MW[]9)@LY*TN.%W"OAGK$PLNH%4#BTFQTHW*SKVU,LP2NB2DU;,[[O3DC5(IQ
MW4S>Y/D"89O;!SCZ.(GHN[)^SA@.)/;_M<W&$JMA&ABFK04C81-'F"=2SL/N
MFR1F.1,M[>C<C\^H N;9*<9?S(4<Q@LZ?'!<EZ>F,7G9"XDS-,DT*TKNC_ %
M&6&%(""/&9DK9+)HG8=N+9_*Q"P3@%":.!QF&:<^G>);I5RHKK?(]'.QA#^U
MGFVI0'XRW=WQY8\NSBH@"U%_2Q"%<<M<KY8M,MA:+]0ISHH0.X!%TH9=:ESE
M%N57250\$I&USG,D"059O0F[(.\U=,K?<A2#).7U\__;.SPX2LZ>.M@G!0 *
MMW]89,N-0"8WTTY(2F-E5PK1I< >59J;6.;BKM<> JF/;]JS@@M6#;>N7M9-
M.;G$H[B]61GDV"RRW,-YCKC@8L9^#JD_UT06QE25/7MW)\:M"L]6%O8 L)4'
M+IDMAF8)JPI<U"#B:0YR24,XX,[L1\".?G;V8U1,>GL0H1YM)^I=\0F[@!BG
MEDBT-R0^)Z_P6G)PV]"V]]-_&_;?AX0$X">P=69E\%--:):HOUR%L-S(R>?H
MS&Z /AB7H#:H&&E!$K?4)@B&)Y$KAXTZ;-1AHW[0$%:56)-114RR)%]I.D5/
M"_9?@%2?->1$-1'B8/=D'3;EL"F'3?E!0\B-.>XRS]Y(J,H?B6%-O^U+5.'4
M96&-4*TCEE14-T4CL<Y=O7\>ENX-^W;8M\.^_<!THT=VE3!0]C9-<OJLYIJM
M8,,6\WEQ;G"&M ?+;(3"$X#YPDZ6W^0Y0,TNM"&"CN(+4,V@^JJIL\FP7X?]
M.NS7#QJ"G8>T3V,H$^S>65U.HKH15(]GZZ8N2_G!L &'#3ALP!O9@(*C-EXG
MTQ)T#IF62')K=4C?)BEHJY#VY ":JS.2.$.4MRB45B=KLYSDA^H1O55F>+IC
M)O5E+O.:FZN#ZLFL"GM-UL.V'[;]L.T_: B7=?.&^<635:4]9>*KNG:N@#V-
M>VS%/EY5 E_32J(4Z5MNV<BJ7DB68:<..W78J1\T!*VB@)O:SM" *?W@.(&9
MPJ>IYR&Y\III8@"ZQ&4QW(617;K*&6'&7@NM:UB..\X6$K'BF-3@WM[=YKT^
M,>NU$%*/!H141D@]^HP04C]ARM[A/+CC\R#PBVC#-"ME,'4G0E!6@V[1\[SV
M>8G,D$*#.$LF+"JX5]T4[9Q+C2O **!!MVBS=HETH_]%GC7+V;]7V1N,<D9N
M(^J4\?>TK.N)H:30>*YH(AC.D,$ '#;\]0OIF">,_3-!X3 DY_RM_BL(T5A?
M7KM<3=;.\%/T8/ZL%3".C]7E\<%5ZIL,UR8@GRH$-0\;*!;33'LWC(S3BJ3+
MPA+&XS(KYI87WJ!#T-)\!A%%FFO W;[Y,N47$:LW]AC"F2L'??;.M7-0DT4U
MDQI8@P$5]@G#\Q#X!9!K,!9;V].?)PTSQC98EQR&0<E/JZQ+BEJ(YIHV6=!I
MS]PB?4S*Z"0JA:N%F9$5BK3_%4:,*;LT5M'=G17X6+K:Q2&="@ /V1; L()=
M$&"M.=:CM NG(XR92O_*(=Z6,;HYWQH!$]"2T!SJ&)G^2#="NX)V+!3%H_,N
M;I<DRM4E['U\5@*/0U 741[IV%-]3]76J8FPS9F1FY:Y&!5+)37:Z&B8;H,1
M"@A)4O(P=.6%$#Q<ZOWDMUE!@[[,C>\$D,19T_@%V=V1%0E>N9I<-25I#V1=
M5I;6=^%8ST6PF%=ZDBLF8  SH;D AI%BR&NX2PJAZQEZ_*@<+,PEL!EH'JOZ
M4ELO/$9"I/@V.:5HE/9"S--+UPMI-CANN3_#]8CL[@AV%(M3SRB$&5<IVW,&
MX1&T%M=/Y]9*F'>W(L,[9(HN\PR 1?VV5Y0KOT%754>U^V=SMV#6UG+%5>)M
M?7=NL%&3C1LLJQIZ-#-,;#SX7;O%]N@E %G??]^DUBG#>$QO!0.,.4]#4F*_
MKH;K.\_64>,7LP]=T?P5PS0ZOKK@W1- >+@Y*ZK?5\Q&#6;T?,([:Z5\U^_2
MO1YX"9<$;\PJ(G\[!E$=OEK62_A?;9L;U7N'I$!9^]PM]G=WCK=-)>_&G#'7
M(*N]"AO'E;1=3G+)T<E;9.U,:2$\0S2^:)?U^(WA+M7)E&9CZ+:\93L6!B'F
M?Y;]D343!LV:Y7-H<]8:,9WV2]_L*PL>8H(RV/\"&%*TMB7CA]&"LH83#  &
MQ_7(_/XY+ >&"P^A812_G%N2]^1 -V=#[(>AM_+699CM3SI8\ZP9RVX-[49:
M:6 ^2H+];TSM5K>NX]OW/:X%M3(;0V$)XI+RT8N9PHB6)>DGM3N]%$8^(]K8
M55@8;G>+O IJ&3#TET944THB8KE>X)(2C+TKA8"3'S*5A%.J:['R@J9?(X)%
M"<'NCG_J)6)2@7'X6&!7!=!)#)^RAIW%U7Q!H3S?57#?S.*.4)C=KDG=1I+I
M]QLH'(>;I\ ^4SK#+B\];): ^'[+V&+H=ZQJN,DQ8G3'TC*/V>574RW<WGA.
M[_( HCB:MM#^R]'P6K&1%;@WC%;GR'T%\E, 100"/I09D$"'@08<K&(:"NT)
MCEA'-**D0(J2*)8&5W_(F PM<98S:D+$N>@37^S"Y/YI[HP$C-C[-(OW@A!\
MEA@$]U<CGKBR7B!PTGYZ]UXR^UK*D8J+?#\Y$=^)X2W$SXAOT_TUX#P+L?Y,
M&Z>A*F;?+\C/*G@Y>R#BD3"]A)IWX^*B*)W8%IVMD%7^$.<Z"Z58_X.+ITHQ
MX*8<G&?;>27H/33!=-O)BO8=O.*T3XOS> Q65]AG)LY,5*:>>![0KWZ/Y?P^
MCER1-S@+*K  WN$0$,(-5 -VN-<J:7Q6HJI'+NP[S-FWK"IM!N7+8L>&U=ON
MSF_BFS*B@CC(DWQ.'MIZTP_RR-%%,U[- 6C#C"DJ7*&.E@J^T&_/2,XDTB/!
ML,#&"6&8 WQ;,P8F?>^BEFW\-O=1%.ZQ$$?0I@$B_GN99@;A_2>LL] @ 3II
M-BEJEJ6\DPB);2&-9 DPD\1Y.984@30%K26"4QHP<UQA:UP#\>BS-#8^=?=0
M7'!VM7S@RY%%X;ATEH.%4I?J(C.!-=O#K/L\8@O.30M;<:2+SNT+EB@?[XK
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MB4\-(PVA;:@$E&LC KJH25243-[UM2UGM*Y@U9IH92$?]HXJ<PBI7%/PGH!
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MYH(UL^V&T;<1 0V-$7U&TO@9;K#WJ\Q^,%1F<V7V@Z$R^S]E&WZP%7D,_TO
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MF;@?,K6\.6RVK3XA9'^EKX76&[!V4E(HE:G(K$XLX*H7,S9-70+K.[*:.8_
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M>15YRKBH3>2<"8'C:?)8M*[8O]O'YN^7G6? )I."USA::!&7H?KMDX5;^&:
M6V"XA6\&N(7[NZD^,,;.ORTF9-U7;Q>'!V^R@X,';A<IW<_KTV>[.X<_<3;I
M\/#'Y-?GKT[/7CS]Y^FCY.SU\>/'R<F+9\].G[\^&YKC;ZXNO\D-5X*Y6%K
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M] ?5.5#2$N4%@1:B\UG8SZPFK3.T/VU?;;L.V$X=#I")R0>_QA[TE+]BMCU
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M9(B9 A8H&]FXM)?% A.J=/>"$#,6*$B0L&&'B=L@**EX+6]E@O7)D3A44L&
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M:Q@%)CVA7E0KCS8$G(]QR<?L'GB8NL#W_@S8X]]&8-EH93."$^H%OA)CBCZ
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M(YZDTM_Y*EA. 7&(*(?Y@K@"EHUCG'B2*R#J!"%/+(<I*(.#%VLF0)UX%#N
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M9EPE($;E\QP#'6-EH;&Z[3L!$L*^%/F>$WK U/COR5>>Z'6@4,C-5.,;<;I
M.O$#)NN>[Y&Y89: T/W4FD[[9X&T%6B;N8I9$H=*%V%8.9+^9GNL3=$R*>Z0
M_:CZRD6J<PK81[@IJ,G!%2>P%7H97Z9"6Q3U=C+ @ F 1$--$AW]L,FJH=[
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M,'[KA>@5:V5'TDJ9%!@XQL;9GP.O=?0M_3LH#_V_^U_V__7A]O-=YY[S!.T
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ME<ARO.W";\"A_1Z/A?44,,SQ\B2M%32X?N)*SXWS^UQ]*Q*$?'2N/HXV$H2
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M(MJ I86\U$IFS"4J@'\XK.OC%>JP/@-2A7BPV(6 MU'Z.G7%2=D*-J;RU&B
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MEXA8WHF(=-K,;/!VG^#/JL*?RV08E-JP'785I>+LJ2?BL$DIT!\SX29-C9*
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MA\.GW#"<=7GU]!X?>33U;K:%1&=6Z+U7.2E?E\KQT+:P18_OOJ1OP8;2$TI
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M^V\Y\_N(SJS?+=\\3*?W)?;IT+7]YJ)I&80%@__I2_L;KNC_4#1D%&;VH/!
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M$[ 0[?30^')[S'2<*TH/NF\QCRNRCEUY:(/)$PNU_#.@>@*AJICD/9K'6,B
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M*)5Q<)X,\I!K2\<3)V/CG")PW"II^</?M:&[C)@'3DCLKP"2MN-M+DX-O)W
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M)K)^&$GF#\,^>WZ]T2Y\CD[<!7,NS%'I1%=.>@245_''UK:2I^8!DZDW(3#
M>>+I+BAZ;CN^7@VR0G92:3^T)(NO;9=U^^6NYW)7:&\N%/:FN5//%B_'T8[Y
M2]&P">PR8%J#WZ4B.NW9L-=$>4^P$V9A^QD.VF9!"C,7HP#^]7>0XB-(L8@9
M3P0>H^2]8Y2\H"*J7EP\GO"M5.W.[&D\2I13V"4N#G<.0K!:X)=3M6AO%83
M/K"CZ^GIGO#X SC^$'600>:"Q[JA@VI<X?7P,A],H&$;*TQ->@AM3-=$OW]?
M4"O=V4TF-'<"Z,UM3?E5!BGI*XUN6@/!V8N 19DWPX6EN +F_R&5@+235R\$
M&K:IRKM/K7;F3XC?(I,[&=,TB>04L$V3+VQW %-/_[D>L/=51:L_'>X>,3AL
M6UU^'_\B R'.> F"O]80(;TB4[F HAUQ#91QLH.L_.-&S^G,2NC]_J6+M.X=
M'PHM'6#&24\PXQQV R5-SMT-4S61PZ:Y?5%J,F?Y:KY6*#&MBU*IS6#34V]>
MY=N5>NTS !ICV_2K)0Q1;R*A>A_[K5C6--0KFV,1++.EM>%^W0O>&'.>6KDM
M'M69/8Z>:NS55:5U+^Q1D>!T5618S_$1-AL:DI  9RPF$IWX0  QJ:&"XC@2
MZ'2I2#,:R+1F8B)CL_/K<T$/>^%Q[@3GL@C'[EIOD\PE'-/BQGSQHJJ<O8Q>
MI97PIH$L8=//.W%K[>47'>/&KJ^UEJ /)'P@;;S\/2.M[AEQUCREZ1OP41T%
MM-D/!&=,,9L_,5XS!6N.!E!S1'0F )1FRTPMS)U 8U[LE=['<&3C:(*X;S2O
M4:#SK?)=C0R@ZHAGV"H_5<_^".=)869/:=\_\#-9,X/HHNF<, 76_75QGVWN
MIFU7W)R=UB0IG]X\KPWN=D26<_2>E?+U_*S&E3NSP4R_>U'/4?EFL(;3FTW0
M#0%-VMSG"<UM10)9.CRL7!*M^6%MR(7AV1B;W+ '*%I@S%%E47"EUYE8)NX3
M#&PU[3UL37SY)*G(.+Z'0,G3L"#4?/PSG67K-7$+P_(6+AJCM?SP3I'=ROCG
MB1QZFU\\XYG9BP8&: #T"D[?N%@RZW-FL@_M2M@G>4-5^DC3R,UJ&2'-=-0V
M.]+;VMTEVZM,^50OT",]S"9HLLT(](&&U46YX@#9B.GA6X)$$(V28:+!?&)&
M!FFBN.R&$PTV"K=M\Y7=+,P$J^7LHK/-EE*Y*=X/Y?/V73H$AV%EQVP0Z:(#
M=C(>L-UP+;_#-EAL+)4,O.OPF]D!,CM H\;&$EF?$R6V:3'=IE-_O;L44(;Q
M4V:Q%F!CU GJ546^"]?](G+-3+:GE_=:.W6+:HG0PLJM4Y;&%EQ2EHQ ]\)(
M]O:^TYA)Z++S2&-ZBL-\W)-O@ -1O;OLS(;MV\=6)C\JO&XC&GX5.=STI3L=
M=SDH0LQU>;(HY$,_$8MG@I^4\"F('-QA&X]E$Z$D.: L UM'WD '<OZXM>J+
M-[>UZ?2I5JWGHI=L=.[0K'>S?K&%-=A#8LT0Q*T9%;H!2"<_9,(R%+H&JO/I
M7>$7;9T_FSO;76!E-]?S\<WE6>_/+-]Z2D7TB/> WXZ@<F_$D9 5.A[CV#W-
M/HHH+8-,_:4RP1W<\?6W$YNK,?_0Z#\67@I5-1YBJB_(^PGGWID^<H9VW[<6
MOH0A9 N23NV8&/J^M]B-E<$9L+3?X&['FXOB?/()FQA=:_!3J.[V8=H<EQ@.
MRW;>NJJ]Y,^*W6$VU+O7[VN, #/;FS(_;"C.6#J[XR7L]Y7&_A@?9!U7SF]8
MN\WUAE\$S4QG-NKGY=1L<INZL[LR=FO8,2U2G'6NST<?'M>9J7T^GD_)%55/
M[&,UP35?F7)6YD7U%A SKA /?7'0)%61QQ-=*XK:FIX[9W_O1L_IS"KR2ZF1
MN;Q6AIE=Z>9HKTMYMM=E.[.Z7BD_7U_)TQHV!N5\I<G<YJLW)>:JE&_=-$M7
MI5J[%49;W2$;O($K!B#*R.8+CA#Z?23HQT<.? Q"N<QO_#=J>4A[JZ(R G81
M>-&"8^V;+75&O_TIXWB'"/"4^!, LJ'1AG& V<'_XG7F39E(/:8+\&$"$E\I
M<H>&).GX"+.*=LCB]Y'">H &4'E9ZR.5X:V+*0+9A#]+C+$TI1\QK&<7Z6\(
MR4"I9_R@,0^.C8@W!KO5*0"!30&&P$1 G(27;/R^A]>!MZ[V*+P$?N]01"I@
MIT[I!D19D"8]<CEV<)" \!O]UG;SZ<K8N[B>2_DKG<ZL+9VN0D<VP_WR4S.<
MR?[E2M*U)7Y=P'\@)!6)S8HQV@0P<S7F9:) [R618]*623!7D2%GVJD[L+[S
M/+.$A++^!-/M%[#>^-$\'I?MQ%?C<3Q4'E<,QM([;ZS0\CK>QJC: W"<8@D(
M71;\#XGD23T1VS,=6R-HYY?-GTX9LB=*G;B)30(&QW'+;EH4;#2[.'Q&PD2E
MOW_#CS979QHTNDAK1=CV 6: A*-C>TE]%;U,L-60IG2#Z%W _QF@$^/3(DD&
MDB/@E&D/L>T#"*4!0$.:QHVY.6V=,@,%2X),41 &2!:F)Q 1DDD?\RNE=T;J
M&! FT<G"7[^5(SCE2(2J'#>RLF@"01\L\!Z5G.U8:G7\=RSHLF+*)3Y(^4WX
M',A)N=BZ',IQ;/5%.IQOK%"@)?_^]_].3IBRB*3>+Z:!->0W?AYHGH IFHW_
M9H@GC%? G)R8O.J)KQ[1Y-)T1:<NI"%QLJ -:1(^;KU;0\FLC,S<?I=5#UY6
M/G'NV-SK;P9@ZGXQ>16;-.$W4\.1!:5'38&=<XG_G[TO:TY<6=9]=X3_@T[?
MLVYT1V"VQ$RO?3L",]AX  QX?'$($$8V("P)V_#K;V5522J-"!"#W3YGQVH,
M&FK(RCF_9._ZCW$;_&3MW'__@U;&8Y$FZ#%''5427XXZ$E)$T9/%X;LXTY9>
M'V:/?_B]F!TG3 #&B&T_8\>W36"6G95()A[GKX7L2'P35#7?C\C.]#U*[FG[
MC2N#[-]$1E-+[>O<[8;&A6R[=KU6O>,:IX7F9:%8OFY7BX6+UN'!:?VB5*V=
M<,5ZLQ$'BVV5*621*?I4SI3+3^]1H[\P,P#KM,6UZVBLM5;]HEHJM,NEPX-*
MM5:H%:N%"Z[51M]0"Y28GMLBOMW9IKZ(2;BMH/-[>]\0P$KJ<=0T6*3'@3%'
M[-.NJ TP"#;Z$]O!:  N\*TLDQN KB];EYL^#M(LTT1^=/3F-2\[GID?3PU3
M$H_9@>QI7D5T5'R)8,!\%@L/Z?9'(7>E^"( DTBOSUA#M7 .&$$46*Y")NX;
M-['0(#T!6H^7W0UGI^1H=R.9%SJI_DW]1LM'MQO.3L<;WHT$'_?%JV/ TE1)
MFTCX(($YTV8.7T_N81RS@?@&3I09/8@)T RIMFI8/.@;UN 1\9%#<GK@/OAX
M_V$UPH&@I1_GG88DSMJ-^]2I'"WKW@T(FN&2;>E*]V6@#)&.J $-Z;,:XF^+
MW;%YQAT;^AF/\T'OO5PI/TE7W:A<V+[P9QE?_RS_.*_T$MG;N]GSC9;Z\:?5
MKA?/0<*7FRWJF>3*5]?5]OWND,^V"\QY*<XX(<,"G)H]L_KR$#RL7!$,TKX,
M-CP<JR*V]8GS *ZO26]B3T1#Z:J2+B(;'UV#@=!BG(3]OR C\6NRY#5QKC%5
MM:F(K'Z*S>KY!@="*'D6'E!0HQHW1381JU U"?_0FB .07&4T^AL/])/&88Q
MFR!NY'8+0\W5[7XT4L;XL0;;GKQ\S&5=5<Y/AB;;#CZRZ2,A;7[*,$WH'<]>
M?'A=TT0L^ AQ\2,KA]E@<,#R,'6KY!Y$<.@F3H.[# >\K&E0QX%S?)!PT-$'
M<%AK Q$Q;(*H#$,DM\:0"8^,]TYP_XBB,H;7(:Y?[Y-AXH>1K]'."H\3N;>Y
MS7G_&%<?6M+#J+2P_=/"D?H!78??SE4Z4>!!_/B3SN=CF6P^ELZ[(2_,K?7>
M-*] #+N1!*_8\.?U<&3&0U5:M*553#P;WL^KTY?:]85>R>O#%?>3#G.GFRGD
M8MD4'Q-2[EIE<R_#[U^<JXYA-F.)+(/)I#U.N@.VWCCOG&A"V[NV/N%DM&0%
M"7YV _$6I4?FY6)&VN;HH'4A/[>?NUKM9!$9+#GDW=)%DH^E,NXLUA6(@NM-
M,59]GSX#0(;QS7&N,E7![3I25"1N)Z&E,H<F@R:(047%J3Y05'F.B,=;.& \
M8E7J30$#O8]6<0%',5>1+$7!?#XVP'IF'X2TD'J</S_-*Q^#BWJ[O["75\"3
M?8Q7V-_4,KOH80L9^YGSZ!MD[J5AFJ*%#^H\NLS:@--L]ESMET_G=_D0 F^5
MM<E$M#9IWUPOCJY,G"L,A]P$2 X3&71^GXYIJ(L0(Y =)4 O5%LKH4 S07KQ
MW;3Z""Q-="NV-3L0X4?*K*J(U# %*U4WVH"H4G]HIC5X,-8XJ]!_4H3_Y8R(
MPO0)7<&E@\P()%C0HO=PL \M(H;UAT#7D' ,>6S$][!7 %JOC#!>.>[<A'Y5
M)6@(8#$?9K^=#(=A29[\)K7$F4(:S)3\0(]6CD\^SL_5TVHI7;K)Y!9V!UCA
M:.6.^.1Z&B(/?<J">Y5Y\!I^O75)/\Z3Y4HRU>IDU-M-L!RT+NGUA.KBA=E!
M:XZ "H_]Z-DA)&U=!@R5<><'&ZU(A!0L)"#3\KW6[IXV/CIR1XZ>@@7TO[!I
MLBM3L)<6L>:Z((YW+2;R)^>Y]CW?W\RZK,?Q!&-50IWMQ8TOKN3SG)Z:]@?)
MEZ_@\\7!@K8T@G-(NLKJ,S__;LD*A?C=@8Z)W._VN_G[6?(IPL3:K*_C%IW,
M9C:?O!FV+]HGB#&VRY>->K/0O-^@NW;'[+?>U17<,<G;.PL>=L0'%9*JVN]+
MN%/,3UC !/\O7&H\P/@1_R3\^XMX!8R$6TC6DO4I-0SE\1O2=!55XW["(^C3
MJL:WQB,L8Q$K$E;W+9<[H0?9)HC70[@40J=O8$WBAE@@,&*!G"K07D=+CG\R
MN!2?2-'V:7S"T[-0'(J:1OT_#J\";!9B4PVDV4O0*<WF7^!3)Z>)D\E)JF-V
M5ZNY+ X\R+7\#^9\?-P. G^42)F?++=#P-C7Y*BI12IDL N"#(PK<-1M*D/2
M5U/J2=((YW^9(^9:Q(<\$8T$;U=XEJ4*!U-JB&I=Q9O<P\%,M*9X"B#+NIN@
MA]JXW2Z7,F(S8]*#-17-.15 L^]!YQ)TI)#]2@CFUR)*"3E'/W&Z40*Y;I4:
M!I'P<9[W!5D\/# G;.,F)F$X*,!B+L VG"0@[(XQ''L3PHET^Y"L0(/0W Y/
MON?@UCOYD9S[XRC.?6(7Y]YGNZ=)Z;@N7,\G=\GM']_H=CFJXWOLVDAZ?O'I
MU94G">>MFQ$(OU-/U!KZ;#^.<'@ ^>B,GD,*?KSRJMB((QOF:< =41")1<H,
M@7N33+<\4AXNGXKC=IZ1%3!R<VD7<@Z_*80BGM!C79N4\G%_+RY#29#O,T$W
M2*3RRQW++S)H&Y(*Z8/BDU3OXP6 O!)P^SY.&U/:UW,]]K[$5LY:]_=767'V
M=M\-AA+P&_22S'TC.T=]\$<)9A-A*7_\<1?=_F-N'C+=D0T#Q@',A^O1"9FV
M1KU:^F7$C*B7W&R.[CJ>3 /%B)GW$IO9G-R^OUZ77I)%7YT=;^:J/'M[QTX
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MF<TG!=D."/:QU)4T#0P6@!^8CGN>'O'D9[ VJHG;-^DNJ13KOLSBK[$V+'N
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M*EX?G^9>1^WY>7 JW!+H:9O?B570TYP569Y):^A,N[:IR-9NDG0UK:*H3<D
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M_<777)?TX[R:/&]-,KUZX<;R;Q;M1]&:_>=L0(ZDD .YGMLL<'T07CW>QCW
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ME[NMMD^Y\T*[4"N81F1G*W;7C@':K/Y"I,Z7=[0\PI2)TW@!20\@%! %F"!
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M"GMLA$NR,R3L?(,G,6%%ZTGXAZY"LAFZ5/6&LER(!HLR1*.^):W]S25+'_,
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M7-F4< . WOHGCX MFH_Y>@EZH7K"!'"8=46S_[9Y\QTCANUQ&ZZ0Y&T2/$9
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MUBHE&>:Y@U?7^T6\X>1$$FQ(S,78Y!?,QA)@,47)T#K70FHDY//W78NAT1'
M_MCA4YUD::45A&)T&UDG+X<@Y7B)C?,^_P2<7(!KEP*D$NJB1QHO-,6^M5#R
MIZIKS>'BCH0$.^ZIJ:@&7_#F?9BD)? /(+*&3B1(5V:/ZN'!: K\4]*07D!:
MI4!2!3P7U"?"][#_=B)V7\"I@/NFF/"EW$\9:=OCV2]*'I:1C4X\X@#D7+)@
M3V[N">N-6,V .9 F9I0'#S.A]XP<& TQHJFNJ#/"E9A[BDI/PL:!MQ]P(^G-
M#LG\)LI#8#;(^,;M SST$Y<#9)WC?')S?3+2IZ=\/D _,0:%>65_JB.*I7;
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M@1O?Z<1MJ:+V1N^V9%DOF9CXO95RG#WH YB+N V@5V.[E1K7E6GK7M_F=4N
MVD8U)I)[MD\CLOIDAQI5>*C-!5NZD5Z%.#7W;VC*6+?8U=\PW1)NWKAG/2@]
M< J#)_*_H> .^2C0,=ELL^)0U+1ZGXIS*LT-YDB3V9VR7B#)P1/^<8J4\$9
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M;A:&WL8='1G;UI/??$[?L5,5(P,XTI7);RXST<TOC!LR^+BM/#/R8!X>[%Y
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M9^=7U9IQ=0[?/ZN=GQP?EJ^JA\;1\5GYK')</C%J5_"+T^K958V+UY_R)!8
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MQVYD?D6VUV37_, S_28Y@H&T&J$'LIGN\VUDI9F&"TLA"N;%1U0,3(()@_\
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M23EO=KX<M"@:[DS W2?"V"Y=/UBM+SL_>_L=NV0^'\;V*!#LT@H$6X!@;ZU
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M.3!/-Q'4#,?F. A.)Q#Z%T?F4HY*<I(8:2 /!K:+$XSSXNS8-D883,?#WKG
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M;^+]:V+.Z"?.\",11)@07<\G? G7V,X;-*YC"8'5Z)B@-Z"[T8U4N-#KV8V
M_$?4>@$W%^QH2Y0RF.Z]C;.47V374UW4$,%A>B'H;%SLU@NIUR2Z$P-1:-NT
MY$\Y6A-/!/V3C?@B2/# (';/%M>I[=-V*!&FRA<BZD-APFXAH=:].SL^_?2>
M 4G*8N:':N92(Y-M5X2=FC/.RI>U\B&_=@AZC9:[(ANV69%5FTALJ?7AZ)ID
MW(J&69MQBHG*#+ *$#;EP.:@$%^:8?%<09P1SR?+[\ "#<FQ!K)CN*8>R()
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M&X4*8UUTQ+\:$H78: (GK*OJ*1& D-%-S#?:-'Y09".,!6CQ)\PI[6+R8A3
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M$P]5J0[NKS:L@:6YB44S^J8=A!3TU'2L'!?5RE"H>B&7P!&0$*A)UX!>")S
M;Z P!H^[OB;"'93@,HR&H($@4%TKCH%9+1)#@.MK18TL<H%:M6+X*I>4_TQI
M-:+/%[8>HIQ3T=<W4 E1:7 #&J8[?!0CB80QJ25+16D_A*+^>J. $U/44,90
MA(3!J1_ >1"[@[.99-0K.O,&D)C 0A+)$CD%4I@S6I8E,J]$*2OY1 61ZC4-
M$@PTAT@A\#F@$<\FL,X<9F0Y)"@83]<.D*#;PU-1H^0000,&Z?G6!D>'Y<,]
M1BSD&A_5+44",,JLCEB)F3;F;7(;@H;74\L1T%),<IQLQIED(O&,LTA%0DF4
M*C+\S6@9! :B?Y4+YK7D-04H2\65$<(I-3NG:N0H@8=AZJ,$,MA&MXV/4,Z/
M#H*>4G0BYL0A>:(A"JR*>Z5RW>0)]2G#)SEP6N8*#6SI32@"!%3DIMTR_S#*
M<C"&DAQ>[1U639I24R_>AOS+2#O1I6 J,(XN#35"'8.8P]D ,5?2",%((LYT
MG BM?P+9N+XVF90S,H5<?#X20<",$EP87  !(T(!82)2^A1 !_?42H,^&I&H
M^EJOV;3$AP"[04HV,[#K+C:-8)R&L,.Y4]:MZ?2C5).N22T2FE:#VHH&6L%-
M,IU8XI!$.9=1FJ49!)0)AKJ0P!L<?HP(48V(FIR&X&(3/#"";OOR-B$I:K5B
M]$IL0J)KT" GFC3RHH3@0WKB+K.N-I?8^Y2;U?#\)FD!*M,T4@"YFI(E)'RB
MVW?:IB8C45L4N@2E,L/=&R0W.,*>%=MCD18:Q/[HQS88$6%<FBWH&:[H0F6Y
MH+.&"K.%4M-E?7!.X<.DL"86A3(Q&POW$K(?)J77>D0$$,TCMFL\*3IG!/FP
MJ=.% KT1Z6_81415J\9>E\)<)JYGGDV4XM2BGF*@-DB8VA2YO;Y69GWG4IWZ
M$0P =W+CBX2CN1]$LIR5&:ZL5TH& PLC,9@(T\XRGQ'A\$*(%'N"X!XB[U?+
MCZ38GRI)[6UH ],EE.I*0@)-#U2"#'-9UP^2@'EZ/NH\= $V>)E)S:0+O-8K
M,#T%K*^EYQ2G2FH4GV*;=42<# '.0E,\ZX&NZ8KNXKFLY$\"FHI7;=FA7B+%
MA#0=-5-C**X:($[*8L\*H@):98$3&)N#K5HP$Y:J?6C9KOB@8/%ZCSA5SB';
M_5HWT2_Y1<L24HC!L!43M]P.3964$*EAR-I<4K^M>[';HG+2@W>"OB_ SW!K
MY'6A0C$L*1.F),@"6"@UOY/Q2/0OW-@.5G3=N-Z=8S51D<?"D1Y_.DBT# XT
ME1FVA.\9:4#DW@@0F-MH65UL^1=5M5"_"#?Z#15M4C&97>_CAOHF&JO_L<(.
M@[4+N/"<>I-@Z+1#"XR3CP=77__?A"HQ*E$^@ZIMC:@9!D!V&1+^$J%OR/$T
M%2EJ$=F.1HYX#7<M:7A-\FK('I/D=<2FW#P:W(S&JR@?BV4,LCZH\,/G*DR?
MDVN6-?\6MKU#1L06(A=J:%"'RB>32B4][AGA6,%HHLU@7\,T*R['@!1UF+4-
MD^QC<9?"5E?M6+2;.0OO9'86JOLXT'3EB$76S0"K:$CE[?7#F%O0--R^C'4%
ML&6-N&OM7>']#'LBN%[.>%=\3^? DB?BQ>MK[TK\%QWF$I[?>J]UITEI>^]'
M&)OL1-S&^=E^D\MKK8 K[\P@Z1'E1@3P)EL\$>=87^MYH4 338B5"$UQ^BT@
M'8W[9J#X@/%]T?2#JR?DER*SH^%;39['J^!!4WSY:US(MSQ?;9_):@<A:B>E
M-B'TW5*-(AG?FFD5U5JCHFJ2Q.; ".)HURU21+%Z6/4Q59)?C*!$._Y)Q]G4
MT'\_>7=HYU&C==- "[S;[^:RJ,CH8AL?& LKLI>A2F8YXM4S0''L[RP_%$?'
M;LL"8-.1?H.((;&N(8!F$!<!-*P,Y*(5M,N*GO[XF]S<PM)#.T/V! APG:H5
MP(J$5B0T*0FA#S<>"<4NK[07\&OTQX(ZM2*H%4%E#FL2? 1LHL(OT\@+#'?0
MJPVS:?U&=PY!FPG7A[ S&%$-ODANBZB"3614:$XF#12HCTK^"@AM19GC65V$
MKY=PN0GOC^9*$UDF?9"ASP5'MFQ&F>;+$S81:!O"QEE?2V9&36\@$\1%2'%$
MT( ]F>/#F.G2_".XG8[%?FM/^GDM['8JC?;UM6&71Z*30<LDK\/*YGKEMUY1
M2D?US1'F-OJ%>E:#NAC# <%P_D!S"%",P^R"+#(IBR2.<PSRB;K$,ERA[%DI
M>I](9K)2E%:$.05A*H^T%KJB&(0,77$W.,NE8]' .;V(+BFFI)HI4\A).IAE
MJR$1H1V7+:RE-Y/[-)G>K*6IV*YQ'%I=8RM?H/"S2FR)YE7;^+*Z#:O;, V;
M9FIGZAW$:3<ENT )?)%F( D/!\Q.,S"#IOD[EF:PY%0Z287M/,'.)ZISW%O5
M.7*=X]8KJG-\,SCX+X$]4H&":!'(-268G6&[?=$E/BLZ%8<G#F6S1PT,W\$D
M()+MV$B./37QE!*MY>,+\+%,PB!7__LZ_O>EE-^^&:8D$L,HFT4VP9!)@]SI
MFK+3,=M*]J?54F$BIF2[MYYS*]+BX"G;5]#K6JH;.^B&0OD9SKIE85!C[8PG
MQA*=,AV/$)JE*RXULTAEY+&1&.M9J[*,R*1,U@EB_G!4*Q@KH$!H:$$Q!!;=
M[/OHO[%"4?%3MQSOCK)X2-/41!WGP(K?.P.MCXO5%/4+(@M4FMD"C3J>J!$M
M,*<W*4C+C(ZM&!,C[^R@@S-2ZTW=MZ$4%VEB3WE"E%)"R2N#J.Q$.3Y7#L]7
MSI6OJ/Q%OUA,$77,C6I2LQ$LGM,2HR*GO(;P'C(6?<231X+2+[G5O/+M+"-%
MBIQTKGM*YCX:+AC7.:/CB0AQE)XM"1(M(+,1ZL5<N:@7==W&6K9>AU(78&!N
M&YX,4>F%8%%M&M:.<V$6/ 2J2Z#W+-0B2E18JCN:9!=U9+NBDLPQ RQ9]"VN
MZY;U##:A"4CS+);$GG &>W=NU$DVK:8<7Z5Z1:]QL[J'JWLXS3T$5074.>Y3
MC=>)"F55&2.W!1HB4$V_T55V4-UZ7!W9BM^3#_$T1]]J63XI\#DM)]>)W1J<
M#"R0A_("*PK48Y)\BF4A<M.U^7!@#CTE,%W@$YB3*U/B<K$2EC;U[M8Q/I0M
MD=.J R++(V<XEML."2A&X&KD1#H[QU.XMG.(/3CVC?5!%O4&B<UX ;Z5U?5]
MSNM;3KN8>G&T3(%'D[HAJHK)'D%;2_[Q#IOR:63I<8=>V6I'SZ_"\$L]JEH
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M6C QE>9.3,,4@B(18V&Z.X1 -1H^8@*A'(7' TI>0N@0'^N902;G=+86]#C
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M&!6$ABTU 3H8$4.!B *1:KE\:B@045Z5Q923@@H,.WCHJ)0KAZ&:E,^4^*%
M1('()LA3T^N'(7]L%T3V6_PH:N6#,(\:A65":%<(ZEA_$Z W 3*Z<3"&$@Q
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M9X\@JWE$X3ZGD&T]ENWZ?<N/EAUEMS8IT5W/##L@:O5;_+__M>-M#(ITSW5
M>AGB)]_M<VF* \;@CR8(4G@_65O(' ];!,0I'[85BH&X[SRTS9L=-)_#S@.V
MP?>-<A%*B/ ?:9-':Q]\T>V"+!5)@\G%VHB8^F2UI4@&@C_N0]C50^EX8@.;
MFWBWI,]C:-G!,"(07"R_=X0O">88_1:X&MS>A4U.[XM$PM !@;#G>M9_@6,E
M2 %]L-X ^KXC/)PL6N!TR1V%A$AE/N'M6#, U9JVQP-_(3K$--?P*C1W>@2/
M0'>4:X^/^,M 1.,#+= $AE.:L1[RQ3T!3\"7[TL?T-[J^\SAC\"S*'\ ]IJ6
MC9.%APH83CU58[;YW UMD7(1C0:&XJ'XX@<CCC8Q:CF<)\NU8]E:6,Z$%&V[
M0U ]AI$@OQS#B*N!/XAQLQD4@0Z'#GL#UJL3 E$ D-(0!(Q0EHP \.9&DK\'
MF@Z=7Q%EZ.3JAKX ;]![<,'Q6R0C*852:X0Y8MJ$B9D3_PDM3]@/28W*<)AJ
M\FR2K]'BER1/CEVBXLPLIK7ZY,S,,K7A$L%!-* E&O-Q=3VWGUHV-)SA8\@Q
MBSE[5M=JH\XCDD<#N1.(E6:,58N2 CN"D=/7DTLM(IPE@[I'37ZP6@!*Z*)P
M_@P]8@A4M-NTP]HFAJ@%8N7?5^2BQ4N-DK&H^X$\%+'4 -2'=LQ9T<5H !L]
M)4=Q.#DJU0DU_X1*27%SSZD46'4L$#_"2$3+-!631*4QB<^X]')WH74*<TLQ
M?HF4<PLGGS*B+O(6LO.D!1DM\A83^R*#(G+0(WS$5A?SJ\TVHN@)4 C4+-A"
MQ-Y9T8 ^=RQ"1<=\E(1#A*%GCSP9-P00%T>.NP>D[/*/J7,J-:EV+/#B"Q^Y
M"P+; ' $@+4M13'TDV3XSV#QXSV8H)7&8B\/X3 AJA2?,?[)D7^+JD"(LU80
M"ME[?/^-^DKH],Z-Z3')W!;PJBG2VH&J(U.(_7W3MJS A_*'T7%PA"=!X]BS
M/^,AXGLR<CF"' ?HU5].7AU7QJ9@PL<W0,N=#7^NYDLE,^:&,O_OW^J5:CU?
M8/1X7EK.(-/&B#:.Z@9023)4\@.<$7*?(?(-0D" -A:AX&B=F*A,)D0&7YCS
MAXAHOGBV$'.%M&:3 "="&^!EXB(_O@K'D'[GB'")]G _;/E6QS(]0L@XXHW'
M;HID4!2R@#[D0/B1QSS&$@11PAE[+HO,Z*/C%S;QV+5 9T6*6' .@F#9#NRA
M@.?H4ZI:FMA[*$KYT0>;!D;P:/D21V7HJ[R"Q+\12\L''+28;AM1WGV&3>SW
MK %[+TU!>#%N:$KI[K*[$':47NR<%*/XDG14>_-%'EV-=D"/[KNH=2#Y4Z5K
M LP/PJ&UB)A/+HFF _=9A 1D'[)QPG+:1)]VU)"I*EW #<_V-HCHOD4NSP6B
M>0\FS:(Z;<OG I^EX&(+B 32*$HNW'ODGD;R##H9I.CG<==[!';^K_P,NZ45
M^A;J)9(EI805,1)*&T;*O80%"LFY)3A=F ,<ORN8EP*R/,* P"3C ;(F?IG-
MV*;O\P3HL *BS;,!=:30P@BRX@A''& )U].0Q"OP0:*X53<6>@0<D<.6I+LV
MBLHIS#33+_JH=E!&HE)YK4=U.=?&J!67VQA"8T@=KED<*>$X&W$3)DQ#K_!7
M"6Q/L:XT;)#[ 67R ;R91,GLTTU+A^+&A\7,8R)6.Y)Q"99.5(W4:3$YLXGS
M8WP.I,LIOM]QOA=+*[C?<5/BF! >$_D'6?+9R=@#"7_%;(P7D%#C"2DG#[^F
M!$8A*4KV_13;U336@QN>\. B23ACN.B (S-"*OG)]"=FD3&^I<:&+GK:'Z.V
M/(JE2#\&"\FEX&'45S 211-[]U)>K-2>VT+>U?ZJY^.NQAD6.Q(Z,IRKL4,5
MUPEX4L;/6'[D]QS7?V3TEA3K,1Q+%!UT3NC#R&-0UHBJ$'5X"TW$P O(]],>
MSAP>1&;?+I=U'=%-XB!=J&B1X_!VJBK=^#E$$4+&$O,=F$/"9\FW)#[)DB03
M[HI1"F"4^>(D&'O?A!*4?O^J5!EQ,D\XJ$W;=^4PZ=E#L:[H"<B<TY2ALV33
MCTWF^&B4FK@T0EYX)';&6%R,*T!G79280#5K]]9&-R=9\9M'-?O8?6C;UM,!
MY"O^$CJ<%5.IBBEC[Z*IBA'19J4JCA-X/$-19B5^EPXKF9,X&:N1E8P7/S/)
M9ID<DLC%,U;-Q2O5"EFY>,='&6_$3(DE<O'\%9+Q (TFLO$2D[U*QEL\.V-R
M7><FXT6W+):,%X>.IU)SIT6N9T8QCVR%;2=M'!]M)L,N\:LMDF5W?+29-#LV
M/<LNIOQ8EAUY-M>=9I<5AC\WRPZDIC6GV<V*@X_I,1X'#YRRYC0[MER6'88#
MK3_-CBV=90><,I%FEZ+C,FEV['"S[/+%UI=4;#W%UM<**K9^8;9^^T+*/&ED
ME132^)V+I8\NDQ":DDP%="91Z>F:.VT06_T9,L>!(>!4"U>T<BI@6@5,;S1@
M6MM@P'1JV=]0R/1DJ'2TV=85*BT%>Y"B7R]4>OQ(R14J'1%];<'268',H TO
M$,D\D>XSBH\JD'F1DV-M@<P3 LO: YE)IAAOUK1:1#,>8:,AS5/]#.,1S>L-
M:#X^RHAH9G% <^;4-QC9'&_([*"^E2.;)VV_8KP3 <W"BQ:7XYL5T'RH<<QS
M?"1?0,RP^9#=FQS8S=M[%TE<TE%V@]17+>DH"3?-3?(=V'F,QE.\)%]AYSEM
MVEU3'"4310NC!Z9<)..CD=4**Q,>DBSO2%86[?CSEJQ%J/P?;\K_,;ZL,]T?
MR,/RCBU[/Z)QODJU*LI?/$#'1VJYE=_#&R''C/(_HHCF:[D]QNKR$.N^IMLC
M/2^L7]N)2:@\'IM [CD0O9))6+YQID68H?%"683?EEXO%DX9A)5!6!F$-V@0
M3F'OFNW!TF)#LLY6[<%9QXFT!I-H\:KF8)E73P-9WAP\?HZJ4V/NJ;$68W 6
M:RE;L+(%9]F"TZJ7,@5OVA3\"UKFVB;[[GJ>Y2M+\**68$&WJ89@_W2,PE/L
MP#<#J>;[^0W!\H&)969\+-(,7%W2##SQN%>P D="Q_&1L@*OQY8POJJSC<#
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M[D2$TMA836F0$COQSW$9,_(HH%LB*HD&$AJ:BL@J]4.97!>?A+(2_8"<-_%
MRD[^H2I*^K!+>&:G8\D:T<*<!",WQ,C9S($G!=9D&=A!O+$ ]P%34/_JF9Z
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M35A.5=0>=1WKA=WV3*]OMGE(!/.3]?U9EJO&F+)3C?%N5_CLV$T[<*D<,%G
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MTX\N7.A3#C1F?3@(?V)!4*PHRJ(SYC!17]3P.MHA-K, Q8.?(LO[HSQQJHB
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M?BC^VDJ\]T?A0]WP\_\!4$L#!!0    ( "6+;59R0/7U AD  +D7 0 5
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MT*$8-1RVNU.BQJ:!Z@ M!MS7L(]LXV2TJ="]A@53V<(HGC$'K<-45/+2\V_
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M>;PPIE>WUV=C(R59':OF_(N^Q0C(FMFX&L7UH-?32:2H>S BY(=3B^&5=+,
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ME+S4J=&7U[:*]4:-&K!#Z>ZY2Q0YGD_Z#)Z(6I2J[CJH7WF^'.S[^)G.P%P
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MJ),!;9LC"+Q#H^Q*X"7511(R\HE4 DX^3)- 4^0& NR+7L!66E42<*OA3@O
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MT02A.9L+J-GPA,+(HW\6NWM7>0A-+D?EBW@+,6+<1-A>]Z!\W<.AAXF,N%5
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MGJ9G8<Q'MF \]0CIFK1Z-E^+3%[!=6F:H361MW:"B6=05A<9['*OR>U0Z<2
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M0G9>:##MTMU<M!3L8*5]FX*A*B<@?ADG'53!-OV>_8?- O2;_P]02P,$%
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M%@-(EBZV@6,99\<=A?;,8G0F3P3S55 XSO0]CB@D-EF\R-(73(J8_G/ ]LP
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M8EJ0W]-L\[A(\&PQ3:/X)8[6VEND-'*NSK,9858'VI1"WEG5ATPZW\1D4;9
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MO^EO* $W\3+2?E/^[N3-#W_@2XO_]O;-R7=OOM.;]48H,Y,',R6QG^GOO%0
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M?PY2FUQ#_.$E'=;KY:Q]M]W^\1U%_S]4L^S%8.P;W/%;F -]D=[TNEN_NN.
MBW"-_$#7E_ESPOG_L*RB<?ITSSY&KKU_Y<#O.@KGW.9S[<51-[T(5O<^4.VZ
M7;649IVN%(31Z<98MV;UA0$S!C#N[15',5(;/LY>!EM%^; ZU'XK9>A'1ST+
MYO]SSZ[[SN,"/V#R(FXY.UAGTK[K>'I5S^?:7_?2O.@SZ6?FVDDG\800E XW
M27BY.%)_@_*"2,UWLU5VV26&5:C)<3M-,*0=!%=B(=LY..6.&-M,V)X'Q4+-
M.R^OEJLDV^"J3ZGK>)NE+^)2!-8/\WE6!$GS.;O\]#8K?L/%/0ZSIY3M9_*:
ME[-&S9=U]&Z7O<+IYVQV*B<O!M,G7=96OFJ9U.+M/AW2 C_?#BV&V^N,E#\Q
M.9W+YQK$9]'%C1_825]7(OC\.[VIVL-Z_PDBVR+ N)[1?ZWS@B_GSK-M!--=
M$$?3]")8Q449SB3[-M47YR$4=7!%]D2"I=H;;WQ!G3OE"XU3Y]CO)V]YVWZ@
M@+$:?NO?-1]S.M7-%YCP2[NWT8 KB@;%U(8(/ <*RITLLW5*[5ZQ)ND\JZK7
M'</-HLZ"8'O UL&K&CGO_+, )P7+/-S=H=>X>'[.$I8=.J>C"=-DQY<SA$OM
MG3?I=>P(P_5RG;"9;@7T+MC0^B67.%J'JHG< #UWO!E0C2V)+)2 ,,H>:9=>
M#554Z:)2&6VUO?LK%TF0Y[/%KP%;%RQFA.]4F9(BFA1<COK]P)L#LU[:.].L
M(78IQA78OGVIPN[HX$I@<@0JJW33D_^O3\D[R:0*]!+M!EQ./BN8 PAW RB/
MGK)NK:37]<.\?)KKUE9&EN6=H[;5[:5N7T&P&6V)7I/K&)='W8'&0REKW+CO
M9,B':JEY9Z^B$KU$;>C YJ0,5!-$W! \T"RDC2^O.TUUC.!2SG@P0,_9+&1(
M->I9B(V2=R(-16HX$7()YAS5J&C\K R*E8)F*UN]_T/_-J\\BKB8 1]O/V=#
M^M_GO6<YK*3^C BN)-%KV;D_SQY:WQOILA$:+SWZ7BI]P(/WT_J-GW=/[593
MWU>K'BJN03U8+@_-C.5*O%3E'O1I.'/#[*#7#IA9W#OM[#'VS!X5W!DQHSQ4
MHUW&>9AD^9K@&TP[3CYYS/EM0%)SZ00=7SIJN#/)#J:T4%^@2QQBWLW?O46L
M1Z)K<4RS3(6)>$G5S1$YNL[HW(RV6L!CS,5KT*]Q\8RHI3D- _K!$W[BD^7*
MS=%L@=YGM#1VL O-4HQ^PP%!OV+ZTX05EB39:XZF*17(UCF=[_EW FYPGF-<
MUY%7\28.'GFZO^H[7*[Q+?Y4S%]Q\H+?9VGQK!O>QQ?G<N#>M=+-(7EL6=ZM
MWIXJT.UDE&'OCH;5K'_.7[,=OTQ="D0.=ZHXAKIE$4?'V#9N!5&_/2ZBTG?J
MMFI'E .6K,UJCJ8K*^0X"=M KJ#L=T=%V6OZ&??P340Q4 G;K.18OK(RCI*N
M#> *MGY_7&R-7_9A7T4Q8-G:J.1HMM(RCI.M6^ *MOYP-&S=\5/ 9.<NK'3*
MQH(=?E M2XQ$W:7B[W_W]OLW?X1-Q@]I%.<AB\+%T=6GD(J*F-PQ7T1?%AB:
M]E77FK.Z@MP0^$=!X!0_L6C5T13NJ427S],T3-81CNJ+W+Q36U,OS;?02KND
M9P_D)@$UHF!&;#.^X=80[H+Y.[?C$B9CELO?:3X\SU&&INDB(TL16'*/193[
M/*O7PH.\L;0-K%]7(ZT5#;?"_GIU%["^4U>20/MT!Y[$K'I+)0SR9[2@W$'L
MNZ"L?I!P?@$C5"<OWSU>!G%:/31=W#F\&'\DM*^DGI[]90 EKC7PWM2+I%(5
M5"XORCPJ?E^63AZ[9\A\Y<#P8L#PVU!):WXKRC@.?NN!]_*[F@&(2YGA$9LY
M+^RB@K@\HVPXYZ:1=4I1$]P6#U6"<,AF0*=V+QO"8,ZR=6MQTW.,S2#ODT,2
M;!./;L"=6^M#:,&G&[NC:LZ&'G$H9/$A9[?Z88MQIJ, )P!K&-QN4W&YTVQQ
MNJ:.4<!$\Q.48N.Z$.RE%> -(P.5$FBP->W254TJ:5CM<4LUUX18.6@*I:-I
M(P7D;FO=M-N)=QY^KY+00ZN,L 4;6.UW,;CQ+HZLY;IX>YNM;"__'D^K/N:D
MJ1I9?Q,Z0TI4I2 <#\> 3K]D)FPTE#RG'2_-SI?SZA=;>,-P&*+$)7%C>WJ8
MWZQ7^K_>N7&)%]0!CRZRM"#QXYI?:D:!ESER2/X^*,)G"KHI,$G3=9!L4[^;
M[^[8ZQM<<O( GZ;)YST6#Z8O[+].TFF>LBBT+(NBO6E;%M3N]#[XQ(ZNB*HV
M'[)+2.I<5L;EV[V4#*#[C/D4%MUF2+'0N\N(NG2[25D$"G@9K3XBCKA5&?6@
M]IBJGZLL1EGUV8(_'&>*;,H%T%N&?X8!0TQ_H=![RN":C.TG!&H_F43+.(U9
ME$@1OU3S$]TB^, R /#?7#T+KJL+@,YK(VKIR&Q+N)IU^I]:3%,ZT<$W69Y?
MTZ9F58S3->VDY329]K!SO,@(%G+SX!/.K^F?\9,N??8N!;KD\NX5;Q)[?&E@
M6+YS%;J4+Y\>(\4OZ3_H5"?<WZ?:E@B<Y-VJ[\CRJKACIGFG#EV>5X\];1+<
MXF);)U6KM00<1]):; &HX2FWU;R;DJO% H=L *_9P0)^6%;]-(R36&37*:YQ
M1+F4/!1!L:88-BUAS5?82\E.;YG9WZ=H71VS>['03H#LKTKRY6VE,%H(;11S
M+50$GXZBKUP\LT14TY1ZV)@0'%$A'O"0L\NYQ8=A\? L/<P.'W?06Z#UH1&?
M:&A_&O *,,/X8>HE9>_F);"+3UXJ%114.D?1PTHGO"5Q&5-%MET>![M\WOZB
MH?4EVX\QM /UE7M4O<:R,IK9'DJH%X?2K$#Y^O&_Z,O8S3#[&Y5T&0"MAEBQ
M>D-_+F\2J28 ]+.)CM[Y:OLMVEU.P?U^C&WRP?V4Z[TS'* R<H*\4A.12E6<
MRPJ%,@JY]E&,(#QTHG%)V0ZF12X*V@BAJ^S0$:%;#K1)]PYU4(:+ V6R:GEG
MT!=1%^"?M::*]7-5I0TK\<=@W(I4"<SEH(KHCF0O<0XD\*0]$;G%1?<LO+SW
M9%!QO/G7"[ZSUZ>5]^X##  I+?>6*LR=+<]<?/-E%8H<X_RKG^#Q;!L@2[WS
MBX"0S2(C_/YAV^]B*L$K"_NK9B2E7ATN1WLQ2QG9V:&&;=PSFZ&%#35X?*7_
MJ'XK]]5;^>O3Z!RG>!$7N3K!/;M#V_9C[N557GO 'C^6L:OLX3W0W. #UE%>
MJ\_"CZ>/3*-U+3N\SL<=>FM;)(3]#@%-P&9KSR3!D[")$N9L2X+\,VEL/O?5
MKQ3VRID68"-GN"2LV9$1H_I :E1YK<)CA<<@ZQT_<+MX(W?FP.RVV>]DC]](
M^P7@]IE4FYOM).X66SN072VOU%-7P4B[M@IP0Z<$JYKNU/9N.TOW3CC]O,V8
M5*=/R\^!86,5U$>'E2I@IMEV./7'B9D::NG!R<.CK=I-7T8>&TT8!)2J8D?"
M&WCY>JRQ#B/CC?<D/F!B[AWEP;#WK/90%U- !H"#)A3S!1V/XZ+)2F.J<Z.&
M2YMC ;W)2X,X&!O3CU$*A>/BK75C_Z0:O*\!91MCV*[%$6Q2#-Z3F.GW(W;F
ME29*S#2P+N-"V-E9^B'7G/(?6XBSR*_1%:QCO :7X)V .\'NDO)#02>7_Q0+
M%;>S&_3E2H@;KYGU-WQV*S?$V,NZWH=4775Z!]>NHG=2CD$[Q$"*2Y%A[!_)
M:X#=59LJ#M_H[0TOQB5?QU:R2=VA98!A\4C@BI LPE.N 3U.\;!^S/$_UM3<
M7[W0_S&MR:E%71+2!+9).I4<&&(9P$G;Y[4HXK)@UM8Z=>A;4-.+>V2/<>E,
M)PN517V+9#*3+!?&W-")A8G<XQ7]0,\L5F221O>XB*FMO5P3D7LMSB(>?:*E
MV* BG-)N1.5:5!R@#X>>PT%+&UKKY2,F+"]QSL40V1:'OJ3#J?C9_RRE4]<[
MDCV18#E9%\\9B?^)RQ4FW>4^UMH>.=M7)0-==:I0F=J#5\I%7RNBE=!$ 5?P
MSLHY<SO79,/K-PG_L6:=K[RXA47LT1[(NY]N$F>M[G0&/;!2K4FTI2X89@X$
MW*7F'8E#;#"?498D 1&YY+@(.$NJ&378S$P[1QE2 CPOH%6UX4X 5P?#W^&8
M50%4&@H?:+7\?9RRK(OG,87*.QP[!*@QE38*SE;!K8#7*]Y&:>\$LH8HY<P4
M.N@QCNAPS,P?V>KFZ';R<#GYZX&8<Y&E.0[7[/C>^3JGDZL\OPPV;,-Z6Q-N
MDE65':#LC%&#*U2SRUH3!M.&PI4VB;?ZZ+$L $6T!+3("%IV.>DI#$5]=F-"
M"%O$9/WC?+,5*6]@G;!U]]F*K]K_3 6+?)H*JZV-)#_ :^!=X'+(2NJGP9E0
M1D],VWX.[)-3^: /T;E>\NH3)F',IF2Q.IC<X>L=<]#H5GFHM73702E5CK(:
M<@Z;81R:IX_]_?6Q^\6NZAU'\;&T+-Q'X4#MW%ZK)N_W"MJP^XT]D>..9"'&
M$8]!G.;YFFW+S<A#D.#9XHIZC^JK_/JUX#7G ,R]B[$QU<?1"=_3=.W2<*]M
MDN?Q4\H9ET;TC_624VGR1#"GYGO,$$N^J9W:WZ,L=-9R]%UK]FK>7U0.ZB#,
M4E:F6AD%*3\)5ZJCH-+_VD?[703Y,R,=)1 ;LZZ#F$BK'T9!6&W4@U**4Z;/
M1=^I;EMD?2O"2]9&$5YE>4PGK*]Q\8P>@_1CCNA,8A&GM,?&/.%I7L2%N OB
M:S1-PV0=T3Z9\3ML/\9IE+/2@I!?L4V-ZW-0H.> 3D^H 'K"*<^:&M*.'(34
M\,8LCW.N>/_7:)+D/)&=*#]_IE!/F:D^0<_4:T@V*(EIG2,J\H++A$GB;=1&
MH$>*AT[ @RBF@I0.U$(5\6."67*\CVGVFI9+Y?S5(?U^G*#TA2D."(,:\[N4
MUH0:)E$J_6U#70Z<,S;3CT")'2_B,&#WB,?Y1UX.#\K(JW +B@*' ;LHMOTL
MIDX*+4?</YY[ZP#7]6TY@2+WG"0!C_(J>-)97$HZT=)U0R\P1JM:S\_G3Z@I
MG"U^#0AWAV>$7RN\=5PN.[F:K96 -9(]8MG)KX101*58X[V6Q3!S1%A!]%_;
MZP/]M&-]9>$\NRM7A\6^\H<TPJ0>)!6K5':*P-IS&&I#7R2XM*1YX]I'9IOK
M'<W2U5NS@GU["Q1AEO(=A2GW/.=9N2-V3^M 2WFFKM$E?L%)MM*V]I "X+7Z
M"/3VK4_[>,Y*+_UZ1H- O "1\@U(N ;U.SSQ@!T2>V).;YS0\3M+<3GOG#TF
M\5/K S;7HWN5H+6W-6+S:)O5XJQ)E\%'S+.QBK+1LBH<K43I?CPAS553W[YY
M^Q=^Z:!Z)F>E!:M9AT"6 XD7&5F*IB0X$4'RM$TC46;K@CBTHJJ(%8LBOM7*
M'?\57XKQTL+7:Y+2"0O!; *;)#R?#YLMK0PS=0L=6*UK#UC59Y=<8&N7T:(J
M3LS;DZ2<W^&J2"\M22>;+"/Z"^:#4;E\Q\A[]N;MCYJ6M-"!U9+V@+LMR000
MUT)U(8AI0FNLLS?#&ZO2.9K&Z@"6&^OL#:3&RC%9WL0A2\#7MXQI$H;6/+U(
MK<QAS,M!B2C(\W1$5,K8-G#;8NRW]_*E_Q(401K<T9GH,@@Q]6["(,EI;]5\
M>[,XK-:PPJH(.*[F;74S)2S1!E]5Y26B5:M(+\UF:<:.P8 -,ETW(,Q3%_)L
M$]#YWAQ_*LX3.MKU-D-''G9[J,'*=BW.$1OBJ3\=Q7F89#ESK>D4F4V-I%%%
M;+V(HD$TX:\4CS#?]LVHT('=E'K >VG.J;]A[(;=!I6D=P'Y>!&LXB)(KM=I
M='-SH36,1GEHS6@#=M!(5A:)6)FH+!2Q4KVTWOO@$XOAW.YTU7<CS1;WV29(
M6&K&NV#3/8\\6!E6NXY KG0G13&-#3_TN$&OSW'XC$A5#%N!9.50Z0UZ+*^0
MPGZ:>\;N?6,'%%APVYUI#TDK":LA^V!JSUU46P-B(XB;4]X]']E3=CE>5.X.
M,:N;!TDEY,WSF7W:T/E\G/+81TH^$JRX&YQK[&R//+!FM )K-:/+RJ*0R,U?
M- KSTVZ;X&><ZN=UG>? VD4)SJX=-@$+R&$Q-EZ^^]:VSQ952.#YAN\QDMFB
ML>THM8BU)JRV&@K;;@NU,;11JQF7Y;)ACN^GDJ8M985[;VOJ/Y.(.E?%ICN0
M7V>D'N;S:=KKWNRE5+@<V;5**OZTV2*[0&SS/64A;_35]$?Z;GZ2B,6L)0D.
MBS7UA5>$W6U$GY1A.,*=8F%W*0YQG@=$*/&-/Q;G5\;IL[]+E7*6%)6ZS/$2
M7I<"$B5NB@LQQ'LF[UT0L8Z:YG%4IHDU<%(6ADHU+=)^!M%&XFT=-K7]M!(I
M<V1Q$RKBDBXQB]-D$SNYG8SBP%K*!JNJK=(Z=#ZJQ2N/FC5>5:[/D:&,^*KG
M!6=OSMYJ/#&#++ &ZP6J7%0J730>TRA.<-;Q<-OE)%:4EY:ZQ_'R<4URL?*Y
MN*-D2HORTJY<:BNC-*S6LH%J\,5601SQQB+-<H1Q9"6QW)&\*"^M)H[8-)Q+
M_1JN7A16>_7B5#66O&#;6/)CO@4(/YE5+>_;N5()P6LA#<+^I5@(:SF\ G7\
MHVS=.L\!?GT)G)26CW_F.@PS1_D*A_$BQNQ(#9!8ASKJF$UIK_$C6=.YA<%!
MZ)$'UDQ68*58S&J"WS%7K-&J0KB/X+V]_ARD0YI+$@?<6CJL0QJK+,-_6ZGR
M(M[B5_XH?ZMO-+,>T-:S JT_@9SBU_9A!1@QSI;5^W9L8WY[E*WY[6?>G-^-
M;<[OCK(YO_O,F_/'L<WYXU$VYX^?=W.>C1TYSXYRZ#S[S,?.'T:VY@_'V)@_
M?&9MR6-*AKNT';6C:$DU9NEX/<^X@^+E*@B+:FONI8J\L6C<;>*/5DX>-J\)
M6$1!7+!<(:OU8Q*'(ER'%9 1%* <TU:,V,RG\Q@P8ZP]K:[>,7)&YV?]BS3#
M2&/MSW7UCI$T.F_N7Z091!I[K[&K=X2DT?J,_R+-(-)8^Z8=M2.DC,XS_1=C
M6HRI4BX9]GJ58@ 9H<-HM\?+MN5%RRO21\ED>(I?<.IU K->+BF39@N>P:&1
M=^->;%;/LQMVHU_.[V(SM.ZH8H"U_BYUD#)1HEP4QV-DN^E,1!! PHOSTNSS
MZ^NS.Y*QB$[-5IDD :NQ=/!,F618#&E +:O()<-*8)&EK @_;7 _I00)4G$H
M6G\<0",'K#V,( <=AZN*0J(L/VU#+39>QJFI62018"VBP]??&$6EZNVHQIRL
M\P+CG$5=)>OE8QQ\2.E027+J=&G;HT\%6OM8XI4<CU*1C2R5*MKJ>FDOGH_Q
ME<0L45=?-)E!%E8+]0.U.O:T;A3C.;RI6:-+ZK1V+[+6"L%MF Y"V;C1J5'.
MAA7F;K>:(BHUF9%;\Z!T&'L*OSY\L,PHHI6$U5Q], =Y![0P(+&"Y411%VO6
M?@RL1538I'A-'#;2D;.9:LZ[QG.65*>@^;Q6E4:7W9U0Q9VQU.PDXE%I/#,%
M4V1YU?-JV81E>"<<\ E:Y^L@239HO6(.NTC4R?.[-Z)%11B\SS8_,[?Y&> V
M/_M7FX]K\W?F-G\'N,W?_:O-Q[5Y7MW]I+G\3RT&D@-JC.I[="D-Q#'9<@VS
MI$)>I<FNC_2]/N.TONU">$XQV:Y\QBD[ZL)%O;8BNP/H&C^R%)C7XEZ1],G<
MFPTJ,%NW%Z_!R=(L3];-R+XH6N!'Q'.(+JKB_31I1C[2=Y=9DN3F:ST&UE0J
M;-*Z<9W-_%6(H[!,"!5P.TJGE9GH:^R:"C];!F,OA&RF&IA$4<S4@D2$@FWO
MH)?W%@[[/E@D<5-9R>RWCM@'M7J=#*DN0"1GJ$Z9B'Q(7.A4)->IAO)@B]C/
M B).RTK-R/N,B&M#Q#"F6S_LTX!%%%NXW:9^^^9_LAW))55!#1TOC72U7"79
M!HMDUM41]IZ4W18ZL!K*'K R97>E7N;NK@KPE[J[/&I+J\ROY\ES<?&E[EXO
MLSBLIK+"JC[6&O [1L):S?N-7]O#ZCR@I;I,7CY9K)6$U39],.6+RANG'\O+
M!ZNQRDN+W.)7'C_0&,LU)DXK":M%^F!*P?SX%<U6/&,/=5^YJJ]KE:HK[,_+
M&^PO@TU^G9'WXOKZ\U@SW;?6A-500V'+7:G61X]E 73ZL1$98Y:B#/081^4-
MV<(KO)T\7$[^BL@Z\=/,]:6_S<0=?.=(2I;S3FKI(<JP&GL$\G_%-O9&P[(O
M.G_-;-(*U&*P>&'$:)U&0'1MED%@ZXG6? +>R^5(]R'*L%IS!/)_]7([#HF[
M01O7C-YL,[Y+'[>'4H/*@LRP,171)MKN6I?R-M;6#:PWS9SXLJD!P!-CIYNF
MXEOMY%G4A4!FQJ :'._Y7E;A6^KYVG@ 6SE8#6<&.= 'F!2GM&U.E[1_XJ*V
MWUY6$>F[0S8YH>-1ML3SX--]4.![-L2$<1*+!?1"W!>ZO=6!;9CQNTFSY.*9
MS5_EE<;]E N+ _NME'D?@?7=*.97)_ $X;AXQ3@MM["XH\ @H"+X5&6L1%\^
MXA0OXN(K?@\H^S7LE:2/5FLF];A!P6J5;"J[$5&=O*#>Q0*S1,$)RW-:K(N,
MNAV- @FM/P\07!',_BX??9ED>?Z5V/L4MPBON?NR*E,.Y\VMTJ#Z8B*I--])
MK37I1T,A_VI^;AM@IUG.@X3UY8=GC(O&D8C+N#RWI#_9,TP=%ME'8;<[Y\6N
MF^8WU#Z*XJGW0LMO;J5[NS*<)4 OCRS=T;X6Q%&96O:"1;DJKXOO5X+5L ,0
MZS?8@SS'1;,7L\Y*:R4NT**S&'97^ 8'!)6IY5/6M$EE MC6_"9,\ F*%RC)
M:/?VLXEV1[(%YGL.07*-<3Y)(\Y[N[8?I V+!&.@Z]FP:I1&!PRVI4-'(-''
MCXH/G;XQ"4-"_>F;.'BDXSN[Y\#2#&@58;%@(&II;3L@A#L,8N4CJ(,5VW:=
M!=L(1UB\C9F-(L#1-M4V^I +*T+P@MU;P0L)Q;L1C]FA/D%]95^-#GT9K;&*
M8.5/>IYM:?:5KQW&;7Q*V@I7&4&]T65!8^.N%=F9H-LW<@O6_.&T&NS^^[)6
M-VC8<W5P"; 8.A;^CKR\,PRO_[*EDX16@XK\G&3T\[$;F%),=-?XF81A<<T"
MJ>20E2I(Z*!*"<1-,>S*WL;"M^VE,4HU6"TU"+.TZB,MSR.FWEK#]]*KPN<8
MOW! 9:2L]F(WO2BL=NK%:;@VAA^U838PV!;"#_#4!VXB^FN2K<0)'8*?UM1;
M8*MES%3GG=L;3M \2^-/*$CRK'%9*KN>JT[@P/38"Q\P[=74UC;B3:E^S)8"
M\X+$?(E/K"VSB[V"_/F$'4'AY?\O.JZLJNP=G@]\3MB"@=13=%;:( R,4_U(
M)2O-ETY@1 "HX3,#5&? N*S7[?3KG..*.8:6M*R#];JG6#=37!3&3_W5;_+3
M1;FIN\?%FJ3SK(J=EB,_-'+ FM,(TGA9*U,1!AF7:I5_'@MWF%EA:I+SQI76
M5P]W=UX:[29XS @?:5A,RLI@5+62L!JN#V:WZ;;RJ%;P?Z/E)>O6T67\$D<X
M[;O/LBT,JSDLD.K7A2,N3DV@D!>7) *XQE)OZ_\2%$$:C!GI.IJP6G$H;+OQ
MS#R8B9+]GXV:<1=8EVE$+PJK!7MQ2D=K&@<+R^D.:IPV.$&B$ #!8(/BX_[_
M]JZMMW%;"?\5OITNH .T.></.)M-3X!T'?BDW8=%L9!EVE$A6X$D)W%_?3F\
MZ4)2HF0['"_VH:VK<$9#?D.*',[%$8AS-$=<:)^J.T-^21.\!Z-&G>* Z0G\
M$IU[U]#JTN%2AW%"_W!6=I]PV"Z$KF:[U8*"/Q-=09@H1(.Z#!$#!+C4Q%-:
M<[_&R;C%21&*=!5 &L3M:KU.$WK+SF$I.XQ1UB&]M6>__8\\$_G@0O6X3G3!
M%MS(6K$3OH**E/]?XT1%0YZH('2N*H1'X-WNH<C9)Z@L1_EDC*''A?HTX7L<
MM@1EZ\JO[;ZE7P?K^K-\8:#:]25E;9_FQ2;>I7\+EU''%.]IBPO084'-+$."
M@K1(0L]$Y3/DP,/=%!<<@W+: GGU#%$4X0]/7B$D1T7O:2:X #RB!Q<723.B
MKU?'0'UUL1!?_3C[G'[9.$J7-).+U:EN#RY\V3"L2$<'Y%YV%*YOZ*V/S<QF
M)N.KS$7@KA3]:/P5H\O6@TXO3J4/ 8VE]^Q8?[=E9SKAN%0*N\'PA;$'%2ZH
MQXAL7B3O5J1)K(PA];UR$/#J/$,+RC,(<P<VF<'+ *VW-2ZP?$2U%@DQDB85
M-7V=J(S?-LOH4V[X*+G/LO3CDQF69$)9\AL/Q0Z4;7/[G!>Q,.!5!_?=LZLA
M+E0'I/3VE*H4'VZ$#%2:IYD8EM^R. N_.%OB0F=(S/Z@]+Q(-RD$(?!M;ET$
M!C*5BVL##,D"_\]%:24ZM%P#&FUP >46T+CHMXZ\V)WPW/++C(?6LWT(^#JC
M<,#I+!(+)MV6NR/P5'H]&5%]"7&!.5+J_DG8FFF6A5)]#86[5:'?55_81T%\
M<DK6[O6&/N=E6MWFQ5RN)?W+JA<5+K#'B.RXKWFB&;<P4<Z*%P>!QX"G8PD.
M,HM_+?*R?"CRA-*5>7AL_1471#;1;!N3#;2#NS#>4&0E:=IY D5A-CTRU6GT
M8UY6)@8];7$A,BQH7_:!U@>MSK"? 'F8X*FDH-#5^5J%>O(O^6->+_W\@>EP
MXDN)"[ZQ8AM@*GI>EU-%QXJD=VQS63,1SX+84#I5^.JBH?/U+%M">63WT6T,
M,2YD)TCN?\3C(<B=<H3">;A^#324+PIC.^L,P,=]D8Y NMT<-[9664^!)F<<
M)M$&O-GEJE#_#1<NIF"&,T*P 1T*=K[Z^<I5X-&?%!<<H^7VB/%^[<9X@\/E
M51C[<OP&YE1QFSE?B[L/X6S\Y:YZRO=5(_1X]@SV<4OQL$E<<.%\3!>ZD$M>
MAJ^\NB!^%0S%4UDL,I8LL<YK5PB-/RDNO$?+/75>_Q(^"*I3.\FU1'O0X,+0
M7V##,ZBG-E2XQ=C9'Y?_ZQ#!A<#5[PG;AU68&W5V8-UO]]Q]6@GW$!\8:7:C
MDMB:UA@?(EQXC9#8<J17I#J.'C*< #%9:>JF$[HPW^AXTF>8B2(WEID7*\SL
M?!.7R'P?L*!*4NZ='V]=,]2#"!?J(R0V9JHD%>EJ2$U,)'6H\F&C(!MHCPLM
M/V%M!<508?0_&F>LA]=I?K=+'+A8VN#"PBU@=_QE2\*:@HMQR&J4C=WO[-<'
M5Y$&=UM<$ P+:B]"V=G#,R($OIN]_LEF</,88ERH39#\AZO_"71(^;H>I4N:
MR<7J5+<'%^?J_^F-%DD*G_X4.OR%EQ"ORD]OS^ )8MF3]C7'!:.7K-9;"DDH
MG409>%30D%?)(PA4UDANQU>WIRTND(8%[2)TVXI #^MBK2OKWN=ER:^?UWG!
ME&15WJ?;5/2ZG.]^+Y6OE@'4: ZXX)LJOL-3C60UE7*XWI<B 6+63" -=8)(
MTGP?B5_B-...BCR']6K/LQ5P1:GB-_X'464HS*=U5])BV[TX=<S>OL;?_O,M
M6V;OI@&M_K0^DCXR&J$2\IJWWC-_%11_DJ\W=!WOLPH")VCVYSMCM"__O8EC
MF>_,EAC"VN#;57 L^N6RII M(R+;!1UD]^BB&]:!\0PTC/V93-RM$ UOCW#F
MTJ&;AM;?AB@#(XYSJ'W&.-#0\J.63%8NSN6V$39;??LOFH'N$<Z,P*B;_HM(
M.X0J!*FV,@\Q#E5G&W0_=(9H<$Z*?E%[9HH^AE2'0"!Q;V<X/\E2+C90NFT0
M@> 4S<RD4\K@6M4TT(#K4X^HYPIG']N86YHA&O8^Z8SD;_K@=2<+M4+S#X&&
M_S/4%%4RS]2Q[S%O6.OD++Z.RS2Q03.2!2+8IDINWN-5;3#)K'F %NQ(DU]$
M.,=@B]SVN:!/;-KK.LJL"_/U8_QF7^^<S1&!Z2.EN0HV:-H01N0S+PM.&'V$
M:R,AS.3S?556; %G*XEU7]=MA,#8,2R;-8$VFRV-MN'#O8ZI*Q >!'\9#<.B
MCO$2+F""C"BZD+/A&E*L-XM5.J>$T1+1$C8@H#V[_+4[N_QG-GIQ^:2V>($
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M(IW1^2A$]ZF.,"LE\3+!-V5"I"TZ#?9LQITZCO_@>+-^<..L/3JZ%N25;-$
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M+Q,6[Q$.25+?R=Z7.]G#>/30&T]_L>SA+7]$ZH'YN_]F#7M3G XFO!NI[F>
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M)NB8<2Y==KNQ$^F;-/* 5\F^*Q]'#_HWO6'U'/KF<=QO[_Z8\C4TH5;@=]$
M+2#%7KE+:EL^SU?L4_'##,BJ$]85_+GHD56]LM;!MXQZJ0UL)^5 KPZ P3\"
M;T&7RBA9E\FXS:^8X9_MKE-6$BBW"=[E8/\LC> 2%7")"FAIR:1U!GWD ;3)
MD0"7T^>W/61>CJXO1]=R!R5;]4M'OX,2V$.>]A%UC7[HH]J;/I;N8C-ER$FV
M(6ZJT<99$."UB7\ _52C7^S/O?9N2S1R5&5Z'>6I*C=Q<56]25=5O:5<?%47
M7Y4):^Z+K^KBJ[KXJBZ^JHNOZN*KNOBJ+KZJBZ^JI8&0+OL_DT!UO:)2"GOH
MT_99"?1$'^$,2W]SQAZL\TF8TY71\'0SS6VF7!V[C^/93#V0Y@;9]>DOHA7,
M>_D1Z+WLT]^-[W&]EYE>1WDORTU<O)=OTGM9;RD7[^7%>VG"+NSBO;QX+R_>
MRXOWLJU54S;;:?DPY56PE_HM>#(AF)SUIN_B"[WX0B^^T"Y]H=D0 AA&31DV
MM;V@=1JBNT"W:3&*B3^E@YJP@AG6?K(!38A#(4>#.91F885$-: !JII!L\)L
M 5R5U.KH@.=UDX2N%UP[,9E-ER1RUOPU6/%RGA^7J&IA#WU@"SLX!()AT=&U
M]XGCDWB7I$&4):12Z@V?W-3J:[*S/>:7>D,_73UYSF- 58ZH[6U@GO?OE9[W
M27[!?31XO+_NV];CL/]S;SSI3W\Q)^?Z*%HX@??'+GM5Z'NSS!:#V4,!_='\
MS@N<P/4<?T)_D]N,,A5[2\U?W/QGZ.9OUP0N1P"7(P!SUNJ7(X#+$<#E".!R
M!-#69N(2P'SR .:8N%\OPN=O9L3+.A7]8=^7Z#]^'9"%X_<"NNS?"(9#6JI2
MR(P^T/T@6*=[JVYW-4'9IX4N*%KDL 0R-76(53 ]E+BK!U+3."$DYL91VOPJ
M'DQ55T0;A2K@58<7N.+=N-'C*"E,X/1?>WNF__CU(0I9;L!1-"'1,QT)!:,.
M+5I?\L\R] @!Z,93#F.-*94+$PN'I+WD=<61^1/"*D*_3H>.1JR[N_?Y1^4#
M5+4<VG@DQZEF<!+IB'ZDIT(^+]<,^/93C^L 7R]ZIP<';R='\KD>4G255=F4
M+-RF9F0^R[LE+29Q?DOI\CM[KZ-K+M],AOT'9\:6V(479Y230ET5[!="3C?8
MBP$SXWB:G9TS 7</SL,.HC^5#Z(G]J!GC>ZLF]']_6AH3::CFY_,.7'N_9XR
M[X?RZ+A<#OL,F#-RO;GQG1A^F%M3R8Q->CT+PN/5&CT,."=ETN2R58: F@//
M^N)F\ &PL_(19+TZE[-$7%HNAX*70\&VEGKEYZ=9N!KMZG1)%- =ZV^LAM0;
MIM, ]A:NA<-#?;RZ\O H!#F*-$W"NGM@KGO"C""+UK@ZMI==:9+6W>-C)^EE
M5SC$Z3/5@)KN7A7K@)J3<?%(=[K12^0QSPHLB$5: \C%]P9S 4"DRXL),!+J
MBT*7 MT]&GL\_#(0+F%$7>Q_+O% 9QL/5)B];YRUESC^71K,!H,;11BBHI;)
MD4! E3L:HFW?]YS )9_]\,GQV>EC0"+Y%3YY%;0)$P U1%GT$(=)^A23WU.J
M:>^933+T4W*WE;#"V0W<*H70KQ_72*:Z=BRI8@@_<GM3<]/2C- V.2KOH: X
M]B&DTL3DA!@VF D22<37F^)?&J6:J6W#D"ZE/>3IZ%API^&3JI-&QJQQ3]\T
M)9QUNRIN>9'VZWL#=M9B(X*NV)@:G:Z-6?R#E_"=?KAU:&59G[E+9;>G%P8Y
M0:MC!SG*3J\/ Y;T $&??@Q+@MY=U"&$04V=*A2>7V8[H]*9=Q>F>#SYRKSD
MY\?]0Q2ZA,SB.PH74XO-(J,H"VS+0H[$Q$/J8N\3=%B'8W&"BP9; :XWW-JB
M@SA#T7$9O#[V831X,M7&I"-N\HCR8<K65%1P/@]D0\27?K(,TX3_:AGZ;(I?
MKZ/PV?$%/#5L"\C9=^B<'845_FK(V6U)'R+/)=0"N;B2&5!8 SM\0&O24^C=
MU?;!B9=WA.S[N6B?4"V''0$ WQ&(=#S!Z3Z+- ]3X?:KOBCV>3X869FFZ"/)
M]E'O7)'M]'43QI#WT.MK 9GY9,*( M'?P!L[HSD5@RWZ\U%0Y<&0E ?O>-$[
MDE+I;H-?Z(>XVR2.*3+*N4!5"0H[KJ<!HHD0>XSK3NEJY42;7*W1.DOZFGC/
M+!@BF.6NRGXP#VDU]L>[,'KPG2"F__V%.%'<8]^[)2[W2WZX8L9 Z[&8MWYL
MTU*^'[[$^;6GG>K%JU/_^+9\=<JRK3@3RPKG5K(D5LR$LT(NG>7DXEE.,+.B
M3$#+VTMHT9]X+2[G[E\;)JW%X;&V\EH?KOYF,9'_QAMC4EM>;#FL%A?\A]V5
M+:2+6GM@^,9H38*8*YD3PX==OJ)[8OEWMX.S^F+7L>TB+>.91#S3<%'F0J3:
M]69?)!?:?G&B66;8\2A-XH0R3<?$;",C6?^W_RED7W<[IE3>8'3%2.,UQ#KS
MZ29.E.!Z8-M#Y@OQ%DM*D4W71W0&Z;W2R<2+"9_63V+!<@&PCP!,-VP(?6_#
MW)_4>#UIXS4F[(B4_IXE#6",I8X_)='JO<+T3RT,]F%(=]T AU;TK?ZQ0\#/
M)&;J!K/>ZYJX],=IR'Y5@,1>T!W9@K+3IQ!X0>RY_#BJNS']")&P3WV,'.6/
MIOAMC/M'(/B9%DSB?I"=QGZ.PEAV+-W%Q["/S8PT; DMYH_+L99R':VNVQ0"
M^Y00QT3;I_&LPSJ.[=)W830G7D))C+,)R\OR+^T0[&[<!7P:^U35R%$83)F^
M87_*##O@:Y/9VS9L'/_)D6)A'X2?9X?0G 7.T^ QW=@:$?2=11(8:9JU2+6R
MR>L%YST^GXLG6\.T.PO%,-VT5?A=#)[BE:/"+KUU/3[7? H]/L5(&Q9R<O:K
M@8)F.,,K6 #T$![3+?//X<,XXCA)C)7H..FJNU/"1L) ^\"?ZYCP"%Y;[@\(
M,7AV'*>K#(?'F 7;L1,BWOA!6%[F[]S>7F/!=^+8NR\D(K#HNZMR]-UT22QG
M+Y&5QCR\CL?0/6\%8X%YQ:"\V%IDPEDS+MTNXDX4<+>/MWNAHEXB[HR-N-OG
M<VCLKH<G:C_V$V:D5^AFA&T/)?RD\8V73 -UAODVVC;#CEKO>VTM7 >=9[I7
MO/8W9A**'V8L_/F-,WFH;#?Y[2%<"!.R; 4T) _](5[U6+:43[X1F/=TJ;M*
M5S(X2T4P'_BKH;X 9JTNW7A;5*AF=Y>EJ!X608L)4J-:I\OY^K#N'"_B 7&%
M3=#8BW^[BPB+F*-[@Y@"DI#<F#J8]K4E0+[&T=[:J:WE0$,._P1&F_553*/=
M2H!]1^.,K?:01#.LMHFKK4[A7=AR1YY2P#>QKTUT:YF=$F6&+;;5^;8J_ASZ
MM!G?2S:GG_@5,F#?@3B/411$Y)_"=D\Z_RMDP+[F<-:V:^(:H&V5;[UG;T:"
M&5/XQ"9[^&GLVP[G9:EUM!F26X0=$+ZKK(! #RK_XWWE067V@O*[:WO2NV6/
M*C_TAA-[VA\-S7E4^7)R>#DYO)P<&CKS74X._QPGAQJVQ/)##9V5XHVAPU)_
M#GX/=49_-GLKCNK%C7(Y,\BJ,S,!WMV^I=$/6 HZNCXJ!I6Q3[__]NJ3]$D-
M4$UL%W.]E103\VD T%%F1(D$[[]M2L&^)K8O]2@*R@!T]>S?BF]C>'+#.&'+
M*O9I)H+\51EE-6SGH!I\J.H=(=];K?UP0S+JMX^HY-R_EX(/J@D=?SJ[0JXF
M0 .!4W,@?U-)70V*?F<WYXY O^5W,!N8OWSL!]6$COV(\Z\& N@NUC_]\WV=
M;"P://;7SKO5E\?^SN"QORG9YLD>1?=AE#VPEKTH(AT? ?6PSQ1@;_Z! 4 ?
M'K.>KGR@N53,C![1]2!74AK_Z>;&6NXU"690)TPW7S/#<FJMOK6T9C+]L5^8
M/EBZ9=MVU2O3DBK863:Z[!$E<U "ASZ4LX2E+%&I=" _*&1&9^QZ&#]0&?WE
MZ5P:U>A;*F8&4S465H^U*:.=P*"XQ5"CHH8W"L1WGN2#3'TCV"-BK7G!9C89
M*NB#FUKFZ4MX/).%1M#3[[1#9046E)M;4Q83-)KW@QF+<DH=7WSI4U#4C!&P
MRPN@ L4+.UI$OKYXR9+O?9G+8>FMIV$O2#R)/Z5.(54C^)=*I78JXTJE&L8E
MU%LO(BYM2G9?LEP&+ZU-$U0KO-2KC#+D]5Z)F[(3TM%\[KD2SQ<M+"H+9:.3
M6\''LR&' ']-D3[%Y/>4HM![IO^C]H()*[SQR4FE?B&GMS%,*MU;XBJ&L"FW
M3C4WQFS"#D53+M+KBT./13N+"E#:F)P1T\:^II&?AP_'VVFR#"/OC_UU@A;#
M<<6?NES=UV2EHU"(QO+NG]$=S>W9S&/5'!]@4_Q=WJZ_BAT!V;Y]G00VDX:V
M)O>U=Y$L+$TKO[BQ"H,LQB5#0#'&=?1-[&!0\R[6@XDZ7UO</XD!>M.GG4]@
M1[Z:9VDB&LPPK!96"L^.Y[,MWUT8\;2TW2_CJE^\W&AO2-+Y6F'O]]1+-OT@
M3J*4^R-&R9)$TZ430-Z$XW^\=1*RNT_=@=FV+R)V[)IY=MZ5&9C1,9I,./Q_
M\I._,=,VWJ^^.U@#R#^'_9:?>>L!"#UF&%\3V(K:93U.E4NLM:]@OY)GWM@H
M(>/,+6Q,Z+ ?>PF9D.B9[N Z-C7AY["?OS/4YA3TH!N?[?-VR:Q>399/)X@E
MDR6T/G8H5V?FH0<@.M^?24"7>[X=S.S9R@L\EB2%'2HKB5961 _QZHQB(&;H
MW/+U_IBB3F584FEOR3/QPS734TDOI"[Z2V6=,0Q'#IWD7>A\-I_40S(,@V>Z
MV"'9'!1/P\3QBW]G.9.&8?(+2<;$#1<!.W(HYAX0V\F)/H_^(%AGIG92_MZN
MM6;KJ+LPRG_%RDD6O:>6 R_6[&SM5\HHNB'SWM6/XW3[U%PF;N93%N=0D&S#
MFC8(-:TS]/ ?AS&ZC=BS_TGCA+M>I^'^;/_!\6;]X,99>TE^T%_=)=0J%X6+
MR%G5[R +G42R.<,2"&JCY^>=1^:XL_1/81K0L3A)HV :;B6MFT^SC$F"TNC)
MAKJ)]5&@TQ4GKINN4IX@8?M)*C'%PK\EL]05K=.YP*"J4+;.R$T,5UY('4)*
MZ.Q%6CK?\7CQ2;I:.2P(+.X'\Y 69%_);@O$++GU-!RE29PXP8S6^,*R._.Q
M:#NB%.)WLG2Y3K"QD\/W<*5OWWZH>_MVOA712IB,5KP3TO+V4EHO5$PKRN2T
MDM *]Y):+[FH[/?K7%C+Y=)N7\V=\Q=R<Z$M)ZF^D'OL0[B"OK;75PJH)"LU
M:T:[%9QERHWOQ/%HGLLXBOC1FR*IM*P.<H1_(^1KYW:9DOA)GFNEJXR$0.H&
MIB5G5ALEA*R!29F4:R64WXF25'E+-!F20;E6-M55)VDE@TF27'>2JM1-4K/\
M6U?2#&;E0M@W"0#V4ER(UNO8T6XA_Y@\8VRY$':(<C- 3Y,3-O_8!PB@'TQ)
MJ-<,T ^&7:>KU:+W2B+7VUU3V*[S\K_&$M]_P^:0K\7!EGN0D1R*G)F\%S:[
MFA0?U#1R[FA$9PT@'0V!AY^/=^:TO<5Q6_\F&JL+JXI]&4N/%+A>)CF7I!MB
MV*MC?R][A+[8X[$]G$ZLZ<AZ>!S?_&A/>NSYL?O1,'N1K+7GQR[^FHN_YN*O
MN?AK+OZ:B[_FXJ]!]]?$=U3V._+$GJ:X\P(G<.DJ%+)#EE8T<FVNW#4#L$#?
M44W8>T8\BI7?#60G:V' 8A<4J;GDU0SN-=*,6W*MT%_6*(FE&M@$Q<T@!V1X
MY<C">H6P,V[E!J;*M%4JANU:E1I3"?A:#;MUJW;B^.\LXA$$9G<N?\3\%F%^
M=[QRMWSK5.PD51GDJ^?HGCT%#^C&=E;>^S/P]YZ-^_XA"EU"9GQ=G$NYE5WV
MDK2TUGEYB$$J&<)6)V/1U@W>Q7ORP.]B+[S,F1@J9'2TI!,,4%P 8=I)527L
M)9_^T1 ,!C,.A<H!P7=IDD;DW@N\5;H:$'8Q(3.R^"Z,1FO"#"E8\#_$+!29
MFMT[UPE<PC-I34FTHEBQM_EXMJ& _$*<Z N)B!UGL<UQ/Y@NPS1V@EDL#3[^
MKGS49-<$ ?_-FG-YK54FL.4SP:QU+K(U#R,KW J=_3'.0I.# [FMA G.PHY7
M5'0KH;);=(%O;:CTU@L5WW+B//(YMO[B!;1$KL-?.X]#SK &'V"5B^/,*0,2
MQX0<VLO <YX\GXY-6XNZ3<F06NSTA?C/Y#X,DJ5DMFC>(M;^0,Y+[>A_+&SH
M:PFH FQ8F+Z$Q].]:PAMF=\AS264SHM=^DW)L72#IM!V %TS7$3JK#B^"U.)
M'U2_);05>\<,%W$Z+X(+D4!'$LQ;0EO+=TUP,6+J7 @^GEC$,.<.":TADJHU
M)Q'=O TRK(3"<\D3EN2"ES32!!Z#&06.760FL]ZK2XMFUYH;VH.X.;0\IVT;
MAPHQ?4OYE%E*0!;L=C*JK0AT%EN#L ):LM$&?"NT-L,YPY.1%>Y^\U?BR&P:
MYOX7)]ZY5:2^E'^4?2F\X8/[VE'6-+N2O763.''!ZW%Q<ZC[SG8.@7:=??DS
M<E'(549?_!R*5\IL/B;LN'[[1^:LE!PWZK=T3BZ(ICB93?!M/DV/Z5BF?%Q(
MOZ5S\D TQ<F,F2]3$78IY6-Y=AOT[$EO<KJ;)^<Y=;$E +MAX>4YK.372 3%
MC;I! NL7]8K@WQ(I"S907Q"15#$C^%-J9 IB!B;=""D+)X^:KB]]_I08<ONC
M+)8J/EI4WDQ")''1(D6ZN>DQ)"]\1"T$GTAC=27EL8.WY!93C-U0*FW8 CB[
M"#Y_I!+',0&O=BO5D(-HE9.?='4K *&Q Y<NDI_"F/RYW'*=!< >QZW,-?=F
M6!V&@9M&D<9VM;:J:<-L0Z:K:+Q%SF\:$GZCR79G\:TML7WS9JE6/[527QP[
MXO4X8M7/I"#XDXIK/Y!3Z?NR4XDE->E/[WLLV4E;GJ7C;]@4M@W!["8,& LD
M<#T2[X67.*:V(<YZS9BQZSM+AU4SP"^.+&S"+HZLBR/KXL@Z4T?6]CFW4;1P
M N^/["J4U)4EK6':?EKLS (HWE7"P)#?/W.S)YX"/H])$9=5,&U;*P9<K3:Z
M^Y ]E#1T5D0^\!^6,G-\D0WXA_*C)W39BJ,:X,OES "^SF0$>'<[D-^2.5U+
M\?5RY#VE# 7VX;]_>_43^Z]T@ '6Q7:JU%M*<8S1 @%]N"EU6O#:YOQ.).H5
M12= 8"[Y@TA1?.\D%(A@42Q@!T'J^#^3.,F>WF/Q0<Y"LMEN]2.FK:]4S'>
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MAO[F_P=02P$"% ,4    "  EBVU6TACWO80#  "F$0  "P
M@ $     97@R,2TP,2YH=&U02P$"% ,4    "  EBVU6WC;7)#\$   [#@
M"P              @ &M P  97@R,RTP,2YH=&U02P$"% ,4    "  EBVU6
MW%!8C;D'  !9*0  "P              @ $5"   97@S,2TP,2YH=&U02P$"
M% ,4    "  EBVU6-X.8@+P'  "V)@  "P              @ 'W#P  97@S
M,2TP,BYH=&U02P$"% ,4    "  EBVU6+P#[5!0%  !Z&   "P
M    @ '<%P  97@S,BTP,2YH=&U02P$"% ,4    "  EBVU6S"WL?(D.  #[
M3   "@              @ $9'0  97@T+3 V+FAT;5!+ 0(4 Q0    ( "6+
M;5:+&_6PYRX$ />")0 3              "  <HK  !T;GAP+3$P:U\Q,C,Q
M,C(N:'1M4$L! A0#%     @ )8MM5H*[]_J5&   F@<! !$
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L '1N>' M,C R,C$R,S%?<')E+GAM;%!+!08     #  , .$"   %H 4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
